Eclipsys Corp – ‘S-4’ on 12/4/98

As of:  Friday, 12/4/98   ·   Accession #:  950133-98-4050   ·   File #:  333-68353

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Registration of Securities Issued in a Business-Combination Transaction   —   Form S-4
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4         Form S-4 Registration Statement Eclipsys Corp.       278   1.49M 
 2: EX-5.1      Opinion of Hale and Dorr LLP                           2     13K 
 3: EX-8.1      Opinion of Hale and Dorr LLP as to Tax Matters         4     15K 
 4: EX-8.2      Form of Opinion of Foley, Hoag & Eliot LLP             3     14K 
 5: EX-23.1     Consent of Pricewaterhousecoopers LLP                  1      7K 
 6: EX-23.2     Consent of Pricewaterhousecoopers LLP                  1      7K 
 7: EX-23.3     Consent of Kpmg Peat Marwick LLP                       1      8K 
 8: EX-23.4     Consent of Pricewaterhousecoopers LLP                  1      8K 
 9: EX-23.5     Consent of Ernst & Young LLP                           1      7K 
10: EX-99.3     Form of Proxy Card for Eclipsys Corp.                  2±    12K 
11: EX-99.4     Form of Proxy Card for Transition Systems, Inc.        2     12K 
12: EX-99.5     Consent of Bt Alex. Brown Incorporated                 1      8K 
13: EX-99.6     Consent of Morgan Stanley & Co.                        1      8K 
14: EX-99.7     Consent of Robert F. Raco                              1      7K 
15: EX-99.8     Consent of Patrick T. Hackett                          1      7K 

S-4   —   Form S-4 Registration Statement Eclipsys Corp.
Document Table of Contents

S-4
1st Page of 278
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 

    AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 4, 1998

                                       REGISTRATION NO. 333-
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------
FORM S-4
REGISTRATION STATEMENT
UNDER 
THE SECURITIES ACT OF 1933
------------------

ECLIPSYS CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

DELAWARE
(STATE OR OTHER JURISDICTION OF 
INCORPORATION OR ORGANIZATION)

7373
(PRIMARY STANDARD INDUSTRIAL
CLASSIFICATION CODE NUMBER) 

65-0632092
(I.R.S. EMPLOYER
IDENTIFICATION NUMBER)

777 EAST ATLANTIC AVENUE
SUITE 200 
DELRAY BEACH, FLORIDA 33483 
(561) 243-1440
(ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE, OF 
REGISTRANT'S PRINCIPAL EXECUTIVE OFFICES) 

HARVEY J. WILSON
CHAIRMAN OF THE BOARD, PRESIDENT
AND CHIEF EXECUTIVE OFFICER 
ECLIPSYS CORPORATION
777 EAST ATLANTIC AVENUE
SUITE 200 
DELRAY BEACH, FLORIDA 33483 
(561) 243-1440
(NAME, ADDRESS, INCLUDING ZIP CODE, AND TELEPHONE NUMBER, INCLUDING AREA CODE,
OF AGENT FOR SERVICE) 

------------------
Copies to:

JOHN A. BURGESS, ESQ. 
BRENT B. SILER, ESQ.
HALE AND DORR LLP 
1455 PENNSYLVANIA AVENUE, N.W.
WASHINGTON, D.C. 20004
TELEPHONE: (202) 942-8400 
TELECOPY: (202) 942-8484
ROBERT W. SWEET, JR., ESQ.
DAVID H. FEINBERG, ESQ. 
FOLEY, HOAG & ELIOT LLP 
ONE POST OFFICE SQUARE
BOSTON, MASSACHUSETTS 02109 
TELEPHONE: (617) 832-1000 
TELECOPY: (617) 832-7000

   APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon as
practicable after this Registration Statement becomes effective and certain     
other conditions under the Merger Agreement are met or waived.                  
If the securities being registered on this Form are being offered in    
connection with the formation of a holding company and there is compliance with 
General Instruction G, check the following box. [ ]                             
If this form is filed to register additional securities for an offering 
pursuant to Rule 462(b) under the Securities Act, check the following box and   
list the Securities Act registration statement number of the earlier effective  
registration statement for the same offering. [ ] __________                    
If this form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act   
registration statement number of the earlier effective registration statement   
for the same offering. [ ] __________                                           
------------------
CALCULATION OF REGISTRATION FEE 

                                                        [Enlarge/Download Table]

========================================================================================================================
                                                            PROPOSED               PROPOSED MAXIMUM          AMOUNT OF  
    TITLE OF EACH CLASS OF         AMOUNT TO BE      MAXIMUM OFFERING PRICE       AGGREGATE OFFERING        REGISTRATION
  SECURITIES TO BE REGISTERED      REGISTERED(1)          PER SHARE(2)                 PRICE(2)                FEE(3)   
------------------------------------------------------------------------------------------------------------------------
                                                                                                                        
Common Stock, $0.01 par value                                                                                           
  per share....................  11,060,808 shares           $18.69                  $206,726,502             $57,470   
========================================================================================================================

(1) Based upon an estimate of the maximum number of shares of the Common Stock  
    of the Registrant issuable in the merger described herein to stockholders of
Transition Systems, Inc. ("TSI").                                       

(2) Estimated solely for the purpose of calculating the registration fee        
   pursuant to Rules 457(c) and 457(f)(1) under the Securities Act of 1933, as
  amended (the "Securities Act"), and based upon the average of the high and
    low sales prices of the Common Stock of TSI on the Nasdaq National Market on
November 27, 1998.                                                      

(3) A fee of $49,707 was previously paid by the Registrant pursuant to Rule     
   14a-6 promulgated under the Securities Exchange Act of 1934, as amended, in
connection with the filing of the preliminary Joint Proxy               
    Statement/Prospectus on November 20, 1998. Pursuant to Rule 457(b) under the
    Securities Act, such fee is being credited against the registration fee and,
    accordingly, $7,763 in additional fees is being paid in connection with this
Registration Statement.                                                 
------------------

  THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION       
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF  
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME     
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SECTION 8(a), MAY  
DETERMINE.                                                                      
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------

S-4
2nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 2nd

JOINT PROXY STATEMENT/PROSPECTUS

[ECLIPSYS LOGO]                                                       [TSI LOGO]

MERGER PROPOSED -- YOUR VOTE IS VERY IMPORTANT

 The Boards of Directors of Eclipsys Corporation and Transition Systems,
Inc. have agreed to a merger in which Eclipsys will acquire TSI. We are seeking 
your vote on this important transaction.                                        

   If the merger is completed, TSI stockholders will receive 0.525 shares of
Eclipsys Voting Common Stock for each share of TSI Voting or Non-Voting Common  
Stock that they own. Eclipsys stockholders will continue to own their existing  
shares after the merger. If the merger is completed, the stockholders of TSI    
prior to the merger will own approximately 33.7% of the total outstanding shares
of Eclipsys Common Stock on a fully diluted basis (assuming the exercise of all 
warrants and stock options of both TSI and Eclipsys, except for options that    
will not be exercisable until after December 31, 1998).                         

  The merger cannot be completed unless TSI stockholders approve and adopt
the merger agreement and the merger and Eclipsys stockholders approve the       
issuance of shares of Eclipsys Voting Common Stock in the merger. We have       
scheduled special meetings for our stockholders to vote on these proposals. Your
vote is very important.                                                         

   Whether or not you plan to attend a meeting, please take the time to vote
by completing and mailing the enclosed proxy card to us. If you sign, date and  
mail your proxy card without indicating how you want to vote, your proxy will be
counted as a vote in favor of the proposals submitted at your meeting. If you   
are a TSI stockholder and fail to return the card, the effect will be a vote    
against the merger, unless you attend your meeting and vote in favor of the     
proposal.                                                                       

The dates, times and places of the meetings are as follows:           

For Eclipsys stockholders:                                            

December 30, 1998                                             
10:00 a.m., local time                                      
Delray Beach Marriott                                       
10 North Ocean Boulevard                                    
Delray Beach, Florida 33444                                 

For TSI stockholders:                                                 

December 30, 1998                                             
10:00 a.m., local time                                      
Foley, Hoag & Eliot LLP                                     
One Post Office Square                                      
16th Floor                                                  
Boston, Massachusetts 02109                                 

This Joint Proxy Statement/Prospectus provides you with detailed      
information about the proposed merger. In addition, you may obtain information  
about our companies from documents that we have filed with the Securities and   
Exchange Commission. We encourage you to read this entire document carefully.   

                                                                [Download Table]
                                                                             
/s/ HARVEY J. WILSON                    /s/ ROBERT F. RACO                   

Harvey J. Wilson,                       Robert F. Raco,                      
President, Chief Executive Officer and  President and Chief Executive Officer
Chairman of the Board                   Transition Systems, Inc.             
Eclipsys Corporation                                                         

 Neither the Securities and Exchange Commission nor any state securities
regulator has approved the Eclipsys Voting Common Stock to be issued in the     
merger or determined if this Joint Proxy Statement/Prospectus is accurate or    
adequate. Any representation to the contrary is a criminal offense.             

Joint Proxy Statement/Prospectus dated December 4, 1998, and first mailed to    
stockholders on or about December 7, 1998.                                      

S-4
3rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 3rd

[ECLIPSYS LETTERHEAD]   

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS 
TO BE HELD ON DECEMBER 30, 1998 

To the Stockholders of Eclipsys Corporation:                                    

NOTICE IS HEREBY GIVEN that a special meeting of stockholders (the    
"Eclipsys Special Stockholders' Meeting") of Eclipsys Corporation, a Delaware   
corporation ("Eclipsys"), will be held on December 30, 1998 at the Delray Beach 
Marriott, 10 North Ocean Boulevard, Delray Beach, Florida 33444, commencing at  
10:00 a.m., local time for the following purposes:                              

      1. To consider and vote upon a proposal to approve the issuance of
       shares of Common Stock, $.01 par value per share, of Eclipsys
            ("Eclipsys Voting Common Stock"), as contemplated by the Agreement
      and Plan of Merger dated as of October 29, 1998 (the "Merger
             Agreement") among Eclipsys Corporation, Exercise Acquisition Corp.,
          a Massachusetts corporation that is a wholly owned subsidiary of
         Eclipsys ("Sub"), and Transition Systems, Inc., a Massachusetts
        corporation ("TSI"). The Merger Agreement provides that, among
          other things, (a) Sub will be merged with and into TSI, with TSI
     being the surviving corporation and becoming a wholly owned
          subsidiary of Eclipsys, and (b) each outstanding share of Voting
            and Non-Voting Common Stock, $.01 par value per share, of TSI will
         be converted into the right to receive 0.525 shares of Eclipsys
Voting Common Stock.                                  

        2. To transact such other business as may properly be brought before
            the Eclipsys Special Stockholders' Meeting, or any adjournments or
postponements thereof.                                

   A copy of the Merger Agreement is attached as Annex A to the accompanying
Joint Proxy Statement/Prospectus.                                               

    Holders of record of Eclipsys Voting Common Stock at the close of business
on November 30, 1998 (the "Record Date") are entitled to notice of and to vote  
at the Eclipsys Special Stockholders' Meeting and any adjournment or            
postponement of the Eclipsys Special Stockholders' Meeting.                     

   All stockholders of Eclipsys are invited to attend the meeting in person.
However, to ensure your representation at the meeting, you are urged to         
complete, sign and return the enclosed proxy card as promptly as possible in the
enclosed postage-prepaid envelope.                                              

                                      By Order of the Board of Directors

                               /s/ T. JACK RISENHOOVER, II

                           T. Jack Risenhoover, II
             Secretary

December 4, 1998                                                                
Delray Beach, Florida                                                           

S-4
4th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 4th

[TSI LETTERHEAD]                                                                

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS 
TO BE HELD ON DECEMBER 30, 1998 

To the Stockholders of Transition Systems, Inc.:                                

 NOTICE IS HEREBY GIVEN that a special meeting of stockholders (the "TSI
Special Stockholders' Meeting") of Transition Systems, Inc., a Massachusetts    
corporation ("TSI"), will be held on December 30, 1998 at the offices of Foley, 
Hoag & Eliot LLP, One Post Office Square, 16th Floor, Boston, Massachusetts     
02109, commencing at 10:00 a.m., local time, for the following purposes:        

      1. To consider and vote upon the Agreement and Plan of Merger dated as
 of October 29, 1998 (the "Merger Agreement") among Eclipsys
Corporation, a Delaware corporation ("Eclipsys"), Exercise
         Acquisition Corp., a Massachusetts corporation ("Sub") and TSI, and
          the merger (the "Merger") contemplated thereby. The Merger Agreement
           provides that, among other things, (a) Sub, a wholly owned subsidiary
   of Eclipsys, will be merged with and into TSI with TSI as the
           surviving corporation and with TSI becoming a wholly owned subsidiary
          of Eclipsys, and (b) each outstanding share of Voting and Non-Voting
           Common Stock of TSI will be converted into the right to receive 0.525
shares of Eclipsys Voting Common Stock.                   

        2. To transact such other business as may properly be brought before the
TSI Special Stockholders' Meeting or any adjournments or  
postponements thereof.                                    

   A copy of the Merger Agreement is attached as Annex A to the accompanying
Joint Proxy Statement/Prospectus.                                               

     If the Merger Agreement and the Merger are approved by the TSI stockholders
at the TSI Special Stockholders' Meeting and the Merger is effected, any        
stockholder (1) who files with TSI, before the taking of the vote at the TSI    
Special Stockholders' Meeting, written objection to the Merger stating that he  
or she intends to demand payment for his or her shares if the Merger is effected
and (2) whose shares are not voted in favor of the Merger has or may have the   
right to demand in writing from TSI, within twenty days after the date of       
mailing to him or her of notice in writing that the Merger has become effective,
payment for his or her shares and an appraisal of the value thereof. TSI and any
such stockholder shall in such cases have the rights and duties and shall follow
the procedure set forth in sections 88 to 98, inclusive, of chapter 156B of the 
General Laws of Massachusetts.                                                  

     Holders of record of TSI Voting and Non-Voting Common Stock at the close of
business on November 30, 1998 (the "Record Date") are entitled to notice of the 
TSI Special Stockholders' Meeting. The holders of record of TSI Voting Common   
Stock on the Record Date are entitled to vote at the TSI Special Stockholders'  
Meeting and any adjournment or postponement thereof.                            

All shareholders of TSI are invited to attend the meeting in person.  
However, to ensure your representation at the meeting, you are urged to         
complete, sign and return the enclosed proxy card as promptly as possible in the
enclosed postage-prepaid envelope.                                              

                                      By Order of the Board of Directors

                      /s/ DONALD R. WARE

                  Donald R. Ware
         Clerk

December 4, 1998                                                                
Boston, Massachusetts                                                           

S-4
5th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 5th

TABLE OF CONTENTS 

                                                                [Download Table]

                                        PAGE
                                        ----
                                            
Questions and Answers about the             
  Proposed Eclipsys/TSI Merger........   ii 
Summary...............................    1 
  The Companies.......................    1 
  Reasons for the Merger..............    1 
  Effects of the Merger; Issuance of        
     New Shares; Treatment of TSI           
     Options and Warrants.............    2 
  The Stockholders' Meetings..........    3 
  Who is Entitled to Vote; What Vote        
     is Required......................    3 
  Voting Agreements...................    3 
  Share Ownership of Management.......    4 
  New TSI Designated Directors........    4 
  Recommendations of the Boards of          
     Directors........................    4 
  Opinions of Financial Advisors......    4 
  Interests of Certain Persons in the       
     Merger...........................    5 
  Anticipated Closing of the Merger...    5 
  Conditions to the Merger............    5 
  Termination of the Merger                 
     Agreement........................    5 
  Appraisal Rights....................    6 
  Regulatory Approvals................    6 
  Accounting Treatment................    6 
  Federal Income Tax Considerations...    6 
  Surrender of Stock Certificates.....    6 
  Certain Effects of the Merger on the      
     Rights of TSI Stockholders.......    6 
  Forward-Looking Statements May Prove      
     Inaccurate.......................    7 
  Explanation of Certain Terms........    7 
Risk Factors..........................    8 
Market Price Information..............   16 
Selected Consolidated Financial Data        
  for Eclipsys........................   17 
Selected Consolidated Financial Data        
  for TSI.............................   19 
Selected Unaudited Pro Forma Combined       
  Financial Data Reflecting the             
  Merger..............................   20 
Comparative Per Share Data............   21 

                                                                [Download Table]

                                        PAGE
                                        ----
                                            
Management's Discussion and Analysis        
  of Financial Condition and Results        
  of Operations of Eclipsys...........   22 
Management's Discussion and Analysis        
  of Financial Condition and Results        
  of Operations of TSI................   32 
Eclipsys Special Stockholders'              
  Meeting.............................   39 
TSI Special Stockholders' Meeting.....   41 
The Merger............................   43 
Unaudited Pro Forma Condensed Combined      
  Consolidated Financial Statements...   60 
The Merger Agreement..................   71 
Business of Eclipsys..................   80 
Eclipsys Management...................   91 
Principal Stockholders of Eclipsys....   96 
Certain Transactions Relating to            
  Eclipsys............................   99 
Business of TSI.......................  101 
Principal Stockholders of TSI.........  108 
Description of Eclipsys Capital             
  Stock...............................  110 
Comparison of Stockholders' Rights....  112 
Legal Matters.........................  118 
Experts...............................  118 
Future Stockholder Proposals..........  118 
Where You Can Find More Information...  119 
Forward-Looking Statements............  119 
Where to Find Certain Defined Terms...  120 
Index to Financial Statements.........  F-1 

ANNEXES                                     
Annex A --  Agreement and Plan of           
            Merger among Eclipsys           
            Corporation, Exercise           
            Acquisition Corp. and           
            Transition Systems, Inc.        
            dated October 29, 1998....  A-1 
Annex B --  Opinion of Morgan Stanley       
            & Co. Incorporated........  B-1 
Annex C --  Opinion of BT Alex. Brown       
            Incorporated..............  C-1 

S-4
6th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 6th

QUESTIONS AND ANSWERS ABOUT THE PROPOSED ECLIPSYS/TSI MERGER

Q: WHY ARE THE TWO COMPANIES PROPOSING TO MERGE?                                

A: We believe that the Merger, by combining the complementary product offerings,
customer bases and other resources of our companies, will position the    
combined company to enjoy greater growth and earnings than either company 
  would have experienced individually. To review the reasons for the merger in
greater detail, see pages 45 through 47.                                  

Q: WHAT DO I NEED TO DO NOW?                                                    

A: After you have carefully read this Joint Proxy Statement/Prospectus, just    
   indicate on your proxy card how you want to vote, and sign and mail it in the
  enclosed postage-prepaid return envelope marked "Proxy" as soon as possible,
 so that your shares may be represented and voted at the appropriate special
meeting, as indicated below:                                              
Eclipsys Special Stockholders' Meeting                      
December 30, 1998                                           
10:00 a.m., local time                                      
Delray Beach Marriott                                       
10 North Ocean Boulevard                                    

Delray Beach, Florida 33444                                 
TSI Special Stockholders' Meeting                                           
December 30, 1998                                                           
10:00 a.m., local time                                                      
Foley, Hoag & Eliot LLP                                                     
One Post Office Square                                                      
16th Floor                                                                  
Boston, Massachusetts 02109                                                 

 Holders of a majority of the shares of Eclipsys Voting Common Stock present
  or represented and voting at the Eclipsys special stockholders' meeting must
  approve the issuance of shares of Eclipsys Voting Common Stock in connection
with the merger, and therefore it is important that Eclipsys stockholders 
 return their signed proxy cards. The Eclipsys board of directors recommends
  voting "FOR" the issuance of the Eclipsys Voting Common Stock in the merger.

   Holders of two-thirds of the outstanding TSI Voting Common Stock must approve
 the merger and the merger agreement, and therefore it is important that TSI
stockholders return their signed proxy cards. The TSI board of directors  
recommends voting "FOR" the merger and the merger agreement.              

Q: IF MY SHARES ARE HELD IN "STREET NAME" BY MY BROKER, WILL MY BROKER VOTE MY  
SHARES FOR ME?                                                            

A: Your broker will vote your shares only if you provide instructions on how to 
  vote. You should follow the directions provided by your broker regarding how
   to instruct your broker to vote your shares. If you do not return your proxy,
 your shares will not be voted on the proposed merger, which, in the case of
TSI stockholders, will have the same effect as voting against the proposed
merger.                                                                   

Q: CAN I CHANGE MY VOTE AFTER I HAVE MAILED MY SIGNED PROXY CARD?               

A: Yes. There are three ways in which you may revoke your proxy and change your 
   vote. First, you may send a written notice to the party to whom you submitted
  your proxy stating that you would like to revoke your proxy. Second, you may
complete and submit a new proxy card. Third, you may attend the Eclipsys  
Special Stockholders' Meeting or the TSI Special Stockholders' Meeting, as
applicable, and vote in person. Simply attending the special meeting,     
  however, will not revoke your proxy. If you have instructed a broker to vote
 your shares, you must follow directions received from your broker to change
your vote.                                                                

Q: SHOULD I SEND IN MY STOCK CERTIFICATES NOW?                                  

A: No. After the merger is completed, Eclipsys will send TSI stockholders       
written instructions for exchanging their stock certificates. Eclipsys    
stockholders will keep their existing stock certificates.                 

ii

S-4
7th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 7th

Q: WHAT WILL HOLDERS OF TSI VOTING AND NON-VOTING COMMON STOCK RECEIVE IN THE   
MERGER?                                                                   

A: At the completion of the merger, each share of TSI Voting and Non-Voting     
Common Stock will be converted into 0.525 shares of Eclipsys Voting Common
Stock. Eclipsys will not issue fractional shares of Eclipsys Voting Common
  Stock. Instead Eclipsys will pay cash with respect to any fractional shares.
  For example, a holder of 100 shares of TSI Voting or Non-Voting Common Stock
  would receive 52 shares of Eclipsys Voting Common Stock, plus a cash payment
equal to the value of 0.5 of a share of Eclipsys Voting Common Stock.     

Q: WHAT IS THE "EXCHANGE RATIO"?                                                

A: The exchange ratio is the fraction of a share of Eclipsys Voting Common Stock
into which each share of TSI Voting and Non-Voting Common Stock will be   
converted upon completion of the merger. The exchange ratio is fixed at   
0.525.                                                                    

  Please note that because the exchange ratio is fixed and the market price of
the shares of Eclipsys Voting Common Stock will receive may fluctuate, TSI
stockholders cannot be sure of the market value of the shares of Eclipsys 
Voting Common Stock they will receive.                                    

Q: WHAT WILL HAPPEN TO THE TSI OPTIONS AND WARRANTS IN THE MERGER?              

A: TSI options and warrants outstanding and unexercised at the time of the      
  merger will be converted into rights to acquire Eclipsys Voting Common Stock
under the same terms, provided that the number of shares will decrease and
   the exercise price per share will increase to reflect the exchange ratio. For
example, an option to purchase 100 shares of TSI Voting Common Stock at an
   exercise price of $5.00 per share will become an option to purchase 52 shares
of Eclipsys Voting Common Stock at an exercise price of $9.52 per share.  

Q: WHAT WILL THE STOCKHOLDERS OF ECLIPSYS VOTING AND NON-VOTING COMMON STOCK    
RECEIVE IN THE MERGER?                                                    

A: Holders of Eclipsys Voting and Non-Voting Common Stock will retain the shares
  that they currently own and such shares will remain unchanged. However, as a
result of the merger, they will own shares of a larger, more diversified  
 company, as more fully described in this Joint Proxy Statement/ Prospectus.

Q: WHEN DO YOU EXPECT THE MERGER TO BE COMPLETED?                               

A: We are working toward completing the merger as quickly as possible. In       
  addition to the approvals of the holders of Eclipsys Voting Common Stock and
   TSI Voting Common Stock, we must also obtain certain regulatory approvals. We
currently expect to close the merger by December 31, 1998.                

Q: WHAT ARE THE TAX CONSEQUENCES OF THE MERGER?                                 

A: We expect that for United States federal income tax purposes, your exchange  
of shares of TSI Voting or Non-Voting Common Stock for shares of Eclipsys 
Voting Common Stock generally will not cause you to recognize any gain or 
   loss. You will, however, recognize income or gain in connection with any cash
 received instead of fractional shares of Eclipsys Voting Common Stock. Your
 holding period for the Eclipsys Voting Common Stock received in the merger,
which determines how any gain or loss should be treated for federal income
tax purposes upon future sales of Eclipsys Voting Common Stock, generally 
   will include the holding period for the TSI Voting or Non-Voting Common Stock
   exchanged in the merger. For a more complete discussion of federal income tax
considerations, see pages 57 to 58.                                       

Q: WILL THE COMPOSITION OF THE ECLIPSYS BOARD OF DIRECTORS CHANGE AS A RESULT OF
THE MERGER?                                                               

A: Yes. At the time the merger is completed, the Eclipsys board of directors    
 will appoint Robert F. Raco and Patrick T. Hackett to the Eclipsys board of
  directors. Mr. Raco and Mr. Hackett are currently directors of TSI. Eclipsys
will have a total of nine directors after the merger is completed.        

 iii

S-4
8th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 8th

Q: WHAT OTHER MATTERS WILL BE VOTED ON AT THE SPECIAL STOCKHOLDERS' MEETINGS?   

A: We do not expect to ask the Eclipsys Voting Common Stockholders to vote on   
any matter other than the issuance of the Eclipsys Voting Common Stock in 
   connection with the merger; and we do not expect to ask the TSI Voting Common
  Stockholders to vote on any matter other than approval of the merger and the
merger agreement.                                                         

Q: WILL THE RIGHTS OF TSI STOCKHOLDERS CHANGE AS A RESULT OF THE MERGER?        

A: Yes. Currently the rights of TSI stockholders are governed by Massachusetts  
   law and TSI's charter and bylaws, whereas the rights of Eclipsys stockholders
are governed by Delaware law and Eclipsys' charter and bylaws. After the  
  merger, TSI stockholders will become stockholders of Eclipsys, and therefore
their rights will be governed by Delaware law and Eclipsys' charter and   
bylaws. For a summary of certain differences between the rights of TSI    
 stockholders and the rights of Eclipsys stockholders, see pages 112 through
117.                                                                      

Q: WHOM SHOULD STOCKHOLDERS CALL WITH QUESTIONS AND TO OBTAIN ADDITIONAL COPIES 
OF THE JOINT PROXY STATEMENT/PROSPECTUS?                                  

A: Eclipsys stockholders should call Karen Young at (561) 266-2324. TSI         
stockholders should call TSI Investor Relations at (617) 305-5283.        

iv

S-4
9th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 9th

SUMMARY 

  This summary highlights selected information from this document and does
not contain all of the information that may be important to you. To understand  
the merger fully and for a more complete description of the legal terms of the  
merger, you should read carefully this entire document and the documents to     
which we have referred you. See "Where You Can Find More Information" on page   
119. We have included page references parenthetically to direct you to a more   
complete discussion of the topics presented in this summary.                    

THE COMPANIES                                                                   

Eclipsys Corporation (page 80)                                        
777 East Atlantic Avenue                                              
Suite 200                                                             
Delray Beach, Florida 33483                                           
(561) 243-1440                                                        

  Eclipsys Corporation ("Eclipsys") is a healthcare information technology
company delivering solutions that enable healthcare providers to achieve        
improved clinical, financial and administrative outcomes. Eclipsys markets its  
products primarily to large hospitals, academic medical centers and integrated  
healthcare delivery networks. Eclipsys offers an integrated suite of healthcare 
products in four critical areas -- clinical management, access management,      
patient financial management and enterprise data warehouse and analysis. These  
products can be purchased in combination to provide an enterprise-wide solution 
or individually to address specific needs. Eclipsys also provides outsourcing,  
remote processing and networking services to assist customers in meeting their  
healthcare information technology requirements. Eclipsys was formed in December 
1995 and has grown to date primarily through three acquisitions, all completed  
since January 1997.                                                             

Transition Systems, Inc. (page 101)                                   
One Boston Place                                                      
Boston, Massachusetts 02108                                           
(617) 723-4222                                                        

     Transition Systems, Inc. ("TSI") provides management information technology
to hospitals, integrated delivery networks, physician groups and other          
healthcare organizations. TSI's software products span a healthcare             
organization's information technology needs, providing data integration         
services, master person identifier solutions, disease management products and a 
clinical data repository as well as enterprise-wide financial, operational and  
clinical decision support in a real-time environment. TSI's products help its   
customers increase efficiency, improve the quality of care and lower the cost of
care delivery.                                                                  

    On December 3, 1998, TSI completed the acquisition of the capital stock of
HealthVISION, Inc. ("HealthVISION") not already owned by TSI. HealthVISION,     
located in Santa Rosa, California, is a provider of electronic medical record   
software. HealthVISION products include CareVISION, a patient-centered clinical 
data repository and lifetime patient record system that is an integral component
of TSI's new generation of decision support solutions. (page 107)               

REASONS FOR THE MERGER (page 45)                                                

We believe that the merger, by combining the complementary product    
offerings, customer bases and other resources of our companies, will position   
the combined company to enjoy greater growth and earnings than either Eclipsys  
or TSI would have experienced individually. We believe the merger will:         

     - enable the combined company to offer a broader range of products, product
features and technical solutions for customers;                   

 1

S-4
10th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 10th

 - combine the highly complementary customer bases of the two companies;

- enable the combined company to achieve efficiencies and economies of
   scale that could not be achieved by either company independently; and

 - provide the combined company with substantially greater financial and
other resources.                                                  

   We believe these factors will benefit the stockholders of both companies.

EFFECTS OF THE MERGER; ISSUANCE OF NEW SHARES; TREATMENT OF TSI OPTIONS AND     
WARRANTS (pages 71 and 74-75)                                                   

If the proposed merger is completed, TSI will become a wholly owned   
subsidiary of Eclipsys. The stockholders of TSI will receive 0.525 shares of    
Eclipsys Voting Common Stock for each share of TSI Voting or Non-Voting Common  
Stock they own. Eclipsys will not issue any fractional shares. Instead, it will 
pay to TSI stockholders an amount equal to the cash value of any fractional     
share of Eclipsys Voting Common Stock in place of receiving such fractional     
shares. The merger agreement describes the method that will be used to determine
the value of fractional shares. Each outstanding share of Eclipsys stock will   
remain unchanged and outstanding after the merger.                              

   After the merger, each outstanding option to acquire shares of TSI Voting
Common Stock, whether such option is vested or unvested, will become an option  
to acquire shares of Eclipsys Voting Common Stock, and each outstanding warrant 
to acquire shares of TSI Non-Voting Common Stock will become a warrant to       
acquire shares of Eclipsys Voting Common Stock. In each case, the number of     
shares purchasable will be decreased, and the per-share exercise price will be  
increased, to reflect the exchange ratio of 0.525 shares of Eclipsys Voting     
Common Stock for every share of TSI Voting and Non-Voting Common Stock. All     
other terms of the original options and warrants will remain the same as prior  
to the completion of the merger.                                                

 If the merger is completed, the stockholders of TSI prior to the merger
will own approximately 33.7% of the total outstanding shares of Eclipsys Voting 
Common Stock on a fully diluted basis (assuming exercise of all warrants and    
exercisable stock options of both TSI and Eclipsys).                            

  The following table illustrates the maximum number of shares of Eclipsys
Voting Common Stock that could be issued in connection with the merger to TSI   
stockholders, option holders and warrant holders. It also illustrates the       
relative ownership of Eclipsys Voting Common Stock by TSI and Eclipsys          
stockholders, option holders and warrant holders after the merger. These        
calculations are based on the shares, options and warrants outstanding on the   
record date and assume that all options and warrants outstanding on that date   
issued by TSI and Eclipsys are exercised prior to the merger, except for options
that will not be exercisable until after December 31, 1998. These calculations  
also treat all shares of Eclipsys Non-Voting Common Stock as if they had been   
converted into Eclipsys Voting Common Stock.                                    

                                                        [Enlarge/Download Table]

                                                                NUMBER OF     PERCENTAGE
                                                             ECLIPSYS SHARES   OF TOTAL 
                                                             ---------------  ----------
                                                                                        
NEW TSI SHARES                                                                          
  TSI stockholders..........................................    9,662,112         29.4% 
  TSI option holders........................................    1,242,284          3.8  
  TSI warrant holders.......................................      156,412          0.5  
EXISTING ECLIPSYS SHARES                                                                
  Eclipsys stockholders.....................................   20,358,073         62.1  
  Eclipsys option holders...................................      413,400          1.3  
  Eclipsys warrant holders..................................      962,833          2.9  
                                                               ----------       ------  
          Total.............................................   32,795,114        100.0% 

 The Eclipsys options used in these calculations have a weighted average
exercise price of $4.91 per share and the Eclipsys warrants have an exercise    
price of $0.01 per share. The TSI options have a                                

 2

S-4
11th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 11th

weighted average exercise price of $3.93 per share and the TSI warrants have an 
exercise price of $0.02 per share. These calculations do not reflect outstanding
options of Eclipsys and TSI that become exercisable after December 31, 1998 (in 
the case of Eclipsys, options to purchase an aggregate of 2,025,058 shares of   
Eclipsys Voting Common Stock and, in the case of TSI, options to purchase an    
aggregate of 1,054,283 shares of TSI Voting Common Stock, or the equivalent of  
553,498 shares of Eclipsys Voting Common Stock).                                

   In addition, Eclipsys has agreed, if the merger is completed on or before
March 31, 1999, to permit current TSI employees to apply an aggregate of        
approximately $90,000 of salary deferred under TSI's existing employee stock    
purchase plan to the purchase of Eclipsys Voting Common Stock on March 31, 1999.
This purchase will be at a price per share equal to the lower of $12.75 per     
share or 85% of the market price of Eclipsys Voting Common Stock at that time.  

THE STOCKHOLDERS' MEETINGS (pages 39 and 41)                                    

 The Eclipsys special stockholders' meeting will be held on December 30,
1998 at the Delray Beach Marriott, 10 North Ocean Boulevard, Delray Beach,      
Florida 33444, commencing at 10:00 a.m., local time for the following purpose:  

      - to approve the issuance of shares of Eclipsys Voting Common Stock in
connection with the merger.                                 

    The TSI special stockholders' meeting will be held on December 30, 1998 at
the offices of Foley, Hoag & Eliot LLP, One Post Office Square, 16th Floor,     
Boston Massachusetts 02109, commencing at 10:00 a.m., local time for the        
following purpose:                                                              

- to approve the merger and the merger agreement.               

WHO IS ENTITLED TO VOTE; WHAT VOTE IS REQUIRED                                  

Eclipsys (page 39)                                                          

     You are entitled to vote any shares of Eclipsys Voting Common Stock held by
you at the close of business on November 30, 1998, the record date, at the      
Eclipsys special stockholders' meeting. On the record date, there were          
19,461,642 outstanding shares of Eclipsys Voting Common Stock, each of which    
will be entitled to one vote. Stockholders holding at least a majority of the   
shares present or represented by proxy and voting at the Eclipsys special       
stockholders' meeting must vote in favor of the proposal submitted for approval 
in order for Eclipsys to proceed with the merger.                               

TSI (page 41)                                                               

    You are entitled to vote any shares of TSI Voting Common Stock held by you
at the close of business on November 30, 1998, the record date, at the TSI      
special stockholders' meeting. On the record date, there were 18,047,762        
outstanding shares of TSI Voting Common Stock, each of which will be entitled to
one vote. Stockholders holding at least two-thirds of the outstanding shares of 
TSI must vote to approve the merger and the merger agreement in order for TSI to
proceed with the merger. Holders of TSI Non-Voting Common Stock are entitled to 
notice of the TSI special stockholders' meeting but are not entitled to vote at 
the meeting.                                                                    

VOTING AGREEMENTS (pages 39 and 41)                                             

  Certain stockholders of Eclipsys have agreed to vote the Eclipsys shares
over which they exercise voting control in favor of the issuance of shares of   
Eclipsys Voting Common Stock in connection with the merger in accordance with   
the terms of the merger agreement. Together, these stockholders control         
approximately 53.8% of the shares of Eclipsys Voting Common Stock outstanding on
the record date.                                                                

 3

S-4
12th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 12th

   Certain stockholders of TSI have agreed to vote the TSI shares over which
they exercise voting control in favor of the approval of the merger and the     
merger agreement. Together, these stockholders control approximately 34.4% of   
the shares of TSI Voting Common Stock outstanding on the record date.           

SHARE OWNERSHIP OF MANAGEMENT (page 56)                                         

    On the record date, directors and executive officers of Eclipsys and their
affiliates had voting control over 11,553,707 outstanding shares of Eclipsys    
Voting Common Stock (including the shares covered by the voting agreements      
described above), or approximately 59.4% of the Eclipsys Voting Common Stock    
outstanding on the record date.                                                 

On the record date, directors and executive officers of TSI and their 
affiliates had voting control over 6,296,672 outstanding shares of TSI Voting   
Common Stock (including the shares covered by the voting agreements described   
above), or approximately 34.9% of the TSI Voting Common Stock outstanding on the
record date.                                                                    

  The directors and executive officers of each company have indicated that
they intend to vote the Eclipsys Voting Common Stock or TSI Voting Common Stock 
owned by them in favor of the proposals submitted for approval at the special   
stockholders' meetings.                                                         

NEW TSI DESIGNATED DIRECTORS (page 92)                                          

   If the merger is completed, Robert F. Raco and Patrick T. Hackett, each a
current director of TSI, will become directors of Eclipsys. Mr. Raco will have a
term ending with the annual stockholders' meeting of Eclipsys to be held in 1999
and Mr. Hackett will have a term ending with the annual stockholders' meeting of
Eclipsys to be held in 2000. There will be a total of nine directors of Eclipsys
after the merger.                                                               

RECOMMENDATIONS OF THE BOARDS OF DIRECTORS (page 45)                            

Eclipsys                                                                    

    The Board of Directors of Eclipsys believes that the merger is fair and is
in the best interests of the stockholders of Eclipsys. Therefore, the Board of  
Directors of Eclipsys recommends that the Eclipsys stockholders vote in favor of
the issuance of shares of Eclipsys Voting Common Stock in connection with the   
merger.                                                                         

TSI                                                                         

  The Board of Directors of TSI believes that the merger is fair and is in
the best interests of the stockholders of TSI. Therefore, TSI's Board of        
Directors recommends that the TSI stockholders vote to approve the merger and   
the merger agreement.                                                           

OPINIONS OF FINANCIAL ADVISORS (page 48)                                        

In deciding to approve the merger, the Eclipsys Board of Directors    
considered the opinion of Morgan Stanley & Co. Incorporated that the exchange   
ratio was, as of the date of the opinion, fair to Eclipsys from a financial     
point of view.                                                                  

The TSI Board of Directors received and considered the opinion of its 
financial advisor, BT Alex. Brown Incorporated, that the exchange ratio was, as 
of the date of the opinion, fair, from a financial point of view, to the holders
of TSI Voting and Non-Voting Common Stock.                                      

Morgan Stanley & Co. Incorporated and BT Alex. Brown Incorporated gave
these opinions subject to certain important qualifications and assumptions.     
These opinions are attached as Annex B and Annex C to this document. Holders of 
Eclipsys Voting Common Stock and TSI Voting and Non-Voting Common Stock should  
read these opinions carefully.                                                  

 4

S-4
13th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 13th

INTERESTS OF CERTAIN PERSONS IN THE MERGER (page 56)                            

    Several directors, executive officers and a significant stockholder of TSI
have interests in the merger that may differ from the interests of other TSI    
stockholders:                                                                   

    - two directors of TSI, Robert F. Raco and Patrick T. Hackett, will become
members of the Eclipsys Board of Directors after the merger;      

 - Eclipsys has agreed to continue certain indemnification and insurance
      arrangements for existing and former directors and officers of TSI after
the merger; and                                                   

- Eclipsys will grant certain registration rights to a significant    
stockholder of TSI.                                               

ANTICIPATED CLOSING OF THE MERGER                                               

We currently anticipate that the merger will be closed by December 31,
1998.                                                                           

CONDITIONS TO THE MERGER (page 75)                                              

  Eclipsys and TSI will complete the merger only if certain conditions are
either satisfied or (in some cases) waived. These conditions include, among     
other things:                                                                   

- the merger and the merger agreement have been approved by the TSI   
stockholders;                                                     

     - the issuance of shares of Eclipsys Voting Common Stock in connection with
the merger has been approved by the Eclipsys stockholders;        

   - the total number of shares of TSI Voting and Non-Voting Common Stock as
   to which appraisal rights have been perfected (see "Appraisal Rights"
    below) is not more than 5% of all outstanding shares of TSI Voting and
Non-Voting Common Stock;                                          

- no governmental agency or court has prohibited consummation of the  
merger;                                                           

  - counsel to Eclipsys has delivered an opinion to Eclipsys in respect of
      certain federal income tax consequences of the merger and counsel to TSI
has delivered a similar opinion to TSI;                           

  - the independent accountants for both Eclipsys and TSI have delivered a
     letter to each company stating that they are not aware of any condition
     that would preclude the merger from qualifying for pooling-of-interests
accounting treatment; and                                         

   - there is no material adverse change in the financial condition, results
   of operations, cash flows, business or properties with respect to the
 other company (the companies have agreed that the failure of either
    company to achieve any level of revenue and earnings at any time shall
not of itself be such a material adverse change).                 

TERMINATION OF THE MERGER AGREEMENT (page 77)                                   

     Eclipsys and TSI can jointly agree to terminate the merger agreement at any
time without completing the merger. In addition, either company can terminate   
the merger agreement if:                                                        

- the merger is not completed by April 30, 1999;                      

- a governmental authority or legal action permanently prohibits the  
merger;                                                           

    - the stockholders of the other company do not vote the required number of
shares in favor of the proposals submitted for their approval;    

  - the other company breaches any of its representations or warranties or
       its obligations under the merger agreement, resulting in the inability to
    satisfy a condition to the completion of the merger, if such breach is
not cured within 20 business days; or                             

  - the other company's board of directors withdraws or adversely modifies
   its recommendation to its stockholders or recommends or announces its
     intention to engage in a designated alternative transaction or fails to
hold its special stockholders' meeting.                           

In addition, TSI may terminate the merger agreement if its Board of   
Directors recommends, accepts or approves a proposal for an alternative         
transaction that is more favorable to the TSI stockholders.                     

 5

S-4
14th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 14th

Under certain circumstances, in the event that the merger agreement is
terminated, TSI or Eclipsys may be required to reimburse the other company for  
actual expenses up to $2.0 million or to pay to the other company a termination 
fee of $9.1 million.                                                            

APPRAISAL RIGHTS (page 59)                                                      

   TSI stockholders who vote against the merger and the merger agreement and
who make a specified written filing with TSI prior to the TSI special           
stockholders' meeting are entitled under Massachusetts law to seek an appraisal 
of the fair value of their shares. No shares held by these stockholders will be 
converted into shares of Eclipsys Voting Common Stock as part of the merger. If 
a TSI stockholder has not properly notified TSI prior to the stockholder vote at
the TSI special stockholders' meeting or has withdrawn the demand for appraisal,
that stockholder's shares will be converted into shares of Eclipsys Voting      
Common Stock in accordance with the terms of the merger agreement.              

    Under Delaware law, Eclipsys stockholders are not entitled to an appraisal
of the value of their shares in connection with the merger.                     

REGULATORY APPROVALS (page 58)                                                  

     Eclipsys and TSI have each filed the notification and report forms required
by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with   
the Antitrust Division of the Department of Justice and the Federal Trade       
Commission. We were granted early termination of the waiting period under that  
Act on November 24, 1998.                                                       

ACCOUNTING TREATMENT (page 57)                                                  

    We expect that the merger will be accounted for as a pooling of interests,
which provides that the companies be treated as if they had always been combined
for accounting and financial reporting purposes. Both Eclipsys and TSI will     
obtain from their independent accountants a letter stating that, as of the date 
of the letter, they are not aware of any condition that would preclude the      
merger from qualifying for pooling-of-interests accounting treatment.           

FEDERAL INCOME TAX CONSIDERATIONS (page 57)                                     

     Eclipsys and TSI will each receive from its outside counsel an opinion that
the merger will constitute a "reorganization" within the meaning of the Internal
Revenue Code. This means that, as a general matter, TSI stockholders will not be
taxed as a result of the exchange of TSI Voting and Non-Voting Common Stock     
solely for Eclipsys Voting Common Stock in the merger. TSI stockholders will be 
taxed to the extent they receive cash for fractional shares.                    

Eclipsys stockholders will not be taxed as a result of the merger.    

SURRENDER OF STOCK CERTIFICATES (page 71)                                       

     When the merger is completed, Eclipsys will mail a notice and a transmittal
form to all holders of record of TSI Voting and Non-Voting Common Stock         
immediately prior to the merger. The notice will contain instructions for       
surrendering the certificates representing TSI Voting or Non-Voting Common Stock
in exchange for certificates representing shares of Eclipsys Voting Common Stock
and a cash payment in lieu of fractional shares, if any.                        

     YOU SHOULD NOT SURRENDER STOCK CERTIFICATES UNTIL YOU RECEIVE THE LETTER OF
TRANSMITTAL.                                                                    

CERTAIN EFFECTS OF THE MERGER ON THE RIGHTS OF TSI STOCKHOLDERS (page 112)      

    When the merger is completed, TSI stockholders will become stockholders of
Eclipsys. Eclipsys is a company governed by Delaware law and Eclipsys' existing 
charter and bylaws. As a result, the rights of TSI stockholders will change with
respect to certain matters.                                                     

 6

S-4
15th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 15th

FORWARD-LOOKING STATEMENTS MAY PROVE INACCURATE (page 119)                      

We have each made forward-looking statements in this document that are
subject to risks and uncertainties. Forward-looking statements include          
information concerning possible or assumed future results of operations of      
Eclipsys and TSI. Also, when we use words such as "believes," "expects,"        
"anticipates," or similar expressions, we are making forward-looking statements.
You should note that many factors, some of which are discussed elsewhere in this
document, including under the caption "Risk Factors" and, in the case of TSI, in
the documents incorporated by reference, could affect the future financial      
results of Eclipsys and TSI and could cause those results to differ materially  
from those expressed in any forward-looking statements contained in or          
incorporated by reference in this document.                                     

EXPLANATION OF CERTAIN TERMS                                                    

We have used the following defined terms throughout this document:    

- We refer to Eclipsys Corporation as "Eclipsys."                     

- We refer to Transition Systems, Inc. as "TSI."                      

  - We refer to Exercise Acquisition Corp., the wholly owned subsidiary of
Eclipsys that will merge with TSI, as "Sub."                      

     - We refer to the proposed merger of Sub with and into TSI as the "Merger."

    - TSI will be the surviving corporation in the Merger with Sub and will be
  a wholly owned subsidiary of Eclipsys after the Merger. We sometimes
refer to TSI, in that capacity after the Merger, as the "Surviving
Corporation."                                                     

    - We refer to the agreement dated October 29, 1998 among Eclipsys, Sub and
TSI relating to the Merger as the "Merger Agreement."             

  - Eclipsys has two classes of common stock: Common Stock, $.01 par value
  per share, and Non-Voting Common Stock, $.01 par value per share. We
refer to these respectively as "Eclipsys Voting Common Stock" and 
     "Eclipsys Non-Voting Common Stock." Sometimes we refer to them together
as "Eclipsys Voting and Non-Voting Common Stock."                 

  - TSI also has two classes of common stock: Common Stock, $.01 par value
  per share, and Non-Voting Common Stock, $.01 par value per share. We
refer to these respectively as "TSI Voting Common Stock" and "TSI 
   Non-Voting Common Stock." Sometimes we refer to them together as "TSI
Voting and Non-Voting Common Stock."                              

- We refer to the per-share exchange ratio by which each share of TSI 
       Voting and Non-Voting Common Stock will be converted into 0.525 shares of
 Eclipsys Voting Common Stock in the Merger as the "Exchange Ratio."

    For an index of other defined terms used in this document, please see page
120.                                                                            

 7

S-4
16th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 16th

RISK FACTORS

As a stockholder of Eclipsys or TSI, you should carefully consider the
following risk factors in determining whether to vote in favor of the proposals 
submitted for approval at the respective special stockholders' meetings. You    
should consider these matters together with the other information included and  
incorporated by reference in this document.                                     

DIFFICULTY OF INTEGRATING ECLIPSYS AND TSI OPERATIONS                           

   Integrating the operations of Eclipsys with those of TSI and HealthVISION
after the Merger will be difficult and time consuming. Management of the        
combined company will need to successfully integrate, among other things, the   
product offerings, the product development, sales and marketing and customer    
service functions, and the management information systems of both companies. In 
addition, the combined company will need to retain the management, key          
employees, customers, distributors, vendors and other business partners of both 
companies. The integration of these organizations may temporarily distract      
management from the day-to-day business of the combined company following the   
Merger. The combined company may fail to manage this integration so as to       
achieve any of the anticipated synergies and other benefits that both companies 
hope to achieve from the Merger.                                                

POTENTIALLY SIGNIFICANT INTEGRATION COSTS AND CHARGES                           

     Eclipsys expects to incur restructuring and integration costs in connection
with the integration of the operations of Eclipsys and TSI. These costs may     
include costs for employee severance and other compensation charges, facilities 
closures, relocation, discontinuance of overlapping products and other          
merger-related costs. Eclipsys has not yet determined the amount of these costs.
Eclipsys expects to charge such costs to operations in the quarter in which the 
Merger is completed.                                                            

POSSIBLE DILUTION IN PER-SHARE EARNINGS                                         

The combination of the two companies' businesses will not necessarily 
result in increased per-share earnings of Eclipsys after the Merger (taking into
consideration the greater number of Eclipsys shares to be outstanding as a      
result of the Merger) or a financial condition superior to that which would have
been achieved by Eclipsys or TSI on a stand-alone basis. Eclipsys does not      
anticipate that the Merger will dilute the earnings per share of its            
stockholders, although TSI does anticipate that the Merger will have such an    
effect for its stockholders. The Merger could fail to produce the benefits both 
companies anticipate, or could have other adverse effects that neither company  
currently foresees. In this event, the Merger could result in a reduction of    
per-share earnings of Eclipsys following the Merger as compared to the per-share
earnings that would have been achieved if the Merger had not occurred.          

FIXED EXCHANGE RATIO DESPITE POTENTIAL SHARE PRICE FLUCTUATIONS                 

     The Exchange Ratio was fixed at 0.525 at the time Eclipsys and TSI executed
the Merger Agreement. The Exchange Ratio is not subject to adjustment. Any      
increase or decrease of the market price of the shares of Eclipsys Voting Common
Stock will correspondingly increase or decrease the value of the merger         
consideration to be received by the holders of TSI Voting and Non-Voting Common 
Stock in the Merger. In addition, neither company will have the right to        
terminate the Merger Agreement or elect not to consummate the Merger as a result
of changes in the market prices of either company's common stock. The relative  
market prices of shares of Eclipsys Voting Common Stock and shares of TSI Voting
Common Stock at the time the Merger is completed may vary significantly from    
their prices on the date the Merger Agreement was executed, the date hereof or  
the date on which the special stockholders' meetings occur. These potential     
fluctuations could result from changes in the business, operations, and         
prospects of Eclipsys or TSI, from market assessments of the Merger, of the     
synergies expected to be achieved in the Merger and of the likelihood that the  
Merger will be completed, and from general market and economic conditions and   
other factors.                                                                  

 8

S-4
17th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 17th

LIMITED OPERATING HISTORY OF ECLIPSYS; HISTORY OF OPERATING LOSSES              

    Eclipsys began operations in 1996 and has grown primarily through a series
of acquisitions completed since January 1997. Accordingly, you have only a      
limited combined operating history of Eclipsys and its acquired operations upon 
which to base an evaluation of Eclipsys and its prospects. In addition to       
managing the integration with TSI, Eclipsys will need to continue to integrate  
the operations of these other acquired businesses and to consolidate their      
product offerings.                                                              

Eclipsys has incurred net losses in each year since its inception,    
including net losses of $131.1 million in 1997 and $16.8 million in the first   
nine months of 1998. These losses resulted primarily from certain write-offs    
related to acquisitions completed by Eclipsys during 1997 and charges in the    
first quarter of 1998 related to the buyout by Eclipsys of certain obligations  
under an agreement entered into in connection with one of the acquisitions.     
Eclipsys expects to continue to incur net losses for the foreseeable future.    
Eclipsys cannot predict when or if it will achieve profitability.               

MANAGEMENT OF GROWTH                                                            

The rapid growth in the size and complexity of Eclipsys' business as a
result of its previous acquisitions has placed a significant strain on Eclipsys'
management and other resources. The difficulties faced by the combined company  
in managing its growth will become more acute following the Merger. To compete  
effectively and to manage future growth, if any, the combined company will need 
to continue to implement and improve operational and financial systems on a     
timely basis and to expand, train, motivate and manage its work force. The      
combined company's personnel, systems, procedures and controls may not be       
adequate to support its operations.                                             

RISKS ASSOCIATED WITH FUTURE ACQUISITIONS                                       

An important element of Eclipsys' business strategy has been expansion
through acquisitions. Eclipsys expects the combined company will continue this  
strategy after the Merger. This acquisition strategy involves a number of risks,
which include:                                                                  

 - There is significant competition for acquisition opportunities in the
       healthcare information technology industry. Competition may intensify due
 to consolidation in the industry, which could increase the costs of
    future acquisitions. The combined company will compete for acquisition
      opportunities with other companies, some of which may have significantly
   greater financial and management resources than the combined company.

    - The anticipated benefits from any acquisition may not be achieved unless
    the operations of the acquired business are successfully combined with
   those of the combined company. The integration of acquired businesses
  requires substantial attention from management. The diversion of the
attention of management and any difficulties encountered in the   
transition process could hurt the combined company.               

    - Future acquisitions could result in the issuance of additional shares of
      capital stock or the incurrence of additional indebtedness, could entail
   the payment of consideration in excess of book value and could have a
dilutive effect on the combined company's net income per share.   

- Many business acquisitions must be accounted for under the purchase 
method of accounting. Consequently, such acquisitions may generate
       significant goodwill or other intangible assets and result in substantial
   amortization charges to the combined company. Acquisitions could also
      involve significant charges reflecting write-offs of acquired in-process
      research and development. As a result of previous acquisitions, Eclipsys
      recorded amortization expenses for acquisition-related intangible assets
of $25.3 million in 1997 and wrote off $99.2 million of in-process
       research and development. As a result of the acquisition of HealthVISION,
TSI expects to write off approximately $2.5 million of in-process 
research and development.                                         

 9

S-4
18th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 18th

POTENTIAL FLUCTUATIONS IN QUARTERLY PERFORMANCE                                 

   Both Eclipsys and TSI have experienced significant variations in revenues
and operating results from quarter to quarter. The quarterly operating results  
of the combined company following the Merger may continue to fluctuate due to a 
number of factors, including:                                                   

  - potential deferrals of sales resulting from customer concerns over the
Year 2000 issue;                                                  

- the timing and size of future acquisitions;                         

   - the timing, size and nature of the combined company's product sales and
implementations;                                                  

- the length of the sales cycle;                                      

- the success of implementation efforts;                              

  - market acceptance of new services, products or product enhancements by
the combined company or its competitors;                          

- product and price competition;                                      

  - the relative proportions of revenues derived from systems and services
and from hardware;                                                

- changes in operating expenses;                                      

- personnel changes;                                                  

- the performance of the combined company's products; and             

- fluctuations in economic and financial market conditions.           

It is difficult to predict the timing of revenues from product sales  
because the sales cycle can vary depending upon several factors. These factors  
include the size of the transaction, the changing business plans of the         
customer, the effectiveness of the customer's management and general economic   
conditions. In addition, because revenue is recognized at various points during 
the term of a contract, the timing of revenue recognition varies considerably.  
Factors affecting the timing of revenue recognition include the type of         
contract, the availability of personnel, the implementation schedule and the    
complexity of the implementation process.                                       

     Because a significant percentage of the combined company's expenses will be
relatively fixed, a variation in the timing of sales and implementations could  
cause significant variations in operating results from quarter to quarter.      

    Neither Eclipsys nor TSI believes that period-to-period comparisons of its
historical results of operations are necessarily meaningful. You should not rely
on these comparisons as indicators of future performance.                       

LONG SALES AND IMPLEMENTATION CYCLES                                            

Both Eclipsys and TSI have experienced long sales and implementation  
cycles. These cycles will likely be just as long for the combined company. How  
and when to implement, replace, expand or substantially modify an information   
system, or modify or add business processes or lines of business, are major     
decisions for customers. Furthermore, the purchase of solutions like those      
provided by Eclipsys and TSI typically require significant capital expenditures 
by the customer. The sales cycle for Eclipsys' systems has ranged from six to 18
months or more from initial contact to contract execution. The sales cycle for  
new TSI accounts typically ranges from six to 12 months or more. Historically,  
Eclipsys' implementation cycle has ranged from 12 to 36 months from contract    
execution to completion of implementation and TSI's implementation cycle has    
ranged from three to 12 months. Although Eclipsys believes that the migration of
its products to its new SOLA architecture will significantly shorten the        
implementation cycle, Eclipsys cannot provide any assurance in this regard.     
During the sales cycle and the implementation cycle,                            

10

S-4
19th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 19th

the combined company will expend substantial time, effort and funds preparing   
contract proposals, negotiating the contract and implementing the solution.     

RISKS ASSOCIATED WITH DEVELOPMENT BY ECLIPSYS OF INTEGRATED CLINICAL MANAGEMENT 
SUITE                                                                           

   Eclipsys is currently in the process of integrating selected features and
functionalities from a number of heritage clinical management products acquired 
in its previous acquisitions and licensed from Partners HealthCare Systems, Inc.
("Partners") to create the Sunrise Clinical Management suite. See "Business of  
Eclipsys." This product suite is currently undergoing field trials. Although    
most of the key functionalities of the Sunrise Clinical Management suite are    
currently available in heritage products, Eclipsys does not expect the          
integrated Sunrise Clinical Management suite to be generally available until    
1999. Eclipsys may not be successful in completing the integration of these     
functionalities on a timely basis. In addition, the field trials may not be     
successful and the Sunrise Clinical Management suite, if and when generally     
available, may not meet the needs of the marketplace or achieve market          
acceptance.                                                                     

COMPETITION                                                                     

The combined company will operate in a market that is intensely       
competitive. The principal competitors of the combined company will include     
Cerner Corp., HBO & Company, IDX Systems Corp. and Shared Medical Systems       
Corporation ("SMS"). The combined company will also face competition from       
providers of practice management systems, general decision support and database 
systems and other segment-specific applications, as well as from healthcare     
technology consultants. A number of existing and potential competitors are more 
established and have greater name recognition and financial, technical and      
marketing resources than will the combined company. Eclipsys and TSI also expect
that competition will continue to increase as a result of consolidation in both 
the information technology and healthcare industries.                           

DEPENDENCE ON RELATIONSHIP WITH PARTNERS AND OTHER THIRD PARTIES                

Eclipsys has an exclusive license granted by Partners to develop,     
commercialize, distribute and support certain intellectual property relating to 
a clinical information systems software developed at Brigham & Women's Hospital 
("Brigham"). If the combined company breaches certain terms of the license,     
Partners has the option to convert the license to a non-exclusive license. Such 
conversion by Partners could cause the intellectual property and the ability to 
develop and commercialize such intellectual property to become more widely      
available to competitors of the combined company. Eclipsys also works closely   
with physicians and research and development personnel at Brigham and its       
affiliate, Massachusetts General Hospital ("MGH"), to develop and commercialize 
new information technology solutions for the healthcare industry and to test and
demonstrate new and existing products. If the combined company breaches the     
Partners license, the cooperative working relationship with Brigham and MGH,    
including future access to products developed by personnel at Brigham granted   
under the Partners license, could become strained or cease altogether. The loss 
of good relations with Brigham or MGH could hurt the ability of the combined    
company to develop new solutions and could cause delays in bringing new products
to the market. In addition, the reputation and status of the combined company in
the industry could be hurt.                                                     

    TSI depends upon licenses for certain technology used in its products from
a number of third-party vendors, including Computer Corporation of America,     
Oracle Corporation and Sterling Software (United States of America), Inc. TSI   
also has licenses from HCIA Inc. and Premier, Inc. for certain database         
management systems and other software components and clinical benchmarking data.
Most of these licenses expire within one to four years, can be renewed only by  
mutual consent and may be terminated if TSI or the combined company breaches the
terms of the license and fails to cure the breach within a specified period of  
time. TSI or the combined company may not be able to continue using the         
technology licensed under these licenses on commercially reasonable terms or at 
all. As a result, TSI or the combined company may have to discontinue, delay or 
reduce product shipments until equivalent technology is obtained, which could   
hurt TSI or the combined company. Most of TSI's third-party licenses, including 
its                                                                             
11

S-4
20th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 20th

license from New England Medical Center, Inc. for the original version of the   
Transition I software, are non-exclusive. The competitors of TSI or the combined
company may obtain the right to use any of the technology covered by the        
licenses and use the technology to directly compete with TSI. In addition, if   
TSI's vendors choose to discontinue to support the licensed technology, TSI may 
not be able to modify or adapt its own products going forward.                  

UNCERTAINTY IN THE HEALTHCARE INDUSTRY                                          

The combined company will operate in an industry subject to changing  
political, economic and regulatory influences. The potential impact of these    
industry changes include:                                                       

- During the past several years, the U.S. healthcare industry has been
     subject to an increase in governmental regulation and reform proposals.
These reforms may increase governmental involvement in healthcare,
       continue to reduce reimbursement rates and otherwise change the operating
       environment for customers of the combined company. Customers may react to
these proposals and the uncertainty surrounding the proposals by  
       curtailing or deferring investments, including those for the products and
services of the combined company.                                 

   - Many healthcare providers are consolidating to create larger healthcare
      delivery enterprises with greater market power. This consolidation could
       erode the customer base of the combined company and could reduce the size
     of its target market. In addition, the resulting enterprises could have
greater bargaining power, which may lead to price erosion.        

POTENTIAL FDA REGULATION                                                        

The U.S. Food and Drug Administration (the "FDA") is likely to become 
increasingly active in regulating computer software intended for use in the     
healthcare setting. The FDA has recently issued a draft guidance document       
addressing the regulation of certain computer products and computer-assisted    
products as medical devices under the Federal Food, Drug, and Cosmetic Act (the 
"FDC Act") and has recently indicated it may modify such draft policy or create 
a new policy. If the FDA chooses to regulate any of the products of the combined
company as medical devices, it can impose extensive requirements upon the       
combined company, including:                                                    

    - the combined company would be required to seek either FDA clearance of a
 premarket notification submission demonstrating that the product is
     substantially equivalent to a device already legally marketed or obtain
      FDA approval of a premarket approval application establishing the safety
and effectiveness of the product;                                 

- the combined company would be required to comply with rigorous      
      regulations governing the preclinical and clinical testing, manufacture,
distribution, labeling and promotion of medical devices; and      

- the combined company would be required to comply with the FDC Act's 
     general controls, including establishment registration, device listing,
       compliance with good manufacturing practices, reporting of certain device
malfunctions and adverse device events.                           

    If the combined company failed to comply with applicable requirements, the
FDA could respond by imposing fines, injunctions or civil penalties, requiring  
recalls or product corrections, suspending production, refusing to grant        
premarket clearance or approval of products, withdrawing clearances and         
approvals, and initiating criminal prosecution. Any final FDA policy governing  
computer products, once issued, may increase the cost and time to market of new 
or existing products.                                                           

NEW REGULATIONS RELATING TO PATIENT CONFIDENTIALITY                             

    State and federal laws regulate the confidentiality of patient records and
the circumstances under which such records may be released. These regulations   
govern both the disclosure and use of confidential                              

12

S-4
21st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 21st

patient medical record information. Regulations governing electronic health data
transmissions are evolving rapidly and are often unclear and difficult to apply.

On August 22, 1996, President Clinton signed the Health Insurance     
Portability and Accountability Act of 1996 ("HIPAA"). This legislation requires 
the Secretary of Health and Human Services (the "Secretary") to adopt national  
standards for certain types of electronic health information transactions and   
the data elements used in such transactions and to adopt standards to ensure the
integrity and confidentiality of health information. The Secretary has recently 
issued proposed standards regarding four of the five sets of standards that are 
ultimately expected. Eclipsys believes that the proposed standards issued to    
date would not materially affect the business of the combined company if adopted
as proposed. Eclipsys cannot predict the potential impact of the standards that 
have not yet been proposed or any other standards that might be finally adopted 
instead of the proposed standards.                                              

     The HIPAA legislation also required the Secretary to submit recommendations
to Congress for legislation to protect privacy and confidentiality of personal  
health information. If Congress fails to enact such legislation by August 21,   
1999, HIPAA requires the Secretary to promulgate such protections by regulation.
Legislation governing the dissemination of medical record information is also   
frequently proposed and debated at the state level. Such legislation, if        
enacted, could require patient consent before even non-individually-identifiable
(e.g., coded or anonymous) patient information may be shared with third parties 
and could also require that holders or users of such information implement      
specified security measures. These laws or regulations, when adopted, could     
restrict the ability of customers to obtain, use or disseminate patient         
information. This could adversely affect demand for the products of the combined
company.                                                                        

YEAR 2000 ISSUES                                                                

   Eclipsys believes that all of its internal management information systems
are currently Year 2000 compliant and, accordingly, does not anticipate any     
significant expenditures to remediate or replace existing internal-use systems. 
Although all of the products currently offered by Eclipsys are Year 2000        
compliant, some of the products previously sold by Alltel and Emtek and         
installed in Eclipsys' customer base are not Year 2000 compliant. Eclipsys has  
developed and tested solutions for these non-compliant installed products.      
Eclipsys currently estimates that the total cost of bringing these installed    
products into Year 2000 compliance, in those cases in which Eclipsys is required
to do so at its own expense, will be approximately $900,000. Eclipsys expects   
that all of this expense will be incurred by mid-1999. In addition, because     
Eclipsys' products are often interfaced with a customer's existing third-party  
applications, Eclipsys' products may experience difficulties interfacing with   
third-party non-compliant applications. Based on currently available            
information, Eclipsys does not expect the cost of compliance related to         
interactions with non-compliant third-party systems to be material. However, any
unexpected difficulties in implementing Year 2000 solutions for the installed   
Alltel or Emtek products or difficulties in interfacing with third-party        
products could hurt the combined company.                                       

   TSI's software license agreements generally contain warranties concerning
the Year 2000 compliance of the licensed product. TSI has tested the products it
has developed internally and believes that, with the exception of its Transition
for Quality product (for which TSI expects to release a fully Year 2000         
compliant version in early 1999), the current release of each of its internally 
developed products is Year 2000 compliant. TSI includes in its products certain 
software licensed from third-party vendors. TSI has not yet completed its       
evaluation of the Year 2000 compliance of all such third-party software. For    
example, TSI has not yet verified that Uniface, licensed from Compuware         
Corporation, is Year 2000 compliant. In order to use TSI's products, customers  
must themselves license software, including certain operating system and        
database management system software, from third-party vendors such as Microsoft 
Corporation and Oracle Corporation. Not all such third-party software may be    
fully Year 2000 compliant. For example, Microsoft Corporation has not certified 
that its Windows NT operating system is Year 2000 compliant. TSI has also       
evaluated the Year 2000 compliance of its critical internal software systems,   
including its financial, payroll and human resources systems and its telephone  
switch, and believes, based in part on certification from the vendors of such   
systems, that such systems are Year 2000 compliant. TSI                         
13

S-4
22nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 22nd

does not expect to incur material costs in completing its Year 2000 assessment  
and remediation program. However, the discovery of previously undetected Year   
2000 defects in TSI's products (including those licensed from third-party       
vendors), in third-party software required for customers to use TSI's products  
or in its internal software systems could damage TSI's business and hurt the    
combined company.                                                               

   Apprehension in the marketplace over Year 2000 compliance issues may lead
businesses, including customers of the combined company, to defer significant   
capital investments in information technology programs and software. They could 
elect to defer those investments either because they decide to focus their      
capital budgets on the expenditures necessary to bring their own existing       
systems into compliance or because they wish to purchase only software with a   
proven ability to process data after 1999. If these deferrals are significant,  
the combined company may not achieve expected revenue or earnings levels.       

POTENTIAL FOR PRODUCT LIABILITY; SECURITY ISSUES                                

 Both TSI and Eclipsys provide products with applications that relate to
patient medical histories and treatment plans. If these products fail to provide
accurate and timely information, customers could assert liability claims against
the combined company. Both companies attempt to contractually limit their       
liability for damages arising from negligence, errors or mistakes. Despite this 
precaution, the limitations of liability set forth in these contracts may not be
enforceable or may not otherwise protect the combined company from liability for
damages. The combined company will maintain general liability insurance         
coverage, including coverage for errors or omissions. However, such coverage may
not continue to be available on acceptable terms or may not be available in     
sufficient amounts to cover one or more large claims. In addition, the insurer  
might disclaim coverage as to any future claim. One or more large claims could  
exceed available insurance coverage. Litigation with respect to liability       
claims, regardless of its outcome, could result in substantial cost to the      
combined company, could divert management's attention from operations and could 
decrease market acceptance of the combined company's products.                  

   Both companies have included security features in their products that are
intended to protect the privacy and integrity of customer data. Despite the     
existence of these security features, these products may be vulnerable to       
break-ins and similar disruptive problems. Break-ins and other disruptions could
jeopardize the security of information stored in and transmitted through the    
computer systems of customers. The combined company may need to expend          
significant capital and other resources to address evolving security issues.    

CONTROL BY DIRECTORS AND OFFICERS                                               

Executive officers and directors of the combined company, and their   
affiliates, will beneficially own approximately 51.5% of the outstanding        
Eclipsys Voting Common Stock following completion of the Merger. These          
stockholders, if acting together, would have the ability to elect Eclipsys'     
directors and to determine the outcome of corporate actions requiring           
stockholder approval, regardless of how other stockholders of Eclipsys may vote.
They might also be able to delay or prevent a change in control of the combined 
company.                                                                        

ANTI-TAKEOVER PROVISIONS                                                        

Eclipsys' charter and by-laws contain certain provisions, including a 
staggered Board of Directors, that could make it more difficult for a third     
party to acquire, and could therefore discourage a third party from attempting  
to acquire, control of Eclipsys. These provisions could limit the price that    
certain investors might be willing to pay in the future for shares of Eclipsys  
Voting Common Stock. In addition, certain provisions of Delaware corporate law  
applicable to Eclipsys could have the effect of delaying, deferring or          
preventing a change in control of Eclipsys.                                     

14

S-4
23rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 23rd

OTHER RISKS                                                                     

The combined company will face a variety of other risks typically     
encountered by technology and software companies. Among other things:           

- The combined company will need to continue to attract, motivate and 
retain highly qualified employees.                                  

  - The combined company will operate in a market characterized by rapidly
changing technology, industry standards and customer requirements.  
Existing products may quickly become obsolete or uncompetitive.     

 - The means utilized by the combined company to protect its proprietary
 technology may not be adequate to prevent misappropriation by others.

- Third parties could assert that the products of the combined company
infringe their proprietary rights. This could result in significant 
 defense costs and, ultimately, in injunctions preventing the combined
company from distributing certain products.                         

  - The software products of the combined company could contain undetected
errors. This could result in product delays, remediation costs and  
decreased market acceptance and customer satisfaction.              

 - The trading price of the Eclipsys Voting Common Stock could be highly
volatile after the merger, including volatility unrelated to the    
particular performance of the combined company.                     

15

S-4
24th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 24th

MARKET PRICE INFORMATION

   The principal trading market for the Eclipsys Voting Common Stock and for
the TSI Voting Common Stock is the Nasdaq National Market. Eclipsys Voting      
Common Stock has been quoted on the Nasdaq National Market under the symbol     
"ECLP" since August 7, 1998. TSI Voting Common Stock has been quoted on the     
Nasdaq National Market under the symbol "TSIX" since April 18, 1996.            

 The following tables set forth the reported high and low sale prices of
Eclipsys Voting Common Stock and TSI Voting Common Stock on the Nasdaq National 
Market for the periods indicated.                                               

                                                                [Download Table]

                                                               HIGH     LOW  
                                                              ------   ------
                                                                             
ECLIPSYS                                                                     
Year Ending December 31, 1998:                                               
  Third Quarter (from August 7, 1998).......................  $23.38   $11.88
  Fourth Quarter (through December 2, 1998).................   26.25    18.38

TSI                                                                          
Fiscal Year Ended September 30, 1997:                                        
  First Quarter.............................................  $22.00   $ 8.25
  Second Quarter............................................   16.63    11.75
  Third Quarter.............................................   18.25     9.00
  Fourth Quarter............................................   21.75    16.88
Fiscal Year Ended September 30, 1998:                                        
  First Quarter.............................................  $23.88   $17.75
  Second Quarter............................................   24.88    17.38
  Third Quarter.............................................   24.25     9.94
  Fourth Quarter............................................   13.25     6.38
Fiscal Year Ending September 30, 1999:                                       
  First Quarter (through December 2, 1998)..................  $12.00   $ 5.50

   On October 28, 1998, the last full trading day prior to the execution and
delivery of the Merger Agreement and the public announcement thereof, the       
reported high and low sale prices on the Nasdaq National Market of Eclipsys     
Voting Common Stock were $26.25 and $24.88, respectively, and of TSI Voting     
Common Stock were $9.31 and $8.63, respectively. On such date, the last reported
sale price on the Nasdaq National Market of Eclipsys Voting Common Stock was    
$25.88 per share and of TSI Voting Common Stock was $8.63 per share. Based on   
the Exchange Ratio of 0.525 shares of Eclipsys Voting Common Stock for each     
share of TSI Voting Common Stock, the equivalent per-share value of TSI Voting  
Common Stock on October 28, 1998 was $13.58 per share.                          

     On December 2, 1998, the most recent practicable date prior to the printing
of this Joint Proxy Statement/Prospectus, the last reported sale price on the   
Nasdaq National Market of Eclipsys Voting Common Stock was $22.50 per share and 
of TSI Voting Common Stock was $11.38 per share, and the equivalent per-share   
value of TSI Voting Common Stock was $11.81 per share.                          

Because the market price of Eclipsys Voting Common Stock is subject to
fluctuation and the Exchange Ratio is fixed, the market value of the shares of  
Eclipsys Voting Common Stock that TSI stockholders will receive in the Merger   
may increase or decrease prior to the Merger.                                   

Eclipsys and TSI stockholders are urged to obtain a current market    
quotation for the Eclipsys Voting Common Stock and the TSI Voting Common Stock. 

16

S-4
25th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 25th

SELECTED CONSOLIDATED FINANCIAL DATA FOR ECLIPSYS 

     The selected consolidated financial data of Eclipsys set forth below should
be read in conjunction with "Management's Discussion and Analysis of Financial  
Condition and Results of Operations of Eclipsys" and the financial statements   
and notes thereto included elsewhere in this document. The statement of         
operations data for the years ended December 31, 1996 and 1997 and the balance  
sheet data at December 31, 1996 and 1997, under the heading "Eclipsys" set forth
below, are derived from, and are qualified by reference to, Eclipsys' audited   
consolidated financial statements, which appear elsewhere in this document.     
Statement of operations data for the years ended December 31, 1995 and 1996,    
under the heading "Predecessor," are derived from, and are qualified by         
reference to, the ALLTEL Healthcare Information Services, Inc. ("Alltel")       
audited financial statements, which appear elsewhere in this document. The      
financial data for the year ended and at December 31, 1994 are derived from     
audited financial statements of Alltel not included in this document. The       
financial data for the year ended and at December 31, 1993 are derived from     
unaudited financial statements of Alltel not included in this document. The     
statement of operations data for the nine months ended September 30, 1997 and   
1998 and the balance sheet data at September 30, 1998 are derived from, and are 
qualified by reference to, Eclipsys' unaudited consolidated financial           
statements, which appear elsewhere in this document and, in the opinion of      
management, include all adjustments (consisting only of normal recurring        
adjustments) necessary to present fairly the financial data for such periods.   
The results of operations for the nine months ended September 30, 1998 are not  
necessarily indicative of the results to be expected for the full year or for   
any future period.                                                              

                                                        [Enlarge/Download Table]

                                                                                                     NINE MONTHS ENDED   
                                                  YEAR ENDED DECEMBER 31,                              SEPTEMBER 30,     
                              ---------------------------------------------------------------      --------------------- 
                                            PREDECESSOR                                     ECLIPSYS                     
                              ---------------------------------------   ------------------------------------------------ 
                               1993      1994       1995       1996       1996       1997(1)        1997(1)     1998(1)  
                              -------   -------   --------   --------   ---------   ---------      ---------   --------- 
                                                          (IN THOUSANDS, EXCEPT SHARE DATA)                              
                                                                                                                         
STATEMENT OF OPERATIONS                                                                                                  
  DATA:                                                                                                                  
Total revenues..............  $74,136   $80,204   $100,114   $108,800   $      --   $  94,077      $  67,479   $  97,743 
                              -------   -------   --------   --------   ---------   ---------      ---------   --------- 
Costs and expenses:                                                                                                      
  Cost of revenues..........   44,209    48,692     61,335     71,483          --      80,036         58,223      61,021 
  Marketing and sales.......   13,082    12,541     11,128     11,091         770      13,662          9,881      13,945 
 Research and development...   10,596    10,186      8,522     10,271       1,704(2)    15,714        11,991      19,267 
  General and administrative.   7,215     7,898      8,168      7,101         603       5,672          4,143       4,580 
  Depreciation and                                                                                                       
    amortization............    3,032     3,788      6,735      8,135          32       9,710          7,292       7,937 
  Write-off of in-process                                                                                                
    research and                                                                                                         
    development(3)..........       --        --         --         --          --      99,189         99,189          -- 
  Write-off of MSA(4).......       --        --         --         --          --          --             --       7,193 
                              -------   -------   --------   --------   ---------   ---------      ---------   --------- 
    Total costs and                                                                                                      
      expenses..............   78,134    83,105     95,888    108,081       3,109     223,983        190,719     113,943 
                              -------   -------   --------   --------   ---------   ---------      ---------   --------- 
Income (loss) from operations...  (3,998)  (2,901)    4,226       719      (3,109)   (129,906)      (123,240)    (16,200)
Interest expense (income),                                                                                               
  net.......................      983     1,324      2,733      3,758        (156)      1,154            727         628 
                              -------   -------   --------   --------   ---------   ---------      ---------   --------- 
Income (loss) before income                                                                                              
  taxes.....................   (4,981)   (4,225)     1,493     (3,039)     (2,953)   (131,060)      (123,967)    (16,828)
Income tax benefit                                                                                                       
  (provision)(5)............       --     1,373       (887)       843          --          --             --          -- 
                              -------   -------   --------   --------   ---------   ---------      ---------   --------- 
Net income (loss)...........   (4,981)   (2,852)       606     (2,196)     (2,953)   (131,060)      (123,967)    (16,828)
Dividends and accretion on                                                                                               
  mandatorily Redeemable                                                                                                 
  Preferred Stock...........       --        --         --         --          --      (5,850)        (4,199)    (10,928)
Preferred stock conversion(6)...      --      --        --         --          --      (3,105)        (3,105)         -- 
                              -------   -------   --------   --------   ---------   ---------      ---------   --------- 
Net income (loss) available                                                                                              
  to common shareholders....  $(4,981)  $(2,852)  $    606   $ (2,196)  $  (2,953)  $(140,015)     $(131,271)  $ (27,756)
                              =======   =======   ========   ========   =========   =========      =========   ========= 
Basic and diluted net loss                                                                                               
  per common share(7).......                                            $    (.98)  $  (39.73)     $  (38.28)  $   (3.41)
Weighted average common                                                                                                  
  shares outstanding(7).....                                            3,022,660   3,524,313      3,429,385   8,133,275 
OTHER DATA:                                                                                                              
EBITDA(8)...................                                                        $     905      $     895   $  11,148 
Net cash provided by                                                                                                     
  operating activities......                                                            1,068          3,292      15,176 
Net cash used by investing                                                                                               
  activities................                                                         (113,670)      (111,778)    (27,824)
Net cash provided by                                                                                                     
  financing activities......                                                          112,771        113,764      20,138 

17

S-4
26th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 26th

                                                        [Enlarge/Download Table]

                                                                                                              AS OF    
                                                               AS OF DECEMBER 31,                         SEPTEMBER 30,
                                          -------------------------------------------------------------   -------------
                                                         PREDECESSOR                              ECLIPSYS             
                                          -----------------------------------------   ---------------------------------
                                            1993       1994       1995       1996      1996      1997         1998     
                                          --------   --------   --------   --------   ------   --------   -------------
                                                                         (IN THOUSANDS)                                
                                                                                                                       
BALANCE SHEET DATA:                                                                                                    
Cash and cash equivalents................ $  2,808   $  1,672   $  2,599   $  2,022   $4,589   $  4,786     $ 12,309   
Working capital (deficit)................   (4,756)    (8,561)    (3,923)    (9,558)   3,956    (31,504)      (8,574)  
Total assets.............................   56,411     70,338     88,381    100,443    5,740    106,765      121,691   
Debt, including current portion..........    1,983        810        260         86       --     16,588           --   
Mandatorily Redeemable Preferred Stock...       --         --         --         --       --     35,607           --   
Shareholders' equity (deficit)...........  (29,310)   (23,633)   (23,011)   (25,387)   4,801    (18,321)      38,567   

---------------                                                                 

(1) The acquisitions of Alltel (the "Alltel Acquisition"), SDK Medical Computer 
   Services Corporation ("SDK") (the "SDK Acquisition") and the North American
operations of the Emtek Healthcare Systems division of Motorola, Inc.   
    ("Emtek") in January 1998 (the "Emtek Acquisition") were accounted for using
the purchase method of accounting and accordingly the statement of      
operations data of Eclipsys for 1997 and 1998 reflect the results of    
operations from these businesses from the respective acquisition dates. 
(2) Includes a write-off of $1.5 million related to licensed technology acquired
from Partners that was not technologically feasible at the time of the  
transaction. See Note 4 of Notes to the Eclipsys Consolidated Financial 
Statements.                                                             
(3) In connection with the Alltel and SDK Acquisitions, Eclipsys wrote off      
in-process research and development of $92.2 million and $7.0 million,  
    respectively, reflecting the appraised values of certain in-process research
   and development acquired in these acquisitions in 1997. See Note 6 of Notes
to the Eclipsys Consolidated Financial Statements.                      
(4) In connection with the buyout in the first quarter of 1998 of Eclipsys'     
 obligations under a Management and Services Agreement (the "MSA") entered
   into in connection with the Alltel Acquisition (the "MSA Buyout"), Eclipsys
recorded a charge of $7.2 million in 1998. See "Certain Transactions    
Relating to Eclipsys" and Note 13 of Notes to the Eclipsys Consolidated 
Financial Statements.                                                   
(5) Eclipsys has not recorded any benefit for income taxes because management   
    believes, based on the evidence available at December 31, 1997 and September
   30, 1998, it is more likely than not that Eclipsys' net deferred tax assets
will not be realized. Accordingly, Eclipsys has recorded a valuation    
allowance against its total net deferred tax assets.                    
(6) Represents the charge related to the January 1997 issuance of Series F      
   Convertible Preferred Stock of Eclipsys in exchange for the cancellation of
Series A Convertible Preferred Stock.                                   
(7) See Note 2 of Notes to Eclipsys Consolidated Financial Statements.          
(8) Represents earnings before interest expense, income tax expense,            
    depreciation and amortization and nonrecurring charges ("EBITDA"). EBITDA is
not a measurement in accordance with generally accepted accounting      
 principles in the United States ("GAAP" or "U.S. GAAP") and should not be
considered an alternative to, or more meaningful than, income from      
  operations, net income or cash flows as defined by GAAP or as a measure of
Eclipsys' profitability or liquidity. All registrants do not calculate  
    EBITDA in the same manner and accordingly, EBITDA may not be comparable with
other registrants. Eclipsys has included information concerning EBITDA  
herein because management believes EBITDA provides useful information.  

18

S-4
27th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 27th

SELECTED CONSOLIDATED FINANCIAL DATA FOR TSI

     The selected consolidated statement of operations data of TSI for the years
ended September 30, 1996, 1997 and 1998 and the selected consolidated balance   
sheet data of TSI at September 30, 1997 and 1998 are derived from, and are      
qualified by reference to, TSI's audited consolidated financial statements,     
which appear elsewhere in this document. The selected consolidated statement of 
operations data of TSI for the years ended September 30, 1994 and 1995 and the  
selected consolidated balance sheet data of TSI at September 30, 1994, 1995 and 
1996 are derived from audited financial statements of TSI not included in this  
document. The selected consolidated statement of operations data for the        
nine-month periods ended June 30, 1997 and 1998 and the selected consolidated   
balance sheet data of TSI at such dates are derived from unaudited financial    
statements of TSI, which appear elsewhere in this document, and in the opinion  
of management of TSI, include all adjustments (consisting only of normal        
recurring adjustments) necessary to present fairly the financial data for such  
periods. The results of operations of TSI for the nine months ended June 30,    
1998 are not necessarily indicative of the results to be expected for the full  
year or for any future period.                                                  

TSI has never declared or paid cash dividends on the TSI Voting or    
Non-Voting Common Stock.                                                        

                                                        [Enlarge/Download Table]

                                                                                                NINE MONTHS   
                                                                                                   ENDED      
                                                   FISCAL YEAR ENDED SEPTEMBER 30,               JUNE 30,     
                                           -----------------------------------------------   -----------------
                                            1994      1995      1996      1997      1998      1997      1998  
                                           -------   -------   -------   -------   -------   -------   -------
                                                          (IN THOUSANDS, EXCEPT PER SHARE DATA)               
                                                                                                              
STATEMENT OF OPERATIONS DATA:                                                                                 
Revenues.................................. $24,497   $27,386   $34,269   $44,565   $43,951   $30,875   $33,946
Income before income taxes and                                                                                
  extraordinary items.....................   8,521     9,975    10,611    12,948    14,762    12,546    11,897
Provision for income taxes................   3,407     4,349     4,324     7,629     5,905     5,018     4,759
Income before extraordinary item..........   5,114     5,626     6,287     5,319     8,857     7,528     7,138
Extraordinary item:                                                                                           
  Loss on early extinguishment of debt....      --        --     2,149        --        --        --        --
Net income................................   5,114     5,626     4,138     5,319     8,857     7,528     7,138
Series A non-voting preferred stock                                                                           
  dividends...............................      --        --       593        --        --        --        --
Net income allocable to common                                                                                
  stockholders............................   5,114     5,626     3,545     5,319     8,857     7,528     7,138
Net income allocable to common                                                                                
  stockholders per share:                                                                                     
  Basic...................................           $  0.19   $  0.27   $  0.31   $  0.49   $  0.43   $  0.39
  Diluted.................................           $  0.19   $  0.22   $  0.27   $  0.43   $  0.38   $  0.35
Weighted average shares:                                                                                      
  Basic...................................            30,060    13,214    17,435    18,210    17,333    18,153
  Diluted.................................            30,060    16,137    19,977    20,394    19,900    20,459
BALANCE SHEET DATA (END OF PERIOD):                                                                           
Total assets.............................. $20,274   $27,737   $74,284   $89,819   $99,864   $86,562   $97,814
Working capital...........................   8,207    14,207    55,672    63,569    73,548    59,766    71,275
Long-term debt............................      --        --        21        --        --        --        --
Stockholders' equity......................  10,566    16,192    60,633    73,519    84,272    70,987    81,720

19

S-4
28th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 28th

SELECTED UNAUDITED PRO FORMA COMBINED FINANCIAL DATA
REFLECTING THE MERGER 

   The following selected unaudited pro forma combined financial information
has been derived from and should be read in conjunction with the Unaudited Pro  
Forma Condensed Combined Financial Statements and notes thereto included        
elsewhere in this Joint Proxy Statement/Prospectus. The following selected      
unaudited pro forma combined financial information reflects adjustments to the  
historical consolidated balance sheets and related historical statements of     
income of Eclipsys and TSI to give effect to the Merger, using the              
pooling-of-interests method of accounting for business combinations, and to     
certain other acquisitions by TSI and Eclipsys. Eclipsys' consolidated financial
statements for its fiscal years ended December 31 have been combined with TSI's 
consolidated financial statements for its fiscal years ended September 30.      
Eclipsys' unaudited consolidated financial statements for the nine months ended 
September 30 have been combined with TSI's unaudited consolidated financial     
statements for the nine months ended June 30. The pro forma combined financial  
data is not necessarily indicative of the operating results or financial        
position that would have been achieved if the Merger had been consummated as of 
the beginning of the periods presented, nor is it necessarily indicative of the 
future operating results or financial position of the combined company.         

  The pro forma information does not reflect any costs associated with the
integration and consolidation of the companies anticipated by the management of 
Eclipsys as a result of the Merger.                                             

                                                        [Enlarge/Download Table]

                                                 YEARS ENDED DECEMBER 31,         NINE MONTHS    
                                              ------------------------------         ENDED       
                                               1995       1996        1997     SEPTEMBER 30, 1998
                                              -------    -------    --------   ------------------
                                                     (IN THOUSANDS, EXCEPT PER SHARE DATA)       
                                                                                                 
COMBINED STATEMENT OF OPERATIONS DATA:                                                           
Total revenues............................... $27,386    $34,269    $179,743        $141,410     
Income (loss) before extraordinary item                                                          
  available to common stockholders(1)........   5,626      2,741     (68,696)        (13,875)    
Income (loss) per share before extraordinary                                                     
  item available to common stockholders(1):                                                      
  Basic...................................... $  0.36    $  0.28    $  (2.39)       $  (0.47)    
  Diluted.................................... $  0.36    $  0.24    $  (2.39)       $  (0.47)    
Weighted average shares:                                                                         
  Basic......................................  15,781      9,959      28,791          29,335     
  Diluted....................................  15,781     11,494      28,791          29,335     

                                                                [Download Table]

                                                              SEPTEMBER 30, 1998
                                                              ------------------
                                                                (IN THOUSANDS)  
                                                                                
COMBINED BALANCE SHEET DATA:                                                    
Cash and cash equivalents...................................       $ 52,450     
Working capital.............................................         32,908     
Total assets................................................        226,305     
Shareholders' equity........................................        117,834     

---------------                                                                 
(1) Represents, for each period other than the year ended December 31, 1996,    
   income (loss) available to common stockholders. For the year ended December
31, 1996, represents income before extraordinary item, after reflecting 
  accretion of $593,000 of dividends on Series A non-voting preferred stock.
    In the year ended December 31, 1996, TSI recorded as an extraordinary item a
 loss on early extinguishment of debt of $2.1 million, attributable to the
    prepayment of certain debt in connection with TSI's initial public offering.
 The pro forma combined income available to common stockholders and income
per share for such period, giving effect to the extraordinary item, are 
$592,000, $0.06 per share (basic) and $0.05 per share (diluted),        
respectively.                                                           

20

S-4
29th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 29th

COMPARATIVE PER SHARE DATA

The following tables set forth certain historical per share data of   
Eclipsys and TSI and combined per share data on an unaudited pro forma basis    
after giving effect to the Merger, on a pooling-of-interests basis (and assuming
the issuance of 0.525 shares of Eclipsys Voting Common Stock in the Merger in   
exchange for each share of TSI Voting and Non-Voting Common Stock). This data   
should be read in conjunction with the selected historical consolidated         
financial data, the Unaudited Pro Forma Condensed Combined Financial Statements,
including the notes thereto, and the separate historical consolidated financial 
statements appearing elsewhere in this document. The pro forma combined         
financial data is not necessarily indicative of the operating results or        
financial position that would have been achieved if the Merger had been         
consummated as of the beginning of the periods presented, nor is it necessarily 
indicative of the future operating results or financial position of Eclipsys.   
Neither Eclipsys nor TSI has paid cash dividends on its Voting or Non-Voting    
Common Stock.                                                                   

The pro forma data does not reflect any costs associated with the     
integration and consolidation of the companies anticipated by the management of 
Eclipsys as a result of the Merger.                                             

                                                        [Enlarge/Download Table]

                                                  YEAR ENDED DECEMBER 31,        NINE MONTHS    
                                                  ------------------------          ENDED       
                                                  1995     1996     1997     SEPTEMBER 30, 1998 
                                                  -----   ------   -------   -------------------
                                                                                                
ECLIPSYS:                                                                                       
Income (loss) before extraordinary item:                                                        
  Historical (basic and diluted)................. $  --   $(0.98)  $(39.73)        $(3.41)      
  Pro forma(1):                                                                                 
     Basic.......................................  0.36     0.28     (2.39)         (0.47)      
     Diluted.....................................  0.36     0.24     (2.39)         (0.47)      
Book value (deficit):                                                                           
  Historical.....................................                    (5.20)          4.74       
  Pro forma(1)...................................                                    4.02       

                                                        [Enlarge/Download Table]

                                                   YEAR ENDED SEPTEMBER 30,       NINE MONTHS    
                                                   ------------------------          ENDED       
                                                   1995     1996     1997        JUNE 30, 1998   
                                                   -----   ------   -------   -------------------
                                                                                                 
TSI:                                                                                             
Income (loss) before extraordinary item available                                                
  to common stockholders(2):                                                                     
  Historical:                                                                                    
     Basic.......................................  $0.19   $ 0.43   $  0.31         $ 0.39       
     Diluted.....................................   0.19     0.35      0.27           0.35       
  Equivalent pro forma(3):                                                                       
     Basic.......................................   0.19     0.15     (1.25)         (0.25)      
     Diluted.....................................   0.19     0.13     (1.25)         (0.25)      
Book value:                                                                                      
  Historical.....................................                      4.22           4.50       
  Equivalent pro forma(3)........................                                     2.11       

---------------                                                                 
(1) Represents the unaudited pro forma combined income (loss) before            
  extraordinary item and unaudited pro forma combined book value of Eclipsys
    and TSI. See Note 1 of "Selected Unaudited Pro Forma Combined Financial Data
Reflecting the Merger" and "Unaudited Pro Forma Condensed Consolidated  
Financial Statements."                                                  

(2) Represents, for each period other than the year ended December 31, 1996,    
   income (loss) available to common stockholders. For the year ended December
31, 1996, represents income before extraordinary item, after reflecting 
  accretion of $593,000 of dividends on Series A non-voting preferred stock.

(3) Represents the unaudited pro forma amounts for Eclipsys set forth above,    
multiplied by the 0.525 Exchange Ratio.                                 

21

S-4
30th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 30th

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL 
CONDITION AND RESULTS OF OPERATIONS OF ECLIPSYS 

 Eclipsys was formed in December 1995, but had no significant operations
until 1997. As a result, the following discussion as it relates to 1995 and 1996
reflects the operations of Alltel, which was Eclipsys' predecessor, acquired by 
Eclipsys in January 1997. The discussion as it relates to 1997 reflects the     
operations of Eclipsys for 1997, which included only 11 months of Alltel        
operations. In addition to the Alltel Acquisition, Eclipsys completed the SDK   
Acquisition in June 1997 and the Emtek Acquisition in January 1998. As a result,
the following discussion regarding period-to-period comparisons may not be      
indicative of future results. The Alltel Acquisition, the SDK Acquisition and   
the Emtek Acquisition are referred to collectively as the "Eclipsys             
Acquisitions."                                                                  

OVERVIEW                                                                        

Eclipsys is a healthcare information technology company delivering    
solutions that enable healthcare providers to achieve improved clinical,        
financial and administrative outcomes. Eclipsys offers an integrated suite of   
core products in four critical areas -- clinical management, access management, 
patient financial management and enterprise data warehouse and analysis. These  
products can be purchased in combination to provide an enterprise-wide solution 
or individually to address specific needs. These solutions take many forms and  
can include a combination of software, hardware, maintenance, consulting        
services, remote processing services, network services and information          
technology outsourcing.                                                         

Founded in 1995, Eclipsys has grown to its current position primarily 
through a series of strategic acquisitions completed since January 1997. In May 
1996, Eclipsys entered into an exclusive license agreement with Partners to     
develop, commercialize, distribute and support certain intellectual property    
relating to a clinical information systems software developed at Brigham &      
Women's Hospital (the "Partners License"). In connection with this license,     
Eclipsys issued to Partners 988,290 shares of Eclipsys Voting Common Stock.     

In January 1997, Eclipsys purchased Alltel from ALLTEL Information    
Services, Inc. ("AIS") for a total purchase price of $201.5 million, after      
giving effect to certain purchase price adjustments. The Alltel Acquisition was 
paid for with cash, the issuance of Series C Redeemable Preferred Stock (which  
was redeemed at the time of the initial public offering) and Series D           
Convertible Preferred Stock (which was converted into shares of Eclipsys Voting 
Common Stock at the time of the initial public offering) and the assumption of  
certain liabilities. The acquisition was accounted for as a purchase, and       
Eclipsys recorded total intangible assets of $154.3 million, consisting of $92.2
million of acquired in-process research and development, $42.3 million of       
acquired technology, $10.8 million to reflect the value of ongoing customer     
relationships and $9.0 million of goodwill. Eclipsys wrote off the acquired     
in-process research and development as of the date of the acquisition, and is   
amortizing the acquired technology over three years on an accelerated basis. The
value of the ongoing customer relationships and the goodwill are being amortized
over five years and twelve years, respectively.                                 

 In June 1997, Eclipsys acquired SDK for a total purchase price of $16.5
million. The SDK Acquisition was paid for with cash as well as the issuance of  
$7.6 million of subordinated promissory notes (the "SDK Notes") and Eclipsys    
Voting Common Stock. The acquisition was accounted for as a purchase, and       
Eclipsys recorded total intangible assets of $14.8 million, consisting of $7.0  
million of acquired in-process research and development, $3.2 million of        
acquired technology and $4.6 million of goodwill. Eclipsys wrote off the        
acquired in-process research and development as of the date of the acquisition, 
and is amortizing both the acquired technology and the goodwill over five years.

   In January 1998, Eclipsys acquired Emtek from Motorola, Inc. ("Motorola")
for a total purchase price of $11.7 million, net of a $9.6 million receivable   
from Motorola. The Emtek Acquisition was paid for with the issuance of Common   
Stock and the assumption of certain liabilities. The acquisition was accounted  
for as a purchase, and Eclipsys recorded total intangible assets of $4.1        
million, consisting of acquired technology which is being amortized over five   
years.                                                                          

22

S-4
31st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 31st

 In April 1998, Eclipsys made a strategic minority investment in Simione
Central Holdings, Inc. ("Simione"), purchasing approximately 4.9% of Simione's  
outstanding common stock from certain stockholders of Simione for approximately 
$5.6 million (the "Simione Investment"). In connection with this investment,    
Eclipsys received the right to designate one member for election to Simione's   
board of directors and an option, which expired unexercised in October 1998, to 
purchase up to an additional 4.9% of Simione's common stock under certain       
circumstances. Concurrently with the Simione Investment, Eclipsys and Simione   
entered into a Remarketing Agreement pursuant to which Eclipsys has certain     
rights to distribute Simione software products. Simione is a provider of home   
healthcare consulting solutions and information systems.                        

The write-off of acquired in-process research and development of $92.2
million and $7.0 million associated with the Alltel Acquisition and the SDK     
Acquisition, respectively, together with the amortization of acquisition-related
intangible assets of $25.3 million, accounted for $124.5 million of Eclipsys'   
$131.1 million net loss in 1997. See "-- Acquired In-Process Research and       
Development."                                                                   

REVENUES                                                              

    Revenues are derived from sales of systems and services, which include the
licensing of software, software and hardware maintenance, remote processing,    
outsourcing, implementation, training and consulting, and from the sale of      
computer hardware. Eclipsys' products and services are generally sold to        
customers pursuant to contracts which range in duration from five to seven      
years.                                                                          

     For contracts in which Eclipsys is required to make significant production,
modification or customization changes, revenues from systems and services are   
recognized using the percentage-of-completion method over the implementation    
period of the contracts. Other systems and services revenues are generally      
recognized on a straight-line basis over the term of licensing and maintenance  
agreements. Remote processing and outsourcing services are marketed under       
long-term agreements and revenues are recognized monthly as the work is         
performed. Revenues related to other support services, such as training,        
consulting, and implementation, are recognized when the services are performed. 
Revenues from the sale of hardware are recognized upon shipment of the product  
to the customer.                                                                

Eclipsys' revenues can vary from quarter to quarter due to a number of
factors. See "Risk Factors -- Potential Fluctuations in Quarterly Performance." 

COST OF REVENUES                                                      

     The principal costs of systems and services revenues are salaries, benefits
and related overhead costs for implementation, remote processing, outsourcing   
and field operations personnel. As Eclipsys implements its growth strategy, it  
is expected that additional operating personnel will be required, which would   
lead to an increase in cost of revenues on an absolute basis. Other significant 
costs of systems and services revenues are the amortization of acquired         
technology and capitalized software development costs. Acquired technology is   
amortized over three to five years based upon the estimated economic life of the
underlying asset, and capitalized software development costs are amortized over 
three years on a straight-line basis commencing upon general release of the     
related product. Eclipsys recorded amortization expenses related to acquired    
technology from the Alltel and SDK Acquisitions of $19.7 million in 1997, and   
expects to record additional acquired technology amortization from the          
Acquisitions of approximately $14.8 million, $10.2 million and $2.1 million in  
1998, 1999 and 2000, respectively. No capitalized software development costs    
were amortized in 1997.                                                         

    Cost of revenues related to hardware sales include only the Company's cost
to acquire the hardware from the manufacturer.                                  

MARKETING AND SALES                                                   

Marketing and sales expenses consist primarily of salaries, benefits, 
commissions and related overhead costs. Other costs include expenditures for    
marketing programs, public relations, trade shows, advertising                  

23

S-4
32nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 32nd

and related communications. As Eclipsys continues to implement its growth       
strategy, marketing and sales expenses are expected to continue to increase on  
an absolute basis.                                                              

RESEARCH AND DEVELOPMENT                                              

   Research and development expenses consist primarily of salaries, benefits
and related overhead associated with the design, development and testing of new 
products by Eclipsys. Eclipsys capitalizes internal software development costs  
subsequent to attaining technological feasibility. Such costs are amortized as  
an element of cost of revenues annually over three to five years either on a    
straight line basis or, if greater, based on the ratio that current revenues    
bear to total anticipated revenues for the applicable product. Eclipsys expects 
to continue to increase research and development spending on an absolute basis  
as it migrates its products to the SOLA architecture.                           

GENERAL AND ADMINISTRATIVE                                            

     General and administrative expenses consist primarily of salaries, benefits
and related overhead costs for administration, executive, finance, legal, human 
resources, purchasing and internal systems personnel, as well as accounting and 
legal fees and expenses. As Eclipsys implements its business plan, general and  
administrative expenses are expected to continue to increase on an absolute     
basis.                                                                          

DEPRECIATION AND AMORTIZATION                                         

Eclipsys depreciates the costs of its tangible capital assets on a    
straight-line basis over the estimated economic life of the asset, which is     
generally not longer than five years. Acquisition-related intangible assets,    
which include the value of ongoing customer relationships and goodwill, are     
amortized based upon the estimated economic life of the asset at the time of the
acquisition, and will therefore vary among acquisitions. Eclipsys recorded      
amortization expenses for acquisition-related intangible assets of $5.7 million 
in 1997.                                                                        

TAXES                                                                 

As of December 31, 1997, Eclipsys had operating loss carryforwards for
federal income tax purposes of $20.1 million. The carryforwards expire in       
varying amounts through 2012 and are subject to certain restrictions. Based on  
evidence then available, Eclipsys did not record any benefit for income taxes at
December 31, 1997, because management believed it was more likely than not that 
Eclipsys would not realize its net deferred tax assets. Accordingly, Eclipsys   
has recorded a valuation allowance against its total net deferred tax assets.   

RESULTS OF OPERATIONS                                                           

NINE MONTHS ENDED SEPTEMBER 30, 1998 COMPARED TO NINE MONTHS ENDED    
SEPTEMBER 30, 1997                                                              

     Total revenues increased 44.8% from $67.5 million for the first nine months
of 1997 to $97.7 million for the first nine months of 1998. Systems and services
revenues increased by $24.1 million, or 37.3%, and hardware revenues increased  
by $6.2 million, or 206%. These increases were caused primarily by the inclusion
in 1998 of nine full months of the operations of Alltel, as compared to only    
eight months in 1997, as well as the inclusion in 1998 of nine months of        
operations of SDK and eight months of operations of Emtek, which were not       
included in the results of operations in the first nine months of 1997. Also    
contributing to the increase was new business contracted in 1998, which was the 
result of an increase in marketing efforts related to the regional realignment  
of Eclipsys' operations completed in 1997 and the successful integration of the 
acquisitions completed in 1997 and 1998.                                        

     Total cost of revenues increased 4.8% from $58.2 million, or 86.2% of total
revenues, in the first nine months of 1997 to $61.0 million, or 62.4% of total  
revenues, in the first nine months of 1998. The increase in cost was due        
primarily to the increase in business activity, offset in part by a reduction in
certain expenses related to integrating the Eclipsys Acquisitions. The reduction
in total cost of revenues as a                                                  

24

S-4
33rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 33rd

percentage of total revenues was due to the relatively small increase in costs  
compared to the increase in revenues.                                           

     Marketing and sales expenses increased 41.1% from $9.9 million, or 14.6% of
total revenues, in the first nine months of 1997 to $13.9 million, or 14.3% of  
total revenues, in the first nine months of 1998. The increase was due primarily
to the addition of marketing and direct sales personnel following the Eclipsys  
Acquisitions and the regional realignment of Eclipsys' sales operations.        

     Total expenditures for research and development, including both capitalized
and non-capitalized portions, increased by 73.0% from $12.7 million, or 18.8% of
total revenues, in the first nine months of 1997 to $22.0 million, or 22.5% of  
total revenues, in the first nine months of 1998. The increase was due primarily
to the inclusion in 1998 of nine full months of the operations of Alltel and SDK
as well as eight months of Emtek operations, as well as the continued           
development of an enterprise-wide, client server platform solution. Research and
development expenditures of $698,000 were capitalized in the first nine months  
of 1997 and $2.7 million were capitalized in the first nine months of 1998. The 
capitalization of software development costs in 1998 was due primarily to       
product development activities related to technology acquired in the Eclipsys   
Acquisitions. As a result of this activity, research and development expense    
increased 60.7% from $12.0 million in the first nine months of 1997 to $19.3    
million in the first nine months of 1998.                                       

   General and administrative expenses increased by $437,000, or 10.5%, from
$4.1 million, or 6.1% of total revenues, in the first nine months of 1997 to    
$4.6 million, or 4.7% of total revenues, in the first nine months of 1998. The  
increase was due primarily to the addition of administrative and finance        
personnel following the Eclipsys Acquisitions.                                  

    Depreciation and amortization expense increased by 8.8% from $7.3 million,
or 10.8% of total revenues, in the first nine months of 1997 to $7.9 million, or
8.1% of total revenues, in the first nine months of 1998. The increase was due  
primarily to the amortization of ongoing customer relationships and goodwill    
related to the Eclipsys Acquisitions. Partially offsetting this increase was a  
reduction in goodwill amortization as a result of the renegotiation of certain  
matters relating to the Alltel Acquisition.                                     

  Eclipsys recorded a $7.2 million charge in the first nine months of 1998
related to the MSA Buyout. In the first nine months of 1997, Eclipsys recorded a
charge of $99.2 million related to the write-off of in-process research and     
development attributable to the Alltel and SDK Acquisitions.                    

     As a result of the foregoing, net loss decreased from $123.9 million in the
first nine months of 1997 to $16.8 million in the first nine months of 1998.    

1997 COMPARED TO 1996                                                 

In the period-to-period comparison below, the 1997 results reflect the
operations of Eclipsys and the 1996 results reflect the operations of its       
predecessor, Alltel.                                                            

  Following the Alltel and SDK Acquisitions in 1997, Eclipsys' efforts and
resources were focused on integrating the acquisitions into its operations.     
Particular emphasis was placed on retaining customers and integrating the       
acquired products into Eclipsys' systems and services offerings in order to     
position Eclipsys for future business opportunities. These efforts included     
refocusing Eclipsys' research and development operations, realigning the sales  
departments and reducing general and administrative overhead. As a result,      
Eclipsys did not actively seek to exploit new business opportunities during     
1997. Eclipsys believes that the investment of time and resources in improving  
the internal structure of Eclipsys and the integration of its acquisitions have 
positioned Eclipsys to capitalize on business opportunities in the future.      

     Total revenues decreased by $14.7 million, or 13.5%, from $108.8 million in
1996 to $94.1 million in 1997. This decrease was caused primarily by the        
inclusion in 1997 of only eleven full months of the operations of Alltel, as    
well as a reduction in revenues from hardware sales of $5.2 million, offset in  
part by the inclusion of $3.5 million in revenues attributable to SDK. In       
addition, in accounting for the Alltel Acquisition, Eclipsys reduced deferred   
revenue by $7.3 million to reflect the estimated fair value of certain          

25

S-4
34th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 34th

contractual obligations. This accounting adjustment had the effect of reducing  
revenues by $4.5 million in 1997 compared to 1996 revenues. Eclipsys does not   
expect the deferred revenue adjustment to materially impact future periods.     
Adding Alltel results for the 23 days from January 1, 1997 to the closing of the
Alltel Acquisition, 1997 total revenues would have been $100.3 million.         

Total cost of revenues increased by $6.8 million, or 9.5%, from $71.5 
million, or 65.7% of total revenues, in 1996 to $80.0 million, or 85.1% of total
revenues, in 1997. The increase was due primarily to a $19.7 million increase in
amortization of acquired technology and $2.2 million of amortization of the     
value of the MSA. This increase was offset, in part, by a $7.2 million decrease 
in amortization of capitalized software costs, as no software costs were        
amortized in 1997. Further offsetting the increase were the timing of the Alltel
Acquisition and the reduction in hardware sales. Adding Alltel results for the  
period prior to the Alltel Acquisition, total cost of revenues in 1997 would    
have been $84.4 million.                                                        

Marketing and sales expenses increased by $2.6 million, or 23.2%, from
$11.1 million, or 10.2% of total revenues, in 1996 to $13.7 million, or 14.5% of
total revenues, in 1997. The increase was due primarily to the addition of      
marketing and direct sales personnel as part of Eclipsys' investment in its     
marketing and sales operations following the Alltel and SDK Acquisitions. This  
increase was offset in part by the timing of the Alltel Acquisition. Adding     
Alltel results for the period prior to the Alltel Acquisition, 1997 marketing   
and sales expenses would have been $14.3 million.                               

     Total expenditures for research and development, including both capitalized
and non-capitalized portions, decreased by $5.1 million, or 22.9%, from $22.4   
million, or 20.6% of total revenues in 1996 to $17.3 million, or 18.4% of total 
revenues, in 1997. These amounts exclude amortization of previously capitalized 
expenditures, which are recorded as cost of revenues. The decrease was due      
primarily to the refocusing of Eclipsys' research and development organization, 
and, to a lesser extent, the timing of the Alltel Acquisition. The portion of   
research and development expenditures that were capitalized decreased by $10.6  
million, from $12.2 million in 1996 to $1.6 million in 1997.                    

   The reduction in capitalized software development costs was due primarily
to Eclipsys' emphasis on enhancing existing technology acquired in the Alltel   
and SDK Acquisitions, the costs of which were expensed as incurred. As a result 
of this emphasis, research and development expense increased $5.4 million, or   
53.0%, from $10.3 million in 1996 to $15.7 million in 1997. Adding Alltel       
results for the period prior to the Alltel Acquisition, 1997 research and       
development expenses would have been $16.5 million.                             

  General and administrative expenses decreased by $1.4 million, or 20.1%,
from $7.1 million, or 6.5% of total revenues, in 1996 to $5.7 million, or 6.0%  
of total revenues, in 1997. The decrease was due primarily to the timing of the 
Alltel Acquisition, as well as savings generated by the rationalization of      
Eclipsys' administrative, financial and legal organizations. Adding Alltel      
results for the period prior to the Alltel Acquisition, 1997 general and        
administrative expense would have been $6.3 million.                            

    Depreciation and amortization expense increased by $1.6 million, or 19.4%,
from $8.1 million, or 7.5% of total revenues, in 1996 to $9.7 million, or 10.5% 
of total revenues, in 1997. The increase was due primarily to the amortization  
of the value of ongoing customer relationships and goodwill related to the      
Alltel and SDK Acquisitions. Adding Alltel results for the period prior to the  
Alltel Acquisition, 1997 depreciation and amortization expense would have been  
$10.3 million.                                                                  

     Write-offs of acquired in-process research and development of $99.2 million
were recorded in 1997, of which $92.2 million was attributable to the Alltel    
Acquisition and $7.0 million was attributable to the SDK Acquisition. There were
no write-offs recorded in 1996.                                                 

    As a result of the foregoing factors, net loss increased from $2.2 million
in 1996 to $131.1 million in 1997.                                              

26

S-4
35th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 35th

1996 COMPARED TO 1995                                                 

    The period-to-period comparison below reflects the operations of Eclipsys'
predecessor, Alltel, for 1996 and 1995.                                         

   Total revenues increased by $8.7 million, or 8.7%, from $100.1 million in
1995 to $108.8 million in 1996. This increase was caused primarily by increases 
in revenues related to outsourcing contracts.                                   

 Total cost of revenues increased by $10.2 million, or 16.5%, from $61.3
million, or 61.3% of total revenues, in 1995 to $71.5 million, or 65.7% of total
revenues, in 1996. The increase was due primarily to increases in staff related 
to outsourcing contracts.                                                       

 Marketing and sales expenses remained constant at $11.1 million in both
periods, representing 11.1% of total revenues in 1995 and 10.2% of total        
revenues in 1996.                                                               

     Total expenditures for research and development, including both capitalized
and non-capitalized portions, increased by $1.0 million, or 4.7%, from $21.4    
million, or 21.4% of total revenues, in 1995 to $22.4 million, or 20.6% of total
revenues, in 1996. These amounts exclude amortization of previously capitalized 
expenditures, which are recorded as cost of revenues. The increase was due      
primarily to wage increases for research and development personnel. The portion 
of research and development expenditures that were capitalized decreased by     
$735,000, from $12.9 million in 1995 to $12.2 million in 1996.                  

  General and administrative expenses decreased by $1.1 million, or 13.1%,
from $8.2 million, or 8.2% of total revenues, in 1995 to $7.1 million, or 6.5%  
of total revenues, in 1996. The decrease was due primarily to a $1.0 million    
decrease in legal fees.                                                         

     Depreciation and amortization expenses increased by $1.4 million, or 20.8%,
from $6.7 million, or 6.7% of total revenues, in 1995 to $8.1 million, or 7.5%  
of total revenues, in 1996. The increase was due primarily to depreciation of   
computer equipment acquired for research and development purposes.              

   As a result of the foregoing factors, net income was $606,000 in 1995 and
net loss was $2.2 million in 1996.                                              

ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT                                    

OVERVIEW                                                              

In connection with the Alltel and SDK Acquisitions, Eclipsys wrote off
in-process research and development totaling $92.2 million and $7.0 million,    
respectively. These amounts were expensed as non-recurring charges on the       
respective acquisition dates. These write-offs were necessary because the       
acquired technology had not yet reached technological feasibility and had no    
future alternative uses. Eclipsys is using the acquired in-process research and 
development to create new clinical management, access management, patient       
financial management and data warehousing products which will become part of the
Sunrise product suite over the next several years. Eclipsys anticipates that    
certain products using the acquired in-process technology will be generally     
released before the end of 1998, with additional product releases in subsequent 
periods through 2001. Eclipsys expects that the acquired in-process research and
development will be successfully developed, but there can be no assurance that  
commercial viability of these products will be achieved.                        

The nature of the efforts required to develop the purchased in-process
technology into commercially viable products principally relate to the          
completion of all planning, designing, prototyping, verification and testing    
activities that are necessary to establish that the product can be produced to  
meet its design specifications, including functions, features and technical     
performance requirements.                                                       

The value of the purchased in-process technology was determined by    
estimating the projected net cash flows related to such products, including     
costs to complete the development of the technology and the future revenues to  
be earned upon commercialization of the products. These cash flows were         
discounted back to their net present value. The resulting projected net cash    
flows from such projects were based on                                          

27

S-4
36th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 36th

management's estimates of revenues and operating profits related to such        
projects. These estimates were based on several assumptions, including those    
summarized below for each of the respective acquisitions.                       

If these projects to develop commercial products based on the acquired
in-process technology are not successfully completed, the sales and             
profitability of Eclipsys may be adversely affected in future periods.          
Additionally, the value of other intangible assets may become impaired.         

ALLTEL                                                                

The primary purchased in-process technology acquired in the Alltel    
Acquisition was the client-server based core application modules of the TDS 7000
product. This project represented an integrated clinical software product whose 
functionality included order management, health information management,         
physician applications, nursing applications, pharmacy, laboratory and radiology
applications and ancillary support. Additionally, the product included          
functionality facilitating the gathering and analysis of data throughout a      
healthcare organization, a data integration engine and various other            
functionality.                                                                  

   Revenue attributable to the in-process technology was assumed to increase
over the twelve-year projection period at annual rates ranging from 234% to 5%, 
resulting in annual revenues of approximately $27 million to $640 million. Such 
projections were based on assumed penetration of the existing customer base, new
customer transactions, historical retention rates and experiences of prior      
product releases. The projections reflect accelerated revenue growth in the     
first five years (1997 to 2001) as the products derived from the in-process     
technology are generally released. In addition, the projections were based on   
annual revenue to be derived from long-term contractual arrangements ranging    
from seven to ten years. New customer contracts for products developed from the 
in-process technology were assumed to peak in 2001, with rapidly declining sales
volume in the years 2002 to 2003 as other new products are expected to enter the
market. The projections assumed no new customer contracts after 2003. Projected 
revenue in years after 2003 was determined using a 5% annual growth rate, which 
reflects contractual increases.                                                 

    Operating profit was projected to grow over the projection period at rates
ranging from 1238% to 5%, resulting in incremental annual operating profit      
(loss) of approximately $(5) million to $111 million. The operating profit      
projections during the years 1997 to 2001 assumed a growth rate slightly higher 
than the revenue projections. The higher growth rate is attributable to the     
increase in revenues discussed above, together with research and development    
costs expected to remain constant at approximately $15 million annually. The    
operating profit projections include a 5% annual growth rate for the years after
2003 consistent with the revenue projections.                                   

To date, revenues and operating profit attributable to in-process     
technology have been adversely impacted by the deferral of one outsourcing      
contract that had been approved but not finalized at the time the projections   
were completed. Although it was successful in contracting outsourcing business  
in 1997, Eclipsys decided in late March 1997 to focus its efforts on integrating
the products acquired in the Acquisitions and lower its sales efforts in the    
outsourcing arena. In late 1997, Eclipsys reorganized the outsourcing operations
and began to refocus on selling such services in the first quarter of 1998.     
Revenue attributable to the deferred contract is expected to be realized in     
1999. Management continues to believe the projections used reasonably estimate  
the future benefits attributable to the in-process technology. However, no      
assurance can be given that deviations from these projections will not occur.   

   The projected net cash flows were discounted to their present value using
the weighted average cost of capital (the "WACC"). The WACC calculation produces
the average required rate of return of an investment in an operating enterprise,
based on required rates of return from investments in various areas of the      
enterprise. The WACC used in the projections was 21%. This rate was determined  
by applying the capital asset pricing model. This method yielded an estimated   
average WACC of approximately 16.5%. A risk premium was added to reflect the    
business risks associated with the stage of development of Eclipsys, as well as 
the technology risk associated with the in-process software, resulting in a WACC
of 21%. In addition, the value of customer relationships was calculated using a 
discount rate of 21% and a return to net tangible assets was estimated using a  
rate of return of 11.25%. The value of the goodwill was                         

28

S-4
37th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 37th

calculated as the remaining intangible value not otherwise allocated to         
identifiable intangible assets (resulting in an implied discount rate on the    
goodwill of approximately 28%).                                                 

   Eclipsys used a 21% discount rate for valuing existing technology because
it faces substantially the same risks as the business as a whole. Accordingly, a
rate equal to the WACC of 21% was used. Eclipsys used a 28% discount rate for   
valuing in-process technology. The spread over the existing technology discount 
rate reflects the inherently greater risk of the research and development       
efforts. The spread reflected the nature of the development efforts relative to 
the existing base of technology and the potential market for the in-process     
technology once the products were released.                                     

Eclipsys estimates that the costs to develop the purchased in-process 
technology acquired in the Alltel Acquisition into commercially viable products 
will be approximately $75 million in the aggregate through 2001 ($15 million per
year from 1997 to 2001).                                                        

SDK                                                                   

The purchased in-process technology acquired in the SDK Acquisition   
comprised three major enterprise-wide modules in the areas of physician billing,
home health care billing and long-term care billing; a graphical user interface;
a corporate master patient index; and a standard query language module.         

   Revenue attributable to the in-process technology was assumed to increase
in the first three years of the ten-year projection period at annual rates      
ranging from 497% to 83% decreasing over the remaining years at annual rates    
ranging from 73% to 14% as other products are released in the marketplace.      
Projected annual revenue ranged from approximately $5 million to $56 million    
over the term of the projections. These projections were based on assumed       
penetration of the existing customer base, synergies as a result of the SDK     
Acquisition, new customer transactions and historical retention rates. Projected
revenues from the in-process technology were assumed to peak in 2000 and decline
from 2000 to 2007 as other new products are expected to enter the market.       

     Operating profit was projected to grow over the projection period at annual
rates ranging from 1497% to 94% during the first three years, decreasing during 
the remaining years of the projection period similar to the revenue growth      
projections described above. Projected annual operating profit ranged from      
approximately $250,000 to $8 million over the term of the projections.          

To date, revenues and operating profit attributable to in-process     
technology have been consistent with the projections. However, no assurance can 
be given that deviations from these projections will not occur in the future.   

     The WACC used in the analysis was 20%. This rate was determined by applying
the capital asset pricing model and a review of venture capital rates of return 
for companies in a similar life cycle stage.                                    

Eclipsys used a 20% discount rate for valuing existing and in-process 
technology because both technologies face substantially the same risks as the   
business as a whole. Accordingly, a rate equal to the WACC of 20% was used.     

Eclipsys estimates that the costs to develop the in-process technology
acquired in the SDK Acquisition will be approximately $1.7 million in the       
aggregate through the year 2000 ($500,000 in 1998, $600,000 in 1999 and $600,000
in 2000).                                                                       

LIQUIDITY AND CAPITAL RESOURCES                                                 

   For purposes of the following discussion, cash flow data for 1997 and the
first nine months of 1998 relate to Eclipsys and cash flow data for 1995 and    
1996 relate to Alltel.                                                          

Eclipsys was formed in December 1995 and has grown primarily through a
series of acquisitions completed since January 1997. Eclipsys' principal sources
of liquidity have been equity capital contributions, borrowings from commercial 
lenders and cash provided by operating activities. The funds                    

29

S-4
38th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 38th

generated by these sources have been applied primarily to acquisitions and      
research and development activities.                                            

Cash provided by operating activities totaled $3.3 million and $15.2  
million in the nine months ended September 30, 1997 and 1998, respectively. The 
increase in cash provided by operating activities was the result of increased   
business activity and the reduction in certain expenses related to integrating  
the Eclipsys Acquisitions. Cash provided by financing activities totaled $113.8 
million and $20.1 million in the nine months ended September 30, 1997 and 1998, 
respectively. The 1997 period included the issuance of $103.8 million of        
Preferred Stock in connection with the Alltel Acquisition, which was            
subsequently converted into Eclipsys Voting Common Stock at the time of         
Eclipsys' initial public offering in August 1998 (the "Eclipsys IPO"). Cash used
by investing activities totaled $111.8 million and $27.8 million in the nine    
months ended September 30, 1997 and 1998, respectively. The 1997 period included
$109.0 million applied to the Alltel and SDK Acquisitions. As of September 30,  
1998, Eclipsys had $12.3 million of cash and cash equivalents.                  

    Cash provided by operating activities totaled $15.9 million, $15.9 million
and $1.1 million in 1995, 1996 and 1997, respectively. The decrease in cash     
provided by operating activities from 1996 to 1997 was primarily the result of a
greater portion of research and development being expensed as incurred, rather  
than being capitalized. Cash provided by financing activities totaled $5.5      
million, $11.9 million and $112.8 million in 1995, 1996 and 1997, respectively. 
The increase from 1996 to 1997 was primarily the result of $103.8 million of    
proceeds from the issuance of Preferred Stock concurrently with the Alltel      
Acquisition. Cash used by investing activities totaled $20.5 million, $28.2     
million and $113.7 million in 1995, 1996 and 1997, respectively. The increase in
cash used by investing activities from 1996 to 1997 was the result of $109.0    
million applied to the Alltel and SDK Acquisitions, offset in part by a $10.6   
million reduction in capitalization of software development costs.              

   Eclipsys invested $7.7 million, $9.2 million and $3.1 million in computer
equipment, leasehold improvements and other capital assets in 1995, 1996 and    
1997, respectively. Eclipsys also incurred $21.4 million, $22.4 million and     
$17.3 million in research and development costs in 1995, 1996 and 1997. Eclipsys
expects that the combined company will invest approximately $6 million and $45  
million in capital expenses and research and development, respectively, through 
the end of 1999.                                                                

In January 1997, Eclipsys entered into a $30 million credit facility, 
consisting of a $10 million term loan (the "Term Loan") and a $20 million       
revolving loan (the "Revolver"). The Term Loan and the Revolver are secured by  
substantially all of Eclipsys' assets, and bear interest at a variable rate. See
Note 7 of Notes to Eclipsys' Consolidated Financial Statements. In January 1998,
the Term Loan was repaid with the proceeds of the issuance of Preferred Stock,  
which was subsequently converted into Eclipsys Voting Common Stock at the time  
of the Eclipsys IPO. In March 1998, pursuant to the MSA Buyout, Eclipsys paid   
AIS $14.0 million. Of this payment, $9.0 million was funded through borrowings  
under the Revolver. In April 1998, Eclipsys borrowed an additional $5.6 million 
under the Revolver to fund its investment in Simione. In May 1998, the Revolver 
was amended to increase the borrowing limit to $50.0 million, under             
substantially similar terms and conditions as contained in the original credit  
facility. As of September 30, 1998, the effective interest rate for the Revolver
was 6.7% and the amount available for borrowing thereunder was $50.0 million.   

   In March 1998, pursuant to the renegotiation in the first quarter of 1998
of certain matters relating to the Alltel Acquisition (the "Alltel              
Renegotiation"), AIS returned to Eclipsys 11,000 shares of Redeemable Preferred 
Stock for cancellation. As part of this transaction, AIS agreed that no         
dividends would accrue on the remaining 4,500 shares of Redeemable Preferred    
Stock held by it until July 1, 1998. Eclipsys redeemed the full $34.5 million   
face value of the outstanding Redeemable Preferred Stock and all accrued        
dividends with a portion of the proceeds from the Eclipsys IPO. A charge to     
additional paid-in capital was recorded in the quarter ended September 30, 1998 
(the period in which the redemption occurred) equal to the difference between   
the redemption price of the Redeemable Preferred Stock and its carrying amount  
($10.9 million). In addition, this charge resulted in an increase in net loss   
available to common stockholders in the statement of operations for the quarter.

30

S-4
39th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 39th

   In August 1998, Eclipsys completed the Eclipsys IPO, selling an aggregate
of 4,830,000 shares of Eclipsys Voting Common Stock and realizing approximately 
$66.0 million in net proceeds, after deducting underwriting discounts and       
commissions and expenses of the offering payable by Eclipsys. Of these net      
proceeds, Eclipsys used (i) approximately $38.8 million to redeem all           
outstanding Redeemable Preferred Stock, including $4.3 million of accrued       
dividends, (ii) approximately $3.9 million to repay the remaining balance of    
subordinated promissory notes issued in connection with the SDK Acquisition and 
(iii) approximately $18.5 million to repay the outstanding balance under the    
Revolver.                                                                       

Eclipsys believes that its existing cash balances, funds generated by 
operations and borrowings available under the Revolver will be sufficient to    
finance its operations for at least the next twelve months. However, to the     
extent acquisitions are completed or anticipated capital and operating          
requirements change, Eclipsys may be required to raise additional financing.    
There can be no assurance that, if needed, such financing would be available, or
would be available on terms satisfactory to Eclipsys.                           

YEAR 2000 ISSUES                                                                

   Eclipsys believes that all of its internal management information systems
are currently Year 2000 compliant and, accordingly, does not anticipate any     
significant expenditures to remediate or replace existing internal-use systems. 
Although all of the products currently offered by Eclipsys are Year 2000        
compliant, some of the products previously sold by Alltel and Emtek and         
installed in Eclipsys' customer base are not Year 2000 compliant. Eclipsys has  
developed and tested solutions for its non-compliant installed products.        
Eclipsys currently estimates that the total cost of bringing these installed    
products into Year 2000 compliance, in those cases in which Eclipsys is required
to do so at its own expense, will be approximately $900,000, all of which is    
expected to be incurred by mid-1999. In addition, because Eclipsys' products are
often interfaced with a customer's existing third-party applications, Eclipsys' 
products may experience difficulties interfacing with third-party non-compliant 
applications. Based on currently available information, Eclipsys does not expect
the cost of compliance related to interactions with non-compliant third-party   
systems to be material. However, any unexpected difficulties in implementing    
Year 2000 solutions for the installed Alltel or Emtek products or difficulties  
in interfacing with third-party products could have a material adverse effect on
Eclipsys' business, financial condition and results of operations.              

BACKLOG                                                                         

Backlog consists of revenues Eclipsys expects to recognize over the   
following twelve months under existing contracts. The revenues to be recognized 
may relate to a combination of one-time fees for software licensing and         
implementation, hardware sales and installations and professional services, or  
annual or monthly fees for licenses, maintenance, and outsourcing or remote     
processing services. As of December 31, 1997, Eclipsys had a backlog of         
approximately $108 million.                                                     

RECENT ACCOUNTING PRONOUNCEMENTS                                                

In June 1997, the Financial Accounting Standards Board issued FAS 130,
"Reporting for Comprehensive Income" and FAS 131, "Disclosure about Segments of 
an Enterprise and Related Information." In October 1997, the American Institute 
of Certified Public Accountants issued Statement of Position 97-2, "Software    
Revenue Recognition." All three statements are effective for fiscal years       
beginning after December 15, 1997, and are not expected to have a material      
impact on Eclipsys' results of operations or financial condition. Effective     
January 1, 1998, Eclipsys adopted Statement of Position 97-2 and implemented FAS
130.                                                                            

31

S-4
40th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 40th

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND 
RESULTS OF OPERATIONS OF TSI

   This discussion and analysis contains certain forward-looking statements.
These forward-looking statements represent TSI's beliefs, expectations and      
intentions concerning future events, including, without limitation, financial   
matters, plans and objectives of management for future operations, products and 
services, the future economic performance of TSI, and the assumptions underlying
such beliefs, expectations and intentions. Such statements are not guaranties of
future performance, and involve certain risks and uncertainties that could cause
TSI's future results to differ materially from those expressed in any           
forward-looking statements made by or on behalf of TSI. Many of such factors are
beyond TSI's ability to control or predict. Readers are accordingly cautioned   
not to place undue reliance on forward-looking statements. TSI disclaims any    
intent or obligation to update publicly any forward-looking statements, whether 
in response to new information, future events or otherwise. These               
forward-looking statements are further qualified by important factors that could
cause actual results to differ materially from those in the forward-looking     
statements, including, without limitation, those discussed above under the      
heading "Risk Factors" at page 8, and in Item 1A, "Risk Factors," in TSI's      
Annual Report on Form 10-K filed with the Securities and Exchange Commission for
the fiscal year ended September 30, 1997.                                       

OVERVIEW                                                                        

 TSI provides management information technology to hospitals, integrated
delivery networks, physician groups and other health care organizations. Using  
TSI products, these organizations are able to increase efficiency, improve      
quality of care and lower the cost of care delivery. TSI product lines span the 
health care organization's information technology needs, providing data         
integration services, master person identifier solutions, disease management    
products and a clinical data repository as well as enterprise-wide financial,   
operational and clinical decision support. TSI was founded in 1985 and has been 
profitable in each fiscal year since 1987.                                      

TSI's revenues are derived from sales of software licenses and related
implementation services and of software maintenance. The software and           
implementation revenues associated with the licensing and installation of TSI's 
products at an individual customer site typically range from $0.1 million to    
$1.2 million. Software maintenance contracts are sold separately at the time of 
the initial software license sale and are generally renewable annually. Annual  
software maintenance fees range from 15% to 18% of the initial software license 
fee for the product and provide a source of recurring revenue for TSI.          

     Software and implementation revenues are accounted for using the percentage
of completion method, and revenue is recognized as contract milestones are      
reached. The implementation process generally takes from three to twelve months.
The length of time required to complete an implementation depends on many       
factors outside the control of TSI, including the state of the customer's       
existing information systems and the customer's ability to commit the personnel 
and other resources necessary to complete elements of the implementation process
for which the customer is responsible. Revenue attributable to a contract       
milestone is recognized upon certification by the customer that the milestone   
has been met. As a result, TSI may be unable to predict accurately the amount of
revenue it will recognize in any period in connection with the sale of its      
products. The payment terms of a contract may provide that the amount of the    
contract price that TSI is entitled to bill upon achievement of a milestone is  
less than the revenue recognized by TSI in connection with the achievement of   
that milestone. In such cases, the excess of the revenue recognized over the    
amount billed is included in accounts receivable as an "unbilled account        
receivable." Software maintenance fees, which are generally received annually in
advance, are recorded as deferred revenue on TSI's balance sheet and are        
recognized as revenue ratably over the life of the contract. See Notes 2 and 3  
of Notes to Consolidated Financial Statements of TSI.                           

    Cost of software and implementation revenue consists primarily of the cost
of third-party software that is resold by TSI or included in TSI's products,    
personnel costs, the cost of related benefits, travel and living expenses, costs
of materials and other costs related to the installation and implementation of  
TSI's                                                                           

32

S-4
41st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 41st

products, and amortization of capitalized software development costs. Cost of   
maintenance revenue consists primarily of maintenance fees payable by TSI       
associated with the third-party software included in TSI's products and         
personnel costs incurred in providing maintenance and technical support services
to TSI's customers.                                                             

TSI's research and development expenses consist primarily of          
personnel-related costs, including employee salaries and benefits and payments  
to consultants. TSI capitalizes certain software development costs in accordance
with Statement of Financial Accounting Standards ("SFAS") No. 86, "Accounting   
for the Costs of Computer Software to be Sold, Leased or Otherwise Marketed."   
Capitalized software costs are amortized over the life of the product (generally
three years) and amounts amortized are included in cost of software and         
implementation revenue. Capitalized software as a percentage of total research  
and development expense has declined from 17.2% in fiscal 1996 to 15.3% in      
fiscal 1997 and 10.6% in fiscal 1998. In each of fiscal 1996, 1997 and 1998, TSI
capitalized $0.7 million of software development costs, while amortization of   
capitalized software development costs in such years amounted to $0.8 million,  
$0.7 million and $0.7 million, respectively.                                    

  In January 1996, TSI repurchased from New England Medical Center and the
other stockholders of TSI 87.4% of the shares of common stock then issued and   
outstanding on a fully diluted basis for an aggregate purchase price of         
approximately $111.4 million (the "Recapitalization"). The principal purpose of 
this transaction was to provide liquidity for the existing stockholders of TSI  
while permitting them to retain an ownership interest in TSI. The transaction   
has been accounted for by TSI as a leveraged recapitalization. To finance the   
repurchase of these shares, TSI issued to Warburg, Pincus Ventures, L.P. and    
NationsBank Investment Corporation ("NIC") shares of preferred stock for an     
aggregate of $55.0 million. TSI also issued to NIC Senior Subordinated Notes in 
the aggregate principal amount of $10.0 million and a related warrant and made  
borrowings of $40.0 million under a term loan and a revolving credit facility.  
In April 1996, TSI completed an initial public offering of 6,900,000 shares of  
its common stock, which generated net proceeds of $114.4 million. The           
outstanding balance of these borrowings was repaid in full and all outstanding  
Series A non-voting preferred stock was redeemed upon the closing of the initial
public offering.                                                                

     In July 1996, TSI acquired substantially all of the outstanding stock and a
note held by a selling principal of Enterprising HealthCare, Inc. ("Enterprising
HealthCare"), based in Tucson, Arizona, for a total purchase price of           
approximately $1.8 million in cash. Enterprising HealthCare provides system     
integration products and services for the health care market. The acquisition   
was accounted for under the purchase method with the results of Enterprising    
HealthCare included from the date of acquisition. Purchased technology costs of 
$1.6 million are being amortized on a straight-line basis over seven years. Pro 
forma results of operations have not been presented, as the effect of this      
acquisition on the financial statements was not material.                       

  In January 1997, TSI acquired a 19.5% ownership interest in HealthVISION
for $6.0 million in cash. HealthVISION is a Santa Rosa, California provider of  
electronic medical record software. Its products include CareVISION, a          
patient-centered clinical data repository and lifetime patient record system,   
which is expected to constitute an integral component of TSI's Transition IV    
product. On December 3, 1998, TSI completed its acquisition of the remaining    
capital stock of HealthVISION not already owned by TSI. See "-- Subsequent      
Events" below.                                                                  

In September 1997, TSI acquired all the outstanding shares of Vital   
Software Inc. ("Vital"), a privately held developer of products that automate   
the clinical processes unique to medical oncology. The purchase price was       
approximately $6.3 million, which was comprised of $2.7 million in cash and     
252,003 shares of TSI's common stock with a value of $3.6 million. The purchase 
price was allocated entirely to purchased research and development. See Note 16 
of Notes to Consolidated Financial Statements of TSI.                           

33

S-4
42nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 42nd

RESULTS OF OPERATIONS                                                           

The following table sets forth certain revenue and expense data as a  
percentage of TSI's total revenues for each period presented:                   

                                                                [Download Table]

                                                               FISCAL YEAR ENDED   
                                                                 SEPTEMBER 30,     
                                                             --------------------- 
                                                             1996    1997    1998  
                                                             -----   -----   ----- 
                                                                                   
Revenues:                                                                          
  Software and implementation...............................  72.5%   74.1%   68.8%
  Maintenance...............................................  27.5    25.9    31.2 
                                                             -----   -----   ----- 
          Total revenues.................................... 100.0   100.0   100.0 
                                                             -----   -----   ----- 
Cost of revenues:                                                                  
  Software and implementation...............................  21.4    23.2    28.1 
  Maintenance...............................................   9.2     6.4     6.7 
Research and development....................................   9.7     8.7    13.5 
Sales and marketing.........................................  13.2    15.5    18.0 
General and administrative..................................   6.9     8.7     7.4 
Compensation charge.........................................   8.8      --      -- 
Acquired in-process research and development................    --    14.1      -- 
                                                             -----   -----   ----- 
Total operating expenses....................................  69.2    76.6    73.7 
Income from operations......................................  30.8    23.4    26.3 
Net interest income.........................................   0.2     5.6     7.3 
Income before income taxes and extraordinary item...........  31.0    29.0    33.6 
Provision for income taxes..................................  12.6    17.1    13.4 
                                                             -----   -----   ----- 
Net income before extraordinary item........................  18.4    11.9    20.2 
Extraordinary item:                                                                
  Loss on early extinguishment of debt, net of taxes........   6.3      --      -- 
                                                             -----   -----   ----- 
Net income..................................................  12.1    11.9    20.2 
Series A non-voting preferred stock dividends...............   1.7      --      -- 
                                                             -----   -----   ----- 
Net income allocable to common stockholders.................  10.4%   11.9%   20.2%
                                                             =====   =====   ===== 

FISCAL YEARS ENDED SEPTEMBER 30, 1998 AND SEPTEMBER 30, 1997                    

  REVENUES.  TSI's total revenues decreased 1.4%, to $44.0 million in 1998
from $44.6 million in 1997. Software and implementation revenues decreased 8.5% 
to $30.2 million in 1998, compared to $33.0 million in 1997. The decrease in    
software and implementation revenue is primarily due to TSI's failure to achieve
planned levels of new system bookings. New system bookings were adversely       
impacted by an overall lengthening of the sales cycle. TSI believes the sales   
cycle was adversely affected by Year 2000 problems in healthcare legacy systems,
which caused delays in the acquisition of new systems due to resource           
constraints. In addition, consolidation among healthcare providers has caused a 
lengthening of the purchasing cycle of most healthcare organizations due to     
management shifts and more complex approval processes. Maintenance revenue grew 
18.9% to $13.7 million in 1998, compared to $11.6 million in 1997, due to       
continued growth in TSI's installed base of customers.                          

  COST OF REVENUES.  Cost of software and implementation revenue increased
20.0% to $12.4 million (or 40.9% of software and implementation revenue) in     
1998, from $10.3 million (or 31.2% of software and implementation revenue) in   
1997. The increase is primarily due to costs associated with additional         
implementation staff and professional consultants as well as increased royalty  
costs for third-party software. Cost of maintenance revenue increased 3.4% to   
$2.9 million (or 21.4% of maintenance revenue) in 1998 from $2.8 million (or    
24.6% of maintenance revenue) in 1997. The increase in cost of maintenance      

34

S-4
43rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 43rd

revenue is primarily due to the increase in the number of technical support     
staff necessary to support the growth in TSI's installed base.                  

RESEARCH AND DEVELOPMENT.  Research and development expenses increased
53.0% to $5.9 million in 1998 from $3.9 million in 1997. Research and           
development expenses as a percent of total revenue also increased to 13.5% in   
1998, compared to 8.7% in 1997. The increase is primarily due to an increase in 
staff and increased professional consulting expense to support new product      
development, including Transition IV and Vital Oncology, without a corresponding
increase in revenue.                                                            

    SALES AND MARKETING.  Sales and marketing expenses increased 14.2% to $7.9
million in 1998, from $6.9 million in 1997. Sales and marketing expenses as a   
percent of total revenue also increased to 18.0% in 1998 from 15.5% in 1997. The
increase in spending is primarily associated with the growth of the sales       
organization and marketing programs to support the expanding product lines.     

    GENERAL AND ADMINISTRATIVE.  General and administrative expenses decreased
16.5% to $3.2 million in 1998, from $3.9 million in 1997. General and           
administrative expenses as a percent of total revenue also decreased to 7.4% in 
1998 from 8.7% in 1997. The decrease in spending is primarily due to a reduction
in performance related compensation expenses during the year as a result of the 
decrease in revenue.                                                            

     ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT.  Acquired in-process research
and development expense for 1997 includes a charge for purchased research and   
development of $6.3 million relating to the acquisition of Vital.               

     NET INTEREST INCOME.  Net interest income increased to $3.2 million in 1998
from $2.5 million in 1997. The increase in net interest income is attributable  
to the interest generated on higher cash balances during fiscal 1998.           

   PROVISION FOR INCOME TAXES.  TSI's effective income tax rate decreased to
40.0% in 1998 from 58.9% in 1997. The decrease was primarily due to the effect  
of the charge for in-process research and development associated with the       
acquisition of Vital, which was not deductible for tax purposes in fiscal year  
1997. No such charge occurred in 1998.                                          

FISCAL YEARS ENDED SEPTEMBER 30, 1997 AND SEPTEMBER 30, 1996                    

   REVENUES.  TSI's total revenues increased 30.0% to $44.6 million in 1997,
from $34.3 million in 1996. Software and implementation revenues grew 32.8% to  
$33.0 million in 1997, compared to $24.9 million in 1996. The growth in software
and implementation revenue is primarily due to sales to new TSI customers,      
increased consolidation among existing customers which resulted in the sale of  
additional site licenses, and the expansion of TSI's product line which resulted
in increased product sales to existing customers. Maintenance revenue grew 22.7%
to $11.5 million in 1997, compared to $9.4 million in 1996, due to continued    
growth in TSI's installed base of customers.                                    

  COST OF REVENUES.  Cost of software and implementation revenue increased
40.5% to $10.3 million (or 31.2% of software and implementation revenue) in     
1997, from $7.3 million (or 29.5% of software and implementation revenue) in    
1996. The dollar increase is primarily due to costs associated with additional  
implementation staff and professional consultants as well as increased royalty  
costs for third-party software. Cost of maintenance revenue decreased 10.4% to  
$2.8 million (or 24.6% of maintenance revenue) in 1997 from $3.2 million (or    
33.6% of maintenance revenue) in 1996. The decrease in cost of maintenance      
revenue is primarily due to the reduced technical support necessary on mature   
products.                                                                       

RESEARCH AND DEVELOPMENT.  Research and development expenses increased
17.0% to $3.9 million in 1997 from $3.3 million in 1996. The increase in        
spending is primarily a result of organizational changes which resulted in a net
increase in the number of staff assigned to research and development roles.     
Research and development expenses as a percent of total revenue decreased       
slightly to 8.7% in 1997, compared to 9.7% in 1996. The decrease is primarily   
due to increased productivity from investments in technologies made in prior    
years and maturing of the core product lines. TSI expects that research and     

35

S-4
44th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 44th

development expenses will increase as a percentage of revenue in future periods 
as new development projects are undertaken.                                     

    SALES AND MARKETING.  Sales and marketing expenses increased 53.6% to $6.9
million in 1997, from $4.5 million in 1996. Sales and marketing expenses as a   
percent of total revenue also increased to 15.5% in 1997 from 13.2% in 1996. The
increase in spending is primarily due to additional staff and marketing programs
as well as increased commission expense directly related to the growth in       
revenue.                                                                        

    GENERAL AND ADMINISTRATIVE.  General and administrative expenses increased
64.2% to $3.9 million in 1997, from $2.4 million in 1996. General and           
administrative expenses as a percent of total revenue also increased to 8.7% in 
1997 from 6.9% in 1996. The increase in spending is primarily due to            
professional services and other costs associated with becoming a publicly traded
company as well as additional administrative expenses related to Enterprising   
HealthCare, which was acquired in July 1996.                                    

    COMPENSATION CHARGE.  In fiscal 1996 TSI incurred a compensation charge of
$3.0 million arising from its acquisition, in connection with the January 1996  
Recapitalization, of shares of common stock issued to certain executive officers
pursuant to the exercise of options.                                            

     ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT.  Acquired in-process research
and development expense includes a charge for purchased research and development
of $6.3 million relating to the acquisition of Vital in September 1997.         

     NET INTEREST INCOME.  Net interest income increased to $2.5 million in 1997
from $0.1 million in 1996. The increase in net interest income is primarily due 
to the repayment out of the proceeds of TSI's initial public offering in April  
1996 of debt incurred in the January 1996 Recapitalization and interest earned  
on cash balances generated from operations and the balance of the proceeds of   
TSI's initial public offering.                                                  

   PROVISION FOR INCOME TAXES.  TSI's effective income tax rate increased to
58.9% in 1997 from 40.6% in 1996, primarily due to the effect of the charge for 
in-process research and development associated with the acquisition of Vital,   
which is not deductible for tax purposes. The tax rate for 1997 without the     
effect of the charge for in-process research and development was 39.7%.         

LIQUIDITY AND CAPITAL RESOURCES                                                 

   At September 30, 1998, TSI had cash and cash equivalents of $38.7 million
and short term investments of $27.3 million, an increase of $7.5 million from   
the amount at September 30, 1997. The increase in cash and cash equivalents and 
short term investments was comprised primarily of net cash provided by operating
activities of $10.0 million. Net cash provided by operating activities in fiscal
1998 was generated primarily from net income.                                   

     TSI has an unsecured revolving line of credit in the amount of $15 million.
The credit facility contains covenants setting minimum net worth, maximum       
leverage ratio and minimum net income requirements for TSI. There have been no  
amounts drawn on this line. Advances under the revolving line of credit bear    
interest, at TSI's election, either at a "base rate" or at a "eurodollar rate." 
The base rate is a floating rate equal to the greater of (a) the prime rate or  
(b) the federal funds effective rate plus one-half of one percent (.50%). The   
eurodollar rate is equal to the sum of (x) a rate determined by reference to the
then-current interbank offered rate for dollar-denominated eurodollar deposits, 
with certain adjustments, plus (y) one percent (1.0%).                          

     TSI believes available funds, cash generated from operations and its unused
line of credit of $15 million will be sufficient to finance TSI's operations and
planned capital expenditures for at least the next twelve months. There can be  
no assurance, however, that TSI will not require additional financing during    
that time or thereafter.                                                        

36

S-4
45th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 45th

YEAR 2000 ISSUES                                                                

   TSI's software license agreements generally contain warranties concerning
the Year 2000 compliance of the licensed product. TSI has tested the products it
has developed internally and believes that, with the exception of its Transition
for Quality product (for which TSI expects to release a fully Year 2000         
compliant version in early 1999), the current release of each of its internally 
developed products is Year 2000 compliant. TSI includes in its products certain 
software licensed from third-party vendors. TSI has not yet completed its       
evaluation of Year 2000 compliance of all such third-party software. For        
example, TSI has not yet verified that Uniface, licensed from Compuware         
Corporation, is Year 2000 compliant. In order to use TSI's products customers   
must themselves license software, including certain operating system and        
database management system software, from third-party vendors such as Microsoft 
Corporation and Oracle Corporation. Not all such third-party software may be    
fully Year 2000 compliant. For example, Microsoft Corporation has not certified 
that its Windows NT operating system is Year 2000 compliant. TSI has also       
evaluated the Year 2000 compliance of its critical internal software systems,   
including its financial, payroll and human resources systems and its telephone  
switch, and believes, based in part on certification from the vendors of such   
systems, that such systems are Year 2000 compliant. TSI does not expect to incur
material costs in completing its Year 2000 assessment and remediation program.  
However, the discovery of previously undetected Year 2000 defects in TSI's      
products (including those licensed from third-party vendors), in third-party    
software required for customers to use TSI's products or in its internal        
software systems could damage TSI's business. Also, apprehension in the         
marketplace over Year 2000 compliance issues has led and may in the future lead 
businesses, including customers of TSI, to defer significant capital investments
in information technology programs and software. They could elect to defer those
investments either because they decide to focus their capital budgets on the    
expenditures necessary to bring their own existing systems into compliance or   
because they wish to purchase only software with a proven ability to process    
data after 1999.                                                                

SUBSEQUENT EVENTS                                                               

On October 29, 1998, TSI entered into the Merger Agreement pursuant to
which a wholly-owned subsidiary of Eclipsys will be merged into TSI, with TSI   
becoming a wholly-owned subsidiary of Eclipsys.                                 

On December 3, 1998, TSI completed its acquisition of HealthVISION by 
acquiring the approximately 80.5% of the outstanding capital stock of           
HealthVISION not already owned by TSI for cash in the amount of $25.6 million   
plus assumed liabilities of $9.3 million, net of cash acquired, plus an earn-out
of up to $10.8 million if specified financial milestones are met. The           
acquisition will be accounted for as a purchase. HealthVISION's total revenues  
for the year ended December 31, 1997 and for the nine-month period ended        
September 30, 1998, were approximately $9.2 million and $9.4 million,           
respectively. HealthVISION incurred net losses of $11.1 million and $6.0 million
for such periods, respectively. At September 30, 1998, HealthVISION employed    
approximately 150 persons in seven offices in the United States, Canada and     
Australia.                                                                      

NEW ACCOUNTING PRONOUNCEMENTS                                                   

In June 1997, the Financial Accounting Standards Board ("FASB") issued
Statement of Financial Accounting Standard No. 130, "Reporting Comprehensive    
Income" ("SFAS 130"), which establishes standards for reporting and display of  
comprehensive income and its components (revenue, expenses, gains and losses) in
a full set of general purpose financial statements. TSI will be required to     
adopt the standard in the first quarter of its 1999 fiscal year, and does not   
believe this statement will have a material effect on TSI's financial position  
or results of operations.                                                       

  In June 1997, the FASB issued Statement of Financial Accounting Standard
No. 131 ("SFAS 131"), "Disclosure about Segments of an Enterprise and Related   
Information." Based on the management approach to segment reporting, SFAS No.   
131 establishes requirements to report selected segment information quarterly   
and to report entity-wide disclosures about products and services, major        
customers                                                                       

37

S-4
46th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 46th

and the countries in which the entity holds material assets and reports material
revenue. TSI will be required to adopt the standard in the first quarter of its 
1999 fiscal year, and does not believe this statement will have a material      
effect on TSI's financial disclosures.                                          

   In June 1998, the FASB issued Statement of Financial Accounting Standards
No. 133 ("SFAS 133") "Accounting for Derivative Instruments and Hedging         
Activities," which establishes accounting and reporting standards for such      
instruments. SFAS 133 is effective for fiscal years beginning after June 15,    
1999. Currently, TSI has no such derivative holdings.                           

 On October 27, 1997, the AICPA Accounting Standards Executive Committee
issued Statement of Position 97-2 ("SOP 97-2"), "Software Revenue Recognition." 
SOP 97-2 supersedes Statement of Position 91-1, "Software Revenue Recognition," 
and provides guidance on when and in what amounts revenue should be recognized  
for the licensing, selling, leasing, or marketing of computer software. SOP 97-2
is effective for transactions beginning in the first quarter of TSI's 1999      
fiscal year. TSI is analyzing the impact of the SOP which may cause a deferral  
of revenue.                                                                     

38

S-4
47th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 47th

ECLIPSYS SPECIAL STOCKHOLDERS' MEETING

GENERAL                                                                         

This Joint Proxy Statement/Prospectus is being furnished to holders of
Eclipsys Voting Common Stock in connection with the solicitation of proxies by  
the Board of Directors of Eclipsys (the "Eclipsys Board") for use at the        
Eclipsys Special Stockholders' Meeting to be held on December 30, 1998, at the  
Delray Beach Marriott, 10 North Ocean Boulevard, Delray Beach, Florida 33444,   
commencing at 10:00 a.m., local time, and at any adjournment or postponement    
thereof.                                                                        

   This Joint Proxy Statement/Prospectus and the accompanying forms of proxy
are first being mailed to stockholders of Eclipsys on or about December 7, 1998.

Eclipsys' management does not expect a representative from Eclipsys'  
accountants to attend the Eclipsys Special Stockholders' Meeting.               

MATTERS TO BE CONSIDERED                                                        

   At the Eclipsys Special Stockholders' Meeting, holders of Eclipsys Voting
Common Stock will be asked to consider and vote upon the issuance of shares of  
Eclipsys Voting Common Stock in connection with the Merger. This matter is      
referred to as the "Eclipsys Voting Proposal."                                  

BOARD OF DIRECTORS' RECOMMENDATIONS                                             

The Eclipsys Board has, by unanimous vote of all directors present,   
approved the Merger and the Merger Agreement and recommends a vote FOR approval 
of the Eclipsys Voting Proposal.                                                

RECORD DATE AND VOTING                                                          

     Holders of record of shares of Eclipsys Voting Common Stock at the close of
business on November 30, 1998 (the "Record Date") are entitled to notice of and 
to vote at the Eclipsys Special Stockholders' Meeting. At such date, there were 
19,461,642 outstanding shares of Eclipsys Voting Common Stock, each of which is 
entitled to one vote at the Eclipsys Special Stockholders' Meeting, which shares
were held by approximately 162 holders of record. The representation, in person 
or by properly executed proxy, of the holders of a majority of all of the shares
of stock entitled to vote at the Eclipsys Special Stockholders' Meeting is      
necessary to constitute a quorum at the Eclipsys Special Stockholders' Meeting. 

   The approval of the Eclipsys Voting Proposal will require the affirmative
vote of the holders of a majority of the shares of Eclipsys Voting Common Stock 
present in person or represented by proxy and voting at the Eclipsys Special    
Stockholders' Meeting.                                                          

    Shares of Eclipsys Voting Common Stock, represented in person or by proxy,
will be counted for the purpose of determining whether a quorum is present at   
the Eclipsys Special Stockholders' Meeting. Shares that abstain from voting as  
to a particular matter will be treated as shares that are present and entitled  
to vote at the Eclipsys Special Stockholders' Meeting for purposes of           
determining whether a quorum exists, but will not be counted as votes cast on   
such matter. If a broker or nominee holding stock in "street name" indicates on 
a proxy that it does not have discretionary authority to vote as to a particular
matter ("broker non-votes"), those shares will be treated as present and        
entitled to vote at the Eclipsys Special Stockholders' Meeting for purposes of  
determining whether a quorum exists, but will not be counted as votes cast on   
such matter. Accordingly, in determining whether the Eclipsys Voting Proposal   
has received the requisite number of affirmative votes, abstentions and broker  
non-votes will have no effect on the voting on such proposal.                   

     Stockholders of Eclipsys who have voting control over outstanding shares of
Eclipsys Voting Common Stock representing 53.8% of the votes that may be cast at
the Eclipsys Special Stockholders' Meeting have irrevocably appointed TSI as    
proxy to vote all shares of Eclipsys Voting Common Stock held by such           

39

S-4
48th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 48th

stockholders, in favor of the Eclipsys Voting Proposal at the Eclipsys Special  
Stockholders' Meeting. In addition, directors and executive officers of Eclipsys
who, together with their affiliates, may be deemed to have voting control over  
approximately 5.6% of the outstanding shares of Eclipsys Voting Common Stock not
covered by the Voting Agreements described in the previous sentence, have       
advised Eclipsys that they intend to vote or direct the vote of all shares of   
Eclipsys Voting Common Stock over which they have voting control for approval of
the Eclipsys Voting Proposal.                                                   

PROXIES                                                                         

This Joint Proxy Statement/Prospectus is being furnished to Eclipsys  
stockholders in connection with the solicitation of proxies by and on behalf of 
the Eclipsys Board for use at the Eclipsys Special Stockholders' Meeting, and is
accompanied by a form of proxy.                                                 

   All shares of Eclipsys Voting Common Stock which are entitled to vote and
are represented at the Eclipsys Special Stockholders' Meeting by properly       
executed proxies received prior to or at such meeting, and not revoked, will be 
voted at such meeting in accordance with the instructions indicated on such     
proxies. If no instructions are indicated (other than in the case of broker     
non-votes), such proxies will be voted for approval of the Eclipsys Voting      
Proposal.                                                                       

If any other matters are properly presented at the Eclipsys Special   
Stockholders' Meeting for consideration, including, among other things,         
consideration of a motion to adjourn such meeting to another time and/or place  
(including, without limitation, for the purpose of soliciting additional        
proxies), the persons named in the enclosed forms of proxy and acting thereunder
will have discretion to vote on such matters in accordance with their best      
judgment.                                                                       

    Any proxy given pursuant to this solicitation may be revoked by the person
giving it at any time before it is voted. Proxies may be revoked by (i) filing  
with the Secretary of Eclipsys, at or before the taking of the vote at the      
Eclipsys Special Stockholders' Meeting, a written notice of revocation bearing a
later date than the proxy, (ii) duly executing a later dated proxy relating to  
the same shares and delivering it to the Secretary of Eclipsys before the taking
of the vote at the Eclipsys Special Stockholders' Meeting, or (iii) attending   
the Eclipsys Special Stockholders' Meeting and voting in person (although       
attendance at the Eclipsys Special Stockholders' Meeting will not in and of     
itself constitute a revocation of a proxy). Any written notice of revocation or 
subsequent proxy should be sent to Eclipsys Corporation, 777 East Atlantic      
Avenue, Suite 200, Delray Beach, Florida 33483, Attention: Secretary, or hand   
delivered to the Secretary of Eclipsys at or before the taking of the vote at   
the Eclipsys Special Stockholders' Meeting.                                     

  All expenses of Eclipsys' solicitation of proxies, including the cost of
preparing and mailing this Joint Proxy Statement/Prospectus to Eclipsys         
stockholders, will be borne by Eclipsys. In addition to solicitation by use of  
the mails, proxies may be solicited from Eclipsys stockholders by directors,    
officers and employees of Eclipsys in person or by telephone, facsimile or other
means of communication. Such directors, officers and employees will not be      
additionally compensated, but may be reimbursed for reasonable out-of-pocket    
expenses in connection with such solicitation. In addition, Eclipsys has engaged
MacKenzie Partners, Inc., a proxy solicitation firm, to assist in the           
solicitation of proxies for the Eclipsys Special Stockholders' Meeting. Such    
firm may solicit proxies in person or by means of telephone, facsimile or other 
means of communication. Such firm has been engaged on customary terms and fees  
paid to such firm will not be material. Arrangements will also be made with     
brokerage houses, custodians, nominees and fiduciaries for forwarding of proxy  
solicitation materials to beneficial owners of shares held of record by such    
brokerage houses, custodians, nominees and fiduciaries, and Eclipsys will       
reimburse such brokerage houses, custodians, nominees and fiduciaries for their 
reasonable expenses incurred in connection therewith.                           

40

S-4
49th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 49th

TSI SPECIAL STOCKHOLDERS' MEETING 

GENERAL                                                                         

    This Joint Proxy Statement/Prospectus is being furnished to holders of TSI
Voting Common Stock in connection with the solicitation of proxies by the Board 
of Directors of TSI (the "TSI Board") for use at the TSI Special Stockholders'  
Meeting to be held on December 30, at the offices of Foley, Hoag & Eliot LLP,   
One Post Office Square, 16th Floor, Boston, Massachusetts 02109, commencing at  
10:00 a.m., local time, and at any adjournment or postponement thereof.         

   This Joint Proxy Statement/Prospectus and the accompanying forms of proxy
are first being mailed to Stockholders of TSI on or about December 7, 1998.     

   TSI's management does not expect a representative of TSI's accountants to
attend the TSI Special Stockholders' Meeting.                                   

MATTERS TO BE CONSIDERED                                                        

At the TSI Special Stockholders' Meeting, holders of TSI Voting Common
Stock will be asked to consider and vote upon a proposal to approve and adopt   
the Merger Agreement and the Merger.                                            

BOARD OF DIRECTORS' RECOMMENDATIONS                                             

    The TSI Board has unanimously approved the Merger Agreement and the Merger
and recommends a vote FOR approval and adoption of the Merger Agreement and the 
Merger.                                                                         

RECORD DATE AND VOTING                                                          

The TSI Board has fixed November 30, 1998 as the record date for the  
determination of the TSI stockholders entitled to notice of and to vote at the  
TSI Special Stockholders' Meeting. Accordingly, only holders of record of shares
of TSI Voting and Non-Voting Common Stock on the Record Date are entitled to    
notice of the TSI Special Stockholders' Meeting and only holders of record of   
shares of TSI Voting Common Stock on the Record Date are entitled to vote at the
TSI Special Stockholders' Meeting. As of the Record Date, there were outstanding
and entitled to vote 18,047,762 shares of TSI Voting Common Stock (constituting 
all of the voting stock of TSI), which shares were held by approximately 30     
holders of record. Each holder of record of shares of TSI Voting Common Stock on
the Record Date is entitled to one vote per share, which may be cast either in  
person or by properly executed proxy, at the TSI Special Stockholders' Meeting. 
The presence, in person or by properly executed proxy, of the holders of a      
majority of the outstanding shares of TSI Voting Common Stock entitled to vote  
at the TSI Special Stockholders' Meeting is necessary to constitute a quorum at 
the TSI Special Stockholders' Meeting.                                          

   The approval and adoption of the Merger Agreement and Merger will require
the affirmative vote of the holders of at least two-thirds of the shares of TSI 
Voting Common Stock outstanding on the Record Date.                             

     Shares of TSI Voting Common Stock represented in person or by proxy will be
counted for the purpose of determining whether a quorum is present at the TSI   
Special Stockholders' Meeting. Shares which abstain from voting as to a         
particular matter, and shares held by a broker or nominee in "street name" which
indicates on a proxy that it does not have discretionary authority to vote as to
a particular matter, will be treated as shares that are present and entitled to 
vote at the TSI Special Stockholders' Meeting for purposes of determining       
whether a quorum exists. Because the Merger Agreement must be approved by the   
holders of at least two-thirds of the shares of TSI Voting Common Stock         
outstanding on the Record Date, abstentions and broker non-votes will have the  
same effect as a vote against the Merger Agreement.                             

Certain stockholders of TSI, who have voting control over outstanding 
shares of TSI Voting Common Stock representing 34.4% of the votes that may be   
cast at the TSI Special Stockholders' Meeting, have                             

41

S-4
50th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 50th

irrevocably appointed Eclipsys as proxy to vote all shares of TSI Voting Common 
Stock held by such stockholders in favor of the proposal to approve the Merger  
Agreement and Merger at the TSI Special Stockholders' Meeting.                  

PROXIES                                                                         

This Joint Proxy Statement/Prospectus is being furnished to TSI       
stockholders in connection with the solicitation of proxies by and on behalf of 
the TSI Board for use at the TSI Special Stockholders' Meeting, and is          
accompanied by a form of proxy.                                                 

  All shares of TSI Voting Common Stock which are entitled to vote and are
represented at the TSI Special Stockholders' Meeting by properly executed       
proxies received prior to or at such meeting, and not revoked, will be voted at 
such meeting in accordance with the instructions indicated on such proxies. If  
no instructions are indicated (other than in the case of broker non-votes), such
proxies will be voted for approval and adoption of the Merger and the Merger    
Agreement.                                                                      

If any other matters are properly presented at the TSI Special        
Stockholders' Meeting for consideration, including, among other things,         
consideration of a motion to adjourn such meeting to another time and/or place  
(including, without limitation, for the purpose of soliciting additional        
proxies), the persons named in the enclosed forms of proxy and acting thereunder
will have discretion to vote on such matters in accordance with their best      
judgment.                                                                       

    Any proxy given pursuant to this solicitation may be revoked by the person
giving it at any time before it is voted. Proxies may be revoked by (i) filing  
with the Clerk of TSI, at or before the taking of the vote at the TSI Special   
Stockholders' Meeting, a written notice of revocation bearing a later date than 
the proxy, (ii) duly executing a later dated proxy relating to the same shares  
and delivering it to the Clerk of TSI before the taking of the vote at the TSI  
Special Stockholders' Meeting or (iii) attending the TSI Special Stockholders'  
Meeting and voting in person (although attendance at the TSI Special            
Stockholders' Meeting will not in and of itself constitute a revocation of a    
proxy). Any written notice of revocation or subsequent proxy should be sent to  
Transition Systems, Inc., One Boston Place, Boston, Massachusetts 02108,        
Attention: Clerk, or hand delivered to the Clerk of TSI at or before the taking 
of the vote at the TSI Special Stockholders' Meeting.                           

All expenses of TSI's solicitation of proxies, including the cost of  
mailing this Joint Proxy Statement/ Prospectus to TSI stockholders, will be     
borne by TSI. In addition to solicitation by use of the mails, proxies may be   
solicited from TSI stockholders by directors, officers and employees of TSI in  
person or by telephone, facsimile or other means of communication. Such         
directors, officers and employees will not be additionally compensated, but may 
be reimbursed for reasonable out-of-pocket expenses in connection with such     
solicitation. In addition, TSI has engaged MacKenzie Partners, Inc., a proxy    
solicitation firm, to assist in the solicitation of proxies for the TSI Special 
Stockholders' Meeting. Such firm may solicit proxies in person or by means of   
telephone, facsimile or other means of communication. Such firm has been engaged
on customary terms and fees paid to such firm will not be material. Arrangements
will also be made with brokerage houses, custodians, nominees and fiduciaries   
for forwarding of proxy solicitation materials to beneficial owners of shares   
held of record by such brokerage houses, custodians, nominees and fiduciaries,  
and TSI will reimburse such brokerage houses, custodians, nominees and          
fiduciaries for their reasonable expenses incurred in connection therewith.     

  TSI STOCKHOLDERS SHOULD NOT SEND ANY STOCK CERTIFICATES WITH THEIR PROXY
CARDS.                                                                          

42

S-4
51st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 51st

THE MERGER

   THE DISCUSSION IN THIS JOINT PROXY STATEMENT/PROSPECTUS OF THE MERGER AND
THE PRINCIPAL TERMS OF THE MERGER AGREEMENT IS SUBJECT TO, AND QUALIFIED IN ITS 
ENTIRETY BY REFERENCE TO, THE MERGER AGREEMENT, A COPY OF WHICH IS ATTACHED TO  
THIS JOINT PROXY STATEMENT/PROSPECTUS AS ANNEX A AND IS INCORPORATED HEREIN BY  
REFERENCE.                                                                      

BACKGROUND TO THE MERGER                                                        

     In March 1998, TSI management began to consider whether, due to competitive
pressures in the healthcare information technology industry, consolidation of   
competitors within this industry and other factors, TSI should investigate      
various strategic alternatives available to it, including a possible sale of    
TSI.                                                                            

On March 30, 1998, TSI retained BT Alex. Brown Incorporated ("BT Alex.
Brown") to provide advisory and investment banking services to TSI with respect 
to its exploration of strategic alternatives, including the possible merger or  
sale of TSI, and authorized management and BT Alex. Brown to contact potential  
acquirors of TSI.                                                               

    From April through October, 1998, at the direction of TSI, representatives
of BT Alex. Brown and TSI management had conversations from time to time with   
various companies concerning the possibility of a strategic alliance or business
combination with TSI. These conversations were exploratory in nature and did not
progress to the point of specific proposals that the TSI Board considered       
acceptable.                                                                     

     On September 16, 1998, Mr. Harvey J. Wilson, the President, Chief Executive
Officer and Chairman of the Board of Eclipsys, met over dinner with Mr. Robert  
F. Raco, the President, Chief Executive Officer and Chairman of the Board of    
TSI, and Ms. Christine Shapleigh, Senior Vice President of Business Development 
for TSI, to explore the possibility of a strategic alliance between Eclipsys and
TSI. Messrs. Wilson and Raco and Ms. Shapleigh determined and agreed that there 
were potential strategic advantages to a combination of Eclipsys and TSI, if    
mutually agreeable terms could be negotiated.                                   

   On September 22, 1998, representatives of Eclipsys, TSI, General Atlantic
Partners, LLC ("General Atlantic") and Warburg, Pincus Ventures, L.P.           
("Warburg") met to explore the possibility of an alliance between the companies.
Representatives of Eclipsys made a presentation to TSI and Warburg to           
familiarize them with the organization, business, products and services of      
Eclipsys.                                                                       

On September 24, 1998, Mr. Wilson wrote to Mr. Raco and Mr. Patrick T.
Hackett, a director of TSI and a Managing Director of Warburg, to propose a     
business combination between Eclipsys and TSI.                                  

  On September 30 and October 1, 1998, representatives of Warburg, General
Atlantic, Eclipsys, TSI and BT Alex. Brown met to discuss the possibility of a  
business combination. Preliminary discussions were held relating to the         
valuation, structure and other terms for such a combination.                    

    On October 2, 1998, TSI and Eclipsys executed a confidentiality agreement,
following which both TSI and Eclipsys began to share financial and other        
confidential information for use by the other company in its due diligence      
investigation.                                                                  

    From October 5, 1998 through October 9, 1998, representatives and advisors
of Eclipsys met at TSI's offices to conduct business, financial and legal due   
diligence reviews of TSI. On October 8 and October 9, 1998, TSI's management    
made presentations to Eclipsys representatives to familiarize them with the     
organization, business, products and services of TSI. On October 12, 1998, an   
initial draft of the Merger Agreement was distributed by Hale and Dorr LLP,     
outside counsel to Eclipsys ("Hale and Dorr").                                  

From October 14, 1998 through October 16, 1998, representatives and   
advisors of TSI met at Eclipsys' Atlanta office to conduct business, financial  
and legal due diligence reviews of Eclipsys and discussions with representatives
of Eclipsys.                                                                    

    On October 19, 1998, representatives of Eclipsys met with TSI customers in
Ohio and California as part of the business due diligence review. On October 20,
1998 and October 21, 1998, representatives of                                   
43

S-4
52nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 52nd

Eclipsys met with representatives and advisors of TSI at HealthVISION's         
headquarters in Santa Rosa, California, to conduct due diligence reviews of     
HealthVISION. Since early 1998, TSI had been engaged in discussions with        
HealthVISION regarding the acquisition by TSI of the 80.5% of the outstanding   
capital stock of HealthVISION not already owned by TSI.                         

    On October 21, 1998, Foley, Hoag & Eliot LLP, outside legal counsel to TSI
("Foley Hoag"), provided written comments on the initial draft of the Merger    
Agreement.                                                                      

 On October 23, 1998, representatives of TSI, Warburg, Eclipsys, General
Atlantic and BT Alex. Brown met to negotiate the principal business terms of the
Merger.                                                                         

   On October 24, 1998, the Eclipsys Board met telephonically to discuss the
proposed merger. The Eclipsys Board reviewed with Eclipsys management and       
discussed, among other things, the status of the discussions with TSI, the      
strategic rationale for the combination, the benefits and risks associated with 
the combination, the proposed financial terms and conditions of the transaction,
a schedule for completing the transaction, as well as the business and the      
prospects of the companies and other related issues. The Eclipsys Board         
authorized management to continue discussions with representatives of TSI       
regarding a possible business combination.                                      

On October 25, 1998, a revised draft of the Merger Agreement was      
distributed by Hale and Dorr.                                                   

On October 26 and 27, 1998, representatives of Foley Hoag conducted   
additional legal due diligence reviews at Eclipsys' offices in Florida. On      
October 27 and October 28, 1998, representatives of Eclipsys met with           
HealthVISION customers in Florida and New York City as part of the business due 
diligence review.                                                               

On October 26, 1998, the TSI Board met telephonically to discuss the  
proposed merger. The TSI Board reviewed with management and its legal and       
financial advisors, among other things, the status of the discussions with      
Eclipsys, the business and prospects of the two companies, the rationale for the
combination and its benefits and risks, the proposed financial terms of the     
transaction and a schedule for completing it, and other related matters. The TSI
Board authorized management to continue discussions with representatives of     
Eclipsys regarding a possible business combination.                             

Over the course of October 26, 27 and 28, 1998, legal counsel and the 
executive officers of Eclipsys and TSI and representatives of Warburg, General  
Atlantic and BT Alex. Brown held further discussions regarding the terms of the 
proposed Merger Agreement and related documents, including the terms of the     
proposed Voting Agreements, the termination rights contained in the proposed    
Merger Agreement, the conditions upon which any termination fees would be       
payable and the amount of such fees, the rights of Eclipsys and TSI under the   
proposed Merger Agreement to consider and negotiate other acquisition proposals 
in certain circumstances and the representations, warranties and covenants to be
made by Eclipsys and TSI. In addition, the management of both companies and     
their financial advisors continued to have further discussions regarding        
valuation issues relevant to negotiation of a mutually acceptable exchange ratio
for the stock of TSI and Eclipsys, as well as other terms and conditions of a   
possible acquisition of TSI by Eclipsys.                                        

    On October 27, 1998, the Eclipsys Board met telephonically to consider and
vote upon the proposed Merger Agreement and the related agreements. At this     
specially scheduled meeting, (i) management of Eclipsys reported that an        
agreement had been reached as to the principal terms of the Merger Agreement,   
including the Exchange Ratio for the stock of Eclipsys and TSI, (ii) the        
Eclipsys Board considered reports from management, legal and financial advisors 
as to the results of their due diligence investigation of TSI, (iii) management 
responded to questions regarding various aspects of the proposed Merger, (iv)   
management reported on the status of TSI's negotiations with HealthVISION       
regarding the acquisition by TSI of the remaining 80.5% of the outstanding      
capital stock of HealthVISION not already owned by TSI, (v) Eclipsys' legal     
advisors reviewed the proposed definitive terms of the Merger Agreement and     
related documents, (vi) Morgan Stanley & Co. Incorporated ("Morgan Stanley")    
made a presentation to the Eclipsys Board regarding the Exchange Ratio, reviewed
its detailed financial analysis and pro forma and other information with respect
to the companies and delivered its oral opinion to the                          
44

S-4
53rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 53rd

effect that, as of such date, the Exchange Ratio was fair to Eclipsys from a    
financial point of view, which opinion was subsequently confirmed in writing    
(see "-- Opinions of Financial Advisors -- Eclipsys") and (vii) the Eclipsys    
Board, by unanimous vote of those present, approved the Merger, the Merger      
Agreement and related agreements.                                               

    On October 28, 1998, the TSI Board met telephonically to consider and vote
upon the proposed Merger and the Merger Agreement and the related agreements. At
this specially scheduled meeting, (i) management of TSI reported that an        
agreement had been reached as to the principal terms of the Merger Agreement,   
including the Exchange Ratio for the stock of TSI and Eclipsys, (ii) the TSI    
Board considered reports from management, legal and financial advisors as to the
results of their due diligence investigation of Eclipsys, (iii) management and  
TSI's financial and legal advisors responded to questions regarding various     
aspects of the proposed Merger, (iv) TSI's legal advisors held discussions      
regarding the TSI Board's fiduciary duties in considering a business combination
and reviewed proposed definitive terms of the Merger Agreement and related      
documents, including the Voting Agreements, (v) BT Alex. Brown reviewed with the
TSI Board the financial analyses performed by BT Alex. Brown in connection with 
its evaluation of the Exchange Ratio and delivered to the TSI Board its oral    
opinion (which was subsequently confirmed by delivery of a written opinion dated
October 29, 1998, the date of execution of the Merger Agreement) to the effect  
that, as of the date of such opinion and based upon and subject to certain      
matters stated therein, the Exchange Ratio was fair, from a financial point of  
view, to the holders of TSI Voting and Non-Voting Common Stock (see "-- Opinions
of Financial Advisors -- TSI") and (vi) the TSI Board approved the Merger, the  
Merger Agreement and related agreements. At this meeting, the TSI Board also    
approved the HealthVISION Acquisition.                                          

In the evening of October 28, 1998, TSI and HealthVISION executed the 
definitive agreement relating to the acquisition by TSI of the 80.5% of the     
outstanding stock of HealthVISION not already owned by TSI (the "HealthVISION   
Acquisition").                                                                  

   Early in the morning of October 29, 1998, the final version of the Merger
Agreement was distributed to and executed by TSI, Eclipsys and Sub and Voting   
Agreements were executed by certain management personnel and a principal        
stockholder of TSI and by certain principal stockholders of Eclipsys. Prior to  
the opening of trading on the Nasdaq National Market, Eclipsys and TSI issued a 
joint press release announcing the Merger.                                      

RECOMMENDATIONS OF THE BOARDS OF DIRECTORS                                      

     The Eclipsys Board has, by unanimous vote of those present, determined that
the Merger is in the best interests of Eclipsys and its stockholders and        
recommends that the stockholders of Eclipsys vote "FOR" approval of the Eclipsys
Voting Proposal for the reasons set forth below.                                

 The TSI Board has unanimously determined that the Merger is in the best
interests of TSI and its stockholders and recommends that the stockholders of   
TSI vote "FOR" approval and adoption of the Merger and the Merger Agreement for 
the reasons set forth below.                                                    

REASONS FOR THE MERGER                                                          

JOINT REASONS FOR THE MERGER                                          

We believe that the Merger, by combining the complementary product    
offerings, customer bases and other resources of our companies, will position   
the combined company to enjoy greater growth and earnings than either company   
would have experienced individually. The Eclipsys and TSI Boards identified a   
number of potential benefits of the Merger which they believe could contribute  
to the success of the combined company and therefore benefit the stockholders of
both companies, including the following:                                        

  - The Boards believe that the Merger will enable the combined company to
offer a broader range of products, product features and technical 
solutions for customers, enhancing the competitive strength of the
     combined company and increasing its ability to satisfy the requirements
of existing and new customers.                                    

45

S-4
54th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 54th

    - The Boards believe that the Merger will combine the highly complementary
customer bases of the two companies, resulting in more diverse and
       stronger revenue sources and an enhanced ability to cross-market existing
    products of each company to the customer base of the other company, as
      well as the ability to market new products to a larger combined customer
base.                                                             

  - The Boards believe that the Merger will enable the combined company to
       achieve efficiencies and economies of scale in product development, sales
    and marketing, customer service, administration and other areas, which
could not be achieved by either company independently.            

 - The Boards believe that the Merger, by providing the combined company
    with substantially greater financial and other resources, will enhance
       the opportunity for the potential realization of the strategic objectives
      of both companies and increase the combined company's ability to compete
more effectively in the highly competitive healthcare information 
technology industry.                                              

ECLIPSYS' REASONS FOR THE MERGER                                      

  In reaching its conclusion to approve the Merger Agreement, the Eclipsys
Board considered the factors described above under "-- Joint Reasons for the    
Merger," as well as the opportunity of the Eclipsys stockholders to participate 
in the potential growth of the combined company after the Merger.               

    In the course of its deliberations during the Eclipsys Board meetings held
on October 24 and October 27, 1998, the Eclipsys Board considered and reviewed  
with management a number of factors relevant to the Merger, including, but not  
limited to, the following: (i) historical information concerning Eclipsys' and  
TSI's respective businesses, prospects, financial performance and condition,    
operations, technology, management and competitive position, including public   
reports concerning results of operations filed during the most recent fiscal    
year and fiscal quarter for each company with the Securities and Exchange       
Commission (the "Commission"); (ii) the financial condition, results of         
operations and businesses of Eclipsys and TSI before and after giving effect to 
the Merger; (iii) current financial market conditions and historical market     
prices, volatility and trading information with respect to the TSI Voting Common
Stock and the Eclipsys Voting Common Stock; (iv) the consideration to be        
received by TSI's stockholders in the Merger and the relationship between the   
market value of the Eclipsys Voting Common Stock to be issued in exchange for   
each share of TSI Voting and Non-Voting Common Stock and a comparison of        
comparable merger transactions; (v) the belief that the terms of the Merger     
Agreement, including the parties' representations, warranties and covenants, and
the conditions to their respective obligations, are reasonable; (vi) the        
prospects of Eclipsys as an independent company; (vii) detailed financial       
analysis and pro forma and other information with respect to the companies      
presented by Morgan Stanley to the Eclipsys Board, including Morgan Stanley's   
opinion that, as of such date, the Exchange Ratio was fair to Eclipsys from a   
financial point of view (a copy of this opinion is annexed hereto as Annex B and
stockholders are urged to review it carefully); and (viii) reports from         
management, legal and financial advisors as to the results of the due diligence 
investigation of TSI. The Eclipsys Board also considered the terms of the       
proposed Merger Agreement, including the possible effects of the provisions     
regarding termination fees. In addition, the Eclipsys Board noted that the      
Merger is expected to be accounted for as a pooling of interests under U.S. GAAP
and that no goodwill is expected to be created on the books of Eclipsys as a    
result thereof.                                                                 

    The Eclipsys Board also considered a number of potential risks relating to
the Merger, including (i) the risk that the synergies and benefits sought in the
Merger would not be fully achieved, (ii) the risk that the Merger would not be  
consummated, and the effect of the public announcement of the Merger on the     
market price of Eclipsys Voting Common Stock, (iii) the risk that the           
announcement of the Merger would result in a certain degree of disruption in    
Eclipsys' and TSI's marketing efforts, (iv) the substantial charges expected to 
be incurred by Eclipsys in connection with the Merger and (v) various other     
risks, including the risks described under "Risk Factors" herein. The Eclipsys  
Board believed that these risks were outweighed by the potential benefits to be 
realized from the Merger.                                                       

   The foregoing discussion of the information and factors considered by the
Eclipsys Board is not intended to be exhaustive but is believed to include all  
material factors considered by the Eclipsys Board.                              
46

S-4
55th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 55th

In view of the wide variety of information and factors considered, the Eclipsys 
Board did not find it practical to, and did not, assign any relative or specific
weights to the foregoing factors, and individual directors may have given       
differing weights to different factors.                                         

TSI'S REASONS FOR THE MERGER                                          

   In reaching its conclusion to approve the Merger Agreement, the TSI Board
considered the factors described above under "-- Joint Reasons for the Merger," 
as well as the opportunity of the TSI stockholders to participate in the        
potential growth of the combined company after the Merger.                      

In the course of its deliberations during TSI Board meetings held on  
October 26 and 28, 1998, the TSI Board considered and reviewed with management a
number of factors relevant to the Merger, including, but not limited to, the    
following: (i) historical information concerning TSI's and Eclipsys' respective 
businesses, prospects, financial performance and condition, operations,         
technology, management and competitive position, including public reports       
concerning results of operations during the most recent fiscal year and fiscal  
quarter for each company with the Commission; (ii) the financial condition,     
results of operations and businesses of TSI and Eclipsys before and after giving
effect to the Merger; (iii) current financial market conditions and historical  
market prices, volatility and trading information with respect to the TSI Voting
Common Stock and the Eclipsys Voting Common Stock and the limited trading       
history of Eclipsys Voting Common Stock; (iv) the consideration to be received  
by TSI's stockholders in the Merger and the relationship between the market     
value of the Eclipsys Voting Common Stock to be issued in exchange for each     
share of TSI Voting and Non-Voting Common Stock and a comparison of comparable  
merger transactions; (v) the belief that the terms of the Merger Agreement,     
including the parties' representations, warranties and covenants, and the       
conditions to their respective obligations, are reasonable; (vi) the prospects  
of TSI as an independent company; (vii) the potential for other third parties to
enter into strategic relationships with or to acquire TSI; (viii) reports from  
management, legal and financial advisors as to the results of TSI's due         
diligence investigation of Eclipsys; (ix) the financial presentation of BT Alex.
Brown to the TSI Board, including its opinion to the effect that, as of the date
of such opinion and based upon and subject to certain matters stated therein,   
the Exchange Ratio was fair, from a financial point of view, to the holders of  
TSI Voting and Non-Voting Common Stock; and (x) the impact of the Merger on     
TSI's customers and employees. The TSI Board also considered the terms of the   
proposed Merger Agreement regarding TSI's rights to consider and negotiate other
acquisition proposals in certain circumstances, as well as the possible effects 
of the provisions regarding termination fees.                                   

   The TSI Board also considered a number of potential risks relating to the
Merger, including, but not limited to: (i) the risk that the potential benefits 
sought in the Merger might not be fully realized; (ii) the possibility that the 
Merger might not be consummated and the effect of the public announcement of the
Merger on (a) TSI's sales, operating results and stock price, (b) TSI's ability 
to attract and retain key management, sales, marketing, product development and 
technical personnel and (c) progress of certain development projects; (iii) the 
substantial charges to be incurred in connection with the Merger, including     
costs of integrating the businesses and transaction expenses arising from the   
Merger; (iv) the risk that despite the efforts of the Surviving Corporation, key
technical and management personnel might not remain employed by the Surviving   
Corporation; (v) risks associated with fluctuations in Eclipsys' stock price    
prior to closing of the Merger; and (vi) various other risks, including the     
risks described under "Risk Factors" herein. The TSI Board believed that these  
risks were outweighed by the potential benefits of the Merger.                  

   The foregoing discussion of the information and factors considered by the
TSI Board is not intended to be exhaustive but is believed to include all       
material factors considered by the TSI Board. In view of the wide variety of    
information and factors considered, the TSI Board did not find it practical to, 
and did not, assign any relative or specific weights to the foregoing factors,  
and individual directors may have given differing weights to different factors. 

47

S-4
56th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 56th

OPINIONS OF FINANCIAL ADVISORS                                                  

ECLIPSYS                                                              

    Eclipsys retained Morgan Stanley to render a financial opinion letter (the
"Morgan Stanley Opinion") to the Eclipsys Board in connection with the Merger   
and related matters based upon Morgan Stanley's qualifications, expertise and   
reputation. On October 28, 1998, Morgan Stanley rendered an oral opinion, which 
was subsequently confirmed in writing, to the Eclipsys Board that, as of such   
date, and based upon and subject to the considerations set forth in the written 
opinion, the Exchange Ratio pursuant to the Merger Agreement is fair from a     
financial point of view to Eclipsys.                                            

    THE FULL TEXT OF THE MORGAN STANLEY OPINION, DATED AS OF OCTOBER 28, 1998,
WHICH SETS FORTH, AMONG OTHER THINGS, THE ASSUMPTIONS MADE, PROCEDURES FOLLOWED,
MATTERS CONSIDERED AND LIMITATIONS ON THE REVIEW UNDERTAKEN, IS ATTACHED AS     
ANNEX B TO THIS JOINT PROXY STATEMENT/ PROSPECTUS. THE MORGAN STANLEY OPINION IS
DIRECTED TO THE ECLIPSYS BOARD AND THE FAIRNESS OF THE EXCHANGE RATIO PURSUANT  
TO THE MERGER AGREEMENT FROM A FINANCIAL POINT OF VIEW TO ECLIPSYS AS OF THE    
DATE OF SUCH OPINION AND DOES NOT ADDRESS ANY OTHER ASPECT OF THE MERGER, NOR   
DOES IT CONSTITUTE A RECOMMENDATION TO ANY ECLIPSYS STOCKHOLDER AS TO HOW SUCH  
STOCKHOLDER SHOULD VOTE AT THE ECLIPSYS SPECIAL STOCKHOLDERS' MEETING HELD IN   
CONNECTION WITH THE MERGER. THE SUMMARY OF THE MORGAN STANLEY OPINION SET FORTH 
IN THIS JOINT PROXY STATEMENT/ PROSPECTUS IS QUALIFIED IN ITS ENTIRETY BY       
REFERENCE TO THE FULL TEXT OF THE MORGAN STANLEY OPINION ATTACHED AS ANNEX B    
HERETO. STOCKHOLDERS OF ECLIPSYS ARE URGED TO, AND SHOULD, READ THE MORGAN      
STANLEY OPINION CAREFULLY AND IN ITS ENTIRETY.                                  

In arriving at the Morgan Stanley Opinion, Morgan Stanley, among other
things: (i) reviewed certain publicly available financial statements and other  
information of TSI and Eclipsys; (ii) reviewed certain internal financial       
statements and other financial and operating data concerning TSI and Eclipsys   
prepared by the managements of TSI and Eclipsys, respectively; (iii) discussed  
the past and current operations and financial condition and the prospects of TSI
with senior executives of TSI; (iv) discussed the past and current operations   
and financial condition and the prospects of Eclipsys, including information    
relating to certain strategic, financial and operational benefits anticipated   
from the Merger, with senior executives of Eclipsys; (v) discussed with the     
senior managements of TSI and Eclipsys certain research analyst projections for 
TSI and Eclipsys, respectively; (vi) reviewed the pro forma impact of the Merger
on Eclipsys' earnings per share and other financial ratios; (vii) reviewed the  
reported prices and trading activity for the TSI Voting Common Stock and the    
Eclipsys Voting Common Stock; (viii) compared the financial performance of TSI  
and Eclipsys and the prices and trading activity of the TSI Voting Common Stock 
and the Eclipsys Voting Common Stock with that of certain other comparable      
publicly-traded companies and their securities; (ix) reviewed the financial     
terms, to the extent publicly available, of certain comparable acquisition      
transactions; (x) participated in discussions among representatives of TSI and  
Eclipsys and their financial and legal advisors; (xi) reviewed the draft Merger 
Agreement dated October 21, 1998 and certain related documents; and (xii)       
performed such other analyses as Morgan Stanley deemed appropriate.             

In arriving at the Morgan Stanley Opinion, Morgan Stanley assumed and 
relied upon without independent verification the accuracy and completeness of   
the information reviewed by Morgan Stanley for the purposes of its opinion. With
respect to the financial projections, including information relating to certain 
strategic, financial and operational benefits anticipated from the Merger,      
Morgan Stanley assumed that they were reasonably prepared on bases reflecting   
the best currently available estimates and judgments of the future financial    
performance of TSI and Eclipsys, respectively. In addition, Morgan Stanley      
assumed that the Merger will be consummated in accordance with the terms set    
forth in the Merger Agreement, including, among other things, that the Merger   
would be accounted for as a "pooling-of-interests" business                     

48

S-4
57th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 57th

combination in accordance with U.S. GAAP and the Merger will be treated as a    
tax-free reorganization and/or exchange pursuant to the Code. Morgan Stanley did
not make any independent valuation or appraisal of the assets or liabilities of 
TSI, nor was Morgan Stanley furnished with any such appraisals. The Morgan      
Stanley Opinion is necessarily based on economic, market and other conditions as
in effect on, and the information made available to Morgan Stanley as of, the   
date of the Morgan Stanley Opinion.                                             

   The following is a summary of certain of the financial analyses performed
by Morgan Stanley in connection with its rendering the Morgan Stanley Opinion to
the Eclipsys Board on October 28, 1998.                                         

Historical Common Stock Performance.  Morgan Stanley's analysis of TSI
Voting Common Stock performance consisted of an historical analysis of closing  
prices and trading volumes over the period from April 18, 1996 to October 23,   
1998. During that period, based on closing prices on the Nasdaq National Market,
TSI Voting Common Stock achieved a high closing price of $35.63 on May 21, 1996 
and a low closing price of $6.50 on October 7, 1998. Additionally, Morgan       
Stanley noted that TSI Voting Common Stock closed at a price of $8.75 on October
23, 1998.                                                                       

Morgan Stanley's analysis of Eclipsys Voting Common Stock performance 
consisted of an historical analysis of closing prices and trading volumes over  
the period from August 7, 1998 (the date of the Eclipsys IPO) to October 23,    
1998. During that period, based on closing prices on the Nasdaq National Market,
Eclipsys Voting Common Stock achieved a high closing price of $25.45 on October 
20, 1998 and a low closing price of $11.88 on August 31, 1998. Morgan Stanley   
noted that Eclipsys Voting Common Stock closed at a price of $24.88 on October  
23, 1998.                                                                       

Comparative Stock Price Performance.  Morgan Stanley performed an     
historical analysis of closing prices from August 7, 1997 to October 23, 1998 of
TSI Voting Common Stock, the S&P 500 Index and an index of comparable healthcare
information services companies ("Comparable Companies") consisting of Cerner    
Corp., HBO & Co., IDX Systems Corp. and SMS. Morgan Stanley observed that over  
this period, TSI Voting Common Stock decreased 65%, the S&P 500 Index increased 
4% and the index of the Comparable Companies increased 19%.                     

     Morgan Stanley also performed an historical analysis of closing prices from
August 7, 1998 to October 23, 1998 of Eclipsys Voting Common Stock, the S&P 500 
Index and the Comparable Companies. Morgan Stanley observed that over the period
from August 7, 1998 to October 23, 1998, Eclipsys Voting Common Stock increased 
19%, the S&P 500 Index decreased 10% and the index of Comparable Companies      
decreased 10%.                                                                  

Comparable Public Company Analysis.  As part of its analysis, Morgan  
Stanley compared certain publicly available financial information of certain    
comparable companies, including HBO & Co., IDX Systems Corp., Medical Manager   
Corporation, Cerner Corp., Quadramed, MECON and SMS ("Information Services      
Comparable Companies"). Morgan Stanley then compared this information to the    
financial performance of TSI and Eclipsys. Such financial information included  
price to earnings multiples, the ratio of the price to earnings multiple to the 
forecasted long-term earnings growth rate, and the aggregate value to revenue   
multiple, based on First Call median EPS forecasts and research analysts' mid-  
range and low estimates of forward operating performance.                       

Such analyses indicated that as of October 23, 1998 and based on the  
mid-range estimates, TSI Voting Common Stock traded at 20.6 times mid-range     
forecasted earnings for the calendar year 1998, 16.2 times mid-range forecasted 
earnings for the calendar year 1999, (representing a multiple of 0.6 times its  
forecasted, long-term earnings growth rate), and aggregate value represented 2.9
times mid-range forecasted revenues for the calendar year 1998. In addition, the
analyses indicated that as of October 23, 1998 and based on the mid-range       
estimates, Eclipsys Voting Common Stock traded at 77.7 times forecasted earnings
for the calendar year 1998, 42.9 times forecasted earnings for the calendar year
1999, (representing a multiple of 2.1 times its forecasted, long-term earnings  
growth rate), and market capitalization represented 4.3 times forecasted        
revenues for the calendar year 1998. These multiples compared to a range of     
multiples based on 1998 forecasted earnings (16.3 to 33.7 times), 1999 earnings 
(13.0 to 17.0 times), the ratio of the price to 1999 earnings multiple to the   
forecasted long-term growth                                                     

49

S-4
58th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 58th

rates (0.7 to 1.2 times), and multiple of aggregate value to forecasted revenues
(1.3 to 6.8 times) for the Information Services Comparable Companies.           

No company utilized in the comparable public company analysis or the  
comparable stock price performance analysis is identical to TSI or Eclipsys.    
Accordingly, an analysis of the results of the foregoing necessarily involves   
complex considerations and judgments concerning differences in financial and    
operating characteristics of TSI or Eclipsys and other factors that could affect
the public trading value of the companies to which they are being compared. In  
evaluating the comparable companies, Morgan Stanley made judgments and          
assumptions with regard to industry performance, general business, economic,    
market and financial conditions and other matters, many of which are beyond the 
control of TSI or Eclipsys, such as the impact of competition on TSI or Eclipsys
and the industry generally, industry growth and/or technological change and the 
absence of any material adverse change in the financial condition and prospects 
of TSI or Eclipsys or the industry or in the financial markets in general.      
Mathematical analysis (such as determining the mean or median) is not, in       
itself, a meaningful method of using comparable company data.                   

  Discounted Equity Analysis.  Morgan Stanley performed an analysis of the
present value per share of TSI Voting Common Stock's respective future trading  
prices based on ranges of the following assumptions: a range of earnings per    
share estimates for the years 2000 and 2001; illustrative multiples of earnings 
per share, ranging from 16.0 to 20.0; and illustrative discount rates, ranging  
from 12.0% to 18.0%. Based on these assumptions, Morgan Stanley calculated the  
present value of future theoretical trading values, ranging from approximately  
$6 per share to $16 per share.                                                  

Analysis of Selected Precedent Transactions.  Using publicly available
information, Morgan Stanley reviewed the terms of certain announced, pending or 
completed healthcare information services acquisition transactions              
(collectively, the "Healthcare Information Services Transactions"). For the     
Healthcare Information Services Transactions, the median multiple of aggregate  
value to trailing revenues was approximately 4.0.                               

No transaction utilized as a comparison in the analysis of selected   
precedent transactions is identical to the Merger. Accordingly, an analysis of  
the results of the foregoing necessarily involves complex considerations and    
judgments concerning differences in financial and operating characteristics and 
other factors that would affect the acquisition value of the companies to which 
it is being compared. In evaluating the precedent transactions, Morgan Stanley  
made judgments and assumptions with regard to industry performance, global      
business, economic, market and financial conditions and other matters, many of  
which are beyond the control of TSI, such as the impact of competition on TSI   
and the industry generally, and the absence of any adverse material change in   
the financial conditions and prospects of TSI or the industry or the financial  
markets in general. Mathematical analysis (such as determining the mean or      
median) is not, in itself, a meaningful method of using precedent transactions  
data.                                                                           

Exchange Ratio Analysis.  Morgan Stanley analyzed the ratio of closing
prices per share of TSI Voting Common Stock and Eclipsys Voting Common Stock    
from August 7, 1998 to October 23, 1998. Morgan Stanley observed that the       
implied exchange ratio had averaged 0.44 since August 7, 1998, 0.39 over the    
last month period prior to October 23, 1998, and 0.39 over the last two weeks   
prior to October 23, 1998. Morgan Stanley also observed that the implied        
exchange ratio based on the closing market prices of TSI Voting Common Stock and
Eclipsys Voting Common Stock on October 23, 1998 was 0.35.                      

 Pro Forma Analysis of the Merger.  Morgan Stanley performed certain pro
forma analyses of the Merger on the earnings per share of the combined company  
in 1999 and 2000. The pro forma results were based on projected earnings and    
cash flow derived from First Call estimates for TSI and Eclipsys. The pro forma 
analysis also took into account the synergies and cost savings expected to be   
derived from the Merger as estimated by management of Eclipsys. Morgan Stanley  
noted that the Merger would be accretive to Eclipsys' earnings per share in 1999
and 2000.                                                                       

50

S-4
59th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 59th

The preparation of a fairness opinion is a complex process and is not 
necessarily susceptible to a partial analysis or summary description. In        
arriving at its opinion, Morgan Stanley considered the results of all of its    
analyses as a whole and did not attribute any particular weight to any          
particular analysis or factor considered by it. Furthermore, selecting any      
portion of Morgan Stanley's analyses, without considering all analyses, would   
create an incomplete view of the process underlying the Morgan Stanley Opinion. 
In addition, Morgan Stanley may have deemed various assumptions more or less    
probable than other assumptions, so that the ranges of valuations resulting from
any particular analysis described above should not be taken to be Morgan        
Stanley's view of the actual value of TSI or Eclipsys.                          

   In performing its analysis, Morgan Stanley made numerous assumptions with
respect to industry performance, general business and economic conditions and   
other matters, many of which are beyond the control of TSI or Eclipsys. The     
analyses performed by Morgan Stanley are not necessarily indicative of actual   
values, which may be significantly more or less favorable than suggested by such
analyses. Such analyses were prepared solely as a part of Morgan Stanley's      
analysis of the fairness of the exchange ratio pursuant to the Merger Agreement 
from a financial point of view to Eclipsys and were provided to the Eclipsys    
Board in connection with the delivery of the Morgan Stanley Opinion. The        
analyses do not purport to be appraisals or to reflect the prices at which TSI  
or Eclipsys might actually be sold. In addition, as described above, the Morgan 
Stanley Opinion was one of many factors taken into consideration by the Eclipsys
Board in making its determination to approve the Merger.                        

Morgan Stanley is an internationally recognized investment banking and
advisory firm. Morgan Stanley, as part of its investment banking business, is   
regularly engaged in the valuation of businesses and their securities in        
connection with mergers and acquisitions, negotiated underwritings, competitive 
biddings, secondary distributions of listed and unlisted securities, private    
placements and valuations for corporate, estate and other purposes. In the      
ordinary course of its trading, brokerage and financing activities, Morgan      
Stanley and its affiliates may, at any time, have a long or short position in,  
and buy and sell the debt or equity securities and senior loans of TSI or       
Eclipsys for its account or the account of its customers. Morgan Stanley and its
affiliates have, in the past, provided financial advisory services to Eclipsys  
and have received fees for the rendering of such services.                      

    Pursuant to a letter agreement dated October 23, 1998 between Eclipsys and
Morgan Stanley, Eclipsys has agreed to pay Morgan Stanley a fee for rendering   
the Morgan Stanley Opinion to the Eclipsys Board in connection with the business
combination. In addition, Eclipsys has agreed to reimburse Morgan Stanley for   
its expenses related to the engagement and to indemnify Morgan Stanley and its  
affiliates, their respective directors, officers, agents and employees and each 
person, if any, controlling Morgan Stanley or any of its affiliates against     
certain liabilities, including liabilities under federal securities laws, and   
expenses, related to or arising out of Morgan Stanley's engagement and the      
transactions in connection therewith.                                           

TSI                                                                         

 TSI engaged BT Alex. Brown to act as its exclusive financial advisor in
connection with the Merger. On October 28, 1998, at a meeting of the TSI Board  
held to evaluate the proposed Merger, BT Alex. Brown rendered to the TSI Board  
an oral opinion (which opinion was subsequently confirmed by delivery of a      
written opinion dated October 29, 1998, the date of execution of the Merger     
Agreement) to the effect that, as of the date of such opinion and based upon and
subject to certain matters stated therein, the Exchange Ratio was fair, from a  
financial point of view, to the holders of TSI Voting and Non-Voting Common     
Stock.                                                                          

  THE FULL TEXT OF THE WRITTEN OPINION OF BT ALEX. BROWN DATED OCTOBER 29,
1998, WHICH SETS FORTH THE ASSUMPTIONS MADE, MATTERS CONSIDERED AND LIMITATIONS 
OF THE REVIEW UNDERTAKEN, IS ATTACHED AS ANNEX C TO THIS JOINT PROXY            
STATEMENT/PROSPECTUS AND IS INCORPORATED HEREIN BY REFERENCE. BT ALEX. BROWN'S  
OPINION IS DIRECTED TO THE TSI BOARD, ADDRESSES ONLY THE FAIRNESS OF THE        
EXCHANGE RATIO FROM A FINANCIAL POINT OF VIEW, AND DOES NOT CONSTITUTE A        
RECOMMENDATION TO ANY STOCKHOLDER AS TO HOW                                     

51

S-4
60th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 60th

SUCH STOCKHOLDER SHOULD VOTE AT THE TSI SPECIAL STOCKHOLDERS' MEETING. THE      
SUMMARY OF THE OPINION OF BT ALEX. BROWN IN THIS JOINT PROXY                    
STATEMENT/PROSPECTUS IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO THE FULL TEXT 
OF SUCH OPINION ATTACHED AS ANNEX C HERETO. HOLDERS OF TSI VOTING AND NON-VOTING
COMMON STOCK ARE URGED TO, AND SHOULD, READ THE BT ALEX. BROWN OPINION CAREFULLY
AND IN ITS ENTIRETY.                                                            

   In connection with BT Alex. Brown's role as financial advisor to TSI, and
in arriving at its opinion, BT Alex. Brown reviewed certain publicly available  
financial and other information concerning TSI and Eclipsys and certain internal
analyses and other information furnished to or discussed with BT Alex. Brown by 
TSI, Eclipsys and their respective advisors. BT Alex. Brown also held           
discussions with members of the senior management of TSI and Eclipsys regarding 
the business and prospects of their respective companies and the joint prospects
of a combined company. In addition, BT Alex. Brown (i) reviewed the reported    
prices and trading activity for TSI Voting Common Stock and Eclipsys Voting     
Common Stock, (ii) compared certain financial and stock market information for  
TSI and Eclipsys with similar information for certain other companies whose     
securities are publicly traded, (iii) reviewed the financial terms of certain   
recent business combinations which BT Alex. Brown deemed comparable in whole or 
in part, (iv) reviewed the terms of the Merger Agreement, and (v) performed such
other studies and analyses and considered such other factors as BT Alex. Brown  
deemed appropriate. In connection with its engagement, BT Alex. Brown was       
authorized to approach, and held discussions with, certain third parties to     
solicit indications of interest with respect to the acquisition of TSI.         

   BT Alex. Brown did not assume responsibility for independent verification
of, and did not independently verify, any information, whether publicly         
available or furnished to BT Alex. Brown, concerning TSI, Eclipsys and the      
combined company, including, without limitation, any financial information,     
forecasts or projections considered in connection with the rendering of its     
opinion. Accordingly, for purposes of its opinion, BT Alex. Brown assumed and   
relied upon the accuracy and completeness of all such information and BT Alex.  
Brown did not conduct a physical inspection of any of the properties or assets, 
and did not prepare or obtain any independent evaluation or appraisal of any of 
the assets or liabilities, of TSI or Eclipsys. With respect to financial        
forecasts and projections made available to BT Alex. Brown and used in its      
analyses, BT Alex. Brown assumed that they were prepared on bases reflecting    
reasonable estimates and judgments as to the matters covered thereby. In        
rendering its opinion, BT Alex. Brown expressed no view as to the reasonableness
of such forecasts and projections or the assumptions on which they are based. BT
Alex. Brown's opinion was necessarily based upon economic, market and other     
conditions as in effect on, and the information made available to BT Alex. Brown
as of, the date of its opinion.                                                 

    For purposes of rendering its opinion, BT Alex. Brown assumed that, in all
respects material to its analysis, the representations and warranties of TSI,   
Eclipsys and Sub contained in the Merger Agreement are true and correct, TSI,   
Eclipsys and Sub will each perform all of the covenants and agreements to be    
performed by it under the Merger Agreement and all conditions to the obligations
of each of TSI, Eclipsys and Sub to consummate the Merger will be satisfied     
without any waiver thereof. BT Alex. Brown also assumed that all material       
governmental, regulatory or other approvals and consents required in connection 
with the consummation of the Merger will be obtained and that in connection with
obtaining any necessary governmental, regulatory or other approvals and         
consents, or any amendments, modifications or waivers to any agreements,        
instruments or orders to which either TSI or Eclipsys is a party or is subject  
or by which it is bound, no limitations, restrictions or conditions will be     
imposed or amendments, modifications or waivers made that would have a material 
adverse effect on TSI or Eclipsys or materially reduce the contemplated benefits
of the Merger to TSI. In addition, BT Alex. Brown was informed by the TSI Board,
and accordingly for purposes of rendering its opinion BT Alex. Brown assumed,   
that the Merger will qualify as a tax-free reorganization for federal income tax
purposes and will be accounted for as a pooling-of-interests. BT Alex. Brown did
not express an opinion as to the price at which Eclipsys Voting Common Stock    
will trade at any time. No other limitations were imposed by the TSI Board upon 

52

S-4
61st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 61st

BT Alex. Brown with respect to the investigations made or the procedures        
followed by it in rendering its opinion.                                        

 The following is a summary of the material analyses underlying BT Alex.
Brown's opinion given to the TSI Board in connection with the Merger:           

 Analysis of Selected Public Companies.  BT Alex. Brown compared certain
financial and stock market information for TSI and the following selected       
publicly held companies in the healthcare information technology industry: DAOU 
Systems, Inc., HCIA Inc., Healthcare Recoveries, Inc., Health Management        
Systems, Inc., Mecon, Inc., National Research Corporation, Oacis Healthcare     
Holdings Corp., ProxyMed, Inc., and Sunquest Information Systems, Inc.          
(collectively, the "Selected Companies"). BT Alex. Brown calculated equity      
market values as multiples of, among other things, latest 12 months and         
estimated calendar years 1998 and 1999 net income, and adjusted market values   
(equity market value, plus debt, less cash) as multiples of, among other things,
latest 12 months EBITDA and earnings before interest and taxes ("EBIT"). All    
multiples were based on closing stock prices on October 23, 1998. Net income    
estimates for TSI and the Selected Companies were based on analysts' estimates  
as reported by I/B/E/S, a market research database. This analysis indicated for 
the Selected Companies a range of (i) implied equity market value multiples of  
latest 12 months and estimated calendar 1998 and 1999 net income of 12.0x to    
32.8x (with a mean of 22.6x), 10.2x to 28.4x (with a mean of 17.2x) and 6.7x to 
18.4x (with a mean of 12.1x), respectively, and (ii) implied adjusted market    
value multiples of latest 12 months revenues, EBITDA and EBIT of 0.5x to 6.0x   
(with a mean of 1.7x), 3.2x to 11.7x (with a mean of 7.5x) and 4.7x to 20.0x    
(with a mean of 11.7x), respectively. Based on the closing price of Eclipsys    
Voting Common Stock on October 23, 1998, the Exchange Ratio equated to implied  
multiples for TSI of latest 12 months and estimated calendar 1998 and 1999 net  
income of 36.3x, 24.0x and 18.0x, respectively, and latest 12 months revenues,  
EBITDA and EBIT of 4.4x, 12.0x and 13.3x, respectively.                         

   Analysis of Recent Mergers and Acquisitions.  BT Alex. Brown reviewed the
purchase prices and implied transaction multiples in eight selected merger and  
acquisition transactions effected in the healthcare information technology      
industry since January 1, 1995 (the "Selected Transactions"). All multiples were
based on publicly available information at the time of announcement of the      
relevant transaction. BT Alex. Brown calculated equity purchase price multiples 
of, among other things, latest 12 months and one-year forward net income, and   
adjusted purchase price multiples of latest 12 months revenues, EBITDA and EBIT.
This analysis indicated for the Selected Transactions a range of (i) implied    
equity purchase price multiples of latest 12 months and one-year forward net    
income of 21.9x to 64.7x (with a mean of 42.9x) and 20.8x to 43.7x (with a mean 
of 32.0x), respectively, and (ii) implied adjusted purchase price multiples of  
latest 12 months revenues, EBITDA and EBIT of 1.5x to 3.4x (with a mean of      
2.3x), 6.3x to 25.6x (with a mean of 17.5x) and 9.1x to 40.4x (with a mean of   
24.9x), respectively. Based on the closing price of Eclipsys Voting Common Stock
on October 23, 1998, the Exchange Ratio equated to implied multiples for TSI of 
latest 12 months and one-year forward net income of 36.3x and 19.1x,            
respectively, and latest 12 months revenues, EBITDA and EBIT of 4.4x, 12.0x and 
13.3x, respectively.                                                            

Discounted Cash Flow Analyses.  BT Alex. Brown performed separate     
discounted cash flow analyses for each of TSI and Eclipsys to estimate the      
present value of the stand-alone, unlevered, after-tax free cash flows that each
of TSI and Eclipsys could generate over the fiscal years 1999 through 2003,     
based on extrapolated analysts' estimates as reported by I/B/E/S. The           
stand-alone discounted cash flow analysis was determined by (i) adding (x) the  
present value of the projected free cash flows over the fiscal years 1999       
through 2003 and (y) the present value of the estimated terminal values in      
fiscal year 2003 and (ii) subtracting the current net debt for TSI and Eclipsys,
respectively. The range of estimated terminal values for TSI and Eclipsys was   
calculated by applying terminal value multiples ranging from 6.5x to 8.5x for   
TSI and 15.0x to 17.0x for Eclipsys to the projected fiscal year 2003 EBITDA of 
TSI and Eclipsys, respectively. The cash flows and terminal values were         
discounted to present value using discount rates ranging from 17% to 19% for TSI
and discount rates ranging from 15% to 17% for Eclipsys. This analysis yielded  
an implied equity reference range for Eclipsys Voting Common Stock of           
approximately $31.03 to $37.20 per share, as compared to the closing price of   
Eclipsys Voting Common Stock on October 23, 1998                                
53

S-4
62nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 62nd

of $24.88. This analysis yielded an implied equity reference range for TSI      
Voting Common Stock of approximately $11.62 to $14.52 per share, as compared to 
the equity value implied by the Exchange Ratio of approximately $13.06 based on 
the closing price of Eclipsys Voting Common Stock on October 23, 1998.          

 Premium Analysis.  BT Alex. Brown analyzed, among other things, the (i)
premiums paid in 100 change of control transactions having transaction values of
between approximately $100 and $400 million effected since January 1, 1996,     
which indicated a range of premiums, based on the target company's stock price  
one day and one month prior to public announcement of the transaction, of       
approximately (26.7)% to 88.9% (with a mean of 26.7%) and (21.7)% to 105.6%     
(with a mean of 38.4%), respectively, (ii) premiums paid in 22 change of control
transactions involving healthcare companies having transaction values between   
approximately $100 million and $400 million, which indicated a range of         
premiums, based on the target company's stock price one day and one month prior 
to public announcement of the transaction, of approximately (26.7)% to 80.5%    
(with a mean of 25.5%) and (17.5)% to 87.2% (with a mean of 41.1%),             
respectively, and (iii) premiums paid in four change of control transactions    
involving healthcare information technology companies having transaction values 
between approximately $83 million and $177 million, which indicated a range of  
premiums, based on the target company's stock price one day and one month prior 
to public announcement of the transaction, of approximately 1.4% to 38.6% (with 
a mean of 15.5%) and 14.2% to 78.3% (with a mean of 40.8%), respectively. The   
implied premiums payable in the Merger based on the closing price of Eclipsys   
Voting Common Stock one day and one month prior to public announcement of the   
Merger were approximately 49.3% and 44.0%, respectively.                        

   Historical Exchange Ratio Analysis.  BT Alex. Brown compared the Exchange
Ratio with the ratio of the closing prices of TSI Voting Common Stock and       
Eclipsys Voting Common Stock on October 23, 1998 and the historical ratio of the
average daily closing prices of TSI Voting Common Stock and Eclipsys Voting     
Common Stock over the five-day, 10-day, 20-day, 30-day, 40-day and 50-day       
periods ended October 23, 1998 (collectively, the "Market Exchange Ratios"). The
Market Exchange Ratios on October 23, 1998 and during such periods were 0.3518, 
0.3672, 0.3831, 0.3809, 0.4033, 0.4172 and 0.4295, respectively, as compared to 
the Exchange Ratio of 0.525. The implied premiums derived by comparing the      
Market Exchange Ratios to the Exchange Ratio do not necessarily reflect the     
underlying market value of either TSI Voting Common Stock or Eclipsys Voting    
Common Stock or how the TSI Voting Common Stock, Eclipsys Voting Common Stock or
the common stock of the pro forma combined company may trade in the future.     

  Pro Forma Merger Analysis.  BT Alex. Brown analyzed, among other things,
the pro forma effects of the Merger on the earnings per share (the "EPS") of    
Eclipsys in calendar years 1999 and 2000 based on analysts' estimates as        
reported by I/B/E/S, both before and after giving effect to certain cost savings
and other potential synergies anticipated by the managements of TSI and Eclipsys
to result from the Merger (excluding non-recurring costs resulting from the     
Merger). This analysis indicated that the Merger could be accretive to the EPS  
of Eclipsys in each of the calendar years analyzed both before and after giving 
effect to potential synergies and other cost savings anticipated by the         
managements of TSI and Eclipsys to result from the Merger (excluding            
non-recurring costs resulting from the Merger). BT Alex. Brown also analyzed the
potential pro forma effect of the Merger on TSI's EPS during calendar years 1999
and 2000 relative to TSI on a stand-alone basis. This analysis indicated that   
the Merger could be dilutive to TSI's EPS in calendar years 1999 and 2000. The  
actual operating or financial results achieved by the pro forma combined company
may vary from projected results and variations may be material as a result of   
business and operational risks, the timing and amount of synergies, the costs   
associated with achieving such synergies and other factors.                     

    Contribution Analysis.  BT Alex. Brown analyzed the relative contributions
of TSI and Eclipsys to, among other things, the net income, revenues, EBITDA and
EBIT of the pro forma combined company for the 12 month period ended June 30,   
1998, the estimated net income of the pro forma combined company for calendar   
years 1999 and 2000 based on analysts' estimates as reported by I/B/E/S and the 
estimated book value of the pro forma combined company as of June 30, 1998, and 
compared such contributions to the pro forma ownership of the current holders of
TSI Common Stock in the pro forma                                               
54

S-4
63rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 63rd

combined company. This analysis indicated that (i) for the 12 month period ended
June 30, 1998, TSI would have contributed approximately 29.5% of revenues, 44.9%
of EBITDA and 100.0% of EBIT for the pro forma combined company; (ii) in        
calendar years 1999 and 2000, TSI would contribute approximately 52.9% and      
48.9%, respectively, of the net income for the pro forma company, and (iii) as  
of June 30, 1998, TSI would contribute approximately 62.0% of book value for the
pro forma combined company. A contribution percentage for the latest 12 month   
period net income was not meaningful as the pro forma combined company had      
negative data for such operating measure. Based on the Exchange Ratio of 0.525, 
current holders of TSI Voting and Non-Voting Common Stock would own             
approximately 32.7% of the pro forma combined company upon consummation of the  
Merger.                                                                         

    Other Factors.  In rendering its opinion, BT Alex. Brown also reviewed and
considered, among other things: (i) historical and projected financial data for 
TSI and Eclipsys; (ii) historical market prices and trading volumes for TSI     
Voting Common Stock and Eclipsys Voting Common Stock and the relationship       
between movements in TSI Voting Common Stock, the movements in the common stock 
of the Selected Companies and movements in the S&P 500 Index and (iii) selected 
analysts' reports on TSI and Eclipsys, including EPS and growth rate estimates  
of such analysts for TSI and Eclipsys.                                          

   The summary set forth above does not purport to be a complete description
of the opinion of BT Alex. Brown to the TSI Board or the financial analyses     
performed and factors considered by BT Alex. Brown in connection with its       
opinion. The preparation of a fairness opinion is a complex analytic process    
involving various determinations as to the most appropriate and relevant methods
of financial analyses and the application of those methods to the particular    
circumstances and, therefore, such an opinion is not readily susceptible to     
summary description. BT Alex. Brown believes that its analyses and the summary  
set forth above must be considered as a whole and that selecting portions of its
analyses, without considering all analyses, or selecting portions of the above  
summary, without considering all factors and analyses, could create a misleading
or incomplete view of the processes underlying such analyses and opinion. In    
performing its analyses, BT Alex. Brown made numerous assumptions with respect  
to industry performance, general business, economic, market and financial       
conditions and other matters, many of which are beyond the control of TSI and   
Eclipsys. No company, transaction or business used in such analyses as a        
comparison is identical to TSI, Eclipsys, the pro forma combined company or the 
proposed Merger, nor is an evaluation of the results of such analyses entirely  
mathematical; rather, such analyses involve complex considerations and judgments
concerning financial and operating characteristics and other factors that could 
affect the Merger, public trading or other values of the companies, business    
segments or transactions being analyzed. The estimates contained in such        
analyses and the ranges of valuations resulting from any particular analysis are
not necessarily indicative of actual values or future results, which may be     
significantly more or less favorable than those suggested by such analyses. In  
addition, analyses relating to the value of businesses or securities do not     
purport to be appraisals or to reflect the prices at which businesses or        
securities actually may be sold. Accordingly, such analyses and estimates are   
inherently subject to substantial uncertainty.                                  

   The type and amount of consideration payable in the Merger was determined
through negotiation between TSI and Eclipsys. Although BT Alex. Brown provided  
financial advice to TSI during the course of these negotiations, the decision to
enter into the Merger was solely that of the TSI Board. BT Alex. Brown's opinion
and financial analyses were only one of many factors considered by the TSI Board
in its evaluation of the proposed Merger and should not be viewed as            
determinative of the views of the TSI Board or the management of TSI with       
respect to the Exchange Ratio or the Merger.                                    

     Pursuant to the terms of BT Alex. Brown's engagement, TSI has agreed to pay
BT Alex. Brown an aggregate financial advisory fee equal to 0.8% of the         
aggregate consideration (including liabilities assumed) payable in connection   
with the Merger, a significant portion of which is contingent upon consummation 
of the Merger. In addition, TSI has agreed to reimburse BT Alex. Brown for its  
reasonable travel and other out-of-pocket expenses, including reasonable fees   
and disbursements of counsel, and to indemnify BT Alex. Brown and certain       
related parties against certain liabilities, including certain liabilities under
the federal securities laws, relating to, or arising out of, its engagement.    

55

S-4
64th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 64th

 BT Alex. Brown is an internationally recognized investment banking firm
and, as a customary part of its investment banking business, is engaged in the  
valuation of businesses and their securities in connection with mergers and     
acquisitions, negotiated underwritings, private placements and valuations for   
estate, corporate and other purposes. TSI selected BT Alex. Brown based on BT   
Alex. Brown's reputation, expertise and familiarity with TSI. BT Alex. Brown and
its affiliates have in the past provided financial services to TSI unrelated to 
the proposed Merger, for which services BT Alex. Brown and its affiliates have  
received compensation. BT Alex. Brown maintains a market in TSI Voting Common   
Stock and regularly publishes research reports regarding the businesses and     
securities of TSI and other publicly traded companies in the healthcare         
information technology industry. In the ordinary course of business, BT Alex.   
Brown may actively trade or hold the securities and other instruments and       
obligations of TSI and Eclipsys for its own account and the accounts of         
customers and, accordingly, may at any time hold a long or short position in    
such securities, instruments or obligations.                                    

INTERESTS OF CERTAIN PERSONS IN THE MERGER                                      

If the Merger is completed, two directors of TSI, Robert F. Raco and  
Patrick T. Hackett will be appointed to serve on the Eclipsys Board of          
Directors.                                                                      

   Eclipsys has agreed to certain indemnification and insurance arrangements
for existing and former directors and officers of TSI. From and after the       
Effective Time, Eclipsys has agreed to, and will cause the Surviving Corporation
to agree to, indemnify each present and former director and officer of TSI      
against any costs or expenses incurred in connection with claims arising out of 
or pertaining to matters occurring prior to the Effective Time. In addition, for
a period of three years after the Effective Time, Eclipsys has agreed to cause  
the Surviving Corporation to maintain a directors' and officers' liability      
insurance policy for the benefit of the directors and officers of TSI who were  
covered by TSI's policy immediately prior to the Effective Time, with coverage  
in an amount and scope at least as favorable as TSI's existing coverage;        
provided that neither Eclipsys nor the Surviving Corporation shall be required  
to expend in excess of 200% of the annual premium paid by TSI as of the date of 
the Merger Agreement for such coverage except to the extent any excess amount is
attributable to Eclipsys' claims history or price increases in the market that  
are unrelated to TSI specifically. If the premium at any time exceeds such      
limitation, the Surviving Corporation will maintain insurance policies that     
provide the maximum and best coverage available at an annual premium equal to   
such limitation. If any legal action has been pending at any time subsequent to 
the second anniversary of the Effective Time against any person currently       
covered by TSI's directors' and officers' liability insurance policy and such   
pending action would be covered in whole or in part by such policy, the         
Surviving Corporation will continue to maintain such policy in effect (subject  
to the limitations above) until the fifth anniversary of the Effective Time.    

     In addition, Eclipsys has agreed to arrange for certain registration rights
for Warburg following the Merger. See "Description of Eclipsys Capital          
Stock -- Registration Rights."                                                  

OWNERSHIP AND VOTING OF STOCK                                                   

 As of the Record Date, directors and executive officers of Eclipsys and
their affiliates may be deemed to have voting control over approximately 59.4%  
of the outstanding shares of Eclipsys Voting Common Stock. See "Principal       
Stockholders of Eclipsys."                                                      

  As of the Record Date, directors and executive officers of TSI and their
affiliates may be deemed to have voting control over approximately 34.9% of the 
outstanding shares of TSI Voting Common Stock. See "Principal Stockholders of   
TSI."                                                                           

 Warburg, Pincus Ventures, L.P., Robert F. Raco, Christine Shapleigh and
Donald C. Cook have each entered into Voting Agreements, dated as of October 29,
1998, with Eclipsys pursuant to which they have agreed to vote all shares of TSI
Voting Common Stock over which they exercise voting control (an aggregate of    
6,212,583 shares of TSI Voting Common Stock on the Record Date) in favor of     
approval and adoption of the Merger Agreement and the Merger.                   

 General Atlantic Partners 28, L.P., General Atlantic Partners 38, L.P.,
General Atlantic Partners 47, L.P., General Atlantic Partners 48, L.P., GAP     
Coinvestment Partners, L.P., Harvey J. Wilson, Wilfam                           

56

S-4
65th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 65th

Ltd. and Partners HealthCare System, Inc. have each entered into Voting         
Agreements, dated as of October 29, 1998, with TSI pursuant to which they have  
agreed to vote all shares of Eclipsys Voting Common Stock over which they       
exercise voting control (an aggregate of 10,470,508 shares of Eclipsys Voting   
Common Stock on the Record Date) in favor of the Eclipsys Voting Proposal.      

ACCOUNTING TREATMENT                                                            

   The Merger is intended to qualify as a pooling of interests for financial
reporting purposes under U.S. GAAP. Under this method of accounting, the        
recorded assets and liabilities of Eclipsys and TSI will be carried forward to  
the combined company at their recorded amounts. The reported operating results  
of the separate companies for periods prior to the combination will be combined 
and restated as the operating results of the combined company. A condition to   
the Merger is that Eclipsys and TSI each shall have received a letter at the    
closing of the Merger from PricewaterhouseCoopers LLP regarding its concurrence,
as of the date of the letter, with the conclusions of management as to the      
appropriateness of pooling-of-interests accounting treatment, under Accounting  
Principles Board Opinion No. 16 and related interpretations, for the Merger.    

     Each of the affiliates of Eclipsys and TSI has executed a written agreement
to the effect that such person will not transfer shares of common stock of      
either Eclipsys or TSI during the period beginning 30 days prior to the         
Effective Time and ending on the date that Eclipsys publishes financial         
statements which reflect 30 days of combined operations of Eclipsys and TSI     
(which agreements relate to the ability of Eclipsys to account for the Merger as
a pooling of interests).                                                        

CERTAIN FEDERAL INCOME TAX CONSIDERATIONS                                       

The following discussion addresses the material federal income tax    
considerations of the Merger that are applicable to holders of TSI Voting and   
Non-Voting Common Stock. TSI stockholders should be aware that this section does
not deal with all federal income tax considerations that may be relevant to     
particular TSI stockholders in light of their particular circumstances, such as 
stockholders who are dealers in securities, who are foreign persons or who      
acquired their TSI Voting or Non-Voting Common Stock through stock option or    
stock purchase programs or in other compensatory transactions or who otherwise  
hold convertible securities, options or warrants. In addition, the following    
discussion does not address the tax consequences of transactions effectuated    
prior to or after the Merger (whether or not such transactions are in connection
with the Merger), including, without limitation, the exercise of options,       
warrants or other rights to purchase TSI Voting or Non-Voting Common Stock in   
anticipation of the Merger. Finally, no foreign, state or local tax             
considerations are addressed herein. ACCORDINGLY, TSI STOCKHOLDERS ARE URGED TO 
CONSULT THEIR OWN TAX ADVISORS AS TO THE SPECIFIC TAX CONSEQUENCES OF THE       
MERGER, INCLUDING THE APPLICABLE FEDERAL, STATE, LOCAL AND FOREIGN TAX          
CONSEQUENCES TO THEM.                                                           

    The following discussion is based on the Internal Revenue Code of 1986, as
amended (the "Code"), applicable Treasury Regulations, judicial authority and   
administrative rulings and practice, all as of the date hereof. The Internal    
Revenue Service (the "IRS") is not bound by such discussion and is not precluded
from adopting a contrary position. In addition, there can be no assurance that  
future legislative, judicial or administrative changes or interpretations will  
not adversely affect the accuracy of the statements and conclusions set forth   
herein. Any such changes or interpretations could be applied retroactively and  
could affect the tax consequences of the Merger to Eclipsys, TSI and their      
respective stockholders.                                                        

    The Merger is intended to constitute a "reorganization" within the meaning
of Section 368(a) of the Code (a "Reorganization"). Assuming the Merger is a    
Reorganization, then, subject to the assumptions, limitations and qualifications
referred to herein, the Merger should result in the following federal income tax
consequences:                                                                   

       (a) No gain or loss will be recognized by the holders of TSI Voting
and Non-Voting Common Stock upon the receipt of Eclipsys Voting Common
     Stock solely in exchange for such TSI Voting and Non-Voting Common Stock in
 the Merger (except to the extent of cash received in lieu of fractional
shares).                                                              

57

S-4
66th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 66th

      (b) The aggregate tax basis of the Eclipsys Voting Common Stock so
    received by TSI stockholders in the Merger (including any fractional share
    of Eclipsys Voting Common Stock not actually received) will be the same as
the aggregate tax basis of the TSI Voting and Non-Voting Common Stock 
surrendered in exchange therefor.                                     

          (c) The holding period of the Eclipsys Voting Common Stock received by
    each TSI stockholder in the Merger will include the holding period for the
  TSI Voting and Non-Voting Common Stock surrendered in exchange therefor,
    provided that the TSI Voting and Non-Voting Common Stock so surrendered is
held as a capital asset.                                              

      (d) Cash payments received by holders of TSI Voting and Non-Voting
   Common Stock in lieu of a fractional share will be treated as received in
   redemption of such fractional share, subject to the provisions of Section
302 of the Code, as if such fractional share of Eclipsys Voting Common
Stock had been issued in the Merger and then redeemed by Eclipsys.    

(e) Each of Eclipsys, Sub and TSI will be a party to the    
Reorganization and as such will not recognize gain or loss solely as a
result of the Merger.                                                 

    Neither Eclipsys nor TSI has requested a ruling from the IRS in connection
with the Merger. However, it is a condition of the respective obligations of    
Eclipsys and TSI to consummate the Merger that such parties receive opinions    
from their respective counsel (the "Tax Opinions") to the effect that, for      
federal income tax purposes, the Merger will constitute a Reorganization. These 
Tax Opinions neither bind the IRS nor preclude the IRS from adopting a contrary 
position. The Tax Opinions will be subject to certain assumptions and           
qualifications and will be based on the truth and accuracy of certain           
representations of Eclipsys, TSI and Sub and certain stockholders of TSI.       

     A successful IRS challenge to the Reorganization status of the Merger would
result in a TSI stockholder recognizing gain or loss with respect to each share 
of TSI Voting and Non-Voting Common Stock surrendered equal to the difference   
between the stockholder's basis in such share and the fair market value, as of  
the Effective Time, of the Eclipsys Voting Common Stock received in exchange    
therefor. In such event, a stockholder's aggregate basis in the Eclipsys Voting 
Common Stock so received would equal its fair market value, and the             
stockholder's holding period for such stock would begin the day after the       
Merger.                                                                         

REGULATORY APPROVALS                                                            

    Under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended
(the "HSR Act") and the rules promulgated thereunder by the Federal Trade       
Commission (the "FTC"), the Merger may not be consummated until notifications   
have been given and certain information has been furnished to the FTC and the   
Antitrust Division of the Department of Justice (the "Antitrust Division") and  
specified waiting period requirements have been satisfied. Early termination of 
the waiting period under the HSR Act was granted on November 24, 1998. At any   
time before or after consummation of the Merger, and notwithstanding that the   
HSR Act waiting period has terminated, the Antitrust Division or the FTC could  
take such action under the antitrust laws as it deems necessary or desirable in 
the public interest, including seeking to enjoin the consummation of the Merger 
or seeking divestiture of assets of Eclipsys or TSI. At any time before or after
the Effective Time of the Merger, and notwithstanding that the HSR Act waiting  
period has terminated, any state could take such action under its antitrust laws
as it deems necessary or desirable in the public interest. Such action could    
include seeking to enjoin the consummation of the Merger or seeking divestiture 
of assets of Eclipsys or TSI. Private parties may also seek to take legal action
under the antitrust laws under certain circumstances.                           

   Based on information available to them, Eclipsys and TSI believe that the
Merger can be effected in compliance with federal and state antitrust laws.     
However, there can be no assurance that a challenge to the consummation of the  
Merger on antitrust grounds will not be made or that, if such a challenge were  
made, Eclipsys and TSI would prevail or would not be required to accept certain 
conditions, including the divestitures of assets, in order to consummate the    
Merger.                                                                         

58

S-4
67th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 67th

FEDERAL SECURITIES LAW CONSEQUENCES                                             

    All shares of Eclipsys Voting Common Stock received by TSI stockholders in
the Merger will be freely transferable, except that shares of Eclipsys Voting   
Common Stock received by persons who are deemed to be "affiliates" of TSI prior 
to the Merger may be resold by them only in transactions permitted by the resale
provisions of Rule 145 promulgated under the Securities Act of 1933, as amended 
(the "Securities Act") (or Rule 144 in the case of such persons who become      
affiliates of Eclipsys) or otherwise in compliance with (or pursuant to an      
exemption from) the registration requirements of the Securities Act. Persons    
deemed to be affiliates of Eclipsys or TSI are those individuals or entities    
that control, are controlled by, or are under common control with, such party   
and generally include executive officers and directors of such party as well as 
certain principal stockholders of such party. The Merger Agreement requires TSI 
to use its best efforts to cause each of its affiliates to execute a written    
agreement to the effect that such person will not offer or sell or otherwise    
dispose of any of the shares of Eclipsys Voting Common Stock issued to such     
person in or pursuant to the Merger except in compliance with the Securities Act
and the rules and regulations promulgated by the Commission thereunder. This    
Joint Proxy Statement/Prospectus does not cover any resales of Eclipsys Voting  
Common Stock received by affiliates of TSI in the Merger.                       

STOCK MARKET QUOTATION                                                          

   It is a condition to the Merger that the shares of Eclipsys Voting Common
Stock to be issued pursuant to the Merger Agreement be approved for quotation on
the Nasdaq National Market, subject to official notice of issuance. An          
application for listing the shares of Eclipsys Voting Common Stock on the Nasdaq
National Market has been filed.                                                 

APPRAISAL RIGHTS                                                                

 TSI stockholders voting against the Merger and the Merger Agreement who
have filed with TSI prior to the stockholder vote at the TSI Special            
Stockholders' Meeting a written objection to the Merger along with a statement  
that they intend to demand payment for their shares are entitled under the      
Massachusetts Business Corporation Law to seek an appraisal of the fair value of
their shares. No such shares will be converted into shares of Eclipsys Voting   
Common Stock as part of the Merger. If a TSI stockholder has not properly       
notified TSI prior to the stockholder vote at the TSI Special Stockholders'     
Meeting, has withdrawn the demand for appraisal or has voted in favor of the    
Merger, such stockholder's shares will be converted into shares of Eclipsys     
Voting Common Stock in accordance with the terms of the Merger Agreement.       

   Under the Delaware General Corporation Law, the Eclipsys stockholders are
not entitled to dissenters' appraisal rights in connection with the Merger      
because Eclipsys is not a constituent corporation in the Merger.                

59

S-4
68th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 68th

UNAUDITED PRO FORMA CONDENSED COMBINED
CONSOLIDATED FINANCIAL STATEMENTS 

   The following unaudited pro forma condensed combined financial statements
reflect adjustments to the historical consolidated balance sheets and statements
of operations of Eclipsys and TSI to give effect to the Merger, using the       
pooling-of-interests method of accounting for business combinations, and to     
certain other acquisitions by Eclipsys and TSI as discussed below.              

     The unaudited pro forma condensed combined statements of operations for the
years ended December 31, 1995, 1996 and 1997 and for the nine months ended      
September 30, 1998 assume the Merger was effected on January 1, 1995. Eclipsys' 
December 31 fiscal year end consolidated financial statements have been combined
with TSI's September 30 fiscal year end consolidated financial statements.      
Eclipsys' unaudited consolidated financial statements for the nine months ended 
September 30 have been combined with TSI's unaudited consolidated financial     
statements for the nine months ended June 30.                                   

The unaudited pro forma combined condensed financial information of   
Eclipsys for the year ended December 31, 1997 and the nine months ended         
September 30, 1998 includes adjustments to give effect to:                      

- the Alltel Acquisition                                        
- the SDK Acquisition                                           
- the Emtek Acquisition                                         
    - the return by AIS to Eclipsys for cancellation of 11,000 shares of
         Redeemable Preferred Stock in return for extinguishing claims against
AIS related to the Alltel Acquisition (the "AIS Settlement")
- the MSA Buyout                                                
 - the issuance of shares of Convertible Preferred Stock for total
       consideration of $9.0 million in February 1998 (the "1998 Preferred
        Stock Issuance") and the use of the proceeds therefrom to repay $9.0
million under the Term Loan                                 
        - the scheduled repayment in April 1998 (the "SDK Partial Repayment") of
         $4.0 million of principal and accrued interest of the $7.6 million of
SDK Notes                                                   
      - the January 1998 scheduled $2.0 million payment to AIS under the MSA
      - borrowings under the Revolver to fund the MSA Buyout and the Simione
Investment                                                  
       - the conversion of Eclipsys' Convertible Preferred Stock in connection
with the Eclipsys IPO                                       
        - the Eclipsys IPO and the use of a portion of the proceeds therefrom to
      repay the outstanding balance under the Revolver and the remaining
       outstanding balance under the SDK Notes and to redeem the remaining
 Redeemable Preferred Stock with a face value of $34.5 million

   The unaudited pro forma condensed combined balance sheet at September 30,
1998 reflects the Eclipsys September 30, 1998 balance sheet combined with the   
TSI June 30, 1998 balance sheet, adjusted for the HealthVISION Acquisition and  
to conform to the Eclipsys financial presentation.                              

Eclipsys acquired Alltel effective January 24, 1997 for an aggregate  
purchase price of $201.5 million, including liabilities assumed of $58.4 million
and after giving effect to the cancellation of 4,500 shares of Redeemable       
Preferred Stock held by Alltel related to an October 1997 settlement of certain 
matters related to the acquisition. Consideration paid consisted of $104.8      
million in cash, 15,500 shares of Redeemable Preferred Stock valued at          
approximately $10.3 million, 2,077,497 shares of Convertible Preferred Stock    
valued at approximately $26.1 million, deferred payments due under the MSA over 
four years valued at $9.5 million and transaction costs of approximately $2.0   
million.                                                                        

 Eclipsys acquired SDK effective June 26, 1997 for an aggregate purchase
price of $16.5 million, including 499,997 shares of Eclipsys Voting Common Stock
valued at approximately $3.2 million, $2.2 million in cash, the SDK Notes       
aggregating $7.6 million and assumed liabilities of approximately $3.5 million. 

Eclipsys acquired Emtek effective January 30, 1998 for an aggregate   
purchase price of approximately $11.7 million, including 1,000,000 shares of    
Eclipsys Voting Common Stock valued at $9.1 million and                         

60

S-4
69th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 69th

liabilities assumed of approximately $12.3 million. In addition, Motorola agreed
to pay Eclipsys $9.6 million in cash for working capital purposes.              

     The unaudited pro forma combined condensed financial information of TSI for
the year ended September 30, 1997 and the nine months ended June 30, 1998       
includes adjustments to give effect to the HealthVISION Acquisition. On December
3, 1998, TSI completed its acquisition of the remaining 80.5% of HealthVISION   
not already owned by TSI for cash in the amount of $25.6 million, plus an       
earn-out of up to $10.8 million if specified milestones are met. The acquisition
will be accounted for under the purchase method of accounting, reflecting an    
estimated aggregate purchase price, including TSI's initial 1997 investment, of 
$40.7 million, which includes $6.4 million previously paid by TSI and $9.3      
million of assumed liabilities, net of cash acquired. The results of operations 
of HealthVISION will be included in TSI's financial statements from the date of 
acquisition.                                                                    

   The pro forma and pro forma combined adjustments are based upon available
information and certain assumptions that Eclipsys and TSI believes are          
reasonable under the circumstances. The unaudited pro forma combined condensed  
financial information should be read in conjunction with the historical         
financial statements of Eclipsys, TSI, Alltel, SDK and HealthVISION and the     
respective notes thereto, "Management's Discussion and Analysis of Financial    
Condition and Results of Operations of Eclipsys" and the other financial        
information included herein. The unaudited pro forma combined condensed         
financial information is provided for information purposes only and does not    
purport to be indicative of the results which would have been obtained had the  
Merger been completed on the date indicated or which may be expected to occur in
the future.                                                                     

61

S-4
70th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 70th

UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
FOR THE YEAR ENDED DECEMBER 31, 1995

                                                        [Enlarge/Download Table]

                                                                                PRO FORMA   PRO FORMA  
                                                   ECLIPSYS(1)    TSI(2)(3)    ADJUSTMENTS  COMBINED   
                                                   -----------   -----------   -----------  ---------  
                                                          (IN THOUSANDS EXCEPT PER SHARE DATA)         
                                                                                                       
Revenues:                                                                                              
  Systems and services............................     $--           $27,386                  2$7,386  
Costs and expenses:                                                                                    
  Cost of systems and services revenues...........      --             7,471                   7,471   
  Marketing and sales.............................      --             3,967                   3,967   
  Research and development........................      --             2,724                   2,724   
  General and administrative......................      --             2,299                   2,299   
  Depreciation and amortization...................      --             1,379                   1,379   
                                                       ---           -------                   -----   
          Total costs and expenses................      --            17,840                  17,840   
                                                       ---           -------                   -----   
Income from operations............................      --             9,546                   9,546   
Interest income, net..............................      --              (429)                   (429)  
                                                       ---           -------                   -----   
  Income before income tax provision..............      --             9,975                   9,975   
Income tax provision..............................      --            (4,349)                 (4,349)  
                                                       ---           -------                   -----   
Net income........................................      --             5,626                   5,626   
Net income available to common stockholders.......     $--           $ 5,626                   $5,626  
                                                       ===           =======                   =====   
Net income available to common stockholders per                                                        
  share:                                                                                               
  Basic...........................................     $--           $  0.19                   $0.36   
  Diluted.........................................     $--           $  0.19                   $0.36   
Weighted average common shares outstanding:                                                            
  Basic...........................................      --            30,060                  15,781(4)
  Diluted.........................................      --            30,060                  15,781(4)

---------------                                                                 

(1) Eclipsys was formed in December 1995 and commenced operations in 1996.      
Accordingly, the Unaudited Pro Forma Condensed Combined Statement of    
Operations only reflects the operating results of TSI.                  

(2) Reflects the operations of TSI for the fiscal year ended September 30, 1995.

(3) The statement of operations data for TSI reflects the reclassification of   
 certain costs and expenses, principally depreciation and amortization, to
conform to the presentation of Eclipsys' consolidated statement of      
operations.                                                             

(4) Gives effect to the conversion in the Merger of TSI common share equivalents
 into Eclipsys common share equivalents based on the 0.525 Exchange Ratio.

62

S-4
71st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 71st

    UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS
    FOR THE YEAR ENDED DECEMBER 31, 1996

                                                        [Enlarge/Download Table]

                                                                            PRO FORMA    PRO FORMA  
                                                  ECLIPSYS     TSI(1)      ADJUSTMENTS   COMBINED   
                                                  --------   -----------   -----------   ---------  
                                                        (IN THOUSANDS EXCEPT PER SHARE DATA)        
                                                                                                    
Revenues:                                                                                           
     Systems and services.......................  $    --        $34,269                  $34,269   
Costs and expenses:                                                                                 
     Cost of systems and services revenues......       --          9,313                    9,313   
     Marketing and sales........................      770          4,424                    5,194   
     Research and development...................    1,704          3,192                    4,896   
     General and administrative.................      603          2,315                    2,918   
     Compensation charge........................       --          3,024                    3,024   
     Depreciation and amortization..............       32          1,443                    1,475   
                                                  -------        -------                  -------   
          Total costs and expenses..............    3,109         23,711                   26,820   
                                                  -------        -------                  -------   
Income (loss) from operations...................   (3,109)        10,558                    7,449   
Interest expense (income), net..................     (156)           (53)                    (209)  
                                                  -------        -------                  -------   
     Income (loss) before income tax                                                                
       provision................................   (2,953)        10,611                    7,658   
Income tax provision............................       --         (4,324)                  (4,324)  
                                                  -------        -------                  -------   
Income (loss) before extraordinary item.........   (2,953)         6,287                    3,334   
Extraordinary item:                                                                                 
     Loss on early extinguishment of debt, net                                                      
       of taxes.................................       --         (2,149)                  (2,149)  
                                                  -------        -------                  -------   
Net income (loss)...............................   (2,953)         4,138                    1,185   
Dividends on Series A non-voting preferred                                                          
  stock.........................................       --           (593)                    (593)  
                                                  -------        -------                  -------   
Income (loss) available to common                                                                   
  stockholders..................................  $(2,953)       $ 3,545                  $   592   
                                                  =======        =======                  =======   
Income (loss) before extraordinary item                                                             
  available to common stockholders per share(2):                                                    
     Basic......................................  $ (0.98)       $  0.43                  $  0.28   
     Diluted....................................  $ (0.98)       $  0.35                  $  0.24   
Net income (loss) per common share:                                                                 
     Basic......................................  $ (0.98)       $  0.27                  $  0.06   
     Diluted....................................  $ (0.98)       $  0.22                  $  0.05   
Weighted average common shares outstanding:                                                         
     Basic......................................    3,022         13,214                    9,959(3)
     Diluted....................................    3,022         16,137                   11,494(3)

---------------                                                                 
(1) Represents the historical results of operations of TSI for the fiscal year  
   ended September 30, 1996 and reflects the reclassification of certain costs
  and expenses, principally depreciation and amortization, to conform to the
presentation of Eclipsys' consolidated statement of operations.         

(2) TSI and Pro Forma Combined information represents income before             
 extraordinary item after reflecting accretion of $593,000 of dividends on
TSI non-voting preferred stock.                                         

(3) Gives effect to the conversion in the Merger of TSI common share equivalents
 into Eclipsys common share equivalents based on the 0.525 Exchange Ratio.

63

S-4
72nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 72nd

UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED STATEMENT OF OPERATIONS 
FOR THE YEAR ENDED DECEMBER 31, 1997

                                                        [Enlarge/Download Table]

                                                                  ECLIPSYS                                         
                                    ---------------------------------------------------------------------          
                                                                                 ACQUISITION                       
                                                                                  AND OTHER     ECLIPSYS           
                                     ECLIPSYS    ALLTEL(1)   SDK(2)   EMTEK(3)   ADJUSTMENTS    PRO FORMA   TSI(4) 
                                    ----------   ---------   ------   --------   -----------    ---------  --------
                                                          (IN THOUSANDS EXCEPT PER SHARE DATA)                     
                                                                                                                   
Revenues:                                                                                                          
  Systems and services.............  $  89,722    $ 6,064    $3,037   $14,274                   $113,097   $44,565 
  Hardware.........................      4,355        122      486      8,464                     13,427        -- 
                                     ---------    -------    ------   --------                  --------   ------- 
        Total revenues.............     94,077      6,186    3,523     22,738                    126,524    44,565 
                                     ---------    -------    ------   --------                  --------   ------- 
Costs and expenses:                                                                                                
  Cost of systems and services                                                                                     
    revenues.......................     77,083      4,277    2,193     11,459      $   341(7)     95,353    11,834 
  Cost of hardware revenues........      2,953        104      340      7,394                     10,791        -- 
  Marketing and sales..............     13,662        660      336      6,235                     20,893     6,805 
  Research and development.........     15,714        794       --     12,804                     29,312     3,725 
  General and administrative.......      5,672        621      992      6,671                     13,956     3,829 
  Depreciation and amortization....      9,710        568       --        904          703(7)     11,885     1,632 
  Write off of in-process research                                                                                 
    and development(9).............     99,189         --       --         --      (99,189)           --     6,293 
                                     ---------    -------    ------   --------                  --------   ------- 
        Total costs and expenses...    223,983      7,024    3,861     45,467                    182,190    34,118 
                                     ---------    -------    ------   --------                  --------   ------- 
Income (loss) from operations......   (129,906)      (838)    (338)   (22,729)                   (55,666)   10,447 
Interest expense (income), net.....      1,154        379      (19)        --       (1,683)(10)     (169)   (2,501)
Foreign currency transaction                                                                                       
  loss.............................         --         --       --         --                         --        -- 
                                     ---------    -------    ------   --------                  --------   ------- 
                                      (131,060)    (1,217)    (319)   (22,729)                   (55,497)   12,948 
Income tax benefit (provision).....         --        437       --         --         (437)(12)       --    (7,629)
                                     ---------    -------    ------   --------                  --------   ------- 
Net income (loss)(14)..............   (131,060)      (780)    (319)   (22,729)                   (55,497)    5,319 
Dividends and accretion on                                                                                         
  mandatorily redeemable preferred                                                                                 
  stock............................     (5,850)        --       --         --        5,850 (15)       --        -- 
Preferred stock conversion(17).....     (3,105)        --       --         --                     (3,105)       -- 
                                     ---------    -------    ------   --------                  --------   ------- 
Net income (loss) available to                                                                                     
  common                                                                                                           
  stockholders.....................  $(140,015)   $  (780)   $(319)   $(22,729)                 $(58,602)  $ 5,319 
                                     =========    =======    ======   ========                  ========   ======= 
Net income (loss) available to                                                                                     
  common stockholders per share:                                                                                   
  Basic............................  $  (39.73)                                                 $  (2.98)  $  0.31 
  Diluted..........................  $  (39.73)                                                 $  (2.98)  $  0.27 
Weighted average common shares                                                                                     
  outstanding:                                                                                                     
  Basic............................      3,524                                                    19,638    17,435 
  Diluted..........................      3,524                                                    19,638    19,977 



                                     HEALTH-     PRO FORMA       PRO FORMA                                         
                                    VISION(5)   ADJUSTMENTS      COMBINED                                          
                                    ---------   -----------      ---------                                         
                                     (IN THOUSANDS EXCEPT PER SHARE DATA)                                          
                                                                                                                   
Revenues:                                                                                                          
  Systems and services............. $  8,607      $ (500)(6)     $165,769                                          
  Hardware.........................      547                       13,974                                          
                                    --------                     --------                                          
        Total revenues.............    9,154                      179,743                                          
                                    --------                     --------                                          
Costs and expenses:                                                                                                
  Cost of systems and services                                                                                     
    revenues.......................    4,814      10,990 (8)      122,991                                          
  Cost of hardware revenues........      398                       11,189                                          
  Marketing and sales..............    4,498                       32,196                                          
  Research and development.........    6,189          (5)(6)       39,221                                          
  General and administrative.......    1,907                       19,692                                          
  Depreciation and amortization....    1,612                       15,129                                          
  Write off of in-process research                                                                                 
    and development(9).............       --                        6,293                                          
                                    --------                     --------                                          
        Total costs and expenses...   19,418                      246,711                                          
                                    --------                     --------                                          
Income (loss) from operations......  (10,264)                     (66,968)                                         
Interest expense (income), net.....        3       1,280 (11)      (1,387)                                         
Foreign currency transaction                                                                                       
  loss.............................       10                           10                                          
                                    --------                     --------                                          
                                     (10,277)                     (65,591)                                         
Income tax benefit (provision).....      (75)      7,704 (13)          --                                          
                                    --------                     --------                                          
Net income (loss)(14)..............  (10,352)                     (65,591)                                         
Dividends and accretion on                                                                                         
  mandatorily redeemable preferred                                                                                 
  stock............................     (795)        795 (16)                                                      
Preferred stock conversion(17).....       --                       (3,105)                                         
                                    --------                     --------                                          
Net income (loss) available to                                                                                     
  common                                                                                                           
  stockholders..................... $(11,147)                    $(68,696)                                         
                                    ========                     ========                                          
Net income (loss) available to                                                                                     
  common stockholders per share:                                                                                   
  Basic............................                              $  (2.39)                                         
  Diluted..........................                              $  (2.39)                                         
Weighted average common shares                                                                                     
  outstanding:                                                                                                     
  Basic............................                                28,791(18)                                      
  Diluted..........................                                28,791(18)                                      

64

S-4
73rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 73rd

---------------                                                                 
(1)  Represents the historical results of operations of Alltel for the period 
from January 1, 1997 through January 23, 1997.                      

(2)  Represents the historical results of operations of SDK from January 1,   
1997 through June 26, 1997.                                         

(3)  Represents the historical results of operations of Emtek from January 1, 
1997 through December 31, 1997.                                     

(4)  Represents the historical results of operations of TSI for the year ended
     September 30, 1997 and reflects the reclassification of certain costs and
  expenses, principally depreciation and amortization, to conform to the
      presentation of Eclipsys' historical consolidated statement of operations.

(5)  Represents the historical results of operations of HealthVISION for the  
     year ended December 31, 1997 and reflects the reclassification of certain
     costs and expenses, principally depreciation and amortization, to conform
 to the presentation of Eclipsys' historical consolidated statement of
operations.                                                         

(6)  Represents the elimination of certain intercompany transactions between  
TSI and HealthVISION.                                               

(7)  Represents adjustments for amortization expense related to the Eclipsys  
     Acquisitions and the Alltel Renegotiation as if they had occurred January
1, 1997 as follows (in thousands):                                  

                                                                [Download Table]

                                                ALLTEL    SDK     EMTEK     TOTAL  
                                                ------   -----   -------   ------- 
                                                                                   
MSA............................................ $  200   $  --   $    --   $   200 
Amortization of capitalized software reflected                                     
  in the historical accounts prior to the                                          
  Eclipsys Acquisitions........................   (377)   (197)   (1,794)   (2,368)
  Acquired technology..........................  1,763     321       425     2,509 
                                                ------   -----   -------   ------- 
                                                $1,586   $ 124   $(1,369)  $   341 
                                                ======   =====   =======   ======= 
Ongoing customer relationships................. $  181   $  --   $    --   $   181 
Goodwill.......................................     66     456        --       522 
                                                ------   -----   -------   ------- 
                                                $  247   $ 456   $    --   $   703 
                                                ======   =====   =======   ======= 

     The Eclipsys Acquisitions were accounted for using the purchase method of
    accounting and accordingly the net assets acquired have been recorded at
estimated fair value on the date of acquisition and the historical  
      statement of operations data of Eclipsys reflect the results of operations
from these businesses from the date acquired. In connection with the
     Eclipsys Acquisitions, Eclipsys acquired intangible assets as follows (in
thousands):                                                         

                                                        [Enlarge/Download Table]

                                            VALUE             FIRST YEAR AMORTIZATION 
                                  -------------------------  -------------------------
                                  ALLTEL     SDK     EMTEK    ALLTEL     SDK    EMTEK 
                                  -------   ------   ------  --------   -----   ------
                                                                                      
Acquired technology.............. $42,312   $3,205   $2,125  $21,156    $641     $425 
Management and service                                                                
  agreement......................   9,543       --       --    2,386      --       -- 
                                  -------   ------   ------  -------    ----     ---- 
                                  $51,855   $3,205   $2,125  $23,542    $641     $425 
                                  =======   ======   ======  =======    ====     ==== 
Ongoing customer relationships... $10,846   $   --   $   --  $ 2,169    $ --     $ -- 
Goodwill.........................   8,997    4,553       --      788     911       -- 
                                  -------   ------   ------  -------    ----     ---- 
                                  $19,843   $4,553   $   --  $ 2,957    $911     $ -- 
                                  =======   ======   ======  =======    ====     ==== 

    The acquired technology costs are being amortized annually over three to
   five years either on a straight line basis or, if greater, based on the
ratio that current revenues bear to total anticipated revenues      
      attributable to the applicable product. Ongoing customer relationships are
     being amortized over five years. Goodwill is being amortized over five to
twelve years.                                                       

(8)  Represents an adjustment to record amortization of acquired technology   
recorded in connection with the HealthVISION Acquisition as if the  
transaction had closed on October 1, 1996. In                       

65

S-4
74th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 74th

    connection with this transaction, TSI will record an acquired technology
   asset of $33.0 million. This asset will be amortized over its estimated
useful life of three years.                                         

(9)  In connection with the Alltel and SDK acquisitions, Eclipsys wrote-off   
  in-process research and development of $92.2 million and $7.0 million,
respectively, related to the appraised values of certain in-process 
  research and development acquired in these acquisitions. In connection
    with TSI's acquisition of Vital Software, Inc., TSI wrote-off in-process
      research and development of $6.3 million related to the appraised value of
     certain in-process research and development acquired in this acquisition.

Based on the preliminary results of an appraisal, TSI anticipates   
     recording a $2.5 million write-off of in-process research and development
  in conjunction with the HealthVISION Acquisition. TSI will record this
 write-off in the period in which the transaction closes. The value of
      in-process research and development was determined by estimating the costs
 to develop the in-process projects into commercially viable products,
estimating the resulting net cash flows from such projects, and     
discounting the net cash flows back to their present values. This   
evaluation considered the inherent difficulties and uncertainties of
      completing the development projects and the risks related to the viability
of and potential changes in future target markets.                  

 The estimated costs to be incurred to complete the development of the
    in-process research and development into commercially viable products is
$2.7 million.                                                       

(10) Includes adjustments to net interest expense to give effect to the       
following (in thousands):                                           

                                                                [Download Table]
                                                                 
Interest income foregone on $2.2 million cash paid for           
 SDK Acquisition for the period from January 1, 1997             
 through June 25, 1997.................................  $    94 
Additional interest expense on $20.6 million of                  
 borrowings under the Revolver to fund the MSA Buyout,           
 SDK Partial Repayment and Simione Investment as if              
 they had occurred on January 1, 1997..................    1,752 
Additional interest expense on the SDK Notes as if they          
 had been issued on January 1, 1997....................      360 
Reduction of interest expense on $3.8 million of SDK             
 Notes as if the SDK Partial Repayment had occurred as           
 of January 1, 1997....................................     (360)
Reduction of interest expense as a result of the                 
 elimination of the accretion of the discount recorded           
 in connection with the MSA as if MSA Buyout had                 
 occurred as of January 1, 1997........................     (563)
Reduction of interest expense from the cancellation of           
 payables to AIS as if the Alltel Acquisition had                
 occurred as of January 1, 1997 (interest calculated on          
 average payables balance of $56.8 million at an annual          
 interest rate of 8%)..................................     (379)
Reduction of interest expense on the Term Loan as if             
 the 1998 Preferred Stock Issuance had occurred as               
 January 1, 1997.......................................     (850)
Repayment of a portion of the pro forma balance of the           
 Revolver as if it had occurred as of January 1,                 
 1997..................................................   (1,377)
Repayment of the pro forma balance of the SDK Notes as           
 if it had occurred as of January 1, 1997..............     (360)
                                                         ------- 
                                                         $(1,683)
                                                         ======= 

(11) Represents an adjustment to reduce interest income of TSI as if the      
HealthVISION Acquisition had occurred on October 1, 1996.           

(12) Represents an adjustment to reduce the income tax benefit related to     
     Alltel for the period from January 1, 1997 through January 23, 1997 as if
the Alltel Acquisition had occurred on January 1, 1997.             

(13) Represents an adjustment to eliminate the income tax provision as if the 
HealthVISION Acquisition had occurred on October 1, 1996.           

66

S-4
75th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 75th

(14) Eclipsys has not recorded any benefit for income taxes as management     
      believes at December 31, 1997 it is more likely than not that Eclipsys net
deferred tax assets will not be realized. Accordingly, Eclipsys has 
     recorded a valuation allowance against its total net deferred tax assets.

 (15) Represents the reduction of $1.1 million in the dividends and accretion on
      Eclipsys Redeemable Preferred Stock held by AIS after giving effect to the
 AIS Settlement and the reduction of $4.7 million in the dividends and
  accretion on the Redeemable Preferred Stock with a face value of $34.5
  million as if the proceeds of the Eclipsys IPO were utilized to redeem
34,500 shares of the Redeemable Preferred Stock on January 1, 1997. 

 (16) Represents the reduction of $795,000 in the dividends and accretion on the
redeemable preferred stock of HealthVISION as if the HealthVISION   
Acquisition had taken place on October 1, 1996.                     

(17) Represents a charge related to the January 1997 conversion of Series A   
Convertible Preferred Stock to Series F Convertible Preferred Stock.

(18) Gives effect to the conversion in the Merger of TSI common share         
 equivalents into Eclipsys common share equivalents based on the 0.525
Exchange Ratio.                                                     

67

S-4
76th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 76th

UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED STATEMENT OF OPERATIONS 
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1998

                                                        [Enlarge/Download Table]

                                               ECLIPSYS                                                                         
                            -----------------------------------------------                                                     
                                                  ACQUISITION                                                                   
                                                   AND OTHER      ECLIPSYS                  HEALTH-    PRO FORMA    PRO FORMA   
                            ECLIPSYS   EMTEK(1)   ADJUSTMENTS     PRO FORMA   TSI(2)       VISION(3)  ADJUSTMENTS   COMBINED    
                            --------   --------   -----------     ---------   -------      ---------  -----------   ---------   
                                                            (IN THOUSANDS EXCEPT PER SHARE DATA)                                
                                                                                                                                
Revenues:                                                                                                                       
    Systems and                                                                                                                 
      services............  $ 88,541   $   705                    $ 89,246    $33,946(4)    $ 9,416       (675)(5)  $131,933    
    Hardware..............     9,202       275                       9,477         --            --                    9,477    
                            --------   -------                    --------    -------       -------                 --------    
        Total revenues....    97,743       980                      98,723     33,946         9,416                  141,410    
                            --------   -------                    --------    -------       -------                 --------    
Costs and expenses:                                                                                                             
    Cost of systems                                                                                                             
      and services                                                                                                              
      revenues............    53,196       744          (77)(6)     53,863     10,316         3,645      8,243(7)     76,067    
    Cost of hardware                                                                                                            
      revenues............     7,825       245                       8,070         --            --                    8,070    
    Marketing and sales...    13,945       580                      14,525      5,911         3,251                   23,687    
    Research and                                                                                                                
      development.........    19,267       738                      20,005      4,273         4,951       (227)(5)    29,002    
    General and                                                                                                                 
      administrative......     4,580       276                       4,856      2,505         2,027                    9,388    
    Depreciation and                                                                                                            
      amortization........     7,937        87                       8,024      1,329           597                    9,950    
    Write-off of MSA(8)...     7,193        --       (7,193)            --         --            --                       --    
                            --------   -------                    --------    -------       -------                 --------    
        Total costs and                                                                                                         
          expenses........   113,943     2,670                     109,343     24,334        14,471                  156,164    
                            --------   -------                    --------    -------       -------                 --------    
Income (loss) from                                                                                                              
  operations..............   (16,200)   (1,690)                    (10,620)     9,612        (5,055)                 (14,754)   
Interest expense (income),                                                                                                      
  net.....................       628        --         (379)(9)        249     (2,285)          176        953(10)      (907)   
Foreign currency                                                                                                                
  transaction loss........        --        --                          --         --            28                       28    
                            --------   -------                    --------    -------       -------                 --------    
                             (16,828)   (1,690)                    (10,869)    11,897        (5,259)                 (13,875)   
Income tax benefit                                                                                                              
  (provision).............        --        --                          --     (4,759)          (87)     4,846(11)        --    
                            --------   -------                    --------    -------       -------                 --------    
Net income (loss)(12).....   (16,828)   (1,690)                    (10,869)     7,138        (5,346)                 (13,875)   
Dividends and accretion on                                                                                                      
  mandatorily redeemable                                                                                                        
  preferred stock.........   (10,928)       --       10,928(13)         --         --          (621)       621(14)        --    
                            --------   -------                    --------    -------       -------                 --------    
Net income (loss)                                                                                                               
  available to                                                                                                                  
  common stockholders.....  $(27,756)  $(1,690)                   $(10,869)   $ 7,138       $(5,967)                $(13,875)   
                            ========   =======                    ========    =======       =======                 ========    
Net income (loss)                                                                                                               
  available to common                                                                                                           
  stockholders per share:                                                                                                       
    Basic.................  $  (3.41)                             $  (0.55)   $  0.39                               $  (0.47)   
    Diluted...............  $  (3.41)                             $  (0.55)   $  0.35                               $  (0.47)   
Weighted average common                                                                                                         
  shares outstanding:                                                                                                           
    Basic.................     8,133                                19,805     18,153                                 29,335(15)
    Diluted...............     8,133                                19,805     20,459                                 29,335(15)

---------------                                                                 
(1) Represents the historical results of operations of Emtek for the period   
from January 1, 1998 through January 30, 1998.                        

(2) Represents the historical results of operations of TSI for the nine months
    ended June 30, 1998 and reflects the reclassification of certain costs and
expenses, principally depreciation and amortization, to conform to the
    presentation of Eclipsys' historical consolidated statement of operations.

(3) Represents the historical results of operations of HealthVISION for the   
nine months ended September 30, 1998.                                 

(4) AICPA Statement of Position 97-2 ("SOP 97-2"), "Software Revenue          
     Recognition," will be effective for TSI transactions beginning in the first
     quarter of TSI's 1999 fiscal year. TSI is analyzing the impact of SOP 97-2,
which may cause a deferral of revenue. After the consummation of the  
   Merger, SOP 97-2 will be applied to TSI transactions beginning on January
   1, 1998 in order to conform to Eclipsys' date of adoption of SOP 97-2. No
   pro forma adjustment has been made to the pro forma combined statement of
 operations to reflect the impact of adoption of SOP 97-2. See Note 2 of
Notes to Consolidated Financial Statements of TSI.                    

 (5) Represents the elimination of certain intercompany transactions between TSI
and HealthVISION.                                                     

68

S-4
77th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 77th

(6) Represents adjustments for amortization expense related to the Emtek      
Acquisition as if it had occurred January 1, 1997 as follows (in      
thousands):                                                           

                                                                [Download Table]
                                                                     
Amortization of capitalized software development costs               
  reflected in the historical accounts prior to                      
  the Emtek Acquisition.....................................   $(145)
Acquired technology.........................................      68 
                                                               ----- 
         Total..............................................   $ (77)
                                                               ===== 

(7) Represents an adjustment to record amortization of acquired technology    
recorded in connection with the HealthVISION Acquisition as if the    
transaction had closed on October 1, 1997.                            

(8) In connection with the MSA Buyout, Eclipsys recorded a charge of $7.2     
   million in 1998. See Note 13 of Notes to Eclipsys' Consolidated Financial
 Statements. Adjustments represent the elimination of this non-recurring
charge.                                                               

(9) Includes adjustments to net interest expense to give effect to the        
following (in thousands):                                             

                                                                [Download Table]
                                                                     
Additional interest expense on $18.6 million of borrowings           
  under the Revolver to fund the MSA Buyout, SDK Partial             
  Repayment and Simione Investment if they had occurred on           
  January 1, 1997...........................................   $ 395 
Reduction of interest expense on $3.8 million of SDK Notes           
  as if the SDK Partial Repayment had occurred on January 1,         
  1997......................................................     (90)
Reduction of interest expense as a result of the elimination         
  of the accretion of the discount recorded in connection            
  with the MSA as if the MSA Buyout had occurred as of               
  January 1, 1997...........................................    (129)
Reduction of interest expense on the Term Loan as if the             
  1998 Preferred Stock Issuance had occurred as of January           
  1, 1997...................................................     (70)
Reduction of interest expense as a result of the repayment           
  of the pro forma balance of the Revolver as if it had              
  occurred as of January 1, 1997............................    (395)
Reduction of interest expense as a result of the repayment           
  of the pro forma balance of the SDK Notes as if it had             
  occurred on January 1, 1997...............................     (90)
                                                               ----- 
          Total.............................................   $(379)
                                                               ===== 

(10) Represents an adjustment to reduce interest income of TSI as if the        
HealthVISION Acquisition had occurred on October 1, 1997.             

(11) Represents an adjustment to reduce the income tax provision as if the      
HealthVISION Acquisition had occurred on October 1, 1997.             

(12) Eclipsys has not recorded any benefit for income taxes as management       
  believes, based on evidence available at December 31, 1997 and September
     30, 1998, it is more likely than not that Eclipsys' net deferred tax assets
will not be realized. Accordingly, Eclipsys has recorded a valuation  
against its total net deferred tax asset.                             

(13) Represents the reduction of $ 181,000 in the dividends and accretion on    
Redeemable Preferred Stock held by AIS after giving effect to the AIS 
  Settlement as if it had occurred on January 1, 1997 and the reduction of
  $10.8 million in the dividends and accretion on the Redeemable Preferred
     Stock with a face value of $34.5 million as if the proceeds of the Eclipsys
     IPO were utilized to redeem 34,500 shares of the Redeemable Preferred Stock
on January 1, 1998.                                                   

(14) Represents the reduction of $621,000 in the dividends and accretion on the 
redeemable preferred stock of HealthVISION as if the HealthVISION     
Acquisition had taken place on October 1, 1997.                       

(15) Gives effect to the conversion in the Merger of TSI common share           
equivalents into Eclipsys common share equivalents based on the 0.525 
Exchange Ratio.                                                       

69

S-4
78th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 78th

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

                                                        [Enlarge/Download Table]

                                                               ADJUSTMENTS FOR                              
                                      SEPTEMBER 30,  JUNE 30,        THE                                    
                                          1998         1998      HEALTHVISION      ADJUSTMENTS    PRO FORMA 
                                        ECLIPSYS       TSI      ACQUISITION(1)    FOR THE MERGER  COMBINED  
                                      -------------  --------  ----------------   --------------  --------- 
                                                                   (IN THOUSANDS)                           
                                                                                                            
ASSETS                                                                                                      
Current assets:                                                                                             
  Cash and cash equivalents..........   $  12,309    $65,179       $(25,038)                      $  52,450 
  Accounts receivable, net...........      40,443     19,662          3,696                          63,801 
  Inventory..........................         539         --                                            539 
  Other current assets...............       9,757      1,179            802                          11,738 
  Deferred income taxes..............                    853                                            853 
                                        ---------    -------                                      --------- 
     Total current assets............      63,048     86,873                                        129,381 
                                        ---------    -------                                      --------- 
Property and equipment, net..........      10,530      1,638            770                          12,938 
Capitalized software development                                                                            
  costs, net.........................       4,277      1,410                                          5,687 
Acquired technology, net.............      18,798      1,219         32,970                          52,987 
Intangible assets, net...............      15,559        674           (400)                         15,833 
Other assets.........................       9,479      6,000         (6,000)                          9,479 
                                        ---------    -------                                      --------- 
                                        $ 121,691    $97,814                                      $ 226,305 
                                        =========    =======                                      ========= 
LIABILITIES AND SHAREHOLDERS'                                                                               
  EQUITY                                                                                                    
Current liabilities:                                                                                        
  Accounts payable...................   $      --    $ 1,334       $    401          $(1,735)(2)  $      -- 
  Accrued liabilities................          --      3,717            750           (4,467)(2)         -- 
  Income taxes payable...............          --      2,871                                          2,871 
  Deferred revenue...................      39,211      7,676          6,660                          53,547 
  Other current liabilities..........      32,411         --          1,442            6,202(2)      40,055 
                                        ---------    -------                                      --------- 
     Total current liabilities.......      71,622     15,598                                         96,473 
                                        ---------    -------                                      --------- 
Deferred revenue.....................       7,789         --                                          7,789 
Other long-term liabilities..........       3,713         --                                          3,713 
Deferred income taxes................          --        496                                            496 
                                        ---------    -------                                      --------- 
     Total liabilities...............      83,124     16,094                                        108,471 
                                        ---------    -------                                      --------- 
Shareholders' equity:                                                                                       
  Common stock, voting...............         193        179                             (92)(3)        280 
  Common stock, non-voting...........           9          4                              (4)(3)          9 
  Non-voting common stock warrant....          --        395                                            395 
  Additional paid-in capital.........     189,341     47,778                              96(3)     237,215 
  Unearned compensation..............        (196)        --                                           (196)
  Retained earnings                                                                                         
     (accumulated deficit)...........    (150,841)    33,364         (2,453)                       (119,930)
  Accumulated other comprehensive                                                                           
     income..........................          61         --                                             61 
                                        ---------    -------                                      --------- 
     Total shareholders' equity......      38,567     81,720                                        117,834 
                                        ---------    -------                                      --------- 
     Total liabilities and                                                                                  
       shareholders' equity..........   $ 121,691    $97,814                                      $ 226,305 
                                        =========    =======                                      ========= 

---------------                                                                 

(1) Represents an entry to record the HealthVISION Acquisition as of June 30,   
1998.                                                                   

(2) Represents adjustments to reclassify accounts payable and accrued           
    liabilities as other current liabilities in order to conform TSI's financial
presentation to that of Eclipsys.                                       

(3) Represents an adjustment to reflect the issuance of approximately 9.6       
million shares in connection with the Merger.                           

70

S-4
79th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 79th

THE MERGER AGREEMENT

The following is a brief summary of certain provisions of the Merger  
Agreement, a copy of which is attached as Annex A to this Joint Proxy           
Statement/Prospectus and is incorporated herein by reference. Such summary is   
qualified in its entirety by reference to the Merger Agreement. Stockholders of 
Eclipsys and TSI are urged to read the Merger Agreement in its entirety for a   
more complete description of the terms and conditions of the Merger.            

GENERAL                                                                         

    The Merger Agreement provides that, following the approval of the Eclipsys
Voting Proposal by the stockholders of Eclipsys, the approval and adoption of   
the Merger and the Merger Agreement by the stockholders of TSI, and the         
satisfaction or waiver of the other conditions to the Merger, Sub will be merged
with and into TSI, with TSI continuing as the Surviving Corporation, which will 
be a wholly owned subsidiary of Eclipsys.                                       

  If all conditions to the Merger are satisfied or waived, the Merger will
become effective at the time (the "Effective Time") of the filing by TSI and Sub
of duly executed Articles of Merger with the Secretary of State of the          
Commonwealth of Massachusetts or at such time thereafter as shall be provided in
the Articles of Merger.                                                         

CONVERSION OF SHARES                                                            

 Upon consummation of the Merger, pursuant to the Merger Agreement, each
issued and outstanding share of TSI Voting and Non-Voting Common Stock (other   
than shares owned by TSI as treasury stock or by Eclipsys, Sub or any other     
wholly owned subsidiary of Eclipsys, all of which will be cancelled, and other  
than shares, if any, as to which dissenters rights, if any, are perfected in    
accordance with Section 2.01(d) of the Merger Agreement) will be converted into 
0.525 shares of Eclipsys Voting Common Stock. Based upon the number of          
outstanding shares of Eclipsys Voting and Non-Voting Common Stock and TSI Voting
and Non-Voting Common Stock as of the Record Date, the stockholders of TSI      
immediately prior to the consummation of the Merger will own approximately 33.7%
of the outstanding shares of Eclipsys Voting Common Stock immediately following 
consummation of the Merger on a fully diluted basis (assuming exercise of all   
warrants and stock options of both TSI and Eclipsys that are exercisable on or  
before December 31, 1998 and assuming conversion of all shares of Eclipsys      
Non-Voting Common Stock into Eclipsys Voting Common Stock). If a holder of      
shares of TSI Voting or Non-Voting Common Stock would be entitled to receive a  
number of shares of Eclipsys Voting Common Stock that includes a fraction, then,
in lieu of the fractional share, such holder will be entitled to receive cash in
an amount equal to such fractional share multiplied by the average of the last  
reported sale price of Eclipsys Voting Common Stock, as reported on the Nasdaq  
National Market on each of the ten trading days immediately preceding the       
closing date of the Merger. Each share of the Common Stock of Sub issued and    
outstanding immediately prior to the Effective Time will be converted into one  
share of common stock of TSI as the Surviving Corporation.                      

 As soon as reasonably practicable after the Effective Time, BankBoston,
N.A. (the "Exchange Agent") will mail transmittal forms and exchange            
instructions to each holder of record of TSI Voting and Non-Voting Common Stock 
to be used to surrender and exchange certificates formerly evidencing shares of 
TSI Voting and Non-Voting Common Stock for certificates evidencing the shares of
Eclipsys Voting Common Stock to which such holder has become entitled. After    
receipt of such transmittal forms, each holder of certificates formerly         
representing TSI Voting and Non-Voting Common Stock will be able to surrender   
such certificates to the Exchange Agent, and each such holder will receive in   
exchange therefor certificates evidencing the number of whole shares of Eclipsys
Voting Common Stock to which such holder is entitled and any cash which may be  
payable in lieu of a fractional share of Eclipsys Voting Common Stock. TSI      
STOCKHOLDERS SHOULD NOT SEND IN THEIR STOCK CERTIFICATES UNTIL THEY RECEIVE A   
TRANSMITTAL FORM.                                                               

71

S-4
80th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 80th

     After the Effective Time, each certificate formerly representing TSI Voting
and Non-Voting Common Stock, until so surrendered and exchanged, shall be       
deemed, for all purposes, to evidence only the right to receive the number of   
whole shares of Eclipsys Voting Common Stock which the holder of such           
certificate is entitled to receive in the Merger and any cash payment in lieu of
a fractional share of Eclipsys Voting Common Stock. The holder of such          
unexchanged certificate will not be entitled to receive any dividends or other  
distributions declared or made by Eclipsys with a record date after the         
Effective Time with respect to Eclipsys Voting Common Stock until the           
certificate has been exchanged. Subject to applicable laws, following surrender 
of such certificates, such dividends and distributions, together with any cash  
payment in lieu of a fractional share of Eclipsys Voting Common Stock, will be  
paid without interest.                                                          

REPRESENTATIONS AND WARRANTIES                                                  

The Merger Agreement contains various customary representations and   
warranties relating to, among other things: (a) due organization, valid         
existence and good standing of each of Eclipsys, TSI and each of their          
respective subsidiaries and certain similar corporate matters; (b) the capital  
structure of each of Eclipsys, TSI and Sub; (c) the authorization, execution,   
delivery and enforceability of the Merger Agreement, the consummation of the    
transactions contemplated by the Merger Agreement and related matters; (d)      
conflicts under their respective charters or bylaws, required consents or       
approvals and violations of any instruments or law; (e) documents and financial 
statements filed by each of Eclipsys and TSI with the Commission and the        
accuracy of information contained therein; (f) undisclosed liabilities; (g) the 
absence of certain material adverse events, changes or other actions (although  
Eclipsys and TSI have both agreed that the failure of either company to achieve 
any level of revenue and earnings at any time shall not of itself constitute a  
material adverse change); (h) taxes and tax returns; (i) properties; (j)        
intellectual property; (k) agreements, contracts and commitments; (l)           
litigation; (m) environmental matters; (n) compliance with laws; (o) accounting 
and tax matters relating to the Merger; (p) the accuracy of information supplied
by each of Eclipsys, TSI and Sub in connection with this Joint Proxy            
Statement/Prospectus and the registration statement of which it is a part (the  
"Registration Statement"); (q) labor matters; (r) employee benefit plans; (s)   
insurance; (t) the absence of existing discussions by TSI or Eclipsys with other
parties with respect to an Acquisition Proposal (as defined under "-- No        
Solicitation" below) (other than discussions regarding the acquisition by TSI of
the capital stock of HealthVISION not owned by TSI); (u) opinions of financial  
advisors; (v) the inapplicability of certain provisions of the General Laws of  
Massachusetts, in the case of TSI, to the Merger and related transactions; and  
(w) the interim operations of TSI and Sub.                                      

CERTAIN COVENANTS                                                               

     Pursuant to the Merger Agreement, each of Eclipsys and TSI has agreed that,
during the period from the date of the Merger Agreement until the Effective     
Time, except as otherwise consented to in writing by the other party or as      
contemplated by the Merger Agreement, it and each of its respective subsidiaries
will, among other things: (a) carry on its business in the ordinary course in   
substantially the same manner as previously conducted; (b) pay its debts and    
taxes and perform other obligations when due subject to good faith disputes over
such debts, taxes or obligations; (c) use all reasonable efforts consistent with
past practices and policies to preserve intact its present business             
organization, management team and business relationships; (d) not accelerate,   
amend or change the period of exercisability of options or restricted stock     
granted under any employee stock plan or authorize cash payments in exchange for
any options granted under any employee stock plan, except as required pursuant  
to the plan or any related agreements; (e) not declare or pay any dividends on  
or make other distributions in respect of any of its capital stock, not effect  
certain other changes in its capitalization, and not purchase or otherwise      
acquire, directly or indirectly, any shares of its capital stock except from    
former employees, directors and consultants in accordance with agreements       
providing for the repurchase of shares in connection with the termination of    
service; (f) not issue or sell, or authorize or propose the issuance or sale of,
any shares of its capital stock or securities convertible into shares of its    
capital stock, or any subscriptions, rights, warrants or options to acquire, or 
other agreements obligating it to issue any such shares or other convertible    
securities, subject to certain exceptions; (g) not make any material            
acquisitions, subject to certain exceptions; (h) not sell, lease,               
72

S-4
81st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 81st

license or otherwise dispose of material properties or assets outside the       
ordinary course of business; (i) not increase the compensation payable to its   
officers or employees (except for increases to non-officer employees consistent 
with past practices), grant additional severance or termination pay or enter    
into employment or severance agreements, enter into any collective bargaining   
agreement or establish, adopt, enter into or amend any plan for the benefit of  
its directors, officers, or employees; (j) not amend its charter or bylaws,     
except as contemplated by the Merger Agreement; and (k) not take, or agree in   
writing or otherwise to take, any of the actions described in (a) through (j)   
above.                                                                          

  In addition, TSI has agreed that, during the period from the date of the
Merger Agreement until the Effective Time, except as otherwise consented to in  
writing by Eclipsys or as contemplated by the Merger Agreement, it and each of  
its respective subsidiaries will not: (a) incur indebtedness for money borrowed 
other than pursuant to credit agreements in effect as of the date of the Merger 
Agreement; (b) initiate, compromise or settle any material litigation or        
arbitration except in connection with the Merger Agreement or the transactions  
contemplated thereby; (c) except in the ordinary course of business modify,     
amend or terminate any material contracts or release material rights or claims; 
or (d) except as required by generally accepted accounting principles, change   
its methods of accounting.                                                      

    Pursuant to the Merger Agreement, Eclipsys and TSI each have agreed to use
their respective best efforts to (a) take all appropriate action to consummate  
the transactions contemplated by the Merger Agreement as promptly as practical, 
(b) obtain any consents, licenses, permits, waivers, approvals, authorizations  
or orders from governmental entities or other third parties required in         
connection with the transactions contemplated by the Merger Agreement and (c)   
make all necessary filings and submissions with respect to the transactions     
contemplated by the Merger Agreement under federal and state securities laws,   
antitrust laws and other applicable laws. Eclipsys and TSI have also agreed to  
use their respective best efforts to obtain any governmental clearances required
under antitrust laws for the closing of the Merger. Neither Eclipsys nor TSI,   
nor any of their respective subsidiaries, are required either to divest any of  
their businesses, product lines or assets or take other action that would       
reasonably be expected to have a material adverse effect on such company.       

NO SOLICITATION                                                                 

    The Merger Agreement provides that neither Eclipsys nor TSI will, directly
or indirectly, through any officer, director, employee, financial advisor,      
representative or agent, (a) solicit, initiate or encourage any inquiries or    
proposals that constitute, or could reasonably be expected to lead to, a        
proposal or offer for a merger, consolidation, business combination, sale of    
substantial assets, sale of shares of capital stock (including without          
limitation by way of a tender offer) or similar transaction involving such      
parties or any of their respective subsidiaries, other than the transactions    
contemplated by the Merger Agreement and, in the case of Eclipsys, certain      
permitted acquisitions (any of the foregoing inquiries or proposals being       
referred to as an "Acquisition Proposal"), (b) engage in negotiations or        
discussions concerning, or provide any non-public information to any person or  
entity relating to, any Acquisition Proposal, or (c) agree to or recommend any  
Acquisition Proposal; provided, however, that nothing contained in the Merger   
Agreement shall prevent Eclipsys or TSI, or their respective Boards of          
Directors, from (i) furnishing non-public information to, or entering into      
discussions or negotiations with, any person or entity in connection with an    
unsolicited bona fide written Acquisition Proposal by such person or entity or  
recommending an unsolicited bona fide written Acquisition Proposal to the       
stockholders of the respective company, if and only to the extent that (1) the  
Board of Directors of such company believes in good faith (after consultation   
with its financial advisor) that such Acquisition Proposal is reasonably capable
of being completed on the terms proposed and, after taking into account, among  
other relevant factors, the strategic benefits anticipated to be derived from   
the Merger and the long-term prospects of TSI and Eclipsys as a combined        
company, would, if consummated, result in a transaction more favorable to the   
stockholders of such company than the transaction contemplated by the Merger    
Agreement (any such more favorable Acquisition Proposal being referred to as a  
"Superior Proposal") and such Board of Directors determines in good faith after 
consultation with outside legal counsel that such action is necessary for such  
Board of Directors to comply with its fiduciary duties to stockholders under    
applicable law and (2) prior to furnishing such non-public                      

73

S-4
82nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 82nd

information to, or entering into discussions or negotiations with, such person  
or entity, such Board of Directors receives from such person or entity an       
executed confidentiality agreement with terms no less favorable to such party   
than those contained in the confidentiality agreement dated October 2, 1998,    
between Eclipsys and TSI; or (ii) complying with Rule 14e-2 promulgated under   
the Exchange Act with regard to an Acquisition Proposal.                        

   Each of Eclipsys and TSI has agreed to notify the other party (orally and
in writing) immediately after receipt by such party or an advisor to such party 
of any Acquisition Proposal or request for non-public information in connection 
with an Acquisition Proposal or for access to the properties, books or records  
of such party by any person or entity that informs such party that it is        
considering making, or has made, an Acquisition Proposal. In addition to        
indicating in reasonable detail the identity of any offeror and the terms and   
conditions of any proposal, each of Eclipsys and TSI has agreed to continue to  
keep the other party informed on a current basis of the status of any           
discussions and the terms being discussed or negotiated.                        

RELATED MATTERS AFTER THE MERGER                                                

   At the Effective Time, Sub will be merged with and into TSI, and TSI will
be the surviving corporation and a wholly owned subsidiary of Eclipsys. Each    
share of Common Stock of Sub issued and outstanding immediately prior to the    
Effective Time will be converted into and exchanged for one validly issued,     
fully paid and nonassessable share of common stock of the Surviving Corporation.

    The Articles of Organization of Sub, as in effect immediately prior to the
Effective Time, will become the Articles of Organization of the Surviving       
Corporation (except that the name of the company shall change to Transition     
Systems, Inc.). The Bylaws of Sub, as in effect immediately prior to the        
Effective Time, will become the Bylaws of the Surviving Corporation (except that
the name of the company shall change to Transition Systems, Inc.).              

    After the Effective Time, all shares of TSI Voting Common Stock will cease
to be listed on the Nasdaq National Market, and the Surviving Corporation will  
terminate the registration of TSI Voting Common Stock under the Exchange Act.   

STOCK OPTIONS AND WARRANTS; EMPLOYEE STOCK PLANS                                

  At the Effective Time, each outstanding option to purchase shares of TSI
Voting Common Stock (a "TSI Stock Option"), whether vested or unvested, will be 
deemed to constitute an option to acquire, on the same terms and conditions as  
were applicable under such TSI Stock Option, the number of shares of Eclipsys   
Voting Common Stock (rounded down to the nearest whole number) as the holder of 
such TSI Stock Option would have received had such holder exercised such option 
in full immediately prior to the Effective Time (thereby being subject to the   
Exchange Ratio calculations). The exercise price per share of each such option, 
as so converted, will be equal to (x) the aggregate exercise price for the      
shares of TSI Voting Common Stock otherwise purchasable pursuant to such TSI    
Stock Option immediately prior to the Effective Time divided by (y) the number  
of whole shares of Eclipsys Voting Common Stock deemed purchasable pursuant to  
such TSI Stock Option as determined above. As of November 30, 1998, options to  
acquire 3,420,540 shares of TSI Voting Common Stock were outstanding. Of these, 
options to purchase 2,366,257 shares of TSI Voting Common Stock will be         
exercisable as of December 31, 1998.                                            

   Eclipsys has agreed to reserve for issuance a sufficient number of shares
of Eclipsys Voting Common Stock for delivery upon exercise of the TSI Stock     
Options assumed as described above. As soon as practicable after the Effective  
Time, Eclipsys will file a registration statement on Form S-8 with respect to   
the shares of Eclipsys Voting Common Stock subject to such options and will use 
its best efforts to maintain the effectiveness of such registration statement   
for so long as such options remain outstanding.                                 

   At the Effective Time, each outstanding warrant to purchase shares of TSI
Non-Voting Common Stock (a "TSI Warrant") will be deemed to constitute a warrant
to acquire, on the same terms and conditions as were applicable under such TSI  
Warrant, the number of shares of Eclipsys Voting Common                         

74

S-4
83rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 83rd

Stock as the holder of such TSI Warrant would have received had such holder     
exercised such warrant in full immediately prior to the Effective Time (thereby 
being subject to the Exchange Ratio calculations). The exercise price per share 
of each such warrant, as so converted, will be equal to (x) the aggregate       
exercise price for the shares of TSI Non-Voting Common Stock otherwise          
purchasable pursuant to such TSI Warrant immediately prior to the Effective Time
divided by (y) the number of whole shares of Eclipsys Voting Common Stock deemed
purchasable pursuant to such TSI Warrant as determined above. As of November 30,
1998, warrants to acquire 297,928 shares of TSI Non-Voting Common Stock were    
outstanding. Eclipsys has agreed to reserve for issuance a sufficient number of 
shares of Eclipsys Voting Common Stock for delivery upon exercise of the TSI    
Warrants assumed as described above.                                            

TSI has agreed to terminate its Employee Stock Purchase Plan (the "TSI
Stock Purchase Plan") in accordance with its terms as of or prior to the        
Effective Time, provided that such termination will not affect the rights of the
plan's participants to purchase shares in the current offering period, which    
commenced on October 1, 1998 and terminates on March 31, 1999. If the Merger is 
closed before March 31, 1999, participants in the current offering under the TSI
Stock Purchase Plan will have the right on March 31, 1999 to apply approximately
$90,000 of deferred salary to the purchase of shares of Eclipsys Voting Common  
Stock (up to an aggregate of 14,227 shares) at an exercise price per share equal
to the lower of $12.75 or 85% of the market value (determined in accordance with
the TSI Stock Purchase Plan) of Eclipsys Voting Common Stock as of March 31,    
1999, all subject to and in accordance with the terms of the TSI Stock Purchase 
Plan. After the Effective Time, Eclipsys will file a registration statement on  
Form S-8 with respect to the shares of Eclipsys Voting Common Stock issuable    
upon such purchase.                                                             

DIRECTOR AND OFFICER INDEMNIFICATION                                            

The Merger Agreement provides that, from and after the Effective Time,
Eclipsys and the Surviving Corporation will indemnify and hold harmless each    
present and former director and officer of TSI against all costs or expenses    
(including attorneys' fees), judgments, fines, losses, claims, damages,         
liabilities or amounts paid in settlement incurred in connection with any claim,
action, suit, proceeding or investigation arising out of or pertaining to any   
matter existing or occurring at or prior to the Effective Time, whether asserted
or claimed prior to, or at or after the Effective Time, to the fullest extent   
permitted under Massachusetts law. Eclipsys and the Surviving Corporation shall 
also be obligated to advance expenses as incurred to the fullest extent         
permitted under applicable law, provided the person to whom expenses are        
advanced provides an undertaking to repay such advances if it is ultimately     
determined that such person is not entitled to indemnification.                 

    For a period of three years after the Effective Time, Eclipsys shall cause
the Surviving Corporation to maintain in effect (to the extent available in the 
market) a directors' and officers' liability insurance policy covering those    
persons who are covered as of the date of the Merger Agreement by TSI's         
directors' and officers' liability insurance policy, with coverage in an amount 
and scope at least as favorable as TSI's existing coverage; provided that       
neither Eclipsys nor the Surviving Corporation shall be required to expend in   
excess of 200% of the annual premium paid by TSI as of the date of the Merger   
Agreement for such coverage except to the extent any excess amount is           
attributable to Eclipsys' claims history or price increases in the market for   
such insurance that are unrelated to TSI specifically. If the premium at any    
time exceeds such limitation, the Surviving Corporation will maintain insurance 
policies that provide the maximum and best coverage available at an annual      
premium equal to such limitation. If any legal action had been pending at any   
time subsequent to the second anniversary of the Effective Time against any     
person currently covered by TSI's directors' and officers' liability insurance  
policy and such pending action would be covered in whole or in part by such     
policy, the Surviving Corporation will continue to maintain such policy in      
effect (subject to the limitations above) until the fifth anniversary of the    
Effective Time.                                                                 

CONDITIONS                                                                      

 The respective obligations of Eclipsys and TSI to effect the Merger are
subject to the satisfaction (or waiver) of the following conditions: (a) the    
Merger and the Merger Agreement shall have been approved by the holders of      
two-thirds of the outstanding shares of TSI Voting Common Stock and the Eclipsys
75

S-4
84th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 84th

Voting Proposal shall have been approved and adopted by the holders of a        
majority of the shares of Eclipsys Voting Common Stock represented in person or 
by proxy and voting at the Eclipsys Special Stockholders' Meeting; (b) the      
waiting period applicable to the consummation of the Merger under the HSR Act   
shall have expired or been terminated; (c) all material governmental            
authorizations, consents, orders or approvals shall have been obtained; (d) the 
Registration Statement shall have become effective and shall not be the subject 
of a stop order or proceedings seeking a stop order; (e) no order, injunction or
judgment, or statute, rule or regulation, shall be in effect that makes the     
Merger illegal or otherwise prohibits the consummation of the Merger; and (f)   
Eclipsys and TSI each shall have received a letter from PricewaterhouseCoopers  
LLP regarding its concurrence, as of the date of the letter, with management's  
conclusions as to the appropriateness of accounting for the Merger as a pooling 
of interests under Accounting Principles Board Opinion No. 16.                  

   In addition, the obligations of Eclipsys and Sub to effect the Merger are
subject to the satisfaction of the following conditions: (a) the representations
and warranties of TSI in the Merger Agreement (including the representation that
there has been no Material Adverse Change, as defined below, as to TSI) shall be
true and correct as of the date of the Merger Agreement and (except to the      
extent such representations and warranties speak as of an earlier date) as of   
the Closing Date as though made on and as of the Closing Date, except for       
changes contemplated by the Merger Agreement and, in the case of breaches which 
are not qualified as to materiality, where the failure to be so true and correct
individually or in the aggregate have not had and are not reasonably likely to  
have a material adverse effect upon either TSI or the consummation of the       
transactions contemplated by the Merger Agreement (the "TSI Representation      
Bringdown Condition"); (b) TSI shall have performed in all material respects all
obligations required to be performed by it under the Merger Agreement at or     
prior to the Closing Date (the "TSI Covenant Condition"); (c) Eclipsys shall    
have received a written legal opinion from its counsel to the effect that the   
Merger will be treated for federal income tax purposes as a reorganization      
within the meaning of Section 368(a) of the Code; and (d) the total number of   
shares of TSI Voting or Non-Voting Common Stock as to which appraisal rights    
have been perfected shall not be greater than 5% of the total number of shares  
of TSI Voting and Non-Voting Common Stock outstanding immediately prior to the  
Effective Date. The Merger Agreement defines a "Material Adverse Change" for    
either TSI or Eclipsys as a material adverse change in the financial condition, 
results of operations, cash flows, business or property of the respective       
company and its subsidiaries, taken as a whole (other than changes that are the 
effect or result of economic factors affecting the economy as a whole or        
economic or market factors affecting the healthcare information systems industry
generally), except that the failure of either company to achieve any level of   
revenues and earnings at any time does not of itself constitute a Material      
Adverse Change.                                                                 

     The obligations of TSI to effect the Merger are subject to the satisfaction
of the following conditions: (a) the representations and warranties of each of  
Eclipsys and Sub in the Merger Agreement (including the representation that     
there has been no Material Adverse Change as to Eclipsys and Sub) shall be true 
and correct as of the date of the Merger Agreement and (except to the extent    
such representations and warranties speak as of an earlier date) as of the      
Closing Date as though made on and as of the Closing Date, except for changes   
contemplated by the Merger Agreement and, in the case of breaches which are not 
qualified as to materiality, where the failure to be so true and correct        
individually or in the aggregate have not had and are not reasonably likely to  
have a material adverse effect upon either Eclipsys or the consummation of the  
transactions contemplated by the Merger Agreement (the "Eclipsys Representation 
Bringdown Condition"); (b) Eclipsys and Sub shall have performed in all material
respects all obligations required to be performed by them under the Merger      
Agreement at or prior to the Closing Date (the "Eclipsys Covenant Condition");  
(c) TSI shall have received a written legal opinion from its counsel to the     
effect that the Merger will be treated for federal income tax purposes as a     
tax-free reorganization within the meaning of Section 368(a) of the Code; (d)   
Eclipsys shall have entered into an agreement with Warburg, Pincus Ventures,    
L.P., a TSI stockholder, granting such stockholder certain registration rights; 
and (e) the shares of Eclipsys Voting Common Stock to be issued in the Merger   
shall have been approved for listing on the Nasdaq National Market.             

76

S-4
85th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 85th

TERMINATION; TERMINATION FEES AND EXPENSES                                      

   The Merger Agreement may be terminated at any time prior to the Effective
Time, whether before or after approval of the matters presented in connection   
with the Merger by the stockholders of Eclipsys and TSI:                        

(a) by mutual written consent of Eclipsys and TSI; or       

   (b) by either Eclipsys or TSI if the Merger shall not have been
     consummated by April 30, 1999 (the "Outside Date") (provided that the right
    to terminate the Merger Agreement under this clause shall not be available
to any party whose failure to fulfill any obligation under the Merger 
     Agreement has been the cause of or resulted in the failure of the Merger to
occur on or before such date); or                                     

         (c) by either Eclipsys or TSI if a Governmental Entity (as defined in
the Merger Agreement) or a court of competent jurisdiction shall have 
 issued a nonappealable final order, decree or ruling or taken any other
   nonappealable final action, in each case having the effect of permanently
restraining, enjoining or otherwise prohibiting the Merger; or        

          (d) by Eclipsys if at the TSI Special Stockholders' Meeting (including
     any adjournment or postponement), the requisite vote of the stockholders of
 TSI in favor of the Merger and the Merger Agreement shall not have been
obtained; or by TSI if at the Eclipsys Special Stockholders' Meeting  
(including any adjournment or postponement), the requisite vote of the
     stockholders of Eclipsys in favor of the Eclipsys Voting Proposal shall not
have been obtained; or                                                

    (e) by Eclipsys, if (i) the Board of Directors of TSI shall have
     withdrawn or modified in a manner adverse to Eclipsys its recommendation of
the Merger Agreement or the Merger; (ii) the Board of Directors of TSI
shall have recommended to the stockholders of TSI an Alternative      
    Transaction (as defined below); (iii) a tender offer or exchange offer for
15% or more of the outstanding shares of TSI Voting Common Stock is   
commenced (other than by Eclipsys or an affiliate of Eclipsys) and the
  Board of Directors of TSI recommends that the stockholders of TSI tender
   their shares in such tender or exchange offer; or (iv) for any reason TSI
     fails to call and hold the TSI Special Stockholders' Meeting by the Outside
     Date (provided that Eclipsys' right to terminate the Merger Agreement under
    this clause (iv) is not available if at such time TSI would be entitled to
  terminate the Merger Agreement because of a breach by Eclipsys or Sub as
described in paragraph (h) below); or                                 

    (f) by TSI, if (i) the Board of Directors of Eclipsys shall have
withdrawn or modified its recommendation of the Merger Agreement, the 
Merger or the Eclipsys Voting Proposal; (ii) the Board of Directors of
Eclipsys shall have recommended to the stockholders of Eclipsys an    
Alternative Transaction (as defined below); (iii) a tender offer or   
     exchange offer for 15% or more of the outstanding shares of Eclipsys Voting
  Common Stock is commenced (other than by TSI or an affiliate of TSI) and
the Board of Directors of Eclipsys recommends that the stockholders of
    Eclipsys tender their shares in such tender or exchange offer; or (iv) for
any reason Eclipsys fails to call and hold the Eclipsys Special       
 Stockholders' Meeting by the Outside Date (provided that TSI's right to
   terminate the Merger Agreement under this clause (iv) is not available if
   at such time Eclipsys would be entitled to terminate the Merger Agreement
because of a breach by TSI as described in paragraph (h) below); or   

        (g) by TSI, if the TSI Board accepts or approves a Superior Proposal
 (as defined under "-- No Solicitation" above), or recommends a Superior
Proposal to the TSI stockholders; or                                  

(h) by Eclipsys or TSI, if there has been a breach of any   
  representation, warranty, covenant or agreement on the part of the other
party set forth in the Merger Agreement, which breach causes the TSI  
  Representation Bringdown Condition or the TSI Covenant Condition (in the
     case of a termination by Eclipsys) or the Eclipsys Representation Bringdown
    Condition or the Eclipsys Covenant Condition (in the case of a termination
by TSI) not to be satisfied and such breach shall                     

77

S-4
86th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 86th

not have been cured within 20 business days following receipt by the breaching  
party of written notice of the breach from the other party.                     

In the event of any termination of the Merger Agreement by either as  
provided above, the Merger Agreement will immediately become void and there will
be no liability or obligation on the part of Eclipsys or TSI or their respective
officers, directors, stockholders or affiliates, except with respect to the     
payment of certain fees and expenses as described below.                        

  Except as described below, whether or not the Merger is consummated, all
fees, costs and expenses incurred in connection with the Merger Agreement and   
the transactions contemplated thereby (other than expenses (other than          
attorneys' fees) incurred with respect to the printing and filing of this Joint 
Proxy Statement/Prospectus and the Registration Statement, including exhibits   
and financial statements, which shall be shared equally) shall be paid by the   
party incurring such expenses.                                                  

TSI has agreed to pay Eclipsys up to $2,000,000 as reimbursement for  
expenses of Eclipsys actually incurred relating to the transactions contemplated
by the Merger Agreement prior to termination (including fees and expenses of    
Eclipsys' counsel, accountants and financial advisors, but excluding any        
discretionary fees paid to such financial advisors), upon the termination of the
Merger Agreement by Eclipsys under the circumstances described in paragraphs    
(d), (e) or (h) above or by TSI under the circumstances described in paragraph  
(g) above.                                                                      

   TSI has also agreed to pay Eclipsys a termination fee of $9,100,000, less
amounts reimbursed for expenses as described in the previous paragraph (the     
"Eclipsys Termination Fee"), upon the earliest to occur of the following events:
(i) termination of the Merger Agreement by Eclipsys under the circumstances     
described in paragraph (e) above; (ii) the termination of the Merger Agreement  
by Eclipsys under the circumstances described in paragraph (h) above after a    
breach by TSI of certain designated covenants set forth in the Merger Agreement;
(iii) consummation of an Alternative Transaction with respect to TSI within 12  
months following the failure to receive the requisite vote for approval of the  
Merger by the stockholders of TSI at the TSI Special Stockholders' Meeting if,  
at the time of such failure, there shall have been announced any Alternative    
Transaction relating to TSI which shall not have been absolutely and            
unconditionally withdrawn and abandoned or (iv) the termination of the Merger   
Agreement by TSI because TSI's Board had accepted, approved or recommended a    
Superior Proposal to the TSI Stockholders.                                      

Eclipsys has agreed to pay TSI up to $2,000,000 as reimbursement for  
expenses of TSI actually incurred relating to the transactions contemplated by  
the Merger Agreement prior to termination (including fees and expenses of TSI's 
counsel, accountants and financial advisors, but excluding any discretionary    
fees paid to such financial advisors), upon the termination of the Merger       
Agreement by TSI under the circumstances described in paragraphs (d), (f) and   
(h) above.                                                                      

Eclipsys has agreed to pay TSI a termination fee of $9,100,000, less  
amounts reimbursed for expenses as described in the previous paragraph (the "TSI
Termination Fee"), upon the earliest to occur of the following events: (i)      
termination of the Merger Agreement by TSI under the circumstances described in 
paragraph (f) above; (ii) termination of the Merger Agreement by TSI under the  
circumstances described in paragraph (h) above after a breach by Eclipsys of    
certain designated covenants set forth in the Merger Agreement; or (iii)        
consummation of an Alternative Transaction with respect to Eclipsys within 12   
months following the failure to receive the requisite vote for approval of      
Eclipsys Voting Proposal by the stockholders of Eclipsys at the Eclipsys Special
Stockholders' Meeting if, at the time of such failure, there shall have been    
announced any Alternative Transaction relating to Eclipsys which shall not have 
been absolutely and unconditionally withdrawn and abandoned.                    

     As used in the Merger Agreement, "Alternative Transaction" means any of (i)
a transaction (other than certain permitted acquisitions by Eclipsys) pursuant  
to which any person (or group of persons), other than Eclipsys or TSI or their  
respective affiliates (a "Third Party"), acquires more than 15% of the          
outstanding shares of TSI Voting Common Stock or Eclipsys Voting Common Stock,  
as the case may be, pursuant to a tender offer or exchange offer or otherwise,  
(ii) a merger or other business combination                                     

78

S-4
87th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 87th

involving Eclipsys or TSI pursuant to which any Third Party acquires more than  
15% of the outstanding shares of TSI Voting Common Stock or Eclipsys Voting     
Common Stock, as the case may be, or the entity surviving such merger or        
business combination, (iii) any other transaction (other than certain permitted 
acquisitions by Eclipsys) pursuant to which any Third Party acquires control of 
assets (including for this purpose the outstanding equity securities of         
subsidiaries of Eclipsys or TSI, and the entity surviving any merger or business
combination including any of them) of Eclipsys or TSI having a fair market value
equal to more than 15% of the fair market value (as determined by the Board of  
Directors of Eclipsys or TSI, as the case may be, in good faith) of all the     
assets of Eclipsys or TSI and its subsidiaries, taken as a whole, as the case   
may be, immediately prior to such transaction or (iv) any public announcement of
a proposal, plan or intention to do any of the foregoing or any agreement to    
engage in any of the foregoing.                                                 

  If applicable, any expenses and fees payable as described above shall be
paid within one business day after the first to occur of the relevant           
termination events. Payment of the Eclipsys Termination Fee or the TSI          
Termination Fee, as the case may be, constitutes liquidated damages and is the  
sole and exclusive remedy to the other party for any losses, damages, claims,   
costs or expenses arising from the occurrence of any event giving rise to the   
obligation to make such payment.                                                

AMENDMENT AND WAIVER                                                            

   The Merger Agreement may be amended by the respective Boards of Directors
of Eclipsys or TSI at any time before or after approval by the stockholders of  
either party of the matters presented in connection with the Merger. After any  
such stockholder approval, however, no amendment may be taken which by law      
requires further approval by such stockholders until such further approval has  
been obtained.                                                                  

   At any time prior to the Effective Time, Eclipsys or TSI, by action taken
or authorized by their respective Boards of Directors, may (i) extend the time  
for the performance of any of the obligations or other acts of the other        
company, (ii) waive any inaccuracies in the representations and warranties of   
the other company contained in the Merger Agreement or in any document delivered
pursuant hereto and (iii) waive compliance with any of the agreements or        
conditions contained therein.                                                   

79

S-4
88th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 88th

BUSINESS OF ECLIPSYS

   The information in this section relates to the business of Eclipsys as it
is currently conducted without giving effect to the Merger.                     

OVERVIEW                                                                        

Eclipsys is a healthcare information technology company delivering    
solutions that enable healthcare providers to achieve improved clinical,        
financial and administrative outcomes. Eclipsys offers an integrated suite of   
healthcare products in four critical areas -- clinical management, access       
management, patient financial management and enterprise data warehouse and      
analysis. These products can be purchased in combination to provide an          
enterprise-wide solution or individually to address specific needs. Eclipsys'   
products have been designed specifically to deliver a measurable impact on      
outcomes, enabling Eclipsys' customers to quantify clinical benefits and return 
on investment in a precise and timely manner. Eclipsys' products can be         
integrated with a customer's existing information systems, which Eclipsys       
believes reduces overall cost of ownership and increases the attractiveness of  
its products. Eclipsys also provides outsourcing, remote processing and         
networking services to assist customers in meeting their healthcare information 
technology requirements. Eclipsys was formed in December 1995 and has grown     
primarily through its three acquisitions, all completed since January 1997.     
These acquisitions, together with internally generated growth, have resulted in 
revenues of $126.5 million in 1997 on the pro forma basis described herein.     

Eclipsys markets its products primarily to large hospitals, academic  
medical centers and integrated healthcare delivery networks. Eclipsys has one or
more of its products installed or being installed in over 350 facilities. To    
provide direct and sustained customer contact, Eclipsys maintains decentralized 
sales, implementation and customer support teams in each of its five North      
American regions. Eclipsys' field sales force has an average of 18 years of     
experience in the healthcare industry.                                          

COMPETITIVE STRENGTHS                                                           

Eclipsys believes that its products and services, focus on physicians'
needs, leading technology, strategic relationships, management team and         
well-positioned customer base are competitive strengths that will enable it to  
capitalize on continued opportunities for growth.                               

  - Comprehensive Product Offering. Through both acquisitions and internal
   development, Eclipsys has assembled a comprehensive suite of products
      that perform core functions in the four areas Eclipsys believes are most
  critical to its customers -- clinical management, access management,
      patient financial management and enterprise data warehouse and analysis.
Eclipsys' individual products can be integrated to provide a      
 comprehensive healthcare information technology solution. Eclipsys'
       product strategy has been to acquire or develop industry-leading products
      in each core category and then integrate them to provide a comprehensive
healthcare information technology solution.                       

    - Physician-Oriented Products. Eclipsys' clinical products are designed to
       reflect and support the way physicians work, and include features such as
   alerts, reminders, just-in-time clinical decision support, sub-second
     response times, an intuitive graphical user interface, continuous event
    monitoring and a customizable rules and protocol engine. This focus on
 physicians is important because Eclipsys believes that they are key
   decision makers in the trend toward the use of healthcare information
    technology solutions to improve work processes and outcomes across the
continuum of healthcare delivery.                                 

   - Leading Technology. Eclipsys has recently announced the development of,
     and has commenced migrating its products to, its new SOLA architecture.
    SOLA is a browser-enabled, multi-tiered, database-neutral architecture
      that supports multiple platforms and can be used across a broad range of
     computing environments from client-server systems to legacy mainframes.
       SOLA is designed to facilitate the integration of Eclipsys' products with
its customers' existing systems, as well as with future products  
developed or acquired by Eclipsys.                                

80

S-4
89th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 89th

- Strategic Relationships. One of Eclipsys' important strategic       
relationships is with Partners, including two of its hospital     
 subsidiaries, Brigham and MGH. This relationship provides intensive
      physician-driven research and development for new and existing products,
     testing and development support. In addition, Brigham and MGH, academic
       medical centers affiliated with Harvard Medical School, provide potential
forums for training future users and customers. Eclipsys also has 
   relationships with other academic medical centers, which also provide
testing and development support.                                  

 - Proven Management Team with Successful Track Record. Eclipsys' senior
      management team averages over 22 years in the healthcare and information
      technology industries and includes four former chief executive officers.
    Harvey J. Wilson, Chairman of the Board, President and Chief Executive
      Officer of Eclipsys, was a co-founder of SMS. Eclipsys believes that the
      range and depth of its senior management team position it to address the
      evolving requirements of its customers and to manage the growth required
to meet its strategic goals.                                      

- Well-positioned Customer Base. Eclipsys' customers include large    
     hospitals, integrated healthcare delivery networks and academic medical
       centers. Eclipsys believes that these entities are generally the first to
 adopt new technology and are the drivers of industry consolidation.
   Management believes that Eclipsys' commitment to quality, innovation,
      rapid product implementation and ongoing customer support has enabled it
to build and maintain strong and stable customer relationships and
   positions it to capitalize on the opportunities for growth within its
     existing customer base. At December 31, 1997, Eclipsys had a backlog of
      approximately $108 million. See "Management's Discussion and Analysis of
    Financial Condition and Results of Operations of Eclipsys -- Backlog."

INDUSTRY                                                                        

   In recent years, the healthcare industry has undergone, and is continuing
to undergo, radical and rapid change. The increasing cost of providing          
healthcare has led the government sector, followed by the private sector, to    
develop new payment mechanisms that encourage healthcare providers to contain   
costs. This has caused the provider reimbursement environment to move away from 
the indemnity model, characterized by fee-for-service arrangements and          
traditional indemnity insurance, toward the managed-care model, in which        
providers are aligned within networks and healthcare delivery must follow       
plan-established rules to qualify for reimbursement. As a result, the emphasis  
of healthcare providers has shifted from providing care regardless of cost to   
providing high-quality care in the most cost-effective manner possible. Many    
providers are realizing that the traditional method of cost containment --      
cutting expenses -- is not by itself enough to maintain their competitiveness in
the face of these pressures. Management believes that providers must also       
improve the processes by which healthcare is provided, including improving the  
quality of care, the efficiency with which it is delivered and patient          
satisfaction. In particular, healthcare providers are focusing on avoiding      
costly adverse clinical events.                                                 

The pressures to achieve successful clinical outcomes more efficiently
while managing costs more effectively has led to significant industry           
consolidation, as healthcare providers seek to offer and control the full       
continuum of healthcare. The result has been the development of large integrated
healthcare delivery networks. These are comprehensive vertical networks of      
healthcare providers, typically organized around an anchor hospital, and include
physicians, outpatient facilities, laboratories, radiology facilities, home     
healthcare providers and long-term and rehabilitative facilities. As these      
networks grow larger and more dispersed, the challenge of effectively managing  
and delivering information throughout the enterprise also increases.            

    Traditional healthcare information systems are limited in their ability to
support restructuring of healthcare delivery processes or the evolving          
requirements of integrated healthcare delivery networks. Such systems have      
generally been financially oriented, focusing primarily on the ability to       
capture charges and generate bills. Many information technology vendors have    
attempted to apply their existing financially oriented systems to meet the      
demand for clinical solutions. However, because these systems were not          
originally developed to address clinical requirements, they often lack the basic
structure and functionality                                                     

81

S-4
90th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 90th

to support better overall management of costs, care quality, outcome measurement
and patient satisfaction across the healthcare delivery continuum. Moreover,    
because these vendors historically developed and marketed such systems primarily
to financial managers, physicians, who influence a significant portion of       
variable healthcare costs, were often excluded from the design of healthcare    
information systems and from the system selection process. In addition,         
traditional systems were typically designed to operate in a single facility,    
which has made them less effective in today's widely dispersed integrated       
healthcare delivery networks.                                                   

The growth of the managed care environment and the rise of integrated 
healthcare delivery networks has created an opportunity for new healthcare      
information technology products and services. Healthcare providers are          
increasingly demanding integrated solutions that offer all of the core functions
required to manage the entire healthcare delivery process. These core functions 
include clinical management, access management and patient financial management 
functions. In addition, large and widely spread healthcare delivery networks    
require data warehouse and analysis tools that permit them to effectively       
extract and analyze data located throughout the enterprise, both to measure     
clinical results and return on investment and to support process improvement.   
These solutions must also allow providers to preserve their investment in       
existing legacy applications and technologies, which often are significant and  
vary from facility to facility. Finally, physician utilization is necessary for 
a healthcare information technology solution to improve clinical outcomes.      
Eclipsys believes that physician utilization will increase as information       
technology solutions provide greater functionality, including alerts, reminders,
sub-second response times, just-in-time clinical decision support, an intuitive 
graphical user interface and the ability to log on to the system remotely.      

Historically, the healthcare industry has invested relatively less in 
technology compared to certain other industries. Eclipsys believes that         
healthcare providers are realizing that a relatively small investment in        
healthcare information technology can significantly reduce variable costs. As a 
result of industry trends, healthcare providers are making significant          
investments in healthcare information technology solutions that capitalize on   
evolving information management technologies. Industry analysts estimate that   
healthcare organizations spent approximately $17 billion in 1997 for information
technology solutions, and anticipate that such expenditures will increase to    
approximately $28 billion annually by 2002.                                     

STRATEGY                                                                        

Eclipsys' objective is to become the leading provider of healthcare   
information technology solutions to meet the needs of the healthcare industry as
it consolidates and evolves. Key elements of Eclipsys' strategy to achieve this 
objective include:                                                              

Provide Comprehensive, Integrated Healthcare Information Technology   
Solutions.  Eclipsys is focusing on providing a full suite of clinical          
management, access management, patient financial management and enterprise data 
warehouse and analysis solutions. Eclipsys' products are designed to be:        

- responsive to physicians' needs for alerts, reminders, sub-second   
response times, continuous event monitoring and practice-specific 
   clinical information, rules, and protocols which provide just-in-time
clinical decision support;                                        

  - outcomes-oriented, so customers can easily determine clinical benefits
and return on investment; and                                     

- user-friendly through an intuitive graphical user interface.        

Eclipsys believes that its healthcare information technology solutions
facilitate the clinical and business decision process, enabling its customers to
improve their overall work processes, clinical outcomes and return on           
investment.                                                                     

 Further Penetrate Existing Customer Base.  Eclipsys believes there is a
significant opportunity to sell its integrated healthcare technology solutions  
to its existing customers. Eclipsys has at least one of its products installed  
or being installed at over 350 facilities. Of these customers, only a few have  
an                                                                              

82

S-4
91st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 91st

enterprise-wide healthcare information system. Eclipsys believes that it is     
well-positioned to capitalize on the growth opportunity within its existing     
customer base as a result of several factors:                                   

- its broad, integrated product suite;                                

- the ability of its products to work with a customer's existing      
information systems;                                              

- the ability to document clinical benefits and return on investment; 

- management's industry experience and relationships;                 

    - alignment of its pricing and payment schedule with the value received by
its customers; and                                                

- its ongoing customer support and service programs.                  

  Employ a Targeted Marketing Approach.  Eclipsys' target market primarily
includes large hospitals, integrated healthcare delivery networks and academic  
medical centers. Eclipsys believes that these entities are the first to adopt   
new technology and are the drivers of industry consolidation. As the size and   
complexity of these customers grow, their need for integrated information       
technology solutions increases. Eclipsys has identified potential new customers,
including those who are currently relying on legacy systems that lack the       
functions and features such customers require, and is targeting decision makers 
within these entities. In particular, Eclipsys believes that physicians are     
becoming increasingly involved in the information technology selection process  
as recent technological developments and the impact of managed care have        
increased the utility of information systems to physicians. Eclipsys believes   
that its clinically oriented, physician-designed products provide it with an    
advantage as it competes for business. Eclipsys also leverages the extensive    
industry experience of its senior management and sales force, as well as its    
strategic relationships with leading institutions such as Brigham and MGH, to   
pursue this opportunity.                                                        

Continue to Enhance and Develop New Solutions.  Eclipsys intends to   
continue upgrading existing products and developing new solutions to meet the   
evolving healthcare information needs of its customers. For example, Eclipsys is
currently focusing on migrating its products to its new SOLA architecture, which
is designed to facilitate the integration of new and existing applications as   
they are developed or acquired by Eclipsys with legacy systems of its customers.
Eclipsys has a team of more than 300 internal research, development and         
technical support professionals dedicated to developing, enhancing, supporting  
and commercializing new and enhanced healthcare information technology products.
Eclipsys also has an exclusive right of first offer to commercialize new        
information technologies developed in connection with Partners. In addition,    
Eclipsys' relationship with Partners allows it to test new and existing products
in a potential forum that provides feedback from medical and administrative     
users, which Eclipsys believes gives it a competitive advantage in developing   
new products.                                                                   

     Pursue Selected Acquisitions and Investments.  Eclipsys intends to continue
pursuing selected acquisitions and investments that will enhance its product    
line, customer base, technological capabilities and management team.            
Historically, Eclipsys has experienced significant growth through acquisitions, 
and intends to continue to target acquisitions and investments that will help it
achieve its overall strategic goals. Eclipsys also believes that such           
transactions will provide it with the opportunity to leverage its existing      
sales, marketing and development teams and offer the potential to achieve       
operating synergies across the organization.                                    

PRODUCTS                                                                        

Eclipsys' products perform the core information technology functions  
required by integrated healthcare delivery networks and other healthcare        
providers across the entire continuum of healthcare. These functions include (i)
clinical management, (ii) access management, (iii) patient financial management 
and (iv) enterprise data warehouse and analysis.                                

     - Clinical Management products assist the physician and other clinicians in
       making clinical decisions throughout the care process. These systems give
physicians and other clinicians immediate access to               

83

S-4
92nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 92nd

      complete and up-to-date patient records at all stages, enable physicians
    to enter on-line orders for specialized services, such as radiology or
laboratory testing and prescriptions, provide clinical rules to   
facilitate clinical decisions and alert the physician to potential
adverse reactions.                                                

     - Access Management products provide access to patient information from any
     point in the healthcare delivery system and coordinate the gathering of
    additional patient data at each stage of the patient encounter. Access
management also coordinates the scheduling of patient appointments
throughout the treatment process.                                 

- Patient Financial Management products coordinate compliance with    
       managed-care contract reimbursement terms, patient billing and collection
     and third-party reimbursement. These products support the growing trend
   toward the centralized business office, which manages compliance with
    managed-care contracts across the entire healthcare enterprise and for
all stages of the healthcare continuum.                           

     - Enterprise Data Warehouse and Analysis products facilitate the extraction
       and analysis of all data collected throughout the organization to support
reporting, strategic planning and decision-making functions.      

    Eclipsys offers products under the Sunrise name in each of these four core
areas. These products enable Eclipsys to offer a comprehensive line of core     
applications that can be purchased individually or combined to form a fully     
integrated single-source information technology solution. Most of Eclipsys'     
products are functional in several different healthcare settings, including     
ambulatory care, critical care and acute care.                                  

The Sunrise Access Management suite, the Sunrise Patient Financial    
Management suite and the Sunrise Enterprise Data Warehouse are generally        
available to Eclipsys' customers. Most of the key functionalities of the Sunrise
Clinical Management suite are currently available in Eclipsys' heritage         
products. Eclipsys is in the process of integrating these key functionalities   
into the Sunrise Clinical Management suite, which is currently in field trials  
and is expected to be generally available to customers in 1999.                 

SUNRISE CLINICAL MANAGEMENT                                                     

Sunrise Clinical Management is a physician-oriented application that  
provides patient information to the physician and other clinicians at the       
point-of-care anywhere in the healthcare continuum, allows a physician to       
quickly and efficiently enter orders directly into the system and provides      
clinical decision support at the time of order entry. The functionality of the  
Sunrise Clinical Management suite is derived from the Alltel TDS 7000 Series,   
Emtek's Continuum 2000 application and the BICS program developed at Brigham and
licensed from Partners. Eclipsys has selected the best features of these        
heritage programs to integrate into its Sunrise Clinical Management suite.      
Eclipsys continues to enhance and support these heritage products for its       
installed customer base in order to allow these customers to make the transition
to the Sunrise Clinical Management suite over time. Sunrise Clinical Management 
includes the following features:                                                

     - Clinical Data Repository, which permanently stores clinical and financial
information into patient care records that are easily and quickly 
 accessible in ambulatory, acute care and other healthcare settings.

- Clinical View, which provides physicians with access to patient     
       information, such as complete patient records covering treatments at both
  ambulatory and acute care facilities, whether they are accessing the
records from within the healthcare facility or a remote location. 

  - Clinical Documentation, which gathers and presents organized, accurate
   and timely patient information. The application creates an electronic
patient chart, accepting and arranging input from caregivers,     
laboratories or monitoring equipment.                             

84

S-4
93rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 93rd

  - Order Entry, Communication and Management, which enables physicians to
       enter on-line prescriptions and orders for laboratory or diagnostic tests
     or procedures. The application also routes the order to the appropriate
department or party within the organization for fulfillment.      

- SOLAssistant, which is a clinical decision support system that is   
activated automatically during the order entry process. This      
sophisticated system provides real-time guidance to physicians by 
alerting them to possible problems with or conflicts between newly
      entered orders and existing patient information using the system's rules
     database. A comprehensive set of clinical rules developed by physicians
       is available with SOLAssistant. Customers can modify these existing rules
or can develop their own clinical rules.                          

 - SOLAsentry, which is a continuous event monitoring system. SOLAsentry
       triggers alerts, which can include e-mail or pager notification, upon the
    occurrence of a specified change in a patient's condition or any other
physician-designated event, such as the delivery of unfavorable   
     laboratory results. The application tracks new patient data, relates it
to information already in the system for that patient, identifies 
significant new relationships, alerts the physician to the changed
relationship and prompts corrective actions on a real-time basis. 

    - Clinical Pathways and Scheduled Activities List, which provide access to
 standardized patient care profiles and assist in the scheduling and
       monitoring of procedures. These applications provide listings of clinical
      treatment procedures for individual patient care and generates scheduled
 activities lists in each department based on information from those
    lists. This allows the resources of a department to be deployed in the
most effective and efficient manner.                              

  Eclipsys is currently developing a clinical reporting application, which
will provide periodic reports to physicians enabling them to identify their     
practice group's clinical performance. Eclipsys is also developing referral and 
medical management features, which will allow a physician to refer a patient    
instantly to another healthcare provider with appropriate patient information   
attached to the referral.                                                       

 Eclipsys' heritage clinical management products are installed or in the
process of being installed at more than 250 facilities.                         

SUNRISE ACCESS MANAGEMENT                                                       

   Sunrise Access Management enables the healthcare provider to identify the
patient at any point in the healthcare delivery system and to collect and       
maintain patient information throughout the entire continuum of patient care on 
an enterprise-wide basis. The single database structure of Sunrise Access       
Management permits simultaneous access to the entire patient record from any    
terminal on the system. The Sunrise Access Management suite is based primarily  
on the products acquired in the SDK Acquisition, which Eclipsys has integrated  
with its other product offerings and has continued to enhance. The elements of  
Sunrise Access Management include:                                              

- Patient Registration/ADT, which is used to register a patient in an 
     ambulatory setting, and to admit, discharge and transfer patients in an
       acute care setting. Patient information -- such as demographics, personal
contacts, primary-care provider, allergies or medications, health 
     history, employment and insurance coverage -- is taken at the patient's
   initial visit and is immediately accessible on-line to all authorized
personnel across the enterprise. Subsequent visits require only   
     confirmation and updates as necessary. Visit-specific information, such
 as the date and the reason for the visit, the care provided and the
caregivers providing service, is collected at each visit.         

 - Patient Scheduling and Resource Management, which is used to schedule
      patient appointments across an organization from any location within the
    enterprise. The application has the flexibility to provide for patient
preferences and resource availability.                            

   - Enterprise Master Person Index, which is a single index of all patients
and healthcare plan members within a healthcare provider's system.
Records can be accessed from the index by searching a             

85

S-4
94th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 94th

       variety of characteristics, such as name, Social Security number or other
   demographic data, including a combination of several characteristics.

    Sunrise Access Management also includes managed care support features such
as verifying insurance eligibility on-line and compliance with managed care plan
rules and procedures, as well as medical records abstracting, which compiles    
patient data into statistical information. The integrated nature of Sunrise     
Access Management allows healthcare providers to complete pre-registration as   
part of the scheduling process and view patient records from multiple sites     
within an enterprise. This eliminates the generation of redundant records,      
thereby saving both patient and caregiver time, and permits the efficient       
scheduling of resources throughout the organization.                            

 Eclipsys' access management products are installed or in the process of
being installed at over 70 facilities.                                          

SUNRISE PATIENT FINANCIAL MANAGEMENT                                            

     Sunrise Patient Financial Management uses a single, integrated database for
patient accounting processes, including the automatic generation of patient     
billing and accounts receivable functions, a system of reimbursement management 
to monitor receivables, the automation of collection activities and contract    
compliance analysis, as well as follow-up processing and reporting functions.   
Billing and receivables management activities are automated through rules-based 
processing and can be customized to reflect each organization's specific        
procedures. This product suite supports the growing trend toward the centralized
business offices for multiple entities, which improves compliance with managed  
care contracts across the entire enterprise and at all stages of the healthcare 
delivery continuum. The Sunrise Patient Financial Management suite is based     
primarily on the products acquired in the SDK Acquisition, which Eclipsys has   
integrated with its other product offerings and has continued to enhance.       
Sunrise Patient Financial Management includes the following functions:          

- Patient Accounting, which automates the patient billing and accounts
     receivable functions. For bill generation, the application incorporates
   rules-based calculations of expected reimbursement and provides users
       with the option for automatic generation of contractual allowances at the
     time of billing or the time of payment. Rules may be generated for each
insurance plan accepted by an organization. Receivables management
  functions include account write-offs, on-line work lists of accounts
     requiring follow-up, extensive account comments and standard and ad hoc
    reporting. Paperless processing is achieved through real-time inquiry,
editing, sorting, reporting, commenting and updating from other   
      applications, including modules in Sunrise Access Management and Sunrise
Clinical Management.                                              

   - Contract Management, which includes a repository for the payment terms,
    restrictions, approval requirements and other rules and regulations of
each insurance plan and managed care contract accepted by an      
 organization. Contract Management is used in conjunction with other
    Sunrise products to ensure that patient care complies with these rules
and regulations.                                                  

- Reimbursement Management, which facilitates monitoring receivables, 
performing collection activity, reconciling with third parties and
analyzing contract compliance and performance.                    

     - Executive Information System, which provides immediate access to the data
contained in the Patient Financial Management database. Executive 
Information System provides reports in tabular or graphic formats.

 Eclipsys' patient financial management products are installed or in the
process of being installed at over 75 facilities.                               

SUNRISE ENTERPRISE DATA WAREHOUSE                                               

   Sunrise Enterprise Data Warehouse, which consolidates data from different
systems, including all of a client's legacy and third-party systems, into a     
single database to facilitate and support data gathering and                    

86

S-4
95th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 95th

analysis throughout an organization. This application enables users to analyze  
collected data, identify sources of the data, automate data extraction, map and 
load data into relational tables for detailed analysis, assure the consistency  
of data across systems and support timely, accurate analysis and reporting of   
data for specific applications. Enterprise Data Warehouse is able to house data 
from other systems and supports data-mining techniques, allowing a customer to  
gather data from all of the organization's systems. Customers can build         
customized reports using the collected data, reducing the need for additional   
software and training. Sunrise Enterprise Data Warehouse is an important        
component of the customers' ability to measure and document improved clinical   
outcomes and return on investment.                                              

OTHER PRODUCTS                                                                  

    Eclipsys' other products include OpenHUB and Orion, both of which Eclipsys
distributes under a license. OpenHUB is Eclipsys' interface engine, which       
provides a fast, flexible means of integrating systems and data, allowing an    
organization to select the best data processing solution regardless of the      
hardware or software platforms. Orion is an electronic document and workflow    
management product that permits providers to reduce their dependency on paper   
communications, thereby improving workflow processes and reducing the risk of   
lost or inaccurate records.                                                     

  In connection with Eclipsys' investment in Simione, Eclipsys and Simione
have entered into a Remarketing Agreement pursuant to which Eclipsys has the    
right to distribute certain Simione software products designed for home         
healthcare providers. See "Management's Discussion and Analysis of              
Eclipsys -- Overview."                                                          

   In connection with providing healthcare information technology solutions,
Eclipsys also sells hardware to its customers.                                  

SOLA ARCHITECTURE                                                               

Eclipsys has recently announced the development of, and has commenced 
migrating its products to, its new SOLA architecture, which Eclipsys believes   
will facilitate integration, enhance automation, increase reliability and       
improve security and workflow processes. SOLA draws on a thin-client            
architecture to integrate business logic with an intuitive graphical user       
interface thereby enhancing automation and reducing the cost of ownership. This 
thin-client architecture enables the user interface to be improved without      
disturbing the core application set and facilitates integration of Eclipsys'    
products with new operating systems, display environments and devices. SOLA also
features a high performance rules engine to implement a sizable portion of the  
business logic for Eclipsys' products. These rules guide clinical and business  
workflow, clinical decision support for order entry, clinical and financial     
event monitoring and screen logic, enabling structured development of new       
applications while maintaining consistency across applications. Because the     
rules are managed and stored as data, customers are able to update the business 
logic without modifying and distributing new code. This enables customers to    
reduce programming expenses, while enhancing the flexibility of Eclipsys'       
applications and facilitating their rapid adoption. SOLA features a seamless and
consistent architecture which promotes reliability for mission-critical         
applications and fault tolerance. The SOLA architecture also uses advanced      
technology to maintain security across the Internet and organization Intranets. 
This ability to support secure communications and incorporate reliable protocols
for authenticating users and services permits the confidentiality of patient    
information to be maintained. Certain products being migrated to the SOLA       
architecture are currently undergoing field trials in several locations.        

SERVICES                                                                        

Drawing on the functionality and flexibility of its software products,
Eclipsys offers a range of professional services as part of its healthcare      
information technology solutions. These services include outsourcing, remote    
processing and network services.                                                

87

S-4
96th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 96th

OUTSOURCING SERVICES                                                        

    Outsourcing Services typically involve Eclipsys assuming the management of
the customer's entire information technology function on-site using Eclipsys'   
employees. Outsourcing Services include Facilities Management, Network          
Outsourcing and Transition Management.                                          

Facilities Management enables customers to improve their information  
technology operations by having Eclipsys assume responsibility for all aspects  
of the customer's information technology operations, from equipment to human    
resources.                                                                      

  Network Outsourcing provides customers with total healthcare information
network support, relieving the customer of the need to secure and maintain      
expensive resources in a rapidly changing technological environment.            

Transition Management offers customers a solution for migrating their 
information technology to new processes, technologies or platforms without      
interfering with the existing rules and initiatives critical to the delivery of 
healthcare.                                                                     

REMOTE PROCESSING SERVICES                                                  

   Remote Processing Services include complete processing of an enterprise's
applications from Eclipsys' site using Eclipsys' equipment and personnel. This  
service frees an organization from having to maintain the environment, equipment
and technical staff required for systems processing and offers support for an   
organization's fault management, configuration management and utilization       
management processes.                                                           

NETWORK SERVICES                                                            

    Network Services is a comprehensive package of services allowing Eclipsys'
customers to receive critical data quickly and accurately without incurring a   
substantial increase in cost. Eclipsys assesses changes in network utilization  
and function, forecasts any necessary upgrades to accommodate growth of the     
customer and designs any changes necessary to provide the customer with the     
required performance and functionality.                                         

Eclipsys offers its services in various forms ranging from on-site    
assistance on a time and expense basis to complete turnkey project deliveries   
with guaranteed fixed price rates and outcomes.                                 

IMPLEMENTATION, PRODUCT SUPPORT AND TRAINING                                    

   Eclipsys believes that a high level of service and support is critical to
its success. Furthermore, Eclipsys believes that a close and active service and 
support relationship is important to customer satisfaction and provides Eclipsys
with important information regarding evolving customer requirements and         
additional sales opportunities. To facilitate successful product implementation,
Eclipsys' consultants assist customers with initial installation of a system,   
conversion of a customer's historical data and ongoing training and support.    
This also includes Year 2000 consulting, programming and conversion services to 
help customers prepare for transition and to address Year 2000 compliance and   
performance issues. In addition, 24-hour telephone support is available and     
Eclipsys offers electronic distribution to provide clients the latest           
information regarding Eclipsys' products. Eclipsys also provides regular        
maintenance releases to its customers. Eclipsys' service and support activities 
are supplemented by comprehensive training programs, including introductory     
training courses for new customers and seminars for existing customers, to      
educate them about the capabilities of Eclipsys' systems.                       

PRICING                                                                         

Historically, Eclipsys has employed a traditional software pricing and
payment model in which the entire software license fee is payable upon          
commencement of the license, service fees are paid as performed and maintenance 
fees, typically equal to a fixed percentage of the license fee, are paid over   
the life of the license. More recently, Eclipsys has begun to offer a variety of
creative pricing models in                                                      

88

S-4
97th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 97th

furtherance of its philosophy that pricing and payment schedules should be      
closely aligned with the value received by the customer. Eclipsys encourages    
customers to elect a payment schedule that spreads software license payments,   
together with service fees and maintenance fees on a bundled basis, regularly   
over the life of the license. In addition, Eclipsys has commenced offering      
software license and maintenance fees that vary with the amount of patient      
traffic serviced by the customer, enabling the customer to analyze the cost on a
per-case basis. Eclipsys also encourages customers to consider pricing models in
which Eclipsys' primary compensation takes the form of sharing in cost savings  
or other performance benefits realized by the customer. The pricing of Eclipsys'
contracts can vary significantly, depending upon the pricing model, product     
configuration and features, and implementation.                                 

CUSTOMERS, MARKETING AND SALES                                                  

    Eclipsys' marketing and sales efforts focus on large hospitals, integrated
healthcare delivery networks and academic medical centers. Eclipsys sells its   
products and services in North America exclusively through its direct sales     
force. To provide direct and sustained customer contact, management of the sales
force is decentralized, with the five Regional Presidents having primary        
responsibility for sales and marketing within their regions. Some multi-region  
accounts are managed by national account representatives. Within each region,   
the direct sales force is generally organized into two groups, one focused      
principally on generating sales to new customers and the other focused on       
additional sales to existing customers. The direct sales force works closely    
with Eclipsys' implementation and product line specialists. Eclipsys' field     
sales force has an average of 18 years of experience in the healthcare industry.
A significant component of compensation for all direct sales personnel is       
performance based, although Eclipsys bases quotas and bonuses on a number of    
factors in addition to actual sales, including customer satisfaction and        
accounts receivable performance.                                                

Eclipsys has customers in Belgium, France, the Netherlands, the United
Kingdom and Japan. International sales representatives generally report to the  
Regional President of the International Region and are responsible for all      
customers within their sales regions. Eclipsys may also use sales agents to     
market its products internationally.                                            

RESEARCH AND DEVELOPMENT                                                        

Eclipsys believes that its future success depends in large part on its
ability to maintain and enhance its current product line, develop new products, 
maintain technological competitiveness and meet an expanding range of customer  
requirements. A significant portion of Eclipsys' research and development and   
product testing effort is performed in conjunction with physicians at Brigham,  
MGH and other academic medical centers. Eclipsys' current development efforts   
are focused on the migration of its products to the SOLA architecture and the   
development of additional functionality and applications for its existing       
products. Eclipsys believes that the open, integrated nature of its SOLA        
architecture will facilitate the development of applications without the need   
for major rewriting or reconfiguration of code. As of October 31, 1998,         
Eclipsys' research, development and technical support organization consisted of 
more than 271 employees. Eclipsys' research and development expenses were $29.3 
million for 1997, on the pro forma basis described herein.                      

COMPETITION                                                                     

     The market for Eclipsys' products and services is intensely competitive and
is characterized by rapidly changing technology, evolving user needs and the    
frequent introduction of new products. Eclipsys' principal competitors include  
Cerner Corp., HBO & Company, IDX Systems Corp. and SMS. Eclipsys also faces     
competition from providers of practice management systems, general decision     
support and database systems and other segment-specific applications, as well as
from healthcare technology consultants. A number of Eclipsys' competitors are   
more established, benefit from greater name recognition and have substantially  
greater financial, technical and marketing resources than Eclipsys. Eclipsys    
also expects that competition will continue to increase as a result of          
consolidation in both the information technology and healthcare industries.     
Eclipsys believes that the principal factors affecting competition in the       
healthcare                                                                      
89

S-4
98th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 98th

information technology market include product functionality, performance,       
flexibility and features, use of open standards technology, quality of service  
and support, company reputation, price and overall cost of ownership. See "Risk 
Factors -- Competition."                                                        

PROPRIETARY RIGHTS                                                              

Eclipsys is dependent upon its proprietary information and technology.
Eclipsys relies primarily on a combination of copyright, trademark and trade    
secret laws and license agreements to establish and protect its rights in its   
software products and other proprietary technology. Eclipsys requires           
third-party consultants and contractors to enter into nondisclosure agreements  
to limit use of, access to and distribution of its proprietary information. In  
addition, Eclipsys currently requires employees who receive option grants under 
any of its stock plans to enter into nondisclosure agreements. There can be no  
assurance that Eclipsys' means of protecting its proprietary rights will be     
adequate to prevent misappropriation. The laws of some foreign countries may not
protect Eclipsys' proprietary rights as fully or in the same manner as do the   
laws of the United States. Also, despite the steps taken by Eclipsys to protect 
its proprietary rights, it may be possible for unauthorized third parties to    
copy aspects of Eclipsys' products, reverse engineer such products or otherwise 
obtain and use information that Eclipsys regards as proprietary. In certain     
limited instances, customers can access source code versions of Eclipsys'       
software, subject to contractual limitations on the permitted use of such source
code. Although Eclipsys' license agreements with such customers attempt to      
prevent misuse of the source code, the possession of Eclipsys' source code by   
third parties increases the ease and likelihood of potential misappropriation of
such software. Furthermore, there can be no assurance that others will not      
independently develop technologies similar or superior to Eclipsys' technology  
or design around the proprietary rights owned by Eclipsys.                      

EMPLOYEES                                                                       

  As of October 31, 1998, Eclipsys employed 1,005 people, including 271 in
research, development and technical support, 528 in operations, 122 in marketing
and sales, 68 in finance and administration and 16 in international operations. 
The success of Eclipsys depends on its continued ability to attract and retain  
highly skilled and qualified personnel. Competition for such personnel is       
intense in the information technology industry, particularly for talented       
software developers, service consultants, and sales and marketing personnel.    
There can be no assurance that Eclipsys will be able to attract and retain      
qualified personnel in the future.                                              

Eclipsys' employees are not represented by any labor unions. Eclipsys 
considers its relations with its employees to be good.                          

FACILITIES                                                                      

    Eclipsys is headquartered in Delray Beach, Florida, where it leases office
space under two separate leases expiring in March 2000 and July 2002. In        
addition, Eclipsys maintains leased office space in Little Rock, Arkansas;      
Newport Beach, California; San Jose, California; Atlanta, Georgia; Oak Brook,   
Illinois; Boston, Massachusetts; Albany, New York; Saratoga Springs, New York;  
Roseland, New Jersey; Malvern, Pennsylvania; and Pittsburgh, Pennsylvania within
the United States and Brussels, Belgium; Paris, France; and London, United      
Kingdom. These leases expire at various times ranging from June 1998 to June    
2009. Aggregate rental payments under all of Eclipsys' leases were $4.1 million 
in 1997.                                                                        

LEGAL PROCEEDINGS                                                               

     Eclipsys is involved from time to time in routine litigation that arises in
the ordinary course of its business, but is not currently involved in any       
litigation that Eclipsys believes could reasonably be expected to have a        
material adverse effect on Eclipsys.                                            

90

S-4
99th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 99th

ECLIPSYS MANAGEMENT 

EXECUTIVE OFFICERS AND DIRECTORS                                                

    The current executive officers and directors of Eclipsys, their respective
ages as of October 31, 1998 and their positions with Eclipsys are as follows:   

                                                        [Enlarge/Download Table]

           NAME             AGE                           POSITION                     
           ----             ---                           --------                     
                                                                                       
Harvey J. Wilson........... 59   President, Chief Executive Officer and Chairman of the
                                 Board of Directors                                    
James E. Hall.............. 65   Senior Vice President, Field Operations and Chief     
                                 Operating Officer                                     
Robert J. Vanaria.......... 52   Senior Vice President, Administration, Chief Financial
                                 Officer and Treasurer                                 
T. Jack Risenhoover, II.... 33   Vice President, General Counsel and Secretary         
Steven A. Denning(1)....... 50   Director                                              
G. Fred DiBona(1).......... 47   Director                                              
Eugene Fife(1)............. 58   Director                                              
William E. Ford(2)......... 37   Director                                              
Jay B. Pieper(2)........... 55   Director                                              
Richard D. Severns(2)...... 52   Director                                              

---------------                                                                 
(1) Member of the Executive Development and Compensation Committee.             

(2) Member of the Audit Committee.                                              

Harvey J. Wilson, Eclipsys' founder, has served as President, Chief   
Executive Officer and Chairman of the Eclipsys Board since Eclipsys was formed  
in December 1995. From January 1993 to December 1995, Mr. Wilson invested       
privately in software and technology companies. Mr. Wilson was a co-founder of  
SMS, a healthcare information systems provider. Mr. Wilson is a director of     
Philadelphia Suburban Corporation, a water utility company.                     

 James E. Hall has served as Senior Vice President, Field Operations and
Chief Operating Officer since January 1997. From August 1995 to January 1997,   
Mr. Hall was Senior Vice President of Sales and Marketing for Multimedia Medical
Systems, Inc., a telemedicine company ("MMS"). From January 1991 to August 1995,
Mr. Hall was President of Asia Pacific Partners Ltd., a consulting firm.        

Robert J. Vanaria has served as Senior Vice President, Administration,
Chief Financial Officer and Treasurer since December 1997. From March 1995 to   
December 1997, Mr. Vanaria was Senior Vice President and Chief Financial Officer
of Greenwich Air Services, Inc., an aviation services subsidiary of General     
Electric Company. From September 1994 to February 1995, Mr. Vanaria was a       
self-employed business consultant. From March 1982 to August 1994, Mr. Vanaria  
was Senior Vice President and Chief Financial Officer of Foamex International,  
Inc., a manufacturing company.                                                  

  T. Jack Risenhoover, II has served as Vice President and General Counsel
since February 1997. From May 1994 to January 1997, Mr. Risenhoover was general 
counsel for The Right Angle, Inc., a marketing firm. Mr. Risenhoover was awarded
his J.D. from Vanderbilt University School of Law in April 1994.                

  Steven A. Denning has served on the Eclipsys Board since March 1997. Mr.
Denning is a Managing Member of General Atlantic Partners, LLC, an equity fund  
that invests worldwide in software and information technology companies, and has
been with General Atlantic since 1980. Mr. Denning is also a director of GT     
Interactive Software Corp., an interactive entertainment software development   
company.                                                                        

     G. Fred DiBona has served on the Eclipsys Board since May 1996. Since 1990,
Mr. DiBona has been the President and Chief Executive Officer of Independence   
Blue Cross and its subsidiaries. Mr. DiBona is also a director of Magellan      
Health Services, Inc., a specialized managed healthcare company; PECO Energy    
Company, a public energy company; Philadelphia Suburban Corporation, a water    
utility company; Tasty Baking Company, a packaged foods company; and the        
Pennsylvania Savings Bank.                                                      

91

S-4
100th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 100th

Eugene Fife has served on the Eclipsys Board since May 1997. Since    
September 1996, Mr. Fife has been the President and Chief Executive Officer of  
MMS. Mr. Fife was a general partner in Goldman Sachs & Co. from June 1970 to    
November 1995, at which time he became a limited partner. Mr. Fife remains a    
limited partner in Goldman Sachs & Co. Mr. Fife is also a director of Baker,    
Fentress Company, an investment company.                                        

   William E. Ford has served on the Eclipsys Board since May 1996. Mr. Ford
is a Managing Member of General Atlantic Partners, LLC and has been with General
Atlantic since 1991. Mr. Ford also serves as a director of GT Interactive       
Software Corp., an interactive entertainment software company; MAPICS, Inc., a  
resources planning software applications company; Envoy Corporation, an         
electronic data processing company; LHS Group Inc., a billing solutions company;
and E-Trade Group, Inc., an on-line discount broker.                            

  Jay B. Pieper has served on the Eclipsys Board since May 1996. Since May
1995, Mr. Pieper has served as Vice President of Corporate Development and      
Treasury Affairs for Partners. From March 1986 to May 1995, Mr. Pieper was      
Senior Vice President and Chief Financial Officer for Brigham.                  

     Richard D. Severns has served on the Eclipsys Board since January 1998. Mr.
Severns has been Senior Vice President and Director of Finance for the GM       
Network Services and Strategy Group of Motorola since August 1991.              

     Each officer of Eclipsys serves at the discretion of the Eclipsys Board and
holds office until his or her successor is elected and qualified or until his or
her earlier resignation or removal. There are no family relationships among any 
of the directors or executive officers of Eclipsys.                             

TSI DESIGNATED DIRECTORS                                                        

The Eclipsys Board has voted to expand the size of the Board so that, 
following the Merger, the Board will consist of nine directors. The Board has   
appointed the following two current directors of TSI to fill the two vacancies  
on the Eclipsys Board, subject to completion of the Merger:                     

                                                                [Download Table]

               NAME                  AGE                POSITION
               ----                  ---                --------
                                                                
Robert F. Raco.....................  61                 Director
Patrick T. Hackett.................  36                 Director

 Robert F. Raco has been nominated for election to the Eclipsys Board of
Directors of the Eclipsys Special Stockholders' Meeting, subject to completion  
of the Merger. Mr. Raco has been President and Chief Executive Officer of       
Transition Systems, Inc. since 1990 and has served as a director of TSI since   
1986. Mr. Raco joined TSI at its inception and served as Executive Vice         
President and Chief Operating Officer from 1986 to 1989. Mr. Raco previously    
served as Vice President of Information Services at New England Medical Center, 
Inc. until 1990. Mr. Raco has more than twenty years of experience in the       
information processing field.                                                   

     Patrick T. Hackett has been nominated for election to the Eclipsys Board of
Directors of the Eclipsys Special Stockholders' Meeting, subject to completion  
of the Merger. Mr. Hackett has been a Managing Director of Warburg, Pincus & Co.
since 1994. Mr. Hackett was an Associate at Warburg, Pincus & Co. from 1990 to  
1991 and a Vice President from 1991 to 1993. Mr. Hackett has served as a        
director of TSI since January 1996. He is also a director of Coventry           
Corporation, a managed healthcare company, VitalCom Inc., a healthcare computer 
networking company and several private companies.                               

CLASSIFIED BOARD                                                                

 The Eclipsys Board is divided into three classes, each of whose members
will serve for a staggered three-year term. The Eclipsys Board currently        
consists of two Class I Directors (Messrs. Fife and Ford), two Class II         
Directors (Messrs. Pieper and Severns) and three Class III Directors (Messrs.   
Denning, DiBona and Wilson). If the merger is completed, the Eclipsys Board will
consist of three Class I Directors (the existing Class I Directors plus Mr.     
Raco), three Class II Directors (the existing Class II Directors plus Mr.       
Hackett) and three Class III Directors. At each annual meeting of stockholders, 
a class of directors is elected for a three-year term to succeed the directors  
of the same class whose terms are then                                          

92

S-4
101st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 101st

expiring. The terms of the Class I Directors, Class II Directors and Class III  
Directors expire upon the election and qualification of successor directors at  
the annual meeting of Eclipsys stockholders held during the calendar years 1999,
2000 and 2001, respectively.                                                    

OBSERVER RIGHTS                                                                 

Subject to certain conditions, Motorola has the right under the Second
Amended and Restated Stockholders' Agreement dated January 24, 1998, by and     
among Eclipsys and certain stockholders of Eclipsys (the "Stockholders          
Agreement") to have an observer present at all regular and special meetings of  
the Eclipsys Board so long as it owns at least 3.5% of the total number of      
shares of Eclipsys Voting Common Stock outstanding (on an as converted and as   
exercised basis).                                                               

COMMITTEES OF THE BOARD OF DIRECTORS                                            

    The Eclipsys Board has an Executive Development and Compensation Committee
composed of Messrs. Denning (Chairman), DiBona and Fife, which makes            
recommendations concerning salaries and incentive compensation for executive    
officers of Eclipsys and administers and grants stock options and awards        
pursuant to the Eclipsys' stock option plans, and an Audit Committee composed of
Messrs. Pieper (Chairman), Ford and Severns, which reviews the results and scope
of the audit and other services provided by the Eclipsys' independent public    
accountants. Mr. Harvey J. Wilson is an ex-officio member of both the Audit     
Committee and the Executive Development and Compensation Committee.             

DIRECTOR COMPENSATION                                                           

Directors of Eclipsys are reimbursed for any expenses incurred in     
connection with attendance at meetings of the Eclipsys Board or any committee of
the Eclipsys Board, but are not otherwise compensated for such service. On April
8, 1998, the seven non-employee directors of Eclipsys were each granted a       
non-qualified stock option to purchase 13,333 shares of Eclipsys Voting Common  
Stock at a purchase price of $13.50 per share under the Eclipsys' 1998 Stock    
Incentive Plan. These options vest annually over a four year period. See "--    
Stock Plans."                                                                   

EXECUTIVE COMPENSATION                                                          

  The following table set forth the total compensation paid or accrued for
the year December 31, 1997 for Eclipsys' Chief Executive Officer and its two    
other executive officers whose total annual salary and bonus exceeded $100,000  
for 1997 (together, the "Named Executive Officers"):                            

SUMMARY COMPENSATION TABLE

                                                        [Enlarge/Download Table]

                                                                                      LONG-TERM  
                                                                                     COMPENSATION
                                                                                     ------------
                                                              ANNUAL COMPENSATION     SECURITIES 
                                                              -------------------     UNDERLYING 
                  NAME AND PRINCIPAL POSITION                 SALARY        BONUS     OPTIONS(1) 
                  ---------------------------                 ------        -----     ---------- 
                                                                                                 
Harvey J. Wilson...........................................  $150,000(2)         --          --  
  Chairman of the Board, President and Chief Executive                                           
     Officer                                                                                     
James E. Hall..............................................   177,971      $ 50,000      50,000  
  Senior Vice President, Field Operations and Chief                                              
     Operating Officer                                                                           
Robert J. Vanaria..........................................     7,692(3)    150,000      99,999  
  Senior Vice President, Administration and Chief Financial                                      
     Officer                                                                                     

---------------                                                                 
(1) Represents the number of shares covered by options to purchase shares of    
Eclipsys Voting Common Stock granted during 1997.                       

(2) Includes $84,000 of deferred compensation.                                  

(3) Mr. Vanaria joined Eclipsys in December 1997.                               

93

S-4
102nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 102nd

Stock Option Grants                                                         

     The following table sets forth grants of stock options to each of the Named
Executive Officers during the year ended December 31, 1997.                     

OPTION GRANTS IN LAST FISCAL YEAR 

                                                        [Enlarge/Download Table]

                                               INDIVIDUAL GRANTS                                              
                            -------------------------------------------------------    POTENTIAL REALIZABLE   
                                          PERCENT OF                                     VALUE AT ASSUMED     
                            NUMBER OF       TOTAL                                      ANNUAL RATES OF STOCK  
                            SECURITIES     OPTIONS                                    PRICE APPRECIATION FOR  
                            UNDERLYING    GRANTED TO    EXERCISE OR                       OPTION TERM(1)      
                             OPTIONS     EMPLOYEES IN   BASE PRICE     EXPIRATION    -------------------------
           NAME              GRANTED     FISCAL YEAR     PER SHARE        DATE          5%             10%    
           ----             ----------   ------------   -----------    ----------       --             ---    
                                                                                                              
Harvey J. Wilson...........       --          --              --              --           --               --
James E. Hall..............    4,000         0.3%          $0.20         1/20/07     $    491       $    1,243
                              46,000         3.5            6.50         1/25/07      187,895          976,162
Robert J. Vanaria..........   99,999         7.6            7.50          2/8/07      471,671        1,195,307

---------------                                                                 
(1) Amounts reported in these columns represent amounts that may be realized    
 upon exercise of the options immediately prior to the expiration of their
  term assuming the specified compound rates of appreciation (5% and 10%) on
  the market value of the Eclipsys Voting Common Stock on the date of option
 grant over the term of the options. These numbers are calculated based on
rules promulgated by the Securities and Exchange Commission and do not  
 reflect Eclipsys' estimate of future stock price growth. Actual gains, if
    any, on stock option exercises and Eclipsys Voting Common Stock holdings are
  dependent on the timing of such exercise and the future performance of the
 Eclipsys Voting Common Stock. There can be no assurance that the rates of
appreciation assumed in this table can be achieved or that the amounts  
reflected will be received by the individuals.                          

Year-End Option Values                                                      

  The following table sets forth certain information concerning the number
and value of unexercised options held by each of the Named Executive Officers on
December 31, 1997. None of the Named Executive Officers exercised any stock     
options during the year ended December 31, 1997.                                

FISCAL YEAR END OPTION VALUES 

                                                        [Enlarge/Download Table]

                                                      NUMBER OF SHARES                                   
                                                         UNDERLYING              VALUE OF UNEXERCISED    
                                                   UNEXERCISED OPTIONS AT        IN-THE-MONEY OPTIONS    
                                                       FISCAL YEAR END           AT FISCAL YEAR END(1)   
                                                 ---------------------------  ---------------------------
                      NAME                       EXERCISABLE   UNEXERCISABLE  EXERCISABLE   UNEXERCISABLE
                      ----                       -----------   -------------  -----------   -------------
                                                                                                         
Harvey J. Wilson................................        --             --            --             --   
James E. Hall...................................        --         50,000            --        $75,450   
Robert J. Vanaria...............................    33,333         66,666            --             --   

---------------                                                                 
(1) Represents the difference between the exercise price and the fair market    
  value of the Eclipsys Voting Common Stock at fiscal year end as determined
by the Eclipsys Board.                                                  

EMPLOYMENT ARRANGEMENTS                                                         

    On May 1, 1996, Harvey J. Wilson entered into an Employment Agreement with
Eclipsys. Eclipsys agreed to employ Mr. Wilson as its Chief Executive Officer   
until May 1, 1999, with an annual salary of $150,000, subject to deferral until 
Eclipsys has reached certain milestones and subject to adjustment from time to  
time thereafter. In January 1998, Mr. Wilson's annual salary was increased to   
$200,000. Upon termination of his employment, unless terminated for cause, Mr.  
Wilson shall be entitled to payment of his salary and continuation of his       
benefits for a period of months determined by the Eclipsys Board which is       
consistent with its practice for senior executives. Mr. Wilson has agreed not to
compete with Eclipsys during his term of employment and for three years         
thereafter.                                                                     

94

S-4
103rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 103rd

STOCK PLANS                                                                     

A total of 4,333,333 shares of Eclipsys Voting Common Stock have been 
reserved for issuance in the aggregate under Eclipsys' three stock plans        
described below.                                                                

     The Eclipsys 1996 Stock Plan (the "1996 Stock Plan") provided for grants of
stock options and awards of restricted and unrestricted Eclipsys Voting Common  
Stock. As of October 31, 1998, options to purchase 1,822,472 shares of Eclipsys 
Voting Common Stock were outstanding and 126,666 restricted shares of Eclipsys  
Voting Common Stock had been granted under the 1996 Stock Plan. The Eclipsys    
Board has provided that no additional grants or awards will be made under the   
1996 Stock Plan.                                                                

Under the Eclipsys 1998 Stock Incentive Plan (the "Incentive Plan"), a
variety of awards, including incentive stock options intended to qualify under  
Section 422 of the Code, nonstatutory stock options, stock appreciation rights, 
restricted and unrestricted stock awards and other stock-based awards, may be   
granted to officers, employees, directors, consultants and advisors of Eclipsys 
and its subsidiaries. The Eclipsys Board has authorized the Executive           
Development and Compensation Committee to administer the Incentive Plan. While  
Eclipsys currently anticipates that most grants under the Incentive Plan will   
consist of stock options, it may also grant stock appreciation rights, which    
represent the right to receive any excess in value of the shares of Eclipsys    
Voting Common Stock over the exercise price; restricted stock awards, which     
entitle recipients to acquire shares of Eclipsys Voting Common Stock, subject to
the right of Eclipsys to repurchase all or part of such shares at their purchase
price in the event that the conditions specified in the award are not satisfied;
or unrestricted stock awards, which represent grants of shares to participants  
free of any restrictions under the Incentive Plan. Options or other awards that 
are granted under the Incentive Plan but expire unexercised are available for   
future grants. As of October 31, 1998, options to purchase 489,986 shares of    
Eclipsys Voting Common Stock have been granted under the Incentive Plan,        
including a nonstatutory option to purchase up to 333,333 shares of Eclipsys    
Voting Common Stock granted to Harvey J. Wilson on April 8, 1998. Mr. Wilson's  
option covers (i) 66,666 shares at a purchase price of $15.00 per share, vesting
over three years following the grant date, (ii) 66,667 shares at a purchase     
price of $30.00 per share, vesting over four years, (iii) 100,000 shares at a   
purchase price of $45.00 per share, vesting over five years, and (iv) 100,000   
shares at a purchase price of $60.00, vesting over five years. Vesting under Mr.
Wilson's option is subject to acceleration at the discretion of the Eclipsys    
Board under certain circumstances.                                              

Under the Eclipsys 1998 Employee Stock Purchase Plan (the "Eclipsys   
Purchase Plan"), employees of Eclipsys, including directors who are also        
employees, are eligible to participate in quarterly plan offerings in which     
payroll deductions may be used to purchase shares of Eclipsys Voting Common     
Stock. As of October 31, 1998, 14,152 shares of Eclipsys Voting Common Stock    
have been purchased pursuant to the Eclipsys Purchase Plan. The purchase price  
of such shares is the lower of 85% of the fair market value of Eclipsys Voting  
Common Stock on the day the offering commences and 85% of the fair market value 
of Eclipsys Voting Common Stock on the day the offering terminates.             

COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION                     

    Mr. Denning, Mr. DiBona and Mr. Fife served during the year ended December
31, 1997 as members of the Executive Development and Compensation Committee of  
the Eclipsys Board. Mr. Harvey J. Wilson, an executive officer of Eclipsys, was 
an ex-officio member of the Executive Development and Compensation Committee and
in such capacity participated in certain deliberations of the Committee. Mr.    
Wilson was a director of MMS during the year ended December 1997. Mr. Fife, one 
of Eclipsys' directors and a member of the Executive Development and            
Compensation Committee, is, and was during 1997, the President and Chief        
Executive Officer of MMS. None of Mr. Denning, Mr. DiBona or Mr. Fife was at any
time during the year ended December 31, 1997, or at any other time, an officer  
or employee of Eclipsys. See "Certain Transactions" for a description of certain
relationships and transactions between Eclipsys and affiliates of Mr. Denning   
and Mr. Wilson.                                                                 

95

S-4
104th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 104th

PRINCIPAL STOCKHOLDERS OF ECLIPSYS

     The following table sets forth certain information regarding the beneficial
ownership of the shares of Eclipsys Voting Common Stock as of October 31, 1998, 
by (i) each person or entity known to Eclipsys to own beneficially more than 5% 
of the Eclipsys Voting Common Stock, (ii) each current director of Eclipsys,    
(iii) Eclipsys' Chief Executive Officer and the other Named Executive Officers  
and (iv) all current directors and executive officers as a group. Unless        
otherwise indicated, each person or entity named in the table has sole voting   
power and investment power (or shares such power with his or her spouse) with   
respect to all shares of capital stock listed as owned by such person or entity.

                                                        [Enlarge/Download Table]

                                                            NUMBER OF SHARES       APPROXIMATE   
                NAME OF BENEFICIAL OWNER                  BENEFICIALLY OWNED(1)  PERCENTAGE OWNED
                ------------------------                  ---------------------  ----------------
                                                                                                 
General Atlantic Partners, LLC(2)........................       6,855,255              35.3%     
  c/o General Atlantic Service Corporation                                                       
  Three Pickwick Plaza                                                                           
  Greenwich, CT 06830                                                                            
Steven A. Denning(2).....................................       6,855,255              35.3      
  c/o General Atlantic Service Corporation                                                       
  Three Pickwick Plaza                                                                           
  Greenwich, CT 06830                                                                            
William E. Ford(2).......................................       6,855,255              35.3      
  c/o General Atlantic Service Corporation                                                       
  Three Pickwick Plaza                                                                           
  Greenwich, CT 06830                                                                            
Wilfam Ltd.(3)...........................................       2,126,288              10.9      
  c/o Eclipsys Corporation                                                                       
  777 East Atlantic Avenue, Suite 200                                                            
  Delray Beach, FL 33483                                                                         
Alltel Information Services, Inc.(4).....................       2,077,497              10.7      
  4001 Rodney Parham Road                                                                        
  Little Rock, AR 72212                                                                          
First Union Corporation(5)...............................       1,199,392               6.2      
  One First Union Center, Floor 18                                                               
  Charlotte, NC 28288                                                                            
Motorola, Inc............................................       1,000,000               5.1      
  1303 East Algonquin Road                                                                       
  Schaumburg, IL 60190                                                                           
Partners HealthCare System, Inc..........................         988,290               5.1      
  Prudential Tower, Suite 1150                                                                   
  800 Boylston Street                                                                            
  Boston, MA 02199                                                                               
Harvey J. Wilson(6)......................................       2,626,963              13.5      
James E. Hall(7).........................................          19,166                 *      
Robert J. Vanaria(8).....................................          49,999                 *      
T. Jack Risenhoover, II(9)...............................           8,809                 *      
G. Fred DiBona...........................................          31,666                 *      
Eugene Fife(10)..........................................          31,666                 *      
Jay B. Pieper(11)........................................         988,290               5.1      
Richard D. Severns(12)...................................       1,000,000               5.1      
All executive officers and directors as a group (10                                              
  persons)(13)...........................................      11,611,814              59.6      

---------------                                                                 

* Less than 1%                                                                  

(1) The number of shares beneficially owned by each stockholder is determined   
  under rules promulgated by the Securities and Exchange Commission, and the
 information is not necessarily indicative of beneficial ownership for any
    other purpose. Under such rules, beneficial ownership includes any shares as
to which the individual or entity has sole or shared voting power or    
investment power and any                                                

96

S-4
105th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 105th

shares as to which the individual or entity has the right to acquire    
   beneficial ownership within 60 days after June 1, 1998 through the exercise
 of any stock option, warrant or other right. The inclusion herein of such
    shares, however, does not constitute an admission that the named stockholder
is a direct or indirect beneficial owner of such shares.                

(2) Consists of 1,052,661 shares held by General Atlantic Partners 28, L.P.     
("GAP 28"), 3,768,830 shares held by General Atlantic Partners 38, L.P. 
   ("GAP 38"), 504,674 shares held by General Atlantic Partners 47, L.P. ("GAP
  47"), 403,883 shares held by General Atlantic Partners 48, L.P. ("GAP 48")
 and 1,125,207 shares held by GAP Coinvestment, L.P. ("GAP Coinvestment").
    The general partner of GAP 28, GAP 38, GAP 47 and GAP 48 is General Atlantic
    Partners, LLC, a Delaware limited liability company. The managing members of
    General Atlantic Partners, LLC are the general partners of GAP Coinvestment.
Messrs. Denning and Ford are both managing members of General Atlantic  
Partners, LLC. Messrs. Denning and Ford disclaim beneficial ownership of
   shares owned by GAP 28, GAP 38, GAP 47, GAP 48 and GAP Coinvestment. 60,236
    shares of Eclipsys Voting Common Stock held by GAP 38 are subject to options
   granted by GAP 38 to AIS, and 10,463 shares of Eclipsys Voting Common Stock
   held by GAP Coinvestment are subject to options granted by GAP Coinvestment
to AIS. See footnote (4) below.                                         

(3) Mr. Harvey J. Wilson is the managing general partner of Wilfam, Ltd.        
("Wilfam") and Mr. Gregory L. Wilson, Mr. Harvey Wilson's son, is the   
investment manager for Wilfam. Mr. Harvey J. Wilson and Mr. Gregory L.  
 Wilson share voting and dispositive control of the shares held by Wilfam.

(4) Affiliates of General Atlantic Partners, LLC and Harvey Wilson agreed in    
   January 1997 to grant to AIS options to purchase 103,602 shares of Eclipsys
Voting Common Stock (as converted at the time of the initial public     
offering), at an exercise price of $.01 per share and pursuant to option
  agreements to be entered into after the closing of the Alltel Acquisition.
   Specifically, (i) GAP 38 granted to AIS an option to purchase 60,236 shares
of Eclipsys Voting Common Stock (as converted at the time of the initial
public offering) held by GAP 38, (ii) GAP Coinvestment granted to AIS an
option to purchase 10,463 shares of Eclipsys Voting Common Stock (as    
converted at the time of the initial public offering) held by GAP       
 Coinvestment and (iii) Wilfam granted to AIS an option to purchase 32,904
shares of Eclipsys Voting Common Stock (as converted at the time of the 
    initial public offering) held by Wilfam. AIS may only exercise these options
  if either of the holders of the Warrants exercises them to purchase shares
of Eclipsys Non-Voting Common Stock, in which case AIS may exercise the 
options to purchase on an aggregate basis one share of Eclipsys Voting  
  Common Stock (as converted at the time of the initial public offering) for
 each approximately 6.67 shares of Eclipsys Non-Voting Common Stock issued
   pursuant to the Warrants. To the extent that AIS exercises the options, the
option shares will be transferred to AIS by GAP 38, GAP Coinvestment and
Wilfam on a pro rata basis.                                             

(5) Includes 601,771 shares of Eclipsys Non-Voting Common Stock issuable upon   
   the exercise of a warrant, all of which Eclipsys Non-Voting Common Stock is
convertible into Eclipsys Voting Common Stock on a one-for-one basis.   

(6) Includes 2,126,288 shares held by Wilfam for which Mr. Wilson is the        
    managing general partner. 32,903 shares of Eclipsys Voting Common Stock held
by Wilfam are subject to options granted by Wilfam to AIS.              

(7) Includes 16,666 shares issuable upon exercise of stock options which are    
exercisable within 60 days of October 31, 1998.                         

(8) Includes 16,666 shares issuable upon exercise of stock options which are    
exercisable within 60 days of October 31, 1998.                         

(9) Includes 8,109 shares issuable upon the exercise of stock options which are 
exercisable within 60 days of October 31, 1998.                         

(10) Includes 16,666 shares issuable upon the exercise of stock options which   
are exercisable within 60 days of October 31, 1998.                   

97

S-4
106th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 106th

(11) These shares are held by Partners. Mr. Pieper is a Vice President of       
Partners. Mr. Pieper disclaims beneficial ownership of these shares.  

(12) These shares are held by Motorola. Mr. Severns is a Senior Vice President  
  of Motorola. Mr. Severns disclaims beneficial ownership of these shares.

(13) See notes (2) and (6) through (12) above.                                  

98

S-4
107th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 107th

CERTAIN TRANSACTIONS RELATING TO ECLIPSYS 

In May 1996, Eclipsys acquired the Partners License from Partners. In 
consideration for this license, Eclipsys issued to Partners 988,290 shares of   
Eclipsys Voting Common Stock and agreed to pay to Partners a royalty in         
connection with sales of the BICS system until Eclipsys completed an initial    
public offering of Eclipsys Voting Common Stock with a per share offering price 
of $10.00 or higher. Under the terms of the Partners License, Eclipsys may      
further develop, commercialize, distribute and support the original technology  
and license it, as well as sell related services, to other healthcare providers 
and hospitals throughout the world (with the exception of the Boston,           
Massachusetts metropolitan area). No sales of the BICS system have been made    
and, consequently, no royalties have been paid by Eclipsys pursuant to the      
Partners License because products based on the licensed technology are still in 
field trials. Eclipsys is obligated to offer to Partners and certain of its     
affiliates an internal use license, granted on most favored customer terms, to  
all new software applications developed by Eclipsys, whether or not derived from
the licensed technology, and major architectural changes to the licensed        
technology. Beginning as of May 3, 1998, Partners and certain of its affiliates 
are also entitled to receive internal use licenses for any changes to any module
or application included in the licensed technology requiring at least one person
year of technical effort. Eclipsys has an exclusive right of first offer to     
commercialize new information technologies developed in connection with         
Partners. If Eclipsys breaches any material term of the license, or if Mr.      
Harvey J. Wilson voluntarily terminates his employment with Eclipsys prior to   
May 1999, the license may become non-exclusive, at Partners' option. If Partners
converts the current license to a non-exclusive license, it must return 370,609 
shares of Eclipsys Voting Common Stock to Eclipsys. As part of the Partners     
License, Eclipsys provided certain development services to Partners. Fees for   
these development services paid by Partners to Eclipsys totaled $2.0 million,   
$2.5 million and $325,000 for 1996, 1997 and the first three months of 1998,    
respectively. Mr. Jay Pieper, a director of Eclipsys, is Vice President of      
Corporate Development and Treasury Affairs for Partners. Partners was not       
affiliated with Eclipsys' at the time of the negotiation of the Partners        
License.                                                                        

 In January 1998, Eclipsys completed the Emtek Acquisition for aggregate
consideration of $11.7 million (net of a $9.6 million receivable from Motorola),
consisting of 1,000,000 shares of Eclipsys Voting Common Stock issued to        
Motorola and the assumption of $12.3 million in liabilities. In connection with 
the Emtek Acquisition, Eclipsys entered into a software and support agreement   
with Motorola pursuant to which Eclipsys agreed to provide certain software and 
support services to Motorola's international customers for a minimum period of  
one year in exchange for negotiated annual payments. As of October 31, 1998,    
payments from Motorola totaled $4.6 million on the $9.6 million receivable owed 
and $500,000 under the software and support agreement. Mr. Richard Severns, a   
Senior Vice President of Motorola, is a director of Eclipsys. Neither Mr.       
Severns nor Emtek was affiliated with Eclipsys at the time of the negotiation of
the Emtek Acquisition.                                                          

     Mr. Harvey J. Wilson, President, Chief Executive Office and Chairman of the
Board of Eclipsys, is the managing general partner of Wilfam, a limited         
partnership whose limited partners are members of the Mr. Wilson's immediate    
family. Mr. Gregory L. Wilson, a general partner, is the investment manager for 
Wilfam. In December 1995, upon the incorporation of Eclipsys, Wilfam purchased  
2,022,700 shares of Eclipsys Voting Common Stock and Mr. Harvey Wilson purchase 
505,675 shares of Eclipsys Voting Common Stock for a purchase price of $.10 per 
share. In January 1997, Wilfam purchased 103,588 shares of Series D Convertible 
Preferred Stock (each of which was converted on a one-for-one basis into        
Eclipsys Voting Common Stock in the initial public offering) at a purchase price
of $12.55 per share.                                                            

    Affiliates of General Atlantic Partners, LLC purchased (i) in May 1996, an
aggregate of $5.0 million of Series A Convertible Participating Preferred Stock 
of Eclipsys, which were subsequently converted into 1,231,747 shares of Series F
Convertible Preferred Stock (each of which was converted on a one-for-one basis 
into Eclipsys Voting Common Stock in the initial public offering), (ii) in      
January 1997, 4,423,509 shares of Series D Convertible Preferred Stock (each of 
which was converted on a one-for-one basis into Eclipsys Voting Common Stock in 
the initial public offering) for an aggregate of $55.5 million, (iii) in        
February 1998, an aggregate of 900,000 shares of Series G Convertible Preferred 
Stock (each of which was converted on a two-for-three basis into Eclipsys Voting
Common Stock in the initial public offering)                                    
99

S-4
108th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 108th

for an aggregate of $9.0 million and (iv) in August 1998, an aggregate of       
600,000 shares of Eclipsys Voting Common Stock. Messrs. William Ford and Steven 
Denning, both of whom are directors of Eclipsys, are Managing Members of General
Atlantic Partners, LLC.                                                         

Wilfam is a limited partner in certain affiliates of General Atlantic 
Partners, LLC. As such, Wilfam participated in the May 1996 and the February    
1998 investments discussed above. The Wilfam indirect investments were          
approximately $12,600 in shares of Series A Convertible Participating Preferred 
Stock and $185,000 in Series G Convertible Preferred Stock, both of which were  
subsequently converted as discussed above.                                      

     During the year ended December 31, 1997 and the nine months ended September
30, 1998, Eclipsys from time to time chartered an airplane for corporate        
purposes from an aircraft charter company. Eclipsys paid $336,000 to the charter
company during 1997 and $384,580 during the first nine months of 1998. The      
aircraft provided for use by Eclipsys was leased by the charter company from    
RMSC of West Palm Beach ("RMSC"), a company that is wholly owned by Mr. Harvey  
J. Wilson. In connection with these charters, RMSC invoiced the charter company 
$219,000 in 1997 and $226,042 in the first nine months of 1998. Mr. Wilson has  
no ownership interest in the charter company. Eclipsys believes that the terms  
of the charters were at least as favorable to it as those that could have been  
negotiated with unaffiliated third parties.                                     

  See "Description of Eclipsys Capital Stock -- Registration Rights" for a
description of registration rights granted to certain significant stockholders  
of Eclipsys.                                                                    

   See "Eclipsys Management -- Observer Rights" for a description of certain
observer rights granted to a significant stockholder of Eclipsys.               

   See "Eclipsys Management -- Employment Arrangements" for a description of
Mr. Harvey J. Wilson's employment agreement with Eclipsys.                      

     Eclipsys has adopted a policy that future transactions between Eclipsys and
its executive officers, directors and affiliates must (i) be on terms no less   
favorable to Eclipsys than could be obtained from unaffiliated third parties and
(ii) be approved by a majority of the members of the Eclipsys Board and by a    
majority of the disinterested members of the Eclipsys Board.                    

 100

S-4
109th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 109th

BUSINESS OF TSI 

 The information in this section relates to the business of TSI as it is
currently conducted, without giving effect to the Merger and the HealthVISION   
Acquisition. See "-- Recent Developments" at page 107.                          

OVERVIEW                                                                        

 TSI provides management information technology to hospitals, integrated
delivery networks, physician groups and other healthcare organizations. Using   
TSI products, these organizations are able to increase efficiency, improve      
quality of care and lower the cost of care delivery. TSI product lines span the 
health care organization's information technology needs, providing data         
integration services, master person identifier solutions, disease management    
products and a clinical data repository as well as enterprise-wide financial,   
operational and clinical decision support.                                      

INDUSTRY                                                                        

 Pressure by employers, health insurers and government payors to control
health care costs is driving a movement towards managed care and new forms of   
reimbursement for health care providers. These new managed care reimbursement   
models, including capitation, case rates, per diems and other fixed payment     
arrangements, are shifting the financial risk of providing care from payors to  
providers. Payors are also demanding that providers differentiate their services
by demonstrating quality of care. These and other pressures are leading to      
industry consolidation and the formation of multi-entity provider networks,     
including integrated delivery networks.                                         

   These changes have altered the information needs of health care providers
trying to compete in this new environment. Institutions must understand their   
costs in order to manage the profitability of their clinical processes and their
many types of managed care contracts. Institutions also need to be able to      
compare practice patterns and outcomes of different clinicians or affiliated    
providers and to monitor utilization and outcomes on a continuous basis.        
Further, systems must be put in place that help clinicians translate their new  
understanding of improved care delivery into daily clinical operations.         
Information tools are required at the point of care that help clinicians improve
their overall productivity as well as insure quality and cost effective care.   

   The existing information systems installed in most provider organizations
were developed to meet the needs of providers in a fee-for-service environment. 
These systems are typically transaction-based departmental systems (e.g.,       
laboratory, pharmacy, radiology and nursing) focused on recording billing       
information for a single department. They are suitable primarily for collecting 
financial data, rather than for analyzing clinical and operational information. 
Existing departmental systems generally have been designed to operate as        
stand-alone systems and typically are limited in their ability to share data.   
Because these legacy systems do not integrate clinical, operational and         
financial data across the enterprise, they do not provide the information TSI   
believes is necessary for managers or clinicians to evaluate the cost of care by
patient, clinical specialty or episode of care. Further, these systems were     
designed mainly to capture charges in a fee-for-service environment, rather than
to lower costs, improve utilization and demonstrate quality.                    

PRODUCTS                                                                        

  TSI's initial product, Transition I, was introduced in 1985. Since 1985,
TSI has developed new products on a regular basis. All TSI products extend the  
core concepts of management information, accountability and control. These      
products are based on the foundation of providing information technology tools  
that enable healthcare organizations to: analyze past clinical, operational and 
financial practices; model new approaches for the future; transform those models
into actionable plans; and measure actual practice against those plans. Recent  
additions to the TSI product lines have extended these capabilities to include  
disease-specific tools that focus on improving the day-to-day efficiency and    
effectiveness of care                                                           

 101

S-4
110th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 110th

providers as well as the real-time measurement of clinical protocols. TSI data  
sources have also expanded to include clinical data repository technology.      

 The focus of TSI products is to empower the enterprise with information
that can be used to change and improve the clinical and financial performance of
the organization. More than 1,100 healthcare organizations in the United States 
and abroad have chosen TSI as their information technology solution to support  
their ongoing improvement efforts.                                              

TSI's current product offerings are as follows:                       

Transition II.  At the core of the Transition family of products is   
Transition II, an integrated decision support system designed to provide the    
clinical, operational and financial information that is needed to manage and    
improve the delivery of care. Together, the clinical and financial components of
Transition II enable an organization to: (i) delineate responsibility and       
accountability for managing costs; (ii) control resource utilization and reduce 
costs; (iii) measure variances from rules-based protocols on a daily basis; (iv)
manage a mix of complex reimbursement contracts by case or member; (v) analyze  
and measure quantifiable improvements in the patient care process; and (vi)     
develop clinical and departmental budgets and variance analyses that adjust for 
actual volume and mix.                                                          

Transition II creates a clinical and financial data repository by     
integrating data from across the enterprise. The system gathers information from
the many departmental information systems within the organization through       
interfaces that enable concurrent updating of distributed data. Transition II   
analyzes this data in order to determine the patient-level costs of care and    
identify areas for improvement. This information allows the organization to     
evaluate its cost structure, make changes in clinical processes to reduce costs 
and accurately price reimbursement contracts on a profitable basis. Transition  
II also analyzes and measures clinical process and outcomes data, identifying   
the practice patterns that most consistently result in the highest quality at   
the lowest cost. In addition, the system includes capabilities for case mix,    
reimbursement and utilization management, cost and profitability analysis,      
strategic planning, modeling and forecasting.                                   

   Enterprise Manager Series, formerly known as Transition II for Integrated
Delivery Systems, contains several different components that meet the needs of  
emerging integrated delivery networks. This product incorporates the            
functionality of Transition II and extends it across multiple entities. It also 
adds capabilities designed to meet the special needs of integrated delivery     
networks, such as analyses focusing on groups of patient-members and their      
associated health care activities. Different types of members can be            
categorized, for example, by disease type, age, sex, insurance product or       
employer.                                                                       

  Enterprise Manager Series includes tools to: (i) measure and monitor the
cost and quality of care longitudinally and determine where in a provider       
network appropriate care can be provided most cost effectively; (ii) manage the 
financial risks of capitation; (iii) provide risk pool accounting and management
both centrally and to physician groups; (iv) manage physician panels and        
determine panel sizing; (v) centrally identify and consolidate multiple patient 
identifiers across an enterprise and resolve them to a common master patient    
index; (vi) manage populations by identifying detailed characteristics and      
demographics, risk factors or chronic conditions, patient outcome status, and   
HEDIS and HEDIS-like indicators; and (vii) link physician and hospital billing  
information with the ability to view utilization, revenue and profitability by  
physician only, hospital only, and combined physician and hospital.             

    Enterprise Person Identifier.  This product is a vendor-neutral enterprise
master person index that uniquely identifies and cross-references patient,      
person, or member identification numbers to link information stored in disparate
systems. This product is increasingly essential for an organization delivering  
care at multiple sites to produce complete and accurate billing statements by   
capturing and correctly linking all visits and related charges incurred by      
patients throughout the network, regardless of the source of the data. This     
capability is also a necessary foundation for enterprise clinical systems, such 
as clinical data repositories and electronic patient records.                   

    Dictionary Manager.  Dictionary Manager enables users to input a change to
semi-static data tables or dictionaries just once, and have that change         
immediately reflected in all designated systems                                 
 102

S-4
111th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 111th

automatically. Changes to the charge masters, the addition of new physicians to 
the users staff, and the elimination of an insurance provider are all updated   
and maintained accurately and automatically by Dictionary Manager.              

  Transition IV.  Transition IV, TSI's next generation of decision support
solutions, extends the capabilities of Transition II by providing access to     
real-time clinical information that can be used to enhance the quality of       
patient care. Transition IV creates a domain of information to improve a        
healthcare organization's ability to perform care analysis, care planning, care 
support, and opportunity analysis. Transition IV provides a single desktop that 
incorporates the HealthVISION real time clinical data repository with the       
clinical and financial planning and analysis capabilities of Transition II.     
Transition IV is comprised of five additive levels of packaging to enable       
initial purchases or upgrades to any level. Among other benefits and features,  
Transition IV:                                                                  

 - Provides detailed clinical information to use for process improvement

- Minimizes re-work through real-time alerts                          

 - Provides real-time collection of clinical data through live HL7 feeds

- Improves patient outcomes through timely intervention               

- Incorporates financial information in analysis and alerts           

- Provides Web-enabled physician desktop                              

   - Provides ease of access to timely data, such as laboratory test results

    Transition For Quality.  TSI's Transition for Quality product offers tools
that complement the analytical power of Transition II's clinical component and  
provides on-line case management. With Transition for Quality, an organization  
can define a broad range of quality issues and identify cases for review and    
follow up based on outcome measures and variance from critical paths. Using this
information, the organization can concurrently monitor the progress and outcomes
of cases and intervene in response to automatic alerts. In addition, Transition 
for Quality provides healthcare organizations with compliance tools to comply   
with the Joint Commission on Accreditation of Healthcare Organizations' Oryx    
initiative.                                                                     

Transition Perspective and Clinical ABCs.  These benchmarking products
offered in conjunction with products of Premier Inc. and HCIA, Inc.,            
respectively, enable Transition II customers to use external benchmarking data  
to further support their process improvement efforts.                           

Vital Oncology.  This product, developed by TSI's subsidiary, Vital   
Software, automates the clinical processes unique to medical oncology while     
enhancing the quality of care. Vital Oncology significantly increases the       
productivity of physicians and nurses, reduces the likelihood of error, and     
improves patient care.                                                          

SERVICES AND SUPPORT                                                            

     Implementation Assistance.  Almost all new sales of products and many sales
of add-on products include implementation assistance. Implementation is carried 
out by a team of specialists overseeing the process on-site. Implementation of  
Transition II typically takes from six to twelve months.                        

    Software Maintenance Contracts.  TSI offers software maintenance contracts
for all software products. Under these contracts, TSI provides ongoing support, 
including updates and enhancements to the software modules and telephone access 
to a Help Desk staffed by an experienced team of support professionals.         

Consulting Services.  TSI also offers post-implementation consulting  
services intended to assist customers in maximizing the benefits available      
through the use of the Transition family of products. TSI's staff can assess    
performance of the customer's system and advise the customer on its growing     
needs. While these services do not currently constitute a major source of       
revenue, TSI believes they have the potential to grow in importance.            
 103

S-4
112th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 112th

   Integration Services.  TSI offers data extraction services to develop the
conversion protocols necessary to obtain data feeds from an organization's      
source systems, so as to enable data from these source systems to be integrated 
with data from TSI applications. Typical extractions are from general ledger,   
payroll, admission/discharge/transfer, medical records abstracting, patient     
billing and various departmental systems. TSI also supports the installation of 
real time HL7 interfaces.                                                       

CUSTOMERS                                                                       

 TSI's customers include a broad range of hospitals, integrated delivery
networks, managed care organizations and physician practices in the United      
States and around the world. TSI's products are installed at more than 1,100    
customer sites.                                                                 

TECHNOLOGY                                                                      

 TSI has products deployed on both two-tier client/server and three-tier
client/server/server architectures. Each of the products utilizes the           
architecture strategy best suited for the data access requirements inherent to  
each product. This enables TSI to provide the power and flexibility of          
distributed data and processing combined with a wide range of user platforms.   
For example, each of Transition II, the Enterprise Manager Series and Transition
IV comprises a broad range of integrated applications that draw from a central  
repository of patient-level clinical and financial data. They feature an open,  
three-tiered client/server/server architecture that includes, at the client     
level, a Microsoft Windows-compliant point-and-click interface. TSI believes    
these features differentiate these products from other available decision       
support products.                                                               

    Multiple Platforms.  TSI's products are designed to operate with a variety
of hardware platforms, operating systems and database management systems. This  
strategy enables TSI to provided a practical and affordable solution for small  
and mid-size group health plans and community hospitals as well as large        
teaching hospitals and vertically-integrated health care delivery networks.     
Microsoft Windows (3.1, 95, 98 and NT) is the client standard for all products. 
Transition II host tier options include IBM 370/390 mainframes running the Model
204 DBMS, IBM AS/400s with DB2/400 and UNIX servers (Hewlett-Packard HP9000 and 
IBM RS/6000) running the Oracle DBMS. The application tier requires an Intel    
based processor. The Enterprise Manager Series of products utilizes the         
Transition II architecture with a SQL Server component for specific population  
studies. Transition for Quality is offered on both the HP9000 and the RS/6000   
running either Oracle or Sybase. Transition IV repository options include UNIX  
servers (HP9000, RS/6000) running either the Oracle, Sybase or Informix DBMS.   
The Transition IV application tier is an Intel processor running NT with the SQL
Server DBMS. Vital Oncology utilizes an Intel processor running NT with the SQL 
Server DBMS.                                                                    

Three-Tiered Client/Server/Server Architecture.  Transition II and    
Transition IV, together with the Enterprise Manager Series, employ a            
three-tiered computing architecture in which workstations (clients) and         
host-servers share the work of managing and processing information. This        
client/server environment allows a user to realize greater processing efficiency
at a lower cost than traditional terminal/ host or PC-LAN configurations.       

The Data Server tier pulls data from an organization's disparate      
transaction system databases and other data sources and batch processes it daily
into a value-added data repository. This tier performs the processing necessary 
to calculate unit costs, reimbursement, quality indicators and critical path    
variances. The system incorporates a variety of communications protocols,       
together with data interfaces developed during the system implementation        
process, to extract data from the disparate databases throughout an organization
in which transnational cost, process and outcomes information is stored,        
allowing the organization to preserve its existing investment in information    
technology.                                                                     

The Application Server, the middle tier, performs the value-added data
integration, storage and access required to support the clinical and financial  
analysis of the data. This tier runs on Windows NT and requires the SQL Server  
DBMS. The Application Server relies on direct data feeds from the Data Server   

 104

S-4
113th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 113th

tier and provides SQL-compliant database structures to integrate other data     
sources and to handle ad-hoc queries among all tiers of the architecture.       

    The Client tier performs on-line clinical and financial analysis through a
Microsoft Windows-compliant point-and-click interface. The Transition II,       
Enterprise Manager Series and Transition IV applications were developed using   
Microsoft's Visual Basic and Visual C++ development environments and are        
compatible with Windows 3.1, 3.11, Windows '95, Windows '98, Windows NT and     
other operating environments supported by the Microsoft Foundation Classes. The 
architecture has been expanded to incorporate a Visual Basic rapid development  
strategy exploiting Microsoft's ActiveX, COM/DCOM and Web enabling directions.  
With Transition II, the Enterprise Manager Series and Transition IV, there is no
need to layer a separate executive information system on top of the application.
Instead, the product includes a graphical, mouse-driven user interface which    
allows even inexperienced users to navigate through intuitive screens and       
windows of information, to select the information to be reviewed at various     
levels of detail and to transform numerical data into charts and graphs. The    
system can be customized to set user preferences, display styles and sorting    
parameters, enabling users to develop their own objects and applications.       

   The system provides tightly coupled interfaces to CCA Model 204, DB2/400,
Oracle and Microsoft SQL Server databases. Additionally, each of Transition II, 
the Enterprise Manager Series and Transition IV system integrates external data 
through compliance with the ODBC (Open Database Connectivity) and OLE 2.0       
(Object Linking and Embedding) protocols. ODBC provides standard SQL            
connectivity to a variety of SQL-compliant relational and non-relational        
databases, while the OLE 2.0 protocol provides a display, update and editing    
environment for Windows programs such as Microsoft Excel, Microsoft Word and PC 
SAS. As a result, additional data from a customer's legacy systems can be used  
in its native form without the need for data import.                            

SALES AND MARKETING                                                             

     At September 30, 1998, TSI had a direct sales force of 23, consisting of 19
direct sales persons and four sales management executives organized in two      
geographic regions covering the United States and Canada. TSI's direct sales and
sales management personnel are compensated through salaries plus commissions    
based on quarterly and annual quotas. TSI also sells through distributors based 
in New Zealand, Australia and the Netherlands. Distributors provide local       
support for implementations and ongoing maintenance support.                    

  TSI uses periodic newsletters and press releases, participation in trade
shows, direct mail and telemarketing to generate and pursue leads. Company      
employees also speak at health care industry conferences and publish case       
studies and articles. TSI sponsors annual user group conferences at which       
customers can learn about TSI's new product offerings and exchange information  
about their own experiences with TSI's products. TSI's May 1998 user group      
conference attracted approximately 1,300 attendees.                             

COMPETITION                                                                     

  The market for health care information systems and services is intensely
competitive and rapidly evolving. TSI competes directly with other vendors of   
decision support systems to health care providers. Other vendors of health care 
information systems, including vendors currently targeting decision support     
systems for payors, may enter the markets in which TSI competes. TSI also faces 
competition from internal management information systems departments of large   
hospital networks, many of which have developed or may develop financial and    
clinical outcomes management systems or other cost control solutions. TSI       
believes that the principal competitive factors influencing the market for its  
products include vendor and product reputation, product architecture,           
functionality and features, ease of use, rapidity of implementation, quality of 
customer support, product performance and price. Competition may result in      
significant price reductions, decreased gross margins, loss of market share and 
lack of acceptance of TSI's products. There can be no assurance that TSI will be
able to compete successfully in the future or that                              

 105

S-4
114th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 114th

competition will not have a material adverse effect on TSI's business, financial
condition and results of operations.                                            

RESEARCH AND PRODUCT DEVELOPMENT                                                

TSI's products consist primarily of internally-developed software. In 
addition, TSI has incorporated in its products DBMSs, graphical user interfaces,
and other software developed by third-party vendors. TSI believes that the      
timely development of new products and enhancements to existing products is     
essential to maintaining its competitive position in the market and positioning 
itself as an innovator. Since TSI's inception in 1985, TSI has developed and    
released functionality upgrades as well as new products on a yearly basis.      

TSI's current research and development efforts include expanding the  
capabilities of Transition IV and extending the Vital Oncology product to       
additional disease-specific applications. In addition, enhancements are planned 
for the Enterprise Person Identifier, Dictionary Manager and Transition for     
Quality products.                                                               

TSI's research and development activities are conducted in its Boston 
office. As of September 30, 1998, its research and development staff consisted  
of 63 employees. TSI's total research and development expenditures were $4.6    
million in fiscal 1997.                                                         

INTELLECTUAL PROPERTY                                                           

     TSI's ability to compete effectively depends to a significant extent on its
ability to protect its proprietary information. TSI relies primarily on trade   
secret laws, confidentiality procedures and licensing arrangements to protect   
its intellectual property rights.                                               

    TSI generally enters into confidentiality agreements with its consultants,
key employees and sales representatives and generally controls access to and    
distribution of its software and other proprietary information. Despite these   
precautions, it may be possible for a third party to copy or otherwise obtain   
and use TSI's products or technology without authorization or to develop similar
technology independently. Although TSI intends to defend its intellectual       
property, there can be no assurance that the steps taken by TSI to protect its  
proprietary information will be adequate to prevent misappropriation of its     
intellectual property or that TSI's competitors will not independently develop  
software that is substantially equivalent or superior to TSI's software.        

TSI is subject to the risk of alleged infringement by it of the       
intellectual property rights of others. Although TSI is not currently aware of  
any material infringement claims with respect to TSI's current or future        
products, there can be no assurance that third parties will not assert such     
claims or that any such claims will not require TSI to enter into license       
arrangements or result in protracted and costly litigation, regardless of the   
merits of such claims. No assurance can be given that any necessary licenses    
will be available or that, if available, such licenses can be obtained on       
commercially reasonable terms. Furthermore, litigation may be necessary to      
enforce TSI's intellectual property rights, to protect TSI's trade secrets, to  
determine the validity and scope of the proprietary rights of others or to      
defend against claims of infringement. Such litigation could result in          
substantial costs and diversion of resources and could have a material adverse  
effect on TSI's business, financial condition and results of operations.        

EMPLOYEES                                                                       

    As of September 30, 1998, TSI had 216 full-time employees, including 98 in
operations, 63 in research and development, 36 in sales and marketing and 19 in 
general administration and finance.                                             

TSI believes its future success will depend in large part upon the    
continued service of its key technical and senior management personnel and upon 
TSI's continuing ability to attract and retain highly-qualified technical and   
managerial personnel. Competition for highly-qualified personnel is intense and 
there can be no assurance that TSI will be able to retain its key managerial and
technical employees or that it will be able to attract and retain additional    
highly-qualified technical and managerial personnel in                          
 106

S-4
115th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 115th

the future. None of the Company's employees is represented by a labor union. TSI
has not experienced any work stoppage and considers its relationships with its  
employees to be good.                                                           

PROPERTIES                                                                      

   TSI's principal offices occupy approximately 27,000 square feet of office
space in Boston, Massachusetts under a lease expiring in August 2000. TSI also  
leases space for offices in Arizona, California, Georgia, Illinois, Pennsylvania
and Texas. TSI believes that its existing facilities will be adequate to meet   
its currently anticipated requirements and that, if additional space is needed, 
such space will be available on acceptable terms.                               

LEGAL PROCEEDINGS                                                               

TSI is not a party to any material litigation, and is not aware of any
pending or threatened litigation that would have a material adverse effect on   
TSI or its business.                                                            

RECENT DEVELOPMENTS                                                             

 On December 3, 1998, TSI completed its acquisition of the approximately
80.5% of the capital stock of HealthVISION not already owned by TSI for cash in 
the amount of $25.6 million, plus an earn-out of up to $10.8 million if         
specified financial milestones are met. The acquisition will be accounted for as
a purchase, reflecting an estimated aggregate purchase price, including TSI's   
initial 1997 investment, of $40.7 million, which includes $6.4 million          
previously paid by TSI and $9.3 million of assumed liabilities, net of cash     
acquired.                                                                       

 HealthVISION is a Santa Rosa, California provider of electronic medical
record software. HealthVISION's products include CareVISION, a patient-centered 
clinical data repository and lifetime patient record system, which is expected  
to constitute an integral component of TSI's Transition IV product.             
HealthVISION's total revenues for the year ended December 31, 1997 and for the  
nine-month period ended September 30, 1998 were approximately $9.2 million and  
$9.4 million, respectively. HealthVISION incurred net losses of $11.1 million   
and $5.6 million for such periods, respectively. At September 30, 1998,         
HealthVISION employed approximately 150 persons in seven offices in the United  
States, Canada and Australia.                                                   

 107

S-4
116th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 116th

PRINCIPAL STOCKHOLDERS OF TSI 

     The following table sets forth certain information regarding the beneficial
ownership of the shares of TSI Voting Common Stock as of November 10, 1998, by  
(i) each person or entity known to TSI to own beneficially more than 5% of the  
TSI Voting Common Stock, (ii) each current director of TSI, (iii) TSI's Chief   
Executive Officer and the four other most highly compensated executive officers 
of TSI during the fiscal year ended September 30, 1998 and (iv) all current     
directors and executive officers as a group. Unless otherwise indicated, each   
person or entity named in the table has sole voting power and investment power  
(or shares such power with his or her spouse) with respect to all shares of     
capital stock listed as owned by such person or entity.                         

                                                        [Enlarge/Download Table]

                                                              NUMBER OF SHARES       APPROXIMATE   
                 NAME OF BENEFICIAL OWNER                  BENEFICIALLY OWNED(1)   PERCENTAGE OWNED
                 ------------------------                  ----------------------  ----------------
                                                                                                   
Warburg, Pincus Ventures, L.P.(2).........................       6,125,000               34.0%     
  466 Lexington Avenue                                                                             
  New York, New York 10017                                                                         
Patrick T. Hackett(2).....................................       6,125,000               34.0      
  c/o Warburg, Pincus Ventures, L.P.                                                               
  466 Lexington Avenue                                                                             
  New York, New York 10017                                                                         
NationsBank Corporation(3)................................       1,114,673                6.2      
  101 South Tryon Street                                                                           
  Charlotte, North Carolina 28255                                                                  
Amvescap P.L.C.(4)........................................         936,955                5.2      
  11 Devonshire Square                                                                             
  London EC2M 4YR England                                                                          
Robert F. Raco(5).........................................         868,766                4.6      
Christine Shapleigh(6)....................................         532,429                2.9      
Donald C. Cook(7).........................................         552,400                2.9      
Thomas H. Zajac(8)........................................         290,650                1.6      
Peter W. Van Etten(9).....................................          28,700                  *      
Allen F. Wise(9)..........................................          28,700                  *      
Robert S. Hillas..........................................              --                 --      
Anthony R. Fonze(10)......................................          35,000                  *      
All directors and executive officers as a group (10                                                
  persons)(11)............................................       8,534,180               42.1      

---------------                                                                 
*  Less than one percent.                                                   

(1) The number of shares beneficially owned by each stockholder is determined 
under rules promulgated by the Commission, and the information is not 
     necessarily indicative of beneficial ownership for any other purpose. Under
such rules, beneficial ownership includes any shares as to which the  
   individual or entity has the right to acquire beneficial ownership within
60 days after the date of this table through the exercise of any stock
  option, warrant or other right. The inclusion herein of shares, however,
    does not constitute an admission that the named stockholder is a direct or
indirect beneficial owner of such shares.                             

(2) Represents shares held by Warburg, Pincus Ventures, L.P. ("WP Ventures"), 
     of which Mr. Hackett may be deemed to have beneficial ownership. The number
of shares beneficially owned by WP Ventures is based on information   
    contained in a Schedule 13G filed with the Commission on February 14, 1997
    by WP Ventures, Warburg, Pincus & Co. ("W.P & Co.") E.M. Warburg, Pincus &
   Co., LLC ("E.M. Warburg"). Each of WP Ventures, WP & Co. and E.M. Warburg
has shared voting power and shared dispositive power with respect to  
    6,125,000 shares of Common Stock. WP & Co., as the sole general partner of
     WP Ventures, has a 20% interest in the profits of WP Ventures. E.M. Warburg
   manages WP Ventures. Lionel I. Pincus is the managing partner of WP & Co.
   and the managing member of E.M. Warburg and may be deemed to control both
  WP & Co. and E.M. Warburg. Mr. Hackett disclaims beneficial ownership of
the shares held by WP Ventures.                                       

(3) Includes 356,262 shares of TSI Voting Common Stock issuable upon exchange 
    of outstanding shares of TSI Non-Voting Common Stock and 297,928 shares of
TSI Voting Common Stock issuable upon                                 
 108

S-4
117th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 117th

 exchange of 297,928 shares of TSI Non-Voting Common Stock issuable upon
exercise of a warrant. The number of shares beneficially owned by     
   NationsBank Corporation ("NationsBank") is based on information contained
in Schedule 13G/A filed with the Commission on February 18, 1998 by   
  NationsBank as a parent holding company for NB Holdings Corporation ("NB
  Holdings"), which is a holding company of its subsidiaries, NationsBank,
N.A. ("NB") and NationsBanc Investment Corporation ("NIC"). Each of   
    NationsBank and NB Holdings has reported sole voting power with respect to
     1,114,673 shares of TSI Voting Common Stock and sole dispositive power with
  respect to 1,114,663 shares of TSI Voting Common Stock. NIC has reported
sole voting power and sole dispositive power with respect to 1,114,663
   shares of TSI Voting Common Stock. NB has reported sole voting power with
respect to 10 shares of TSI Voting Common Stock.                      

(4) The number of shares beneficially owned by Amvescap P.L.C. ("Amvescap") is
     based on a Schedule 13G/A filed with the Commission on February 12, 1998 by
   Amvescap, AVZ, Inc. ("AVZ"), AIM Management Group, Inc. ("AIM"), Amvescap
Group Services ("AGS"), Invesco, Inc. ("Invesco"), Invesco Capital    
   Management, Inc. ("ICM"), Invesco PLC ("IP") and Invesco Realty Advisors,
 Inc. ("IRA"). Each of Amvescap, AVZ, AIM, AGS, Invesco, ICM, INAH, IFG,
    IMG, IP and IRA have shared voting power and shared dispositive power with
respect to 937,355 shares of TSI Voting Common Stock.                 

(5) Represents shares subject to stock options exercisable within 60 days of  
    the date of this table. Does not include 150,468 shares subject to options
not exercisable within 60 days of the date of this table.             

(6) Includes 2,000 shares held in custody by Dr. Shapleigh for the benefit of 
her two minor children and 529,429 shares subject to stock options    
exercisable within 60 days of the date of this table. Does not include
     55,777 shares subject to options not exercisable within 60 days of the date
of this table.                                                        

(7) Includes 1,250 shares held in custody by the spouse of Mr. Cook for the   
benefit of Mr. Cook's two minor children and 467,817 shares subject to
  stock options exercisable within 60 days of the date of this table. Does
 not include 116,900 shares subject to options not exercisable within 60
days of the date of this table.                                       

(8) Represents 290,650 shares subject to stock options exercisable within 60  
    days of the date of this table. Does not include 100,000 shares subject to
options not exercisable within 60 days of the date of this table.     

(9) Represents shares subject to stock options exercisable within 60 days of  
the date of this table.                                               

(10) Mr. Fonze tendered his resignation from his office as Vice President and   
 General Manager of TSI's Vital Software subsidiary on October 27, 1998.
     Represents options Mr. Fonze had the right to exercise through November 30,
    1998, the date on which his employment with TSI, and his right to exercise
options, ended.                                                       

(11) See Notes (2) and (5) through (10). Does not include Mr. Fonze.            

 109

S-4
118th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 118th

DESCRIPTION OF ECLIPSYS CAPITAL STOCK 

 Under Eclipsys' Third Amended and Restated Certificate of Incorporation
(the "Eclipsys Charter"), Eclipsys is authorized to issue 200,000,000 shares of 
Eclipsys Voting Common Stock, 5,000,000 shares of Eclipsys Non-Voting Common    
Stock and 5,000,000 shares of Preferred Stock, $.01 par value per share         
("Eclipsys Preferred Stock").                                                   

COMMON STOCK AND NON-VOTING COMMON STOCK                                        

   Holders of Eclipsys Voting Common Stock are entitled to one vote for each
share held on all matters submitted to a vote of stockholders and do not have   
cumulative voting rights. Holders of Eclipsys Non-Voting Common Stock do not    
have voting rights other than as provided by statute. Accordingly, holders of a 
majority of the shares of Eclipsys Voting Common Stock entitled to vote in any  
election of directors may elect all of the directors standing for election.     
Holders of Eclipsys Voting Common Stock and Eclipsys Non-Voting Common Stock are
entitled to receive ratably such dividends, if any, as may be declared by the   
Eclipsys Board out of funds legally available therefor, subject to any          
preferential dividend rights of outstanding Eclipsys Preferred Stock. Upon the  
liquidation, dissolution or winding up of Eclipsys, the holders of Eclipsys     
Voting Common Stock and Eclipsys Non-Voting Common Stock are entitled to receive
ratably the net assets of Eclipsys available after the payment of all debts and 
other liabilities and subject to the prior rights of any outstanding Eclipsys   
Preferred Stock. Holders of Eclipsys Voting Common Stock and Eclipsys Non-Voting
Common Stock have no preemptive, subscription or redemption rights. The         
outstanding shares of Eclipsys Voting Common Stock and Eclipsys Non-Voting      
Common Stock are fully paid and nonassessable. The rights, preferences and      
privileges of holders of Eclipsys Voting Common Stock are subject to, and may be
adversely affected by, the rights of the holders of shares of any series of     
Preferred Stock which Eclipsys may designate and issue in the future. Certain   
holders of Eclipsys Voting Common Stock and Eclipsys Non-Voting Common Stock    
have the right to require Eclipsys to effect the registration of their shares of
Eclipsys Voting Common Stock, or the Eclipsys Voting Common Stock into which the
Eclipsys Non-Voting Common Stock is convertible, as the case may be, in certain 
circumstances.                                                                  

Shares of Eclipsys Non-Voting Common Stock may be converted, at the   
holder's option, into shares of Eclipsys Voting Common Stock at the rate of one 
share of Eclipsys Voting Common Stock for each share of Eclipsys Non-Voting     
Common Stock surrendered for conversion, subject to certain adjustments. The    
holder can elect to convert all or any part of its Eclipsys Non-Voting Common   
Stock at any time, except that, if the holder is subject to certain federal     
banking regulations, the holder may only convert in connection with specified   
sales of the Eclipsys Voting Common Stock to be issued upon the conversion.     

PREFERRED STOCK                                                                 

    Under the terms of the Eclipsys Charter, the Eclipsys Board is authorized,
subject to any limitations prescribed by law, without stockholder approval, to  
issue up to 5,000,000 shares of Eclipsys Preferred Stock in one or more series. 
Each such series of Eclipsys Preferred Stock shall have such rights,            
preferences, privileges and restrictions, including voting rights, dividend     
rights, conversion rights, redemption privileges and liquidation preferences, as
shall be determined by the Eclipsys Board. The purpose of authorizing the       
Eclipsys Board to issue Eclipsys Preferred Stock and determine its rights and   
preferences is to eliminate delays associated with a stockholder vote on        
specific issuances. The issuance of Eclipsys Preferred Stock, while providing   
desirable flexibility in connection with possible acquisitions and other        
corporate purposes, could have the effect of making it more difficult for a     
third party to acquire, or of discouraging a third party from acquiring, a      
majority of the outstanding voting stock of Eclipsys. Eclipsys has no present   
plans to issue any shares of Eclipsys Preferred Stock.                          

WARRANTS                                                                        

  In January 1997, Eclipsys issued two warrants (the "Eclipsys Warrants"),
each exercisable at a purchase price of $.01 per share, to purchase up to       
1,124,822 and up to 674,893 shares of Eclipsys Non-                             

 110

S-4
119th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 119th

Voting Common Stock, respectively, to First Union Corporation and BT Investment 
Partners L.P. The number of shares purchasable pursuant to each Eclipsys Warrant
was subject to adjustment based on the timing of the redemption of the Series B 
Redeemable Preferred Stock, which occurred upon the closing of the Eclipsys IPO.
Because the Eclipsys IPO closed prior to December 31, 1998, the Eclipsys        
Warrants are exercisable for an aggregate of 962,833 shares of Eclipsys         
Non-Voting Common Stock. In lieu of payment of the exercise price, each         
warrantholder may elect to convert its Eclipsys Warrant, in whole or in part,   
into shares of Eclipsys Non-Voting Common Stock having a value equal to the     
value of the shares issuable at the time of the conversion less the aggregate   
exercise price for such shares under the Eclipsys Warrant. Both Eclipsys        
Warrants expire on August 6, 2001.                                              

REGISTRATION RIGHTS                                                             

 Pursuant to a Second Amended and Restated Registration Rights Agreement
(the "Registration Rights Agreement") dated January 28, 1998 among Eclipsys and 
certain of its stockholders (the "Rightsholders"), such Rightsholders will be   
entitled, commencing February 6, 1999, to certain rights with respect to the    
registration under the Securities Act of a total of approximately 17,890,233    
shares of Eclipsys Voting Common Stock (the "Registrable Shares"), including    
shares issuable upon exercise of the Warrants. In general, the Registration     
Rights Agreement provides that Rightsholders with demand and incidental         
registration rights beginning no earlier than February 6, 1999, six months after
the effective date of the Eclipsys IPO.                                         

  In connection with the Merger, Eclipsys has agreed to use its reasonable
efforts to amend the Registration Rights Agreement to add Warburg as a party to 
the agreement. In the event that Eclipsys is unable to amend the Registration   
Rights Agreement, Eclipsys will enter into a separate registration rights       
agreement with Warburg containing terms that are substantially identical to the 
Registration Rights Agreement.                                                  

    Certain of the Rightsholders, holding approximately 16,589,691 Registrable
Shares, may require Eclipsys to prepare and file a registration statement under 
the Securities Act with respect to their Registrable Shares if such registration
would result in an offering with net proceeds to the requesting Rightsholder or 
Rightsholders of at least $5.0 million. In addition, one of the Rightsholders   
may compel registration for a smaller amount if the offering is to include all  
the shares of Eclipsys stock then owned by such Rightsholder, none of which are 
then available for sale pursuant to Rule 144 under the Securities Act. Two of   
the Rightsholders may each require Eclipsys to prepare and file two registration
statements. Each of five other Rightsholders are entitled to one such           
registration request. After the merger, Warburg will be entitled to one         
registration request, but may not require Eclipsys to prepare and file a        
registration statement prior to January 1, 2000. Eclipsys is not required to    
file a demand registration statement for six months after the effective date of 
its initial public offering or within three months after the effective date of  
any other registration statement, subject to certain restrictions.              

     If Eclipsys proposes to register any of its securities under the Securities
Act, the Rightsholders will be entitled to include Registrable Shares in such   
offering, subject to the right of the managing underwriter of any underwritten  
public offering to limit for marketing reasons the number of shares of          
Registrable Shares included in the offering.                                    

TRANSFER AGENT AND REGISTRAR                                                    

The transfer agent and registrar for Eclipsys Voting Common Stock is  
BankBoston, N.A.                                                                

 111

S-4
120th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 120th

COMPARISON OF STOCKHOLDERS' RIGHTS

    At the Effective Time, the stockholders of TSI will become stockholders of
Eclipsys, a corporation governed by Delaware law and a Certificate of           
Incorporation and Bylaws adopted thereunder. The following discussion summarizes
the material differences between the rights of holders of TSI Voting Common     
Stock and holders of Eclipsys Voting Common Stock, based on a comparison of the 
Delaware and Massachusetts corporation laws and differences between the charters
and bylaws of TSI and Eclipsys. The Restated Articles of Organization and the   
Amended and Restated Bylaws of TSI are referred to herein as the "TSI Charter"  
and the "TSI Bylaws," respectively, and the Third Amended and Restated          
Certificate of Incorporation and the Amended and Restated Bylaws of Eclipsys are
referred to herein as the "Eclipsys Charter" and the "Eclipsys Bylaws,"         
respectively. This summary does not purport to be complete and is qualified in  
its entirety by reference to the TSI Charter and TSI Bylaws, the Eclipsys       
Charter and Eclipsys Bylaws and the relevant provisions of the Delaware General 
Corporation Law (the "Delaware Law") and the Massachusetts Business Corporation 
Law (the "Massachusetts Law").                                                  

MEETINGS OF STOCKHOLDERS                                                        

The Delaware Law provides that special meetings of stockholders may be
called only by the directors or by any other person authorized by a             
corporation's certificate of incorporation or bylaws. The Eclipsys Charter and  
the Eclipsys Bylaws provide that a special meeting of stockholders may only be  
called by the president, the chairman of the board or the Eclipsys Board.       

   The Massachusetts Law provides that special meetings of stockholders of a
corporation with a class of voting stock registered under the Securities        
Exchange Act of 1934, as amended (the "Exchange Act"), may be called by the     
president or the directors of such corporation, and unless otherwise provided in
the corporation's charter or bylaws shall be called by the clerk or other       
officer upon the written application of the owners of not less than 40% in      
interest of the corporation's stock entitled to vote at such meeting. The TSI   
Bylaws authorize the president, the chairman of the board, or the TSI Board to  
call special meetings of the stockholders and require that the Clerk or any     
other officer call a special meeting of the stockholders upon written           
application by the owners of not less than 20% in interest of the corporation's 
stock entitled to vote at such meeting.                                         

INSPECTION RIGHTS                                                               

    Inspection rights under the Delaware Law are more extensive than under the
Massachusetts Law. Under the Delaware Law, stockholders demonstrating a proper  
purpose have the right to inspect a corporation's stock ledger, stockholder     
list, and other books and records.                                              

  Under the Massachusetts Law, a corporation's stockholders have the right
for a proper purpose to inspect the corporation's articles of organization,     
bylaws, records of all meetings of incorporators and stockholders, and stock and
transfer records, including the stockholder list. In addition, stockholders of a
Massachusetts business corporation have a qualified common law right under      
certain circumstances to inspect other books and records of the corporation.    

ACTION BY CONSENT OF STOCKHOLDERS                                               

Under the Delaware Law, unless otherwise provided in a corporation's  
certificate of incorporation, any action required or permitted to be taken at an
annual or special meeting of stockholders may be taken without such a meeting,  
without prior notice and without a vote, if a consent in writing, setting forth 
the action to be taken is signed by the holders of outstanding stock            
representing the number of shares necessary to take such action at a meeting at 
which all shares entitled to vote were present. However, the Eclipsys Charter   
prohibits stockholders from taking any action by written consent in lieu of a   
meeting.                                                                        

 112

S-4
121st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 121st

Under the Massachusetts Law and the TSI Bylaws, any action required or
permitted to be taken at any meeting of stockholders may be taken without a     
meeting if all stockholders entitled to vote consent to the action in writing.  

CUMULATIVE VOTING                                                               

 Under the Delaware Law, a corporation may provide in its certificate of
incorporation for cumulative voting by stockholders in elections of directors   
(i.e., each stockholder casts as many votes for directors as he has shares of   
stock multiplied by the number of directors to be elected). The Eclipsys Charter
does not provide for cumulative voting rights.                                  

   The Massachusetts Law does not authorize or provide for cumulative voting
rights. Neither the TSI Charter nor the TSI Bylaws provide for cumulative       
voting.                                                                         

ISSUANCE OF STOCK; PREFERRED STOCK                                              

    Shares of Eclipsys Voting Common Stock may be issued from time to time, in
such amounts and for such consideration, as may be determined by the Eclipsys   
Board. No holder of Eclipsys Voting or Non-Voting Common Stock has any          
preemptive or preferential rights to purchase or to subscribe for any shares of 
capital stock or other securities that may be issued by Eclipsys. Eclipsys has  
5,000,000 authorized shares of Eclipsys Preferred Stock. None of such shares is 
outstanding. The Eclipsys Preferred Stock is issuable in one or more series. The
Eclipsys Board is empowered to authorize without stockholder approval the       
issuance of each series of Eclipsys Preferred Stock and is empowered to fix the 
voting rights, if any (in addition to those prescribed by law), dividend rights,
liquidation preferences, redemption provisions, if any, conversion rights, if   
any, and other rights of each such series, any of which rights could adversely  
affect the voting and other rights of the holders of Eclipsys Voting Common     
Stock.                                                                          

     Shares of TSI Voting Common Stock may be issued by TSI from time to time as
approved by the TSI Board without stockholder approval. Holders of the capital  
stock of TSI are not entitled to preemptive or preferential rights to purchase  
or to subscribe for any shares of capital stock or other securities that may be 
issued by TSI. TSI has 1,000,000 authorized shares of Preferred Stock, par value
$.01 per share (the "TSI Preferred Stock"). None of such shares is outstanding. 
The TSI Preferred Stock is issuable in one or more series. The TSI Board can    
authorize, without stockholder approval, the issuance of each series of TSI     
Preferred Stock and can fix the voting rights, if any, dividend rights,         
liquidation preferences, redemption provisions, if any, conversion rights, if   
any, and other rights of each such series, any of which rights could adversely  
affect the voting and other rights of the holders of TSI Voting Common Stock.   

DIVIDENDS AND REPURCHASES OF STOCK                                              

     Under the Delaware Law, a corporation generally is permitted to declare and
pay dividends out of surplus or out of net profits for the current and/or       
preceding fiscal year, provided that such dividends will not reduce capital     
below the amount of capital represented by all classes of stock having a        
preference upon the distribution of assets. Also under the Delaware Law, a      
corporation may generally redeem or repurchase shares of its stock if such      
redemption or repurchase will not impair the capital of the corporation. The    
directors of a Delaware corporation may be jointly and severally liable to the  
corporation for a willful or negligent violation of such provisions of Delaware 
law. The Eclipsys Charter provides that the declaration and payment of any      
dividend is within the discretion of the Eclipsys Board and subject to the      
rights of the holders of any Eclipsys Preferred Stock.                          

     Under the Massachusetts Law, the payment of dividends and the repurchase of
the corporation's stock are generally permissible if such actions are not taken 
when the corporation is insolvent, do not render the corporation insolvent, and 
do not violate the corporation's articles of organization. The directors of a   
Massachusetts corporation may be jointly and severally liable to the corporation
to the extent that a dividend authorized by the directors exceeds such          
permissible amounts and is not repaid to the                                    

 113

S-4
122nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 122nd

corporation. The TSI Charter provides that the declaration and payment of any   
dividend is within the discretion of the TSI Board and subject to the rights of 
the holders of any TSI preferred stock.                                         

CLASSIFICATION OF THE BOARD OF DIRECTORS                                        

The Delaware Law permits (but does not require) classification of a   
corporation's board of directors into one, two or three classes. The Eclipsys   
Charter provides that the Eclipsys Board is divided into three classes with no  
one class having more than one director more than any other class, elected for  
staggered three year terms.                                                     

   The Massachusetts Law generally requires that publicly held Massachusetts
corporations have a classified board of directors consisting of three classes as
nearly equal in size as possible, unless those corporations elect to opt out of 
the statute's coverage. The TSI Bylaws divide the TSI Board into three classes, 
with no one class having more than one director more than any other class, for  
staggered three year terms.                                                     

REMOVAL OF DIRECTORS                                                            

   Under the Delaware Law, stockholders may remove directors with or without
cause by a majority vote unless otherwise provided in the certificate of        
incorporation. The Eclipsys Charter provides that directors may be removed only 
for cause by the holders of at least 75% of the then issued and outstanding     
shares of capital of the corporation. Unlike Massachusetts law, Delaware law    
does not permit directors to remove other directors.                            

Under the Massachusetts Law, except as otherwise provided in the      
corporation's charter or bylaws, directors of a public company subject to that  
section may be removed from office with or without cause by the holders of a    
majority of the shares outstanding and entitled to vote in the election of      
directors or with cause by a majority of the directors then in office, provided 
that the directors elected by a particular class of stockholders may be removed 
only by the vote of the holders of a majority of the shares of the particular   
class entitled to vote for the election of such directors. The TSI Bylaws       
provide that any director may be removed with or without cause by the vote of   
the holders of a majority of the shares issued, then outstanding and entitled to
vote in the election of directors, or with cause by the majority of the Board of
Directors.                                                                      

VACANCIES ON THE BOARD OF DIRECTORS                                             

     Under the Delaware Law, unless otherwise provided in the charter or bylaws,
vacancies on the board of directors and newly created directorships resulting   
from any increase in the authorized number of directors may be filled by the    
remaining directors. The Eclipsys Charter and Bylaws provide that only a vote of
the majority of the directors in office, even if less than a quorum, shall fill 
any vacancy on the Eclipsys Board.                                              

   Under the Massachusetts Law, unless otherwise provided in a corporation's
articles of organization, any vacancy in the board of directors may be filled in
the manner prescribed in the bylaws or in the absence of such a bylaw, by the   
directors. The TSI Charter does not address the manner in which vacancies on the
board of directors may be filled. The TSI Bylaws provide that any vacancy may be
filled by a vote of the majority of the directors in office (even if less than a
quorum) or, in the absence of such election by the directors, by the            
stockholders.                                                                   

LIMITATION ON DIRECTORS' LIABILITY; INDEMNIFICATION OF OFFICERS AND DIRECTORS   

The Delaware Law allows a corporation to include in its certificate of
incorporation a provision that limits or eliminates the personal liability of   
directors to the corporation and its shareholders for monetary damages for      
breach of fiduciary duty as a director. The Delaware Law does not, however,     
permit a                                                                        

 114

S-4
123rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 123rd

corporation to limit or eliminate the personal liability of a director for (i)  
any breach of the director's duty of loyalty to the corporation or its          
stockholders, (ii) acts or omissions not in good faith or which involve         
intentional misconduct or a knowing violation of law, (iii) intentional or      
negligent payment of unlawful dividends or stock purchase or redemption, or (iv)
any transaction from which the director derived an improper personal benefit.   
The Eclipsys Charter provides for limitations on directors' liability as        
permitted by this statute.                                                      

    The Delaware Law also provides that a corporation may indemnify any of its
officers and directors party to any action, suit or proceeding by reason of the 
fact that he or she was a director, officer, employee or agent of the           
corporation by, among other things, a majority vote consisting of directors who 
were not parties to such action, suit or proceeding, provided that such officer 
or director acted in good faith and in a manner he or she reasonably believed to
be in or not opposed to the best interests of the corporation. The Eclipsys     
Charter and the Eclipsys Bylaws provide for indemnification of officers and     
directors of Eclipsys to the fullest extent permitted by this statute.          

The Massachusetts Law allows a corporation to include in its charter a
provision that limits or eliminates the personal liability of directors to the  
corporation and its shareholders for monetary damages for breach of fiduciary   
duty as a director. The Massachusetts Law does not, however, permit a           
corporation to limit or eliminate the personal liability of a director for (i)  
any breach of the director's duty of loyalty to the corporation or its          
stockholders, (ii) acts or omissions not in good faith or which involve         
intentional misconduct or a knowing violation of law, (iii) payment of dividends
or stock purchase or redemption, except a distribution of stock of the          
corporation, in violation of the corporation's charter, or (iv) any loans to any
officer or director of the corporation. The TSI Charter provides for limitations
on directors' liability as permitted by this statute.                           

     The Massachusetts Law provides that indemnification of directors, officers,
employees and other agents of a corporation, and persons who serve at its       
request as directors, officers, employees and other agents of another           
organization, may be provided by it to whatever extent specified in or          
authorized by (i) the charter, (ii) a bylaw adopted by the stockholders, or     
(iii) a vote adopted by the holders of a majority of the shares of stock        
entitled to vote on the election of directors. The TSI Bylaws provide that TSI  
will indemnify its directors or officers (including persons who serve at its    
request as directors, officers or trustees of any organization in which TSI has 
an interest as a stockholder, creditor or otherwise), to the fullest extent     
permitted by the Massachusetts Law, against liabilities and expenses arising out
of legal proceedings brought or threatened against them by reason of their      
status as directors or officers. Under this provision each director and officer 
is entitled to indemnification even if not successful on the merits, if such    
director or officer acted in good faith in the reasonable belief that his or her
action was in the best interest of TSI.                                         

INTERESTED DIRECTOR TRANSACTIONS                                                

  The Delaware Law and each of the Eclipsys and TSI Bylaws provide that no
transaction between a corporation and one or more of its directors or officers  
or an entity in which one or more of its directors or officers are directors or 
officers or have a financial interest, shall be void or voidable solely for that
reason. In addition, no such transaction shall be void or voidable solely       
because the director or officer is present at, participates in, or votes at the 
meeting of the board of directors, or committee thereof, which authorizes the   
transaction. In order that such a transaction not be found void or voidable, it 
must, after disclosure of material facts, be approved by a majority of the      
disinterested directors, a committee of disinterested directors, or the         
stockholders, or the transaction must be fair as to the corporation. The        
Massachusetts Law has no comparable provision.                                  

SALE, LEASE OR EXCHANGE OF ASSETS AND MERGERS                                   

     The Delaware Law requires the approval of the directors and the vote of the
holders of a majority of the outstanding stock entitled to vote thereon for the 
sale, lease, or exchange of all or substantially all of a                       

 115

S-4
124th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 124th

corporation's property and assets or a merger or consolidation of the           
corporation into any other corporation, although the certificate of             
incorporation may require a higher stockholder vote. The Massachusetts Law      
provides that a vote of two-thirds of the shares of each class of stock         
outstanding and entitled to vote thereon is required to authorize the sale,     
lease, or exchange of all or substantially all of a corporation's property and  
assets or a merger or consolidation of the corporation into any other           
corporation, except that the articles of organization may provide that the vote 
of a greater or lesser proportion, but not less than a majority of the          
outstanding shares of each class, is required. Neither the Eclipsys Charter or  
Bylaws nor the TSI Charter or Bylaws address this issue.                        

AMENDMENTS TO CHARTER                                                           

Under the Delaware Law, charter amendments require the approval of the
directors and the vote of the holders of a majority of the outstanding stock and
a majority of each class of stock outstanding and entitled to vote thereon as a 
class, unless the certificate of incorporation requires a greater proportion.   
The Eclipsys Charter does not require a greater proportion except with respect  
to amendment, repeal or modification of the following provisions, which require 
a vote of at least 75% of the issued and outstanding shares entitled to vote    
thereon: the provisions regarding indemnification and exculpation of directors; 
the provisions regarding classification, number, election, nomination and       
removal of directors; the provisions prohibiting actions by the unanimous       
written consent of stockholders in lieu of a meeting; and the provisions        
regarding the calling of special stockholders meetings. In addition, Delaware   
law requires a class vote when, among other things, an amendment will adversely 
affect the powers, preferences or special rights of a class of stock.           

Under the Massachusetts Law, amendments to a corporation's articles of
organization relating to certain changes in capital or in the corporate name    
require the vote of at least a majority of each class of stock outstanding and  
entitled to vote thereon. Amendments relating to other matters require a vote of
at least two-thirds of each class outstanding and entitled to vote thereon or,  
if the articles of organization so provide, a greater or lesser proportion but  
not less than a majority of the outstanding shares of each class. Under         
Massachusetts law, the articles of organization or bylaws may provide that all  
outstanding classes of stock vote as a single class, but a separate vote of any 
class of stock adversely affected by the amendment also is required. The TSI    
Charter does not address this issue.                                            

APPRAISAL RIGHTS                                                                

  Dissenting stockholders have the right to obtain the fair value of their
shares ("appraisal rights") in more circumstances under the Massachusetts Law   
than under the Delaware Law. Under the Delaware Law, a stockholder is entitled  
to appraisal rights in the event of certain mergers or consolidations, but not  
in the event of the sale, lease, or exchange of all or substantially all of a   
corporation's assets or the adoption of an amendment to its certificate of      
incorporation, unless such rights are granted in the corporation's certificate  
of incorporation. The Eclipsys Charter does not grant such rights. The Delaware 
and Massachusetts Laws further provide that a dissenting stockholder must not   
vote in favor of the proposal in order to preserve his or her appraisal rights. 
In order to perfect his or her appraisal rights, both jurisdictions require a   
dissenting stockholder to notify the company in writing, prior to the vote on   
the proposal, of his or her intention to demand payment for his or her shares if
the action is taken. The Delaware Law does not grant appraisal rights to a      
holder of securities listed on a national securities exchange or designated as  
national market system securities if the stockholder receives such securities in
exchange.                                                                       

    Under the Massachusetts Law, a properly dissenting stockholder is entitled
to receive the appraised value of his shares when the corporation votes (i) to  
sell, lease, or exchange all or substantially all of its property and assets,   
(ii) to adopt an amendment to its articles of organization which adversely      
affects the rights of the stockholder or (iii) to merge or consolidate with     
another corporation. The TSI Charter does not address this issue.               

 116

S-4
125th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 125th

ANTI-TAKEOVER PROVISIONS                                                        

  The Charters and Bylaws of both Eclipsys and TSI contain provisions that
could discourage potential takeover attempts and prevent stockholders from      
changing the company's management, including provisions authorizing the Eclipsys
Board to issue shares of preferred stock in series and restrictions on the      
ability of stockholders to call a special meeting of stockholders.              

The Delaware Law is substantially similar to the Massachusetts Law.   
However, while the Delaware Law provides that, if a person acquires 15% or more 
of the stock of a Delaware corporation without the approval of its board of     
directors (an "interested stockholder"), such person may not engage in certain  
transactions with the corporation for a period of three years, the Massachusetts
Law lowers the 15% threshold to 5% (except in the case of certain stockholders  
eligible to file Schedule 13G under the Exchange Act). Both the Delaware Law and
the Massachusetts Law include certain exceptions to this prohibition; for       
example, if the board of directors approves the acquisition of stock or the     
transaction prior to the time that the person became an interested stockholder, 
or if the interested stockholder acquires 85% (in the Delaware Law) or 90% (in  
the Massachusetts Law) of the voting stock of the corporation (excluding voting 
stock owned by directors who are also officers and certain employee stock plans)
in one transaction, or if the transaction is approved by the board of directors 
and by the affirmative vote of two-thirds of the outstanding voting stock which 
is not owned by the interested stockholder, the prohibition does not apply. The 
Eclipsys Board has approved the Merger pursuant to the Delaware Law, and TSI is 
currently subject to the Massachusetts Law.                                     

 117

S-4
126th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 126th

LEGAL MATTERS 

   The validity of the shares of Eclipsys Voting Common Stock offered hereby
will be passed upon for Eclipsys by Hale and Dorr LLP. Certain legal matters in 
connection with the Merger will be passed upon for TSI by Foley, Hoag & Eliot   
LLP.                                                                            

EXPERTS 

  The financial statements of Eclipsys Corporation as of December 31, 1997
and 1996 and for each of the two years in the period ended December 31, 1997    
included in this Joint Proxy Statement/Prospectus have been so included in      
reliance on the report of PricewaterhouseCoopers LLP, independent accountants,  
given on the authority of said firm as experts in auditing and accounting.      

  The financial statements of Transition Systems, Inc. as of September 30,
1998 and 1997 and for each of the three years in the period ended September 30, 
1998 included in this Joint Proxy Statement/ Prospectus have been so included in
reliance on the report of PricewaterhouseCoopers LLP, independent accountants,  
given on the authority of said firm as experts in auditing and accounting.      

  The consolidated balance sheets of HealthVISION, Inc. as of December 31,
1996 and 1997 and the consolidated statements of operations, stockholders'      
equity and cash flows for the years then ended appearing in this Joint Proxy    
Statement/Prospectus have been audited by Ernst & Young LLP, independent        
auditors, as set forth in their report thereon appearing elsewhere herein, and  
are included in reliance upon such report given on the authority of such firm as
experts in accounting and auditing.                                             

     The financial statements of ALLTEL Healthcare Information Services, Inc. as
of January 23, 1997, December 31, 1996 and 1995 and for the period from January 
1, 1997 through January 23, 1997 and each of the two years in the period ended  
December 31, 1996 included in this Joint Proxy Statement/ Prospectus have been  
so included in reliance on the report of PricewaterhouseCoopers LLP, independent
accountants, given on the authority of said firm as experts in auditing and     
accounting.                                                                     

    The financial statements of SDK Healthcare Information Systems as of April
30, 1997 and 1996 and for each of the years in the two-year period ended April  
30, 1997 included in this Joint Proxy Statement/ Prospectus have been examined  
by KPMG Peat Marwick LLP, independent certified public accountants. Such        
financial statements have been included in the registration statement in        
reliance upon the reports with respect thereto of KPMG Peat Marwick LLP,        
appearing elsewhere herein, and upon the authority of said firm as experts in   
accounting and auditing.                                                        

FUTURE STOCKHOLDER PROPOSALS

     Stockholder proposals intended for inclusion in the proxy statement for the
next Eclipsys annual stockholders' meeting should be sent to the Secretary of   
Eclipsys at 777 East Atlantic Ave., Suite 200, Delray Beach, Florida 33483.     
Under the Eclipsys Bylaws, notice of any stockholder proposal to be made at an  
annual meeting of stockholders of Eclipsys must be received no less than 60 days
nor more than 90 days prior to the date of the annual meeting of stockholders of
Eclipsys. If public notice of the annual meeting of stockholders of Eclipsys is 
not given at least 70 days before the meeting date, any stockholder proposal    
must be received by Eclipsys within 10 days after such public notice. A copy of 
the current Bylaws may be obtained from the Secretary of Eclipsys. The          
provisions in the Bylaws relevant to the foregoing will be continued unchanged  
after the Merger.                                                               

  TSI expects to consummate the Merger prior to its annual meeting in 1999
and, accordingly, does not currently intend to call the 1999 annual meeting. If 
the Merger is not completed and TSI calls the 1999 annual meeting to be held on 
or before March 12, 1999, stockholders of TSI will not be entitled to include   
any proposals in TSI's proxy statement for that meeting. All such proposals were
required to have been submitted to the Clerk of TSI on or before September 8,   
1998. If TSI calls the 1999 annual meeting to be held after March 12, 1999, TSI 
stockholders must submit any proposals to be included in TSI's proxy statement  
to the Clerk of TSI a reasonable time before TSI begins to print its proxy      
materials.                                                                      
 118

S-4
127th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 127th

In addition, the TSI Bylaws provide that a TSI stockholder must give  
written notice to TSI not less than sixty days prior to the scheduled annual    
meeting describing any proposal to be brought before such meeting, even if the  
item is not to be included in TSI's proxy statement relating to such meeting.   
Such procedural requirements are fully set forth in Article III of the TSI      
Bylaws. To bring an item of business before the 1999 annual meeting, a          
stockholder must deliver the requisite notice of such item to the Clerk of TSI  
no later than Friday, December 11, 1998.                                        

WHERE YOU CAN FIND MORE INFORMATION 

  Eclipsys filed a Registration Statement on Form S-4 to register with the
Commission the Eclipsys Voting Common Stock to be issued to TSI stockholders in 
the Merger. This Joint Proxy Statement/ Prospectus is a part of that            
Registration Statement and constitutes a prospectus of Eclipsys in addition to a
proxy statement of Eclipsys and TSI for their respective Special Stockholders'  
Meetings. As allowed by Commission rules, this Joint Proxy Statement/Prospectus 
does not contain all the information you can find in the Registration Statement 
or the exhibits to the Registration Statement.                                  

Eclipsys and TSI file annual, quarterly and special reports, proxy    
statements and other information with the Commission. You may read and copy any 
reports, statements or other information we file at the Commission's public     
reference rooms in Washington, D.C., New York, New York and Chicago, Illinois.  
Please call the Commission at 1-800-SEC-0330 for further information on the     
public reference rooms. Our Commission filings are also available to the public 
from commercial document retrieval services and at the web site maintained by   
the Commission at http://www.sec.gov.                                           

FORWARD-LOOKING STATEMENTS

This Joint Proxy Statement/Prospectus includes various statements     
concerning possible future events or circumstances for Eclipsys, TSI or the     
combined company that are subject to risks and uncertainties that could cause   
actual results or events to differ significantly from the results or events     
stated in this Joint Proxy Statement/Prospectus, such as those set forth under  
the caption "Risk Factors". These forward-looking statements include information
and projections concerning future results of, operations of Eclipsys, TSI and   
the combined company, and statements elsewhere in this document using words such
as "believes," "expects," "anticipates," "plans," "intends" or similar          
expressions.                                                                    

 119

S-4
128th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 128th

WHERE TO FIND CERTAIN DEFINED TERMS 

                                                                [Download Table]

                            TERM                              PAGE
                            ----                              ----
                                                                  
AIS.........................................................    22
AIS Settlement..............................................    60
Alltel......................................................    17
Alltel Acquisition..........................................    18
Alltel Renegotiation........................................    30
Antitrust Division..........................................    58
Brigham.....................................................    11
BT Alex. Brown..............................................    43
Code........................................................    57
Commission..................................................    39
Delaware Law................................................   112
EBIT........................................................    53
EBITDA......................................................    18
EPS.........................................................    54
Eclipsys....................................................     1
Eclipsys Acquisitions.......................................    22
Eclipsys Board..............................................    39
Eclipsys Bylaws.............................................   112
Eclipsys Charter............................................   110
Eclipsys Covenant Condition.................................    76
Eclipsys IPO................................................    30
Eclipsys Non-Voting Common Stock............................     7
Eclipsys Preferred Stock....................................   110
Eclipsys Purchase Plan......................................    96
Eclipsys Representation Bringdown Condition.................    76
Eclipsys Termination Fee....................................    78
Eclipsys Voting Common Stock................................     7
Eclipsys Voting Proposal....................................    39
Eclipsys Warrants...........................................   110
Effective Time..............................................    71
Emtek.......................................................    18
Emtek Acquisition...........................................    18
Exchange Act................................................   112
Exchange Agent..............................................    71
Exchange Ratio..............................................     7
FDA.........................................................    12
FDC Act.....................................................    12
Foley Hoag..................................................    44
FTC.........................................................    58
GAAP........................................................    18
GAP 28......................................................    97
GAP 38......................................................    97
GAP 47......................................................    97
GAP 48......................................................    97
GAP Coinvestment............................................    97
General Atlantic............................................    43
Hale and Dorr...............................................    43
HealthVISION................................................     1
HealthVISION Acquisition....................................    45
HIPAA.......................................................    13
HSR Act.....................................................    58
Incentive Plan..............................................    96

 120

S-4
129th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 129th

                                                                [Download Table]

                            TERM                              PAGE
                            ----                              ----
                                                                  
IRS.........................................................    57
Massachusetts Law...........................................   112
Material Adverse Change.....................................    76
Merger......................................................     7
Merger Agreement............................................     7
MGH.........................................................    11
Morgan Stanley..............................................    44
Morgan Stanley Opinion......................................    48
Motorola....................................................    22
MSA.........................................................    18
MSA Buyout..................................................    18
1996 Stock Plan.............................................    95
1998 Preferred Stock Issuance...............................    60
Named Executive Officers....................................    93
Outside Date................................................    77
Partners....................................................    11
Partners License............................................    22
Record Date.................................................    39
Registrable Shares..........................................   111
Registration Rights Agreement...............................   111
Registration Statement......................................    65
Reorganization..............................................    57
Revolver....................................................    30
Rightsholder................................................   111
Securities Act..............................................    59
SDK.........................................................    18
SDK Acquisition.............................................    18
SDK Notes...................................................    22
SDK Partial Repayment.......................................    60
Simione.....................................................    23
Simione Investment..........................................    23
SMS.........................................................    11
Stockholders Agreement......................................    93
Sub.........................................................     7
Surviving Corporation.......................................     7
Tax Opinions................................................    58
Term Loan...................................................    30
TSI.........................................................     1
TSI Board...................................................    41
TSI Bylaws..................................................   112
TSI Charter.................................................   112
TSI Covenant Condition......................................    76
TSI Non-Voting Common Stock.................................     7
TSI Preferred Stock.........................................   113
TSI Representation Bringdown Condition......................    76
TSI Stock Option............................................    74
TSI Stock Purchase Plan.....................................    75
TSI Termination Fee.........................................    78
TSI Voting Common Stock.....................................     7
TSI Warrant.................................................    74
U.S. GAAP...................................................    18
Warburg.....................................................    43
Wilfam......................................................    97

 121

S-4
130th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 130th

INDEX TO FINANCIAL STATEMENTS 

                                                                [Download Table]

                                                              PAGE
                                                              ----
                                                                  
Eclipsys Corporation........................................   F-2
  Report of Independent Accountants.........................   F-2
  Consolidated Balance Sheets as of December 31, 1996 and         
     1997, and September 30, 1998 (unaudited)...............   F-3
  Consolidated Statements of Operations for the years ended       
     December 31, 1996 and 1997 and the nine months ended         
     September 30, 1997 and 1998 (unaudited)................   F-4
  Consolidated Statements of Shareholders' Equity (Deficit)       
     for the years ended December 31, 1996 and 1997 and the       
     nine months ended September 30, 1998 (unaudited).......   F-5
  Consolidated Statements of Cash Flows for the years ended       
     December 31, 1996 and 1997 and the nine months ended         
     September 30, 1997 and 1998 (unaudited)................   F-6
  Notes to Consolidated Financial Statements................   F-7
ALLTEL Healthcare Information Services, Inc.................  F-25
  Report of Independent Accountants.........................  F-25
  Consolidated Balance Sheets as of December 31, 1995 and         
     1996...................................................  F-26
  Consolidated Statements of Operations for the years ended       
     December 31, 1995 and 1996 and for the period from           
     January 1, 1997 through January 23, 1997...............  F-27
  Consolidated Statements of Shareholder's Deficit for the        
     years ended December 31, 1995 and 1996 and for the           
     period from January 1, 1997 through January 23, 1997...  F-28
  Consolidated Statements of Cash Flows for the years ended       
     December 31, 1995 and 1996 and for the period from           
     January 1, 1997 through January 23, 1997...............  F-29
  Notes to Consolidated Financial Statements................  F-30
SDK Healthcare Information Systems..........................  F-37
  Independent Auditors' Report..............................  F-37
  Balance Sheets as of April 30, 1997 and 1996..............  F-38
  Statements of Operations and Retained Earnings for the          
     years ended April 30, 1997 and 1996....................  F-39
  Statements of Cash Flows for the years ended April 30,          
     1997 and 1996..........................................  F-40
  Notes to Financial Statements.............................  F-41
Transition Systems, Inc.....................................  F-47
  Report of Independent Accountants.........................  F-47
  Consolidated Balance Sheets as of September 30, 1997 and        
     1998, and June 30, 1998 (unaudited)....................  F-48
  Consolidated Statements of Operations for the years ended       
     September 30, 1996, 1997 and 1998 and the nine months        
     ended June 30, 1997 and 1998 (unaudited)...............  F-49
  Consolidated Statements of Cash Flows for the years ended       
     September 30, 1996, 1997 and 1998 and the nine months        
     ended June 30, 1997 and 1998 (unaudited)...............  F-50
  Consolidated Statements of Stockholders' Equity for the         
     years ended September 30, 1996, 1997 and 1998..........  F-51
  Notes to Consolidated Financial Statements................  F-52
HealthVISION, Inc. .........................................  F-63
  Report of Independent Auditors............................  F-63
  Consolidated Balance Sheets as of December 31, 1996 and         
     1997...................................................  F-64
  Consolidated Statements of Operations for the years ended       
     December 31, 1996 and 1997.............................  F-65
  Consolidated Statements of Changes in Stockholders' Equity      
     (Deficit) for the years ended December 31, 1996 and          
     1997...................................................  F-66
  Consolidated Statement of Cash Flows for the years ended        
     December 31, 1996 and 1997.............................  F-67
  Notes to Consolidated Financial Statements................  F-68
  Condensed Consolidated Balance Sheet as of September 30,        
     1998 (unaudited).......................................  F-77
  Condensed Consolidated Statements of Operations for the         
     nine months ended September 30, 1997 and 1998                
     (unaudited)............................................  F-78
  Condensed Consolidated Statement of Changes in                  
     Stockholders' Equity (Deficit) for the nine months           
     ended September 30, 1998 (unaudited)...................  F-79
  Condensed Consolidated Statements of Cash Flows for the         
     nine months ended September 30, 1997 and 1998                
     (unaudited)............................................  F-80
  Notes to the Condensed Consolidated Financial                   
     Statements.............................................  F-81

 F-1

S-4
131st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 131st

REPORT OF INDEPENDENT ACCOUNTANTS 

To the Board of Directors                                                       
and Shareholders of Eclipsys Corporation                                        

In our opinion, the accompanying consolidated balance sheets and the  
related consolidated statements of operations, of changes in shareholders'      
equity (deficit) and of cash flows present fairly, in all material respects, the
financial position of Eclipsys Corporation and its subsidiaries at December 31, 
1996 and 1997, and the results of their operations and their cash flows for the 
years then ended in conformity with generally accepted accounting principles.   
These financial statements are the responsibility of the Company's management;  
our responsibility is to express an opinion on these financial statements based 
on our audits. We conducted our audits of these statements in accordance with   
generally accepted auditing standards which require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are 
free of material misstatement. An audit includes examining, on a test basis,    
evidence supporting the amounts and disclosures in the financial statements,    
assessing the accounting principles used and significant estimates made by      
management, and evaluating the overall financial statement presentation. We     
believe that our audits provide a reasonable basis for the opinion expressed    
above.                                                                          

                                                      PRICEWATERHOUSECOOPERS LLP

Atlanta, Georgia                                                                
April 20, 1998, except as to Note 13,                                           
which is as of June 9, 1998                                                 

 F-2

S-4
132nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 132nd

ECLIPSYS CORPORATION
CONSOLIDATED BALANCE SHEETS 
(IN THOUSANDS, EXCEPT SHARE DATA) 

                                                        [Enlarge/Download Table]

                                                                 DECEMBER 31,                     
                                                              -------------------   SEPTEMBER 30, 
                                                               1996       1997           1998     
                                                              -------   ---------   --------------
                                                                                     (UNAUDITED)  
                                                                                                  
                                              ASSETS                                              
Current assets:                                                                                   
  Cash and cash equivalents.................................  $ 4,589   $   4,786     $  12,309   
  Accounts receivable, net of allowance for doubtful                                              
    accounts of $0, $1,739, $2,088..........................      190      30,969        40,443   
  Inventory.................................................       --         866           539   
  Other current assets......................................       59       1,114         9,757   
                                                              -------   ---------     ---------   
    Total current assets....................................    4,838      37,735        63,048   
Property and equipment, net.................................      322       9,517        10,530   
Capitalized software development costs......................       --       1,591         4,277   
Acquired technology, net....................................       --      25,802        18,798   
Intangible assets, net......................................       --      28,288        15,559   
Other assets................................................      580       3,832         9,479   
                                                              -------   ---------     ---------   
    Total assets............................................  $ 5,740   $ 106,765     $ 121,691   
                                                              =======   =========     =========   
                 LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)                                   
Current liabilities:                                                                              
  Current maturities of long-term debt......................  $    --   $  12,794            --   
  Deferred revenue..........................................       --      25,295     $  39,211   
  Other current liabilities.................................      882      31,150        32,411   
                                                              -------   ---------     ---------   
    Total current liabilities...............................      882      69,239        71,622   
Deferred revenue............................................                6,966         7,789   
Other long-term liabilities.................................       57       9,480         3,713   
Long-term debt..............................................       --       3,794            --   
                                                              -------   ---------     ---------   
    Total liabilities.......................................      939      89,479        83,124   
                                                              -------   ---------     ---------   
Mandatorily redeemable preferred stock (Note 5).............       --      35,607            --   
                                                              -------   ---------     ---------   
Commitments and contingencies (Note 11)                                                           
Shareholders' equity (deficit)                                                                    
  Preferred stock:..........................................                                      
    Series A, $.01 par value, 1,000,000 shares authorized,                                        
     issued and outstanding 1,000,000, $6 per share                                               
     liquidation preference, 1996; no shares authorized,                                          
     issued or outstanding, 1997 and 1998...................       10          --            --   
    Series D, $.01 par value, 7,200,000 shares authorized,                                        
     issued and outstanding 7,058,786, $12.55 per share                                           
     liquidation preference, 1997; no shares authorized,                                          
     issued or outstanding, 1996 and 1998...................       --          71            --   
    Series E, $.01 par value, 920,000 shares authorized,                                          
     issued and outstanding 896,431, $12.55 per share                                             
     liquidation preference, 1997; no shares authorized,                                          
     issued or outstanding, 1996 and 1998...................       --           9            --   
    Series F, $.01 par value, 1,530,000 shares authorized,                                        
     issued and outstanding 1,478,097, $6 per share                                               
     liquidation preference, 1997; no shares authorized,                                          
     issued or outstanding, 1996 and 1998...................       --          15            --   
  Common stock:                                                                                   
    Voting, $.01 par value, 30,000,000 and 50,000,000                                             
     authorized; issued and outstanding 3,626,662, 4,198,730                                      
     and 19,418,685.........................................       36          42           193   
    Non-Voting, $.01 par value, 3,000,000 shares authorized;                                      
     issued and outstanding 0, 0 and 896,431................       --          --             9   
  Additional paid-in capital................................    7,974     115,777       189,341   
  Unearned compensation.....................................     (266)       (250)         (196)  
  Accumulated deficit.......................................   (2,953)   (134,013)     (150,841)  
  Accumulated other comprehensive income....................       --          28            61   
                                                              -------   ---------     ---------   
    Total shareholders' equity (deficit)....................    4,801     (18,321)       38,567   
                                                              -------   ---------     ---------   
    Total liabilities and shareholders' equity (deficit)....  $ 5,740   $ 106,765     $ 121,691   
                                                              =======   =========     =========   

The accompanying notes are an integral part of these consolidated financial 
statements. 

 F-3

S-4
133rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 133rd

ECLIPSYS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS 
(IN THOUSANDS, EXCEPT SHARE DATA) 

                                                        [Enlarge/Download Table]

                                                       YEAR ENDED           NINE MONTHS ENDED    
                                                      DECEMBER 31,            SEPTEMBER 30,      
                                                 ----------------------   ---------------------- 
                                                   1996         1997         1997        1998    
                                                 ---------   ----------   ----------   --------- 
                                                                               (UNAUDITED)       
                                                                                                 
Revenues:                                                                                        
  Systems and services.......................... $      --   $   89,722   $   64,470   $  88,541 
  Hardware......................................        --        4,355        3,009       9,202 
                                                 ---------   ----------   ----------   --------- 
     Total revenues.............................        --       94,077       67,479      97,743 
                                                 ---------   ----------   ----------   --------- 
Costs and expenses:                                                                              
  Cost of systems and services revenues.........        --       77,083       56,168      53,196 
  Cost of hardware revenues.....................        --        2,953        2,055       7,825 
  Marketing and sales...........................       770       13,662        9,881      13,945 
  Research and development......................     1,704       15,714       11,991      19,267 
  General and administrative....................       603        5,672        4,143       4,580 
  Depreciation and amortization.................        32        9,710        7,292       7,937 
  Write-off of in-process research and                                                           
     development (Note 6).......................        --       99,189       99,189          -- 
  Write-off of MSA..............................        --           --           --       7,193 
                                                 ---------   ----------   ----------   --------- 
     Total costs and expenses...................     3,109      223,983      190,719     113,943 
                                                 ---------   ----------   ----------   --------- 
Loss from operations............................    (3,109)    (129,906)    (123,240)    (16,200)
Interest (income) expense, net..................      (156)       1,154          727         628 
                                                 ---------   ----------   ----------   --------- 
Net loss........................................    (2,953)    (131,060)    (123,967)    (16,828)
Dividends and accretion on mandatorily                                                           
  redeemable preferred stock....................        --       (5,850)      (4,199)    (10,928)
Preferred stock conversion......................        --       (3,105)      (3,105)         -- 
                                                 ---------   ----------   ----------   --------- 
Net loss available to common shareholders....... $  (2,953)  $ (140,015)  $ (131,271)  $ (27,756)
                                                 =========   ==========   ==========   ========= 
Basic and diluted net loss per common share..... $    (.98)  $   (39.73)  $   (38.28)  $   (3.41)
                                                 =========   ==========   ==========   ========= 
Weighted average common shares outstanding...... 3,022,660    3,524,313    3,429,385   8,133,275 
                                                 =========   ==========   ==========   ========= 

The accompanying notes are an integral part of these consolidated financial 
statements. 

 F-4

S-4
134th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 134th

ECLIPSYS CORPORATION
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) 
(IN THOUSANDS, EXCEPT SHARE DATA) 

                                                        [Enlarge/Download Table]

                                                                                        PREFERRED STOCK                        
                                                                ---------------------------------------------------------------
                                             COMMON STOCK             SERIES A               SERIES D             SERIES E     
                                          -------------------   ---------------------   -------------------   -----------------
                                            SHARES     AMOUNT     SHARES      AMOUNT      SHARES     AMOUNT    SHARES    AMOUNT
                                          ----------   ------   ----------   --------   ----------   ------   --------   ------
                                                                                                                               
 Capital contribution at December 22,                                                                                          
   1995                                                                                                                        
   (inception date)......................    520,000    $  5                                                                   
                                          ----------    ----    ----------   --------   ----------    ----    --------    ---  
Balance at December 31, 1995.............    520,000       5                                                                   
 Capital contribution....................  2,008,373      20                                                                   
 Stock grants............................    109,999       1                                                                   
 Issuance of Series A Preferred stock....                        1,000,000   $     10                                          
 Issuance of common stock................    988,290      10                                                                   
 Issuance of stock options...............                                                                                      
 Compensation expense recognized.........                                                                                      
 Net loss................................                                                                                      
                                          ----------    ----    ----------   --------   ----------    ----    --------    ---  
Balance at December 31, 1996.............  3,626,662      36     1,000,000         10                                          
 Issuance of Series D Preferred stock....                                                4,981,289    $ 50                     
 Acquisition of Alltel...................                                                2,077,497      21                     
 Issuance of Series E Preferred stock....                                                                      896,431    $ 9  
 Issuance of common stock warrants.......                                                                                      
 Exchange of Series A for Series F.......                       (1,000,000)       (10)                                         
 Acquisition of SDK......................    499,997       5                                                                   
 Stock option exercises..................     57,071       1                                                                   
 Stock grants............................     15,000                                                                           
 Dividends and accretion on mandatorily                                                                                        
   redeemable preferred stock............                                                                                      
 Issuance of stock options...............                                                                                      
 Compensation expense recognized.........                                                                                      
 Comprehensive income:                                                                                                         
   Net loss..............................                                                                                      
   Foreign currency translation                                                                                                
    adjustment...........................                                                                                      
   Other comprehensive income............                                                                                      
 Comprehensive income....................                                                                                      
                                          ----------    ----    ----------   --------   ----------    ----    --------    ---  
Balance at December 31, 1997.............  4,198,730      42            --         --    7,058,786      71     896,431      9  
                                          ----------    ----    ----------   --------   ----------    ----    --------    ---  
 EMTEK Acquisition.......................  1,000,000      10                                                                   
 Sale of common stock....................  4,830,000      48                                                                   
 Conversion of preferred stock........... 10,033,313     100                            (7,058,786)    (71)   (896,431)    (9) 
 Issuance of Series G Preferred Stock....                                                                                      
 Stock option exercises..................    253,073       2                                                                   
 Dividends, accretion and redemption                                                                                           
   related to mandatorily redeemable                                                                                           
   preferred stock ......................                                                                                      
 Compensation expense recognized.........                                                                                      
 Comprehensive income:                                                                                                         
 Net loss................................                                                                                      
 Foreign currency translation                                                                                                  
   adjustment............................                                                                                      
 Other comprehensive income..............                                                                                      
 Comprehensive income....................                                                                                      
                                          ----------    ----    ----------   --------   ----------    ----    --------    ---  
BALANCE AT SEPTEMBER 30, 1998                                                                                                  
 (UNAUDITED)............................. 20,315,116    $202            --   $     --           --    $ --          --    $--  
                                          ==========    ====    ==========   ========   ==========    ====    ========    ===  


                                                      PREFERRED STOCK                                                          
                                          ---------------------------------------                                              
                                               SERIES F             SERIES G        ADDITIONAL                                 
                                          -------------------   -----------------    PAID-IN       UNEARNED     ACCUMULATED    
                                            SHARES     AMOUNT    SHARES    AMOUNT    CAPITAL     COMPENSATION     DEFICIT      
                                          ----------   ------   --------   ------   ----------   ------------   -----------    
                                                                                                                               
 Capital contribution at December 22,                                                                                          
   1995                                                                                                                        
   (inception date)......................                                            $     45                                  
                                          ----------    ----    --------    ---      --------       -----        ---------     
Balance at December 31, 1995.............                                                  45                                  
 Capital contribution....................                                                 178                                  
 Stock grants............................                                                                                      
 Issuance of Series A Preferred stock....                                               5,991                                  
 Issuance of common stock................                                               1,472                                  
 Issuance of stock options...............                                                 288       $(288)                     
 Compensation expense recognized.........                                                              22                      
 Net loss................................                                                                        $  (2,953)    
                                          ----------    ----    --------    ---      --------       -----        ---------     
Balance at December 31, 1996.............                                               7,974        (266)          (2,953)    
 Issuance of Series D Preferred stock....                                              62,464                                  
 Acquisition of Alltel...................                                              26,051                                  
 Issuance of Series E Preferred stock....                                              11,241                                  
 Issuance of common stock warrants.......                                              10,501                                  
 Exchange of Series A for Series F.......  1,478,097    $ 15                               (5)                                 
 Acquisition of SDK......................                                               3,243                                  
 Stock option exercises..................                                                   6                                  
 Stock grants............................                                                  97                                  
 Dividends and accretion on mandatorily                                                                                        
   redeemable preferred stock............                                              (5,850)                                 
 Issuance of stock options...............                                                  55         (55)                     
 Compensation expense recognized.........                                                              71                      
 Comprehensive income:                                                                                                         
   Net loss..............................                                                                         (131,060)    
   Foreign currency translation                                                                                                
    adjustment...........................                                                                                      
   Other comprehensive income............                                                                                      
 Comprehensive income....................                                                                                      
                                          ----------    ----    --------    ---      --------       -----        ---------     
Balance at December 31, 1997.............  1,478,097      15                          115,777        (250)        (134,013)    
                                          ----------    ----    --------    ---      --------       -----        ---------     
 EMTEK Acquisition.......................                                               9,050                                  
 Sale of common stock....................                                              65,897                                  
 Conversion of preferred stock........... (1,478,097)    (15)   (900,000)   $(9)            4                                  
 Issuance of Series G Preferred Stock....                        900,000      9         8,991                                  
 Stock option exercises..................                                                 550                                  
 Dividends, accretion and redemption                                                                                           
   related to mandatorily redeemable                                                                                           
   preferred stock ......................                                             (10,928)                                 
 Compensation expense recognized.........                                                              54                      
 Comprehensive income:                                                                                                         
 Net loss................................                                                                          (16,828)    
 Foreign currency translation                                                                                                  
   adjustment............................                                                                                      
 Other comprehensive income..............                                                                                      
 Comprehensive income....................                                                                                      
                                          ----------    ----    --------    ---      --------       -----        ---------     
BALANCE AT SEPTEMBER 30, 1998                                                                                                  
 (UNAUDITED).............................         --    $ --          --    $--      $189,341        (196)       $(150,841)    
                                          ==========    ====    ========    ===      ========       =====        =========     



                                                           ACCUMULATED                                                         
                                                              OTHER                                                            
                                          COMPREHENSIVE   COMPREHENSIVE                                                        
                                             INCOME          INCOME         TOTAL                                              
                                          -------------   -------------   ---------                                            
                                                                                                                               
 Capital contribution at December 22,                                                                                          
   1995                                                                                                                        
   (inception date)......................                                 $      50                                            
                                                               ---        ---------                                            
Balance at December 31, 1995.............                                        50                                            
 Capital contribution....................                                       198                                            
 Stock grants............................                                         1                                            
 Issuance of Series A Preferred stock....                                     6,001                                            
 Issuance of common stock................                                     1,482                                            
 Issuance of stock options...............                                        --                                            
 Compensation expense recognized.........                                        22                                            
 Net loss................................                                    (2,953)                                           
                                                               ---        ---------                                            
Balance at December 31, 1996.............                                     4,801                                            
 Issuance of Series D Preferred stock....                                    62,514                                            
 Acquisition of Alltel...................                                    26,072                                            
 Issuance of Series E Preferred stock....                                    11,250                                            
 Issuance of common stock warrants.......                                    10,501                                            
 Exchange of Series A for Series F.......                                        --                                            
 Acquisition of SDK......................                                     3,248                                            
 Stock option exercises..................                                         7                                            
 Stock grants............................                                        97                                            
 Dividends and accretion on mandatorily                                                                                        
   redeemable preferred stock............                                    (5,850)                                           
 Issuance of stock options...............                                        --                                            
 Compensation expense recognized.........                                        71                                            
 Comprehensive income:                                                                                                         
   Net loss..............................   $(131,060)                     (131,060)                                           
   Foreign currency translation                                                                                                
    adjustment...........................          28          $28               28                                            
                                            ---------                                                                          
   Other comprehensive income............          28                                                                          
                                            ---------                                                                          
 Comprehensive income....................    (131,032)                                                                         
                                            ---------          ---        ---------                                            
Balance at December 31, 1997.............                       28          (18,321)                                           
                                                               ---        ---------                                            
 EMTEK Acquisition.......................                                     9,060                                            
 Sale of common stock....................                                    65,945                                            
 Conversion of preferred stock...........                                        --                                            
 Issuance of Series G Preferred Stock....                                     9,000                                            
 Stock option exercises..................                                       552                                            
 Dividends, accretion and redemption                                                                                           
   related to mandatorily redeemable                                                                                           
   preferred stock ......................                                   (10,928)                                           
 Compensation expense recognized.........                                        54                                            
 Comprehensive income:                                                                                                         
 Net loss................................     (16,828)                      (16,828)                                           
 Foreign currency translation                                                                                                  
   adjustment............................          33           33               33                                            
                                            ---------                                                                          
 Other comprehensive income..............          33                                                                          
                                            ---------                                                                          
 Comprehensive income....................     (16,795)                                                                         
                                            ---------          ---        ---------                                            
BALANCE AT SEPTEMBER 30, 1998                                                                                                  
 (UNAUDITED).............................   $      --          $61        $  38,567                                            
                                            =========          ===        =========                                            

The accompanying notes are an integral part of these consolidated financial 
statements. 

 F-5

S-4
135th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 135th

ECLIPSYS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS 
(IN THOUSANDS)

                                                        [Enlarge/Download Table]

                                                        YEAR ENDED         NINE MONTHS ENDED   
                                                       DECEMBER 31,          SEPTEMBER 30,     
                                                    -------------------   -------------------- 
                                                     1996       1997        1997        1998   
                                                    -------   ---------   ---------   -------- 
                                                                              (UNAUDITED)      
                                                                                               
Operating activities:                                                                          
  Net loss......................................... $(2,953)  $(131,060)  $(123,967)  $(16,828)
                                                    -------   ---------   ---------   -------- 
  Adjustments to reconcile net loss to net cash                                                
     provided (used) by operating activities:                                                  
     Depreciation and amortization.................      32      31,622      23,156     20,155 
     Provision for bad debts.......................      --         600         450        750 
     Loss on disposal of property and equipment....      --         557         570          8 
     Write off of in-process research and                                                      
       development.................................      --      99,189      99,189         -- 
     Write-off of MSA intangible asset.............      --          --          --      7,193 
     Write-off of contributed technology...........   1,482          --          --         -- 
     Stock compensation expense....................      22         168         151         54 
     Changes in operating assets and liabilities,                                              
       net of acquisitions:                                                                    
       Accounts receivable.........................    (190)       (816)       (505)    (5,295)
       Inventory...................................      --         655         137        327 
       Other current assets........................     (59)       (276)       (475)     1,025 
       Other assets................................     (34)        (71)        681        (81)
       Deferred revenue............................      --      (2,044)     (1,772)     9,689 
       Other current liabilities...................     882       2,196       3,986     (1,756)
       Other long-term liabilities.................      57         348       1,691        (65)
                                                    -------   ---------   ---------   -------- 
          Total adjustments........................   2,192     132,128     127,259     32,004 
                                                    -------   ---------   ---------   -------- 
     Net cash provided (used) by operating                                                     
       activities..................................    (761)      1,068       3,292     15,176 
                                                    -------   ---------   ---------   -------- 
Investing activities:                                                                          
  Purchase of property and equipment, net of                                                   
     acquisitions..................................    (354)     (3,096)     (2,097)    (3,573)
  Capitalized software development costs...........      --      (1,591)       (698)    (2,686)
  Acquisitions, net of cash acquired...............      --    (108,983)   (108,983)        -- 
  Changes in other assets..........................    (546)         --          --    (21,565)
                                                    -------   ---------   ---------   -------- 
     Net cash used in investing activities.........    (900)   (113,670)   (111,778)   (27,824)
                                                    -------   ---------   ---------   -------- 
Financing activities:                                                                          
  Borrowings.......................................      --      10,000      10,000     18,500 
  Payments on borrowings...........................      --      (1,000)         --    (35,088)
  Exercise of stock options........................     199           7          --        453 
  Sale of common stock.............................      --          --          --     66,044 
  Sale of convertible preferred stock..............   6,001      73,764      73,764      9,000 
  Sale/(redemption) of mandatorily redeemable                                                  
     preferred stock...............................      --      30,000      30,000    (38,771)
                                                    -------   ---------   ---------   -------- 
     Net cash provided by financing activities.....   6,200     112,771     113,764     20,138 
                                                    -------   ---------   ---------   -------- 
Effect of exchange rate changes on cash and cash                                               
  equivalents......................................      --          28          21         33 
                                                    -------   ---------   ---------   -------- 
     Net increase in cash and cash equivalents.....   4,539         197       5,299      7,523 
Cash and cash equivalents, beginning of year.......      50       4,589       4,589      4,786 
                                                    -------   ---------   ---------   -------- 
Cash and cash equivalents, end of year............. $ 4,589   $   4,786   $   9,888   $ 12,309 
                                                    =======   =========   =========   ======== 
Cash paid for interest............................. $    --   $     978   $     493   $  1,275 
                                                    =======   =========   =========   ======== 
Cash paid for income taxes......................... $    --   $      --   $      --   $     -- 
                                                    =======   =========   =========   ======== 

The accompanying notes are an integral part of these consolidated financial 
statements. 

 F-6

S-4
136th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 136th

ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS                                     

   Eclipsys Corporation ("Eclipsys") and its subsidiaries (collectively, the
"Company") is a healthcare information technology solutions provider which was  
formed in December 1995 and commenced operations in January 1996. The Company   
provides, on an integrated basis, enterprise-wide, clinical patient care and    
financial software solutions to healthcare organizations. Additionally, Eclipsys
provides other information technology solutions including outsourcing, remote   
processing, networking technologies and other related services.                 

Subsequent to December 31, 1996, the Company made the following       
acquisitions (Note 6):                                                          

        Effective January 24, 1997, ALLTEL Healthcare Information Services, Inc.
     ("Alltel"), a wholly-owned subsidiary of ALLTEL Information Services,
Inc. ("AIS")                                                    

   Effective June 26, 1997, SDK Healthcare Information Systems ("SDK")

      Effective January 30, 1998, the Company acquired the net assets of the
       North American operations of the Emtek Healthcare Division of Motorola,
Inc. ("Emtek").                                                 

     These acquisitions have been accounted for as purchases and accordingly the
accompanying financial statements reflect the results of operations of these    
businesses from the date acquired.                                              

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                                   

PRINCIPLES OF CONSOLIDATION                                                     

The financial statements include the accounts of Eclipsys and its     
wholly-owned subsidiaries. All significant intercompany transactions have been  
eliminated in consolidation.                                                    

FINANCIAL STATEMENT PRESENTATION                                                

     The preparation of the consolidated financial statements in conformity with
generally accepted accounting principles requires management to make estimates  
and assumptions that affect the reported amounts of assets, liabilities,        
revenues and expenses and disclosures of contingent assets and liabilities. The 
estimates and assumptions used in the accompanying consolidated financial       
statements are based upon management's evaluation of the relevant facts and     
circumstances as of the date of the financial statements. Actual results could  
differ from those estimates.                                                    

CASH AND CASH EQUIVALENTS                                                       

For purposes of the consolidated statement of cash flows, the Company 
considers all highly liquid investments with an original maturity of three      
months or less to be cash equivalents.                                          

REVENUE RECOGNITION                                                             

     The Company's products are sold to customers based on long-term contractual
agreements. Revenues are derived from the licensing of computer software,       
software and hardware maintenance, remote processing and outsourcing, training, 
implementation assistance, consulting, and the sale of computer hardware.       

SYSTEMS AND SERVICES                                                  

For contracts in which the Company is required to make significant    
production, modification, or customization changes, revenues from software      
license fees are recognized using the percentage-of-                            

 F-7

S-4
137th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 137th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                       
completion method over the implementation period of the contracts based on      
implementation hours incurred. Other software license fees are generally        
recognized on a straight-line basis over the term of the licensing and          
maintenance agreements, which range from five to seven years. Remote processing 
and outsourcing services are marketed under long-term agreements generally over 
periods from five to seven years and revenues are recognized monthly as the work
is performed. Software maintenance fees are marketed under annual and multi-year
agreements and are recognized ratably over the term of the agreements.          
Implementation revenues are recognized as the services are performed or on a    
percentage-of-completion basis for fixed fee arrangements. Hardware maintenance 
revenues are billed and recognized monthly over the term of agreements. Revenues
related to other support services, such as training, consulting, and            
implementation, are recognized when the services are performed.                 

The Company warrants its products will perform in accordance with     
specifications as outlined in the respective customer contracts. The Company    
records a reserve for warranty costs at the time it recognizes revenue.         
Historically, warranty costs have been minimal.                                 

    The Company accrues for product returns at the time it recognizes revenue,
based on actual experience. Historically, product return costs have been        
minimal.                                                                        

HARDWARE SALES                                                                  

     Hardware sales are recognized upon shipment of the product to the customer.

UNBILLED ACCOUNTS RECEIVABLE                                                    

  Unbilled accounts receivable represent amounts owed to the Company under
noncancelable agreements for software license fees with extended payment terms  
and computer hardware purchases which have been financed over extended payment  
terms. The current portion of unbilled accounts receivable of $3.9 million as of
December 31, 1997 is included in accounts receivable in the accompanying        
financial statements. The non-current portion of unbilled accounts receivable of
$1.8 million as of December 31, 1997 is included in other assets in the         
accompanying financial statements. The non-current portion of unbilled accounts 
receivable provides for payment terms that generally range from three to five   
years and carry annual interest rates ranging from 7% to 10%. The Company       
recognizes revenue in advance of billings under certain of its non-cancelable   
long-term contracts that contain extended payment terms. The Company does not   
have any obligation to refund any portion of its fees and has a history of      
enforcement and collection of amounts due under such arrangements. Payments owed
under contracts with extended payment terms are due in accordance with the terms
of the respective contract. Historically, the Company has had minimal write-offs
of amounts due under such arrangements.                                         

Additionally, included in unbilled accounts receivable are costs and  
earnings in excess of billings related to certain software license fee          
arrangements which are being recognized on a percentage-of-completion basis.    
These amounts totaled approximately $1.0 million as of December 31, 1997.       

INVENTORY                                                                       

   Inventory consists of computer parts and peripherals and is stated at the
lower of cost or market. Cost is determined using the first-in, first-out       
method.                                                                         

PROPERTY AND EQUIPMENT                                                          

  Property and equipment are stated at cost. Depreciation and amortization
are provided using the straight-line method over the estimated useful lives,    
which range from two to ten years. Computer                                     

 F-8

S-4
138th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 138th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                       
equipment is depreciated over two to five years. Office equipment is depreciated
over two to ten years. Purchased software for internal use is amortized over    
three to five years. Leasehold improvements are amortized over the shorter of   
the useful lives of the assets or the remaining term of the lease. When assets  
are retired or otherwise disposed of, the related costs and accumulated         
depreciation are removed from the accounts and any resulting gain or loss is    
reflected in income. Expenditures for repairs and maintenance not considered to 
substantially lengthen the property and equipment lives are charged to expense  
as incurred.                                                                    

CAPITALIZED SOFTWARE DEVELOPMENT COSTS                                          

The Company capitalizes a portion of its internal computer software   
development costs incurred. Salaries, benefits, and other directly related costs
incurred in connection with programming and testing software products are       
capitalized subsequent to establishing technological feasibility. Capitalization
ceases when the products are generally released for sale to customers.          
Management monitors the net realizable value of all capitalized software        
development costs to ensure that the investment will be recovered through       
margins from future sales. These costs are amortized over the greater of the    
ratio that current revenues bear to total and anticipated future revenues for   
the applicable product or the straight line method over three to five years.    
Capitalized costs related to software development were approximately $1.6       
million for the year ended December 31, 1997.                                   

ACQUIRED TECHNOLOGY AND INTANGIBLE ASSETS                                       

  The intangible assets arose from the Company's acquisitions (Note 6) and
consist of the following as of December 31, 1997 (in thousands):                

                                                        [Enlarge/Download Table]

                                                     ACCUMULATED   NET BOOK     USEFUL   
                                             GROSS   AMORTIZATION   VALUE        LIFE    
                                            -------  ------------  --------  ------------
                                                                                         
Acquired Technology........................ $45,517    $19,715     $25,802    3 - 5 Years
Ongoing customer relationships.............  10,846      1,988       8,858        5 Years
Management and services agreement..........   9,543      2,197       7,346        4 Years
Goodwill...................................  13,550      1,466      12,084   5 - 12 Years
                                            -------    -------     -------               
                                            $79,456    $25,366     $54,090               
                                            =======    =======     =======               

The carrying value of the excess of cost over fair value of net assets
acquired is reviewed if the facts and circumstances suggest that it may be      
impaired. This review indicates if the assets will not be recoverable as        
determined based on future expected cash flows. Based on its review, the Company
does not believe that an impairment of its excess of cost over fair value of net
assets acquired has occurred.                                                   

FAIR VALUE OF FINANCIAL INSTRUMENTS                                             

     The carrying amounts of the Company's financial instruments, including cash
and cash equivalents, accounts receivable, and other current liabilities,       
approximate fair value. The recorded amount of long-term debt approximates fair 
value as the debt bears interest at a floating market rate.                     

INCOME TAXES                                                                    

   The Company accounts for income taxes utilizing the liability method, and
deferred income taxes are determined based on the estimated future tax effects  
of differences between the financial reporting and income tax basis of assets   
and liabilities and tax carryforwards given the provisions of the enacted tax   
laws.                                                                           

 F-9

S-4
139th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 139th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                       
STOCK-BASED COMPENSATION                                                        

    The Company has chosen to continue to account for stock-based compensation
using the intrinsic value method prescribed in Accounting Principles Board      
Opinion ("APB") No. 25, "Accounting for Stock Issued to Employees", and related 
Interpretations and to elect the disclosure option of Statement of Financial    
Accounting Standards ("FAS") No. 123, "Accounting for Stock-Based Compensation".
Accordingly, compensation cost for stock options is measured as the excess, if  
any, of the estimated market price of the Company's stock at the date of the    
grant over the amount an employee must pay to acquire the stock.                

BASIC AND DILUTED NET LOSS PER SHARE                                            

    For all periods presented, basic net loss per common share is presented in
accordance with FAS 128, "Earnings per Share", which provides for new accounting
principles used in the calculation of earnings per share and was effective for  
financial statements for both interim and annual periods ended after December   
15, 1997. Basic net loss per common share is based on the weighted average      
number of shares of common stock outstanding during the period. Stock options to
acquire 657,500 and 1,831,652 shares of common stock in 1996 and 1997,          
respectively, warrants to acquire up to 1,799,715 shares of common stock in     
1997, and convertible preferred stock (convertible into 1,000,000 and 9,433,314 
shares of common stock in 1996 and 1997, respectively) were the only securities 
issued which would have been included in the diluted earnings per share         
calculation had they not been antidilutive due to the net loss reported by the  
Company. The Company has excluded 370,609 contingently returnable shares of     
common stock from basic and diluted earnings per share computations (Notes 4 and
5).                                                                             

CONCENTRATION OF CREDIT RISK                                                    

   The Company's customers operate primarily in the healthcare industry. The
Company sells its products and services under contracts with varying terms. The 
accounts receivable amounts are unsecured. Management believes the allowance for
doubtful accounts is sufficient to cover credit losses.                         

FOREIGN CURRENCY TRANSLATION                                                    

  The financial position and results of operations of foreign subsidiaries
are measured using the currency of the respective countries as the functional   
currency. Assets and liabilities are translated at the foreign exchange rate in 
effect at the balance sheet date, while revenue and expenses for the year are   
translated at the average exchange rate in effect during the year. Translation  
gains and losses are not included in determining net income or loss but are     
accumulated and reported as a separate component of shareholders' equity        
(deficit). The Company has not entered into any hedging contracts during the two
year period ended December 31, 1997.                                            

COMPREHENSIVE INCOME                                                            

   Effective January 1, 1998, the Company implemented Statement of Financial
Accounting Standards No. 130 "Reporting Comprehensive Income." This standard    
requires that the total changes in equity resulting from revenue, expenses, and 
gains and losses, including those which do not affect the accumulated deficit,  
be reported. Accordingly, those amounts which are comprised solely of foreign   
currency translation adjustments, are included in other comprehensive income in 
the consolidated statement of shareholders' equity (deficit).                   

F-10

S-4
140th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 140th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                       
UNAUDITED INFORMATION                                                           

     The interim financial information as of September 30, 1998 and for the nine
months ended September 30, 1997 and 1998 is unaudited. However, in the opinion  
of management, such information has been prepared on the same basis as the      
audited financial statements and includes all adjustments, consisting solely of 
normal recurring adjustments, necessary for a fair presentation of the financial
position and results of operations for the periods presented. The interim       
results, however, are not necessarily indicative of results for any future      
period.                                                                         

NEW ACCOUNTING PRONOUNCEMENTS                                                   

In June 1997, the Financial Accounting Standards Board issued FAS 131,
"Disclosure about Segments of an Enterprise and Related Information". In October
1997, the American Institute of Certified Public Accountants issued Statement of
Position 97-2 ("SOP 97-2"), "Software Revenue Recognition". All these statements
are effective for fiscal years beginning after December 15, 1997, and are not   
expected to have a material impact on the Company's financial statements.       
Effective January 1, 1998, the Company adopted SOP 97-2.                        

3. PROPERTY AND EQUIPMENT                                                       

Property and equipment are summarized as follows (in thousands):      

                                                                [Download Table]

                                                               DECEMBER 31,  
                                                              -------------- 
                                                              1996    1997   
                                                              ----   ------- 
                                                                             
Computer equipment..........................................  $107   $ 8,467 
Office equipment and other..................................   199     1,834 
Purchased software..........................................    --     3,382 
Leasehold improvements......................................    48     2,122 
                                                              ----   ------- 
                                                               354    15,805 
Less: Accumulated depreciation and amortization.............   (32)   (6,288)
                                                              ----   ------- 
                                                              $322   $ 9,517 
                                                              ====   ======= 

  Depreciation of property and equipment totaled approximately $32,000 and
$6.3 million in 1996 and 1997, respectively.                                    

4. LICENSING ARRANGEMENT                                                        

  In May 1996, the Company entered into an exclusive licensing arrangement
with Partners HealthCare System, Inc. ("Partners") to further develop,          
commercialize, distribute and support certain intellectual property which was   
being developed at Partners. In consideration for the license, the Company      
issued 988,290 shares of Common Stock of the Company and agreed to pay royalties
to Partners on sales of the developed product until the Company completes an    
initial public offering of common stock with a per share offering price of      
$10.00 or higher. There was no revenue recognized by the Company or royalties   
paid to Partners under the arrangement in 1996 or 1997. Under the terms of the  
license, the Company may further develop, market, distribute and support the    
original technology and license it, as well as market related services, to other
healthcare providers and hospitals throughout the world (other than in the      
Boston, Massachusetts metropolitan area). The Company is obligated to offer to  
Partners and certain of their affiliates an internal use license, granted on    
most favored customer terms, to any new software applications developed by the  
Company, whether or not derived from the licensed technology, and major         

F-11

S-4
141st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 141st
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

4. LICENSING ARRANGEMENT (CONTINUED)                                            
architectural changes to the licensed software. After May 3, 1998, Partners and 
certain of their affiliates are entitled to receive internal use licenses for   
any changes to any modules or applications included in the licensed technology, 
as defined. The Company has an exclusive right of first offer to commercialize  
new information technologies developed in connection with Partners. If the      
Company fails to pay the required royalties, breaches any material term under   
the licensing arrangement or if the current Chairman of the Board, President and
Chief Executive Officer of the Company voluntarily terminates his employment    
with the Company prior to May 1999, the license may become non-exclusive, at the
option of Partners. If Partners elects to convert the license to non-exclusive, 
it must return 370,609 shares of Common Stock to the Company. The Company has   
the option to purchase the technology it licenses from Partners upon the        
completion of an IPO.                                                           

At the time the license arrangement was consummated, the licensed     
technology had not reached technological feasibility and had no alternative     
future use. The licensed technology being developed consisted of                
enterprise-wide, clinical information software. It is expected that the Company 
will release certain commercial products derived from the licensed technology in
late 1998. The Company accounted for the license arrangement with Partners by   
recording a credit to additional paid-in capital of $1.5 million (representing  
the estimated fair value of the licensed technology) and a corresponding charge 
to its statement of operations for the year ended December 31, 1996. The charge 
was taken because the technology had not reached technological feasibility and  
had no alternative future use.                                                  

    As part of the agreement, the Company has provided development services to
Partners related to commercializing the intellectual property; fees for these   
development services totaled $2.0 million, and $2.5 million for the years ended 
December 31, 1996 and 1997, respectively, and are included as a reduction in    
research and development expenses in the accompanying consolidated statements of
operations.                                                                     

5. SHAREHOLDERS' EQUITY AND MANDATORILY REDEEMABLE PREFERRED STOCK              

STOCK SPLIT                                                                     

In May 1997, the Company declared a three-for-two split for all Common
Stock and Non-Voting Common Stock issued and outstanding. In addition, the      
shareholders approved an increase in the number of authorized shares of Common  
Stock from 30,000,000 to 50,000,000. In June 1998, the Company effected a       
two-for-three reverse stock split of all Common Stock and Non-Voting Common     
Stock outstanding. The accompanying consolidated financial statements give      
retroactive effect to the May 1997 and June 1998 stock splits as if they had    
occurred at inception of the Company.                                           

MANDATORILY REDEEMABLE PREFERRED STOCK                                          

 In connection with its acquisition of Alltel (Note 6), the Company sold
30,000 shares of Series B 8.5% Cumulative Redeemable Preferred Stock ("Series   
B") and warrants to purchase up to 1,799,715 shares of Non-Voting Common Stock  
at $.01 per share for total consideration of $30.0 million. The number of       
warrants to be issued is subject to adjustment in the event the Company redeems 
all or a portion of the Series B prior to its mandatory redemption date. The    
Series B is non-voting and is entitled to a liquidation preference of $1,000 per
share plus any unpaid dividends. Dividends are cumulative and accrue at an      
annual rate of 8.5%. In the event that dividends are not paid when due for      
quarters ending after December 31, 1999, the dividend rate will increase to     
12.5%.                                                                          

  The Series B is redeemable by the Company at its redemption price at any
time on or before the mandatory redemption date of December 31, 2001. The       
redemption price, as defined, equals the                                        

F-12

S-4
142nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 142nd
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

5. SHAREHOLDERS' EQUITY AND MANDATORILY REDEEMABLE PREFERRED STOCK (CONTINUED)  
liquidation preference amount plus all accrued and unpaid dividends. With       
respect to liquidation preferences, the Series B ranks equal to the Series C    
8.5% Cumulative Redeemable Preferred Stock ("Series C") and senior to all other 
equity instruments. In the event that certain shareholders cease to continue to 
own a specified percentage of common or convertible preferred stock of the      
Company, the holders of the Series B may elect to put the securities back to the
Company at their redemption price, as defined. Additionally, the Series B may be
put back to the Company at their redemption value in the event of a change of   
control, as defined.                                                            

   In January 1997, 20,000 shares of the Series C were issued to AIS as part
of the consideration paid for Alltel (Note 6). The Series C contains            
substantially the same terms, including voting rights, ability to redeem and    
liquidation preferences as the Series B. The Series B has preferential rights in
the event of a change of ownership percentages of certain of the Company's      
stockholders; the Series C does not have these preferential rights. The Series C
redemption price is determined the same as Series B.                            

    The Series C must be redeemed on or before December 31, 2001. The Series C
may be put back to the Company at their redemption value in the event of a      
change in control, as defined.                                                  

    The Company has accounted for the Series B and C as mandatorily redeemable
preferred stock. Accordingly, the Company is accruing dividends and amortizing  
any discount over the redemption period with a charge to additional paid-in     
capital ("APIC"). The Company recorded a discount on the Series B at the time of
its issuance for the estimated fair value of the warrants ($10.5 million). The  
Company valued the maximum amount of warrants that would be issued up to the    
mandatory redemption date of the Series B as of the acquisition date and        
December 31, 1997. The Company recorded the Series C on the date of acquisition 
of Alltel at $10.3 million (after adjustment for the 4,500 shares returned by   
AIS (Note 6)), which included a discount from its face amount of $5.2 million.  
The amount charged to APIC related to the Series B and C for the year ended     
December 31, 1997 was $4.1 million and $1.8 million, respectively.              

The Series B and Series C consist of the following (in thousands):    

                                                        [Enlarge/Download Table]

                                         DATE OF ISSUE                         DECEMBER 31, 1997           
                             --------------------------------------  --------------------------------------
                             FACE VALUE   DISCOUNT   CARRYING VALUE  FACE VALUE   DISCOUNT   CARRYING VALUE
                             ----------   --------   --------------  ----------   --------   --------------
                                                                                                           
Series B....................  $30,000     $10,501       $19,499       $30,000      $6,476       $23,524    
Series C....................   15,500       5,242        10,258        15,500       3,417        12,083    
                              -------     -------       -------       -------      ------       -------    
                              $45,500     $15,743       $29,757       $45,500      $9,893       $35,607    
                              =======     =======       =======       =======      ======       =======    

SERIES A CONVERTIBLE PREFERRED STOCK                                            

In May 1996, concurrent with entering into the Partners' licensing    
arrangement, the Company sold 1,000,000 shares of Series A Convertible Preferred
Stock ("Series A") for $6.0 million to outside investors. The Series A was      
convertible on a one-to-one basis to shares of Common Stock of the Company at   
the discretion of the outside investors. The Series A had voting rights         
equivalent to Common Stock on an as converted basis and a liquidation preference
of $6 per share. The Company did not declare or pay any dividends on Series A.  
In January 1997, the Company issued 1,478,097 shares of Series F Convertible    
Preferred Stock ("Series F") in exchange for the cancellation of Series A. The  
Company accounted for the transaction analogously to an extinguishment of debt  
with a related party and, accordingly, recorded a charge of $3.1 million to     
additional paid-in capital at the date of this transaction. In addition, the    
charge is recorded as an increase to net loss available to common shareholders  
in the accompanying statement of operations.                                    

F-13

S-4
143rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 143rd
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

5. SHAREHOLDERS' EQUITY AND MANDATORILY REDEEMABLE PREFERRED STOCK (CONTINUED)  
SERIES D CONVERTIBLE PREFERRED STOCK                                            

In January 1997, the Company sold 4,981,289 shares of the Series D    
Convertible Preferred Stock ("Series D") for $62.5 million to private investors 
and issued 2,077,497 shares to AIS in connection with the acquisition of Alltel.
Each share of Series D is convertible into one share of Common Stock. The Series
D contains voting rights as if it were converted into Common Stock and has a    
liquidation preference of $12.55 per share plus any declared but unpaid         
dividends. The Series D is equivalent to Series E Convertible Preferred Stock   
("Series E") with respect to liquidation preference and rank.                   

 Both the Series D and E rank junior to the Series B and C and senior to
Series F. To date, the Company has not declared or paid any dividends on the    
Series D.                                                                       

SERIES E CONVERTIBLE PREFERRED STOCK                                            

In January 1997, the Company sold 896,431 shares of Series E for $11.3
million. The Series E is non-voting and is identical to the Series D with       
respect to liquidation preference and rank. Each share of Series E is           
convertible into one share of Non-Voting Common Stock. To date, the Company has 
not declared or paid any dividends on the Series E.                             

SERIES F CONVERTIBLE PREFERRED STOCK                                            

As described above, in January 1997, 1,478,097 shares of Series F were
issued in exchange for the cancellation of the outstanding shares of Series A.  
The Series F contains a liquidation preference of $6 per share. The Series F    
ranks junior to the Company's other classes of preferred stock with respect to  
liquidation preferences. Each share of Series F is convertible into one share of
Common Stock. To date, the Company has not declared or paid any dividends on the
Series F.                                                                       

COMMON STOCK AND NON-VOTING COMMON STOCK                                        

Holders of Common Stock are entitled to one vote per share. Holders of
Non-Voting Common Stock do not have voting rights other than as provided by     
statute.                                                                        

UNDESIGNATED PREFERRED STOCK                                                    

  The Company has available for issuance, 1,000,000 shares of undesignated
preferred stock (the "Undesignated Preferred"). The liquidation, voting,        
conversion and other related provisions of the Undesignated Preferred will be   
determined by the Board at the time of issuance. Currently, there are no        
outstanding shares.                                                             

6. ACQUISITIONS                                                                 

   Effective January 24, 1997, Eclipsys completed the acquisition of Alltel.
As consideration for this transaction, Eclipsys paid AIS $104.8 million cash,   
issued 15,500 (after consideration of the return of 4,500 shares by AIS in      
October 1997) shares of Series C valued at approximately $10.3 million and      
2,077,497 shares of Series D valued at approximately $26.1 million. Concurrent  
with the acquisition, the Company and Alltel entered into the Management and    
Services Agreement ("MSA") whereby Alltel agreed to provide certain services to 
the Company and its customers together with certain non-compete provisions. In  
exchange, the Company agreed to pay Alltel $11.0 million in varying installments
through December 2000. The obligation and equivalent corresponding asset were   
recorded at its net present value of $9.5 million at the date of signing. To    
finance the transaction, the Company sold, for $30.0 million, 30,000 shares of  
Series B and warrants to purchase up to 1,799,715 shares of Non-Voting Common   
Stock to private investors. Additionally, the Company sold 4,981,289 shares of  
Series D and 896,431 shares of Series E for total proceeds of $73.8 million.    

F-14

S-4
144th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 144th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

6. ACQUISITIONS (CONTINUED)                                                     
The transaction was accounted for as a purchase and accordingly, the  
purchase price was allocated based on the fair value of the net assets acquired.
The purchase price is composed of and allocated as follows (in thousands):      

                                                                [Download Table]
                                                                      
Cash, net of cash acquired..................................  $104,814
Issuance of Series D........................................    26,072
Issuance of Series C........................................    10,258
Transaction costs...........................................     2,008
Liabilities assumed.........................................    58,397
                                                              --------
                                                               201,549
                                                              --------
Current assets..............................................    31,803
Property and equipment......................................    12,242
Other assets................................................     3,148
Identifiable intangible assets:                                       
     In-process research and development....................    92,201
     Acquired technology....................................    42,312
     Ongoing customer relationships.........................    10,846
                                                              --------
                                                               192,552
                                                              --------
Goodwill....................................................  $  8,997
                                                              ========

    The acquisition agreement contains certain provisions whereby the purchase
price could be adjusted within twelve months from the acquisition date based on 
certain criteria defined in the agreement. Based on these provisions, in October
1997, AIS returned 4,500 shares of Series C to Eclipsys. In December 1997, the  
Company presented its final analysis to AIS of items for which, under the       
agreement, the Company believed it was entitled to consideration. In March 1998,
the Company negotiated an agreement with AIS, which settled these issues related
to any adjustments that could be made pursuant to the provisions in the         
acquisition agreement (Note 13). After accounting for this adjustment, the      
Company's total consideration paid for this acquisition was $201.5 million,     
including liabilities assumed, net of cash acquired.                            

    In connection with the recording of the acquisition of Alltel, the Company
reduced the predecessor's reported deferred revenue by $7.3 million to the      
amount that reflects the estimated fair value of the contractual obligations    
assumed. This adjustment results from the Company's requirement, in accordance  
with generally accepted accounting principles, to record the fair value of the  
obligation assumed with respect to arrangements for which the related revenue   
was previously collected by the predecessor company. The Company's liability at 
acquisition includes its estimated costs in fulfilling those contract           
obligations.                                                                    

  Effective June 26, 1997, the Company acquired all of the common stock of
SDK in exchange for 499,997 shares of Common Stock valued at approximately $3.2 
million, $2.2 million in cash and acquisition debt due to SDK shareholders      
totaling $7.6 million. The transaction was accounted for as a purchase and,     
accordingly, the purchase price was allocated based on the estimated fair value 
of the net assets acquired.                                                     

F-15

S-4
145th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 145th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

6. ACQUISITIONS (CONTINUED)                                                     
    The purchase price is composed of and allocated as follows (in thousands):

                                                                [Download Table]
                                                                     
Cash, net of cash acquired..................................  $ 2,161
Issuance of Common Stock....................................    3,248
SDK acquisition debt........................................    7,588
Liabilities assumed.........................................    3,514
                                                              -------
                                                               16,511
                                                              -------
Current assets..............................................    1,061
Property and equipment......................................      671
Other assets................................................       33
Identifiable intangible assets:                                      
     In-process research and development....................    6,988
     Acquired technology....................................    3,205
                                                              -------
                                                               11,958
                                                              -------
Goodwill....................................................  $ 4,553
                                                              =======

  The Company is using the acquired in-process research and development to
create new clinical, patient financial, access management and data warehousing  
products which will become part of its Sunrise product suite over the next      
several years. The Company anticipates that certain products will be generally  
released during 1998, with additional product releases in subsequent periods    
through 2001. It is management's expectation that the acquired in-process       
research and development will be successfully developed, however there can be no
assurance that commercial viability of these products will be achieved. In the  
event that these products are not generally released in a timely manner, the    
Company may experience fluctuations in future earnings as a result of such      
delays.                                                                         

   In connection with the Alltel and SDK acquisitions, the Company wrote off
in-process research and development charges of $92.2 million and $7.0 million,  
respectively, related to the appraised values of certain in-process research and
development acquired in these acquisitions.                                     

    Unaudited pro forma results of operations for the years ended December 31,
1996 and 1997, as if the aforementioned acquisitions had occurred on January 1, 
1996 is as follows (in thousands, except per share data):                       

                                                                [Download Table]

                                                                  YEAR ENDED      
                                                                 DECEMBER 31,     
                                                             -------------------- 
                                                               1996       1997    
                                                             --------   --------- 
                                                                                  
Revenues.................................................... $115,606   $ 103,786 
Net loss....................................................   (5,696)   (132,159)
Basic and diluted loss per share............................ $  (1.62)  $  (37.39)

  Effective January 30, 1998, the Company acquired the net assets of Emtek
for an aggregate purchase price of approximately $11.7 million, including       
1,000,000 shares of Common Stock valued at $9.1 million and liabilities assumed 
of approximately $12.3 million. In addition, Motorola agreed to pay the Company 
$9.6 million in cash due within one year for working capital purposes.          

F-16

S-4
146th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 146th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

6. ACQUISITIONS (CONTINUED)                                                     
The purchase price is composed of and allocated as follows:           

                                                                [Download Table]
                                                                      
Issuance of Common Stock....................................  $ 9,060 
Receivable from Motorola....................................   (9,600)
Liabilities assumed.........................................   12,275 
                                                              ------- 
                                                              $11,735 
                                                              ------- 
Current assets..............................................    5,033 
Property and equipment......................................    2,629 
                                                              ------- 
                                                              $ 7,662 
                                                              ------- 
Identifiable intangible assets (acquired technology)........  $ 4,073 
                                                              ======= 

7. LONG-TERM DEBT                                                               

Long-term debt consists of the following as of December 31, 1997 (in  
thousands):                                                                     

                                                                [Download Table]
                                                                       
Term Loan...................................................  $  9,000 
SDK acquisition debt, interest payable quarterly at 9.5%,              
  principal due in two annual installments of $3,794,                  
  commencing April 1998.....................................     7,588 
                                                              -------- 
                                                                16,588 
Less current portion........................................   (12,794)
                                                              -------- 
Long-term debt..............................................  $  3,794 
                                                              ======== 

   In connection with the Alltel acquisition, the Company entered into a $30
million credit facility (the "Facility"). The Facility included a $10 million   
term loan (the "Term Loan") and a $20 million revolving credit facility (the    
"Revolver"). Borrowings under the Facility are secured by substantially all of  
the assets of the Company. The Term Loan was payable in varying quarterly       
installments through January 2000. As more fully discussed in Note 13, the Term 
Loan was repaid in full with the proceeds of the sale of Series G Convertible   
Preferred Stock in February 1998. As such, the entire balance of the Term Loan  
is classified as current in the accompanying financial statements.              

  Borrowings under the Facility bear interest, at the Company's option, at
(i) LIBOR plus 1% to 3% or (ii) the higher of a) the banks prime lending rate or
b) the Federal Funds Rate plus 0.5%; plus 0% to 1.75%. The interest rates vary  
based on the Company's ratio of earnings to consolidated debt, as defined. At   
December 31, 1997, the Company's borrowing rate under the Facility was 6.85%.   
Under the terms of the Facility, the Company is required to maintain certain    
financial covenants related to consolidated debt to earnings, consolidated      
earnings to interest expense and consolidated debt to capital. In addition, the 
Company has limitations on the amounts of certain types of expenditures and is  
required to obtain certain approvals related to mergers and acquisitions, as    
defined. The Company was in compliance with all provisions of the Facility as of
December 31, 1997.                                                              

   As of December 31, 1997, the Company has $20 million available for future
borrowings under the Revolver. The Revolver expires on the third anniversary of 
the Facility. Under the terms of the Revolver, the Company pays an annual       
commitment fee of .375% for any unused balance, as defined. Additionally, the   
Company pays a fee of .125% for any Letters of Credit issued under the          
agreement. As of December 31, 1997, unused Letters of Credit totaling           
approximately $5.0 million were outstanding against                             

F-17

S-4
147th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 147th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

7. LONG-TERM DEBT (CONTINUED)                                                   
the Revolver. As discussed in Note 13, in May 1998 the Company increased its    
borrowings under the Revolver.                                                  

8. OTHER CURRENT LIABILITIES                                                    

Other current liabilities consist of the following (in thousands):    

                                                                [Download Table]

                                                               DECEMBER 31, 
                                                              --------------
                                                              1996    1997  
                                                              ----   -------
                                                                            
Accounts payable............................................  $120   $ 4,606
Accrued compensation and incentive..........................   237     7,847
Customer deposits...........................................    --     7,959
Payment due AIS under MSA...................................    --     2,000
Accrued acquisition costs...................................   501        --
Accrued interest............................................    --       672
Other.......................................................    24     8,066
                                                              ----   -------
                                                              $882   $31,150
                                                              ====   =======

9. INCOME TAXES                                                                 

    The Company has no current or deferred income tax provision due to the net
losses reported by the Company.                                                 

     A reconciliation of the federal statutory rate and the effective income tax
rate follows (in thousands):                                                    

                                                                [Download Table]

                                                                 YEARS ENDED     
                                                                DECEMBER 31,     
                                                             ------------------- 
                                                               1996       1997   
                                                             --------   -------- 
                                                                                 
Statutory federal income tax rate (34%).....................  $(500)    $(45,481)
SDK in-process research and development.....................     --        2,376 
Meals and entertainment.....................................      8          460 
State income taxes..........................................    (58)      (5,163)
Non-deductible amortization.................................     --          747 
Valuation allowance.........................................    550       46,976 
Other.......................................................     --           85 
                                                              -----     -------- 
Income tax benefit (provision)..............................  $  --     $     -- 
                                                              =====     ======== 

F-18

S-4
148th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 148th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

9. INCOME TAXES (CONTINUED)                                                     
    The significant components of the Company's net deferred tax asset were as
follows (in thousands):                                                         

                                                                [Download Table]

                                                                DECEMBER 31,     
                                                             ------------------- 
                                                               1996       1997   
                                                             --------   -------- 
                                                                                 
Deferred tax assets:                                                             
Alltel in-process research and development..................  $  --     $ 34,969 
Intangible assets...........................................     --        5,353 
Deferred revenue............................................     --        3,990 
Allowance for doubtful accounts.............................     --          660 
Compensation related accrued liabilities....................     58          249 
Accrued expenses............................................     --        3,569 
Depreciation and amortization...............................     --        1,257 
Net operating loss carryforwards............................    504        5,220 
                                                              -----     -------- 
                                                                562       55,267 
                                                              -----     -------- 
Deferred tax liabilities:                                                        
  Capitalization of software development costs..............     --          604 
  Depreciation and amortization.............................     12           -- 
  Other.....................................................     --           -- 
                                                              -----     -------- 
Net deferred tax asset......................................    550       54,663 
                                                              -----     -------- 
Valuation allowance.........................................   (550)     (54,663)
                                                              -----     -------- 
                                                              $  --     $     -- 
                                                              =====     ======== 

    At December 31, 1997, the Company had net operating loss carryforwards for
federal income tax purposes of approximately $20.1 million. The carryforwards   
expire in varying amounts through 2012.                                         

In addition, under the Tax Reform Act of 1986, the amounts of, and the
benefits from, net operating loss carryforwards may be impaired or limited in   
certain circumstances. The Company experienced an ownership change as defined   
under Section 382 of the Internal Revenue Code in January, 1997. As a result of 
the ownership change, net operating loss carryforwards of approximately $1.5    
million, which were incurred prior to the date of change, are subject to annual 
limitation on their future use. As of December 31, 1997, a valuation allowance  
has been established against the deferred tax assets which the Company does not 
believe are more likely than not to be realized. The future reduction of the    
valuation allowance, up to $7.2 million, will be reflected as a reduction of    
goodwill.                                                                       

10. EMPLOYEE BENEFIT PLANS                                                      

STOCK OPTION PLAN                                                               

    In April 1996, the Board of Directors of the Company (the "Board") adopted
the 1996 Stock Plan (the "1996 Stock Plan"). The 1996 Stock Plan, as amended,   
provides for grants of stock options, awards of Company stock free of any       
restrictions and opportunities to make direct purchases of restricted stock of  
the Company. The 1996 Stock Plan allows for the issuance of options or other    
awards to purchase up to 2,500,000 shares of Common Stock. Pursuant to the terms
of the 1996 Stock Plan, a committee of the                                      

F-19

S-4
149th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 149th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

10. EMPLOYEE BENEFIT PLANS (CONTINUED)                                          
Board is authorized to grant awards to employees and non employees and establish
vesting terms. The options expire ten years from the date of grant. The         
following table summarizes activity under the Plan:                             

                                                        [Enlarge/Download Table]

                                                    1996                        1997            
                                          -------------------------  ---------------------------
                                                       WEIGHTED                     WEIGHTED    
                                                        AVERAGE                      AVERAGE    
                                          OPTIONS   EXERCISE PRICE    OPTIONS    EXERCISE PRICE 
                                          -------   ---------------  ---------   ---------------
                                                                                                
Outstanding at beginning of year.........      --        $ --          657,500        $ .11     
  Granted................................ 657,500         .11        1,309,889         6.52     
  Exercised..............................                  --          (57,071)         .11     
  Forfeited..............................                  --          (78,666)        4.81     
                                          -------        ----        ---------        -----     
Outstanding at end of year............... 657,500         .11        1,831,652         4.49     
                                          -------        ----        ---------        -----     
Options exercisable at end of year.......      --                      197,978                  
                                          -------                    ---------                  
Weighted average fair value of options                                                          
  granted during the year................                $.45                         $1.75     
                                                         ====                         =====     

                                                        [Enlarge/Download Table]

                                                   1996                            1997             
                                      ------------------------------  ------------------------------
                                          WEIGHTED        WEIGHTED        WEIGHTED        WEIGHTED  
                                      AVERAGE EXERCISE   FAIR MARKET  AVERAGE EXERCISE   FAIR MARKET
  OPTIONS GRANTED DURING THE YEAR          PRICE            VALUE          PRICE            VALUE   
------------------------------------  ----------------   -----------  ----------------   -----------
                                                                                                    
Option price > fair market value            $.10            $  --          $6.73            $1.76   
Option price = fair market value              --               --             --               --   
Option price < fair market value             .15             1.39            .20             1.35   

 During 1996 and 1997, pursuant to the 1996 Stock Plan, the Board issued
109,999 and 15,000 shares of Common Stock, respectively, to employees and       
nonemployees for services. Compensation expense of approximately $1,000 and     
$97,000 was recorded in 1996 and 1997, respectively, related to these           
transactions.                                                                   

In addition, during 1996 and 1997, the Company recorded compensation  
expense of $22,000 and $71,000, respectively, related the granting of certain   
stock options to employees with exercise prices below the estimated fair market 
value of the Common Stock at the date of grant.                                 

The Company has adopted the disclosure only provision of FAS 123. Had 
compensation cost for the Company's stock option grants described above been    
determined based on the fair value at the grant date for awards in 1996 and 1997
consistent with the provisions of FAS 123, the Company's net loss and loss per  
share would have been increased to the pro forma amounts indicated below (in    
thousands, except share data):                                                  

                                                                [Download Table]

                                                                 YEARS ENDED      
                                                                 DECEMBER 31,     
                                                             -------------------- 
                                                               1996       1997    
                                                             --------   --------- 
                                                                                  
Net loss:                                                                         
  As reported............................................... $(2,953)   $(131,060)
  Pro forma.................................................  (2,954)    (131,324)
Basic and diluted net loss per share:                                             
  As reported............................................... $  (.98)   $  (39.73)
  Pro forma.................................................    (.98)      (39.80)

F-20

S-4
150th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 150th
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

10. EMPLOYEE BENEFIT PLANS (CONTINUED)                                          
     The fair value of each option grant is estimated on the date of grant using
the Black-Scholes option-pricing model with the following weighted-average      
assumptions used for grants in 1996 and 1997, respectively: dividend yield of 0%
for all years, risk-free interest rate of 5.90% and 6.06% and expected life of  
5.0 years and 5.2 years. As a nonpublic entity, the Company used the minimum    
value method which does not incorporate a volatility assumption.                

    The following table summarizes information about stock options outstanding
at December 31, 1997:                                                           

                                                        [Enlarge/Download Table]

                                           OPTIONS OUTSTANDING             OPTIONS EXERCISABLE   
                                   ------------------------------------  ------------------------
                                                  WEIGHTED                                       
                                                   AVERAGE     WEIGHTED                 WEIGHTED 
                                     NUMBER       REMAINING    AVERAGE     NUMBER       AVERAGE  
            RANGE OF               OUTSTANDING   CONTRACTUAL   EXERCISE  EXERCISABLE    EXERCISE 
         EXERCISE PRICE            AT 12/31/97      LIFE        PRICE     12/31/97       PRICE   
---------------------------------  -----------   -----------   --------  -----------   ----------
                                                                                                 
$0.10 to $0.20...................     621,929       8.36        $ .12      160,789       $ .11   
$6.50 to $7.50...................   1,209,723       9.54        $6.74       37,189       $7.52   

EMPLOYEE SAVINGS PLAN                                                           

   During 1997, the Company established a Savings Plan (the "Plan") pursuant
to Section 401(k) of the Internal Revenue Code (the "Code"), whereby employees  
may contribute a percentage of their compensation, not to exceed the maximum    
amount allowable under the Code. At the discretion of the Board, the Company may
elect to make matching contributions, as defined in the Plan. For the year end  
December 31, 1997, the Board authorized matching contributions totaling         
$780,000.                                                                       

11. COMMITMENTS AND CONTINGENCIES                                               

NONCANCELABLE OPERATING LEASES                                                  

The Company leases its office space and certain equipment under       
noncancelable operating leases. Rental expense under operating leases was       
approximately $70,000 and $6.2 million for the years ended December 31, 1996 and
1997, respectively. Future minimum rental payments for noncancelable operating  
leases as of December 31, 1997 are as follows (in thousands):                   

                                                                [Download Table]

                        YEAR ENDING                                  
                        DECEMBER 31,                                 
                        ------------                                 
                                                                     
1998........................................................  $ 5,801
1999........................................................    4,930
2000........................................................    2,616
2001........................................................    1,877
2002........................................................    1,632
Thereafter..................................................    4,575
                                                              -------
                                                              $21,431
                                                              =======

LITIGATION                                                                      

  The Company is involved in litigation incidental to its business. In the
opinion of management, after consultation with legal counsel, the ultimate      
outcome of such litigation will not have a material adverse effect on the       
Company's financial position or results of operations or cash flows.            

F-21

S-4
151st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 151st
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

12. RELATED PARTY TRANSACTIONS                                                  

During 1997, the Company paid AIS $1.7 million for certain transition 
services provided by AIS related to accounting services, computer processing and
other various activities.                                                       

   During 1997, Eclipsys paid a total of $348,000 to certain subsidiaries of
AIS and Alltel Corporation related to the purchase of various goods and         
services.                                                                       

  The Company leases office space from the former owner of SDK. During the
year ended December 31, 1997 the Company paid $178,000 under this lease. The    
lease is noncancelable and expires in 2009.                                     

   In 1997, the Company paid $336,000 to a charter company for the use of an
aircraft for corporate purposes. The aircraft provided for the Company's use was
leased by the charter company from a company owned by the Chairman of the Board,
President and Chief Executive Officer of the Company (the "Chairman"). The      
Chairman's company received $219,000 for these transactions. The Chairman has no
interest in the charter company. In the opinion of management, the Company      
believes that the terms of charters were comparable to rates that would be      
charged by unaffiliated parties.                                                

  The Company has an employment agreement with the Chairman through May 1,
1999. Under the provisions of the agreement, the Chairman earns an annual salary
of $150,000, subject to adjustment from time to time. The payment of amounts    
earned under the agreement were to be deferred until certain earnings were      
attained by the Company. During 1997, $66,000 was paid under the agreement.     
Effective January 1, 1998, the Chairman's annual salary was increased to        
$200,000.                                                                       

13. SUBSEQUENT EVENTS                                                           

SHAREHOLDERS' EQUITY (DEFICIT)                                                  

    In January 1998, the Company amended its Certificate of Incorporation (the
"Certificate"). Under the amended Certificate, the Company increased the number 
of authorized shares of Undesignated Preferred to 1,100,000 and created Series G
Convertible Preferred Stock ("Series G"). There are 900,000 authorized shares of
Series G. The Series G is convertible on a two-for-three basis to shares of     
Common Stock. The conversion rate is subject to adjustment in certain           
circumstances. The Series G has a liquidation preference of $10 per share. In   
the event of an involuntary liquidation of the Company, the Series G will       
participate on a pro rata basis with the Series D and E. In February 1998, the  
Company sold 900,000 shares of Series G to outside investors for total          
consideration of $9 million. The proceeds were utilized to repay the outstanding
Term Loan balance.                                                              

  In addition, the Company amended the terms of (i) all of its convertible
preferred stock to require that it automatically be converted into Common Stock 
or Non-Voting Common Stock, as applicable, upon a qualifying IPO and (ii) all of
its Mandatorily Redeemable Preferred Stock to require that it be mandatorily    
redeemed upon a qualifying IPO.                                                 

   In June 1998, the Company effected a two-for-three reverse stock split of
all Common Stock and Non-Voting Common Stock outstanding.                       

CREDIT FACILITY                                                                 

    In March 1998, the Company borrowed $9.0 million under the Revolver to pay
a portion of the AIS settlement, described herein.                              

On May 29, 1998, the Company entered into an agreement to increase the
available borrowings under the Revolver (Note 7) from $20.0 million to $50.0    
million (unaudited).                                                            

F-22

S-4
152nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 152nd
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

13. SUBSEQUENT EVENTS (CONTINUED)                                               
1998 STOCK INCENTIVE PLAN                                                       

In January 1998, the Board adopted the 1998 Stock Incentive Plan (the 
"Incentive Plan"). The Incentive Plan provides for the granting of stock        
options, stock appreciation rights, restricted stock awards or unrestricted     
stock awards. Under the provisions of the Incentive Plan, no options or other   
awards may be granted after April 2008. There are currently 4,333,333 shares of 
common stock reserved under the Incentive Plan, together with the 1996 Stock    
Plan and the 1998 Employee Stock Purchase Plan. Options granted under the       
Incentive Plan will be granted at the fair market value of the stock as of the  
date of grant.                                                                  

1998 EMPLOYEE STOCK PURCHASE PLAN                                               

     Under the Company's 1998 Employee Stock Purchase Plan (the "Purchase Plan")
(implemented in April 1998), employees of the Company, including directors of   
the Company who are employees are eligible to participate in quarterly plan     
offerings in which payroll deductions may be used to purchase shares of Common  
Stock. The purchase price of such shares is the lower of 85% of the fair market 
value of the Common Stock on the day the offering commences and 85% of the fair 
market value of the Common Stock on the day the offering terminates. The first  
offering period under the Purchase Plan will not commence until after the       
completion of the Eclipsys IPO.                                                 

ALLTEL SETTLEMENT                                                               

In the first quarter of 1998, the Company and AIS renegotiated, in two
separate transactions, certain matters relating to the acquisition of Alltel. In
one transaction, AIS returned to the Company, for cancellation, 11,000 shares of
Series C in exchange for resolving certain open issues in connection with the   
Alltel acquisition, and the Company agreed, at AIS' option, to redeem the       
remaining 4,500 shares of Series C held by AIS for an aggregate price of $4.5   
million at the time of the IPO and for a period of 30 days thereafter. The      
Company will use a portion of the net proceeds of the IPO to redeem the         
remaining Series C held by AIS. In the second transaction, the Company paid AIS 
an aggregate of $14.0 million in exchange for terminating all of the rights and 
obligations of both parties under the MSA. The Company recorded a charge of     
approximately $7.2 million related to the write-off of the MSA intangible asset.
In addition, the Company recorded a reduction to goodwill of approximately $7.8 
million related to the final settlement of certain issues related to the Alltel 
acquisition resulting in the return of the 11,000 shares of Series C.           

SIMIONE INVESTMENT                                                              

   In April 1998, the Company made a strategic investment in Simione Central
Holdings, Inc. ("Simione"), a publicly traded company, purchasing 420,000 shares
of restricted common stock from certain stockholders of Simione for $5.6        
million. At the time of the transaction, the common stock represented 4.9% of   
Simione's outstanding common stock. The Company accounts for its investment in  
these shares using the cost method.                                             

Concurrent with the investment, the Company and Simione entered into a
remarketing agreement pursuant to which the Company has certain rights to       
distribute Simione software products.                                           

14. EVENTS (UNAUDITED) SUBSEQUENT TO THE DATE OF THE REPORT OF INDEPENDENT      
ACCOUNTANTS                                                                     

INITIAL PUBLIC OFFERING                                                         

     Effective August 6, 1998, the Company completed an initial public offering.
Net proceeds from the offering were $66.0 million, including proceeds from the  
exercise of the underwriters' overallotment option.                             
F-23

S-4
153rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 153rd
ECLIPSYS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1996 AND 1997 AND SEPTEMBER 30, 1998 (UNAUDITED) -- (CONTINUED)

14. EVENTS (UNAUDITED) SUBSEQUENT TO THE DATE OF THE REPORT OF INDEPENDENT      
ACCOUNTANTS (CONTINUED)                                                         
The Company used the net proceeds from the offering to redeem the outstanding   
shares of the Company's Mandatorily Redeemable Preferred Stock, repay the       
principal balance and accrued interest on acquisition related debt and to repay 
amounts outstanding under the Revolver. In connection with the redemption of the
Mandatorily Redeemable Preferred Stock, the Company recorded an increase to net 
loss available to common shareholders of $10.9 million reflecting the difference
between the carrying value and redemption value of the stock.                   

Concurrent with the initial public offering, all Series of Convertible
Preferred Stock were automatically converted into Common Stock or Non-Voting    
Common Stock.                                                                   

TSI MERGER AGREEMENT                                                            

     On October 29, 1998, the Company entered into a merger agreement to acquire
Transition Systems, Inc. ("TSI") for approximately $270.0 million in stock.     
Under the terms of the agreement, each share of TSI stock will be converted     
using a fixed exchange rate of .525 shares of the Company's stock, with no      
collar. The transaction, which is subject to regulatory as well as stockholder  
approval, is intended to be accounted for as a pooling of interests and is      
anticipated to close by the end of December 1998.                               

F-24

S-4
154th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 154th

REPORT OF INDEPENDENT ACCOUNTANTS 

To the Board of Directors                                                       
and Shareholders of Eclipsys Corporation                                        

In our opinion, the accompanying consolidated balance sheets and the  
related consolidated statements of operations, of changes in shareholder's      
deficit and of cash flows present fairly, in all material respects, the         
financial position of ALLTEL Healthcare Information Services, Inc. (the Company)
(a Delaware corporation, wholly-owned by ALLTEL Information Services, Inc., an  
Arkansas corporation) and its subsidiaries at December 31, 1995 and 1996, and   
the results of their operations and their cash flows for the years then ended   
and for the period from January 1, 1997 through January 23, 1997 in conformity  
with generally accepted accounting principles. These financial statements are   
the responsibility of the Company's management; our responsibility is to express
an opinion on these financial statements based on our audits. We conducted our  
audits of these statements in accordance with generally accepted auditing       
standards which require that we plan and perform the audit to obtain reasonable 
assurance about whether the financial statements are free of material           
misstatement. An audit includes examining, on a test basis, evidence supporting 
the amounts and disclosures in the financial statements, assessing the          
accounting principles used and significant estimates made by management, and    
evaluating the overall financial statement presentation. We believe that our    
audits provide a reasonable basis for the opinion expressed above.              

As discussed in Note 10, effective January 24, 1997, the Company was acquired by
Eclipsys Corporation.                                                           

                                                      PRICEWATERHOUSECOOPERS LLP

Atlanta, Georgia                                                                
June 27, 1997                                                                   

F-25

S-4
155th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 155th

ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
CONSOLIDATED BALANCE SHEETS 
(IN THOUSANDS)

                                                                [Download Table]

                                                                 DECEMBER 31,     
                                                              ------------------- 
                                                                1995       1996   
                                                              --------   -------- 
                                                                                  
                           ASSETS                                                 
Current assets:                                                                   
  Cash and cash equivalents.................................  $  2,599   $  2,022 
  Accounts receivable, net of allowance for doubtful                              
     accounts of $749 and $1,274 at December 31, 1995 and                         
     1996, respectively.....................................    29,435     29,713 
  Inventory.................................................     2,081      1,576 
  Deferred tax asset........................................     3,676      3,682 
  Other current assets......................................       678        634 
                                                              --------   -------- 
     Total current assets...................................    38,469     37,627 
Property and equipment, net.................................    10,168     10,739 
Purchased software, net of accumulated amortization of                            
  $2,985 and $4,453 at December 31, 1995 and 1996,                                
  respectively..............................................     4,098      2,882 
Capitalized software development costs, net of accumulated                        
  amortization of $4,671 and $11,880 at December 31, 1995                         
  and 1996, respectively....................................    27,632     35,306 
Intangible assets, net of accumulated amortization of $1,129                      
  and $2,101 at December 31, 1995 and 1996, respectively....     5,670      4,698 
Other assets................................................     2,344      9,191 
                                                              --------   -------- 
     Total assets...........................................  $ 88,381   $100,443 
                                                              ========   ======== 
           LIABILITIES AND SHAREHOLDER'S DEFICIT                                  
Current liabilities:                                                              
  Deferred revenue..........................................  $ 24,724   $ 26,807 
  Other current liabilities.................................    17,668     20,378 
                                                              --------   -------- 
     Total current liabilities..............................    42,392     47,185 
Deferred revenue............................................    15,913     10,148 
Other long-term liabilities.................................                1,250 
Deferred income taxes.......................................     7,002      9,294 
Intercompany payable to parent..............................    46,085     57,953 
                                                              --------   -------- 
     Total liabilities......................................   111,392    125,830 
Shareholder's deficit:                                                            
  Common stock, $.01 par value, 1,000 shares authorized,                          
     issued and outstanding.................................         1          1 
  Additional paid-in capital................................    15,678     15,678 
  Accumulated deficit.......................................   (38,236)   (40,432)
  Cumulative foreign currency translation adjustment........      (454)      (634)
                                                              --------   -------- 
     Total shareholder's deficit............................   (23,011)   (25,387)
                                                              --------   -------- 
          Total liabilities and shareholder's deficit.......  $ 88,381   $100,443 
                                                              ========   ======== 

The accompanying notes are an integral part of these financial statements.

F-26

S-4
156th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 156th

ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS 
(IN THOUSANDS)

                                                        [Enlarge/Download Table]

                                                               YEAR ENDED          PERIOD FROM   
                                                              DECEMBER 31,       JANUARY 1, 1997 
                                                           -------------------       THROUGH     
                                                             1995       1996     JANUARY 23, 1997
                                                           --------   --------   ----------------
                                                                                                 
Revenues:                                                                                        
  Service and systems..................................... $ 90,737   $ 99,213       $ 6,064     
  Hardware................................................    9,377      9,587           122     
                                                           --------   --------       -------     
     Total revenues.......................................  100,114    108,800         6,186     
                                                           --------   --------       -------     
Costs and expenses:                                                                              
  Cost of service and systems revenues....................   53,385     63,572         4,277     
  Cost of hardware revenues...............................    7,950      7,911           104     
  Marketing and sales.....................................   11,128     11,091           660     
  Research and development................................    8,522     10,271           794     
  General and administrative..............................    8,168      7,101           621     
  Depreciation and amortization...........................    6,735      8,135           568     
                                                           --------   --------       -------     
     Total costs and expenses.............................   95,888    108,081         7,024     
                                                           --------   --------       -------     
Income (loss) from operations.............................    4,226        719          (838)    
Interest expense, net.....................................   (2,733)    (3,758)         (379)    
                                                           --------   --------       -------     
Income (loss) before income taxes.........................    1,493     (3,039)       (1,217)    
Income tax benefit (provision)............................     (887)       843           437     
                                                           --------   --------       -------     
Net income (loss)......................................... $    606   $ (2,196)      $  (780)    
                                                           ========   ========       =======     

The accompanying notes are an integral part of these financial statements.

F-27

S-4
157th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 157th

ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDER'S DEFICIT
(IN THOUSANDS EXCEPT SHARE DATA)

                                                        [Enlarge/Download Table]

                                                                                 EQUITY              
                                                                               ADJUSTMENT            
                                                                                  FROM               
                                      COMMON STOCK    ADDITIONAL                 FOREIGN             
                                     ---------------   PAID-IN    ACCUMULATED   CURRENCY             
                                     SHARES   AMOUNT   CAPITAL      DEFICIT    TRANSLATION   TOTAL   
                                     ------   ------  ----------  -----------  -----------  -------- 
                                                                                                     
Balance at December 31, 1994........ 1,000      $1     $15,678     $(38,842)      $(470)    $(23,633)
Net income..........................                                    606                      606 
Foreign translation adjustment......                                                 16           16 
                                     -----      --     -------     --------       -----     -------- 
Balance at December 31, 1995........ 1,000       1      15,678      (38,236)       (454)     (23,011)
Net loss............................                                 (2,196)                  (2,196)
Foreign translation adjustment......                                               (180)        (180)
                                     -----      --     -------     --------       -----     -------- 
Balance at December 31, 1996........ 1,000       1      15,678      (40,432)       (634)     (25,387)
Net loss............................                                   (780)                    (780)
Foreign translation adjustment......                                                  3            3 
                                     -----      --     -------     --------       -----     -------- 
Balance at January 23, 1997......... 1,000      $1     $15,678     $(41,212)      $(631)    $(26,164)
                                     =====      ==     =======     ========       =====     ======== 

The accompanying notes are an integral part of these financial statements.

F-28

S-4
158th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 158th

ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS 
(IN THOUSANDS)

                                                        [Enlarge/Download Table]

                                                                YEAR ENDED          PERIOD FROM   
                                                               DECEMBER 31,       JANUARY 1, 1997 
                                                            -------------------       THROUGH     
                                                              1995       1996     JANUARY 23, 1997
                                                            --------   --------   ----------------
                                                                                                  
Operating activities:                                                                             
  Net income (loss).......................................  $    606   $ (2,196)      $  (780)    
                                                            --------   --------       -------     
  Adjustments to reconcile net income to net cash provided                                        
     by (used in) operating activities:                                                           
     Depreciation and amortization........................    13,205     15,344           945     
     Deferred income taxes................................     6,040      2,286           (52)    
     Changes in assets and liabilities                                                            
       Accounts receivable................................    (6,574)      (278)          325     
       Inventory..........................................       566        505            55     
       Other current assets...............................       (74)        44            10     
       Deferred revenue...................................     1,090     (3,682)        1,951     
       Other current liabilities..........................       906      2,710         2,351     
       Other long term liabilities........................        --      1,250        (1,250)    
       Other assets.......................................       162        (43)          (81)    
                                                            --------   --------       -------     
          Total adjustments...............................    15,321     18,136         4,254     
                                                            --------   --------       -------     
            Net cash provided by operating activities.....    15,927     15,940         3,474     
                                                            --------   --------       -------     
Investing activities:                                                                             
  Purchase of property, equipment and software............    (7,716)    (9,231)         (323)    
  Capitalized software development costs..................   (12,905)   (12,170)         (661)    
  Changes in other assets.................................        96     (6,804)           27     
                                                            --------   --------       -------     
     Net cash used in investing activities................   (20,525)   (28,205)         (957)    
                                                            --------   --------       -------     
Financing activities:                                                                             
  Net change in intercompany payable to parent............     5,509     11,868        (1,855)    
                                                            --------   --------       -------     
Effect of exchange rate changes on cash and cash                                                  
  equivalents.............................................        16       (180)            3     
                                                            --------   --------       -------     
Net (decrease) increase in cash and cash equivalents......       927       (577)          665     
Cash and cash equivalents, beginning of year..............     1,672      2,599         2,022     
                                                            --------   --------       -------     
Cash and cash equivalents, end of year....................  $  2,599   $  2,022       $ 2,687     
                                                            ========   ========       =======     

The accompanying notes are an integral part of these financial statements.

F-29

S-4
159th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 159th

ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995 AND 1996

1. ORGANIZATION AND DESCRIPTION OF BUSINESS                                     

    Alltel Healthcare Information Services, Inc. ("AHIS") and its subsidiaries
(collectively, the "Company") are engaged in one business segment primarily     
providing enterprise-wide clinical, patient care and financial software         
solutions, as well as outsourcing, remote processing, networking technologies   
and other services to healthcare organizations throughout the United States and 
Western Europe.                                                                 

  The Company is a wholly owned subsidiary of Alltel Information Services,
Inc. ("AIS") which is a wholly owned subsidiary of Alltel Corporation           
("Alltel").                                                                     

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                                   

PRINCIPLES OF CONSOLIDATION                                                     

    The financial statements include the accounts of AHIS and its wholly owned
subsidiaries. All significant intercompany transactions have been eliminated in 
consolidation.                                                                  

FINANCIAL STATEMENT PRESENTATION                                                

     The preparation of the consolidated financial statements in conformity with
generally accepted accounting principles requires management to make estimates  
and assumptions that affect the reported amounts of assets, liabilities,        
revenues and expenses and disclosure of contingent assets and liabilities. The  
estimates and assumptions used in the accompanying consolidated financial       
statements are based upon management's evaluation of the relevant facts and     
circumstances as of the date of the financial statements. Actual results could  
differ from those estimates.                                                    

  The consolidated statements of operations include all revenues and costs
directly attributable to the operations of AHIS, including the costs of         
facilities, administration, and other various costs. As more fully described in 
Notes 8 and 11, certain costs related to interest, benefits, and other costs    
were allocated to AHIS based on usage and other defined criteria.               

  All of the allocations utilized in the consolidated financial statements
are based on assumptions that AHIS management believes are reasonable under the 
circumstances. However, these allocations are not necessarily indicative of the 
costs which would have resulted had AHIS been a separate entity.                

CASH AND CASH EQUIVALENTS                                                       

For purposes of the consolidated statement of cash flows, the Company 
considers all highly liquid investments with an original maturity of three      
months or less to be cash equivalents.                                          

REVENUE RECOGNITION                                                             

The Company's products are sold to customers based on contractual     
agreements. Revenues are derived from the licensing of computer software, the   
sale of computer hardware, hardware and software maintenance, remote processing 
and outsourcing, training, implementation assistance, custom development, and   
consulting.                                                                     

SERVICE AND SYSTEMS                                                             

Revenues from software license fees are recognized using the          
percentage-of-completion method for contracts in which the Company is required  
to make significant production, modification, or customization changes over the 
implementation period of the contracts based on implementation hours incurred.  
Other software license fees are generally recognized on a monthly basis over the
term of the licensing and maintenance agreements which are generally five years.
Remote processing and outsourcing services are                                  

F-30

S-4
160th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 160th
ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995 AND 1996 -- (CONTINUED) 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                       
marketed under long-term agreements generally over periods from five to seven   
years and revenues are recognized monthly as the work is performed. Software    
maintenance fees are marketed under annual and multiyear agreements and are     
recognized ratably over the term of the agreements. Implementation revenues are 
recognized as the services are performed or on a percentage-of-completion basis 
for fixed fee arrangements. Hardware maintenance revenues are billed and        
recognized monthly over the term of the agreements. Revenues related to other   
support services, such as training, consulting, and custom development, are     
recognized when the services are performed.                                     

The Company warrants its products will perform in accordance with     
specifications as outlined in the respective customer contracts. The Company    
records a reserve for warranty costs at the time it recognizes revenue.         
Historically, warranty costs have been minimal.                                 

    The Company accrues for product returns at the time it recognizes revenue,
based on actual experience. Historically, product return costs have been        
minimal.                                                                        

HARDWARE SALES                                                                  

     Hardware sales are recognized upon shipment of the product to the customer.

UNBILLED ACCOUNTS RECEIVABLE                                                    

  Unbilled accounts receivable represent amounts owed to the Company under
noncancelable agreements for software license fees with extended payment terms  
and computer hardware purchases which have been financed over extended payment  
terms. The current portion of unbilled accounts receivable of $4,883,000 and    
$3,245,000 as of December 31, 1995 and 1996, respectively, is included in       
accounts receivable in the accompanying financial statements. The non-current   
portion of unbilled accounts receivable of $2,109,000 and $2,151,000 as of      
December 31, 1995 and 1996, respectively, is included in other assets in the    
accompanying financial statements. The non-current portion of unbilled accounts 
receivable provides for payment terms that generally range from three to five   
years and carry annual interest rates ranging from 7% to 10%. The Company       
recognizes revenue in advance of billings under certain of its non-cancelable   
long-term contracts that contain extended payment terms. The Company does not   
have any obligation to refund any portion of its fees and has a history of      
enforcement and collection of amounts due under such arrangements. Payments owed
under contracts with extended payment terms are due in accordance with the terms
of the respective contract. Historically, the Company has had minimal write-offs
of amounts due under such arrangements.                                         

Additionally, included in unbilled accounts receivable are costs and  
earnings in excess of billings related to certain software license fee          
arrangements which are being recognized on a percentage-of-completion basis.    
These amounts totaled approximately $1,572,000 and $1,240,000 as of December 31,
1995 and 1996, respectively.                                                    

INVENTORY                                                                       

   Inventory consists of computer parts and peripherals and is stated at the
lower of cost or market. Cost is determined using the first-in, first-out       
method.                                                                         

FOREIGN CURRENCY TRANSLATION                                                    

  The financial position and results of operations of foreign subsidiaries
are measured using the currency of the respective countries as the functional   
currency. Assets and liabilities are translated at the foreign exchange rate in 
effect at the balance sheet date, while revenues and expenses for the year are  
translated at the average exchange rate in effect during the year. Translation  
gains and losses are not included in                                            

F-31

S-4
161st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 161st
ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995 AND 1996 -- (CONTINUED) 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                       
determining net income or loss but are accumulated and reported as a separate   
component of shareholder's deficit. The Company has not entered into any hedging
contracts during the two year period ended December 31, 1996.                   

PROPERTY AND EQUIPMENT                                                          

Property and equipment are stated at cost. For financial reporting    
purposes, depreciation and amortization are provided using the straight-line    
method over the estimated useful lives, which range from two to ten years.      
Computer equipment is depreciated over useful lives which range from two to five
years. Office furniture and equipment is depreciated over two to ten years.     
Leasehold improvements are amortized over the shorter of the useful lives of the
assets or the remaining term of the lease. When assets are retired or otherwise 
disposed of, the related costs and accumulated depreciation are removed from the
accounts and any resulting gain or loss is reflected in income. Expenditures for
repairs and maintenance not considered to substantially lengthen the property   
lives are charged to expense as incurred.                                       

CAPITALIZED SOFTWARE DEVELOPMENT COSTS                                          

The Company capitalizes a portion of the internal computer software   
development costs incurred. Salaries, overhead, and other related costs incurred
in connection with programming and testing software products are capitalized    
subsequent to establishing technological feasibility. Management monitors the   
net realizable value of all capitalized software development costs to ensure    
that the investment will be recovered through margins from future sales. These  
costs are amortized utilizing the straight-line method over periods of 36-60    
months. Capitalized costs related to software development were approximately    
$12,905,000 and $12,170,000, for the years ended December 31, 1995 and 1996,    
respectively and $750,000 for the period from January 1, 1997 through January   
23, 1997. Amortization of capitalized software development costs amounted to    
approximately $6,470,000 and $7,209,000 for the years ended December 31, 1995   
and 1996, respectively, and $377,000 for the period from January 1, 1997 through
January 23, 1997 and is included in operating expenses in the accompanying      
statements of operations.                                                       

INTANGIBLE ASSETS                                                               

The intangible assets arose from the acquisition of Medical Data      
Technology, Inc. (see Note 5), are stated at cost less accumulated amortization,
and consist of contracts and the excess of cost over fair value of net assets   
acquired. The intangible assets are being amortized using the straight-line     
method over seven years.                                                        

The carrying value of the excess of cost over fair value of net assets
acquired is reviewed if the facts and circumstances suggest that it may be      
impaired. This review indicates if the asset will not be recoverable as         
determined based on future expected cash flows. Based on its review, the Company
does not believe that an impairment of its excess of cost over fair value of net
assets acquired has occurred.                                                   

FAIR VALUE OF FINANCIAL INSTRUMENTS                                             

     The carrying amounts of the Company's financial instruments, including cash
and cash equivalents, accounts receivable, and other current liabilities        
approximate fair value. The carrying amount of the intercompany payable to      
parent balance approximates fair value based on current rates of interest       
available to Alltel, and accordingly, the Company, for loans of similar         
maturities.                                                                     

F-32

S-4
162nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 162nd
ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995 AND 1996 -- (CONTINUED) 

3. PROPERTY AND EQUIPMENT                                                       

   Property and equipment consists of the following at December 31, 1995 and
1996 (in thousands):                                                            

                                                                [Download Table]

                                                               1995       1996   
                                                             --------   -------- 
                                                                                 
Computer equipment.......................................... $ 21,106   $ 25,093 
Office furniture and equipment..............................    2,815      4,198 
Leasehold improvements and other............................    2,407      3,461 
                                                             --------   -------- 
                                                               26,328     32,752 
Less: Accumulated depreciation and amortization.............  (16,160)   (22,013)
                                                             --------   -------- 
                                                             $ 10,168   $ 10,739 
                                                             ========   ======== 

4. OTHER ASSETS                                                                 

     During 1996, the Company entered into a marketing agreement with Integrated
Medical Networks, Inc. ("IMN") for the marketing rights of certain software     
which will provide financial and managed care applications for entities within  
the healthcare industry. Under the terms of the agreement, IMN will perform     
significant enhancements to existing technology over a three year period. AHIS  
will retain worldwide, perpetual marketing rights, as defined, for the resulting
technology. For the year ended December 31, 1996, AHIS made payments totaling   
approximately $5,811,000 under this agreement and is included in other assets in
the accompanying financial statements. As discussed in Note 12, this agreement  
and related asset was transferred to Alltel in conjunction with the sale of the 
Company.                                                                        

5. OTHER CURRENT LIABILITIES                                                    

     Included in other current liabilities were the following as of December 31,
1995 and 1996 (in thousands):                                                   

                                                                [Download Table]

                                                              1995     1996  
                                                             -------  -------
                                                                             
Accrued compensation and incentives......................... $ 6,434  $ 6,603
Accrued hardware costs......................................   3,700    3,326
Accrued royalty costs.......................................   1,045      648
Current portion of long-term debt...........................     260       86
Other.......................................................   6,229    9,715
                                                             -------  -------
                                                             $17,668  $20,378
                                                             =======  =======

6. INCOME TAXES                                                                 

     The Company files its income tax return with AIS which files as part of the
consolidated Alltel group. Income tax expense and related balances shown in the 
accompanying financial statements have been determined as if the Company filed  
its tax return on a separate company basis.                                     

F-33

S-4
163rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 163rd
ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995 AND 1996 -- (CONTINUED) 

6. INCOME TAXES (CONTINUED)                                                     
The income tax benefit (provision) consists of the following (in      
thousands):                                                                     

                                                        [Enlarge/Download Table]

                                                                        PERIOD ENDED  
                                                   1995      1996     JANUARY 23, 1997
                                                  -------   -------   ----------------
                                                                                      
Current                                                                               
  Federal........................................ $ 4,123   $ 2,503         $ --      
  State and other................................   1,030       626           --      
                                                  -------   -------         ----      
Deferred.........................................   5,153     3,129           --      
                                                  -------   -------         ----      
  Federal........................................  (4,833)   (1,829)         377      
  State and other................................  (1,207)     (457)          69      
                                                  -------   -------         ----      
                                                   (6,040)   (2,286)         446      
                                                  -------   -------         ----      
                                                  $  (887)  $   843         $446      
                                                  =======   =======         ====      

     A reconciliation of the federal statutory rate and the effective income tax
rate follows (in thousands):                                                    

                                                                [Download Table]

                                                                    PERIOD ENDED  
                                                 1995     1996    JANUARY 23, 1997
                                                 -----   ------   ----------------
                                                                                  
Statutory federal income tax rate (34%)......... $(508)  $1,033         $413      
  Meals and entertainment.......................  (128)    (164)         (14)     
  State income taxes............................  (141)      76           46      
  Non-deductible amortization...................   (91)    (101)          (8)     
  Other.........................................   (19)      (1)          --      
                                                 -----   ------         ----      
  Income tax benefit (provision)................ $(887)  $  843         $437      
                                                 =====   ======         ====      

     The significant components of the Company's net deferred tax liability were
as follows (in thousands):                                                      

                                                                [Download Table]

                                                               1995       1996   
                                                             --------   -------- 
                                                                                 
Deferred tax assets                                                              
  Deferred revenue.......................................... $  4,009   $  3,596 
  Inventory and accounts receivable allowances..............      710        846 
  Compensation related accrued expenses.....................      584        806 
  Accrued expenses..........................................    1,627      1,624 
  Deferred rent.............................................      660        484 
  Other.....................................................    1,949        844 
                                                             --------   -------- 
                                                                9,539      8,200 
                                                             --------   -------- 
Deferred tax liabilities                                                         
  Capitalization of software development costs..............  (10,298)   (11,475)
  Depreciation..............................................   (1,039)      (856)
  Other.....................................................   (1,528)    (1,481)
                                                             --------   -------- 
                                                              (12,865)   (13,812)
                                                             --------   -------- 
Net deferred tax liability.................................. $ (3,326)  $ (5,612)
                                                             ========   ======== 

F-34

S-4
164th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 164th
ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995 AND 1996 -- (CONTINUED) 

7. EMPLOYEE BENEFIT PLANS                                                       

 Effective January 1, 1995, through Alltel, employees of the Company may
participate in a noncontributory, trusteed profit-sharing plan which covers     
substantially all employees who meet certain length-of-service requirements.    
Company contributions are determined annually by the Board of Directors of      
Alltel. Contributions to the plan approximated $1,516,000 and $1,781,000 for the
years ended December 31, 1995 and 1996, respectively. During 1994, the Company  
maintained a defined contribution profit-sharing plan. This plan was merged into
the Alltel trusteed thrift plan, discussed below during 1995.                   

Also, effective January 1, 1995, through Alltel, substantially all    
employees of the Company may participate in the Alltel trusteed thrift plan.    
Employees may contribute up to 10% of the employee's salary and the employer's  
matching contribution is the lesser of 25% of the employee's contribution or    
1.5% of the employee's salary. The trusteed thrift plan is intended to meet all 
requirements of qualifications under Section 401(k) of the Internal Revenue     
Code. Company contributions to the trusteed thrift plan were approximately      
$412,000 and $452,000 for the years ended December 31, 1995 and 1996,           
respectively.                                                                   

     During 1995, employees of the Company became eligible to participate in the
AIS Employee Stock Purchase Plan (the "ESPP") which has reserved for issuance   
1,000,000 shares of Alltel common stock. The ESPP provides for the purchase of  
shares of common stock by employees through payroll deductions which may not    
exceed five percent of employee compensation, as defined. The employee          
contributes 85% of the prevailing market price of the shares, which are         
purchased on the open market. The remaining 15% is expensed by the Company in   
the period the contribution is made. Company contributions to the ESPP were     
approximately $104,000 and $48,000 for the years ended December 31, 1995 and    
1996, respectively. On June 30, 1996, the ESPP was terminated.                  

     During 1995, the employees of the Company became eligible to participate in
various benefit plans which were administered by Alltel. In addition to the     
trusteed profit-sharing plan and trusteed thrift plan, employees were also      
eligible to participate in certain benefit plans including group medical, dental
and other various plans. Total expenses related to these plans were             
approximately $2,196,000 and $2,328,000 for the years ended December 31, 1995   
and 1996, respectively and $194,000 for the period from January 1, 1997 through 
January 23, 1997.                                                               

8. COMMITMENTS AND CONTINGENCIES                                                

NONCANCELABLE OPERATING LEASES                                                  

The Company leases offices and certain equipment under noncancelable  
operating leases. Rental expense under operating leases was approximately       
$7,014,000 and $5,531,000 for the years ended December 31, 1995 and 1996,       
respectively, and $461,000 for the period from January 1, 1997 through January  
23, 1997. Future minimum rental payments for noncancelable operating leases as  
of December 31, 1996 are as follows (in thousands):                             

                                                                [Download Table]

             YEAR ENDING DECEMBER 31,                           
             ------------------------                           
                                                                
1997...................................................  $ 4,877
1998...................................................    4,818
1999...................................................    3,625
2000...................................................    1,535
2001...................................................    1,414
Thereafter.............................................    1,798
                                                         -------
                                                         $18,067
                                                         =======

F-35

S-4
165th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 165th
ALLTEL HEALTHCARE INFORMATION SERVICES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995 AND 1996 -- (CONTINUED) 

8. COMMITMENTS AND CONTINGENCIES (CONTINUED)                                    
LITIGATION                                                                      

  The Company is involved in litigation incidental to its business. In the
opinion of management, after consultation with legal counsel, the ultimate      
outcome of such litigation will not have a material adverse effect on the       
Company's financial position or results of operations or cash flows.            

9. RELATED PARTY TRANSACTIONS                                                   

The intercompany payable to parent balance represents amounts owed to 
Alltel related to cash disbursements and receipts activity and certain other    
transactions. All vendor related invoices are charged to this account at the    
time an invoice is processed and, consequently, the accompanying financial      
statements do not reflect an accounts payable balance. The intercompany balance 
is reduced upon the posting of cash receipts. Intercompany interest of          
approximately $2,833,000 and $3,858,000 for the years ended December 31, 1995   
and 1996, respectively, and $379,000 for the period from January 1, 1997 through
January 23, 1997 was charged to this account at interest rates which ranged from
3.5% to 8.0% which represented the incremental borrowing rates of Alltel. As    
more fully discussed in Note 12, the intercompany payable balance was converted 
to equity on January 24, 1997 in connection with the sale of the Company.       

    For the years ended December 31, 1995 and 1996, Alltel charged the Company
approximately $2,277,000 and $2,100,000, respectively, and $175,000 for the     
period January 1, 1997 through January 24, 1997 for costs related to providing  
certain data center charges in conjunction with an outsourcing contract between 
the Company and one of its customers.                                           

  During 1995 and 1996, legal services and external fees were provided and
paid by Alltel. These costs were approximately $1,869,000 and $964,000 for the  
years ended December 31, 1995 and 1996, respectively, and are reflected in      
general and administrative expenses in the accompanying financial statements.   

     During 1996 certain administrative services were performed by AIS, the cost
of which was estimated to be approximately $585,000 and is reflected in general 
and administrative expenses in the accompanying financial statements. Prior to  
1996, these functions were performed directly by employees of the Company and,  
accordingly, the related costs are reflected in the accompanying financial      
statements.                                                                     

10. SUBSEQUENT EVENT                                                            

On January 24, 1997, the Company was purchased by Eclipsys Corporation
(formerly Integrated Healthcare Solutions, Inc.) for cash and other             
consideration totaling approximately $201,500,000, including liabilities        
assumed. Pursuant to the acquisition agreement, Alltel will retain the rights to
certain assets of the Company. These assets include the IMN marketing rights    
(Note 4) with a balance of approximately $5,811,000 as of December 31, 1996 and 
one of the Company's software products with related net capitalized software    
costs as of December 31, 1996 of approximately $6,543,000.                      

F-36

S-4
166th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 166th

INDEPENDENT AUDITORS' REPORT

The Board of Directors                                                          
SDK Healthcare Information Systems:                                             

We have audited the accompanying balance sheets of SDK Healthcare     
Information Systems as of April 30, 1997 and 1996, and the related statements of
operations and retained earnings, and cash flows for the years then ended. These
financial statements are the responsibility of the Company's management. Our    
responsibility is to express an opinion on these financial statements based on  
our audits.                                                                     

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain 
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting 
the amounts and disclosures in the financial statements. An audit also includes 
assessing the accounting principles used and significant estimates made by      
management, as well as evaluating the overall financial statement presentation. 
We believe that our audits provide a reasonable basis for our opinion.          

    In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of SDK Healthcare Information  
Systems at April 30, 1997 and 1996, and the results of its operations and its   
cash flows for the years then ended, in conformity with generally accepted      
accounting principles.                                                          

                         KPMG PEAT MARWICK LLP

Boston, Massachusetts                                                           
June 12, 1997 (except for note 10 which is as of June 26, 1997)                 

F-37

S-4
167th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 167th

SDK HEALTHCARE INFORMATION SYSTEMS
BALANCE SHEETS
APRIL 30, 1997 AND 1996 

                                                                [Download Table]

                                                                1997        1996   
                                                             ----------  ----------
                                                                                   
                           ASSETS                                                  
Current assets:                                                                    
  Cash and cash equivalents................................. $  674,047  $  384,920
  Accounts receivable, trade, less allowance for doubtful                          
     accounts of $148,522 in 1997 and 1996 (note 9).........  1,038,868   1,314,429
  Revenue in excess of billings.............................    230,456     473,264
  Current portion of notes receivable.......................     72,236      85,836
  Prepaid expenses..........................................     14,480      13,998
                                                             ----------  ----------
          Total current assets..............................  2,030,087   2,272,447
                                                             ----------  ----------
Property, plant and equipment (notes 3 and 5)...............  5,268,787   5,210,881
  Less accumulated depreciation and amortization............  4,444,571   4,236,990
                                                             ----------  ----------
     Net property, plant and equipment......................    824,216     973,891
                                                             ----------  ----------
Software production costs, net (note 2c)....................    780,829     719,367
Notes receivable, net of current portion....................     14,264      86,500
Other assets................................................     32,766      32,356
                                                             ----------  ----------
          Total assets...................................... $3,682,162  $4,084,561
                                                             ==========  ==========
            LIABILITIES AND STOCKHOLDERS' EQUITY                                   
Current liabilities:                                                               
  Current capital lease obligation, building (note 5)....... $  182,499  $  149,705
  Accounts payable..........................................    285,665     310,275
  Accrued expenses..........................................    332,951     295,467
  Income taxes payable......................................    164,703     232,504
Deferred revenue............................................    525,186     263,320
Deferred income taxes (note 6)..............................     60,236      47,344
                                                             ----------  ----------
          Total current liabilities.........................  1,551,240   1,298,615
                                                             ----------  ----------
Capital lease obligation, building, excluding current                              
  installment (note 5)......................................    264,035     446,534
Deferred income taxes (note 6)..............................    144,210     279,001
                                                             ----------  ----------
          Total liabilities.................................  1,959,485   2,024,150
                                                             ----------  ----------
Stockholders' equity (note 7):                                                     
  Preferred stock, $6 noncumulative, no par. Authorized,                           
     issued and outstanding 2,500 shares ($100 per share                           
     liquidation preference)................................    250,000     250,000
  Common stock, voting, no par. Authorized 10,000; issued                          
     and outstanding 5,000 shares...........................     10,000      10,000
  Common stock, nonvoting, $.01 par. Authorized 700,000                            
     shares; issued and outstanding 505,500 shares..........      5,055       5,055
  Additional paid-in capital................................     52,046      52,046
  Retained earnings.........................................  1,405,576   1,743,310
                                                             ----------  ----------
          Total stockholders' equity........................  1,722,677   2,060,411
                                                             ----------  ----------
               Total liabilities and stockholders' equity... $3,682,162  $4,084,561
                                                             ==========  ==========

See accompanying notes to financial statements. 
F-38

S-4
168th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 168th

SDK HEALTHCARE INFORMATION SYSTEMS
STATEMENTS OF OPERATIONS AND RETAINED EARNINGS
YEARS ENDED APRIL 30, 1997 AND 1996 

                                                        [Enlarge/Download Table]

                                                                1997         1996    
                                                             ----------   ---------- 
                                                                                     
Revenues (note 9)........................................... $6,801,412   $9,545,114 
Operating expenses:                                                                  
  Cost of revenues..........................................  4,624,029    5,775,035 
  Sales and marketing.......................................    916,891    1,013,875 
  General and administrative................................  1,334,808    1,270,825 
  Research and development..................................    308,570      378,574 
                                                             ----------   ---------- 
     Total operating expenses...............................  7,184,298    8,438,309 
                                                             ----------   ---------- 
     Income (loss) from operations..........................   (382,886)   1,106,805 
                                                             ----------   ---------- 
Other (income) expense:                                                              
  Interest income...........................................    (24,825)     (14,077)
  Interest expense -- capital leases........................    105,871      132,773 
  Interest expense -- other.................................        866        8,144 
                                                             ----------   ---------- 
     Total other expense....................................     81,912      126,840 
                                                             ----------   ---------- 
     Income (loss) before income taxes......................   (464,798)     979,965 
                                                             ----------   ---------- 
Income tax expense (benefit) (note 6):                                               
  Current...................................................     (5,165)     287,315 
  Deferred..................................................   (121,899)     119,867 
                                                             ----------   ---------- 
                                                               (127,064)     407,182 
                                                             ----------   ---------- 
     Net income (loss)......................................   (337,734)     572,783 
Retained earnings at beginning of year......................  1,743,310    1,170,527 
                                                             ----------   ---------- 
Retained earnings at end of year............................ $1,405,576   $1,743,310 
                                                             ==========   ========== 
Earnings (loss) per common share............................ $     (.66)  $     1.12 
                                                             ==========   ========== 
Weighted average common shares outstanding..................    510,500      510,500 
                                                             ==========   ========== 

See accompanying notes to financial statements. 
F-39

S-4
169th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 169th

SDK HEALTHCARE INFORMATION SYSTEMS
STATEMENTS OF CASH FLOWS
YEARS ENDED APRIL 30, 1997 AND 1996 

                                                                [Download Table]

                                                               1997         1996    
                                                             ---------   ---------- 
                                                                                    
Cash flows from operating activities:                                               
  Net income (loss)......................................... $(337,734)  $  572,783 
  Adjustments to reconcile net income (loss) to net cash                            
     provided by operating activities:                                              
     Depreciation and amortization..........................   609,405      644,518 
     Recovery of losses on accounts receivable..............        --      (20,971)
     Deferred income taxes..................................  (121,899)      86,855 
     Changes in operating assets and liabilities:                                   
       Accounts receivable, trade...........................   275,561      400,350 
       Prepaid expenses.....................................      (482)          72 
       Other current assets.................................   242,808     (445,347)
       Accounts payable.....................................   (24,610)    (159,748)
       Accrued expenses.....................................    37,484       36,312 
       Income taxes payable.................................   (67,801)     232,504 
       Deferred revenue.....................................   261,866       85,350 
                                                             ---------   ---------- 
          Net cash provided by operating activities.........   874,598    1,432,678 
                                                             ---------   ---------- 
Cash flows from investing activities:                                               
  Additions to property, plant and equipment................   (65,737)    (155,817)
  Additions to software production costs....................  (455,455)    (448,031)
  Other assets..............................................      (410)        (988)
                                                             ---------   ---------- 
          Net cash used for investing activities............  (521,602)    (604,836)
                                                             ---------   ---------- 
Cash flows from financing activities:                                               
  Net repayments under line-of-credit agreement.............        --     (633,114)
  Payments on obligations under capital leases..............  (149,705)    (122,803)
  Decrease in notes receivable..............................    85,836       86,491 
                                                             ---------   ---------- 
          Net cash used for financing activities............   (63,869)    (669,426)
                                                             ---------   ---------- 
Net increase in cash and cash equivalents...................   289,127      158,416 
Cash and cash equivalents at beginning of year..............   384,920      226,504 
                                                             ---------   ---------- 
Cash and cash equivalents at end of year.................... $ 674,047   $  384,920 
                                                             =========   ========== 
Supplemental disclosures of cash flow information:                                  
  Cash paid during the year for:                                                    
     Interest............................................... $ 106,737   $  140,917 
                                                             =========   ========== 
     Income taxes........................................... $  19,725   $   88,118 
                                                             =========   ========== 

See accompanying notes to financial statements. 
F-40

S-4
170th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 170th

SDK HEALTHCARE INFORMATION SYSTEMS
NOTES TO FINANCIAL STATEMENTS 
APRIL 30, 1997 AND 1996 

(1) NATURE OF BUSINESS                                                          

  The Company designs, markets, installs and supports a totally integrated
Patient Financial Management System. This turnkey software solution provides    
single facility and multi-entity organizations with the ability to track and    
process billing for traditional and managed care patients from initial patient  
scheduling through final account resolution. The Company additionally offers    
complete installation and training services, as well as facilities management   
and remote processing from its corporate based data center. The Company does    
business as SDK Healthcare Information Systems; however, its legal name is SDK  
Medical Computer Services Corporation. The Company has offices in Boston,       
Massachusetts (corporate headquarters) and Albany, New York.                    

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                                  

(a) Revenue Recognition                                                     

  Revenue from software licensing fees is recognized: (a) upon delivery of
the software, if no significant obligations remain; (b) when the software has   
been delivered and the obligations have been performed, if significant          
obligations are required; and (c) under the percentage-of-completion method of  
accounting, if significant production, modification or customization of the     
software is required.                                                           

The Company recognizes service revenue from its remote data processing
services upon delivery of the service.                                          

  Revenues from maintenance agreements are recognized over the term of the
agreement. Advance billings to customers are recorded as deferred revenue until 
earned. The Company recognizes revenues from hardware sales upon shipment of the
hardware.                                                                       

(b) Property, Plant and Equipment                                           

 Property, plant and equipment is stated at cost. Property under capital
leases is stated at the lower of the present value of minimum lease payments at 
the beginning of the lease term or fair value at the inception of the lease.    

Depreciation on property, plant and equipment is calculated using     
straight-line and accelerated methods over the estimated useful lives of the    
assets. Property held under capital lease and leasehold improvements are        
amortized on the straight-line method over the shorter of the lease term or     
estimated useful life of the asset.                                             

    In accordance with Financial Accounting Standards Board Statement No. 121,
Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to 
be Disposed of, the Company reviews its long-lived assets for impairment        
whenever events or changes in circumstances indicate that the carrying amount of
an asset may not be recoverable. If it is determined that the carrying amount of
an asset cannot be fully recovered, an impairment loss is recognized.           

(c) Software Production Costs                                               

  The Company capitalizes the costs of producing software product masters,
which include coding and testing. Direct costs of establishing technological    
feasibility (planning and designing, including detailed program design) are     
charged to research and development expense as incurred.                        

 The total amount of software production costs capitalized during fiscal
1997 and 1996 amounted to $445,455 and $448,031, respectively. Such costs are   
amortized on a product-by-product basis at the greater of the amount computed   
using (a) the ratio that current revenues for the product bear to the total of  
current and anticipated future revenues for that product or (b) the             
straight-line method over the estimated                                         
F-41

S-4
171st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 171st
SDK HEALTHCARE INFORMATION SYSTEMS
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
APRIL 30, 1997 AND 1996 

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)                      
economic life of the product, generally three years. The recoverability of such 
costs is reviewed on an ongoing basis. Amortization totaled $393,993 and        
$450,251 for 1997 and 1996, respectively.                                       

(d) Research and Development Costs                                          

   Research and development costs are charged to operations as incurred. For
the years ended April 30, 1997 and 1996, research and development costs incurred
were $308,570 and $378,574, respectively.                                       

(e) Cash and Cash Equivalents                                               

For purposes of the statement of cash flows, all highly liquid debt   
instruments with an original maturity of three months or less are considered to 
be cash equivalents.                                                            

(f) Income Taxes                                                            

  The Company uses the asset and liability method of accounting for income
taxes. Under the asset and liability method, deferred tax assets and liabilities
are recognized for the future tax consequences attributable to differences      
between the financial statement carrying amounts of existing assets and         
liabilities and their respective tax bases and operating loss and tax credit    
carryforwards. Deferred tax assets and liabilities are measured using enacted   
tax rates expected to apply to taxable income in the years in which those       
temporary differences are expected to be recovered or settled. The effect on    
deferred tax assets and liabilities of a change in tax rates is recognized in   
income in the period that includes the enactment date.                          

(g) Use of Estimates                                                        

  Management of the Company has made a number of estimates and assumptions
relating to the reporting of assets and liabilities and the disclosure of       
contingent assets and liabilities to prepare these financial statements in      
conformity with generally accepted accounting principles. Actual results could  
differ from those estimates.                                                    

(h) Fair Value of Financial Instruments                                     

    Financial instruments of the Company consist of cash and cash equivalents,
accounts receivable, notes receivable, accounts payable and notes payable. The  
carrying amount of these financial instruments approximates their fair value.   

(i) Earnings per share                                                      

Net income (loss) per share is computed based on the weighted average 
number of equivalent shares of the Company's common stock outstanding during    
each period. Fully diluted net income (loss) per share is not significantly     
different from primary net income (loss) per share amounts.                     

(j) Reclassifications                                                       

 Certain reclassifications were made to the 1996 financial statements to
conform to the 1997 presentation.                                               

F-42

S-4
172nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 172nd
SDK HEALTHCARE INFORMATION SYSTEMS
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
APRIL 30, 1997 AND 1996 

(3) PROPERTY, PLANT AND EQUIPMENT                                               

Property, plant and equipment consisted of the following at April 30: 

                                                                [Download Table]

                                                                1997        1996   
                                                             ----------  ----------
                                                                                   
Land and buildings.......................................... $1,101,702  $1,101,702
Building improvements.......................................    730,370     730,370
Equipment...................................................  3,113,776   3,071,653
Furniture and fixtures......................................    236,263     220,480
Motor vehicles..............................................     86,676      86,676
                                                             ----------  ----------
                                                             $5,268,787  $5,210,881
                                                             ==========  ==========

(4) FINANCING ARRANGEMENT                                                       

The Company has available a bank line-of-credit which provides for    
unsecured borrowings of up to $1,250,000. There were no borrowings outstanding  
at April 30, 1997 or 1996. Interest is payable monthly at an annual rate equal  
to the prime rate plus .75%. At April 30, 1997 and 1996, this rate was 8.5% and 
9.0%, respectively.                                                             

(5) LEASE OBLIGATIONS                                                           

 The Company leases its principal operating facilities from a trust, the
beneficiaries of which are certain stockholders of the Company. The original    
lease, entered into in June 1984, called for expiration in July 1989 and allowed
for renewal of three five-year terms. In April 1990, the lease was revised to   
extend the expiration date through July 1999 and reduce the monthly rental      
payments. In addition to the basic annual rent, as adjusted for changes in the  
Consumer Price Index, the Company is obligated to pay all real estate taxes. The
lease has been accounted for as a capital lease.                                

     The Company leased computer equipment under capital leases which expired at
various dates through 1996. The Company also leases equipment under leases      
expiring through 1999, which have been accounted for as operating leases.       

   The present value of future minimum capital lease payments and the future
minimum lease payments under noncancelable operating leases as of April 30,     
1997, are as follows:                                                           

                                                                [Download Table]

                                                              CAPITAL    OPERATING
                                                              LEASES      LEASES  
                                                             ---------   ---------
                                                                                  
Year ending April 30:                                                             
  1998...................................................... $ 255,576    $26,270 
  1999......................................................   255,576      3,160 
  2000......................................................    42,596         -- 
                                                             ---------    ------- 
     Minimum future lease payments..........................   553,748    $29,430 
                                                                          ======= 
Less amounts representing interest..........................  (107,214)           
                                                             ---------            
     Present value of minimum future lease payments.........   446,534            
Less current installments...................................  (182,499)           
                                                             ---------            
     Obligations under capital leases, excluding current                          
       installments......................................... $ 264,035            
                                                             =========            

     Rent expense under operating leases amounted to $33,787 in 1997 and $61,825
in 1996.                                                                        

F-43

S-4
173rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 173rd
SDK HEALTHCARE INFORMATION SYSTEMS
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
APRIL 30, 1997 AND 1996 

(5) LEASE OBLIGATIONS (CONTINUED)                                               
     The related assets and accumulated amortization thereon under capital lease
obligations are included in property, plant and equipment at April 30, 1997, as 
follows:                                                                        

                                                                [Download Table]
                                                                          
Building....................................................  $ 1,101,702 
Equipment...................................................      148,157 
                                                              ----------- 
                                                                1,249,859 
Less accumulated amortization...............................   (1,087,775)
                                                              ----------- 
                                                              $   162,084 
                                                              =========== 

(6) INCOME TAXES                                                                

Income tax expense (benefit) consists of the following at April 30:   

                                                        [Enlarge/Download Table]

                                                     CURRENT    DEFERRED      TOTAL   
                                                     --------   ---------   --------- 
                                                                                      
1997:                                                                                 
  Federal........................................... $  3,668   $ (93,221)  $ (89,553)
  State.............................................   (8,833)    (28,678)    (37,511)
                                                     --------   ---------   --------- 
                                                     $ (5,165)  $(121,899)  $(127,064)
                                                     ========   =========   ========= 
1996:                                                                                 
  Federal........................................... $195,370   $ 117,104   $ 312,474 
  State.............................................   91,945       2,763      94,708 
                                                     --------   ---------   --------- 
                                                     $287,315   $ 119,867   $ 407,182 
                                                     ========   =========   ========= 

 Total income tax expense (benefit) differs from the amounts computed by
applying the U.S. federal income tax rate of 34% as a result of the following:  

                                                                [Download Table]

                                                               1997        1996  
                                                             ---------   --------
                                                                                 
Computed "expected" tax expense (benefit)................... $(136,611)  $333,188
State and local income taxes (benefit), net of federal tax                       
  benefit...................................................   (23,539)    62,507
Research and development credit.............................        --         --
Nondeductible expenses......................................     8,968      5,765
Other.......................................................    24,118      5,722
                                                             ---------   --------
                                                             $(127,064)  $407,182
                                                             =========   ========

F-44

S-4
174th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 174th
SDK HEALTHCARE INFORMATION SYSTEMS
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
APRIL 30, 1997 AND 1996 

(6) INCOME TAXES (CONTINUED)                                                    
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities at April 30 are
presented below:                                                                

                                                                [Download Table]

                                                               1997        1996    
                                                             ---------   --------- 
                                                                                   
Current deferred tax assets (liabilities):                                         
  Deferred revenues......................................... $  16,315   $  45,634 
  Accounts receivable due to allowance for doubtful                                
     accounts...............................................    59,810      45,716 
  Cash basis adjustment.....................................  (153,438)   (153,438)
  Other.....................................................    17,077      14,744 
                                                             ---------   --------- 
     Total net current deferred tax liabilities.............   (60,236)    (47,344)
                                                             ---------   --------- 
Noncurrent deferred tax assets (liabilities):                                      
  Capital lease treated as operating lease for tax                                 
     purposes...............................................   117,141     147,302 
  State net operating loss carryforward.....................     7,176          -- 
  Research credit and alternative minimum tax credits.......    45,119      21,539 
  Cash basis adjustment.....................................        --    (153,438)
  Software capitalized for books, expensed for tax                                 
     purposes...............................................  (314,440)   (289,688)
  Property, plant and equipment, principally depreciation...       794      (4,716)
                                                             ---------   --------- 
     Total net noncurrent deferred tax liabilities..........  (144,210)   (279,001)
                                                             ---------   --------- 
     Net deferred tax liabilities........................... $(204,446)  $(326,345)
                                                             =========   ========= 

The Company has research credit carryovers of approximately $45,000   
expiring in various amounts through the year 2010 which can be used to offset   
future federal taxable income and income taxes.                                 

(7) COMMON STOCK                                                                

 At April 30, 1986, options to purchase 7,500 shares of nonvoting common
stock of the Company were held by certain key employees under Nonqualified Stock
Option Agreements. The options were exercised in 1987 at prices of $.99-1.39 per
share, the fair market value at the date of grant. Shares issued under these    
agreements must be offered to the Company for repurchase at the then current    
book value as of the immediately preceding April 30 upon termination of         
employment or upon the occurrence of certain other events. There was no activity
during 1996 or 1997 under the agreements.                                       

(8) PROFIT-SHARING PLAN                                                         

 The Company maintains a profit-sharing plan for the benefit of eligible
employees. The Plan provides that the Company's contribution be determined by a 
resolution of the board of directors, and there is no minimum contribution      
required. The Company incurred profit-sharing expense of $137,921 and $100,000  
in 1997 and 1996, respectively.                                                 

(9) BUSINESS AND CREDIT CONCENTRATION                                           

    Substantially all of the Company's sales for 1997 and 1996 were to medical
facilities. Accordingly, all of the Company's accounts receivable at April 30,  
1997 and 1996, are due from medical facilities.                                 

F-45

S-4
175th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 175th
SDK HEALTHCARE INFORMATION SYSTEMS
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
APRIL 30, 1997 AND 1996 

(9) BUSINESS AND CREDIT CONCENTRATION (CONTINUED)                               
   The following table summaries sales to major customers as a percentage of
total sales for the period:                                                     

                                                                [Download Table]

                                                              1997   1996
                                                              ----   ----
                                                                         
Customer A..................................................  15%     -- 
Customer B..................................................  13%    21% 
Customer C..................................................  10%    17% 
Customer D..................................................   --    12% 

(10) SUBSEQUENT EVENT                                                           

On June 26, 1997, the Company was acquired by Eclipsys Corporation.   

F-46

S-4
176th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 176th

REPORT OF INDEPENDENT ACCOUNTANTS 

To the Board of Directors and                                                   
Stockholders of Transition Systems, Inc.:                                       

In our opinion, the accompanying consolidated balance sheets and the  
related consolidated statements of operations, of cash flows and of             
stockholders' equity present fairly, in all material respects, the financial    
position of Transition Systems, Inc. at September 30, 1997 and 1998, and the    
results of its operations and its cash flows for each of the three years in the 
period ended September 30, 1998, in conformity with generally accepted          
accounting principles. These financial statements are the responsibility of the 
Company's management; our responsibility is to express an opinion on these      
financial statements based on our audits. We conducted our audits of these      
statements in accordance with generally accepted auditing standards which       
require that we plan and perform the audit to obtain reasonable assurance about 
whether the financial statements are free of material misstatement. An audit    
includes examining, on a test basis, evidence supporting the amounts and        
disclosures in the financial statements, assessing the accounting principles    
used and significant estimates made by management, and evaluating the overall   
financial statement presentation. We believe that our audits provide a          
reasonable basis for the opinion expressed above.                               

                                  PRICEWATERHOUSECOOPERS LLP

Boston, Massachusetts                                                           
November 16, 1998                                                               

F-47

S-4
177th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 177th

TRANSITION SYSTEMS, INC.
CONSOLIDATED BALANCE SHEETS 
(IN THOUSANDS EXCEPT SHARE DATA)

                                                        [Enlarge/Download Table]

                                                                  SEPTEMBER 30,                     
                                                          -----------------------------   JUNE 30,  
                                                              1997            1998          1998    
                                                          -------------   -------------  -----------
                                                                                         (UNAUDITED)
                                                                                                    
ASSETS                                                                                              
Current assets:                                                                                     
  Cash and cash equivalents..............................    $58,485        $ 38,660       $65,179  
  Investments (Note 4)...................................         --          27,291            --  
  Accounts receivable, net (Note 3)......................     19,339          18,994        19,662  
  Other current assets...................................        696           1,483         1,179  
  Deferred income taxes (Note 13)........................        853           1,960           853  
                                                             -------        --------       -------  
     Total current assets................................     79,373          88,388        86,873  
                                                             -------        --------       -------  
  Property and equipment, net (Note 5)...................      1,357           1,457         1,638  
  Capitalized software costs, net........................      1,411           1,411         1,410  
  Purchased technology (Note 16).........................      1,376           1,160         1,219  
  Intangible assets, net.................................        302           1,448           674  
  Investment (Note 6)....................................      6,000           6,000         6,000  
                                                             -------        --------       -------  
     Total assets........................................    $89,819        $ 99,864       $97,814  
                                                             =======        ========       =======  
LIABILITIES AND STOCKHOLDERS' EQUITY                                                                
Current liabilities:                                                                                
  Accounts payable.......................................    $   279        $  1,168       $ 1,334  
  Accrued expenses.......................................      6,680           4,515         3,717  
  Income taxes payable...................................      1,476           1,067         2,871  
  Deferred revenue.......................................      7,369           8,090         7,676  
                                                             -------        --------       -------  
     Total current liabilities...........................     15,804          14,840        15,598  
                                                             -------        --------       -------  
  Deferred income taxes (Note 13)........................        496             752           496  
                                                             -------        --------       -------  
     Total liabilities...................................     16,300          15,592        16,094  
                                                             -------        --------       -------  
Commitments (Note 15)                                                                               
Stockholders' equity (Notes 2 and 9):                                                               
  Common stock, $.01 par value; 30,000,000 shares                                                   
     authorized at September 30, 1997 and 1998;                                                     
     17,713,683 shares issued and outstanding at                                                    
     September 30, 1997; 18,029,095 shares issued and                                               
     outstanding at September 30, 1998...................        177             180           179  
  Non-voting common stock, $.01 par value; 1,000,000                                                
     shares authorized at September 30, 1997 and 1998;                                              
     356,262 shares issued and outstanding at September                                             
     30, 1997 and 1998...................................          4               4             4  
  Non-voting common stock warrant........................        395             395           395  
  Additional paid-in capital.............................     46,717          48,610        47,778  
  Retained earnings......................................     26,226          35,083        33,364  
                                                             -------        --------       -------  
     Total stockholders' equity..........................     73,519          84,272        81,720  
                                                             -------        --------       -------  
     Total liabilities and stockholders' equity..........    $89,819        $ 99,864       $97,814  
                                                             =======        ========       =======  

The accompanying notes are an integral part of the consolidated financial 
statements. 
F-48

S-4
178th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 178th

TRANSITION SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS 
(IN THOUSANDS EXCEPT PER SHARE DATA)

                                                        [Enlarge/Download Table]

                                                                                 NINE MONTHS ENDED
                                               FISCAL YEAR ENDED SEPTEMBER 30,       JUNE 30,     
                                              ---------------------------------  -----------------
                                                1996        1997        1998      1997      1998  
                                              ---------   ---------   ---------  -------   -------
                                                                                    (UNAUDITED)   
                                                                                                  
Revenues:                                                                                         
  Software and implementation................  $24,860     $33,017     $30,224   $22,537   $23,881
  Maintenance................................    9,409      11,548      13,727     8,338    10,065
                                               -------     -------     -------   -------   -------
     Total revenues..........................   34,269      44,565      43,951    30,875    33,946
                                               -------     -------     -------   -------   -------
Cost of revenues:                                                                                 
  Software and implementation................    7,341      10,313      12,371     7,293     9,190
  Maintenance................................    3,165       2,835       2,932     2,062     2,125
Research and development.....................    3,310       3,872       5,925     2,709     4,435
Sales and marketing..........................    4,506       6,922       7,907     5,067     6,023
General and administrative...................    2,365       3,884       3,245     2,996     2,561
Compensation charge..........................    3,024          --          --        --        --
Acquired in-process research and development                                                      
  (Note 16)..................................       --       6,292          --        --        --
                                               -------     -------     -------   -------   -------
     Total operating expenses................   23,711      34,118      32,380    20,127    24,334
                                               -------     -------     -------   -------   -------
Income from operations.......................   10,558      10,447      11,571    10,748     9,612
Interest income..............................    1,294       2,501       3,191     1,798     2,285
Interest expense.............................   (1,241)         --          --        --        --
                                               -------     -------     -------   -------   -------
Income before income taxes and                                                                    
  extraordinary items........................   10,611      12,948      14,762    12,546    11,897
Provision for income taxes...................    4,324       7,629       5,905     5,018     4,759
                                               -------     -------     -------   -------   -------
Net income before extraordinary item.........    6,287       5,319       8,857     7,528     7,138
Extraordinary item:                                                                               
  Loss on early extinguishment of debt                                                            
     (net of taxes of $1,492)................    2,149          --          --        --        --
                                               -------     -------     -------   -------   -------
       Net income............................  $ 4,138     $ 5,319     $ 8,857   $ 7,528   $ 7,138
                                               =======     =======     =======   =======   =======
Series A non-voting preferred stock                                                               
  dividends..................................      593          --          --        --        --
                                               -------     -------     -------   -------   -------
     Net income allocable to common                                                               
       stockholders..........................  $ 3,545     $ 5,319     $ 8,857   $ 7,528   $ 7,138
                                               =======     =======     =======   =======   =======
Income per share (Note 2 and 9):                                                                  
  Net income allocable to common                                                                  
     stockholders............................  $ 3,545     $ 5,319     $ 8,857   $ 7,528   $ 7,138
     Basic income allocable per share........     0.27        0.31        0.49      0.43      0.39
     Diluted income allocable per share......     0.22        0.27        0.43      0.38      0.35
  Weighted average shares outstanding                                                             
     Basic...................................   13,214      17,435      18,210    17,333    18,153
     Diluted.................................   16,137      19,977      20,394    19,900    20,459

The accompanying notes are an integral part of the consolidated financial 
statements. 
F-49

S-4
179th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 179th

TRANSITION SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS 
(IN THOUSANDS)

                                                        [Enlarge/Download Table]

                                                                                                 NINE MONTHS ENDED  
                                                              FISCAL YEAR ENDED SEPTEMBER 30,        JUNE 30,       
                                                              -------------------------------   ------------------- 
                                                                1996       1997       1998        1997       1998   
                                                              --------   --------   ---------   --------   -------- 
                                                                                                    (UNAUDITED)     
                                                                                                                    
Cash flows from operating activities:                                                                               
  Net income................................................  $  4,138   $  5,319   $   8,857   $  7,528   $  7,138 
  Adjustments to reconcile net income to net cash provided                                                          
    by operating activities:                                                                                        
    Extraordinary item, gross...............................     3,642         --          --         --         -- 
    Write-off of in-process research and development........        --      6,292          --         --         -- 
    Deferred income taxes...................................    (1,640)     2,448        (851)     1,409         -- 
    Depreciation and amortization...........................     1,443      1,632       1,805      1,195      1,329 
    Compensation charge in connection with the                                                                      
      recapitalization......................................     3,024         --          --         --         -- 
    Compensation charge related to options granted..........        91        (91)         --        (92)        -- 
  Tax benefit from stock option exercises...................        --      2,770       1,201      2,162        467 
  Changes in operating assets and liabilities net of effects                                                        
    from purchase of businesses:                                                                                    
    Accounts receivable.....................................    (1,789)    (5,921)        345     (4,140)      (323)
    Other current assets....................................      (963)     1,135        (359)      (161)      (483)
    Accounts payable........................................       (98)      (315)        889       (289)     1,055 
    Accrued expenses........................................       243      2,388      (2,165)     1,428     (2,963)
    Due to affiliates.......................................        (9)        --          --         --         -- 
    Deferred revenue........................................     1,220      1,114         721        323        307 
    Income taxes payable....................................       731       (539)       (409)       468      1,395 
                                                              --------   --------   ---------   --------   -------- 
      Net cash provided by operating activities.............    10,033     16,232      10,034      9,831      7,922 
                                                              --------   --------   ---------   --------   -------- 
Cash flows provided by (used by) investing activities:                                                              
  Purchase of investments...................................    (1,595)      (250)    (36,870)      (250)        -- 
  Maturities of investments.................................     3,164        250       9,329         --         -- 
  Sales of investments......................................     5,755         --         250         --         -- 
  Note from related party...................................        --         --        (428)        --         -- 
  Purchase of property and equipment........................      (572)      (911)       (951)      (699)      (904)
  Additions to capitalized software costs...................      (704)      (712)       (700)      (537)      (524)
  Additions to intangible assets............................      (124)      (217)     (1,184)      (212)      (396)
  Investment................................................        --     (6,000)         --     (6,000)        -- 
  Acquisition of businesses, net of cash acquired...........    (1,728)    (2,667)         --         --         -- 
                                                              --------   --------   ---------   --------   -------- 
      Net cash (used by) provided by investing activities...     4,196    (10,507)    (30,554)    (7,698)    (1,824)
                                                              --------   --------   ---------   --------   -------- 
Cash flows provided by (used by) financing activities:                                                              
  Proceeds from initial public offering.....................   114,429         --          --         --         -- 
  Issuance of Series A preferred stock......................    20,000         --          --         --         -- 
  Redemption of Series A preferred stock....................   (20,000)        --          --         --         -- 
  Payments of Series A preferred stock dividends............      (593)        --          --         --         -- 
  Proceeds from issuance of debt............................    49,605         --          --         --         -- 
  Early extinguishment of debt..............................   (50,000)        --          --         --         -- 
  Proceeds from issuance of Series B preferred stock........    33,612         --          --         --         -- 
  Proceeds from issuance of Series C preferred stock........     1,388         --          --         --         -- 
  Payment of fees related to recapitalization...............    (3,360)        --          --         --         -- 
  Purchase of common stock..................................  (111,410)        --          --         --         -- 
  Exercise of options.......................................       783      1,237         594        760        495 
  Payments on note payable..................................        --         (9)         --         (7)        -- 
  Proceeds from stock purchase plan.........................        --         32         101         --        101 
  Proceeds from warrants issued.............................       394         --          --         --         -- 
  Equity issuance costs.....................................    (1,416)        (5)         --         (5)        -- 
                                                              --------   --------   ---------   --------   -------- 
      Net cash provided by financing activities.............    33,432      1,255         695        748        596 
                                                              --------   --------   ---------   --------   -------- 
Net increase (decrease) in cash and cash equivalents........    47,661      6,980     (19,825)     2,881      6,694 
Cash and cash equivalents -- beginning of year..............     3,844     51,505      58,485     51,505     58,485 
                                                              --------   --------   ---------   --------   -------- 
Cash and cash equivalents -- end of year....................  $ 51,505   $ 58,485   $  38,660   $ 54,386   $ 65,179 
                                                              ========   ========   =========   ========   ======== 
Supplemental information:                                                                                           
  Income taxes paid.........................................  $  3,063   $  2,508   $   5,631   $    956   $  2,728 
  Interest paid.............................................  $  1,119         --          --         --         -- 

The accompanying notes are an integral part of the consolidated financial 
statements. 
F-50

S-4
180th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 180th

TRANSITION SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 
(IN THOUSANDS, EXCEPT SHARE DATA) 

                                                        [Enlarge/Download Table]

                                                                         NON-VOTING                                           
                                                   COMMON STOCK         COMMON STOCK     NON-VOTING       TREASURY STOCK      
                                                -------------------   ----------------  COMMON STOCK  ----------------------- 
                                                  SHARES     AMOUNT   SHARES    AMOUNT    WARRANT       SHARES       AMOUNT   
                                                ----------   ------   ------    ------  ------------  -----------   --------- 
                                                                                                                              
Balance at September 30, 1995.................  30,060,000    $301                                     (1,670,000)  $  (1,471)
 Stock options exercised......................   1,320,191      13                                                            
 Repurchase of common stock in connection with                                                                                
   the recapitalization.......................                                                        (28,592,404)   (108,386)
 Retirement of treasury shares................  (30,262,404)  (303)                                    30,262,404     109,857 
 Issuance of common stock warrant.............                                              $395                              
 Issuance of common stock in initial public                                                                                   
   offering...................................   6,900,000      69                                                            
 Equity issuance costs........................                                                                                
 Issuance of common stock with conversion of                                                                                  
   Series B convertible preferred stock.......   8,627,310      86                                                            
 Issuance of non-voting common stock with                                                                                     
   conversion of Series C convertible                                                                                         
   preferred stock............................                        356,262    $  4                                         
 Compensation expense.........................                                                                                
 Dividends on Series A non-voting preferred                                                                                   
   stock......................................                                                                                
 Net income...................................                                                                                
                                                ----------    ----    -------    ----       ----      -----------   --------- 
Balance at September 30, 1996.................  16,645,097     166    356,262       4        395               --          -- 
                                                ----------    ----    -------    ----       ----      -----------   --------- 
 Stock options exercised......................     813,371       8                                                            
 Issuance of common stock related to                                                                                          
   acquisition of Vital Software..............     252,003       3                                                            
 Issuance of common stock in connection with                                                                                  
   employee stock purchase plan...............       3,212      --                                                            
 Equity issuance costs........................                                                                                
 Cancellation of compensatory stock option                                                                                    
   grants.....................................                                                                                
 Income tax benefit from stock options                                                                                        
   exercised..................................                                                                                
 Net income...................................                                                                                
                                                ----------    ----    -------    ----       ----      -----------   --------- 
Balance at September 30, 1997.................  17,713,683     177    356,262       4        395               --          -- 
                                                ----------    ----    -------    ----       ----      -----------   --------- 
 Stock options exercised......................     307,770       3                                                            
 Issuance of common stock in connection with                                                                                  
   employee stock purchase plan...............       7,642                                                                    
 Income tax benefit from stock options                                                                                        
   exercised..................................                                                                                
 Net income...................................                                                                                
                                                ----------    ----    -------    ----       ----      -----------   --------- 
Balance at September 30, 1998.................  18,029,095    $180    356,262    $  4       $395               --   $      -- 
                                                ==========    ====    =======    ====       ====      ===========   ========= 



                                                ADDITIONAL                   TOTAL                                            
                                                 PAID-IN     RETAINED    STOCKHOLDERS'                                        
                                                 CAPITAL     EARNINGS       EQUITY                                            
                                                ----------   --------    -------------                                        
                                                                                                                              
Balance at September 30, 1995.................                $17,362       $16,192                                           
 Stock options exercised......................   $   770                        783                                           
 Repurchase of common stock in connection with                                                                                
   the recapitalization.......................                             (108,386)                                          
 Retirement of treasury shares................  (109,554)                        --                                           
 Issuance of common stock warrant.............                                  395                                           
 Issuance of common stock in initial public                                                                                   
   offering...................................   114,360                    114,429                                           
 Equity issuance costs........................    (1,416)                    (1,416)                                          
 Issuance of common stock with conversion of                                                                                  
   Series B convertible preferred stock.......    33,526                     33,612                                           
 Issuance of non-voting common stock with                                                                                     
   conversion of Series C convertible                                                                                         
   preferred stock............................     1,384                      1,388                                           
 Compensation expense.........................        91                         91                                           
 Dividends on Series A non-voting preferred                                                                                   
   stock......................................                   (593)         (593)                                          
 Net income...................................                  4,138         4,138                                           
                                                 -------      -------       -------                                           
Balance at September 30, 1996.................    39,161       20,907        60,633                                           
                                                 -------      -------       -------                                           
 Stock options exercised......................     1,229                      1,237                                           
 Issuance of common stock related to                                                                                          
   acquisition of Vital Software..............     3,622                      3,625                                           
 Issuance of common stock in connection with                                                                                  
   employee stock purchase plan...............        32                         32                                           
 Equity issuance costs........................        (6)                        (6)                                          
 Cancellation of compensatory stock option                                                                                    
   grants.....................................       (91)                       (91)                                          
 Income tax benefit from stock options                                                                                        
   exercised..................................     2,770                      2,770                                           
 Net income...................................                  5,319         5,319                                           
                                                 -------      -------       -------                                           
Balance at September 30, 1997.................    46,717       26,226        73,519                                           
                                                 -------      -------       -------                                           
 Stock options exercised......................       591                        594                                           
 Issuance of common stock in connection with                                                                                  
   employee stock purchase plan...............       101                        101                                           
 Income tax benefit from stock options                                                                                        
   exercised..................................     1,201                      1,201                                           
 Net income...................................                  8,857         8,857                                           
                                                 -------      -------       -------                                           
Balance at September 30, 1998.................   $48,610      $35,083       $84,272                                           
                                                 =======      =======       =======                                           

The accompanying notes are an integral part of the consolidated financial 
statements. 

F-51

S-4
181st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 181st

TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1.  NATURE OF THE BUSINESS                                                 

Transition Systems, Inc. (the "Company") is a leading provider of     
integrated clinical and financial decision support systems for hospitals,       
integrated delivery networks, physician groups and other healthcare             
organizations. The Company was founded in 1985 as a for-profit, majority-owned  
subsidiary of New England Medical Center, Inc. ("NEMC"). The Company was a      
majority-owned subsidiary of NEMC until the January 1996 leveraged              
recapitalization transaction (the "Recapitalization") described in Note 10.     

NOTE 2.  SUMMARY OF ACCOUNTING POLICIES                                         

PRINCIPLES OF CONSOLIDATION                                           

  The consolidated financial statements include the accounts of Transition
Systems, Inc. and its wholly-owned subsidiaries. All significant intercompany   
transactions have been eliminated.                                              

CASH EQUIVALENTS                                                      

For purposes of the consolidated statements of cash flows, the Company
considers all highly liquid debt instruments with a maturity date of three      
months or less at the time of purchase to be cash equivalents. Cash equivalents 
are stated at cost plus accrued interest which approximates market.             

INVESTMENTS IN DEBT AND EQUITY SECURITIES                             

    Management determines the appropriate classification of its investments in
debt and equity securities at the time of purchase and reevaluates such         
determination at each balance sheet date. Realized or unrealized gains or losses
applicable to the transfer of securities to the available-for-sale category and 
subsequent sale of these investments were immaterial.                           

CAPITALIZED SOFTWARE COSTS                                            

     Software development costs subsequent to the establishment of technological
feasibility are capitalized. Capitalized internally developed software costs    
approximated $700,000 for fiscal years 1996, 1997 and 1998. Amortization of     
capitalized software costs, which begins with the general release of a product  
to customers, is included in cost of software and implementation revenues and   
amounted to approximately $767,000, $700,000 and $700,000 for the fiscal years  
ended 1996, 1997 and 1998, respectively. Amortization of capitalized software   
costs is provided on a product-by-product basis at the greater of the amount    
calculated on a straight-line basis over the estimated economic life of the     
products, generally three years, or the ratio that current gross revenues for a 
product bear to the total of current and anticipated future gross revenues for  
that product. Accumulated amortization of software development costs was        
$4,116,000, $4,816,000 and $5,516,000 at the end of fiscal years 1996, 1997 and 
1998, respectively.                                                             

All other expenditures for research and development are charged to    
operations when incurred.                                                       

PURCHASED TECHNOLOGY COSTS                                            

Purchased technology costs are carried at cost less accumulated       
amortization which is calculated on a straight-line basis over an estimated     
useful life of seven years. Accumulated amortization on purchased technology    
costs was $0, $275,000 and $491,000 at the end of fiscal years 1996, 1997 and   
1998, respectively.                                                             

F-52

S-4
182nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 182nd
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

INTANGIBLE ASSETS                                                     

Intangible assets include the costs incurred to register trademarks,  
copyrights and related legal expenses, acquisition related costs, and debt      
issuance costs. Amortization is computed using the straight-line method over    
estimated useful lives ranging from three to five years.                        

PROPERTY AND EQUIPMENT                                                

   Property and equipment are stated at cost. Depreciation is computed using
the straight-line method over the estimated useful lives of the assets as       
follows:                                                                        

                                                        [Enlarge/Download Table]
                                                                                          
Equipment........................... 3 to 5 years                                         
Furniture and fixtures.............. 3 to 5 years                                         
Leasehold improvements.............. the lesser of the useful life or remaining lease term

     Maintenance and repair costs are expensed when incurred and betterments are
capitalized. Upon retirement or sale, the cost of the assets disposed of and the
related accumulated depreciation are removed from the accounts and any resulting
gain or loss is credited or charged to income.                                  

REVENUE RECOGNITION                                                   

 The percentage of completion method is used by the Company primarily in
connection with sales in which the customer is implementing the Company's core  
products for the first time. Add-on sales in which an existing customer licenses
new modules or adds additional functionality generally do not involve           
substantial implementation effort and are recognized upon contract execution and
shipment of the product. In fiscal 1996, the Company changed its method of      
recognizing software license revenue when associated with substantial           
implementation effort from percentage of completion based principally on costs  
incurred to percentage of completion based principally upon progress and        
performance as measured by achievement of contract milestones. The change in    
method was made in accordance with Accounting Principles Board Opinion No. 20 in
contemplation of an initial public offering and in recognition of the Company's 
increased focus on providing a solution that combines software and              
implementation, as well as to facilitate the timely quarterly reporting         
requirements as a Securities and Exchange Commission ("SEC") registrant.        

     Revenues from maintenance contracts are recognized ratably over the life of
the service contract, generally twelve months. Deferred revenue relates         
primarily to these maintenance contracts.                                       

ADVERTISING AND PROMOTION EXPENSES                                    

    All advertising and promotion costs are expensed as incurred. All contract
procurement costs are included in sales and marketing expense and are expensed  
as incurred.                                                                    

INCOME TAXES                                                          

Deferred tax assets and liabilities are recognized based on temporary 
differences between the financial statement and tax basis of assets and         
liabilities using enacted tax rates in effect for the year in which the         
temporary differences are expected to reverse.                                  

RISKS AND UNCERTAINTIES                                               

     The Company sells its products primarily to hospitals and other health care
institutions. The Company performs ongoing credit evaluations of its customers. 
The Company maintains reserves for potential credit losses and such losses have 
been within management's expectations.                                          

 The Company invests its daily excess cash in a money market fund with a
major bank. The Company has not experienced any material losses on its          
investments.                                                                    

F-53

S-4
183rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 183rd
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

The preparation of financial statements in conformity with generally  
accepted accounting principles requires management to make estimates and        
assumptions that affect the reported amounts of assets and liabilities and      
disclosure of contingent assets, liabilities and litigation at the date of the  
financial statements and the reported amounts of revenues and expenses during   
the reporting period. Actual results could differ from those estimates and would
impact future results of operations and cash flows.                             

BASIC AND DILUTED NET INCOME PER SHARE                                

     The Company has adopted Statement of Financial Accounting Standards No. 128
("SFAS 128"), "Earnings per Share," for the period ending September 30, 1998 and
prior period amounts have been restated to conform to the provisions of this    
statement.                                                                      

   Basic earnings per share is computed using the weighted average number of
shares outstanding, and diluted earnings per share reflects the potential       
dilution from assumed conversions of all dilutive securities such as stock      
options. A reconciliation of the numerator and denominator of the basic EPS     
computation to the numerator and denominator of the diluted EPS computation is  
shown below.                                                                    

                                                        [Enlarge/Download Table]

                                               FISCAL YEAR ENDED SEPTEMBER 30,                      
                          --------------------------------------------------------------------------
                                          1996                                  1997                
                          ------------------------------------   -----------------------------------
                                                     PER SHARE                             PER SHARE
                            INCOME       SHARES       AMOUNT       INCOME       SHARES      AMOUNT  
                          ----------   -----------   ---------   ----------   ----------   ---------
                                                                                                    
BASIC EPS                                                                                           
  Net income............. $3,545,000    13,214,433     $0.27     $5,319,000   17,434,729     $0.31  
EFFECT OF DILUTIVE                                                                                  
  SECURITIES                                                                                        
  Warrants...............                  251,781                               220,749            
  Dilutive stock                                                                                    
    options..............                2,670,941                             2,321,616            
                                       -----------                            ----------            
DILUTED EPS                                                                                         
  Income to common                                                                                  
    stockholders......... $3,545,000    16,137,155     $0.22     $5,319,000   19,977,094     $0.27  
                          ----------   -----------     -----     ----------   ----------     -----  


                            FISCAL YEAR ENDED SEPTEMBER 30,                                         
                          -----------------------------------                                       
                                         1998                                                       
                          -----------------------------------                                       
                                                    PER SHARE                                       
                            INCOME       SHARES      AMOUNT                                         
                          ----------   ----------   ---------                                       
                                                                                                    
BASIC EPS                                                                                           
  Net income............. $8,857,000   18,210,050     $0.49                                         
EFFECT OF DILUTIVE                                                                                  
  SECURITIES                                                                                        
  Warrants...............                 231,291                                                   
  Dilutive stock                                                                                    
    options..............               1,952,551                                                   
                                       ----------                                                   
DILUTED EPS                                                                                         
  Income to common                                                                                  
    stockholders......... $8,857,000   20,393,892     $0.43                                         
                          ----------   ----------     -----                                         

  For the fiscal year ended September 30, 1996, basic and diluted earnings
per share for income before extraordinary item were $0.37 and $0.32,            
respectively, and the impact to basic and diluted earnings per share of the     
extraordinary item was a reduction of $0.13 and $0.11, respectively.            

   For the twelve months ended September 30, 1996, 1997 and 1998, 0, 330,000
and 626,000 options, respectively, were excluded from the computation of diluted
EPS. These options were excluded because the effect would have been antidilutive
for the period.                                                                 

UNAUDITED INFORMATION                                                 

   The interim financial information for the nine months ended June 30, 1997
and 1998 is unaudited. However, in the opinion of management, such information  
has been prepared on the same basis as the audited financial statements and     
includes all adjustments, consisting solely of normal recurring adjustments,    
necessary for a fair presentation of the financial position and results of      
operations for the periods presented. The interim results, however, are not     
necessarily indicative of results for any future period.                        

NEW ACCOUNTING PRONOUNCEMENTS                                         

In June 1997, the Financial Accounting Standards Board ("FASB")issued 
Statement of Financial Accounting Standard No. 130, "Reporting Comprehensive    
Income" ("SFAS 130"), which establishes standards for reporting and display of  
comprehensive income and its components (revenue, expenses, gains and losses) in
a full set of general purpose financial statements. The Company will be required
to adopt the standard in the first quarter of its 1999 fiscal year, and does not
believe this statement will have a material effect on the Company's financial   
position or results of operations.                                              

F-54

S-4
184th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 184th
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

  In June 1997, the FASB issued Statement of Financial Accounting Standard
No. 131 ("SFAS 131"), "Disclosure about Segments of an Enterprise and Related   
Information." Based on the management approach to segment reporting, SFAS No.   
131 establishes requirements to report selected segment information quarterly   
and to report entity-wide disclosures about products and services, major        
customers and the countries in which the entity holds material assets and       
reports material revenue. The Company will be required to adopt the standard in 
the first quarter of its 1999 fiscal year, and does not believe this statement  
will have a material effect on the Company's financial disclosures.             

   In June 1998, the FASB issued Statement of Financial Accounting Standards
No. 133 ("SFAS 133") "Accounting for Derivative Instruments and Hedging         
Activities," which establishes accounting and reporting standards for such      
instruments. SFAS 133 is effective for fiscal years beginning after June 15,    
1999. Currently, the Company has no such derivative holdings.                   

 On October 27, 1997, the AICPA Accounting Standards Executive Committee
issued Statement of Position 97-2 ("SOP 97-2"), "Software Revenue Recognition." 
SOP 97-2 supersedes Statement of Position 91-1, "Software Revenue Recognition," 
and provides guidance on when and in what amounts revenue should be recognized  
for the licensing, selling, leasing, or marketing of computer software. SOP 97-2
is effective for transactions beginning in the first quarter of the Company's   
1999 fiscal year. The Company is analyzing the impact of the SOP which may cause
a deferral of revenue.                                                          

NOTE 3.  ACCOUNTS RECEIVABLE                                                    

At September 30, accounts receivable consisted of the following (in   
thousands):                                                                     

                                                                [Download Table]

                                                               1997      1998   
                                                              -------   ------- 
                                                                                
Billed......................................................  $11,973   $10,862 
Unbilled....................................................    7,541     8,332 
                                                              -------   ------- 
                                                               19,514    19,194 
Allowance for doubtful accounts.............................     (175)     (200)
                                                              -------   ------- 
                                                              $19,339   $18,994 
                                                              =======   ======= 

Unbilled accounts receivable arise from differences in the timing of  
revenue recognition and billing under the contract terms. Write-offs for bad    
debts for fiscal years 1996, 1997 and 1998 were $73,000, $102,000 and $166,000, 
respectively.                                                                   

NOTE 4.  INVESTMENTS                                                            

 As of September 30, 1998, the Company has classified all investments as
held to maturity. The securities totaled $27,291,000 as of September 30, 1998   
and consist of federal agency obligations. The estimated fair value of each     
investment approximates the amortized cost plus accrued interest. Unrealized    
gains at September 30, 1998 were $71,000.                                       

NOTE 5.  PROPERTY AND EQUIPMENT                                                 

At September 30, property and equipment consisted of the following (in
thousands):                                                                     

                                                                [Download Table]

                                                              1997      1998   
                                                             -------   ------- 
                                                                               
Equipment................................................... $ 3,537   $ 2,064 
Furniture and fixtures......................................   1,079       372 
Leasehold improvements......................................     355       356 
                                                             -------   ------- 
                                                               4,971     2,792 
Accumulated depreciation and amortization...................  (3,614)   (1,335)
                                                             -------   ------- 
                                                             $ 1,357   $ 1,457 
                                                             =======   ======= 

F-55

S-4
185th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 185th
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

     Depreciation expense for the fiscal years 1996, 1997 and 1998 was $514,000,
$662,000 and $851,000 respectively. During fiscal 1998, the Company retired     
assets of $2,911,000 which had no book value.                                   

NOTE 6.  INVESTMENT IN HEALTHVISION                                             

On January 31, 1997 the Company acquired a 19.5% ownership interest in
HealthVISION, Inc. ("HealthVISION") for $6 million in cash. HealthVISION is a   
provider of electronic medical record software based in Santa Rosa, California. 
This investment is being accounted for on the cost basis. The Company holds an  
option to purchase the remaining outstanding shares of HealthVISION. This option
expires on December 31, 1998. (See note 17.)                                    

NOTE 7.  RELATED PARTY AGREEMENTS AND TRANSACTIONS                              

The Company had an arrangement to reimburse NEMC for administrative   
services provided to the Company by employees of NEMC. Under this arrangement,  
the Company incurred expenses of $24,000 in fiscal year 1996. This arrangement  
was terminated as of January 24, 1996. Since that date, these administrative    
services have been performed internally by Company personnel. This change has   
not resulted in a material increase in the Company's costs.                     

    The Company obtained certain other services through NEMC, including health
benefits for its employees, for which it incurred a total of $134,000 in        
operating expenses in fiscal year 1996. The Company discontinued this           
arrangement as of December 31, 1995, and arranged to provide comparable benefits
directly to its employees. This change has not resulted in a material increase  
in the Company's cost of providing and administering these employee benefits.   

Additionally, the Company used the computer facilities of New England 
Medical Center Hospitals, Inc., an affiliate of NEMC, pursuant to a data        
processing agreement. This service was provided at a charge of $82,000 in fiscal
year 1996. This service was discontinued in June 1996.                          

NOTE 8.  LINE OF CREDIT -- BANK                                                 

On April 26, 1996, the Company entered into a $25 million unsecured   
revolving line of credit with a bank group led by NationsBank, N.A. as agent and
as lender. The credit facility contains covenants setting minimum net worth,    
maximum leverage ratio and minimum net income requirements for the Company. On  
September 20, 1996, the Company amended its total revolving credit commitment   
from $25 million to $15 million. There have been no amounts drawn on this line. 
Advances under the revolving line of credit bear interest, at the Company's     
election, either at a "base rate" or at a "eurodollar rate." The base rate is a 
floating rate equal to the greater of (a) the prime rate or (b) the federal     
funds effective rate plus one-half of one percent (.50%). The eurodollar rate is
equal to the sum of (x) a rate determined by reference to the then-current      
interbank offered rate for dollar denominated eurodollar deposits, with certain 
adjustments, plus (y) one percent (1.0%). The eurodollar interest rate was 5.43%
at September 30, 1998.                                                          

NOTE 9.  STOCKHOLDERS' EQUITY                                                   

     On February 26, 1996, the Company's Board of Directors approved a 334-for-1
split of the Company's Common Stock to be effected in the form of a stock       
dividend to the stockholders of record as of March 28, 1996. This stock split   
has resulted in a reclassification of $112,695 and $187,003 from the Company's  
additional paid-in capital and retained earnings accounts, respectively, to the 
Company's Common Stock account, representing the par value of shares issued. All
share and per share amounts have been restated to retroactively reflect the     
stock split. In addition, on February 26, 1996, the Board of Directors also     
voted to retire and return to the status of authorized and unissued capital     
stock all shares of Common Stock then held in the Company's treasury, and adopt 
an amendment to the Articles of Organization of the Company to, among other     
things, increase the authorized shares of Common Stock                          

F-56

S-4
186th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 186th
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

and Non-Voting Common Stock to 30,000,000 and 1,000,000 shares, respectively,   
which was subsequently approved by the stockholders of the Company.             

On April 18, 1996, the Company completed an initial public offering of
6,900,000 shares of its common stock which generated net proceeds of $114.4     
million. A substantial part of the proceeds were used to redeem $20.6 million of
Series A preferred stock and accrued dividends, to repay the $34.7 million      
outstanding principal amount and accrued interest under the secured term loan   
facility, to repay the $10.3 million outstanding principal amount and accrued   
interest under the senior subordinated notes and to repay the $5.1 million      
outstanding principal amount and accrued interest under the Company's revolving 
credit facility.                                                                

STOCK OPTION PLANS                                                    

 In 1995, the Company's Board of Directors adopted, and the stockholders
approved, the 1995 Incentive and Nonstatutory Stock Option Plan. The Plan       
provides for the grant of nonqualified and incentive stock options to employees 
and others to purchase the Company's Common Stock. Options granted during fiscal
1995 provided for vesting over three years and expiration ten years after the   
date of grant. Options granted during fiscal 1996, 1997 and 1998 provided for   
vesting over five years and expiration ten years after the date of grant. At    
September 30, 1997 and 1998, 6,070,116 shares of Common Stock were authorized   
under the plan.                                                                 

A summary of the Company's stock option activity for the years ended  
September 30 follows:                                                           

                                                                [Download Table]

                                                                          WEIGHTED
                                                                          AVERAGE 
                                                             NUMBER OF    EXERCISE
                                                              OPTIONS      PRICE  
                                                             ----------   --------
                                                                                  
Outstanding at                                                                    
  September 30, 1995........................................  4,331,646    $ 1.02 
     Granted................................................  1,079,564      6.74 
     Exercised.............................................. (1,320,191)     0.59 
     Canceled...............................................    (27,165)     1.20 
                                                             ----------    ------ 
Outstanding at                                                                    
  September 30, 1996........................................  4,063,854      2.67 
     Granted................................................    802,400     15.15 
     Exercised..............................................   (813,371)     1.52 
     Canceled...............................................   (495,364)    13.71 
                                                             ----------    ------ 
Outstanding at                                                                    
  September 30, 1997........................................  3,557,519      4.22 
                                                             ----------    ------ 
     Granted................................................    425,000     20.32 
     Exercised..............................................   (307,770)     1.93 
     Canceled...............................................    (74,821)    15.75 
                                                             ----------    ------ 
Outstanding at                                                                    
  September 30, 1998........................................  3,599,928    $ 6.08 
                                                             ==========    ====== 

Statement of Financial Accounting Standards No. 123, "Accounting for  
Stock-Based Compensation" ("SFAS 123"), requires that companies either recognize
compensation expense for grants of stock, stock options, and other equity       
instruments based on fair value, or provide pro forma disclosure of net income  
and earnings per share in the notes to the financial statements. The Company    
adopted the disclosure provisions of SFAS 123 in 1997 and has applied APB       
Opinion 25 and related interpretations in accounting for its stock option plans 
in 1997 and 1998. Accordingly, no compensation cost has been recognized for its 
stock option plans. The effects of applying SFAS 123 in this pro forma          
disclosure are not likely to be                                                 

F-57

S-4
187th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 187th
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

representative of the effects on reported income or loss for future years. SFAS 
123 does not apply to awards prior to 1996 and additional awards in future years
are anticipated.                                                                

 At September 30, 1996, 1997 and 1998, respectively, options to purchase
2,195,716, 2,080,823 and 2,372,645 shares of Common Stock were exercisable with 
a weighted average exercise price of $1.20, $1.80 and $2.04, respectively.      
Exercise prices for options outstanding as of September 30, 1998 ranged from    
$1.20 to $23.00. The weighted average remaining contractual life of those       
options is 7.34 years.                                                          

  The weighted average fair value of the Common Stock at date of grant for
options granted in fiscal 1996, 1997 and 1998 was $3.61, $8.12 and $10.90 per   
option, respectively. The fair value of these options at date of grant was      
estimated using the Black-Scholes model with the following assumptions: a risk  
free interest rate of 5.4% in fiscal 1996, 6.1% in fiscal 1997 and 5.7% in      
fiscal 1998; a dividend yield of 0%; a volatility factor of the expected market 
price of the Company's Common Stock of 55% and a weighted average expected life 
of the options of 5 years.                                                      

     Had compensation cost for the Company's stock-based compensation plans been
determined based on the fair value at the grant dates as calculated in          
accordance with SFAS 123, the Company's net income and earnings per share for   
the years ended September 30, 1996, 1997 and 1998 would have been reduced to the
pro forma amounts indicated as follows:                                         

                                                        [Enlarge/Download Table]

                                                                1996        1997        1998   
                                                                ----        ----        ----   
                                                                                               
Net income as reported...................................... $3,545,000  $5,319,000  $8,857,000
    Basic earnings per share................................        .21         .31         .49
    Diluted earnings per share..............................        .18         .27         .43
Net income pro forma........................................  2,696,000   3,970,000   6,190,000
    Basic earnings per share................................        .16         .23         .34
    Diluted earnings per share..............................        .14         .20         .30

At September 30, 1996, 1997 and 1998, options to purchase 1,354,071,  
1,047,035 and 696,856 shares of Common Stock, respectively, were available for  
grant.                                                                          

    The following table summarizes information about stock options outstanding
at September 30, 1998:                                                          

                                                        [Enlarge/Download Table]

                                              OPTIONS OUTSTANDING                     OPTIONS EXERCISABLE     
                                 ----------------------------------------------  -----------------------------
                                                  REMAINING        WEIGHTED-                      WEIGHTED-   
        RANGE OF                    NUMBER       CONTRACTUAL        AVERAGE         NUMBER         AVERAGE    
        EXERCISE PRICES           OUTSTANDING        LIFE       EXERCISE PRICE   EXERCISABLE    EXERCISE PRICE
        ---------------           -----------    -----------    --------------   -----------    --------------
                                                                                                              
$ 1.20..........................   1,944,437         6.6            $ 1.20        1,944,437         $ 1.20    
  3.90..........................     713,491         7.3              3.90          338,408           3.90    
 10.38 -- 13.50.................     316,000         8.5             11.99           89,800          13.32    
 18.50 -- 18.81.................     280,000         8.8             18.61               --             --    
 19.62 -- 23.00.................     346,000         9.2                --               --             --    
                                  ----------                                      ---------                   
                                   3,599,928         7.3            $ 6.08        2,372,645         $ 2.04    

In connection with the Recapitalization, the Company accelerated the  
vesting of options to purchase an aggregate of 2,442,208 shares of Common Stock 
granted to certain executive officers during fiscal 1995, so as to make such    
options exercisable in full immediately prior to the closing of the             
Recapitalization. On January 24, 1996, an aggregate of 638,608 shares of Common 
Stock were issued to such officers upon their exercise of such options.         

NOTE 10.  RECAPITALIZATION                                                      

    In January 1996, prior to its contemplation of an initial public offering,
the Company effected a Recapitalization, in which the Company repurchased       
28,592,404 shares of Common Stock then issued and outstanding from NEMC and the 
other stockholders of the Company for an aggregate of approximately $111.4      
million. In addition, Warburg, Pincus Ventures, L.P. ("WP Ventures") purchased  
from certain executive officers of the Company an aggregate of 2,308,608 shares 
of Common Stock, including an                                                   

F-58

S-4
188th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 188th
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

aggregate of 638,608 shares of Common Stock acquired by such executive officers 
pursuant to their exercise of stock options, for an aggregate of approximately  
$9.0 million. WP Ventures then contributed such shares of Common Stock to the   
Company. The principal purpose of the Recapitalization was to provide liquidity 
to the Company's existing stockholders while permitting them to retain an       
ownership interest in the Company, and the Company has accounted for the        
transaction as a leveraged recapitalization. To finance the repurchase of these 
shares, the Company issued to certain institutional investors 20,000 shares of  
Series A non-voting preferred stock for an aggregate of $20.0 million, 33,512   
shares of Series B convertible preferred stock (convertible into 8,627,310      
shares of Common Stock) for an aggregate of $33.6 million and 1,388 shares of   
Series C non-voting convertible preferred stock (convertible into 356,262 shares
of Common Stock) for an aggregate of $1.4 million. In addition, the Company     
entered into a secured term loan in the amount of $35.0 million and received an 
advance of $5.0 million under a secured revolving credit facility in the maximum
principal amount of $15.0 million, and issued Senior Subordinated Notes, due    
2003, in the aggregate principal amount of $10.0 million (the "Senior           
Subordinated Notes"). The holder of the Senior Subordinated Notes also received 
a warrant to acquire an aggregate of 297,928 shares of non-voting common stock  
at an initial exercise price of $3.90 per share, subject to adjustment in       
certain circumstances. In addition, in the second quarter of fiscal 1996 the    
Company incurred a non-cash compensation charge of $3.0 million. This           
compensation charge arose from the purchase by the Company (both directly and   
indirectly, through WP Ventures) from certain of its executive officers of      
972,608 shares of Common Stock that had been acquired by such officers          
immediately prior to the Recapitalization through the exercise of employee stock
options. The amount of the compensation charge is equal to the difference       
between the aggregate $765,800 exercise price paid by such officers upon such   
exercise and the $3,789,764 of aggregate proceeds received by the officers from 
the purchase by the Company of such shares.                                     

NOTE 11.  EXTRAORDINARY ITEM                                                    

     In fiscal 1996, the Company incurred an extraordinary loss of approximately
$2,149,000 representing the after tax effect of the write-off of approximately  
$3,642,000 of unamortized capitalized financing costs. These costs were         
attributable to indebtedness incurred in the Recapitalization that was repaid   
out of the proceeds of the Company's initial public offering.                   

NOTE 12.  PREFERRED STOCK DIVIDEND                                              

    The holders of the Series A preferred stock (issued in connection with the
Recapitalization on January 24, 1996) were entitled to receive, when and as     
declared by the Board of Directors, out of funds legally available therefor,    
preferential cumulative dividends at the rate of 12% per annum. The Company was 
not obligated to pay dividends prior to the redemption of the Series A preferred
stock, and no dividends were declared by the Board. The Series A preferred stock
was subject to mandatory redemption, provided funds were legally available      
therefor, upon the closing of an initial public offering or the sale of the     
Company, but in no event later than January 2006. Upon the closing of the       
Company's initial public offering, on April 23, 1996, at which time funds became
legally available for the redemption of the Series A preferred stock and payment
of dividends, the Company redeemed in full the Series A preferred stock and paid
dividends thereon from the date of the Recapitalization.                        

F-59

S-4
189th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 189th
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

NOTE 13.  INCOME TAXES                                                          

    At September 30, provision for income taxes consisted of the following (in
thousands):                                                                     

                                                                [Download Table]

                                                          1996      1997    1998  
                                                         -------   ------  ------ 
                                                                                  
Federal:                                                                          
  Current............................................... $ 5,129   $4,535  $5,731 
  Deferred..............................................  (1,413)   2,090    (723)
                                                         -------   ------  ------ 
                                                           3,716    6,625   5,008 
State:                                                                            
  Current...............................................     835      646   1,025 
  Deferred..............................................    (227)     358    (128)
                                                         -------   ------  ------ 
                                                             608    1,004     897 
                                                         -------   ------  ------ 
Provision for income taxes.............................. $ 4,324   $7,629  $5,905 
                                                         =======   ======  ====== 

A reconciliation between the Company's effective rate and the U.S.    
statutory rate is as follows:                                                   

                                                                [Download Table]

                                                                SEPTEMBER 30,     
                                                             -------------------- 
                                                             1996    1997    1998 
                                                             ----    ----    ---- 
                                                                                  
U.S. statutory rate......................................... 35.0%   35.0%   35.0%
State taxes, net of federal benefits........................  5.6     5.0     4.0 
Acquired in-process research and development................   --    17.0      -- 
Other.......................................................   --     1.9     1.0 
                                                             ----    ----    ---- 
Effective income tax rate................................... 40.6%   58.9%   40.0%
                                                             ====    ====    ==== 

Components of the Company's deferred tax liabilities and assets are as
follows (in thousands):                                                         

                                                                [Download Table]

                                                               SEPTEMBER 30,  
                                                              --------------- 
                                                              1997      1998  
                                                              -----    ------ 
                                                                              
Capitalized software........................................  $(576)   $ (576)
Depreciation................................................    103       178 
Accounts receivable reserve.................................     51        82 
Accrued compensation........................................    280       675 
Reserves and other..........................................    499       849 
                                                              -----    ------ 
Net deferred tax assets.....................................  $ 357    $1,208 
                                                              =====    ====== 

   There are no valuation allowances recorded against the Company's deferred
tax assets, since taxable income in the carryback period is sufficient to       
realize the benefit of future deductions.                                       

NOTE 14.  EMPLOYEE BENEFIT PLANS                                                

401(k) PLAN                                                           

The Company maintains a savings plan for its eligible employees under 
Section 401(k) of the Internal Revenue Code. The plan allows employees to defer 
up to a percentage of their income equal to the lesser of the IRS statutory rate
or 15% on a pre-tax basis through contributions to the plan. Contributions by   
the Company under this plan are discretionary. Total contributions by the       
Company under the plan approximated $263,000, $306,000, and $376,000 in fiscal  
years 1996, 1997 and 1998, respectively.                                        

     The Company previously obtained health benefit plans through NEMC (see Note
6). Beginning January 1, 1996, the Company established independent health       
benefit plans for its employees that provide a similar level of benefits.       

F-60

S-4
190th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 190th
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

EMPLOYEE STOCK PURCHASE PLAN                                          

  In 1996, the Company adopted an Employee Stock Purchase Plan (the "Stock
Purchase Plan"), under which employees may purchase up to 300,000 shares of     
Common Stock.                                                                   

During each six-month offering period under the Stock Purchase Plan,  
participating employees are entitled to purchase shares through payroll         
deductions. The maximum number of shares which may be purchased is determined on
the first day of the offering period pursuant to a formula under which a        
specific percentage of the employee's projected base pay for the offering period
is divided by a percentage of the market value of one share of Common Stock on  
the first day of the offering period. During each offering period, the price at 
which the employee will be able to purchase the Common Stock will be a specific 
percentage of the last reported sale price of the Common Stock of the NASDAQ    
National Market on the date on which the offering period commences or concludes,
whichever is lower.                                                             

    The Stock Purchase Plan is administered by the Compensation Committee. All
employees, other than certain highly-compensated employees, who meet certain    
minimum criteria based on hours worked per week and length of tenure with the   
Company are eligible to participate in the Stock Purchase Plan. No employee may 
purchase shares pursuant to the Stock Purchase Plan if, after such purchase such
employee would own more than five percent of the total combined voting power or 
value of the securities of the Company.                                         

NOTE 15.  COMMITMENTS                                                           

The Company leases office and office equipment under operating lease  
arrangements which expire on various dates through 2002. Certain operating lease
arrangements include options to renew for additional periods or payment terms   
that are subject to increases due to taxes and other operating costs of the     
lessor. Future minimum lease commitments, by year and in the aggregate, under   
these long-term noncancelable operating leases consist of the following at      
September 30, 1998 (in thousands):                                              

                                                                [Download Table]

                                                             OPERATING
FISCAL YEAR                                                   LEASES  
-----------                                                  ---------
                                                                      
1999.......................................................   $  627  
2000.......................................................      495  
2001.......................................................       58  
2002.......................................................        2  
                                                              ------  
  Total minimum lease payments.............................   $1,182  
                                                              ======  

   Rent expense amounted to $370,000, $553,000, and $753,000 in fiscal years
1996, 1997 and 1998, respectively.                                              

     The Company has an agreement with a vendor of third-party software to pay a
fixed annual license and maintenance fees through June 2003. Aggregate annual   
expenses under the agreement as renegotiated are expected to approximate        
$2,500,000. The annual fees may be adjusted in the fourth and fifth year of the 
amendment for changes in the number of users of the software. Aggregate license 
and maintenance fees under this agreement were $2,004,000, $2,000,000 and       
$2,019,000 for fiscal years 1996, 1997 and 1998, respectively.                  

NOTE 16.  CONSOLIDATION AND ACQUISITIONS                                        

     On July 22, 1996, the Company acquired substantially all of the outstanding
stock and a note held by a selling principal of Enterprising HealthCare, Inc.   
("Enterprising HealthCare"), based in Tucson, Arizona, for a total purchase     
price of approximately $1.8 million in cash. Enterprising HealthCare provides   
system integration products and services for the health care market.            

F-61

S-4
191st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 191st
TRANSITION SYSTEMS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

The acquisition was accounted for under the purchase method with the  
results of Enterprising HealthCare included from July 22, 1996. Purchased       
technology costs of $1.6 million are being amortized on a straight-line basis   
over 7 years. Pro forma results of operations have not been presented, as the   
effect of this acquisition on the financial statements was not material.        

     On September 19, 1997, the Company acquired all outstanding shares of Vital
Software Inc. ("Vital"), a privately held developer of products that automate   
the clinical processes unique to medical oncology. The purchase price was       
approximately $6.3 million, which was comprised of $2.7 million in cash and     
252,003 shares of the Company's common stock with a value of $3.6 million.      

  The amount allocated to acquired in-process research and development was
based on the results of an independent appraisal. Acquired in-process research  
and development represented development projects in areas that had not reached  
technological feasibility and had no alternative future use. Accordingly, the   
amount of $6.3 million was charged to operations at the date of the acquisition.

     The value of completed technologies and in-process research and development
were determined using a risk-adjusted, discounted cash flow approach. The value 
of in-process research and development, specifically, was determined by         
estimating the costs to develop the in-process projects into commercially viable
products, estimating the resulting net cash flows from such projects, and       
discounting the net cash flows back to their present values. This evaluation    
considered the inherent difficulties and uncertainties in completing the        
development projects and the risks related to the viability of and potential    
changes in future target markets.                                               

    In-process research and development projects identified at the acquisition
date focus primarily on a flexible architecture to accommodate multiple disease 
categories, functionality including internet access, porting code to a 32 bit   
environment, multi-resource scheduling capabilities, billing and HL-7           
interfaces, integrating protocol modeling with financial and scheduling         
modeling, clinical repository integration and development of decision support   
objects. The nature of the efforts to develop the purchased in-process          
technology into commercially viable products principally relates to the         
following activities: (i) redesign and rewrite software code of the application 
to support multiple disease category framework, (ii) add internet content       
download for protocols and reference materials, (iii) write software code to    
integrate multi-resource scheduling, clinical repository, billing and HL-7      
interfaces, (iv) port entire application to 32 bit format, (v) enhance and      
develop disease specific decision support objects.                              

NOTE 17.  SUBSEQUENT EVENTS                                                     

HEALTHVISION ACQUISITION                                              

   On October 28, 1998, the Company signed a definitive agreement to acquire
the approximately 80.5% of the outstanding capital stock of HealthVISION not    
already owned by the Company for cash in the amount of $25.6 million, the       
assumption of $9.3 million of liabilities, plus an earn-out of up to $10.8      
million if specified financial milestones are met. The acquisition will be      
accounted for as a purchase. HealthVISION is a provider of electronic medical   
record software. HealthVISION's products include CareVISION, a patient-centered 
clinical data repository and lifetime patient record system, which is expected  
to constitute an integral component of the Company's Transition IV product. The 
Company expects to close the acquisition in the first quarter of fiscal 1999.   

ECLIPSYS CORPORATION MERGER                                           

On October 29, 1998, the Company entered into a merger agreement with 
Eclipsys Corporation, a healthcare information technology company delivering    
solutions that enable healthcare providers to achieve improved clinical,        
financial and administrative outcomes. Under the terms of the agreement, each   
share of the Company's common stock will be converted to .525 shares of         
Eclipsys' common stock. The transaction, which is subject to regulatory as well 
as stockholder approval, is intended to be accounted for as a pooling of        
interests and is expected to close by the end of December 1998.                 

F-62

S-4
192nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 192nd

REPORT OF INDEPENDENT AUDITORS

To the Board of Directors and Stockholders                                      
HealthVISION, Inc.                                                              

We have audited the accompanying consolidated balance sheets of       
HealthVISION, Inc. as of December 31, 1996 and 1997, and the related            
consolidated statements of operations, stockholders' equity (deficit) and cash  
flows for the years then ended. These financial statements are the              
responsibility of the Company's management. Our responsibility is to express an 
opinion on these financial statements based on our audits.                      

We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain 
reasonable assurance about whether the consolidated financial statements are    
free of material misstatement. An audit includes examining, on a test basis,    
evidence supporting the amounts and disclosures in the financial statements. An 
audit also includes assessing the accounting principles used and significant    
estimates made by management, as well as evaluating the overall financial       
statement presentation. We believe that our audits provide a reasonable basis   
for our opinion.                                                                

 In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the consolidated financial position of
HealthVISION, Inc. as of December 31, 1996 and 1997 and the consolidated results
of its operations and its cash flows for the years then ended in conformity with
generally accepted accounting principles.                                       

                     ERNST & YOUNG LLP

Walnut Creek, California                                                        
March 13, 1998, except for Note 12                                              
as to which the date is October 28, 1998                                        

F-63

S-4
193rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 193rd

HEALTHVISION, INC.

CONSOLIDATED BALANCE SHEETS 

                                                        [Enlarge/Download Table]

                                                              DECEMBER 31,  DECEMBER 31, 
                                                                  1996          1997     
                                                              ------------  ------------ 
                                                                                         
ASSETS                                                                                   
Current assets:                                                                          
  Cash and cash equivalents.................................  $ 2,316,324   $    644,317 
  Accounts receivable, less allowance for doubtful accounts                              
     of $300,000 and $617,407 at December 31, 1996 and 1997,                             
     respectively...........................................    1,744,231      1,417,358 
  Unbilled receivables......................................      920,303        201,963 
  Prepaid expenses..........................................      720,046        879,578 
                                                              -----------   ------------ 
          Total current assets..............................    5,700,904      3,143,216 
Equipment and furniture, net................................    1,641,181      1,122,834 
Capitalized and purchased software, net of accumulated                                   
  amortization..............................................      591,745        101,744 
Deposits....................................................      329,185         95,795 
                                                              -----------   ------------ 
          Total assets......................................  $ 8,263,015   $  4,463,589 
                                                              ===========   ============ 
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                                           
Current liabilities:                                                                     
  Accounts payable..........................................  $   769,995   $    288,619 
  Accrued compensation and related liabilities..............    1,030,661        701,499 
  Deferred revenue..........................................    2,710,878      3,101,132 
  Other accrued liabilities.................................      786,233      1,262,402 
  Current portion of long-term debt.........................      542,190        421,630 
  Notes payable to stockholder..............................           --      1,005,753 
                                                              -----------   ------------ 
          Total current liabilities.........................    5,839,957      6,781,035 
Long-term debt, less current portion........................      466,356         44,725 
Commitments and contingencies                                                            
Redeemable senior preferred stock, $.01 par value;                                       
  designated -- 60,000 shares; issued and                                                
  outstanding -- 60,000 shares at December 31, 1997                                      
  (aggregate liquidation preference $6,384,329).............           --      6,384,329 
Stockholders' equity (deficit):                                                          
  Preferred stock, 118,678 shares authorized; 7% preferred                               
     stock, $.01 par value; designated -- 58,678 shares;                                 
     issued and outstanding -- 58,678 shares at December 31,                             
     1996 and 1997 (aggregate liquidation preference                                     
     $6,440,151)............................................          587            587 
  Common stock, $.01 par value; authorized -- 10,000,000                                 
     shares; issued and outstanding -- 5,735,392 and                                     
     5,757,630 shares at December 31, 1996 and 1997,                                     
     respectively...........................................       57,354         57,576 
  Additional paid-in capital................................    5,806,283      5,432,964 
  Accumulated deficit.......................................   (3,903,361)   (14,255,193)
  Cumulative translation adjustment.........................       (4,161)        17,566 
                                                              -----------   ------------ 
Total stockholders' equity (deficit)........................    1,956,702     (8,746,500)
                                                              -----------   ------------ 
Total liabilities and stockholders' equity (deficit)........  $ 8,263,015   $  4,463,589 
                                                              ===========   ============ 

See accompanying notes. 
F-64

S-4
194th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 194th

HEALTHVISION, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS 

                                                        [Enlarge/Download Table]

                                                              YEAR ENDED     YEAR ENDED  
                                                             DECEMBER 31,   DECEMBER 31, 
                                                                 1996           1997     
                                                             ------------   ------------ 
                                                                                         
Revenue:                                                                                 
  Software licenses, maintenance and services............... $  7,996,395   $  8,607,541 
  Hardware..................................................      635,584        546,792 
                                                             ------------   ------------ 
          Total revenue.....................................    8,631,979      9,154,333 
Cost of revenue:                                                                         
  Software licenses, maintenance and services...............    8,331,227      5,654,084 
  Hardware..................................................      556,933        397,874 
                                                             ------------   ------------ 
          Total cost of revenue.............................    8,888,160      6,051,958 
                                                             ------------   ------------ 
Gross profit................................................     (256,181)     3,102,375 
Operating expenses:                                                                      
  Product development.......................................    6,192,610      6,657,470 
  Sales and marketing.......................................    5,066,466      4,689,598 
  General and administration................................    4,407,792      2,018,936 
                                                             ------------   ------------ 
          Total operating expenses..........................   15,666,868     13,366,004 
                                                             ------------   ------------ 
Loss from operations........................................  (15,923,049)   (10,263,629)
Other income (expense), net.................................      (56,465)       (13,203)
Net loss before foreign taxes...............................  (15,979,514)   (10,276,832)
Foreign taxes...............................................           --        (75,000)
                                                             ------------   ------------ 
Net loss....................................................  (15,979,514)   (10,351,832)
Preferred stock dividend....................................      161,605        795,075 
                                                             ------------   ------------ 
Net loss applicable to common stockholders.................. $(16,141,119)  $(11,146,907)
                                                             ============   ============ 

See accompanying notes. 

F-65

S-4
195th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 195th

HEALTHVISION, INC.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

                                                        [Enlarge/Download Table]

                                                                      SERIES A-1    SERIES A-2                          
                                                             7%       CONVERTIBLE   CONVERTIBLE             ADDITIONAL  
                                                          PREFERRED    PREFERRED     PREFERRED    COMMON     PAID-IN    
                                                            STOCK        STOCK         STOCK       STOCK     CAPITAL    
                                                          ---------   -----------   -----------   -------  ------------ 
                                                                                                                        
Balance at December 31, 1995............................   $2,570      $ 52,785      $ 28,838     $45,884  $ 48,546,696 
  Issuance of 90,000 shares of 7% preferred stock at                                                                    
    $100 per share......................................      900            --            --          --     8,999,100 
  Translation adjustment................................       --            --            --          --            -- 
  Net loss from January 1, 1996 through July 14, 1996...       --            --            --          --            -- 
                                                           ------      --------      --------     -------  ------------ 
Balance at July 14, 1996................................    3,470        52,785        28,838      45,884    57,545,796 
  Reorganization of company as of July 15, 1996                                                                         
    (issuance of common stock in exchange for assets and                                                                
    liabilities distributed by the shareholders of the                                                                  
    Predecessor Company)................................   (3,470)      (52,785)      (28,838)     11,440   (57,607,976)
  Issuance of 58,678 shares of 7% preferred stock at                                                                    
    $100 per share......................................      587            --            --          --     5,867,213 
  Exercise of stock options.............................       --            --            --          30         1,250 
  Translation adjustment................................       --            --            --          --            -- 
  Net loss from July 15, 1996 through December 31,                                                                      
    1996................................................       --            --            --          --            -- 
                                                           ------      --------      --------     -------  ------------ 
Balance at December 31, 1996............................      587            --            --      57,354     5,806,283 
  Issuance of shares of common stock upon exercise of                                                                   
    options.............................................                     --                       222        11,010 
  Accretion of redeemable senior preferred stock........       --            --            --          --      (384,329)
  Net loss..............................................                     --                        --            -- 
  Translation adjustment................................                     --                        --            -- 
                                                           ------      --------      --------     -------  ------------ 
Balance at December 31, 1997............................   $  587      $     --      $     --     $57,576  $  5,432,964 
                                                           ======      ========      ========     =======  ============ 



                                                                         CUMULATIVE        TOTAL                        
                                                          ACCUMULATED    TRANSLATION   STOCKHOLDER'S                    
                                                            DEFICIT      ADJUSTMENT       EQUITY                        
                                                          ------------   -----------   -------------                    
                                                                                                                        
Balance at December 31, 1995............................  $(29,252,891)   $(319,690)   $ 19,104,192                     
  Issuance of 90,000 shares of 7% preferred stock at                                                                    
    $100 per share......................................            --           --       9,000,000                     
  Translation adjustment................................            --      (54,712)        (54,712)                    
  Net loss from January 1, 1996 through July 14, 1996...   (12,076,153)          --     (12,076,153)                    
                                                          ------------    ---------    ------------                     
Balance at July 14, 1996................................   (41,329,044)    (374,402)     15,973,327                     
  Reorganization of company as of July 15, 1996                                                                         
    (issuance of common stock in exchange for assets and                                                                
    liabilities distributed by the shareholders of the                                                                  
    Predecessor Company)................................    41,329,044      374,402     (15,978,183)                    
  Issuance of 58,678 shares of 7% preferred stock at                                                                    
    $100 per share......................................            --           --       5,867,800                     
  Exercise of stock options.............................            --           --           1,280                     
  Translation adjustment................................            --       (4,161)         (4,161)                    
  Net loss from July 15, 1996 through December 31,                                                                      
    1996................................................    (3,903,361)          --      (3,903,361)                    
                                                          ------------    ---------    ------------                     
Balance at December 31, 1996............................    (3,903,361)      (4,161)      1,956,702                     
  Issuance of shares of common stock upon exercise of                                                                   
    options.............................................            --           --          11,232                     
  Accretion of redeemable senior preferred stock........            --           --        (384,329)                    
  Net loss..............................................   (10,351,832)          --     (10,351,832)                    
  Translation adjustment................................            --       21,727          21,727                     
                                                          ------------    ---------    ------------                     
Balance at December 31, 1997............................  $(14,255,193)   $  17,566    $ (8,746,500)                    
                                                          ============    =========    ============                     

See accompanying notes. 

F-66

S-4
196th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 196th

HEALTHVISION, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS 

                                                        [Enlarge/Download Table]

                                                              YEAR ENDED     YEAR ENDED  
                                                             DECEMBER 31,   DECEMBER 31, 
                                                                 1996           1997     
                                                             ------------   ------------ 
                                                                                         
OPERATING ACTIVITIES:                                                                    
Net loss.................................................... $(15,979,514)  $(10,351,832)
Adjustments to reconcile net loss to net cash used in                                    
  operating activities:                                                                  
  Depreciation and amortization.............................      941,005      1,019,765 
  Amortization of intangible assets.........................    3,224,425        591,745 
  (Gain) loss on disposal of equipment......................           --         29,255 
  Changes in operating assets and liabilities:                                           
     Accounts and unbilled receivables......................     (870,741)     1,045,213 
     Prepaid expenses.......................................     (198,095)        73,858 
     Accounts payable.......................................     (510,227)      (481,376)
     Accrued compensation and related liabilities...........      (49,983)      (329,162)
     Accrued interest on notes payable to stockholders......           --          5,753 
     Deferred revenue.......................................    1,533,520        390,254 
     Other accrued liabilities..............................     (348,407)       476,169 
                                                             ------------   ------------ 
Net cash used in operating activities.......................  (12,258,017)    (7,530,358)
INVESTING ACTIVITIES:                                                                    
Purchase of equipment and furniture.........................     (204,469)      (530,672)
Purchase of capitalized software development costs..........     (607,389)      (101,745)
Deposits....................................................     (329,185)            -- 
                                                             ------------   ------------ 
Net cash provided by (used in) investing activities.........   (1,141,043)      (632,417)
FINANCING ACTIVITIES:                                                                    
Proceeds from issuance of redeemable senior preferred                                    
  stock.....................................................           --      6,000,000 
Proceeds from issuance of notes payable to stockholder......           --      1,000,000 
Proceeds from issuance of common stock......................        1,280         11,232 
Proceeds from issuance of 7% preferred stock................   14,867,800             -- 
Principal payments made on long-term debt...................     (684,279)      (542,191)
                                                             ------------   ------------ 
Net cash provided by financing activities...................   14,184,801      6,469,041 
Effect of exchange rate changes on cash.....................      (58,874)        21,727 
                                                             ------------   ------------ 
Net increase (decrease) in cash and equivalents.............      726,867     (1,672,007)
Cash and equivalents, beginning of period...................    1,589,457      2,316,324 
                                                             ------------   ------------ 
Cash and equivalents, end of period......................... $  2,316,324   $    644,317 
                                                             ============   ============ 
SUPPLEMENTAL DISCLOSURE:                                                                 
Cash paid for interest...................................... $    100,000   $    107,507 
                                                             ============   ============ 

See accompanying notes. 

F-67

S-4
197th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 197th

HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 1996 AND 1997

1.  THE COMPANY, ORGANIZATION AND BASIS OF PRESENTATION                         

  HealthVISION, Inc. develops, markets and supports healthcare information
products focused on lowering costs of health care and improving clinical        
processes for integrated delivery systems, hospitals and office-based           
physicians.                                                                     

    HealthVISION, Inc. (the "Predecessor Company") was organized as a Delaware
corporation on February 2, 1994, began operations on February 15, 1994 and was  
incorporated to acquire HVC Holdings Canada Ltd., HealthVISION corporation and  
their subsidiaries.                                                             

   On August 8, 1996, the shareholders of the Predecessor Company merged the
stock of HealthVISION, Inc. and its subsidiary LBA Health Care Management, Inc. 
("LBA") with HCIA, Inc. in exchange for $130,000,000 in cash and stock.         
Immediately prior to the transaction, all of the assets, liabilities and        
subsidiaries of HealthVISION, Inc., other than certain assets identified, were  
distributed to a newly formed Company, HVISION II, Inc. which was incorporated  
as a Delaware corporation on July 15, 1996. These assets and liabilities were   
recorded at their historical cost, which was a net book deficit of $4,856, as   
both companies were under common control and there was no change in ownership.  
On August 10, 1996, HVISION II, Inc. changed its name to HealthVISION, Inc. (the
"Company").                                                                     

On January 29,1997, the Company entered into an agreement, the "Stock 
Purchase Agreement," with Transition Systems Inc.("TSI") under which the Company
granted TSI the option to acquire all of the capital stock of the Company. In   
addition, the Company issued $6,000,000 of redeemable senior preferred stock to 
TSI (see Note 6).                                                               

     The consolidated financial statements include the accounts of HealthVISION,
Inc. and its subsidiary companies, all of which are wholly owned. The           
consolidated financial statements include the operations of the Predecessor     
Company prior to the merger with HCIA, Inc. combined with the operations of     
HealthVISION, Inc. relating only to the reporting entity which exists subsequent
to the merger which excludes all operations of LBA. All intercompany            
transactions and balances have been eliminated in consolidation.                

    The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company incurred a significant net
loss of $10,351,832 for the year ended December 31, 1997. Management expects the
Company to incur additional losses and recognizes that the Company may need to  
raise additional debt or equity capital during 1998 in order to continue        
operations. The Company has obtained representation from a major shareholder as 
to its intent and ability to fund operations of the Company through at least    
January 1, 1999.                                                                

2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                                  

REVENUE RECOGNITION                                                             

 Software licenses, maintenance and services -- Revenue from license and
service contracts is recognized on the percentage-of-completion method with     
progress-to-completion measured based upon labor costs incurred. Services       
include revenue derived from implementation and professional services related to
project management, training, and hardware support. Revenue from maintenance is 
recognized over the period the customer support services are provided.          

Hardware revenue -- Hardware revenues represent revenue from sales of 
computers and related network equipment. Revenue from hardware sales is         
recognized at the later of shipment of the product or completion of significant 
obligations to the customer.                                                    

F-68

S-4
198th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 198th
HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

Deferred revenue -- Deferred revenues result from advance billings for
which revenues have not been recognized.                                        

Unbilled receivables -- Unbilled receivables result from differences  
between revenue recognized and amounts invoiced to customers under the terms of 
the contracts.                                                                  

The Company's revenue recognition policy is in accordance with the    
provisions of the American Institute of Certified Public Accountant's Statement 
of Position 91-1, "Software Revenue Recognition," ("SOP 91-1").                 

 In October 1997, the American Institute of Certified Public Accountants
issued Statement of Position 97-2, "Software Revenue Recognition," ("SOP 97-2") 
which supersedes 91-1. The Company will be required to adopt this standard for  
the year ended December 31, 1998. Restatement of prior financial statements is  
prohibited. The Company does not expect the adoption of SOP 97-2 to adversely   
affect its financial position or results of operations for the year ending      
December 31, 1998.                                                              

CASH AND CASH EQUIVALENTS                                                       

   Cash and cash equivalents consist of demand deposits and commercial paper
which are highly liquid short-term investments with original maturities from    
date of purchase of 90 days or less. Such investments are stated at cost, which 
approximates fair value.                                                        

ACCOUNTS RECEIVABLE                                                             

 Accounts receivable are primarily from health care organizations in the
United States and Canada. The Company conducts ongoing credit evaluations of its
customers, maintains reserves for potential credit losses and does not require  
collateral. An allowance for doubtful accounts is maintained to provide for     
estimated uncollectible receivables. Actual uncollectible amounts could differ  
from such estimates.                                                            

EQUIPMENT AND FURNITURE                                                         

     Equipment and furniture are recorded at cost less accumulated depreciation.
Depreciation is computed using rates calculated to amortize the cost of the     
assets less their residual values over their estimated useful lives of three to 
five years. Leasehold improvements are amortized over the terms of the          
respective leases, or useful lives of the assets, whichever is shorter.         

SOFTWARE DEVELOPMENT COSTS                                                      

Costs to develop the Company's products are expensed as incurred in   
accordance with Statement of Financial Accounting Standards No. 2, "Accounting  
for Research and Development Costs," which establishes accounting and reporting 
standards for research and development.                                         

In accordance with Statement of Financial Accounting Standards No. 86,
"Accounting for the Costs of Computer Software to be Sold, Leased or Otherwise  
Marketed," costs to complete a software product once technological feasibility  
has been established are capitalized and amortized over the estimated economic  
life of the software product on the straight-line basis, generally over three   
years. At each balance sheet date, the Company performs an evaluation assessing 
the recoverability of the unamortized capitalized costs by comparing such costs 
to the net realizable value of the related product. Costs related to the        
development of new software products incurred prior to establishing             
technological feasibility are expensed as incurred. The write-off and           
amortization of capitalized software development costs for the years ended      
December 31, 1996 and 1997, was $109,738 and $591,745, respectively.            

F-69

S-4
199th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 199th
HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

INCOME TAXES                                                                    

The Company accounts for income taxes in accordance with Statement of 
Financial Accounting Standards No. 109 ("FAS 109"), "Accounting for Income      
Taxes." Under FAS 109, the liability method is used to account for income taxes.
Under this method, deferred tax assets and liabilities are determined based on  
differences between the financial reporting and tax bases of assets and         
liabilities and are measured using the enacted tax rates and laws that will be  
in effect when the differences are expected to reverse.                         

FOREIGN CURRENCY TRANSLATION                                                    

 Assets and liabilities denominated in foreign currencies are translated
into U.S. dollars at the exchange rate as of the balance sheet date. Income and 
expense items are translated at average rates of exchange prevailing during the 
period. Translation adjustments are accumulated and reported as a separate      
component of stockholders' equity. Foreign exchange transaction adjustments are 
recorded in other income/expense in the period in which they occur.             

USE OF ESTIMATES                                                                

The preparation of financial statements in conformity with generally  
accepted accounting principles requires management to make estimates and        
assumptions that affect the amounts reported in the financial statements and    
accompanying notes. Actual results could differ from those estimates.           

STOCK-BASED COMPENSATION                                                        

The Company accounts for employee stock options in accordance with    
Accounting Principles Board Opinion No. 25 and has adopted the disclosure only  
option of Statement of Financial Accounting Standards No. 123, "Accounting for  
Stock-Based Compensation," ("FAS 123"). The effect of applying the fair value   
method under FAS 123 to the Company's stock options would result in pro forma   
net losses that are not materially different from the historical amounts        
reported.                                                                       

ACCOUNTING FOR THE IMPAIRMENT OF LONG-LIVED ASSETS                              

    The Company accounts for long-lived assets in accordance with Statement of
Financial Accounting Standards No. 121, "Accounting for the Impairment of       
Long-Lived Assets and for Long-Lived Assets to be Disposed Of," which requires  
impairment losses to be recorded on long-lived assets used in operations, such  
as property, equipment and improvements, and intangible assets, when indicators 
of impairment are present and the undiscounted cash flows estimated to be       
generated by those assets are less than the carrying amount of the assets.      

COMPREHENSIVE INCOME                                                            

  In 1997, the FASB issued Statement of Financial Accounting Standards No.
130 ("FAS 130"), "Reporting Comprehensive Income," which requires that all items
that are required to be recognized under accounting standards as components of  
comprehensive income (revenues, expenses, gains, and losses) be reported in a   
financial statement that is displayed with the same prominence as other         
financial statements. The Company will comply with the requirements of FAS 130  
for the year ending December 31, 1998.                                          

F-70

S-4
200th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 200th
HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

3.  EQUIPMENT AND FURNITURE                                                     

Equipment and furniture consist of the following at December 31:      

                                                        [Enlarge/Download Table]

                                                               1996         1997     
                                                            ----------   ----------- 
                                                                                     
Equipment.................................................. $1,641,833   $ 1,991,971 
Furniture, fixtures and leasehold improvements.............    378,558       383,007 
                                                            ----------   ----------- 
                                                             2,020,391     2,374,978 
Less accumulated depreciation and amortization.............   (379,210)   (1,252,144)
                                                            ----------   ----------- 
                                                            $1,641,181   $ 1,122,834 
                                                            ==========   =========== 

4.  INDEBTEDNESS                                                                

    On December 10, 1997, the Company issued a promissory note to its majority
shareholder for $1,000,000. The note bears annual interest at 10% and is payable
on demand. Accrued interest was $5,753 at December 31, 1997.                    

Long-term debt consists of the following at December 31:              

                                                        [Enlarge/Download Table]

                                                                 1996        1997    
                                                              ----------   --------- 
                                                                                     
Loan from Western Diversification Fund, noninterest                                  
  bearing...................................................  $  105,054   $      -- 
Capital lease obligations, bearing interest at rates ranging                         
  from 8% to 15.5% per annum, payable in varying monthly                             
  installments plus interest through 1999...................     903,492     466,355 
                                                              ----------   --------- 
                                                               1,008,546     466,355 
Less current portion........................................    (542,190)   (421,630)
                                                              ----------   --------- 
                                                              $  466,356   $  44,725 
                                                              ==========   ========= 

Scheduled maturities of long-term debt as of December 31, 1997 are as 
follows:                                                                        

                                                                [Download Table]

                                                                CAPITAL LEASE
                                                                 OBLIGATIONS 
                                                                -------------
                                                                             
1998........................................................      $454,275   
1999........................................................        45,962   
                                                                  --------   
Total minimum payments......................................       500,237   
Less amount representing interest...........................       (33,881)  
                                                                  --------   
Present value of minimum payments...........................      $466,356   
                                                                  ========   

Equipment and furniture and the related accumulated depreciation under
capital leases at December 31, 1996 were $982,473 and $152,150, respectively,   
and at December 31, 1997 were $982,473 and $609,762, respectively.              

F-71

S-4
201st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 201st
HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

5.  INCOME TAXES                                                                

     Significant components of the Company's deferred tax assets are as follows:

                                                        [Enlarge/Download Table]

                                                                 DECEMBER 31,         
                                                          --------------------------- 
                                                             1996            1997     
                                                          -----------    ------------ 
                                                                                      
Net operating loss and research credit carryforwards..... $ 6,400,000    $  9,100,000 
Other....................................................          --         900,000 
                                                          -----------    ------------ 
Total deferred tax assets................................   6,400,000      10,000,000 
Valuation allowance......................................  (6,400,000)    (10,000,000)
                                                          -----------    ------------ 
Net deferred tax assets.................................. $        --    $         -- 
                                                          ===========    ============ 

The valuation allowance increased by $6,400,000 and $3,600,000 for the
years ended December 31, 1996 and 1997, respectively.                           

 At December 31, 1997, the Company has total U.S. and foreign (primarily
Canada) net operating loss carryforwards of approximately $20,000,000 for income
tax purposes. The December 31, 1997 balance consists of approximately $7,000,000
of Canadian loss carryforwards which expire in tax years 1998 through 2004 and  
approximately $11,000,000 of U.S. loss carryforwards which expire in tax years  
2011 through 2012.                                                              

 Due to various limitations concerning utilization of net operating loss
carryforwards, these loss carryforwards could expire prior to the statutory     
expiration dates.                                                               

6.  STOCKHOLDERS' EQUITY                                                        

REDEEMABLE SENIOR PREFERRED STOCK                                               

On January 29, 1997, the Company entered into an agreement, the "Stock
Purchase Agreement," with a third party, TSI, under which the Company issued    
60,000 shares of redeemable senior preferred stock at $100 per share for total  
cash proceeds of $6,000,000.                                                    

The redeemable senior preferred stock has a par value of $.01, is     
convertible into common stock and has a cumulative dividend rate of 7% per      
annum. The holder of the redeemable senior preferred stock is entitled to voting
rights equivalent to the number of common shares into which the preferred stock 
is convertible. The holder may convert any or all of the redeemable senior      
preferred stock into shares of common stock at a price equal to $100 per share  
plus an amount equal to any and all dividends accrued and unpaid. Each share of 
redeemable senior preferred stock shall be automatically converted into shares  
of common stock at the then effective conversion price upon the closing of an   
initial public offering. In the event of any liquidation, dissolution or winding
up of the Company, and before any distribution or payment shall be made to the  
holders of the 7% preferred stock, the holders of redeemable senior preferred   
stock shall be entitled to an amount equal to $100 per share plus any and all   
dividends accrued and unpaid as of the date of such distribution or payment.    

So long as any shares of the redeemable senior preferred stock remain 
outstanding, in no event shall any dividend, whether in cash or other property, 
be paid or declared, or any distribution be made on the 7% preferred stock or   
the common stock. If liquidation occurs, redeemable senior preferred            
stockholders are entitled to receive a distribution of their liquidation        
preference first, followed by distributions to 7% preferred stockholders, and   
thereafter, any remaining assets will be distributed to common stockholders.    
Cumulative dividends earned but undeclared were $384,329 at December 31, 1997.  

  At the written election of any holder of senior preferred stock made not
less than 30 days prior to each of January 1, 2000, 2001, and 2002, the Company 
shall call for redemption, and shall redeem from                                

F-72

S-4
202nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 202nd
HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

such holder not later than 60 days after whichever January 1 shall be           
applicable, on each of the first two such redemption dates, up to one-third of  
the shares of senior preferred stock held by such holder on January 1, 2000, and
on the last such redemption date up to the balance of senior preferred stock    
held by such holder, at a redemption price per share equal to the sum of the    
stated value thereof, plus an amount equal any and all dividends accrued or     
declared but unpaid on, and any and all other amounts owing with respect to,    
such shares on the redemption date. After March 31, 1998 or, if later, the      
option expiration date specified in the Stock Purchase Agreement, the Company   
shall have the right at its option to redeem as a whole, or from time to time in
part, shares of senior preferred stock at a price equal to the stated value     
thereof per share, plus an amount equal to any and all dividends accrued and    
unpaid thereon, through the date of redemption.                                 

7% PREFERRED STOCK                                                              

  The Company's 7% preferred stock consists of 58,678 designated shares of
$.01 par preferred stock of which 58,678 shares were issued in August 1996 at   
$100 per share for cash proceeds totaling $5,867,800. The 7% preferred stock is 
non-voting and is entitled to a cumulative dividend rate of 7% per annum. The 7%
preferred stock shares are not convertible into common stock. The Company may   
redeem any or all of the 7% preferred stock, at any time, at a price equal to   
$100 per share plus an amount equal to any and all dividends accrued and unpaid.
Cumulative dividends earned but undeclared were $161,605 and $572,351 at        
December 31, 1996 and December 31, 1997, respectively.                          

WARRANTS                                                                        

   In connection with its capital leases, the Company issued to the lessor a
warrant to purchase 39,670 shares of its common stock at a price of $5.04 per   
share (the "Warrant"). The Warrant expires at the earlier of ten years after the
date of grant, July 2005, or five years after the closing of an initial public  
offering of the Company's common stock. The holder also has the right to convert
the Warrant into a number of shares of the Company's common stock based on the  
value of the warrant given the then-current fair market value of the Company's  
common stock.                                                                   

7.  STOCK OPTIONS                                                               

1996 STOCK OPTION PLAN                                                          

The Company's 1996 Stock Option Plan (the "Stock Option Plan") was    
established effective August 10, 1996. The maximum number of shares authorized  
to be issued under the Stock Option Plan, as amended, is 1,400,000 shares of    
common stock. The Compensation Committee of the Company designated 362,583 of   
the shares authorized to be issued under the Stock Option Plan as bonus options 
(the "Bonus Options"). As of December 31, 1997, options to purchase 69,478      
shares of common stock outstanding were Bonus Options.                          

    In order to protect all of the rights of Bonus Option holders in the event
of a Liquidity Event (as defined below), Bonus Option agreements provide for the
acceleration of vesting of all or a portion of outstanding Bonus Options upon   
the occurrence of a Liquidity Event. A Liquidity Event is defined as either (i) 
the consummation of an underwritten initial public offering of the Company's    
common stock, which has been registered under the Securities Act of 1933, as    
amended, or (ii) a Change of Control, as defined.                               

    During the year ended December 31, 1997, the Compensation Committee of the
Company granted options to purchase 764,438 shares of common stock under the    
Plan which become vested at the rate of 30% 18 months after the grant date of   
the options and at the rate of 10% each six months thereafter. In addition, if  
TSI, a related party, exercises its purchase option, then these options shall   
vest in full.                                                                   

F-73

S-4
203rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 203rd
HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

  The outstanding options granted under the Plan generally vest and become
exercisable at a rate of 30% 18 months after the date of grant and an additional
10% every 6 months thereafter, subject to continued service as an employee;     
however, Bonus Options vest and become exercisable 10 days prior to the         
termination date of the Bonus Option, subject to continued service as an        
employee. Generally, the term of each outstanding option is 10 years. The       
exercise price for options granted under the Stock Option Plan is at least equal
to 100% of the fair market value of the common stock of the Company on the date 
of grant. The Stock Option Plan permits the granting of stock options, including
incentive stock options ("ISOs") as defined under Section 422 of the Internal   
Revenue Code of 1986, as amended (the "Code"), and non-qualified stock options  
("NQSOs") which do not qualify as ISOs.                                         

Stock option transactions are summarized as follows:                  

                                                        [Enlarge/Download Table]

                                                    SHARES UNDER   EXERCISE    WEIGHTED-AVERAGE
                                                      OPTIONS        PRICE      EXERCISE PRICE 
                                                    ------------  -----------  ----------------
                                                                                               
Outstanding at July 15, 1996.......................         --    $        --       $  --      
  Granted..........................................  1,169,066     .43 - 2.10         .59      
  Exercised........................................     (2,975)           .43         .43      
  Canceled.........................................   (269,240)    .43 - 2.10         .52      
                                                     ---------    -----------       -----      
Outstanding at December 31, 1996...................    896,851      43 - 2.10         .64      
  Granted..........................................    769,438           2.10        2.10      
  Exercised........................................    (21,238)           .43         .43      
  Canceled.........................................   (626,692)    .43 - 2.10         .59      
                                                     ---------    -----------       -----      
Outstanding at December 31, 1997...................  1,018,359    $.43 - 2.10       $1.78      
                                                     =========    ===========       =====      

  Of the shares under options granted, 92,718 shares at a weighted-average
exercise price of $.82 are exercisable and 331,644 shares are available for     
future option grants as of December 31, 1997.                                   

    The weighted-average remaining contractual life for options outstanding at
December 31, 1997 is nine years and the weighted-average grant date fair value  
of options granted during 1997 was $.53.                                        

1996 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN                                    

    On July 15, 1996, the Company adopted the 1996 Non-Employee Director Stock
Option Plan (the "Director Stock Option Plan"). The Director Stock Option Plan  
provides for an automatic grant of NQSOs to purchase 3,000 shares of common     
stock to non-employee directors on the date such individuals are first appointed
directors of the Company, and an automatic grant of an option to purchase an    
additional 1,000 shares of common stock on the day after each subsequent annual 
meeting of the Company's stockholders. The option price is equal to the fair    
market value of the common stock on the date of grant. Initial option grants    
vest and become exercisable as to one-third of the shares covered by the option 
on each annual anniversary of the date of grant if the holder remains a director
on such date, provided that such options may become fully exercisable upon a    
director's resignation from the Board of Directors or death of the holder.      
Annual option grants vest and become exercisable as to 100% of the shares       
covered by the option on the six-month anniversary of the date of grant if the  
holder remains a director on such date, provided that such options may become   
fully exercisable upon a director's resignation from the Board of Directors or  
death of the holder. The Company has reserved 50,000 shares of common stock for 
issuance under the Director Stock Option Plan. All options granted under the    
Plan were either exercised or expired and no options were outstanding at        
December 31, 1997.                                                              

F-74

S-4
204th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 204th
HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

8.  COMMITMENTS AND CONTINGENCIES                                               

OPERATING LEASES                                                                

Future minimum payments, under noncancellable office and equipment    
operating leases with initial terms of one year or more, consist of the         
following for the periods ended December 31:                                    

                                                                [Download Table]
                                                                        
1998........................................................  $  836,778
1999........................................................     771,660
2000........................................................     152,930
2001........................................................      31,952
2002........................................................          --
                                                              ----------
                                                              $1,793,320
                                                              ==========

    Total rent expense under all operating leases was approximately $1,113,000
and $1,160,000 for the years ended December 31, 1996 and 1997, respectively.    

LEGAL PROCEEDINGS                                                               

   A subsidiary of the Company is currently a defendant to a civil complaint
filed on July 6, 1995, in the Supreme Court of British Columbia, Canada, by     
Stratford General Hospital. The complaint alleges that Stratford General        
Hospital entered into a contract with the subsidiary for the maintenance and    
support of an integrated hospital management information system and that the    
subsidiary has refused to perform its obligations under such alleged contract.  
Stratford General Hospital is seeking unspecified compensatory damages from the 
subsidiary. The subsidiary has filed a defense denying that it entered into such
an alleged contract with Stratford General Hospital. The Company believes that  
the suit is totally without merit and intends to defend its position vigorously.
In the opinion of management, resolution of this matter is not expected to have 
a material adverse effect on the financial position of the Company. However,    
depending on the amount and timing, an unfavorable resolution of this matter    
could materially affect the Company's future results of operations or cash flows
in a particular period.                                                         

9.  DEFINED CONTRIBUTION PENSION PLAN                                           

  The Company has a deferred compensation plan for all full-time employees
which qualifies under Section 401(k) of the Internal Revenue Code. Under the    
terms of the 401(k) Plan, member employees may contribute varying amounts of    
their annual compensation (to a maximum of $9,500). The Plan provides for       
discretionary employer contributions to the Plan. As of December 31, 1997, there
have been no employer contributions to the Plan.                                

10.  RELATED PARTY TRANSACTIONS                                                 

 In July 1997, the Company entered into a marketing assistance and value
added remarketer agreement with TSI, a related party and shareholder. This      
agreement requires the Company to pay from 5% to 20% of the software license fee
for any contracts in which TSI was involved in the marketing efforts on the     
Company's behalf. The Company had an outstanding payable at December 31, 1997 of
$399,770 to TSI for marketing and consulting services performed for various     
customers on behalf of the Company. These marketing and consulting fees were    
incurred and expensed during 1997.                                              

F-75

S-4
205th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 205th
HEALTHVISION, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED) 

11.  INFORMATION BY GEOGRAPHIC AREA                                             

   Information regarding the Company's operations by geographic area for the
years ended December 31, 1996 and 1997 is as follows:                           

                                                        [Enlarge/Download Table]

                                                             1996           1997     
                                                         ------------   ------------ 
                                                                                     
Revenues:                                                                            
  Canada................................................ $  5,433,695   $  4,222,950 
  United States.........................................    1,986,585      3,815,613 
  Other.................................................    1,211,699      1,115,770 
                                                         ------------   ------------ 
          Total......................................... $  8,631,979   $  9,154,333 
                                                         ============   ============ 
Operating income (losses):                                                           
  Canada................................................ $ (4,623,713)  $ (4,468,669)
  United States.........................................  (11,824,893)    (6,452,996)
  Other.................................................      469,092        658,036 
                                                         ------------   ------------ 
          Total......................................... $(15,979,514)  $(10,263,629)
                                                         ============   ============ 
Total assets:                                                                        
  Canada................................................ $  3,416,642   $  1,702,319 
  United States.........................................    4,441,670      2,691,569 
  Other.................................................      404,703         69,701 
                                                         ------------   ------------ 
          Total......................................... $  8,263,015   $  4,463,589 
                                                         ============   ============ 

12.  SUBSEQUENT EVENTS                                                          

ISSUANCE OF PROMISSORY NOTES                                                    

     In February, August and September 1998, the Company issued promissory notes
aggregating approximately $2,600,000 to certain stockholders in exchange for    
cash. The notes bear an annual interest rate of 10% and are payable on demand.  

MERGER WITH TSI                                                                 

On October 28, 1998, the Company entered into an agreement and plan of
reorganization with TSI, under the terms of which the Company will be merging   
with a subsidiary of TSI subject to customary closing conditions. The purchase  
price consists of $25.6 million of cash and contingent payments based upon      
future sales milestones of up to an additional $10.8 million of cash.           

F-76

S-4
206th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 206th

 The unaudited interim condensed consolidated financial statements as of
September 30, 1998 and for the nine month periods ended September 30, 1997 and  
1998, include all adjustments, consisting of normal recurring accruals, which   
the Company considers necessary for a fair presentation of the financial        
position and results of operations for these periods. Ernst & Young LLP has not 
compiled, reviewed or performed any audit procedures relating to the unaudited  
interim financial information as of September 30, 1998 or for the nine month    
periods ended September 30, 1997 and 1998.                                      

HEALTHVISION, INC.

CONDENSED CONSOLIDATED BALANCE SHEET
AS OF SEPTEMBER 30, 1998
(UNAUDITED) 

                                                                [Download Table]

                                                              SEPTEMBER 30,
                                                                  1998     
                                                              -------------
                                                                           
                                  ASSETS                                   
Current assets:                                                            
  Cash and cash equivalents.................................  $    562,318 
  Accounts receivable, net..................................     3,046,806 
  Unbilled receivables......................................       649,373 
  Prepaid expenses..........................................       801,919 
                                                              ------------ 
          Total current assets..............................     5,060,416 
Equipment and furniture, net................................       667,824 
Capitalized and purchased software, net.....................       101,744 
                                                              ------------ 
          Total assets......................................  $  5,829,984 
                                                              ============ 

                   LIABILITIES AND STOCKHOLDERS' DEFICIT                   
Current liabilities:                                                       
  Accounts payable..........................................  $    400,749 
  Accrued compensation and related liabilities..............       750,201 
  Deferred revenue..........................................     6,660,022 
  Other accrued liabilities.................................     1,328,360 
  Current portion of long-term debt.........................       114,170 
  Notes to stockholders.....................................     3,818,079 
                                                              ------------ 
          Total current liabilities.........................    13,071,581 
Redeemable preferred stock..................................     6,000,000 

Stockholders' deficit:                                                     
  Preferred stock...........................................           587 
  Common stock..............................................        57,627 
  Additional paid-in capital................................     6,219,918 
  Cumulative foreign currency adjustment....................        80,990 
  Accumulated deficit.......................................   (19,600,719)
                                                              ------------ 
          Total stockholders' deficit.......................   (13,241,597)
                                                              ------------ 
            Total liabilities and stockholders' deficit.....  $  5,829,984 
                                                              ============ 

The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements 
F-77

S-4
207th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 207th

HEALTHVISION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1997 AND 1998 
(UNAUDITED) 

                                                        [Enlarge/Download Table]

                                                             NINE MONTHS ENDED SEPTEMBER 30, 
                                                             --------------------------------
                                                                 1997               1998     
                                                             -------------      -------------
                                                                                             
Revenues:                                                                                    
  Software licenses, maintenance and services...............  $ 6,395,282        $ 9,415,809 
  Hardware..................................................      557,085                 -- 
                                                              -----------        ----------- 
          Total revenues....................................    6,952,367          9,415,809 
                                                              -----------        ----------- 
Costs and expenses:                                                                          
  Cost of systems and services revenues.....................    3,812,476          3,796,015 
  Cost of hardware revenues.................................      405,364                 -- 
  Product development.......................................    4,799,639          5,274,155 
  Sales and marketing.......................................    3,276,834          3,348,979 
  General and administrative................................    1,576,560          2,052,328 
                                                              -----------        ----------- 
          Total costs and expenses..........................   13,870,873         14,471,477 
                                                              -----------        ----------- 
            Loss from operations............................   (6,918,506)        (5,055,668)
Other income (expense):                                                                      
  Interest income...........................................       95,498             15,610 
  Interest expense..........................................      (83,859)          (191,322)
  Foreign currency transaction loss.........................      (12,409)           (27,724)
                                                              -----------        ----------- 
          Total other income (expense) net..................         (770)          (203,436)
                                                              -----------        ----------- 
Net loss before foreign taxes...............................   (6,919,276)        (5,259,104)
Foreign taxes...............................................      (75,000)           (86,422)
                                                              -----------        ----------- 
Net loss....................................................   (6,994,276)        (5,345,526)
Preferred stock dividend....................................     (585,681)          (621,352)
                                                              -----------        ----------- 
Net loss available to common stockholders...................  $(7,579,957)       $(5,966,878)
                                                              ===========        =========== 

The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements 
F-78

S-4
208th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 208th

HEALTHVISION, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) 
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1998
(UNAUDITED) 

                                                        [Enlarge/Download Table]

                                                   ADDITIONAL                 CUMULATIVE       TOTAL    
                            7% PREFERRED  COMMON    PAID-IN    ACCUMULATED    TRANSLATION  STOCKHOLDER'S
                               STOCK       STOCK    CAPITAL      DEFICIT      ADJUSTMENT      DEFICIT   
                            ------------  -------  ----------  ------------   -----------  -------------
                                                                                                        
Balance at December 31,                                                                                 
  1997.....................     $587      $57,576  $5,817,293  $(14,255,193)    $17,566    $ (8,362,171)
Issuance of shares of                                                                                   
  common stock upon                                                                                     
  exercise of options......                    51       2,625                                     2,676 
Equity contribution........                           400,000                                   400,000 
Translation adjustment.....                                                      63,424          63,424 
Net loss...................                                      (5,345,526)                 (5,345,526)
                                ----      -------  ----------  ------------     -------    ------------ 
Balance at September 30,                                                                                
  1998.....................     $587      $57,627  $6,219,918  $(19,600,719)    $80,990    $(13,241,597)
                                ====      =======  ==========  ============     =======    ============ 

F-79

S-4
209th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 209th

HEALTHVISION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 1997 AND 1998 
(UNAUDITED) 

                                                        [Enlarge/Download Table]

                                                                 NINE MONTHS ENDED     
                                                                   SEPTEMBER 30,       
                                                             ------------------------- 
                                                                1997          1998     
                                                             -----------   ----------- 
                                                                                       
Operating activities:                                                                  
Net loss.................................................... $(6,994,276)  $(5,345,526)
                                                             -----------   ----------- 
Adjustments to reconcile net loss to net cash used in                                  
  operating activities:                                                                
  Depreciation and amortization.............................     980,566       596,881 
  Capitalized software development costs....................    (250,000)           -- 
  Loss on disposal of equipment.............................      29,307         2,823 
  Changes in operating assets and liabilities:                                         
     Accounts receivable....................................    (549,474)   (1,629,448)
     Unbilled receivables...................................     170,498      (447,410)
     Prepaid expenses.......................................    (193,024)      173,454 
     Accounts payable.......................................     (18,743)      112,130 
     Accrued compensation and related liabilities...........    (306,684)       48,702 
     Accrued interest on notes payable to stockholders......          --       159,938 
     Deferred revenue.......................................     601,214     3,558,890 
     Other accrued liabilities..............................     211,659        65,958 
                                                             -----------   ----------- 
          Total adjustments to reconcile net loss to net                               
            cash provided by operating activities...........     675,319     2,641,918 
                                                             -----------   ----------- 
               Net cash used in operating activities........  (6,318,957)   (2,703,608)
                                                             -----------   ----------- 
Investing activities:                                                                  
Proceeds from sale of equipment.............................       1,708           125 
Purchase of equipment and furniture.........................    (454,282)     (144,819)
Purchase of capitalized software development costs..........     (99,142)           -- 
                                                             -----------   ----------- 
       Net cash used in investing activities................    (551,716)     (144,694)
                                                             -----------   ----------- 
Financing activities:                                                                  
Proceeds from issuance of redeemable senior preferred                                  
  stock.....................................................   6,000,000            -- 
Proceeds from issuance of notes payable to stockholder......          --     2,652,388 
Proceeds from issuance of common stock......................       4,666         2,676 
Sale of common stock........................................          --            -- 
Equity contribution.........................................          --       400,000 
Principal payments on long-term debt........................    (427,540)     (352,185)
                                                             -----------   ----------- 
       Net cash provided by financing activities............   5,577,126     2,702,879 
                                                             -----------   ----------- 
Effect of exchange rate changes on cash and cash                                       
  equivalents...............................................      27,021        63,424 
                                                             -----------   ----------- 
Net increase in cash and cash equivalents...................  (1,266,526)      (81,999)
Cash and cash equivalents, beginning of period..............   2,316,324       644,317 
                                                             -----------   ----------- 
Cash and cash equivalents, end of period.................... $ 1,049,798   $   562,318 
                                                             ===========   =========== 
Supplemental disclosure:                                                               
Cash paid for interest...................................... $    83,859   $    31,384 
                                                             ===========   =========== 

The accompanying notes are an integral part to these unaudited condensed        
consolidated financial statements.                                              
F-80

S-4
210th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 210th

HEALTHVISION, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
SEPTEMBER 30, 1998

1.  BASIS OF PRESENTATION                                                       

 The condensed consolidated financial statements include all adjustments
that, in the opinion of management, are necessary for a fair presentation of the
results for the periods indicated. All such adjustments are considered of normal
recurring nature. Quarterly results of operations are not necessarily indicative
of annual results.                                                              

     Certain financial information and footnote disclosures normally included in
financial statements prepared in accordance with generally accepted accounting  
principles have been condensed or omitted. These condensed consolidated         
financial statements should be read in conjunction with the consolidated        
financial statements and the notes thereto included in this Joint Proxy         
Statement/Prospectus.                                                           

2.  SUBSEQUENT EVENT                                                            

    On October 28, 1998, the Company entered into a definitive agreement to be
acquired by TSI. The purchase price will consist of $25.6 million cash and the  
assumption of certain liabilities totalling $9.3 million. The acquisition will  
be accounted for as a purchase, reflecting an estimated aggregate purchase      
price, including TSI's initial 1997 investment, of $40.7 million, which includes
$6.4 million previously paid by TSI and $9.3 million of assumed liabilities, net
of cash acquired. The acquisition is expected to be completed in early December 
1998.                                                                           

F-81

S-4
211th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 211th

                                                                         ANNEX A

                                                                  EXECUTION COPY

AGREEMENT AND PLAN OF MERGER

AMONG 

ECLIPSYS CORPORATION

EXERCISE ACQUISITION CORP.

AND 

TRANSITION SYSTEMS, INC.

October 29, 1998

S-4
212th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 212th

TABLE OF CONTENTS 

                                                                [Download Table]

                                                              PAGE
                                                              ----
                                                                  
ARTICLE I                                                         
  THE MERGER................................................   A-1
  Section 1.01 Effective Time of the Merger.................   A-1
  Section 1.02 Closing......................................   A-1
  Section 1.03 Effects of the Merger........................   A-1
  Section 1.04 Directors of Eclipsys........................   A-1

ARTICLE II                                                        
  CONVERSION OF SECURITIES..................................   A-2
  Section 2.01 Conversion of Capital Stock..................   A-2
  Section 2.02 Exchange of Certificates.....................   A-3

ARTICLE III                                                       
  REPRESENTATIONS AND WARRANTIES OF TSI.....................   A-5
  Section 3.01 Organization of TSI..........................   A-5
  Section 3.02 TSI Capital Structure........................   A-5
  Section 3.03 Authority; No Conflict; Required Filings and       
     Consents...............................................   A-6
  Section 3.04 SEC Filings; Financial Statements............   A-7
  Section 3.05 No Undisclosed Liabilities...................   A-7
  Section 3.06 Absence of Certain Changes or Events.........   A-7
  Section 3.07 Taxes........................................   A-8
  Section 3.08 Properties...................................   A-9
  Section 3.09 Intellectual Property........................   A-9
  Section 3.10 Agreements, Contracts and Commitments........  A-10
  Section 3.11 Litigation...................................  A-11
  Section 3.12 Environmental Matters........................  A-11
  Section 3.13 Employee Benefit Plans.......................  A-11
  Section 3.14 Compliance With Laws.........................  A-12
  Section 3.15 Accounting and Tax Matters...................  A-12
  Section 3.16 Registration Statement; Proxy                      
     Statement/Prospectus...................................  A-12
  Section 3.17 Labor Matters................................  A-13
  Section 3.18 Insurance; Risk Management...................  A-13
  Section 3.19 No Existing Discussions......................  A-13
  Section 3.20 Opinion of Financial Advisor.................  A-13
  Section 3.21 Anti-Takeover Laws...........................  A-13
  Section 3.22 Insider Trading Policies and Practices.......  A-13

ARTICLE IV                                                        
  REPRESENTATIONS AND WARRANTIES OF ECLIPSYS AND SUB........  A-14
  Section 4.01 Organization of Eclipsys and Sub.............  A-14
  Section 4.02 Eclipsys Capital Structure...................  A-14
  Section 4.03 Authority; No Conflict; Required Filings and       
     Consents...............................................  A-15
  Section 4.04 SEC Filings; Financial Statements............  A-16
  Section 4.05 No Undisclosed Liabilities...................  A-16
  Section 4.06 Absence of Certain Changes or Events.........  A-16
  Section 4.07 Taxes........................................  A-16
  Section 4.08 Properties...................................  A-17
  Section 4.09 Intellectual Property........................  A-17

 A-i

S-4
213th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 213th

                                                                [Download Table]

                                                              PAGE
                                                              ----
                                                                  
  Section 4.10 Agreements, Contracts and Commitments........  A-18
  Section 4.11 Litigation...................................  A-18
  Section 4.12 Environmental Matters........................  A-18
  Section 4.13 Employee Benefit Plans.......................  A-19
  Section 4.14 Compliance With Laws.........................  A-19
  Section 4.15 Accounting and Tax Matters...................  A-19
  Section 4.16 Registration Statement; Proxy                      
     Statement/Prospectus...................................  A-19
  Section 4.17 Labor Matters................................  A-20
  Section 4.18 Insurance; Risk Management...................  A-20
  Section 4.19 No Existing Discussions......................  A-20
  Section 4.20 Opinion of Financial Advisor.................  A-20
  Section 4.21 Anti-Takeover Laws...........................  A-20
  Section 4.22 Insider Trading Policies and Practices.......  A-20
  Section 4.23 Interim Operations of Sub....................  A-20

ARTICLE V                                                         
  CONDUCT OF BUSINESS.......................................  A-21
  Section 5.01 Covenants of TSI.............................  A-21
  Section 5.02 Covenants of Eclipsys........................  A-22
  Section 5.03 Cooperation..................................  A-23
  Section 5.04 HealthVISION Acquisition.....................  A-23
  Section 5.05 Voting Agreements............................  A-23
  Section 5.06 Eclipsys Permitted Acquisitions..............  A-23

ARTICLE VI                                                        
  ADDITIONAL AGREEMENTS.....................................  A-24
  Section 6.01 No Solicitation..............................  A-24
  Section 6.02 Proxy Statement/Prospectus; Registration           
     Statement..............................................  A-24
  Section 6.03 Nasdaq Quotation.............................  A-25
  Section 6.04 Access to Information........................  A-25
  Section 6.05 Stockholders' Meetings.......................  A-25
  Section 6.06 Legal Conditions to Merger...................  A-25
  Section 6.07 Public Disclosure............................  A-26
  Section 6.08 Tax-Free Reorganization......................  A-26
  Section 6.09 Pooling Accounting...........................  A-26
  Section 6.10 Affiliate Agreements.........................  A-27
  Section 6.11 Nasdaq Quotation.............................  A-27
  Section 6.12 Stock Plans and Warrants.....................  A-27
  Section 6.13 Brokers or Finders...........................  A-28
  Section 6.14 Indemnification..............................  A-28
  Section 6.15 Letter of Eclipsys' Accountants..............  A-29
  Section 6.16 Letter of TSI's Accountants..................  A-29
  Section 6.17 Warburg Registration Rights Agreement........  A-29

ARTICLE VII                                                       
  CONDITIONS TO MERGER......................................  A-29
  Section 7.01 Conditions to Each Party's Obligation To           
     Effect the Merger......................................  A-29
  Section 7.02 Additional Conditions to Obligations of            
     Eclipsys and Sub.......................................  A-30
  Section 7.03 Additional Conditions to Obligations of            
     TSI....................................................  A-31

A-ii

S-4
214th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 214th

                                                                [Download Table]

                                                              PAGE
                                                              ----
                                                                  
ARTICLE VIII                                                      
  TERMINATION AND AMENDMENT.................................  A-31
  Section 8.01 Termination..................................  A-31
  Section 8.02 Effect of Termination........................  A-32
  Section 8.03 Fees and Expenses............................  A-32
  Section 8.04 Amendment....................................  A-34
  Section 8.05 Extension; Waiver............................  A-34

ARTICLE IX                                                        
MISCELLANEOUS...............................................  A-35
  Section 9.01 Nonsurvival of Representations, Warranties         
     and Agreements.........................................  A-35
  Section 9.02 Notices......................................  A-35
  Section 9.03 Interpretation...............................  A-35
  Section 9.04 Counterparts.................................  A-36
  Section 9.05 Entire Agreement; No Third Party                   
     Beneficiaries..........................................  A-36
  Section 9.06 Governing Law................................  A-36
  Section 9.07 Assignment...................................  A-36
Exhibit A -- Voting Agreement...............................  A-38
Exhibit B -- Affiliate Agreement............................  A-48

 A-iii

S-4
215th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 215th

                                                                [Download Table]

                                                              PAGE           
                                                              ----           
                   TABLE OF DEFINED TERMS                                    
                                                                             
Acquisition Proposal........................................  Section 6.01(a)
Affiliate...................................................  Section 6.10   
Affiliate Agreement.........................................  Section 6.10   
Agreement...................................................  Preamble       
Alternative Transaction.....................................  Section 8.03(g)
Antitrust Laws..............................................  Section 6.06(b)
Articles of Merger..........................................  Section 1.01   
Bankruptcy and Equity Exception.............................  Section 3.03(a)
Certificates................................................  Section 2.02(b)
Closing.....................................................  Section 1.02   
Closing Date................................................  Section 1.02   
Code........................................................  Preamble       
Confidentiality Agreement...................................  Section 6.01(a)
Constituent Corporations....................................  Section 1.03   
Costs.......................................................  Section 6.14(a)
Dissenting Shares...........................................  Section 2.01(d)
Effective Time..............................................  Section 1.01   
Environmental Law...........................................  Section 3.12(a)
ERISA.......................................................  Section 3.13(a)
ERISA Affiliate.............................................  Section 3.13(a)
Exchange Act................................................  Section 3.03(c)
Exchange Agent..............................................  Section 2.02(a)
Exchange Fund...............................................  Section 2.02(a)
Exchange Ratio..............................................  Section 2.01(c)
Eclipsys....................................................  Preamble       
Eclipsys Affiliated Group...................................  Section 4.07(a)
Eclipsys Affiliated Period..................................  Section 4.07(a)
Eclipsys Balance Sheet......................................  Section 4.04(b)
Eclipsys Common Stock.......................................  Section 4.02(a)
Eclipsys Disclosure Schedule................................  Article IV     
Eclipsys Employee Plans.....................................  Section 4.13(a)
Eclipsys Intellectual Property Rights.......................  Section 4.09(a)
Eclipsys Material Adverse Effect............................  Section 4.01   
Eclipsys Material Contracts.................................  Section 4.10   
Eclipsys Material Covenants.................................  Section 8.03(d)
Eclipsys Non-Voting Common Stock............................  Section 4.02(a)
Eclipsys Permitted Acquisition..............................  Section 5.02(d)
Eclipsys Possible Acquisition...............................  Section 4.19   
Eclipsys Preferred Stock....................................  Section 4.02(a)
Eclipsys SEC Reports........................................  Section 4.04(a)
Eclipsys Stock Plans........................................  Section 4.02(a)
Eclipsys Stockholders' Meeting..............................  Section 3.16   
Eclipsys Termination Fee Event..............................  Section 8.03(c)
Eclipsys Third Party Intellectual Property Rights...........  Section 4.09(b)
Eclipsys Voting Common Stock................................  Section 2.01(b)
Eclipsys Voting Proposals...................................  Section 6.05(a)
Eclipsys Warrants...........................................  Section 4.02(a)

A-iv

S-4
216th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 216th

                                                                [Download Table]
                                                                             
GAAP........................................................  Section 3.04(b)
Governmental Entity.........................................  Section 3.03(c)
Hazardous Substance.........................................  Section 3.12(c)
HealthVISION................................................  Section 3.19   
HealthVISION Acquisition....................................  Section 3.19   
IISR ACT....................................................  Section 3.03(a)
Indemnified Parties.........................................  Section 6.14(a)
IRS.........................................................  Section 3.07(b)
Joint Proxy Statement.......................................  Section 3.16   
Material Adverse Change.....................................  Section 3.06   
MBCL........................................................  Section 1.01   
Merger......................................................  Preamble       
Off-the-Shelf Software......................................  Section 3.09(a)
Order.......................................................  Section 7.01(e)
Outside Date................................................  Section 8.01(b)
Registration Rights Agreement...............................  Section 6.17   
Registration Statement......................................  Section 3.16   
Rule 145....................................................  Section 6.10   
SEC.........................................................  Section 3.03(c)
Second Request..............................................  Section 6.06(b)
Securities Act..............................................  Section 3.04(a)
Stock Purchase Plan.........................................  Section 6.12(f)
Sub.........................................................  Preamble       
Subsidiary..................................................  Section 3.01   
Superior Proposal...........................................  Section 6.01(a)
Surviving Corporation.......................................  Section 1.03   
Tax.........................................................  Section 3.07(a)
Taxes.......................................................  Section 3.07(a)
Tax Returns.................................................  Section 3.07(a)
Third Party.................................................  Section 8.03(g)
TSI.........................................................  Preamble       
TSI Affiliated Group........................................  Section 3.07(b)
TSI Affiliated Period.......................................  Section 3.07(b)
TSI Balance Sheet...........................................  Section 3.04(b)
TSI Common Stock............................................  Section 2.01(b)
TSI Designees...............................................  Section 1.04(a)
TSI Disclosure Schedule.....................................  Article III    
TSI Employee Plans..........................................  Section 3.13(a)
TSI Intellectual Property Rights............................  Section 3.09(a)
TSI Material Adverse Effect.................................  Section 3.01   
TSI Material Contracts......................................  Section 3.10   
TSI Material Covenants......................................  Section 8.03(b)
TSI Non-Voting Common Stock.................................  Section 2.01(b)
TSI Preferred Stock.........................................  Section 3.02(a)
TSI SEC Reports.............................................  Section 3.04(a)
TSI Stock Option............................................  Section 6.12(a)
TSI Stock Plans.............................................  Section 3.02(a)
TSI Stockholders' Meeting...................................  Section 3.16   
TSI Termination Fee Event...................................  Section 8.03(e)

 A-v

S-4
217th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 217th

                                                                [Download Table]
                                                                             
TSI Third Party Intellectual Property.......................  Section 3.09(b)
TSI Voting Common Stock.....................................  Section 2.01(b)
TSI Warrants................................................  Section 3.02(a)
Warburg.....................................................  Section 5.05   
Warburg Registration Rights Agreement.......................  Section 6.17   
Year 2000 Compliant.........................................  Section 3.09(d)

A-vi

S-4
218th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 218th

AGREEMENT AND PLAN OF MERGER

 AGREEMENT AND PLAN OF MERGER (the "Agreement"), dated as of October 29,
1998, by and among Eclipsys Corporation, a Delaware corporation ("Eclipsys"),   
Exercise Acquisition Corp., a Massachusetts corporation and a direct,           
wholly-owned subsidiary of Eclipsys ("Sub"), and Transition Systems, Inc., a    
Massachusetts corporation ("TSI").                                              

    WHEREAS, the Boards of Directors of Eclipsys and TSI deem it advisable and
in the best interests of each corporation and its respective stockholders that  
Eclipsys and TSI combine in order to advance the long-term business interests of
Eclipsys and TSI;                                                               

     WHEREAS, the combination of Eclipsys and TSI shall be effected by the terms
of this Agreement through a merger in which the stockholders of TSI will become 
stockholders of Eclipsys (the "Merger");                                        

  WHEREAS, for Federal income tax purposes, it is intended that the Merger
shall qualify as a reorganization within the meaning of Section 368(a) of the   
Internal Revenue Code of 1986, as amended (the "Code"); and                     

   WHEREAS, for accounting purposes, it is intended that the Merger shall be
accounted for as a pooling of interests;                                        

NOW, THEREFORE, in consideration of the foregoing and the respective  
representations, warranties, covenants and agreements set forth below, the      
parties agree as follows:                                                       

ARTICLE I 

THE MERGER

  SECTION 1.01 Effective Time of the Merger.  Subject to the provisions of
this Agreement, articles of merger in such form as shall be required by the     
relevant provisions of the Massachusetts Business Corporation Law ("MBCL") (the 
"Articles of Merger") shall be duly prepared, executed and acknowledged by the  
Surviving Corporation (as defined in Section 1.03) and thereafter delivered to  
the Secretary of State of the Commonwealth of Massachusetts, for filing, as     
provided in the MBCL, as soon as practicable on or after the Closing Date (as   
defined in Section 1.02). The Merger shall become effective upon the filing of  
the Articles of Merger with the Secretary of State of the Commonwealth of       
Massachusetts or at such time thereafter as shall be provided in the Articles of
Merger (the "Effective Time").                                                  

    SECTION 1.02 Closing.  The closing of the Merger (the "Closing") will take
place at 10:00 a.m., Eastern Time, on a date to be specified by Eclipsys and    
TSI, which shall be no later than the second business day after satisfaction of 
the latest to occur of the conditions set forth in Sections 7.01, 7.02 and 7.03 
(the "Closing Date"), at the offices of Hale and Dorr LLP, 60 State Street,     
Boston, Massachusetts, unless another date, place or time is agreed to in       
writing by Eclipsys and TSI.                                                    

     SECTION 1.03 Effects of the Merger.  At the Effective Time (i) the separate
existence of Sub shall cease and Sub shall be merged with and into TSI (Sub and 
TSI are sometimes referred to below as the "Constituent Corporations" and TSI is
sometimes referred to herein as the "Surviving Corporation"), (ii) the Articles 
of Organization of Sub immediately prior to the Effective Time shall be the     
Articles of Organization of the Surviving Corporation, except that the name of  
the corporation set forth therein shall be changed to the name of TSI, (iii) the
Bylaws of the Sub as in effect immediately prior to the Effective Time shall be 
the Bylaws of the Surviving Corporation, except that the name of the corporation
set forth therein shall be changed to the name of TSI, and (iv) the purpose of  
the Surviving Corporation shall be as set forth in Article II of the Articles of
Organization of Sub immediately prior to the Effective Date.                    

SECTION 1.04 Directors of Eclipsys.                                   

    (a) Prior to the Effective Time, Eclipsys shall (i) increase the number of
the members of the Board of Directors of Eclipsys to nine and (ii) take such    
action as may be necessary such that Robert F. Raco                             

 A-1

S-4
219th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 219th

and Patrick T. Hackett (the "TSI Designees") shall have been elected to the     
Board of Directors of Eclipsys as of the Effective Time, Mr. Raco to be assigned
to Class II and Mr. Hackett to be assigned to Class III on the Eclipsys Board of
Directors. If, prior to the Effective Time, any of the TSI Designees shall      
decline or be unable to serve as a TSI Designee, TSI shall designate another    
person to serve in such person's stead, which person shall be reasonably        
acceptable to Eclipsys.                                                         

 (b) The directors of Eclipsys elected pursuant to Section 1.04(a) shall
hold their positions until their resignation or removal or the election or      
appointment of their successors in the manner provided by Eclipsys' charter     
documents and applicable law.                                                   

ARTICLE II

CONVERSION OF SECURITIES

 SECTION 2.01 Conversion of Capital Stock.  As of the Effective Time, by
virtue of the Merger and without any action on the part of the holder of any    
shares of TSI Common Stock or capital stock of Sub:                             

       (a) Capital Stock of Sub.  Each issued and outstanding share of the
    capital stock of Sub shall be converted into and become one fully paid and
nonassessable share of Common Stock of the Surviving Corporation.     

     (b) Cancellation of Treasury Stock and Eclipsys-Owned Stock.  All
    shares of Common Stock of TSI, $.01 par value ("TSI Voting Common Stock"),
and all shares of Non-Voting Common Stock of TSI, $.01 par value ("TSI
  Non-Voting Common Stock" and, together with the TSI Voting Common Stock,
     "TSI Common Stock"), that are owned by TSI as treasury stock and any shares
of TSI Common Stock owned by Eclipsys, Sub or any other wholly-owned  
    Subsidiary (as defined in Section 3.01) of Eclipsys shall be cancelled and
retired and shall cease to exist and no stock of Eclipsys or other    
     consideration shall be delivered in exchange therefor. All shares of Common
Stock, $.01 par value per share, of Eclipsys ("Eclipsys Voting Common 
Stock") owned by TSI shall be unaffected by the Merger.               

      (c) Exchange Ratio for TSI Common Stock.  Subject to Section 2.02,
   each issued and outstanding share of TSI Common Stock (other than shares,
     if any, as to which dissenters' rights, if any, are perfected and shares to
  be cancelled in accordance with Section 2.01(b)) shall be converted into
     the right to receive 0.525 shares (the "Exchange Ratio") of Eclipsys Voting
     Common Stock. All such shares of TSI Common Stock, when so converted, shall
   no longer be outstanding and shall automatically be cancelled and retired
     and shall cease to exist, and each holder of a certificate representing any
     such shares shall cease to have any rights with respect thereto, except the
     right to receive the shares of Eclipsys Voting Common Stock and any cash in
   lieu of fractional shares of Eclipsys Voting Common Stock to be issued or
  paid in consideration therefor upon the surrender of such certificate in
accordance with Section 2.02, without interest. Notwithstanding the   
     foregoing, if between the date of this Agreement and the Effective Time the
    outstanding shares of Eclipsys Voting Common Stock shall have been changed
  into a different number of shares or a different class, by reason of any
 stock dividend, subdivision, reclassification, recapitalization, split,
combination or exchange of shares, then the Exchange Ratio shall be   
correspondingly adjusted to reflect such stock dividend, subdivision, 
reclassification, recapitalization, split, combination or exchange of 
shares.                                                               

       (d) Dissenting Shares.  For purposes of this Agreement, "Dissenting
     Shares" means shares of TSI Common Stock held as of the Effective Time by a
   stockholder of TSI who has not voted such shares in favor of the adoption
    of this Agreement and the Merger and with respect to which appraisal shall
have been duly demanded and perfected in accordance with Sections 85  
    through 98 of the MBCL and not effectively withdrawn or forfeited prior to
the Effective Time. Dissenting Shares shall not be converted into or  
   represent the right to receive any shares of Eclipsys Voting Common Stock
unless such stockholder's right to appraisal shall have ceased in     
accordance with Section 96 of the MBCL. If such stockholder has so    
  forfeited or withdrawn his right to appraisal of Dissenting Shares, then
 (i) as of the occurrence of such event, such holder's Dissenting Shares
shall cease to be                                                     

 A-2

S-4
220th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 220th
    Dissenting Shares and shall thereupon be deemed to have been converted, as
    of the Effective Time, into and represent shares of Eclipsys Voting Common
     Stock, without interest thereon, as provided in Section 2.01(c) hereof. TSI
    shall give Eclipsys (x) prompt notice of any written demands for appraisal
 of any shares of TSI Common Stock, withdrawals of such demands, and any
   other instruments that relate to such demands received by TSI and (y) the
opportunity to direct all negotiations and proceedings with respect to
    demands for appraisal under the MBCL. TSI shall not, except with the prior
   written consent of Eclipsys, make any payment with respect to any demands
  for appraisal of shares of TSI Common Stock or offer to settle or settle
any such demands.                                                     

SECTION 2.02 Exchange of Certificates.  The procedures for exchanging 
outstanding shares of TSI Common Stock for Eclipsys Voting Common Stock pursuant
to the Merger are as follows:                                                   

         (a) Exchange Agent.  As of the Effective Time, Eclipsys shall deposit
    with a bank or trust company designated by Eclipsys and TSI (the "Exchange
    Agent"), for the benefit of the holders of shares of TSI Common Stock, for
    exchange in accordance with this Section 2.02, through the Exchange Agent,
  (i) certificates representing the shares of Eclipsys Voting Common Stock
   (such shares of Eclipsys Voting Common Stock, together with any dividends
     or distributions with respect thereto, being hereinafter referred to as the
"Exchange Fund") issuable pursuant to Section 2.01 in exchange for    
outstanding shares of TSI Common Stock and (ii) an amount of cash     
 sufficient to fund all cash payments in lieu of fractional shares to be
paid pursuant to subsection (e) below.                                

         (b) Exchange Procedures.  As soon as reasonably practicable after the
     Effective Time, the Exchange Agent shall mail to each holder of record of a
   certificate or certificates which immediately prior to the Effective Time
 represented outstanding shares of TSI Common Stock (the "Certificates")
whose shares were converted pursuant to Section 2.01 into the right to
    receive shares of Eclipsys Voting Common Stock (i) a letter of transmittal
    (which shall specify that delivery shall be effected, and risk of loss and
title to the Certificates shall pass, only upon delivery of the       
    Certificates to the Exchange Agent and shall be in such form and have such
other provisions as Eclipsys and TSI may reasonably specify) and (ii) 
  instructions for effecting the surrender of the Certificates in exchange
    for certificates representing shares of Eclipsys Voting Common Stock (plus
    cash in lieu of fractional shares, if any, of Eclipsys Voting Common Stock
     as provided below). Upon surrender of a Certificate for cancellation to the
Exchange Agent or to such other agent or agents as may be appointed by
    Eclipsys and TSI, together with such letter of transmittal, duly executed,
 the holder of such Certificate shall be entitled to receive in exchange
     therefor a certificate representing that number of whole shares of Eclipsys
    Voting Common Stock which such holder has the right to receive pursuant to
     the provisions of this Article II, and the Certificate so surrendered shall
  immediately be cancelled. In the event of a transfer of ownership of TSI
Common Stock which is not registered in the transfer records of TSI, a
 certificate representing the proper number of shares of Eclipsys Voting
    Common Stock may be issued to a transferee if the Certificate representing
  such TSI Common Stock is presented to the Exchange Agent, accompanied by
     all documents required to evidence and effect such transfer and by evidence
    that any applicable stock transfer taxes have been paid. Until surrendered
   as contemplated by this Section 2.02, each Certificate shall be deemed at
  any time after the Effective Time to represent only the right to receive
    upon such surrender the certificate representing shares of Eclipsys Voting
   Common Stock and cash in lieu of any fractional shares of Eclipsys Voting
Common Stock as contemplated by this Section 2.02.                    

          (c) Distributions with Respect to Unexchanged Shares.  No dividends or
    other distributions declared or made after the Effective Time with respect
     to Eclipsys Voting Common Stock with a record date after the Effective Time
   shall be paid to the holder of any unsurrendered Certificate with respect
  to the shares of Eclipsys Voting Common Stock represented thereby and no
    cash payment in lieu of fractional shares shall be paid to any such holder
pursuant to subsection (e) below until the holder of record of such   
Certificate shall surrender such Certificate. Subject to the effect of
   applicable laws, following surrender of any such Certificate, there shall
    be paid to the record holder of the certificates representing whole shares
of Eclipsys Voting Common Stock issued in exchange therefor, without  
     interest, (i) at the time of such surrender, the amount of any cash payable
in lieu of a                                                          

 A-3

S-4
221st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 221st
  fractional share of Eclipsys Voting Common Stock to which such holder is
  entitled pursuant to subsection (e) below and the amount of dividends or
    other distributions with a record date after the Effective Time previously
     paid with respect to such whole shares of Eclipsys Voting Common Stock, and
(ii) at the appropriate payment date, the amount of dividends or other
distributions with a record date after the Effective Time but prior to
   surrender and a payment date subsequent to surrender payable with respect
to such whole shares of Eclipsys Voting Common Stock.                 

       (d) No Further Ownership Rights in TSI Common Stock.  All shares of
Eclipsys Voting Common Stock issued upon the surrender for exchange of
   Certificates in accordance with the terms hereof (including any cash paid
    pursuant to subsection (c) or (e) of this Section 2.02) shall be deemed to
have been issued in full satisfaction of all rights pertaining to such
shares of TSI Common Stock, subject, however, to the Surviving        
Corporation's obligation to pay any dividends or make any other       
     distributions with a record date prior to the Effective Time which may have
been declared or made by TSI on such shares of TSI Common Stock in    
    accordance with the terms of this Agreement (to the extent permitted under
Section 5.01) prior to the date hereof and which remain unpaid at the 
 Effective Time, and from and after the Effective Time there shall be no
further registration of transfers on the stock transfer books of the  
Surviving Corporation of the shares of TSI Common Stock which were    
outstanding immediately prior to the Effective Time. If, after the    
     Effective Time, Certificates are presented to the Surviving Corporation for
any reason, they shall be cancelled and exchanged as provided in this 
Section 2.02.                                                         

   (e) No Fractional Shares.  No certificate or scrip representing
    fractional shares of Eclipsys Voting Common Stock shall be issued upon the
     surrender for exchange of Certificates, and such fractional share interests
will not entitle the owner thereof to vote or to any other rights of a
stockholder of Eclipsys. Notwithstanding any other provision of this  
    Agreement, each holder of shares of TSI Common Stock exchanged pursuant to
    the Merger who would otherwise have been entitled to receive a fraction of
a share of Eclipsys Voting Common Stock (after taking into account all
     Certificates delivered by such holder) shall receive, in lieu thereof, cash
     (without interest) in an amount equal to such fractional part of a share of
     Eclipsys Voting Common Stock multiplied by the average of the last reported
 sales prices of Eclipsys Voting Common Stock, as reported on the Nasdaq
    National Market, on each of the ten trading days immediately preceding the
Closing Date.                                                         

       (f) Termination of Exchange Fund.  Any portion of the Exchange Fund
   which remains undistributed to the stockholders of TSI for 180 days after
 the Effective Time shall be delivered to Eclipsys, upon demand, and any
     stockholders of TSI who have not previously complied with this Section 2.02
shall thereafter look only to Eclipsys for payment of their claim for 
Eclipsys Voting Common Stock, any cash in lieu of fractional shares of
Eclipsys Voting Common Stock and any dividends or distributions with  
respect to Eclipsys Voting Common Stock.                              

      (g) No Liability.  Neither Eclipsys nor TSI shall be liable to any
  holder of shares of TSI Common Stock or Eclipsys Voting Common Stock, as
the case may be, for such shares (or dividends or distributions with  
    respect thereto) delivered to a public official pursuant to any applicable
abandoned property, escheat or similar law.                           

(h) Withholding Rights.  Each of Eclipsys and the Surviving 
     Corporation shall be entitled to deduct and withhold from the consideration
     otherwise payable pursuant to this Agreement to any holder of shares of TSI
 Common Stock such amounts as it is required to deduct and withhold with
   respect to the making of such payment under the Code, or any provision of
     state, local or foreign tax law. To the extent that amounts are so withheld
     by the Surviving Corporation or Eclipsys, as the case may be, such withheld
    amounts shall be treated for all purposes of this Agreement as having been
  paid to the holder of the shares of TSI Common Stock in respect of which
 such deduction and withholding was made by the Surviving Corporation or
Eclipsys, as the case may be.                                         

    (i) Lost Certificates.  If any Certificate shall have been lost,
  stolen or destroyed, upon the making of an affidavit of that fact by the
  person claiming such Certificate to be lost, stolen or destroyed and, if
     required by the Surviving Corporation, the posting by such person of a bond
in such                                                               

 A-4

S-4
222nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 222nd
reasonable amount as the Surviving Corporation may direct as indemnity
against any claim that may be made against it with respect to such    
Certificate, the Exchange Agent will issue in exchange for such lost, 
    stolen or destroyed Certificate the shares of Eclipsys Voting Common Stock
and any cash in lieu of fractional shares, and unpaid dividends and   
distributions on shares of Eclipsys Voting Common Stock deliverable in
respect thereof pursuant to this Agreement.                           

     (j) Affiliates.  Notwithstanding anything herein to the contrary,
Certificates surrendered for exchange by any Affiliate (as defined in 
    Section 6.10) of TSI shall not be exchanged until Eclipsys has received an
Affiliate Agreement (as defined in Section 6.10) from such Affiliate. 

ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF TSI 

TSI represents and warrants to Eclipsys and Sub that the statements   
contained in this Article III are true and correct except as set forth in the   
disclosure schedule delivered by TSI to Eclipsys on or before the date of this  
Agreement (the "TSI Disclosure Schedule"). The TSI Disclosure Schedule shall be 
arranged in sections and paragraphs corresponding to the numbered and lettered  
sections and paragraphs contained in this Article III and the disclosure in any 
section or paragraph shall qualify other sections and paragraphs in this Article
III only to the extent that it is reasonably apparent from a reading of such    
disclosure that it also qualifies or applies to such other sections and         
paragraphs.                                                                     

 SECTION 3.01 Organization of TSI.  Each of TSI and its Subsidiaries (as
defined below) is a corporation duly organized, validly existing and in good    
standing under the laws of the jurisdiction of its incorporation, has all       
requisite corporate power to own, lease and operate its property and to carry on
its business as now being conducted and as proposed to be conducted, and is duly
qualified to do business and is in good standing as a foreign corporation in    
each jurisdiction in which the failure to be so qualified would have a TSI      
Material Adverse Effect (as defined below). Except as set forth in the TSI SEC  
Reports (as defined in Section 3.04) filed prior to the date hereof, neither TSI
nor any of its Subsidiaries directly or indirectly owns any equity or similar   
interest in, or any interest convertible into or exchangeable or exercisable    
for, any corporation, partnership, joint venture or other business association  
or entity, excluding securities in any publicly traded company held for         
investment by TSI and comprising less than five percent (5%) of the outstanding 
stock of such company. As used in this Agreement, the word "Subsidiary" means,  
with respect to any party, any corporation or other organization, whether       
incorporated or unincorporated, of which (i) such party or any other Subsidiary 
of such party is a general partner (excluding partnerships, the general         
partnership interests of which held by such party or any Subsidiary of such     
party do not have a majority of the voting interest in such partnership) or (ii)
at least a majority of the securities or other interests having by their terms  
ordinary voting power to elect a majority of the Board of Directors or others   
performing similar functions with respect to such corporation or other          
organization is directly or indirectly owned or controlled by such party or by  
any one or more of its Subsidiaries, or by such party and one or more of its    
Subsidiaries. For purposes of this Agreement, the term "TSI Material Adverse    
Effect" means any effect that is, or would reasonably be expected to be,        
materially adverse to the financial condition, results of operations, cash      
flows, business or properties of TSI and its Subsidiaries, taken as a whole.    

SECTION 3.02 TSI Capital Structure.                                   

  (a) The authorized capital stock of TSI consists of 30,000,000 shares of
TSI Voting Common Stock, $.01 par value, 1,000,000 shares of TSI Non-Voting     
Common Stock, $.01 par value, and 1,000,000 shares of Preferred Stock, $.01 par 
value ("TSI Preferred Stock"). As of September 30, 1998, (i) 18,035,983 shares  
of TSI Voting Common Stock and 356,262 shares of TSI Non-Voting Common Stock    
were issued and outstanding, all of which are validly issued, fully paid and    
nonassessable, (ii) 297,928 shares of TSI Non-Voting Common Stock were reserved 
for issuance upon the exercise of certain warrants (the "TSI Warrants") having  
an exercise price of $.01 per share, and (iii) no shares of TSI Common Stock    
were held in the treasury of TSI or by Subsidiaries of TSI. Section 3.02 of the 
TSI Disclosure Schedule                                                         

 A-5

S-4
223rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 223rd

shows the number of shares of TSI Voting Common Stock reserved for future       
issuance pursuant to stock options granted and outstanding as of September 30,  
1998 and the plans under which such options were granted (collectively, the "TSI
Stock Plans"). No material change in such capitalization has occurred between   
September 30, 1998 and the date of this Agreement. As of the date of this       
Agreement, none of the shares of TSI Preferred Stock is issued and outstanding. 
All shares of TSI Common Stock subject to issuance as specified above are duly  
authorized and, upon issuance on the terms and conditions specified in the      
instruments pursuant to which they are issuable, shall be validly issued, fully 
paid and nonassessable. There are no obligations, contingent or otherwise, of   
TSI or any of its Subsidiaries to repurchase, redeem or otherwise acquire any   
shares of TSI Common Stock or the capital stock of any Subsidiary or to provide 
funds to or make any material investment (in the form of a loan, capital        
contribution or otherwise) in any such Subsidiary or any other entity other than
guarantees of bank obligations of Subsidiaries entered into in the ordinary     
course of business. All of the outstanding shares of capital stock of each of   
TSI's Subsidiaries are duly authorized, validly issued, fully paid and          
nonassessable and all such shares (other than directors' qualifying shares in   
the case of foreign Subsidiaries) are owned by TSI or another Subsidiary free   
and clear of all security interests, liens, claims, pledges, agreements,        
limitations in TSI's voting rights, charges or other encumbrances of any nature.

(b) Except as set forth in this Section 3.02 or as reserved for future
grants of options under the TSI Stock Plans, the TSI Warrants or the Eclipsys   
Stock Option Agreement, there are no equity securities of any class of TSI or   
any of its Subsidiaries, or any security exchangeable into or exercisable for   
such equity securities, issued, reserved for issuance or outstanding. Except as 
set forth in the TSI SEC Reports filed prior to the date hereof, in the Eclipsys
Stock Option Agreement or disclosed in Section 3.02 of the TSI Disclosure       
Schedule, there are no options, warrants, equity securities, calls, rights,     
commitments or agreements of any character to which TSI or any of its           
Subsidiaries is a party or by which it is bound obligating TSI or any of its    
Subsidiaries to issue, deliver or sell, or cause to be issued, delivered or     
sold, additional shares of capital stock of TSI or any of its Subsidiaries or   
obligating TSI or any of its Subsidiaries to grant, extend, accelerate the      
vesting of or enter into any such option, warrant, equity security, call, right,
commitment or agreement. No consent is required from the holders of TSI Stock   
Options (as defined below) in connection with the conversion of the TSI Stock   
Options into options to purchase Eclipsys Voting Common Stock as contemplated by
Section 6.12. To the best knowledge of TSI, there are no voting trusts, proxies 
or other voting agreements or understandings with respect to the shares of      
capital stock of TSI.                                                           

SECTION 3.03 Authority; No Conflict; Required Filings and Consents.   

    (a) TSI has all requisite corporate power and authority to enter into this
Agreement and to consummate the transactions contemplated by this Agreement. The
execution and delivery of this Agreement and the consummation of the            
transactions contemplated by this Agreement by TSI have been duly authorized by 
all necessary corporate action on the part of TSI, subject only to the approval 
of the Merger by TSI's stockholders under the MBCL. This Agreement has been duly
executed and delivered by TSI and constitutes the valid and binding obligation  
of TSI, enforceable in accordance with its terms, subject to bankruptcy,        
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of 
general applicability relating to or affecting creditors' rights and to general 
equity principles (the "Bankruptcy and Equity Exception").                      

   (b) The execution and delivery of this Agreement by TSI does not, and the
consummation of the transactions contemplated by this Agreement will not, (i)   
conflict with, or result in any violation or breach of, any provision of the    
Articles of Organization or Bylaws of TSI, each as amended to date, (ii) result 
in any violation or breach of, or constitute (with or without notice or lapse of
time, or both) a default (or give rise to a right of termination, cancellation  
or acceleration of any obligation or loss of any material benefit) under, or    
require a consent or waiver under, any of the terms, conditions or provisions of
any note, bond, mortgage, indenture, lease, contract or other agreement,        
instrument or obligation to which TSI or any of its Subsidiaries is a party or  
by which any of them or any of their properties or assets may be bound, or (iii)
conflict with or violate any permit, concession, franchise, license, judgment,  
order, decree, statute, law, ordinance, rule or regulation applicable to TSI or 
any of its Subsidiaries or any of its or their                                  

 A-6

S-4
224th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 224th

properties or assets, except in the case of clauses (ii) and (iii) for any such 
conflicts, violations, breaches, defaults, terminations, cancellations,         
accelerations or losses which are not, individually or in the aggregate,        
reasonably likely to have a TSI Material Adverse Effect.                        

(c) No consent, approval, order or authorization of, or registration, 
declaration or filing with, any court, administrative agency or commission or   
other governmental authority or instrumentality ("Governmental Entity") is      
required by or with respect to TSI or any of its Subsidiaries in connection with
the execution and delivery of this Agreement or the consummation of the         
transactions contemplated hereby, except for (i) the filing of a pre-merger     
notification report under the Hart-Scott-Rodino Antitrust Improvements Act of   
1976, as amended (the "HSR Act") and any other documents or information         
requested by the United States Department of Justice or the United States       
Federal Trade Commission in connection therewith, (ii) the filing of the        
Articles of Merger with the Secretary of State of Massachusetts, (iii) the      
filing of the Joint Proxy Statement (as defined in Section 3.16 below) with the 
Securities and Exchange Commission (the "SEC") in accordance with the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), (iv) such consents,      
approvals, orders, authorizations, registrations, declarations and filings as   
may be required under applicable state securities laws and the laws of any      
foreign country and (v) such other consents, authorizations, filings, approvals 
and registrations which, if not obtained or made, would not be reasonably likely
to have a TSI Material Adverse Effect.                                          

SECTION 3.04 SEC Filings; Financial Statements.                       

 (a) TSI has filed and made available to Eclipsys all forms, reports and
documents required to be filed by TSI with the SEC since April 18, 1996 other   
than registration statements on Form S-8 (collectively, the "TSI SEC Reports"). 
The TSI SEC Reports (i) at the time filed, complied in all material respects    
with the applicable requirements of the Securities Act of 1933, as amended (the 
"Securities Act"), and the Exchange Act, as the case may be, and (ii) did not at
the time they were filed (or if amended or superseded by a filing prior to the  
date of this Agreement, then on the date of such filing) contain any untrue     
statement of a material fact or omit to state a material fact required to be    
stated in such TSI SEC Reports or necessary in order to make the statements in  
such TSI SEC Reports, in the light of the circumstances under which they were   
made, not misleading. None of TSI's Subsidiaries is required to file any forms, 
reports or other documents with the SEC.                                        

     (b) Each of the consolidated financial statements (including, in each case,
any related notes) contained in the TSI SEC Reports complied as to form in all  
material respects with the applicable published rules and regulations of the SEC
with respect thereto, was prepared in accordance with U.S. generally accepted   
accounting principles ("GAAP") applied on a consistent basis throughout the     
periods involved (except as may be indicated in the notes to such financial     
statements or, in the case of unaudited statements, as permitted by Form 10-Q of
the SEC) and fairly presented the consolidated financial position of TSI and its
Subsidiaries as of the dates and the consolidated results of its operations and 
cash flows for the periods indicated, except that the unaudited interim         
financial statements were or are subject to normal and recurring year-end       
adjustments which were not or are not expected to be material in amount. The    
unaudited balance sheet of TSI as of June 30, 1998 is referred to herein as the 
"TSI Balance Sheet."                                                            

  SECTION 3.05 No Undisclosed Liabilities.  Except as disclosed in the TSI
SEC Reports filed prior to the date hereof, and except for normal or recurring  
liabilities incurred since June 30, 1998 in the ordinary course of business     
consistent with past practices, TSI and its Subsidiaries do not have any        
liabilities, either accrued, contingent or otherwise (whether or not required to
be reflected in financial statements in accordance with GAAP), and whether due  
or to become due, which individually or in the aggregate are reasonably likely  
to have a TSI Material Adverse Effect.                                          

    SECTION 3.06 Absence of Certain Changes or Events.  Except as disclosed in
the TSI SEC Reports filed prior to the date hereof, from and after the date of  
the TSI Balance Sheet, TSI and its Subsidiaries have conducted their businesses 
only in the ordinary course and in a manner consistent with past practice and,  
during such period, there has not been (i) any material adverse change in the   
financial condition, results of operations, cash flows, business or properties, 
subject to the last sentence of this                                            

 A-7

S-4
225th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 225th

Section 3.06 (a "Material Adverse Change") of TSI and its Subsidiaries, taken as
a whole (other than changes that are the effect or result of economic factors   
affecting the economy as a whole or economic or market factors affecting the    
healthcare information systems industry generally) or any development or        
combination of developments of which the management of TSI is aware that,       
individually or in the aggregate, has had, or is reasonably likely to have, a   
TSI Material Adverse Effect (other than economic factors affecting the economy  
as a whole or economic or market factors affecting the healthcare information   
systems industry generally); (ii) any damage, destruction or loss (whether or   
not covered by insurance) with respect to TSI or any of its Subsidiaries having 
a TSI Material Adverse Effect; (iii) any material change by TSI in its          
accounting methods, principles or practices to which Eclipsys has not previously
consented in writing; (iv) any revaluation by TSI of any of its assets having a 
TSI Material Adverse Effect; or (v) any other action or event that would have   
required the consent of Eclipsys pursuant to Section 5.01 of this Agreement had 
such action or event occurred after the date of this Agreement and that, in the 
case of this clause (v), individually or in the aggregate, has had or is        
reasonably likely to have a TSI Material Adverse Effect. Notwithstanding the    
foregoing, the failure of TSI or Eclipsys to achieve any level of revenue and   
earnings at any time shall not of itself constitute a Material Adverse Change of
TSI and its Subsidiaries, taken as a whole, or Eclipsys and its Subsidiaries,   
taken as a whole, as the case may be.                                           

SECTION 3.07 Taxes.                                                   

   (a) For the purposes of this Agreement, a "Tax" or, collectively, "Taxes"
means any and all material federal, state, local and foreign taxes, assessments 
and other governmental charges, duties, impositions and liabilities, including  
taxes based upon or measured by gross receipts, income, profits, sales, use and 
occupation, and value added, ad valorem, transfer, gains, franchise,            
withholding, payroll, recapture, employment, excise, unemployment insurance,    
social security, business license, occupation, business organization, stamp,    
environmental and property taxes, together with all interest, penalties and     
additions imposed with respect to such amounts. "Tax Returns" means all reports,
returns, declarations, statements or other information required to be supplied  
to a taxing authority in connection with Taxes.                                 

    (b) Each of TSI and its Subsidiaries has filed all Tax Returns that it was
required to file, and all such Tax Returns were correct and complete. Each group
of corporations with which TSI or any of its Subsidiaries has filed (or was     
required to file) consolidated, combined, unitary or similar Tax Returns (a "TSI
Affiliated Group") has filed all such Tax Returns that it was required to file  
with respect to any period in which TSI or one of its Subsidiaries was a member 
of such TSI Affiliated Group (a "TSI Affiliated Period"), and all such Tax      
Returns were correct and complete. Each of TSI and its Subsidiaries has paid all
Taxes (whether or not shown on such Tax Returns) that were due and payable, and 
each TSI Affiliated Group has paid all Taxes (whether or not shown on such Tax  
Returns) that were due and payable with respect to all TSI Affiliated Periods   
and with respect to which TSI or any of its Subsidiaries may be liable by       
operation of law or otherwise. The unpaid Taxes of TSI and its Subsidiaries for 
tax periods through the date of the TSI Balance Sheet do not exceed the accruals
and reserves for Taxes set forth on the TSI Balance Sheet (exclusive of any     
accruals for "deferred taxes" or similar items that reflect timing differences  
between Tax and financial accounting principles). The unpaid Taxes of TSI and   
its Subsidiaries for tax periods from the date of the TSI Balance Sheet through 
the Closing Date are attributable solely to the conduct of their businesses in  
the ordinary course and in a manner consistent with past practices. All Taxes   
that TSI or any of its Subsidiaries is or was required by law to withhold or    
collect have been duly withheld or collected and, to the extent required, have  
been paid to the proper Governmental Entity. Each of the representations        
contained in this Section 3.07(b) shall be limited in its application to items  
which are reasonably likely, individually or in the aggregate, to have a TSI    
Material Adverse Effect.                                                        

     (c) No examination or audit by any Governmental Entity of any Tax Return of
TSI, any of its Subsidiaries or any TSI Affiliated Group with respect to a TSI  
Affiliated Period is currently in progress or, to the knowledge of TSI and its  
Subsidiaries, threatened or contemplated, in each case, which involve claims    
that individually or in the aggregate are reasonably likely to have a TSI       
Material Adverse Effect. Neither TSI nor any of its Subsidiaries has been       
informed by any jurisdiction that the jurisdiction believes                     

 A-8

S-4
226th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 226th

that TSI or any of its Subsidiaries was required to file any Tax Return that was
not filed which failure or failures individually, or in the aggregate, are      
reasonably likely to have a TSI Material Adverse Effect.                        

   (d) Neither TSI nor any of its Subsidiaries is a "consenting corporation"
within the meaning of Section 341(f) of the Code, and none of the assets of TSI 
and its Subsidiaries is subject to an election under Section 341(f) of the Code.

   (e) Neither TSI nor any of its Subsidiaries has been a United States real
property holding corporation within the meaning of Section 897(c)(2) of the Code
during the applicable period specified in Section 897(c)(l)(A)(ii) of the Code. 

     (f) None of TSI or any of its Subsidiaries is a party to any Tax allocation
or sharing agreement.                                                           

   (g) None of TSI or any of its Subsidiaries has any material liability for
Taxes of any person (other than TSI or any of its Subsidiaries (under Treasury  
Regulation Section 1.1502-6 or any similar provision of state, local or foreign 
law)), as a transferee or successor, by contract, or otherwise.                 

SECTION 3.08 Properties.                                              

(a) TSI does not own of record any real property.                     

  (b) All material real property leases of TSI and its Subsidiaries are in
good standing, valid and effective in accordance with their respective terms,   
and neither TSI nor any of its Subsidiaries is in default under any of such     
leases, except where the lack of such good standing, validity or effectiveness  
or the existence of such default would not be reasonably likely to have a TSI   
Material Adverse Effect.                                                        

SECTION 3.09 Intellectual Property.                                   

(a) TSI and its Subsidiaries own, or are licensed or otherwise possess
legally enforceable rights to use, all patents, trademarks, trade names, service
marks, copyrights and mask works, any applications for and registrations of such
patents, trademarks, trade names, service marks, copyrights and mask works, and 
all processes, formulae, methods, schematics, technology, know-how, computer    
software programs or applications and tangible or intangible proprietary        
information or material that are necessary to conduct the business of TSI and   
its Subsidiaries as currently conducted, or planned to be conducted, the absence
of which would be reasonably likely to have a TSI Material Adverse Effect (the  
"TSI Intellectual Property Rights"). Section 3.09 of the TSI Disclosure Schedule
sets forth a complete and accurate list of (i) all patents, registered          
copyrights, registered trademarks, registered service marks and all software    
programs, other than commercial, off-the-shelf software, subject to a perpetual 
license, in connection with which no future license fees or royalties are due   
("Off-the-Shelf Software"), owned, used or licensed by or to TSI or any of its  
Subsidiaries and (ii) all other intellectual property that is licensed by or to 
TSI or any of its Subsidiaries that is used in or is necessary for the conduct  
of TSI's business. TSI has promulgated and used commercially reasonable efforts 
to enforce the trade secret protection program described in Section 3.09 of the 
TSI Disclosure Schedule.                                                        

    (b) Neither TSI nor any of its Subsidiaries is, or will as a result of the
execution and delivery of this Agreement or the performance of TSI's obligations
under this Agreement or otherwise be, in breach of any license, sublicense or   
other agreement relating to the TSI Intellectual Property Rights, or any        
material licenses, sublicenses and other agreements as to which TSI or any of   
its Subsidiaries is a party and pursuant to which TSI or any of its Subsidiaries
is authorized to use any third party patents, trademarks or copyrights ("TSI    
Third Party Intellectual Property Rights"), including software which is used in 
the manufacture of, incorporated in, or forms a part of any product sold by or  
expected to be sold by TSI or any of its Subsidiaries, the breach of which would
be reasonably likely to have a TSI Material Adverse Effect.                     

(c) All patents, registered trademarks, registered service marks and  
registered copyrights which are held by TSI or any of its Subsidiaries and which
are material to the business of TSI and its Subsidiaries, taken as a whole, are 
valid and subsisting. TSI (i) has not been sued in any suit, action or          
proceeding, or received in writing any claim or notice, which involves a claim  
of infringement of any patents, trademarks,                                     

 A-9

S-4
227th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 227th

service marks, copyrights or violation of any trade secret or other proprietary 
right of any third party; and (ii) has no knowledge that the manufacturing,     
marketing, licensing or sale of its products infringes any patent, trademark,   
service mark, copyright, trade secret or other proprietary right of any third   
party, which infringement would reasonably be expected to have a TSI Material   
Adverse Effect.                                                                 

     (d) Section 3.09 of the TSI Disclosure Schedule identifies each "year 2000"
audit, report or investigation that has been performed by or on behalf of TSI   
with respect to its business and operations, and TSI has provided to Eclipsys   
true and correct copies of all such audits, reports or investigations. Except as
set forth in such audits, reports and investigations, TSI is not aware of any   
failure to be Year 2000 Compliant of (i) any software products sold or licensed 
by TSI or any of its Subsidiaries to third parties or (ii) any computer software
products used by or licensed to TSI or its Subsidiaries from third parties for  
internal use by TSI or its Subsidiaries. For purposes of this Agreement, "Year  
2000 Compliant" means, with respect to each software product referred to in the 
prior sentence, that such system (i) will accurately receive, record, store,    
provide, recognize and process all date and time data from, during, into and    
between the twentieth and twenty-first centuries; (ii) will accurately perform  
all date-dependent calculations and operations (including, without limitation,  
mathematical operations, sorting, comparing and reporting) from, during, into   
and between the twentieth and twenty-first centuries; and (iii) will not        
malfunction, cease to function or provide invalid or incorrect results as a     
result of (x) the change of century, (y) date data, including date data which   
represents or references different centuries or more than one century or (z) the
occurrence of any particular date; in each case without human intervention,     
other than original data entry; provided, in each case, that all applications,  
hardware and other systems used in conjunction with such system which are not   
owned or licensed by TSI correctly exchange date data with or provide data to   
such system. Except as set forth in Section 3.09(d) of the TSI Disclosure       
Statement, TSI has not provided any guarantee or warranty for any product sold  
or licensed, or services provided, by TSI to the effect that such product or    
service (i) complies with or accounts for the fact of the arrival of the year   
2000 or (ii) will not be adversely affected with respect to functionally        
interoperability, performance or volume capacity (including without limitation  
the processing and reporting of data) by virtue of the arrival of the year 2000.

     SECTION 3.10 Agreements, Contracts and Commitments.  Except as set forth on
Section 3.10 of the TSI Disclosure Schedule, neither TSI nor any of its         
Subsidiaries, nor any of their respective assets, businesses, or operations, is 
a party to, or is bound or affected by, or receives benefits under (i) any      
severance, termination or retirement agreement or any employment or consulting  
agreement providing for aggregate payments to any person in any calendar year in
excess of $100,000 or continuing for more than one year, (ii) any agreement     
relating to the borrowing of money by TSI or any of its Subsidiaries or the     
guarantee by any TSI or any of its Subsidiaries of any such obligation (other   
than agreements evidencing trade payables or relating to borrowings or          
guarantees made in the ordinary course of business), (iii) any agreement which  
prohibits or restricts TSI or any of its Subsidiaries from engaging in any      
business activities in any geographic area, line of business or otherwise in    
competition with any other person, (iv) any agreement involving TSI Intellectual
Property Rights or TSI Third Party Intellectual Property Rights (other than     
Off-the-Shelf Software licenses) which provide for annual payments of $100,000  
or more, (v) any agreement relating to the provision of computer software,      
computer hardware, data processing systems or equipment, network communication, 
transactional billing, management information or other technical systems or     
services, including maintenance with respect to the foregoing matters, to or by 
TSI or any of its Subsidiaries which provides for annual payments of $100,000 or
more, (vi) any agreement relating to the purchase or lease of real property, and
(vii) any other agreement or amendment thereto that would be required to be     
filed as an exhibit to a Form 10-K filed by TSI with the SEC as of the date of  
this Agreement (collectively, the "TSI Material Contracts"). With respect to    
each TSI Material Contract and except as disclosed in Section 3.10 of the TSI   
Disclosure Schedule: (i) the TSI Material Contract is in full force and effect; 
(ii) neither TSI nor any of its Subsidiaries is in default or breach thereunder 
in any material respect; (iii) neither TSI nor any of its Subsidiaries has      
repudiated or waived any material provision of any such TSI Material Contract;  
(iv) no other party to any such TSI Material Contract is, to the knowledge of   
TSI, in default or breach in any material respect or has repudiated or waived   
any material provision thereunder; (v) there exists no actual, or, to the       
knowledge of                                                                    

A-10

S-4
228th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 228th

TSI, threatened, cancellation, termination, or limitation of, or any amendment, 
modification, or change to, any TSI Material Contract; (vi) neither TSI nor any 
of its Subsidiaries has received formal notice that any party to a TSI Material 
Contract will not renew such contract at the end of its existing term; and (vii)
no TSI Material Contract requires consent or notice in connection with the      
transactions contemplated by this Agreement. All of the indebtedness of TSI or  
any of its Subsidiaries for money borrowed is prepayable at any time without    
penalty or premium.                                                             

    SECTION 3.11 Litigation.  Except as described in the TSI SEC Reports filed
prior to the date hereof, there is no action, suit or proceeding, claim,        
arbitration or investigation against TSI or any of its Subsidiaries pending or  
as to which TSI or any such Subsidiary has received any written notice of       
assertion, which, individually or in the aggregate, is reasonably likely to have
a TSI Material Adverse Effect or a material adverse effect on the ability of TSI
to consummate the transactions contemplated by this Agreement.                  

SECTION 3.12 Environmental Matters.                                   

(a) Except as disclosed in the TSI SEC Reports filed prior to the date
hereof and except for such matters that, individually or in the aggregate, are  
not reasonably likely to have a TSI Material Adverse Effect: (i) TSI and its    
Subsidiaries have complied with all applicable Environmental Laws (as defined in
Section 3.12(b)); (ii) the properties currently owned or operated by TSI and its
Subsidiaries (including soils, groundwater, surface water, buildings or other   
structures) are not contaminated with any Hazardous Substances (as defined in   
Section 3.12(c)); (iii) the properties formerly owned or operated by TSI or any 
of its Subsidiaries were not contaminated with Hazardous Substances during the  
period of ownership or operation by TSI or any of its Subsidiaries; (iv) neither
TSI nor any of its Subsidiaries are subject to liability for any Hazardous      
Substance disposal or contamination on any third-party property; (v) neither TSI
nor any of its Subsidiaries has been associated with any release or threat of   
release of any Hazardous Substance; (vi) neither TSI nor any of its Subsidiaries
has received any notice, demand, letter, claim or request for information       
alleging that TSI or any of its Subsidiaries may be in violation of or liable   
under any Environmental Law; (vii) neither TSI nor any of its Subsidiaries is   
subject to any orders, decrees, injunctions or other arrangements with any      
Governmental Entity or is subject to any indemnity or other agreement with any  
third party relating to liability under any Environmental Law or relating to    
Hazardous Substances; and (viii) there are no circumstances or conditions       
involving TSI or any of its Subsidiaries that could reasonably be expected to   
result in any claims, liabilities, investigations, costs or restrictions on the 
ownership, use or transfer of any property of TSI pursuant to any Environmental 
Law.                                                                            

    (b) As used herein, the term "Environmental Law" means any federal, state,
local or foreign law, regulation, order, decree, permit, authorization, opinion,
common law or agency requirement relating to: (i) the protection, investigation 
or restoration of the environment, health and safety, or natural resources, (ii)
the handling, use, presence, disposal, release or threatened release of any     
Hazardous Substance or (iii) noise, odor, wetlands, pollution, contamination or 
any injury or threat of injury to persons or property.                          

     (c) As used herein, the term "Hazardous Substance" means any substance that
is: (i) listed, classified or regulated pursuant to any Environmental Law; (ii) 
any petroleum product or by-product, asbestos-containing material,              
lead-containing paint or plumbing, polychlorinated biphenyls, radioactive       
materials or radon; or (iii) any other substance which is the subject of        
regulatory action by any Governmental Entity pursuant to any Environmental Law. 

SECTION 3.13 Employee Benefit Plans.                                  

(a) TSI has listed in Section 3.13 of the TSI Disclosure Schedule all 
employee benefit plans (as defined in Section 3(3) of the Employee Retirement   
Income Security Act of 1974, as amended ("ERISA")), and all bonus, stock option,
stock purchase, incentive, deferred compensation, supplemental retirement,      
severance and other similar employee benefit plans, and all unexpired severance 
agreements, written or otherwise, for the benefit of, or relating to, any       
current or former employee of TSI or any trade or business (whether or not      
incorporated) which is a member or which is under common control) within        

A-11

S-4
229th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 229th

the meaning of Section 414 of the Code (an "ERISA Affiliate") with TSI or any   
Subsidiary of TSI (collectively, the "TSI Employee Plans").                     

(b) With respect to each TSI Employee Plan, TSI has made available to 
Eclipsys a true and correct copy of (i) the most recent annual report (Form     
5500) filed with the IRS, (ii) such TSI Employee Plan, (iii) each trust         
agreement and group annuity contract, if any, relating to such TSI Employee Plan
and (iv) the most recent actuarial report or valuation relating to a TSI        
Employee Plan subject to Title IV of ERISA.                                     

(c) With respect to the TSI Employee Plans, individually and in the   
aggregate, no event has occurred and, to the knowledge of TSI, there exists no  
condition or set of circumstances in connection with which TSI could be subject 
to any liability that is reasonably likely to have a TSI Material Adverse Effect
under ERISA, the Code or any other applicable law.                              

(d) With respect to the TSI Employee Plans, individually and in the   
aggregate, there are no funded benefit obligations for which contributions have 
not been made or properly accrued and there are no unfunded benefit obligations 
which have not been accounted for by reserves, or otherwise properly footnoted  
in accordance with GAAP, on the financial statements of TSI, which obligations  
are reasonably likely to have a TSI Material Adverse Effect.                    

    (e) Except as disclosed in TSI SEC Reports filed prior to the date of this
Agreement, and except as provided for in this Agreement, neither TSI nor any of 
its Subsidiaries is a party to any oral or written (i) agreement with any       
officer or other key employee of TSI or any of its Subsidiaries, the benefits of
which are contingent, or the terms of which are materially altered, upon the    
occurrence of a transaction involving TSI of the nature contemplated by this    
Agreement, (ii) agreement with any officer of TSI providing any term of         
employment or compensation guarantee extending for a period longer than one year
from the date hereof and for the payment of compensation in excess of $100,000  
per annum, or (iii) agreement or plan, including any stock option plan, stock   
appreciation right plan, restricted stock plan or stock purchase plan, any of   
the benefits of which will be increased, or the vesting of the benefits of which
will be accelerated, by the occurrence of any of the transactions contemplated  
by this Agreement or the value of any of the benefits of which will be          
calculated on the basis of any of the transactions contemplated by this         
Agreement.                                                                      

  SECTION 3.14 Compliance With Laws.  TSI and each of its Subsidiaries has
complied with, is not in violation of, and has not received any notices of      
violation with respect to, any federal, state, local or foreign statute, law or 
regulation with respect to the conduct of its business, or the ownership or     
operation of its business, except for failures to comply or violations which,   
individually or in the aggregate, have not had and are not reasonably likely to 
have a TSI Material Adverse Effect.                                             

SECTION 3.15 Accounting and Tax Matters.  To its knowledge, after     
consulting with its independent auditors, neither TSI nor any of its Affiliates 
(as defined in Section 6.10) has taken or agreed to take any action which would 
(i) prevent Eclipsys from accounting for the business combination to be effected
by the Merger as a pooling of interests or (ii) prevent the Merger from         
constituting a transaction qualifying as a reorganization under 368(a) of the   
Code.                                                                           

SECTION 3.16 Registration Statement; Proxy Statement/Prospectus.  The 
information to be supplied by TSI for inclusion in the registration statement on
Form S-4 pursuant to which shares of Eclipsys Voting Common Stock issued in the 
Merger will be registered under the Securities Act (the "Registration           
Statement") shall not at the time the Registration Statement is declared        
effective by the SEC contain any untrue statement of a material fact or omit to 
state any material fact required to be stated in the Registration Statement or  
necessary in order to make the statements in the Registration Statement, in     
light of the circumstances under which they were made, not misleading. The      
information supplied by TSI for inclusion in the joint proxy                    
statement/prospectus to be sent to the stockholders of Eclipsys and TSI in      
connection with the meeting of TSI's stockholders (the "TSI Stockholders'       
Meeting") to consider this Agreement and the Merger and in connection with the  
meeting of Eclipsys' stockholders (the "Eclipsys Stockholders' Meeting") to     
consider the issuance of shares of Eclipsys Voting                              

A-12

S-4
230th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 230th

Common Stock pursuant to the Merger (the "Joint Proxy Statement") shall not, on 
the date the Joint Proxy Statement is first mailed to stockholders of TSI or    
Eclipsys, at the time of the TSI Stockholders' Meeting and the Eclipsys         
Stockholders' Meeting and at the Effective Time, contain any statement which, at
such time and in light of the circumstances under which it shall be made, is    
false or misleading with respect to any material fact, or omit to state any     
material fact necessary in order to make the statements made in the Joint Proxy 
Statement not false or misleading; or omit to state any material fact necessary 
to correct any statement in any earlier communication with respect to the       
solicitation of proxies for the TSI Stockholders' Meeting or the Eclipsys       
Stockholders' Meeting which has become false or misleading. If at any time prior
to the Effective Time any event relating to TSI or any of its Affiliates,       
officers or directors should be discovered by TSI which should be set forth in  
an amendment to the Registration Statement or a supplement to the Joint Proxy   
Statement, TSI shall promptly inform Eclipsys.                                  

   SECTION 3.17 Labor Matters.  Neither TSI nor any of its Subsidiaries is a
party to or otherwise bound by any collective bargaining agreement, contract or 
other agreement or understanding with a labor union or labor organization, nor, 
as of the date hereof, is TSI or any of its Subsidiaries the subject of any     
material proceeding asserting that TSI or any of its Subsidiaries has committed 
an unfair labor practice or is seeking to compel it to bargain with any labor   
union or labor organization nor, as of the date of this Agreement, is there     
pending or, to the knowledge of the executive officers of TSI, threatened, any  
material labor strike, dispute, walkout, work stoppage, slow-down or lockout    
involving TSI or any of its Subsidiaries.                                       

   SECTION 3.18 Insurance; Risk Management.  All material fire and casualty,
general liability, business interruption, product liability, and sprinkler and  
water damage insurance policies maintained by TSI or any of its Subsidiaries are
with reputable insurance carriers, provide full and adequate coverage for all   
normal risks incident to the business of TSI and its Subsidiaries and their     
respective properties and assets, and are in character and amount at least      
equivalent to that carried by persons engaged in similar businesses and subject 
to the same or similar perils or hazards, except for any such failures to       
maintain insurance policies that, individually or in the aggregate, are not     
reasonably likely to have a TSI Material Adverse Effect. The steps taken by TSI 
to manage the various risks incident to the business and operations of TSI and  
its Subsidiaries and their respective properties and assets are at least        
equivalent to those taken by persons engaged in similar businesses, except for  
any failures to take such steps that, individually or in the aggregate, are not 
reasonably likely to have a TSI Material Adverse Effect.                        

SECTION 3.19 No Existing Discussions.  Except for discussions or      
negotiations relating to the acquisition by TSI of the capital stock of         
HealthVISION, Inc. ("HealthVISION") not owned, as of the date hereof, by TSI    
(the "HealthVISION Acquisition") as of the date hereof, TSI is not engaged,     
directly or indirectly, in any discussions or negotiations with any other party 
with respect to an Acquisition Proposal (as defined in Section 6.01).           

   SECTION 3.20 Opinion of Financial Advisor.  The financial advisor of TSI,
BT Alex. Brown Incorporated, has delivered to the Board Directors of TSI an     
opinion dated the date of this Agreement to the effect that, as of the date of  
such opinion, the Exchange Ratio is fair, from a financial point of view, to the
holders of TSI Common Stock.                                                    

    SECTION 3.21 Anti-Takeover Laws.  No "fair price", "business combination",
"moratorium", "control share acquisition" or other form of antitakeover statute 
or regulation, including, without limitation, Chapter 110C of the General Laws  
of the Commonwealth of Massachusetts, is or will be applicable to the execution,
delivery or performance of this Agreement or the consummation of the Merger or  
the other transactions contemplated by this Agreement.                          

   SECTION 3.22 Insider Trading Policies and Practices.  Section 3.22 to the
TSI Disclosure Schedule sets forth a copy of TSI's insider trading policy as in 
effect on the date hereof. TSI and each of its directors, officers and employees
who are subject to such policy have complied in all material respects with the  
terms of such policy.                                                           

A-13

S-4
231st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 231st

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF ECLIPSYS AND SUB

     Eclipsys and Sub represent and warrant to TSI that the statements contained
in this Article IV are true and correct except as set forth in the disclosure   
schedule delivered by Eclipsys to TSI on or before the date of this Agreement   
(the "Eclipsys Disclosure Schedule"). The Eclipsys Disclosure Schedule shall be 
arranged in paragraphs and sections corresponding to the numbered and lettered  
paragraphs and sections contained in this Article IV and the disclosure in any  
paragraph or section shall qualify other paragraphs and sections in this Article
IV only to the extent that it is reasonably apparent from a reading of such     
document that it also qualifies or applies to such other paragraphs and         
sections.                                                                       

  SECTION 4.01 Organization of Eclipsys and Sub.  Each of Eclipsys and Sub
and Eclipsys' other Subsidiaries is a corporation duly organized, validly       
existing and in good standing under the laws of the jurisdiction of its         
incorporation, has all requisite corporate power to own, lease and operate its  
property and to carry on its business as now being conducted and as proposed to 
be conducted, and is duly qualified to do business and is in good standing as a 
foreign corporation in each jurisdiction in which the failure to be so qualified
would have an Eclipsys Material Adverse Effect (as defined below). Except as set
forth in the Eclipsys SEC Reports (as defined in Section 4.04) filed prior to   
the date hereof, neither Eclipsys nor any of its Subsidiaries directly or       
indirectly owns any equity or similar interest in, or any interest convertible  
into or exchangeable or exercisable for, any corporation, partnership, joint    
venture or other business association or entity, excluding securities in any    
publicly traded company held for investment by Eclipsys and comprising less than
five percent (5%) of the outstanding stock of such company. For purposes of this
Agreement, the term "Eclipsys Material Adverse Effect" means any effect that is,
or would reasonably be expected to be, materially adverse to the financial      
condition, results of operations, cash flows, business or properties of Eclipsys
and its Subsidiaries, taken as a whole.                                         

SECTION 4.02 Eclipsys Capital Structure.                              

     (a) The authorized capital stock of Eclipsys consists of 200,000,000 shares
of Eclipsys Voting Common Stock, $.01 par value, 5,000,000 shares of Non-Voting 
Common Stock, $.01 par value ("Eclipsys Non-Voting Common Stock" and, together  
with the Eclipsys Voting Common Stock, "Eclipsys Common Stock"), and 5,000,000  
shares of Preferred Stock, $.01 par value ("Eclipsys Preferred Stock"). As of   
September 30, 1998, (i) 19,393,241 shares of Eclipsys Voting Common Stock and   
896,431 shares of Eclipsys Non-Voting Common Stock were issued and outstanding, 
all of which are validly issued, fully paid and nonassessable, (ii) 962,833     
shares of Eclipsys Non-Voting Common Stock were reserved for issuance upon the  
exercise of certain warrants (the "Eclipsys Warrants") having an exercise price 
of $.01 per share, and (iii) no shares of Eclipsys Common Stock were held in the
treasury of Eclipsys or by Subsidiaries of Eclipsys. Section 4.02 of the        
Eclipsys Disclosure Schedule shows the number of shares of Eclipsys Voting      
Common Stock reserved for future issuance pursuant to stock options granted and 
outstanding as of September 30, 1998 and the plans under which such options were
granted (collectively, the "Eclipsys Stock Plans"). No material change in such  
capitalization has occurred between September 30, 1998 and the date of this     
Agreement. As of the date of this Agreement, none of the shares of Eclipsys     
Preferred Stock is issued and outstanding. All shares of Eclipsys Common Stock  
subject to issuance as specified above are duly authorized and, upon issuance on
the terms and conditions specified in the instruments pursuant to which they are
issuable, shall be validly issued, fully paid and nonassessable. There are no   
obligations, contingent or otherwise, of Eclipsys or any of its Subsidiaries to 
repurchase, redeem or otherwise acquire any shares of Eclipsys Common Stock or  
the capital stock of any Subsidiary or to provide funds to or make any material 
investment (in the form of a loan, capital contribution or otherwise) in any    
such Subsidiary or any other entity other than guarantees of bank obligations of
Subsidiaries entered into in the ordinary course of business. All of the        
outstanding shares of capital stock of each of Eclipsys' Subsidiaries are duly  
authorized, validly issued, fully paid and nonassessable and all such shares    
(other than directors' qualifying shares in the case of foreign Subsidiaries)   
are owned by Eclipsys or another Subsidiary free and clear of all security      
interests, liens, claims, pledges, agreements, limitations in Eclipsys' voting  
rights, charges or other encumbrances of any nature.                            

A-14

S-4
232nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 232nd

(b) Except as set forth in this Section 4.02 or as reserved for future
grants of options under the Eclipsys Stock Plans or the Eclipsys Warrant, there 
are no equity securities of any class of Eclipsys or any of its Subsidiaries, or
any security exchangeable into or exercisable for such equity securities,       
issued, reserved for issuance or outstanding. Except as set forth in the        
Eclipsys SEC Reports (as defined in Section 4.04 below) filed prior to the date 
hereof or disclosed in Section 4.02 of the Eclipsys Disclosure Schedule, there  
are no options, warrants, equity securities, calls, rights, commitments or      
agreements of any character to which Eclipsys or any of its Subsidiaries is a   
party or by which it is bound obligating Eclipsys or any of its Subsidiaries to 
issue, deliver or sell, or cause to be issued, delivered or sold, additional    
shares of capital stock of Eclipsys or any of its Subsidiaries or obligating    
Eclipsys or any of its Subsidiaries to grant, extend, accelerate the vesting of 
or enter into any such option, warrant, equity security, call, right, commitment
or agreement. To the best knowledge of Eclipsys, there are no voting trusts,    
proxies or other voting agreements or understandings with respect to the shares 
of capital stock of Eclipsys.                                                   

SECTION 4.03 Authority; No Conflict; Required Filings and Consents.   

(a) Each of Eclipsys and the Sub has all requisite corporate power and
authority to enter into this Agreement and to consummate the transactions       
contemplated by this Agreement. The execution and delivery of this Agreement and
the consummation of the transactions contemplated by this Agreement by Eclipsys 
have been duly authorized by all necessary corporate action on the part of each 
of Eclipsys and Sub (including the approval of the Merger by Eclipsys as the    
sole stockholder of Sub), subject only to the approval of the Eclipsys Voting   
Proposals (as \defined in Section 6.05) by Eclipsys' stockholders. This         
Agreement has been duly executed and delivered by Eclipsys and the Sub and      
constitutes the valid and binding obligation of Eclipsys and the Sub,           
enforceable in accordance with its terms, subject to the Bankruptcy and Equity  
Exception.                                                                      

  (b) The execution and delivery of this Agreement by Eclipsys and the Sub
does not, and the consummation of the transactions contemplated by this         
Agreement will not, (i) conflict with, or result in any violation or breach of, 
any provision of the Certificate of Incorporation or Bylaws of Eclipsys or Sub, 
each as amended to date, (ii) result in any violation or breach of, or          
constitute (with or without notice or lapse of time, or both) a default (or give
rise to a right of termination, cancellation or acceleration of any obligation  
or loss of any material benefit) under, or require a consent or waiver under,   
any of the terms, conditions or provisions of any note, bond, mortgage,         
indenture, lease, contract or other agreement, instrument or obligation to which
Eclipsys or any of its Subsidiaries is a party or by which any of them or any of
their properties or assets may be bound, or (iii) conflict with or violate any  
permit, concession, franchise, license, judgment, order, decree, statute, law,  
ordinance, rule or regulation applicable to Eclipsys or any of its Subsidiaries 
or any of its or their properties or assets, except in the case of clauses (ii) 
and (iii) for any such conflicts, violations, breaches, defaults, terminations, 
cancellations, accelerations or losses which are not, individually or in the    
aggregate, reasonably likely to have an Eclipsys Material Adverse Effect.       

(c) No consent, approval, order or authorization of, or registration, 
declaration or filing with, any Governmental Entity is required by or with      
respect to Eclipsys or any of its Subsidiaries in connection with the execution 
and delivery of this Agreement or the consummation of the transactions          
contemplated hereby, except for (i) the filing of a pre-merger notification     
report under the HSR Act and any other documents or information requested by the
United States Department of Justice or the United States Federal Trade          
Commission in connection herewith, (ii) the filing of the Registration Statement
with the SEC in accordance with the Securities Act, (iii) the filing of the     
Articles of Merger with the Secretary of State of Massachusetts, (iv) the filing
of the Joint Proxy Statement with the SEC in accordance with the Exchange Act,  
(v) such consents, approvals, orders, authorizations, registrations,            
declarations and filings as may be required under applicable state securities   
laws and the laws of any foreign country and (vi) such other consents,          
authorizations, filings, approvals and registrations which, if not obtained or  
made, would not be reasonably likely to have an Eclipsys Material Adverse       
Effect.                                                                         

A-15

S-4
233rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 233rd

SECTION 4.04 SEC Filings; Financial Statements.                       

 (a) Eclipsys has filed and made available to TSI all forms, reports and
documents required to be filed by Eclipsys with the SEC since July 29, 1998     
other than registration statements on Form S-8 (collectively, the "Eclipsys SEC 
Reports"). The Eclipsys SEC Reports (i) at the time filed, complied in all      
material respects with the applicable requirements of the Securities Act and the
Exchange Act, as the case may be, and (ii) did not at the time they were filed  
(or if amended or superseded by a filing prior to the date of this Agreement,   
then on the date of such filing) contain any untrue statement of a material fact
or omit to state a material fact required to be stated in such Eclipsys SEC     
Reports or necessary in order to make the statements in such Eclipsys SEC       
Reports, in the light of the circumstances under which they were made, not      
misleading. None of Eclipsys' Subsidiaries is required to file any forms,       
reports or other documents with the SEC.                                        

     (b) Each of the consolidated financial statements (including, in each case,
any related notes) contained in the Eclipsys SEC Reports complied as to form in 
all material respects with the applicable published rules and regulations of the
SEC with respect thereto, was prepared in accordance with GAAP applied on a     
consistent basis throughout the periods involved (except as may be indicated in 
the notes to such financial statements or, in the case of unaudited statements, 
as permitted by Form 10-Q of the SEC) and fairly presented the consolidated     
financial position of Eclipsys and its Subsidiaries as of the dates and the     
consolidated results of its operations and cash flows for the periods indicated,
except that the unaudited interim financial statements were or are subject to   
normal and recurring year-end adjustments which were not or are not expected to 
be material in amount. The unaudited balance sheet of Eclipsys as of June 30,   
1998 is referred to herein as the "Eclipsys Balance Sheet."                     

SECTION 4.05 No Undisclosed Liabilities.  Except as disclosed in the  
Eclipsys SEC Reports filed prior to the date hereof, and except for normal or   
recurring liabilities incurred since June 30, 1998 in the ordinary course of    
business consistent with past practices, Eclipsys and its Subsidiaries do not   
have any liabilities, either accrued, contingent or otherwise (whether or not   
required to be reflected in financial statements in accordance with GAAP), and  
whether due or to become due, which individually or in the aggregate, are       
reasonably likely to have an Eclipsys Material Adverse Effect.                  

    SECTION 4.06 Absence of Certain Changes or Events.  Except as disclosed in
the Eclipsys SEC Reports filed prior to the date hereof, from and after the date
of the Eclipsys Balance Sheet, Eclipsys and its Subsidiaries have conducted     
their businesses only in the ordinary course and in a manner consistent with    
past practice and, during such period, there has not been (i) any Material      
Adverse Change in Eclipsys and its Subsidiaries, taken as a whole (other than   
changes that are the effect or result of economic factors affecting the economy 
as a whole or economic or market factors affecting the healthcare information   
systems industry generally) or any development or combination of developments of
which the management of Eclipsys is aware that, individually or in the          
aggregate, has had, or is reasonably likely to have, an Eclipsys Material       
Adverse Effect (other than economic factors affecting the economy as a whole or 
economic or market factors affecting the healthcare information systems industry
generally); (ii) any damage, destruction or loss (whether or not covered by     
insurance) with respect to Eclipsys or any of its Subsidiaries having an        
Eclipsys Material Adverse Effect; (iii) any material change by Eclipsys in its  
accounting methods, principles or practices to which TSI has not previously     
consented in writing; (iv) any revaluation by Eclipsys of any of its assets     
having an Eclipsys Material Adverse Effect; or (v) any other action or event    
that would have required the consent of TSI pursuant to Section 5.01 of this    
Agreement had such action or event occurred after the date of this Agreement and
that, in the case of this clause (v), individually or in the aggregate, has had 
or is reasonably likely to have an Eclipsys Material Adverse Effect.            

SECTION 4.07 Taxes.                                                   

     (a) Each of Eclipsys and its Subsidiaries has filed all Tax Returns that it
was required to file, and all such Tax Returns were correct and complete. Each  
group of corporations with which Eclipsys or any of its Subsidiaries has filed  
(or was required to file) consolidated, combined, unitary or similar Tax Returns
(an "Eclipsys Affiliated Group") has filed all such Tax Returns that it was     
required to file with respect to any                                            

A-16

S-4
234th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 234th

period in which Eclipsys or one of its Subsidiaries was a member of such        
Eclipsys Affiliated Group (an "Eclipsys Affiliated Period"), and all such Tax   
Returns were correct and complete. Each of Eclipsys and its Subsidiaries has    
paid all Taxes (whether or not shown on such Tax Returns) that were due and     
payable, and each Eclipsys Affiliated Group has paid all Taxes (whether or not  
shown on such Tax Returns) that were due and payable with respect to all        
Eclipsys Affiliated Periods and with respect to which Eclipsys or any of its    
Subsidiaries may be liable by operation of law or otherwise. The unpaid Taxes of
Eclipsys and its Subsidiaries for tax periods through the date of the Eclipsys  
Balance Sheet do not exceed the accruals and reserves for Taxes set forth on the
Eclipsys Balance Sheet (exclusive of any accruals for "deferred taxes" or       
similar items that reflect timing differences between Tax and financial         
accounting principles). The unpaid Taxes of Eclipsys and its Subsidiaries for   
tax periods from the date of the Eclipsys Balance Sheet through the Closing Date
are attributable solely to the conduct of their businesses in the ordinary      
course and in a manner consistent with past practices. All Taxes that Eclipsys  
or any of its Subsidiaries is or was required by law to withhold or collect have
been duly withheld or collected and, to the extent required, have been paid to  
the proper Governmental Entity. Each of the representations contained in this   
Section 4.07(a) shall be limited in its application to items which are          
reasonably likely, individually or in the aggregate, to have an Eclipsys        
Material Adverse Effect.                                                        

     (b) No examination or audit by any Governmental Entity of any Tax Return of
Eclipsys, any of its Subsidiaries or any Eclipsys Affiliated Group with respect 
to an Eclipsys Affiliated Period is currently in progress or, to the knowledge  
of Eclipsys and its Subsidiaries, threatened or contemplated, in each case,     
which involve claims that individually or in the aggregate are reasonably likely
to have an Eclipsys Material Adverse Effect. Neither Eclipsys nor any of its    
Subsidiaries has been informed by any jurisdiction that the jurisdiction        
believes that Eclipsys or any of its Subsidiaries was required to file any Tax  
Return that was not filed which failure or failures individually, or in the     
aggregate, are reasonably likely to have an Eclipsys Material Adverse Effect.   

(c) Neither Eclipsys nor any of its Subsidiaries is a "consenting     
corporation" within the meaning of Section 341(f) of the Code, and none of the  
assets of Eclipsys and its Subsidiaries is subject to an election under Section 
341(f) of the Code.                                                             

   (d) Neither Eclipsys nor any of its Subsidiaries has been a United States
real property holding corporation within the meaning of Section 897(c)(2) of the
Code during the applicable period specified in Section 897(c)(l)(A)(ii) of the  
Code.                                                                           

(e) None of Eclipsys or any of its Subsidiaries is a party to any Tax 
allocation or sharing agreement.                                                

    (f) None of Eclipsys or any of its Subsidiaries has any material liability
for Taxes of any person (other than Eclipsys and any of its Subsidiaries (under 
Treasury Regulation Section 1.1502-6 or any similar provision of state, local or
foreign law)), as a transferee or successor by contract, or otherwise.          

SECTION 4.08 Properties.                                              

(a) Eclipsys does not own of record any real property.                

    (b) All material real property leases of Eclipsys and its Subsidiaries are
in good standing, valid and effective in accordance with their respective terms,
and neither Eclipsys nor its Subsidiaries is in default under any of such       
leases, except where the lack of such good standing, validity or effectiveness  
or the existence of such default would not be reasonably likely to have an      
Eclipsys Material Adverse Effect.                                               

SECTION 4.09 Intellectual Property.                                   

     (a) Eclipsys and its Subsidiaries own, or are licensed or otherwise possess
legally enforceable rights to use, all patents, trademarks, trade names, service
marks, copyrights and mask works, any applications for and registrations of such
patents, trademarks, trade names, service marks, copyrights and mask works, and 
all processes, formulae, methods, schematics, technology, know-how, computer    
software programs or applications and tangible or intangible proprietary        
information or material that are necessary to conduct the business of Eclipsys  
and its Subsidiaries as currently conducted, or planned to be conducted, the    
absence of which would be reasonably likely to have an Eclipsys Material Adverse
Effect (the "Eclipsys Intellectual Property Rights").                           

A-17

S-4
235th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 235th

     (b) Neither Eclipsys nor any of its Subsidiaries is, or will as a result of
the execution and delivery of this Agreement or the performance of Eclipsys'    
obligations under this Agreement or otherwise be, in breach of any license,     
sublicense or other agreement relating to the Eclipsys Intellectual Property    
Rights, or any material licenses, sublicenses and other agreements as to which  
Eclipsys or any of its Subsidiaries is a party and pursuant to which Eclipsys or
any of its Subsidiaries is authorized to use any third party patents, trademarks
or copyrights ("Eclipsys Third Party Intellectual Property Rights"), including  
software which is used in the manufacture of, incorporated in, or forms a part  
of any product sold by or expected to be sold by Eclipsys or any of its         
Subsidiaries, the breach of which would be reasonably likely to have an Eclipsys
Material Adverse Effect.                                                        

(c) All patents, registered trademarks, registered service marks and  
registered copyrights which are held by Eclipsys or any of its Subsidiaries and 
which are material to the business of Eclipsys and its Subsidiaries, taken as a 
whole, are valid and subsisting. Eclipsys (i) has not been sued in any suit,    
action or proceeding, or received in writing any claim or notice, which involves
a claim of infringement of any patents, trademarks, service marks, copyrights or
violation of any trade secret or other proprietary right of any third party; and
(ii) has no knowledge that the manufacturing, marketing, licensing or sale of   
its products infringes any patent, trademark, service mark, copyright, trade    
secret or other proprietary right of any third party, which infringement would  
reasonably be expected to have an Eclipsys Material Adverse Effect.             

SECTION 4.10 Agreements, Contracts and Commitments.  Eclipsys has not 
breached, or received in writing any claim or notice that it has breached, any  
of the terms or conditions of any agreement, contract or commitment filed as an 
exhibit to the Eclipsys SEC Reports (collectively, "Eclipsys Material           
Contracts") in such a manner as, individually or in the aggregate, are          
reasonably likely to have an Eclipsys Material Adverse Effect. Each Eclipsys    
Material Contract that has not expired by its terms is in full force and effect.

   SECTION 4.11 Litigation.  Except as described in the Eclipsys SEC Reports
filed prior to the date hereof, there is no action, suit or proceeding, claim,  
arbitration or investigation against Eclipsys or any of its Subsidiaries pending
or as to which Eclipsys or any such Subsidiary has received any written notice  
of assertion, which, individually or in the aggregate, is reasonably likely to  
have an Eclipsys Material Adverse Effect or a material adverse effect on the    
ability of Eclipsys to consummate the transactions contemplated by this         
Agreement.                                                                      

  SECTION 4.12 Environmental Matters.  Except as disclosed in the Eclipsys
SEC Reports filed prior to the date hereof and except for such matters that,    
individually or in the aggregate, are not reasonably likely to have an Eclipsys 
Material Adverse Effect: (i) Eclipsys and its Subsidiaries have complied with   
all applicable Environmental Laws; (ii) the properties currently owned or       
operated by Eclipsys and its Subsidiaries (including soils, groundwater, surface
water, buildings or other structures) are not contaminated with any Hazardous   
Substances; (iii) the properties formerly owned or operated by Eclipsys or any  
of its Subsidiaries were not contaminated with Hazardous Substances during the  
period of ownership or operation by Eclipsys or any of its Subsidiaries; (iv)   
neither Eclipsys nor any of its Subsidiaries are subject to liability for any   
Hazardous Substance disposal or contamination on any third-party property; (v)  
neither Eclipsys nor any of its Subsidiaries has been associated with any       
release or threat of release of any Hazardous Substance; (vi) neither Eclipsys  
nor any of its Subsidiaries has received any notice, demand, letter, claim or   
request for information alleging that Eclipsys or any of its Subsidiaries may be
in violation of or liable under any Environmental Law; (vii) neither Eclipsys   
nor any of its Subsidiaries is subject to any orders, decrees, injunctions or   
other arrangements with any Governmental Entity or is subject to any indemnity  
or other agreement with any third party relating to liability under any         
Environmental Law or relating to Hazardous Substances; and (viii) there are no  
circumstances or conditions involving Eclipsys or any of its Subsidiaries that  
could reasonably be expected to result in any claims, liabilities,              
investigations, costs or restrictions on the ownership, use or transfer of any  
property of Eclipsys pursuant to any Environmental Law.                         

A-18

S-4
236th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 236th

SECTION 4.13 Employee Benefit Plans.                                  

     (a) Eclipsys has listed in Section 4.13 of the Eclipsys Disclosure Schedule
all employee benefit plans (as defined in Section 3(3) of ERISA) and all bonus, 
stock option, stock purchase, incentive, deferred compensation, supplemental    
retirement, severance and other similar employee benefit plans, and all material
unexpired severance agreements, written or otherwise, for the benefit of, or    
relating to, any current or former employee of Eclipsys or any ERISA Affiliate  
of Eclipsys, or any Subsidiary of Eclipsys (collectively, the "Eclipsys Employee
Plans").                                                                        

(b) With respect to each Eclipsys Employee Plan, Eclipsys has made    
available to TSI, a true and correct copy of (i) the most recent annual report  
(Form 5500) filed with the IRS, (ii) such Eclipsys Employee Plan, (iii) each    
trust agreement and group annuity contract, if any, relating to such Eclipsys   
Employee Plan and (iv) the most recent actuarial report or valuation relating to
an Eclipsys Employee Plan subject to Title IV of ERISA.                         

  (c) With respect to the Eclipsys Employee Plans, individually and in the
aggregate, no event has occurred and, to the knowledge of Eclipsys, there exists
no condition or set of circumstances in connection with which Eclipsys could be 
subject to any liability that is reasonably likely to have an Eclipsys Material 
Adverse Effect under ERISA, the Code or any other applicable law.               

  (d) With respect to the Eclipsys Employee Plans, individually and in the
aggregate, there are no funded benefit obligations for which contributions have 
not been made or properly accrued and there are no unfunded benefit obligations 
which have not been accounted for by reserves, or otherwise properly footnoted  
in accordance with GAAP, on the financial statements of Eclipsys, which         
obligations are reasonably likely to have an Eclipsys Material Adverse Effect.  

    (e) Except as disclosed in Eclipsys SEC Reports filed prior to the date of
this Agreement, and except as provided for in this Agreement, neither Eclipsys  
nor any of its Subsidiaries is a party to any oral or written (i) agreement with
any officer or other key employee of Eclipsys or any of its Subsidiaries, the   
benefits of which are contingent, or the terms of which are materially altered, 
upon the occurrence of a transaction involving Eclipsys of the nature           
contemplated by this Agreement, (ii) agreement with any officer of Eclipsys     
providing any term of employment or compensation guarantee extending for a      
period longer than one year from the date hereof or for the payment of          
compensation in excess of $100,000 per annum, or (iii) agreement or plan,       
including any stock option plan, stock appreciation right plan, restricted stock
plan or stock purchase plan, any of the benefits of which will be increased, or 
the vesting of the benefits of which will be accelerated, by the occurrence of  
any of the transactions contemplated by this Agreement or the value of any of   
the benefits of which will be calculated on the basis of any of the transactions
contemplated by this Agreement.                                                 

   SECTION 4.14 Compliance With Laws.  Eclipsys and each of its Subsidiaries
has complied with, is not in violation of, and has not received any notices of  
violation with respect to, any federal, state, local or foreign statute, law or 
regulation with respect to the conduct of its business, or the ownership or     
operation of its business, except for failures to comply or violations which,   
individually or in the aggregate, have not had and are not reasonably likely to 
have an Eclipsys Material Adverse Effect.                                       

SECTION 4.15 Accounting and Tax Matters.  To its knowledge, after     
consulting with its independent auditors, neither Eclipsys nor any of its       
Affiliates has taken or agreed to take any action which would (i) prevent       
Eclipsys from accounting for the business combination to be effected by the     
Merger as a pooling of interests or (ii) prevent the Merger from constituting a 
transaction qualifying as a reorganization under Section 368(a) of the Code.    

SECTION 4.16 Registration Statement; Proxy Statement/Prospectus.  The 
information to be supplied by Eclipsys for inclusion in the Registration        
Statement shall not at the time the Registration Statement is declared effective
by the SEC contain any untrue statement of a material fact or omit to state any 
material fact required to be stated in the Registration Statement or necessary  
in order to make the statements in the Registration Statement, in light of the  
circumstances under which they were made, not misleading. The information       
supplied by Eclipsys for inclusion in the Joint Proxy Statement shall not, on   
the date the Joint Proxy Statement is first mailed to stockholders of Eclipsys  
or TSI, at the time of the                                                      

A-19

S-4
237th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 237th

Eclipsys Stockholders' Meeting and the TSI Stockholders' Meeting and at the     
Effective Time, contain any statement which, at such time and in light of the   
circumstances under which it shall be made, is false or misleading with respect 
to any material fact, or omit to state any material fact necessary in order to  
make the statements made in the Joint Proxy Statement not false or misleading;  
or omit to state any material fact necessary to correct any statement in any    
earlier communication with respect to the solicitation of proxies for the       
Eclipsys Stockholders' Meeting or the TSI Stockholders' Meetings which has      
become false or misleading. If at any time prior to the Effective Time any event
relating to Eclipsys or any of its Affiliates, officers or directors should be  
discovered by Eclipsys which should be set forth in an amendment to the         
Registration Statement or a supplement to the Joint Proxy Statement, Eclipsys   
shall promptly inform TSI.                                                      

   SECTION 4.17 Labor Matters.  Neither Eclipsys nor any of its Subsidiaries
is a party to or otherwise bound by any collective bargaining agreement,        
contract or other agreement or understanding with a labor union or labor        
organization, nor, as of the date hereof, is Eclipsys or any of its Subsidiaries
the subject of any material proceeding asserting that Eclipsys or any of its    
Subsidiaries has committed an unfair labor practice or is seeking to compel it  
to bargain with any labor union or labor organization nor, as of the date of    
this Agreement, is there pending or, to the knowledge of the executive officers 
of Eclipsys, threatened, any material labor strike, dispute, walkout, work      
stoppage, slow-down or lockout involving Eclipsys or any of its Subsidiaries.   

   SECTION 4.18 Insurance; Risk Management.  All material fire and casualty,
general liability, business interruption, product liability, and sprinkler and  
water damage insurance policies maintained by Eclipsys or any of its            
Subsidiaries are with reputable insurance carriers, provide full and adequate   
coverage for all normal risks incident to the business of Eclipsys and its      
Subsidiaries and their respective properties and assets, and are in character   
and amount at least equivalent to that carried by persons engaged in similar    
businesses and subject to the same or similar perils or hazards, except for any 
such failures to maintain insurance policies that, individually or in the       
aggregate, are not reasonably likely to have an Eclipsys Material Adverse       
Effect. The steps taken by Eclipsys to manage the various risks incident to the 
business and operations of Eclipsys and its Subsidiaries and their respective   
properties and assets are at least equivalent to those taken by persons engaged 
in similar businesses, except for any failures to take such steps that,         
individually or in the aggregate, are not reasonably likely to have an Eclipsys 
Material Adverse Effect.                                                        

SECTION 4.19 No Existing Discussions.  Except for discussions or      
negotiations relating to possible acquisitions by Eclipsys of those companies   
previously disclosed by Eclipsys to TSI ("Eclipsys Possible Acquisitions"), as  
of the date hereof, Eclipsys is not engaged, directly or indirectly, in any     
discussions or negotiations with any other party with respect to an Acquisition 
Proposal (as defined in Section 6.01).                                          

SECTION 4.20 Opinion of Financial Advisor.  The financial advisor of  
Eclipsys, Morgan Stanley & Co. Incorporated, has delivered to the Board of      
Directors of Eclipsys an opinion dated the date of this Agreement to the effect 
that the Exchange Ratio is fair to Eclipsys from a financial point of view.     

    SECTION 4.21 Anti-Takeover Laws.  No "fair price", "business combination",
"moratorium", "control share acquisition" or other form of antitakeover statute 
or regulation is or will be applicable to the execution, delivery or performance
of this Agreement or the consummation of the Merger or the other transactions   
contemplated by this Agreement.                                                 

   SECTION 4.22 Insider Trading Policies and Practices.  Section 4.22 to the
Eclipsys Disclosure Schedule sets forth a copy of Eclipsys' insider trading     
policy as in effect on the date hereof. Eclipsys and each of its directors,     
officers and employees who are subject to such policy have complied in all      
material respects with the terms of such policy.                                

SECTION 4.23 Interim Operations of Sub.  Sub was formed solely for the
purpose of engaging in the transactions contemplated by this Agreement, has     
engaged in no other business activities and has conducted its operations only as
contemplated by this Agreement.                                                 

A-20

S-4
238th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 238th

ARTICLE V 

CONDUCT OF BUSINESS 

 SECTION 5.01 Covenants of TSI.  During the period from the date of this
Agreement and continuing until the earlier of the termination of this Agreement 
or the Effective Time, TSI agrees as to itself and its Subsidiaries (except to  
the extent that Eclipsys shall otherwise consent in writing), to carry on its   
business in the usual, regular and ordinary course in substantially the same    
manner as previously conducted, to pay its debts and Taxes when due subject to  
good faith disputes over such debts or Taxes, to pay or perform its other       
obligations when due, and, to the extent consistent with such business, use all 
reasonable efforts consistent with past practices and policies to preserve      
intact its present business organization, keep available the services of its    
present officers and key employees and preserve its relationships with          
customers, suppliers, distributors and others having business dealings with it. 
TSI shall promptly notify Eclipsys of any material event or occurrence not in   
the ordinary course of business. Except as expressly contemplated by this       
Agreement, TSI shall not (and shall not permit any of its Subsidiaries to),     
without the written consent of Eclipsys:                                        

   (a) Accelerate, amend or change the period of exercisability of
   options or restricted stock granted under any employee stock plan of such
    party or authorize cash payments in exchange for any options granted under
any of such plans except as required by the terms of such plans or any
related agreements in effect as of the date of this Agreement;        

       (b) Declare or pay any dividends on or make any other distributions
(whether in cash, stock or property) in respect of any of its capital 
     stock, or split, combine or reclassify any of its capital stock or issue or
     authorize the issuance of any other securities in respect of, in lieu of or
   in substitution for shares of its capital stock, or purchase or otherwise
 acquire, directly or indirectly, any shares of its capital stock except
from former employees, directors and consultants in accordance with   
  agreements providing for the repurchase of shares in connection with any
termination of service to such party;                                 

     (c) Issue, deliver or sell, or authorize or propose the issuance,
delivery or sale of, any shares of its capital stock or securities    
 convertible into shares of its capital stock, or subscriptions, rights,
   warrants or options to acquire, or other agreements or commitments of any
character obligating it to issue any such shares or other convertible 
    securities, other than the issuance of shares of TSI Common Stock pursuant
     to the exercise of options outstanding on the date of this Agreement or the
TSI Warrants;                                                         

        (d) Acquire or agree to acquire by merging or consolidating with, or
  by purchasing a substantial equity interest in or substantial portion of
 the assets of, or by any other manner, any business or any corporation,
partnership or other business organization or division, or otherwise  
acquire or agree to acquire any assets (other than inventory and other
items in the ordinary course of business), except for (i) any such    
acquisitions involving aggregate consideration (including assumed     
    indebtedness) of not more than $1,000,000 or (ii) subject to Section 5.04,
the HealthVISION Acquisition;                                         

        (e) Sell, lease, license or otherwise dispose of any of its material
 properties or assets, except for transactions in the ordinary course of
business;                                                             

        (f) (i) Increase or agree to increase the compensation payable or to
     become payable to its officers or employees, except for increases in salary
or wages of employees (other than officers) in accordance with past   
  practices, (ii) grant any additional severance or termination pay to, or
  enter into any employment or severance agreements with, any employees or
    officers, (iii) enter into any collective bargaining agreement (other than
 as required by law or extensions to existing agreements in the ordinary
    course of business), (iv) establish, adopt, enter into or amend any bonus,
profit sharing, thrift, compensation, stock option, restricted stock, 
pension, retirement, deferred compensation, employment, termination,  
     severance or other plan, trust, fund, policy or arrangement for the benefit
of any directors, officers or employees;                              

A-21

S-4
239th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 239th

  (g) Amend or propose to amend its charter or bylaws, except as
contemplated by this Agreement;                                       

        (h) Incur any indebtedness for borrowed money other than pursuant to
credit agreements in effect as of the date hereof;                    

 (i) Initiate, compromise or settle any material litigation or
arbitration proceeding (other than as a result of a breach of this    
Agreement);                                                           

   (j) Except in the ordinary course of business, modify, amend or
terminate any TSI Material Contract or waive, release or assign any   
material rights or claims;                                            

         (k) Change in any material respect its accounting methods, principles
   or practices, except insofar as may be required by a generally applicable
change in GAAP; or                                                    

          (l) Take, or agree in writing or otherwise to take, any of the actions
described in paragraphs (a) through (k) above.                        

 SECTION 5.02 Covenants of Eclipsys.  During the period from the date of
this Agreement and continuing until the earlier of the termination of this      
Agreement or the Effective Time, Eclipsys agrees as to itself and its           
Subsidiaries (except to the extent that TSI shall otherwise consent in writing),
to carry on its business in the usual, regular and ordinary course in           
substantially the same manner as previously conducted, to pay its debts and     
Taxes when due subject to good faith disputes over such debts or Taxes, to pay  
or perform its other obligations when due, and, to the extent consistent with   
such business, use all reasonable efforts consistent with past practices and    
policies to preserve intact its present business organization, keep available   
the services of its present officers and key employees and preserve its         
relationships with customers, suppliers, distributors and others having business
dealings with it. Eclipsys shall promptly notify TSI of any material event or   
occurrence not in the ordinary course of business. Except as expressly          
contemplated by this Agreement, Eclipsys shall not (and shall not permit any of 
its Subsidiaries to), without the written consent of TSI:                       

   (a) Accelerate, amend or change the period of exercisability of
   options or restricted stock granted under any employee stock plan of such
    party or authorize cash payments in exchange for any options granted under
any of such plans except as required by the terms of such plans or any
related agreements in effect as of the date of this Agreement;        

       (b) Declare or pay any dividends on or make any other distributions
(whether in cash, stock or property) in respect of any of its capital 
     stock, or split, combine or reclassify any of its capital stock or issue or
     authorize the issuance of any other securities in respect of, in lieu of or
   in substitution for shares of its capital stock, or purchase or otherwise
 acquire, directly or indirectly, any shares of its capital stock except
from former employees, directors and consultants in accordance with   
  agreements providing for the repurchase of shares in connection with any
termination of service to such party;                                 

     (c) Issue, deliver or sell, or authorize or propose the issuance,
delivery or sale of, any shares of its capital stock or securities    
 convertible into shares of its capital stock, or subscriptions, rights,
   warrants or options to acquire, or other agreements or commitments of any
character obligating it to issue any such shares or other convertible 
securities, other than (i) the grant of options consistent with past  
    practices to employees, which options represent in the aggregate the right
   to acquire no more than 200,000 shares (net of cancellations) of Eclipsys
     Common Stock, (ii) the issuance of shares of Eclipsys Common Stock pursuant
     to the exercise of options outstanding on the date of this Agreement or the
Eclipsys Warrants or (iii) the issuance of Eclipsys Common Stock in   
connection with any Eclipsys Permitted Acquisition (as defined below);

        (d) Acquire or agree to acquire by merging or consolidating with, or
  by purchasing a substantial equity interest in or substantial portion of
 the assets of, or by any other manner, any business or any corporation,
partnership or other business organization or division, or otherwise  
acquire or agree to acquire any assets (other than inventory and other
items in the ordinary course of business), except for (i) any Eclipsys
Possible Acquisition or (ii) any other such acquisitions involving    
aggregate                                                             

A-22

S-4
240th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 240th

consideration (including assumed indebtedness) of not more than $100,000,000    
(Eclipsys Possible Acquisitions and such other acquisitions being collectively  
referred to as "Eclipsys Permitted Acquisitions");                              

        (e) Sell, lease, license or otherwise dispose of any of its material
 properties or assets, except for transactions in the ordinary course of
business;                                                             

        (f) (i) Increase or agree to increase the compensation payable or to
     become payable to its officers or employees, except for increases in salary
or wages of employees (other than officers) in accordance with past   
  practices, (ii) grant any additional severance or termination pay to, or
  enter into any employment or severance agreements with, any employees or
    officers, (iii) enter into any collective bargaining agreement (other than
 as required by law or extensions to existing agreements in the ordinary
    course of business), (iv) establish, adopt, enter into or amend any bonus,
profit sharing, thrift, compensation, stock option, restricted stock, 
pension, retirement, deferred compensation, employment, termination,  
     severance or other plan, trust, fund, policy or arrangement for the benefit
of any directors, officers or employees;                              

  (g) Amend or propose to amend its charter or bylaws, except as
contemplated by this Agreement;                                       

          (h) Take, or agree in writing or otherwise to take, any of the actions
described in paragraphs (a) through (f) above.                        

    SECTION 5.03 Cooperation.  Subject to compliance with applicable law, from
the date hereof until the Effective Time, each of Eclipsys and TSI shall confer 
on a regular and frequent basis with one or more representatives of the other   
party to report on the general status of ongoing operations and shall promptly  
provide the other party or its counsel with copies of all filings made by such  
party with any Governmental Entity in connection with this Agreement, the Merger
and the transactions contemplated hereby and thereby.                           

   SECTION 5.04 HealthVISION Acquisition.  TSI shall use its best efforts to
cause the HealthVISION Acquisition to be closed as promptly as reasonably       
practicable following the execution of this Agreement upon terms at least as    
favorable to TSI as those set forth in that certain Agreement and Plan of       
Reorganization dated October 28, 1998 among HealthVISION, TSI and the other     
parties identified therein. TSI shall keep Eclipsys reasonably apprised as to   
the status of its progress toward closing the HealthVISION Acquisition.         

  SECTION 5.05 Voting Agreements.  Concurrently with the execution of this
Agreement, and in order to induce Eclipsys and TSI, respectively, to enter into 
this Agreement, (i) Eclipsys is entering into Voting Agreements, substantially  
in the form attached hereto as Exhibit A-1, with Warburg, Pincus Ventures, L.P. 
("Warburg"), Robert Raco, Christine Shapleigh and Donald Cook, and (ii) TSI is  
entering into Voting Agreements, substantially in the form attached hereto as   
Exhibit A-2, with General Atlantic Partners 28, L.P., General Atlantic Partners 
38, L.P., General Atlantic Partners 47, L.P., General Atlantic Partners 48,     
L.P., GAP Coinvestment Partners, L.P., Partners HealthCare System, Inc., Harvey 
Wilson and Wilfam Ltd.                                                          

     SECTION 5.06 Eclipsys Permitted Acquisitions.  Eclipsys shall notify TSI at
any time that Eclipsys believes it has become reasonably likely that a          
definitive agreement will be executed with respect to an Eclipsys Permitted     
Acquisition or that an Eclipsys Permitted Acquisition will be completed, and    
shall thereafter keep TSI reasonably apprised as to the status of such Eclipsys 
Permitted Acquisition.                                                          

A-23

S-4
241st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 241st

ARTICLE VI

ADDITIONAL AGREEMENTS 

SECTION 6.01 No Solicitation.                                         

  (a) TSI and Eclipsys each shall not, directly or indirectly, through any
officer, director, employee, financial advisor, representative or agent of such 
party (i) solicit, initiate or encourage any inquiries or proposals that        
constitute, or could reasonably be expected to lead to, a proposal or offer for 
a merger, consolidation, business combination, sale of substantial assets, sale 
of shares of capital stock (including without limitation by way of a tender     
offer) or similar transaction involving such party or any of its Subsidiaries,  
other than the transactions contemplated by this Agreement and other than, in   
the case of Eclipsys, transactions constituting Eclipsys Permitted Acquisitions 
(any of the foregoing inquiries or proposals being referred to in this Agreement
as an "Acquisition Proposal"), (ii) engage in negotiations or discussions       
concerning, or provide any non-public information to any person or entity       
relating to, any Acquisition Proposal, or (iii) agree to or recommend any       
Acquisition Proposal; provided, however, that nothing contained in this         
Agreement shall prevent TSI or Eclipsys, or their respective Boards of          
Directors, from (A) furnishing non-public information to, or entering into      
discussions or negotiations with, any person or entity in connection with an    
unsolicited bona fide written Acquisition Proposal by such person or entity or  
recommending an unsolicited bona fide written Acquisition Proposal by such      
person or entity or recommending an unsolicited bona fide written Acquisition   
Proposal to the stockholders of such party, if and only to the extent that (1)  
the Board of Directors of such party believes in good faith (after consultation 
with its financial advisor) that such Acquisition Proposal is reasonably capable
of being completed on the terms proposed and, after taking into account, among  
other relevant factors, the strategic benefits anticipated to be derived from   
the Merger and the long-term prospects of TSI and Eclipsys as a combined        
company, would, if consummated, result in a transaction more favorable to the   
stockholders of such party than the transactions contemplated by this Agreement 
(any such more favorable Acquisition Proposal being referred to in this         
Agreement as a "Superior Proposal") and the Board of Directors of such party    
determines in good faith after consultation with outside legal counsel that such
action is necessary for such Board of Directors to comply with its fiduciary    
duties to stockholders under applicable law and (2) prior to furnishing such    
non-public information to, or entering into discussions or negotiations with,   
such person or entity, such Board of Directors receives from such person or     
entity an executed confidentiality agreement with terms no less favorable to    
such party than those contained in that certain letter agreement dated October  
2, 1998 between TSI and Eclipsys regarding the confidentiality of certain       
materials (the "Confidentiality Agreement"); or (B) complying with Rule 14e-2   
promulgated under the Exchange Act with regard to an Acquisition Proposal.      

  (b) TSI and Eclipsys shall each notify the other party immediately after
receipt by TSI or Eclipsys (or their advisors) of any Acquisition Proposal or   
any request for non-public information in connection with an Acquisition        
Proposal or for access to the properties, books or records of such party by any 
person or entity that informs such party that it is considering making, or has  
made, an Acquisition Proposal. Such notice shall be made orally and in writing  
and shall indicate in reasonable detail the identity of the offeror and the     
terms and conditions of such proposal, inquiry or contact. Such party shall     
continue to keep the other party hereto informed, on a current basis, of the    
status of any such discussions or negotiations and the terms being discussed or 
negotiated.                                                                     

SECTION 6.02 Proxy Statement/Prospectus; Registration Statement.      

(a) As promptly as practical after the execution of this Agreement,   
Eclipsys and TSI shall prepare and file with the SEC the Joint Proxy Statement, 
and Eclipsys shall prepare and file with the SEC the Registration Statement, in 
which the Joint Proxy Statement will be included as a prospectus, provided that 
Eclipsys may delay the filing of the Registration Statement until approval of   
the Joint Proxy Statement by the SEC. Eclipsys and TSI shall use all reasonable 
efforts to cause the Registration Statement to become effective as soon after   
such filing as practical. The Joint Proxy Statement, and any amendment or       
supplement thereto, shall include the recommendation of the Board of Directors  
of TSI in favor of this Agreement and the Merger and the recommendation of the  
Board of Directors of Eclipsys in favor of the                                  

A-24

S-4
242nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 242nd

issuance of shares of Eclipsys Voting Common Stock pursuant to the Merger;      
provided that the Board of Directors of either party may withdraw such          
recommendation and refrain from soliciting proxies if such Board of Directors   
believes in good faith after consultation with outside legal counsel that the   
withdrawal of such recommendation is necessary for such Board of Directors to   
comply with its fiduciary duties under applicable law.                          

   (b) Eclipsys and TSI shall make all necessary filings with respect to the
Merger under the Securities Act, the Exchange Act, applicable state blue sky    
laws and the rules and regulations thereunder.                                  

     SECTION 6.03 Nasdaq Quotation.  Each of Eclipsys and TSI agrees to continue
the quotation of Eclipsys Voting Common Stock and TSI Voting Common Stock, as   
the case may be, on the Nasdaq National Market during the term of this          
Agreement.                                                                      

SECTION 6.04 Access to Information.  Upon reasonable notice, TSI and  
Eclipsys shall each (and shall cause each of their respective Subsidiaries to)  
afford to the officers, employees, accountants, counsel and other               
representatives of the other, access, during normal business hours during the   
period prior to the Effective Time, to all its properties, books, contracts,    
commitments and records and, during such period, each of TSI and Eclipsys shall 
(and shall cause each of their respective Subsidiaries to) furnish promptly to  
the other (a) a copy of each report, schedule, registration statement and other 
document filed or received by it during such period pursuant to the requirements
of federal securities laws and (b) all other information concerning its         
business, properties and personnel as such other party may reasonably request.  
Unless otherwise required by law, the parties will hold any such information    
which is non-public in confidence in accordance with the Confidentiality        
Agreement. No information or knowledge obtained in any investigation pursuant to
this Section 6.04 shall affect or be deemed to modify any representation or     
warranty contained in this Agreement or the conditions to the obligations of the
parties to consummate the Merger.                                               

  SECTION 6.05 Stockholders' Meetings.  TSI and Eclipsys shall each call a
meeting of its respective stockholders to be held as promptly as practicable for
the purpose of voting, in the case of TSI, upon this Agreement and the Merger   
and, in the case of Eclipsys, upon (i) the issuance of shares of Eclipsys Voting
Common Stock pursuant to the Merger, and (ii) the election of directors of      
Eclipsys in accordance with Section 1.04 (collectively, the "Eclipsys Voting    
Proposals"). Subject to Sections 6.01 and 6.02, TSI and Eclipsys will, through  
their respective Boards of Directors, recommend to their respective stockholders
approval of such matters and will coordinate and cooperate with respect to the  
timing of such meetings and shall use their best efforts to hold such meetings  
on the same day and as soon as practicable after the date hereof. Subject to    
Section 6.02, each party shall use all reasonable efforts to solicit from       
stockholders of such party proxies in favor of such matters.                    

SECTION 6.06 Legal Conditions to Merger.                              

(a) TSI and Eclipsys shall each use their best efforts to (i) take, or
cause to be taken, all appropriate action, and do, or cause to be done, all     
things necessary and proper under applicable law to consummate and make         
effective the transactions contemplated hereby as promptly as practicable, (ii) 
obtain from any Governmental Entity any consents, licenses, permits, waivers,   
approvals, authorizations or orders required to be obtained or made by TSI or   
Eclipsys or any of their Subsidiaries in connection with the authorization,     
execution and delivery of this Agreement and the consummation of the            
transactions contemplated hereby, including, without limitation, the Merger, and
(iii) as promptly as practicable, make all necessary filings, and thereafter    
make any other required submissions, with respect to this Agreement and the     
Merger required under (A) the Securities Act and the Exchange Act, and any other
applicable federal or state securities laws, (B) the HSR Act and any related    
governmental request thereunder, and (C) any other applicable law. TSI and      
Eclipsys shall cooperate with each other in connection with the making of all   
such filings, including providing copies of all such documents to the non-filing
party and its advisors prior to filing and, if requested, to accept all         
reasonable additions, deletions or changes suggested in connection therewith.   
TSI and Eclipsys shall use their best efforts to furnish to each other all      
information required for any application or other filing to be made pursuant to 
the rules and regulations of any applicable law (including all information      
required to be included in the Joint Proxy Statement and the                    

A-25

S-4
243rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 243rd

Registration Statement) in connection with the transactions contemplated by this
Agreement. Without limiting the generality of the foregoing, TSI shall use its  
best efforts to cause HealthVISION to prepare and deliver for inclusion in the  
Joint Proxy Statement and the Registration Statement any financial statements of
HealthVISION and its subsidiaries required by the rules of the SEC to be        
included therein.                                                               

(b) Eclipsys and TSI agree, and shall cause each of their respective  
Subsidiaries, to cooperate and to use their respective best efforts to obtain   
any government clearances or approvals required for the Closing under the HSR   
Act, the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade
Commission Act, as amended, and any other Federal, state or foreign law,        
regulation or decree designed to prohibit, restrict or regulate actions for the 
purpose or effect of monopolization or restraint of trade (collectively,        
"Antitrust Laws"), to respond to any government requests for information under  
any Antitrust Law, and to contest and resist any action, including any          
legislative, administrative or judicial action, and to have vacated, lifted,    
reversed or overturned any decree, judgment, injunction or other order (whether 
temporary, preliminary or permanent) that restricts, prevents or prohibits the  
consummation of the Merger or any other transactions contemplated by this       
Agreement under any Antitrust Law. The parties hereto will consult and cooperate
with one another, and consider in good faith the views of one another, in       
connection with any analyses, appearances, presentations, memoranda, briefs,    
arguments, opinions and proposals made or submitted by or on behalf of any party
hereto in connection with proceedings under or relating to any Antitrust Law. In
the event of a challenge to the transactions contemplated by this Agreement     
pursuant to the HSR Act, TSI and Eclipsys shall use their best efforts to defeat
such challenge, including by institution and defense of litigation, or to settle
such challenge on terms that permit the consummation of the Merger; provided,   
however, that nothing herein shall require either party to agree to divest or   
hold separate any portion of its business or otherwise take action that could   
reasonably be expected to have a TSI Material Adverse Effect or an Eclipsys     
Material Adverse Effect. Without limiting the foregoing, in the event that      
either the Federal Trade Commission or the Antitrust Division of the United     
States Department of Justice issues a Request for Additional Information or     
Documentary Material under 17 C.F.R. sec. 803.20 (a "Second Request"), then TSI 
and Eclipsys each agree to use their best efforts to respond fully to such      
Second Request within 20 days after its receipt and shall promptly make any     
further filings or information submissions and make any employee available for  
interview or testimony pursuant to the foregoing (both before and after any     
Second Request) that may be necessary, proper or advisable. In case at any time 
after the Effective Time any further action is necessary or desirable to carry  
out the purposes of this Agreement or to vest the Surviving Corporation with    
full title to all properties, assets, rights, approvals, immunities and         
franchises of either of the Constituent Corporations, the proper officers and   
directors of each party to this Agreement shall take all such necessary or      
desirable action.                                                               

   (c) Each of TSI and Eclipsys shall give (and shall cause their respective
Subsidiaries to give) any notices to third parties, and use, and cause their    
respective Subsidiaries to use, their best efforts to obtain any third-party    
consents related to or required in connection with the Merger that are (i)      
necessary to consummate the transactions contemplated hereby, (ii) disclosed or 
required to be disclosed in the TSI Disclosure Schedule or the Eclipsys         
Disclosure Schedule, as the case may be, or (iii) required to prevent a TSI     
Material Adverse Effect or an Eclipsys Material Adverse Effect from occurring   
prior to or after the Effective Time.                                           

   SECTION 6.07 Public Disclosure.  Eclipsys and TSI shall consult with each
other before issuing any press release or otherwise making any public statement 
with respect to the Merger or this Agreement and shall not issue any such press 
release or make any such public statement prior to such consultation, except as 
may be required by law or any listing agreement with a national securities      
exchange or the Nasdaq National Market, and in any event in accordance with the 
terms of the Confidentiality Agreement.                                         

    SECTION 6.08 Tax-Free Reorganization.  Eclipsys and TSI shall each use its
best efforts to cause the Merger to be treated as a reorganization within the   
meaning of Section 368(a) of the Code.                                          

    SECTION 6.09 Pooling Accounting.  From and after the date hereof and until
the Effective Time, neither TSI nor Eclipsys, nor any of their respective       
Subsidiaries shall knowingly take any action, or                                

A-26

S-4
244th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 244th

knowingly fail to take any action, that is reasonably likely to jeopardize the  
treatment of the Merger as a pooling of interests for accounting purposes.      

   SECTION 6.10 Affiliate Agreements.  Upon the execution of this Agreement,
Eclipsys and TSI will provide each other with a list of those persons who are,  
in Eclipsys' or TSI's respective reasonable judgment, "affiliates" of Eclipsys  
or TSI, respectively, within the meaning of Rule 145 promulgated under the      
Securities Act ("Rule 145") (each such person who is an "affiliate" of Eclipsys 
or TSI within the meaning of Rule 145 is referred to as an "Affiliate").        
Eclipsys and TSI shall provide each other with such information and documents as
TSI or Eclipsys shall reasonably request for purposes of reviewing such list and
shall notify the other party in writing regarding any change in the identity of 
its Affiliates prior to the Closing Date. TSI and Eclipsys shall each use its   
best efforts to deliver or cause to be delivered to each other by November 20,  
1998 (and in any case prior to the Effective Time) from each of its Affiliates, 
an executed Affiliate Agreement, in form attached hereto as Exhibit B-1, in the 
case of Affiliates of TSI, and in the form attached hereto as Exhibit B-2, in   
the case of Affiliates of Eclipsys (each, an "Affiliate Agreement"). Eclipsys   
shall be entitled to place appropriate legends on the certificates evidencing   
any Eclipsys Voting Common Stock to be received by such Affiliates of TSI       
pursuant to the terms of this Agreement, and to issue appropriate stop transfer 
instructions to the transfer agent for the Eclipsys Voting Common Stock,        
consistent with the terms of the Affiliate Agreements (provided that such       
legends or stop transfer instructions shall be removed, two years after the     
Effective Date, upon the request of any stockholder that is not then an         
Affiliate of Eclipsys).                                                         

SECTION 6.11 Nasdaq Quotation.  Eclipsys shall use its best efforts to
cause the shares of Eclipsys Voting Common Stock to be issued in the Merger to  
be approved for quotation on the Nasdaq National Market, subject to official    
notice of issuance, prior to the Closing Date.                                  

SECTION 6.12 Stock Plans and Warrants.                                

  (a) At the Effective Time, each outstanding option to purchase shares of
TSI Voting Common Stock (a "TSI Stock Option") under the TSI Stock Plans,       
whether vested or unvested, shall be deemed to constitute an option to acquire, 
but otherwise on the same terms and conditions as were applicable under such TSI
Stock Option, the same number of shares of Eclipsys Voting Common Stock as the  
holder of such TSI Stock Option would have been entitled to receive pursuant to 
the Merger had such holder exercised such option in full immediately prior to   
the Effective Time (rounded downward to the nearest whole number), at a price   
per share (rounded upward to the nearest whole cent) equal to (y) the aggregate 
exercise price for the shares of TSI Voting Common Stock purchasable pursuant to
such TSI Stock Option immediately prior to the Effective Time divided by (z) the
number of full shares of Eclipsys Voting Common Stock deemed purchasable        
pursuant to such TSI Voting Stock Option in accordance with the foregoing. The  
adjustment pursuant to this Section 6.12(a) is intended to comply with Section  
424(a) of the Code with respect to any options which are incentive stock options
and shall be construed consistent with Section 424(a) of the Code.              

    (b) At the Effective Time, each outstanding TSI Warrant shall be deemed to
constitute a warrant to acquire, on the same terms and conditions as were       
applicable under such TSI Warrant, the number of shares of Eclipsys Voting      
Common Stock at the price per share as shall be determined under the existing   
terms of the respective TSI Warrant.                                            

     (c) As soon as practicable after the Effective Time, Eclipsys shall deliver
to the participants in the TSI Stock Plans appropriate notice setting forth such
participants' rights pursuant thereto and the grants pursuant to the TSI Stock  
Plans shall continue in effect on the same terms and conditions (subject to the 
adjustments required by this Section 6.12 after giving effect to the Merger).   

(d) Eclipsys shall take all corporate action necessary to reserve for 
issuance a sufficient number of shares of Eclipsys Voting Common Stock for      
delivery under the TSI Stock Plans assumed in accordance with this Section 6.12 
and the TSI Warrants. As soon as practicable after the Effective Time, Eclipsys 
shall file a registration statement on Form S-8 (or any successor or other      
appropriate forms), or another appropriate form with respect to the shares of   
Eclipsys Voting Common Stock subject to such options, and                       

A-27

S-4
245th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 245th

shall use its best efforts to maintain the effectiveness of such registration   
statement or registration statements (and maintain the current status of the    
prospectus or prospectuses contained therein) for so long as such options remain
outstanding.                                                                    

  (e) The Board of Directors of TSI shall, prior to or as of the Effective
Time, take any necessary actions, pursuant to and in accordance with the terms  
of the TSI Stock Plans and the instruments evidencing the TSI Stock Options, to 
provide for the conversion of the TSI Stock Options into options to acquire     
Eclipsys Voting Common Stock in accordance with this Section 6.12.              

(f) TSI shall terminate its Employee Stock Purchase Plan (the "Stock  
Purchase Plan") as of or prior to the Effective Time; provided, however, that,  
in accordance with Section 17 of the Stock Purchase Plan, said termination shall
not affect the rights of participants in the Stock Purchase Plan to purchase    
shares pursuant to the current offering under the Stock Purchase Plan which     
commenced on October 1, 1998 and which terminates on March 31, 1999. Eclipsys   
and TSI acknowledge and agree that, assuming that the Effective Time of the     
Merger occurs prior to April 1, 1999, participants in the current offering under
the Stock Purchase Plan shall have the right to purchase a number of shares of  
Eclipsys Voting Common Stock determined by applying the Exchange Ratio to the   
number of shares of TSI Voting Common Stock that such participants would have   
been entitled to purchase had the Merger not been completed at such time and    
that such purchase shall occur at an exercise price equal to 85% of the lower of
(x) the market value (determined in accordance with the Stock Purchase Plan) of 
TSI Common Stock as of October 1, 1998 or (y) the product of (I) the Exchange   
Ratio and (II) the market value (determined in accordance with the Stock        
Purchase Plan) of Eclipsys Voting Common Stock as of March 31, 1999, all subject
to and in accordance with the terms of the Stock Purchase Plan.                 

   SECTION 6.13 Brokers or Finders.  Each of Eclipsys and TSI represents, as
to itself, its Subsidiaries and its Affiliates, that no agent, broker,          
investment banker, financial advisor or other firm or person is or will be      
entitled to any broker's or finder's fee or any other commission or similar fee 
in connection with any of the transactions contemplated by this Agreement except
Morgan Stanley & Co. Incorporated, whose fees and expenses will be paid by      
Eclipsys in accordance with Eclipsys' agreement with such firm (a copy of which 
has been delivered by Eclipsys to TSI prior to the date of this Agreement), and 
BT Alex. Brown Incorporated whose fees and expenses will be paid by TSI in      
accordance with TSI's agreement with such firm (a copy of which has been        
delivered by TSI to Eclipsys prior to the date of this Agreement). Each of      
Eclipsys and TSI agrees to indemnify and hold the other harmless from and       
against any and all claims, liabilities or obligations with respect to any such 
fees, commissions or expenses asserted by any person on the basis of any act or 
statement alleged to have been made by such party or any of its Affiliates.     

SECTION 6.14 Indemnification.                                         

  (a) From and after the Effective Time, Eclipsys agrees that it will, and
will cause the Surviving Corporation to, indemnify and hold harmless each       
present and former director and officer of TSI (the "Indemnified Parties"),     
against any costs or expenses (including attorneys' fees), judgments, fines,    
losses, claims, damages, liabilities or amounts paid in settlement              
(collectively, "Costs") incurred in connection with any claim, action, suit,    
proceeding or investigation, whether civil, criminal, administrative or         
investigative, arising out of or pertaining to matters existing or occurring at 
or prior to the Effective Time, whether asserted or claimed prior to, at or     
after the Effective Time, to the fullest extent that TSI would have been        
permitted under Massachusetts law and its articles of organization or bylaws in 
effect on the date hereof to indemnify such Indemnified Party (and Eclipsys and 
the Surviving Corporation shall also advance expenses as incurred to the fullest
extent permitted under applicable law, provided the Indemnified Party to whom   
expenses are advanced provides an undertaking to repay such advances if it is   
ultimately determined that such Indemnified Party is not entitled to            
indemnification).                                                               

(b) For a period of three (3) years after the Effective Time, Eclipsys
shall cause the Surviving Corporation to maintain (to the extent available in   
the market) in effect a directors' and officers' liability insurance policy     
covering those persons who are currently covered by TSI's directors' and        
officers' liability insurance policy (a copy of which has been heretofore       
delivered to Eclipsys) with coverage in amount and                              

A-28

S-4
246th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 246th

scope at least as favorable as TSI's existing coverage; provided, that in no    
event shall Eclipsys or the Surviving Corporation be required to expend in      
excess of 200% of the annual premium currently paid by TSI for such coverage    
(currently $203,500), except to the extent such excess is attributable to       
Eclipsys' claims history or price increases in the market for such insurance    
that is unrelated to TSI specifically; and if such premium would at any time    
exceed such limitation, the Surviving Corporation shall maintain insurance      
policies that provide the maximum and best coverage available at an annual      
premium equal to such limitation; and provided further that, if any legal action
had been pending at any time subsequent to the second anniversary of the        
Effective Time against any person currently covered by TSI's directors' and     
officers' liability insurance policy that would be covered in whole or in part  
by such policy, the Surviving Corporation shall thereafter continue to maintain 
such policy in effect (subject to the foregoing proviso) until the fifth        
anniversary of the Effective Time.                                              

   (c) The provisions of this Section 6.14 are intended to be in addition to
the rights otherwise available to the current officers and directors of TSI by  
law, charter, statute, bylaw or agreement, and shall operate for the benefit of,
and shall be enforceable by, each of the Indemnified Parties, their heirs and   
their representatives.                                                          

SECTION 6.15 Letter of Eclipsys' Accountants.  Eclipsys shall use     
reasonable efforts to cause to be delivered to TSI and Eclipsys a letter of     
PricewaterhouseCoopers LLP, Eclipsys' independent auditors, dated a date within 
two business days before the date on which the Registration Statement shall     
become effective and addressed to TSI, in form reasonably satisfactory to TSI   
and customary in scope and substance for letters delivered by independent public
accountants in connection with registration statements similar to the           
Registration Statement.                                                         

     SECTION 6.16 Letter of TSI's Accountants.  TSI shall use reasonable efforts
to cause to be delivered to Eclipsys and TSI letters of PricewaterhouseCoopers  
LLP, TSI's independent auditors, and Ernst & Young LLP, HealthVISION's auditors,
each dated a date within two business days before the date on which the         
Registration Statement shall become effective and addressed to Eclipsys, in form
reasonably satisfactory to Eclipsys and customary in scope and substance for    
letters delivered by independent public accountants in connection with          
registration statements similar to the Registration Statement.                  

     SECTION 6.17 Warburg Registration Rights Agreement.  Eclipsys shall use its
reasonable efforts to amend its existing Second Amended and Restated            
Registration Rights Agreement, dated January 1998, among Eclipsys and certain of
its stockholders (the "Registration Rights Agreement") (i) to add Warburg as a  
"Designated Holder" (as defined in the Registration Rights Agreement) for all   
purposes of the Registration Rights Agreement and (ii) to provide Warburg with  
one demand registration pursuant to Section 3(a) of the Registration Rights     
Agreement, which demand may not be exercised prior to January 1, 2000. In the   
event Eclipsys is unable for any reason to amend the Registration Rights        
Agreement as provided in the immediately preceding sentence, Eclipsys shall     
enter into a registration rights agreement with Warburg, containing the         
foregoing terms and otherwise substantially identical to the Registration Rights
Agreement, except that the only Designated Holder therein shall be Warburg (such
agreement, either as the amendment to the Registration Rights Agreement or the  
separate registration rights agreement, the "Warburg Registration Rights        
Agreement").                                                                    

ARTICLE VII 

CONDITIONS TO MERGER

SECTION 7.01 Conditions to Each Party's Obligation To Effect the      
Merger.  The respective obligations of each party to this Agreement to effect   
the Merger shall be subject to the satisfaction prior to the Closing Date of the
following conditions:                                                           

       (a) Stockholder Approval.  This Agreement and the Merger shall have
been approved and adopted by the affirmative vote of the holders of   
 two-thirds of the outstanding shares of TSI Voting Common Stock and the
    Eclipsys Voting Proposals shall have been approved by the affirmative vote
of                                                                    

A-29

S-4
247th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 247th

the holders of a majority of the shares of Eclipsys Voting Common Stock present 
or represented at the Eclipsys Stockholders' Meeting at which a quorum is       
present.                                                                        

          (b) HSR Act.  The waiting period applicable to the consummation of the
Merger under the HSR Act shall have expired or been terminated.       

       (c) Approvals.  Other than the filing provided for by Section 1.01,
  all authorizations, consents, orders or approvals of, or declarations or
filings with, or expirations of waiting periods imposed by, any       
Governmental Entity the failure of which to file, obtain or occur is  
reasonably likely to have an Eclipsys Material Adverse Effect or a TSI
   Material Adverse Effect shall have been filed, been obtained or occurred.

      (d) Registration Statement.  The Registration Statement shall have
   become effective under the Securities Act and shall not be the subject of
any stop order or proceedings seeking a stop order.                   

    (e) No Injunctions.  No Governmental Entity or federal, state or
foreign court of competent jurisdiction shall have enacted, issued,   
    promulgated, enforced or entered any order, executive order, stay, decree,
     judgment or injunction (each an "Order") or statute, rule, regulation which
is in effect and which has the effect of making the Merger illegal or 
otherwise prohibiting consummation of the Merger.                     

     (f) Pooling Letters.  Eclipsys and TSI shall each have received a
letter from PricewaterhouseCoopers LLP addressed to Eclipsys and TSI, 
     respectively, regarding its concurrence with management's conclusions as to
 the appropriateness of pooling-of-interests accounting under Accounting
Principles Board Opinion No. 16 for the Merger, as contemplated to be 
  effected as of the date of the letter, it being agreed that Eclipsys and
 TSI shall each provide reasonable cooperation to PricewaterhouseCoopers
LLP, to enable them to issue such a letter.                           

        (g) Nasdaq.  The shares of Eclipsys Voting Common Stock to be issued
     in the Merger shall have been approved for quotation on the Nasdaq National
Market.                                                               

     SECTION 7.02 Additional Conditions to Obligations of Eclipsys and Sub.  The
obligations of Eclipsys and Sub to effect the Merger are subject to the         
satisfaction of each of the following conditions, any of which may be waived in 
writing exclusively by Eclipsys:                                                

(a) Representations and Warranties.  The representations and
    warranties of TSI set forth in this Agreement shall be true and correct as
of the date of this Agreement and (except to the extent such          
representations and warranties speak as of an earlier date) as of the 
   Closing Date as though made on and as of the Closing Date, except (i) for
changes contemplated by this Agreement and (ii) in the case of        
  representations and warranties that are not qualified as to materiality,
where the failures to be true and correct, individually or in the     
aggregate, have not had and are not reasonably likely to have a TSI   
    Material Adverse Effect or a material adverse effect upon the consummation
     of the transactions contemplated hereby; and Eclipsys shall have received a
    certificate signed on behalf of TSI by the chief executive officer and the
chief financial officer of TSI to such effect.                        

       (b) Performance of Obligations of TSI.  TSI shall have performed in
    all material respects all obligations required to be performed by it under
 this Agreement at or prior to the Closing Date; and Eclipsys shall have
received a certificate signed on behalf of TSI by the chief executive 
officer and the chief financial officer of TSI to such effect.        

         (c) Tax Opinion.  Eclipsys shall have received a written opinion from
    Hale and Dorr LLP, counsel to Eclipsys, to the effect that the Merger will
 be treated for Federal income tax purposes as a tax-free reorganization
within the meaning of Section 368(a) of the Code.                     

       (d) Dissenting Shares.  The total number of Dissenting Shares shall
  not be greater than 5% of the total number of shares of TSI Common Stock
outstanding immediately prior to the Effective Date.                  

A-30

S-4
248th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 248th

   SECTION 7.03 Additional Conditions to Obligations of TSI.  The obligation
of TSI to effect the Merger is subject to the satisfaction of each of the       
following conditions, any of which may be waived in writing exclusively by TSI: 

(a) Representations and Warranties.  The representations and
  warranties of Eclipsys and Sub set forth in this Agreement shall be true
     and correct as of the date of this Agreement and (except to the extent such
representations speak as of an earlier date) as of the Closing Date as
though made on and as of the Closing Date, except (i) for changes     
    contemplated by this Agreement and (ii) in the case of representations and
    warranties that are not qualified as to materiality, where the failures to
     be true and correct, individually or in the aggregate, have not had and are
not reasonably likely to have an Eclipsys Material Adverse Effect or a
material adverse effect upon the consummation of the transactions     
  contemplated hereby; and TSI shall have received a certificate signed on
   behalf of Eclipsys by the chief executive officer and the chief financial
officer of Eclipsys to such effect.                                   

         (b) Performance of Obligations of Eclipsys and Sub.  Eclipsys and Sub
   shall have performed in all material respects all obligations required to
    be performed by them under this Agreement at or prior to the Closing Date,
   and TSI shall have received a certificate signed on behalf of Eclipsys by
    the chief executive officer and the chief financial officer of Eclipsys to
such effect.                                                          

          (c) Tax Opinion.  TSI shall have received the opinion of Foley, Hoag &
  Eliot LLP, counsel to TSI, to the effect that the Merger will be treated
 for Federal income tax purposes as a tax-free reorganization within the
meaning of Section 368(a) of the Code.                                

   (d) Warburg Registration Rights Agreement.  Eclipsys shall have
executed and delivered the Warburg Registration Rights Agreement.     

ARTICLE VIII

TERMINATION AND AMENDMENT 

 SECTION 8.01 Termination.  This Agreement may be terminated at any time
prior to the Effective Time (with respect to Sections 8.01(b) through 8.01(g),  
by written notice by the terminating party to the other party), whether before  
or after approval of the matters presented in connection with the Merger by the 
stockholders of TSI or Eclipsys:                                                

(a) by mutual written consent of Eclipsys and TSI; or       

   (b) by either Eclipsys or TSI if the Merger shall not have been
     consummated by April 30, 1999 (the "Outside Date") (provided that the right
to terminate this Agreement under this Section 8.01(b) shall not be   
   available to any party whose failure to fulfill any obligation under this
     Agreement has been the cause of or resulted in the failure of the Merger to
occur on or before such date); or                                     

         (c) by either Eclipsys or TSI if a court of competent jurisdiction or
  other Governmental Entity shall have issued a nonappealable final order,
 decree or ruling or taken any other nonappealable final action, in each
   case having the effect of permanently restraining, enjoining or otherwise
prohibiting the Merger; or                                            

        (d) by Eclipsys, if, at the TSI Stockholders' Meeting (including any
     adjournment or postponement), the requisite vote of the stockholders of TSI
    in favor of this Agreement and the Merger shall not have been obtained; or
     by TSI if, at the Eclipsys Stockholders' Meeting (including any adjournment
 or postponement), the requisite vote of the stockholders of Eclipsys in
 favor of the Eclipsys Voting Proposals shall not have been obtained; or

    (e) by Eclipsys, if (i) the Board of Directors of TSI shall have
     withdrawn or modified in a manner adverse to Eclipsys its recommendation of
     this Agreement or the Merger; (ii) the Board of Directors of TSI shall have
recommended to the stockholders of TSI an Alternative Transaction (as 
     defined in Section 8.03(h)); (iii) a tender offer or exchange offer for 15%
or more of the outstanding                                            

A-31

S-4
249th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 249th

shares of TSI Voting Common Stock is commenced (other than by Eclipsys or an    
Affiliate of Eclipsys) and the Board of Directors of TSI recommends that the    
stockholders of TSI tender their shares in such tender or exchange offer; or    
(iv) for any reason (other than by reason of the Joint Proxy Statement not      
having been cleared by the SEC) TSI fails to call and hold the TSI Stockholders'
Meeting by the Outside Date (provided that Eclipsys' right to terminate this    
Agreement under such clause (iv) shall not be available if at such time TSI     
would be entitled to terminate this Agreement under Section 8.01(h)); or        

    (f) by TSI, if (i) the Board of Directors of Eclipsys shall have
     withdrawn or modified in a manner adverse to TSI its recommendation of this
   Agreement, the Merger or the Eclipsys Voting Proposals; (ii) the Board of
Directors of Eclipsys shall have recommended to the stockholders of   
     Eclipsys an Alternative Transaction; (iii) a tender offer or exchange offer
   for 15% or more of the outstanding shares of Eclipsys Voting Common Stock
  is commenced (other than by TSI or an Affiliate of TSI) and the Board of
   Directors of Eclipsys recommends that the stockholders of Eclipsys tender
     their shares in such tender offer or exchange offer; or (iv) for any reason
    (other than by reason of the Joint Proxy Statement not having been cleared
by the SEC) Eclipsys fails to call and hold the Eclipsys Stockholders'
  Meeting by the Outside Date (provided that TSI's right to terminate this
 Agreement under such clause (iv) shall not be available if at such time
Eclipsys would be entitled to terminate this Agreement under Section  
8.01(h)); or                                                          

      (g) by TSI, if the Board of Directors of TSI accepts or approves a
     Superior Proposal, or recommends a Superior Proposal to the stockholders of
TSI; or                                                               

(h) by Eclipsys or TSI, if there has been a breach of any   
  representation, warranty, covenant or agreement on the part of the other
 party set forth in this Agreement, any of which breaches (i) causes the
    conditions set forth in Section 7.02(a) or (b) (in the case of termination
     by Eclipsys) or 7.03(a), (b) or (d) (in the case of termination by TSI) not
     to be satisfied, and (ii) shall not have been cured within 20 business days
   following receipt by the breaching party of written notice of such breach
from the other party.                                                 

  SECTION 8.02 Effect of Termination.  In the event of termination of this
Agreement as provided in Section 8.01, this Agreement shall immediately become  
void and there shall be no liability or obligation on the part of Eclipsys, TSI,
Sub or their respective officers, directors, stockholders or Affiliates, except 
as set forth in Section 8.03; provided, that no such termination shall limit or 
otherwise relieve the liability of any party for any breach of this Agreement   
(except to the extent that liability may be limited by Section 8.03(c) or       
Section 8.03(e) below); and provided further, that the provisions of Section    
8.03 of this Agreement and the Confidentiality Agreement shall remain in full   
force and effect and survive any termination of this Agreement.                 

SECTION 8.03 Fees and Expenses.                                       

(a) Except as set forth in this Section 8.03, all fees and expenses   
incurred in connection with this Agreement and the transactions contemplated    
hereby shall be paid by the party incurring such expenses, whether or not the   
Merger is consummated; provided, however, that TSI and Eclipsys shall share     
equally all fees and expenses, other than attorneys' fees, incurred in relation 
to the printing and filing of the Joint Proxy Statement (including any related  
preliminary materials) and the Registration Statement (including financial      
statements and exhibits) and any amendments or supplements.                     

   (b) TSI shall pay Eclipsys up to $2,000,000 as reimbursement for expenses
of Eclipsys actually incurred relating to the transactions contemplated by this 
Agreement prior to termination (including, but not limited to, fees and expenses
of Eclipsys' counsel, accountants and financial advisors, but excluding any     
discretionary fees paid to such financial advisors), upon the termination of    
this Agreement by Eclipsys pursuant to Section 8.01(d) as a result of the       
failure to receive the requisite vote for approval of this Agreement and the    
Merger by the stockholders of TSI at the TSI Stockholders' Meeting, Section     
8.01(e), Section 8.01(g) or Section 8.01(h) as a result of a breach by TSI of   
any of the covenants set forth in any                                           

A-32

S-4
250th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 250th

of Sections 5.01, 5.04, 6.01, 6.02, 6.03, 6.04, 6.05, 6.06, 6.07, 6.08, 6.09,   
6.10, 6.16 or 6.18 of this Agreement (collectively, the "TSI Material           
Covenants").                                                                    

(c) TSI shall pay Eclipsys a termination fee of $9,100,000 upon the   
earliest to occur of the following events (each an "Eclipsys Termination Fee    
Event"):                                                                        

         (i) the termination of this Agreement by Eclipsys pursuant to Section
8.01(e); or                                                           

          (ii) the termination of this Agreement by Eclipsys pursuant to Section
8.01(h) after a breach by TSI of any of the TSI Material Covenants; or

        (iii) consummation of an Alternative Transaction with respect to TSI
  within twelve (12) months following the failure to receive the requisite
   vote for approval of this Agreement and the Merger by the stockholders of
   TSI at the TSI Stockholders' Meeting if, at the time of such failure, any
     Alternative Transaction relating to TSI had been announced and had not been
absolutely and unconditionally withdrawn and abandoned; or            

     (iv) the termination of this Agreement by TSI pursuant to Section
8.01(h).                                                              

Notwithstanding the foregoing, any amount payable pursuant to this Section      
8.03(c) shall be reduced, on a dollar-for-dollar basis, by any amount           
theretofore paid to Eclipsys pursuant to Section 8.03(b). TSI agrees that it    
will not structure any transaction or agreement for the purpose of avoiding     
payment of the termination fee required by this Section 8.03(c). TSI further    
acknowledges that the agreements contained in this Section 8.03(c) are an       
integral part of the transactions contemplated by this Agreement, and that,     
without these agreements, Eclipsys would not enter into this Agreement;         
accordingly, if TSI fails to promptly pay the amount due pursuant to this       
Section 8.03(c), and, in order to obtain such payment, Eclipsys commences a suit
which results in a judgment against TSI for the fee set forth in this Section   
8.03(c), TSI shall pay to Eclipsys its costs and expenses (including fees and   
disbursements of counsel) in connection with such suit, together with interest  
on the amount of the termination fee at the prime rate of Citibank, N.A. on the 
date such payment was required to be made. Eclipsys and TSI further acknowledge 
and agree that it may be difficult and impractical to measure in money the      
damages which will accrue by reason of the occurrence of an Eclipsys Termination
Fee Event. Therefore, Eclipsys and TSI agree that payment of the termination fee
and any other fees, costs or expenses due under this Section 8.03(c) shall      
constitute liquidated damages and not a penalty and shall further constitute the
sole and exclusive remedy of Eclipsys for any losses, damages, claims, costs or 
expenses arising from the occurrence of any Eclipsys Termination Fee Event.     

   (d) Eclipsys shall pay TSI up to $2,000,000 as reimbursement for expenses
of TSI actually incurred relating to the transactions contemplated by this      
Agreement prior to termination (including, but not limited to, fees and expenses
of TSI's counsel, accountants and financial advisors, but excluding any         
discretionary fees paid to such financial advisors), upon the termination of    
this Agreement by TSI pursuant to Section 8.01(d) as a result of the failure to 
receive the requisite vote for approval of the Eclipsys Voting Proposals by the 
stockholders of Eclipsys at the Eclipsys Stockholders' Meeting, Section 8.01(f) 
or Section 8.01(h) as a result of a breach by Eclipsys of any of the covenants  
set forth in Sections 5.02, 6.01, 6.03, 6.04, 6.05, 6.06, 6.07, 6.08, 6.09,     
6.10, 6.11, 6.12, 6.15, 6.17 or 6.18 of this Agreement (collectively, the       
"Eclipsys Material Covenants").                                                 

(e) Eclipsys shall pay TSI a termination fee of $9,100,000 upon the   
earliest to occur of the following events (each a "TSI Termination Fee Event"): 

    (i) the termination of this Agreement by TSI pursuant to Section
8.01(f), or                                                           

     (ii) the termination of this Agreement by TSI pursuant to Section
8.01(g) after a breach by Eclipsys of any of the Eclipsys Material    
Covenants; or                                                         

    (iii) consummation of an Alternative Transaction with respect to
 Eclipsys within twelve (12) months following the failure to receive the
requisite vote for approval of the Eclipsys Voting Proposals by the   
   stockholders of Eclipsys at the Eclipsys Stockholders' Meeting if, at the
time of such                                                          

A-33

S-4
251st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 251st

failure, any Alternative Transaction relating to Eclipsys had been    
 announced and had not been absolutely and unconditionally withdrawn and
abandoned.                                                            

Notwithstanding the foregoing, any amount payable pursuant to this Section      
8.03(e) shall be reduced, on a dollar-for-dollar basis, by any amount           
theretofore paid to TSI pursuant to Section 8.03(d). Eclipsys agrees that it    
will not structure any transaction or agreement for the purpose of avoiding     
payment of the termination fee required by this Section 8.03(e). Eclipsys       
further acknowledges that the agreements contained in this Section 8.03(e) are  
an integral part of the transactions contemplated by this Agreement, and that,  
without these agreements, TSI would not enter into this Agreement; accordingly, 
if Eclipsys fails to promptly pay the amount due pursuant to this Section       
8.03(e), and, in order to obtain such payment, TSI commences a suit which       
results in a judgment against Eclipsys for the fee set forth in this Section    
8.03(e), Eclipsys shall pay to TSI its costs and expenses (including fees and   
disbursements of counsel) in connection with such suit, together with interest  
on the amount of the termination fee at the prime rate of Citibank, N.A. on the 
date such payment was required to be made. Eclipsys and TSI further acknowledge 
and agree that it may be difficult and impractical to measure in money the      
damages which will accrue by reason of the occurrence of a TSI Termination Fee  
Event. Therefore, Eclipsys and TSI agree that payment of the termination fee and
any other fees, costs or expenses due under this Section 8.03(e) shall          
constitute liquidated damages and not a penalty and shall further constitute the
sole and exclusive remedy of TSI for any losses, damages, claims, costs or      
expenses arising from the occurrence of any TSI Termination Fee Event.          

(g) The expenses and fees, if applicable, payable pursuant to Section 
8.03(b), 8.03(c), 8.03(d) and 8.03(e) shall be paid within one business day     
after the first to occur of the events described in Section 8.03(b), 8.03(c),   
8.03(d) or 8.03(e)(i), (ii) or (iii); provided that in no event shall Eclipsys  
or TSI, as the case may be, be required to pay the expenses and fees, if        
applicable, to the other, if, immediately prior to the termination of this      
Agreement, the party to receive the expenses and fees, if applicable, was in    
material breach of its obligations under this Agreement.                        

     (h) As used in this Agreement, "Alternative Transaction" means any of (i) a
transaction other than an Eclipsys Permitted Acquisition pursuant to which any  
person (or group of persons) other than Eclipsys or TSI or their respective     
affiliates (a "Third Party"), acquires more than 15% of the outstanding shares  
of TSI Voting Common Stock or Eclipsys Voting Common Stock, as the case may be, 
pursuant to a tender offer or exchange offer or otherwise, (ii) a merger or     
other business combination involving Eclipsys or TSI other than an Eclipsys     
Permitted Acquisition pursuant to which any Third Party acquires more than 15%  
of the outstanding equity securities of Eclipsys or TSI or the entity surviving 
such merger or business combination, (iii) any other transaction other than an  
Eclipsys Permitted Acquisition pursuant to which any Third Party acquires       
control of assets (including for this purpose the outstanding equity securities 
of Subsidiaries of Eclipsys or TSI, and the entity surviving any merger or      
business combination including any of them) of Eclipsys or TSI having a fair    
market value (as determined by the Board of Directors of Eclipsys or TSI, as the
case may be, in good faith) equal to more than 15% of the fair market value of  
all the assets of Eclipsys or TSI and its Subsidiaries, taken as a whole,       
immediately prior to such transaction, or (iv) any public announcement of a     
proposal, plan or intention to do any of the foregoing or any agreement to      
engage in any of the foregoing.                                                 

SECTION 8.04 Amendment.  This Agreement may be amended by the parties 
hereto, by action taken or authorized by their respective Boards of Directors,  
at any time before or after approval of the matters presented in connection with
the Merger by the stockholders of TSI or of Eclipsys, but, after any such       
approval, no amendment shall be made which by law requires further approval by  
such stockholders without such further approval. This Agreement may not be      
amended except by an instrument in writing signed on behalf of each of the      
parties hereto.                                                                 

   SECTION 8.05 Extension; Waiver.  At any time prior to the Effective Time,
the parties hereto, by action taken or authorized by their respective Boards of 
Directors, may, to the extent legally allowed, (i) extend the time for the      
performance of any of the obligations or other acts of the other parties hereto,
(ii) waive any inaccuracies in the representations and warranties contained     
herein or in any document                                                       

A-34

S-4
252nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 252nd

delivered pursuant hereto and (iii) waive compliance with any of the agreements 
or conditions contained herein. Any agreement on the part of a party hereto to  
any such extension or waiver shall be valid only if set forth in a written      
instrument signed on behalf of such party.                                      

ARTICLE IX

MISCELLANEOUS 

SECTION 9.01 Nonsurvival of Representations, Warranties and           
Agreements.  None of the representations, warranties and agreements in this     
Agreement or in any instrument delivered pursuant to this Agreement shall       
survive the Effective Time, except for the agreements contained in Sections     
1.04, 2.01, 2.02, 6.12, 6.14, 8.03 and Article IX, and the agreements of the    
Affiliates delivered pursuant to Section 6.10. The Confidentiality Agreement    
shall survive the execution and delivery of this Agreement.                     

     SECTION 9.02 Notices.  All notices and other communications hereunder shall
be in writing and shall be deemed given if delivered personally, telecopied     
(which is confirmed) or mailed by registered or certified mail (return receipt  
requested) to the parties at the following addresses (or at such other address  
for a party as the party shall specify by like notice):                         

(a) if to Eclipsys or Sub, to                                   

Eclipsys Corporation                                    
777 East Atlantic Avenue                                
Suite 200                                               
Delray Beach, FL 33483                                  
Attn: Chief Executive Officer                           
Telecopy: (561) 243-8850                                

with a copy to:                                         

Eclipsys Corporation                                    
777 East Atlantic Avenue                                
Suite 200                                               
Delray Beach, FL 33483                                  
Attn: General Counsel                                   
Telecopy: (561) 243-8850                                

(b) if to TSI, to                                               

Transition Systems, Inc.                                
One Boston Place                                        
Boston, MA 02108                                        
Attn: Chief Executive Officer                           
Telecopy: (617) 723-8700                                

with a copy to:                                         

Foley, Hoag & Eliot LLP                                 
One Post Office Square                                  
Boston, MA 02109                                        
Attn: Robert W. Sweet, Jr., Esq.                        
Telecopy: (617) 832-7000                                

     SECTION 9.03 Interpretation.  When a reference is made in this Agreement to
Sections, such reference shall be to a Section of this Agreement unless         
otherwise indicated. The table of contents and headings contained in this       
Agreement are for reference purposes only and shall not affect in any way the   
meaning or interpretation of this Agreement. Whenever the words "include,"      
"includes" or "including" are used in this Agreement they shall be deemed to be 
followed by the words "without limitation." The phrase                          

A-35

S-4
253rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 253rd

"made available" in this Agreement shall mean that the information referred to  
has been made available if requested by the party to whom such information is to
be made available. The phrases "the date of this Agreement," "the date hereof," 
and terms of similar import, unless the context otherwise requires, shall be    
deemed to refer to October 29, 1998.                                            

   SECTION 9.04 Counterparts.  This Agreement may be executed in two or more
counterparts, all of which shall be considered one and the same agreement and   
shall become effective when two or more counterparts have been signed by each of
the parties and delivered to the other parties, it being understood that all    
parties need not sign the same counterpart.                                     

SECTION 9.05 Entire Agreement; No Third Party Beneficiaries.  This    
Agreement (including the documents and the instruments referred to herein) (a)  
constitutes the entire agreement and supersedes all prior agreements and        
understandings, both written and oral, among the parties with respect to the    
subject matter hereof, and (b) except as provided in Section 6.14 is not        
intended to confer upon any person other than the parties hereto any rights or  
remedies hereunder; provided that the Confidentiality Agreement shall remain in 
full force and effect until the Effective Time. Each party hereto agrees that,  
except for the representations and warranties contained in this Agreement,      
neither TSI nor Eclipsys makes any other representations or warranties, and each
hereby disclaims any other representations and warranties made by itself or any 
of its officers, directors, employees, agents, financial and legal advisors or  
other representatives, with respect to the execution and delivery of this       
Agreement or the transactions contemplated hereby, notwithstanding the delivery 
or disclosure to the other or the other's representatives of any documentation  
or other information with respect to any one or more of the foregoing.          

SECTION 9.06 Governing Law.  This Agreement shall be governed by and  
construed in accordance with the laws of the State of Delaware without regard to
any applicable principles of conflicts of law.                                  

 SECTION 9.07 Assignment.  Neither this Agreement nor any of the rights,
interests or obligations hereunder shall be assigned by any of the parties      
hereto (whether by operation of law or otherwise) without the prior written     
consent of the other parties. Subject to the preceding sentence, this Agreement 
will be binding upon, inure to the benefit of and be enforceable by the parties 
and their respective successors and assigns.                                    

[Remainder of page intentionally left blank.] 

A-36

S-4
254th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 254th

    IN WITNESS WHEREOF, Eclipsys, Sub and TSI have caused this Agreement to be
signed by their respective officers thereunto duly authorized as of the date    
first written above.                                                            

                                                                [Download Table]
                                                            

                        Eclipsys Corporation                
                      By: /s/ HARVEY J. WILSON              
[seal]  ----------------------------------------------------
                             President                      
                     By: /s/ ROBERT J. VANARIA              
        ----------------------------------------------------
                             Treasurer                      

                     Eclipsys Acquisition Corp.             
[seal]                By: /s/ HARVEY J. WILSON              
        ----------------------------------------------------
                             President                      
                     By: /s/ ROBERT J. VANARIA              
        ----------------------------------------------------
                             Treasurer                      

                      Transition Systems, Inc.              
[seal]                 By: /s/ ROBERT F. RACO               
        ----------------------------------------------------
                             President                      
                      By: /s/ PAULA J. MALZONE              
        ----------------------------------------------------
                             Treasurer                      

A-37

S-4
255th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 255th

                                                                     EXHIBIT A-1

                                              TSI STOCKHOLDERS' VOTING AGREEMENT

VOTING AGREEMENT

   VOTING AGREEMENT (the "Agreement"), dated as of October 29, 1998, between
              (the "Stockholder"), who is a stockholder of Transition Systems,
Inc., a Massachusetts corporation (the "Company"), and Eclipsys Corporation, a  
Delaware corporation ("Buyer").                                                 

  WHEREAS, concurrently with the execution of this Agreement, the Company,
Buyer and a wholly-owned subsidiary of Buyer ("Sub") have entered into an       
Agreement and Plan of Merger (as the same may be amended from time to time, the 
"Merger Agreement"), providing for the merger (the "Merger") of Sub with and    
into the Company pursuant to the terms and conditions of the Merger Agreement;  
and                                                                             

WHEREAS, the Stockholder owns of record and beneficially the number of
shares of capital stock of the Company set forth beneath his signature below    
(the "Shares") and wishes to enter into this Agreement with respect to all of   
such Shares; and                                                                

   WHEREAS, in order to induce Buyer to enter into the Merger Agreement, the
Stockholder has agreed, upon the terms and subject to the conditions set forth  
herein, to vote the Shares and to deliver an irrevocable proxy to Buyer to vote 
the Shares at a meeting of the Company's stockholders, in favor of approval and 
adoption of the Merger Agreement and the Merger.                                

NOW THEREFORE, for good and valuable consideration, the receipt,      
sufficiency and adequacy of which is hereby acknowledged, the parties hereto    
agree as follows:                                                               

        1. Agreement to Vote Shares.  The Stockholder agrees during the term
    of this Agreement to vote the Stockholder's Shares, in person or by proxy,
     in favor of approval and adoption of the Merger Agreement and the Merger at
    every meeting of the stockholders of the Company at which such matters are
considered and at every adjournment thereof. The Stockholder agrees to
     deliver to Buyer upon request immediately prior to any vote contemplated by
   clause (a) or (b) above a proxy substantially in the form attached hereto
     as Annex A (a "Proxy"), which Proxy shall be irrevocable during the term of
   this Agreement to the extent permitted under Massachusetts law, and Buyer
   agrees to vote the Shares subject to each such Proxy in favor of approval
and adoption of the Merger Agreement and the Merger.                  

          2. No Voting Trusts.  The Stockholder agrees that the Stockholder will
 not, nor will the Stockholder permit any entity under the Stockholder's
  control to, deposit any of the Stockholder's Shares in a voting trust or
    subject any of its Shares to any arrangement with respect to the voting of
the Shares inconsistent with this Agreement.                          

       3. Limitation on Dispositions and Proxies.  During the term of this
    Agreement, the Stockholder agrees not to sell, assign, pledge, transfer or
otherwise dispose of, or grant any proxies with respect to (except as 
contemplated by this Agreement) any of the Stockholder's Shares.      

         4. Specific Performance.  Each party hereto acknowledges that it will
    be impossible to measure in money the damage to the other party if a party
    hereto fails to comply with the obligations imposed by this Agreement, and
  that, in the event of any such failure, the other party will not have an
     adequate remedy at law or in damages. Accordingly, each party hereto agrees
   that injunctive relief or other equitable remedy, in addition to remedies
    at law or damages, is the appropriate remedy for any such failure and will
  not oppose the granting of such relief on the basis that the other party
  has an adequate remedy at law. Each party hereto agrees that it will not
     seek, and agrees to waive any requirement for, the securing or posting of a
bond in connection with any other party's seeking or obtaining such   
equitable relief.                                                     

         5. Term of Agreement; Termination.  Subject to Section 9(e), the term
    of this Agreement shall commence on the date hereof and such term and this
Agreement shall terminate upon the earliest to                        

A-38

S-4
256th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 256th

occur of (i) the Effective Time (as defined in the Merger Agreement), and (ii)  
the date on which the Merger Agreement is terminated in accordance with its     
terms. Upon such termination, no party shall have any further obligations or    
liabilities hereunder; provided, that such termination shall not relieve any    
party from liability for any breach of this Agreement prior to such termination.

          6. Representations and Warranties of the Stockholder.  The Stockholder
represents and warrants to Buyer that, as of the date hereof, (a) the 
    Stockholder has full legal power and authority to execute and deliver this
Agreement and the Proxy, and (b) the Stockholder's Shares are free and
clear of all proxies.                                                 

         7. Entire Agreement.  This Agreement supersedes all prior agreements,
written or oral, among the parties hereto with respect to the subject 
matter hereof and contains the entire agreement among the parties with
  respect to the subject matter hereof. This Agreement may not be amended,
supplemented or modified, and no provisions hereof may be modified or 
     waived, except by an instrument in writing signed by all parties hereto. No
  waiver of any provisions hereof by any party shall be deemed a waiver of
     any other provisions hereof by any such party, nor shall any such waiver be
deemed a continuing waiver of any provisions hereof by such party.    

8. Notices.  All notices, requests, claims, demands or other
     communications hereunder shall be in writing and shall be deemed given when
   delivered personally, upon receipt of a transmission confirmation if sent
by facsimile or like transmission (with confirmation) and on the next 
    business day when sent by Federal Express, Express mail or other reputable
    overnight courier service to the parties at the following addresses (or at
such other address for a party as shall be specified by like notice): 

If to Buyer:                                                    

Eclipsys Corporation                                      
777 East Atlantic Avenue                                  
Suite 200                                                 
Delray Beach, FL 33483                                    
Attention: Chief Executive Officer                        
Fax: (561) 243-8850                                       

With a copy to:                                                 

Eclipsys Corporation                                      
777 East Atlantic Avenue                                  
Suite 200                                                 
Delray Beach, FL 33483                                    
Attention: General Counsel                                
Fax: (561) 243-8850                                       

If to Stockholder:                                              

With a copy to:                                                 

Foley, Hoag & Eliot LLP                                   
One Post Office Square                                    
Boston, MA 02109                                          
Attention: Robert W. Sweet, Jr., Esq.                     
Fax: (617) 832-7000                                       

A-39

S-4
257th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 257th

9. Miscellaneous.                                           

         (a) This Agreement shall be deemed a contract made under, and for all
purposes shall be construed in accordance with, the laws of The       
  Commonwealth of Massachusetts, without reference to its conflicts of law
principles.                                                           

     (b) If any provision of this Agreement or the application of such
provision to any person or circumstances shall be held invalid or     
unenforceable by a court of competent jurisdiction, such provision or 
     application shall be unenforceable only to the extent of such invalidity or
   unenforceability, and the remainder of the provisions not held invalid or
unenforceable and the application of such provisions to persons or    
    circumstances other than the party as to which it is held invalid, and the
remainder of this Agreement, shall not be affected.                   

        (c) This Agreement may be executed in one or more counterparts, each
    of which shall be deemed to be an original but all of which together shall
constitute one and the same instrument.                               

         (d) All Section headings herein are for convenience of reference only
    and are not part of this Agreement, and no construction or reference shall
be derived therefrom.                                                 

      (e) The obligations of the Stockholder set forth in this Agreement
 shall not be effective or binding upon the Stockholder until after such
time as the Merger Agreement is executed and delivered by the Company,
     Buyer and Sub, and the parties agree that there is not and has not been any
  other agreement, arrangement or understanding between the parties hereto
with respect to the matters set forth herein.                         

[Signature page follows]

A-40

S-4
258th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 258th

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this
Agreement as of the date first written above.                                   

                        Eclipsys Corporation

       By:
                                            ------------------------------------
                 Name:
                  Title:

               STOCKHOLDER

                                          --------------------------------------

                                          --------------------------------------
                                         Signature

           Shares:
                                              ----------------------------------

                                              ----------------------------------

A-41

S-4
259th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 259th

                                                                       (ANNEX A)

PROXY 

The undersigned, for consideration received, hereby appoints Eclipsys 
Corporation, a Delaware corporation ("Buyer"), its proxy to vote all shares of  
capital stock owned by the undersigned which the undersigned is entitled to vote
at any meeting of stockholders of Transition Systems, Inc., a Massachusetts     
corporation (the "Company"), and at any adjournment thereof, to be held for the 
purpose of voting upon a proposal to approve and adopt the Agreement and Plan of
Merger, dated as of October 29, 1998 (the "Merger Agreement"), by and among the 
Company, Buyer and a wholly-owned subsidiary of Buyer ("Sub"), providing for the
merger (the "Merger") of Sub with and into the Company, FOR such proposal and   
AGAINST any Acquisition Proposal that is not a Superior Proposal (as such terms 
are defined in the Merger Agreement). This proxy is subject to the terms of the 
Voting Agreement dated as of October 29, 1998 between the undersigned and Buyer,
a copy of such Agreement being attached hereto (the "Voting Agreement"), is     
coupled with an interest and revokes all prior proxies granted by the           
undersigned with respect to such shares, is irrevocable and shall terminate and 
be of no further force or effect automatically at such time as the Voting       
Agreement terminates in accordance with its terms.                              

                           Dated: October 29, 1998

               STOCKHOLDER

                                          --------------------------------------

                                          --------------------------------------
                                         Signature

A-42

S-4
260th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 260th

                                                                     EXHIBIT A-2

                                         ECLIPSYS STOCKHOLDERS' VOTING AGREEMENT

VOTING AGREEMENT

   VOTING AGREEMENT (the "Agreement"), dated as of October 29, 1998, between
   (the "Stockholder"), who is a stockholder of Eclipsys
Corporation, a Delaware corporation ("Buyer"), and Transition Systems, Inc., a  
Massachusetts corporation (the "Company").                                      

  WHEREAS, concurrently with the execution of this Agreement, the Company,
Buyer and a wholly-owned subsidiary of Buyer ("Sub") have entered into an       
Agreement and Plan of Merger (as the same may be amended from time to time, the 
"Merger Agreement"), providing for the merger (the "Merger") of Sub with and    
into the Company pursuant to the terms and conditions of the Merger Agreement;  
and                                                                             

WHEREAS, the Stockholder owns of record and beneficially the number of
shares of capital stock of Buyer set forth beneath his signature below (the     
"Shares") and wishes to enter into this Agreement with respect to all of such   
Shares; and                                                                     

     WHEREAS, in order to induce the Company to enter into the Merger Agreement,
the Stockholder has agreed, upon the terms and subject to the conditions set    
forth herein, to vote the Shares and to deliver an irrevocable proxy to the     
Company to vote the Shares at a meeting of Buyer's stockholders, in favor of the
Eclipsys Voting Proposals (as defined in the Merger Agreement) pursuant to the  
terms of the Merger Agreement.                                                  

NOW THEREFORE, for good and valuable consideration, the receipt,      
sufficiency and adequacy of which is hereby acknowledged, the parties hereto    
agree as follows:                                                               

        1. Agreement to Vote Shares.  The Stockholder agrees during the term
    of this Agreement to vote the Stockholder's Shares, in person or by proxy,
in favor of the Eclipsys Voting Proposals at every meeting of the     
 stockholders of Buyer at which such matters are considered and at every
    adjournment thereof. The Stockholder agrees to deliver to the Company upon
    request immediately prior to any vote contemplated by this section a proxy
 substantially in the form attached hereto as Annex A (a "Proxy"), which
    Proxy shall be irrevocable during the term of this Agreement to the extent
 permitted under Delaware law, and the Company agrees to vote the Shares
    subject to each such Proxy in favor of approval and adoption of the Merger
Agreement and the Merger.                                             

          2. No Voting Trusts.  The Stockholder agrees that the Stockholder will
 not, nor will the Stockholder permit any entity under the Stockholder's
  control to, deposit any of the Stockholder's Shares in a voting trust or
    subject any of its Shares to any arrangement with respect to the voting of
the Shares inconsistent with this Agreement.                          

       3. Limitation on Dispositions and Proxies.  During the term of this
    Agreement, the Stockholder agrees not to sell, assign, pledge, transfer or
otherwise dispose of, or grant any proxies with respect to (except as 
contemplated by this Agreement) any of the Stockholder's Shares.      

         4. Specific Performance.  Each party hereto acknowledges that it will
    be impossible to measure in money the damage to the other party if a party
    hereto fails to comply with the obligations imposed by this Agreement, and
  that, in the event of any such failure, the other party will not have an
     adequate remedy at law or in damages. Accordingly, each party hereto agrees
   that injunctive relief or other equitable remedy, in addition to remedies
    at law or damages, is the appropriate remedy for any such failure and will
  not oppose the granting of such relief on the basis that the other party
  has an adequate remedy at law. Each party hereto agrees that it will not
     seek, and agrees to waive any requirement for, the securing or posting of a
bond in connection with any other party's seeking or obtaining such   
equitable relief.                                                     

         5. Term of Agreement; Termination.  Subject to Section 9(e), the term
    of this Agreement shall commence on the date hereof and such term and this
Agreement shall terminate upon the earliest to                        

A-43

S-4
261st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 261st

occur of (i) the Effective Time (as defined in the Merger Agreement), and (ii)  
the date on which the Merger Agreement is terminated in accordance with its     
terms. Upon such termination, no party shall have any further obligations or    
liabilities hereunder; provided, that such termination shall not relieve any    
party from liability for any breach of this Agreement prior to such termination.

          6. Representations and Warranties of the Stockholder.  The Stockholder
     represents and warrants to the Company that, as of the date hereof, (a) the
    Stockholder has full legal power and authority to execute and deliver this
Agreement and the Proxy, and (b) the Stockholder's Shares are free and
clear of all proxies.                                                 

         7. Entire Agreement.  This Agreement supersedes all prior agreements,
written or oral, among the parties hereto with respect to the subject 
matter hereof and contains the entire agreement among the parties with
  respect to the subject matter hereof. This Agreement may not be amended,
supplemented or modified, and no provisions hereof may be modified or 
     waived, except by an instrument in writing signed by all parties hereto. No
  waiver of any provisions hereof by any party shall be deemed a waiver of
     any other provisions hereof by any such party, nor shall any such waiver be
deemed a continuing waiver of any provisions hereof by such party.    

8. Notices.  All notices, requests, claims, demands or other
     communications hereunder shall be in writing and shall be deemed given when
   delivered personally, upon receipt of a transmission confirmation if sent
by facsimile or like transmission (with confirmation) and on the next 
    business day when sent by Federal Express, Express mail or other reputable
    overnight courier service to the parties at the following addresses (or at
such other address for a party as shall be specified by like notice): 

If to the Company:                                          

Transition Systems, Inc.                                  
One Boston Place                                          
Boston, MA 02108                                          
Attention: Chief Executive Officer                        
Fax: (617) 723-8700                                       

With a copy to:                                             

Foley, Hoag & Eliot LLP                                   
One Post Office Square                                    
Boston, MA 02109                                          
Attention: Robert W. Sweet, Esq.                          
Fax: (617) 832-7000                                       

If to Stockholder:                                          

With a copy to:                                             

Eclipsys Corporation                                      
777 East Atlantic Avenue                                  
Suite 200                                                 
Delray Beach, FL 33483                                    
Attention: General Counsel                                
Fax: (561) 243-8850                                       

A-44

S-4
262nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 262nd

9. Miscellaneous.                                           

         (a) This Agreement shall be deemed a contract made under, and for all
  purposes shall be construed in accordance with, the laws of the State of
Delaware, without reference to its conflicts of law principles.       

     (b) If any provision of this Agreement or the application of such
provision to any person or circumstances shall be held invalid or     
unenforceable by a court of competent jurisdiction, such provision or 
     application shall be unenforceable only to the extent of such invalidity or
   unenforceability, and the remainder of the provisions not held invalid or
unenforceable and the application of such provisions to persons or    
    circumstances other than the party as to which it is held invalid, and the
remainder of this Agreement, shall not be affected.                   

        (c) This Agreement may be executed in one or more counterparts, each
    of which shall be deemed to be an original but all of which together shall
constitute one and the same instrument.                               

         (d) All Section headings herein are for convenience of reference only
    and are not part of this Agreement, and no construction or reference shall
be derived therefrom.                                                 

      (e) The obligations of the Stockholder set forth in this Agreement
 shall not be effective or binding upon the Stockholder until after such
time as the Merger Agreement is executed and delivered by the Company,
     Buyer and Sub, and the parties agree that there is not and has not been any
  other agreement, arrangement or understanding between the parties hereto
with respect to the matters set forth herein.                         

[Signature page follows]

A-45

S-4
263rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 263rd

 IN WITNESS WHEREOF, the parties hereto have executed and delivered this
Agreement as of the date first written above.                                   

                            Transition Systems, Inc.

       By:
                                             -----------------------------------
               Name:
                Title:

               STOCKHOLDER

                                          --------------------------------------

                                          --------------------------------------
                                         Signature

           Shares:
                                                 -------------------------------

                                              ----------------------------------

A-46

S-4
264th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 264th

                                                                       (ANNEX A)

PROXY 

 The undersigned, for consideration received, hereby appoints Transition
Systems, Inc., a Massachusetts corporation (the "Company"), its proxy to vote   
all shares of capital stock owned by the undersigned which the undersigned is   
entitled to vote at any meeting of stockholders of Eclipsys Corporation, a      
Delaware corporation ("Buyer"), and at any adjournment thereof, to be held for  
the purpose of voting upon the Eclipsys Voting Proposals, as such term is       
defined in the Agreement and Plan of Merger, dated as of October 29, 1998 (the  
"Merger Agreement"), by and among the Company, Buyer and a wholly-owned         
subsidiary of Buyer ("Sub"), providing for the merger (the "Merger") of Sub with
and into the Company FOR such proposals. This proxy is subject to the terms of  
the Voting Agreement dated as of October 29, 1998 between the undersigned and   
the Company, a copy of such Agreement being attached hereto (the "Voting        
Agreement"), is coupled with an interest and revokes all prior proxies granted  
by the undersigned with respect to such shares, is irrevocable and shall        
terminate and be of no further force or effect automatically at such time as the
Voting Agreement terminates in accordance with its terms.                       

                           Dated: October 29, 1998

               STOCKHOLDER

                                          --------------------------------------

                                          --------------------------------------
                                         Signature

A-47

S-4
265th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 265th

                                                                     EXHIBIT B-1

                                                         TSI AFFILIATE AGREEMENT

AFFILIATE AGREEMENT 

                        , 1998

Eclipsys Corporation                                                            
777 East Atlantic Avenue                                                        
Suite 200                                                                       
Delray Beach, FL 33483                                                          

Transition Systems, Inc.                                                        
One Boston Place                                                                
Boston, MA 02108                                                                

Ladies and Gentlemen:                                                           

An Agreement and Plan of Merger dated as of October 29, 1998 (the     
"Agreement") has been entered into by and among Eclipsys Corporation, a Delaware
corporation ("Eclipsys"), Fitness Merger Corp., a Massachusetts corporation and 
a wholly-owned subsidiary of Eclipsys (the "Sub"), and Transition Systems, Inc.,
a Massachusetts corporation ("TSI"). The Agreement provides for the merger of   
the Sub with and into TSI (the "Merger"). In accordance with the Agreement,     
shares of Common Stock, $.01 par value per share, and Non-Voting Common stock,  
$.01 par value per share of TSI (collectively the "TSI Common Stock") shall be  
converted into shares of Common Stock, $.01 par value per share, of Eclipsys    
(the "Eclipsys Voting Common Stock"), as described in the Agreement.            

    The undersigned has been advised that as of the date of this agreement the
undersigned may be deemed to be an "affiliate" of TSI, as the term "affiliate"  
is defined for purposes of paragraphs (c) and (d) of Rule 145 of the Rules and  
Regulations of the Securities and Exchange Commission (the "Commission") under  
the Securities Act of 1933, as amended (the "Securities Act"), and/or as such   
term is used in, and for purposes of, Accounting Series Releases Nos. 130 and   
135, as amended, of the Commission.                                             

 In consideration of the mutual agreements, provisions and covenants set
forth in the Agreement and hereinafter in this agreement, the undersigned       
represents and agrees as follows:                                               

        1. Pooling Requirements.  The undersigned will not within the 30 day
 period prior to the Effective Time (as defined in the Agreement), sell,
transfer, pledge, hypothecate or otherwise dispose of, or reduce the  
undersigned's interest in or risk relating to, any shares of Eclipsys 
     Common Stock or TSI Common Stock owned by the undersigned. In addition, the
undersigned will not sell, transfer, pledge, hypothecate or otherwise 
  dispose of, or reduce the undersigned's interest in or risk relating to,
    any Eclipsys Voting Common Stock issued to the undersigned pursuant to the
 Merger, or any other shares of Eclipsys capital stock, until after such
 time as Eclipsys has published (within the meaning of Accounting Series
    Release No. 135, as amended, of the Commission) financial results covering
at least 30 days of combined operations of Eclipsys and TSI.          

2. Rule 145.  The undersigned will not offer, sell, pledge, 
     hypothecate, transfer or otherwise dispose of, or reduce its interest in or
    risk relating to, any of the shares of Eclipsys Voting Common Stock issued
to the undersigned in the Merger unless at such time either: (i) such 
   transaction is permitted pursuant to the provisions of Rule 145 under the
  Securities Act; (ii) the undersigned shall have furnished to Eclipsys an
     opinion of counsel, reasonably satisfactory to Eclipsys, to the effect that
    such transaction is otherwise exempt from the registration requirements of
    the Securities Act; or (iii) a registration statement under the Securities
   Act covering the proposed offer, sale, pledge, hypothecation, transfer or
other disposition shall be effective under the Securities Act.        

A-48

S-4
266th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 266th

3. Legend.                                                  

      (a) The undersigned understands that all certificates representing
   Eclipsys Voting Common Stock delivered to the undersigned pursuant to the
     Merger shall bear a legend in substantially the form set forth below, until
the earlier to occur of (i) one of the events referred to in Section 2
  above or (ii) the date on which the undersigned requests removal of such
legend, provided, that such request occurs at least two years from the
Effective Date (as defined in the Merger Agreement) and that the      
     undersigned is not at the time of such request, and has not been during the
  three months period preceding to such request, an affiliate of Eclipsys.

        "The shares represented by this certificate were issued in a transaction
       to which Rule 145 of the Securities Act of 1933 applies and may only be
        transferred in accordance with the provisions of such rule. In addition,
     the shares represented by this certificate may only be transferred in
accordance with the terms of an affiliate agreement dated       
                              , 1998 between the initial holder hereof and
       Eclipsys Corporation, a copy of which agreement may be inspected by the
holder of this certificate at the principal offices of Eclipsys 
       Corporation, or furnished by Eclipsys Corporation to the holder of this
certificate upon written request, without charge."              

       (b) Eclipsys in its discretion may cause stop transfer orders to be
 placed with its transfer agent with respect to the certificates for the
shares of Eclipsys Voting Common Stock that are required to bear the  
foregoing legend.                                                     

   4. General Provisions.  This agreement shall be governed by and
 construed in accordance with the laws of the State of Delaware, without
   giving effect to principles of conflicts of laws. This agreement shall be
   binding on the undersigned's successors and assigns, including his or her
heirs, executors and administrators.                                  

A-49

S-4
267th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 267th

The undersigned has carefully read this agreement and discussed its   
requirements, to the extent the undersigned believed necessary, with its counsel
or counsel for TSI.                                                             

                     Very truly yours,

                                          --------------------------------------
             Signature

                                          --------------------------------------
              Print Name

Accepted:                                                                       

ECLIPSYS CORPORATION                                                            

By:                                                                             
-------------------------------------------------                         

Name:                                                                           
--------------------------------------------                          

Title:                                                                          
--------------------------------------------                        

Dated:                                                                          
-------------------------------------------                         

TRANSITION SYSTEMS, INC.                                                        

By:                                                                             
-------------------------------------------------                         

Name:                                                                           
--------------------------------------------                          

Title:                                                                          
--------------------------------------------                        

Dated:                                                                          
-------------------------------------------                         

A-50

S-4
268th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 268th

                                                                     EXHIBIT B-2

                                                    ECLIPSYS AFFILIATE AGREEMENT

AFFILIATE AGREEMENT 

            , 1998

Eclipsys Corporation                                                            
777 East Atlantic Avenue                                                        
Suite 200                                                                       
Delray Beach, FL 33483                                                          

Transition Systems, Inc.                                                        
One Boston Place                                                                
Boston, MA 02108                                                                

Ladies and Gentlemen:                                                           

An Agreement and Plan of Merger dated as of October 29, 1998 (the     
"Agreement") has been entered into by and among Eclipsys Corporation, a Delaware
corporation ("Eclipsys"), Fitness Merger Corp., a Massachusetts corporation and 
a wholly-owned subsidiary of Eclipsys (the "Sub"), and Transition Systems, Inc.,
a Massachusetts corporation ("TSI"). The Agreement provides for the merger of   
the Sub with and into TSI (the "Merger"). In accordance with the Agreement,     
shares of Common Stock, $.01 par value per share, and Non-Voting Common Stock,  
$.01 par value per share, of TSI (collectively the "TSI Common Stock") shall be 
converted into shares of Common Stock, $.01 par value per share (the "Eclipsys  
Voting Common Stock"), as described in the Agreement.                           

    The undersigned has been advised that as of the date of this agreement the
undersigned may be deemed to be an "affiliate" of Eclipsys, as the term         
"affiliate" is defined under the Rules and Regulations of the Securities and    
Exchange Commission (the "Commission") under the Securities Act of 1933, as     
amended, and/or as such term is used in, and for purposes of, Accounting Series 
Releases Nos. 103 and 135, as amended, of the Commission.                       

 In consideration of the mutual agreements, provisions and covenants set
forth in the Agreement and hereinafter in this agreement, the undersigned       
represents and agrees as follows:                                               

        1. Pooling Requirements.  The undersigned will not within the 30 day
 period prior to the Effective Time (as defined in the Agreement), sell,
transfer, pledge, hypothecate or otherwise dispose of, or reduce the  
undersigned's interest in or risk relating to, any shares of Eclipsys 
     Common Stock or TSI Common Stock owned by the undersigned. In addition, the
undersigned will not sell, transfer, pledge, hypothecate or otherwise 
     dispose of, or reduce the undersigned's interest in or risk relating to any
 shares of Eclipsys capital stock, until after such time as Eclipsys has
published (within the meaning of Accounting Series Release No. 135, as
    amended, of the Commission) financial results covering at least 30 days of
combined operations of Eclipsys and TSI.                              

   2. General Provisions.  This agreement shall be governed by and
 construed in accordance with the laws of the State of Delaware, without
   giving effect to principles of conflicts of laws. This agreement shall be
   binding on the undersigned's successors and assigns, including his heirs,
executors and administrators.                                         

A-51

S-4
269th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 269th

The undersigned has carefully read this agreement and discussed its   
requirements, to the extent the undersigned believed necessary, with its counsel
or counsel for Eclipsys.                                                        

                     Very truly yours,

                                          --------------------------------------
             Signature

                                          --------------------------------------
              Print Name

Accepted:                                                                       

ECLIPSYS CORPORATION                                                            

By:                                                                             
--------------------------------------------------------                

Name:                                                                           
-------------------------------------------------------             

Title:                                                                          
------------------------------------------------------              

Dated:                                                                          
-------------------------------------------------------             

TRANSITION SYSTEMS, INC.                                                        

By:                                                                             
--------------------------------------------------------                

Name:                                                                           
-------------------------------------------------------             

Title:                                                                          
------------------------------------------------------              

Dated:                                                                          
-------------------------------------------------------             

A-52

S-4
270th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 270th

ANNEX B 

[LETTERHEAD OF MORGAN STANLEY & CO. INCORPORATED] 

                                                                October 28, 1998

Board of Directors                                                              
Eclipsys Corporation                                                            
777 East Atlantic Avenue                                                        
Suite 200                                                                       
Delray Beach, Florida 33483                                                     

Members of the Board:                                                           

  We understand that Transition Systems Inc. ("TSI"), Eclipsys Corporation
("Eclipsys" or the "Company"), and Exercise Acquisition Corp. ("Merger Sub"), a 
wholly owned subsidiary of Eclipsys, propose to enter into an Agreement and Plan
of Merger, substantially in the form of the draft dated October 28, 1998 (the   
"Merger Agreement"), which provides, among other things, for the merger (the    
"Merger") of Merger Sub with and into TSI. Pursuant to the Merger, TSI will     
become a wholly-owned subsidiary of the Company and each outstanding share of   
common stock, par value of $0.01 per share (the "TSI Common Stock"), of TSI,    
other than shares held in treasury or by Eclipsys or any subsidiary of TSI or   
Eclipsys, shall be converted into the right to receive 0.525 shares (the        
"Exchange Ratio") of common stock, par value $0.01 per share, of Eclipsys (the  
"Eclipsys Common Stock"). The terms and conditions of the Merger are more fully 
set forth in the Merger Agreement and certain related documents.                

     You have asked for our opinion as to whether the Exchange Ratio pursuant to
the Merger Agreement is fair from a financial point of view to the Company.     

For purposes of the opinion set forth herein, we have:                

          (a) reviewed certain publicly available financial statements and other
information of TSI and Eclipsys, respectively;                        

          (b) reviewed certain internal financial statements and other financial
    and operating data concerning TSI and Eclipsys prepared by the managements
of TSI and Eclipsys, respectively;                                    

         (c) discussed the past and current operations and financial condition
and the prospects of TSI with senior executives of TSI;               

         (d) discussed the past and current operations and financial condition
  and the prospects of Eclipsys, including information relating to certain
    strategic, financial and operational benefits anticipated from the Merger,
with senior executives of Eclipsys;                                   

         (e) discussed with the senior managements of TSI and Eclipsys certain
research analyst projections for TSI and Eclipsys, respectively;      

         (f) reviewed the pro forma impact of the Merger on Eclipsys' earnings
per share and other financial ratios;                                 

     (g) reviewed the reported prices and trading activity for the TSI
Common Stock and the Eclipsys Common Stock;                           

      (h) compared the financial performance of TSI and Eclipsys and the
     prices and trading activity of the TSI Common Stock and the Eclipsys Common
   Stock with that of certain other comparable publicly-traded companies and
their securities;                                                     

          (i) reviewed the financial terms, to the extent publicly available, of
certain comparable acquisition transactions;                          

    (j) participated in discussions among representatives of TSI and
Eclipsys and their financial and legal advisors;                      

 B-1

S-4
271st Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 271st

      (k) reviewed the draft Merger Agreement dated October 21, 1998 and
certain related documents; and                                        

    (l) performed such other analyses as we have deemed appropriate.

We have assumed and relied upon without independent verification the  
accuracy and completeness of the information reviewed by us for the purposes of 
this opinion. With respect to the financial projections, including information  
relating to certain strategic, financial and operational benefits anticipated   
from the Merger, we have assumed that they have been reasonably prepared on     
bases reflecting the best currently available estimates and judgments of the    
future financial performance of Eclipsys and TSI, respectively. In addition, we 
have assumed that the Merger will be consummated in accordance with the terms   
set forth in the Merger Agreement, including, among other things, that the      
Merger will be accounted for as a "pooling-of-interests" business combination in
accordance with U.S. Generally Accepted Accounting Principles and the Merger    
will be treated as a tax-free reorganization and/or exchange, each pursuant to  
the Internal Revenue Code of 1986. We have not made any independent valuation or
appraisal of the assets or liabilities of TSI, nor have we been furnished with  
any such appraisals. Our opinion is necessarily based on economic, market and   
other conditions as in effect on, and the information made available to us as   
of, the date hereof.                                                            

We have been retained to render a financial opinion to the Board of   
Directors of Eclipsys in connection with this transaction and will receive a fee
for our services. In the past, Morgan Stanley & Co. Incorporated and its        
affiliates have provided financial advisory and financing services for the      
Company and their affiliates and have received fees for the rendering of these  
services.                                                                       

  It is understood that this letter is for the information of the Board of
Directors of the Company, except that this opinion may be included in its       
entirety in any filing made by the Company in respect of the transaction with   
the Securities and Exchange Commission. In addition, this opinion does not in   
any manner address the prices at which Eclipsys Common Stock will trade         
following consummation of the Merger, and Morgan Stanley expresses no opinion or
recommendation as to how the shareholders of the Company and TSI should vote at 
the shareholders' meeting held in connection with the Merger.                   

    Based upon and subject to the foregoing, we are of the opinion on the date
hereof that the Exchange Ratio pursuant to the Merger Agreement is fair from a  
financial point of view to the Company.                                         

                     Very truly yours,

                                     MORGAN STANLEY & CO. INCORPORATED

                                 By:    /s/ SCOTT R. BRAKEBILL
                                            ------------------------------------
                                            Scott R. Brakebill
                                           Managing Director

 B-2

S-4
272nd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 272nd

ANNEX C 
[LETTERHEAD OF BT ALEX. BROWN INCORPORATED] 

                                                                October 29, 1998

Board of Directors                                                              
Transition Systems, Inc.                                                        
One Boston Place, Suite 2700                                                    
Boston, Massachusetts 02108                                                     

Members of the Board:                                                           

BT Alex. Brown Incorporated ("BT Alex. Brown") has acted as financial 
advisor to Transition Systems, Inc. ("TSI") in connection with the proposed     
merger transaction involving TSI and Eclipsys Corporation ("Eclipsys") pursuant 
to the Agreement and Plan of Merger, dated as of October 29, 1998 (the "Merger  
Agreement"), among Eclipsys, Exercise Acquisition Corp., a wholly owned         
subsidiary of Eclipsys ("Sub"), and TSI. The Merger Agreement provides, among   
other things, for the merger of Sub with and into TSI (the "Merger") pursuant to
which TSI will become a wholly owned subsidiary of Eclipsys. As set forth more  
fully in the Merger Agreement, as a result of the Merger, each outstanding share
of the common stock, par value $0.01 per share, of TSI ("TSI Voting Common      
Stock") and each outstanding share of the non-voting common stock, par value    
$0.01 per share, of TSI ("TSI Non-Voting Common Stock" and, together with the   
TSI Voting Common Stock, "TSI Common Stock") will be converted into the right to
receive 0.525 of a share (the "Exchange Ratio") of the common stock, par value  
$0.01 per share, of Eclipsys ("Eclipsys Voting Common Stock").                  

You have requested BT Alex. Brown's opinion as to the fairness, from a
financial point of view, of the Exchange Ratio to the holders of TSI Common     
Stock.                                                                          

   In connection with BT Alex. Brown's role as financial advisor to TSI, and
in arriving at its opinion, BT Alex. Brown has reviewed certain publicly        
available financial and other information concerning TSI and Eclipsys and       
certain internal analyses and other information furnished to or discussed with  
it by TSI, Eclipsys and their respective advisors. BT Alex. Brown has also held 
discussions with members of the senior management of TSI and Eclipsys regarding 
the business and prospects of their respective companies and the joint prospects
of a combined company. In addition, BT Alex. Brown has (i) reviewed the reported
prices and trading activity for TSI Voting Common Stock and Eclipsys Voting     
Common Stock, (ii) compared certain financial and stock market information for  
TSI and Eclipsys with similar information for certain other companies whose     
securities are publicly traded, (iii) reviewed the financial terms of certain   
recent business combinations which it deemed comparable in whole or in part,    
(iv) reviewed the terms of the Merger Agreement, and (v) performed such other   
studies and analysis and considered such other factors as it deemed appropriate.
In connection with its engagement, BT Alex. Brown was authorized to approach,   
and held discussions with, certain third parties to solicit indications of      
interest with respect to the acquisition of TSI.                                

    BT Alex. Brown has not assumed responsibility for independent verification
of, and has not independently verified, any information, whether publicly       
available or furnished to it, concerning TSI, Eclipsys and the combined company,
including, without limitation, any financial information, forecasts or          
projections considered in connection with the rendering of its opinion.         
Accordingly, for purposes of its opinion, BT Alex. Brown has assumed and relied 
upon the accuracy and completeness of all such information and BT Alex. Brown   
has not conducted a physical inspection of any of the properties or assets, and 
has not prepared or obtained any independent evaluation or appraisal of any of  
the assets or liabilities, of TSI or Eclipsys. With respect to the financial    
forecasts and projections made available to BT Alex. Brown and used in its      
analyses, BT Alex. Brown has assumed that they have been prepared on bases      
reflecting reasonable estimates and judgments as to the matters covered thereby.
In rendering its opinion, BT Alex. Brown expresses no view as to the            
reasonableness of such forecasts and projections or the assumptions on which    
they are based. BT Alex. Brown's opinion is necessarily based upon economic,    
market and other conditions as in effect on, and the information made available 
to it as of, the date hereof.                                                   
 C-1

S-4
273rd Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 273rd

Board of Directors                                                              
Transition Systems, Inc.                                                        
October 29, 1998                                                                
Page 2                                                                          

    For purposes of rendering its opinion, BT Alex. Brown has assumed that, in
all respects material to its analysis, the representations and warranties of    
TSI, Eclipsys and Sub contained in the Merger Agreement are true and correct,   
TSI, Eclipsys and Sub will each perform all of the covenants and agreements to  
be performed by it under the Merger Agreement and all conditions to the         
obligations of each of TSI, Eclipsys and Sub to consummate the Merger will be   
satisfied without any waiver thereof. BT Alex. Brown has also assumed that all  
material governmental, regulatory or other approvals and consents required in   
connection with the consummation of the Merger will be obtained and that in     
connection with obtaining any necessary governmental, regulatory or other       
approvals and consents, or any amendments, modifications or waivers to any      
agreements, instruments or orders to which either TSI or Eclipsys is a party or 
is subject or by which it is bound, no limitations, restrictions or conditions  
will be imposed or amendments, modifications or waivers made that would have a  
material adverse effect on TSI or Eclipsys or materially reduce the contemplated
benefits of the Merger to TSI. In addition, you have informed BT Alex. Brown,   
and accordingly for purposes of rendering its opinion BT Alex. Brown has        
assumed, that the Merger will qualify as a tax-free reorganization for federal  
income tax purposes and will be accounted for as a pooling of interests. BT     
Alex. Brown is expressing no opinion as to the price at which the Eclipsys      
Voting Common Stock will trade at any time.                                     

    This opinion is addressed to, and for the use and benefit of, the Board of
Directors of TSI and is not a recommendation to any shareholder as to how such  
shareholder should vote with respect to matters relating to the proposed Merger.
This opinion is limited to the fairness, from a financial point of view, of the 
Exchange Ratio to the holders of TSI Common Stock, and BT Alex. Brown expresses 
no opinion as to the merits of the underlying decision by TSI to engage in the  
Merger.                                                                         

   BT Alex. Brown, as a customary part of its investment baking business, is
engaged in the valuation of businesses and their securities in connection with  
mergers and acquisitions, negotiated underwritings, private placements and      
valuations for estate, corporate and other purposes. We have acted as financial 
advisor to TSI in connection with the Merger and will receive a fee for our     
services, a significant portion of which is contingent upon the consummation of 
the Merger and portion of which is payable upon delivery of this opinion. BT    
Alex. Brown and its affiliates have in the past provided financial services to  
TSI unrelated to the proposed Merger, for which services BT Alex. Brown and its 
affiliates have received compensation. BT Alex. Brown maintains a market in TSI 
Common Stock and regularly publishes research reports regarding the businesses  
and securities of TSI and other publicly traded companies in the health care    
information technology industry. In the ordinary course of business, BT Alex.   
Brown and its affiliates may actively trade or hold the securities and other    
instruments and obligations of TSI and Eclipsys for their own account and for   
the accounts of customers and, accordingly, may at any time hold a long or short
position in such securities, instruments or obligations.                        

 Based upon and subject to the foregoing, it is BT Alex. Brown's opinion
that, as of the date of this letter, the Exchange Ratio is fair, from a         
financial point of view, to the holders of TSI Common Stock.                    

                     Very truly yours,

                                  /s/BT ALEX. BROWN INCORPORATED
                                  ------------------------------
                               BT ALEX. BROWN INCORPORATED

 C-2

S-4
274th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 274th

PART II 

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 20.  INDEMNIFICATION OF DIRECTORS AND OFFICERS                             

   Article EIGHTH of the Registrant's Third Amended and Restated Certificate
of Incorporation provides that no director of the Registrant shall be personally
liable for monetary damages for breach of his or her fiduciary duty as a        
director, except for (i) any breach of such director's duty of loyalty to the   
Registrant, (ii) acts or omissions not in good faith or which involve           
intentional misconduct or a knowing violation of law, (iii) any transaction from
which such director derived an improper person benefit or (iv) actions under    
Section 174 of the Delaware General Corporation Law and to the extent that the  
Delaware General Corporation Law prohibits the elimination or limitation of     
liability of directors.                                                         

Section 145 of the Delaware General Corporation Law provides that a   
corporation has the power to indemnify a director, officer, employee or agent of
the corporation and certain other persons serving at the request of the         
corporation in related capacities against amounts paid and expenses incurred in 
connection with an action or proceeding to which he is or is threatened to be   
made a party by reason of such position, if such person shall have acted in good
faith and in a manner he reasonably believed to be in or not opposed to the best
interests of the corporation, and, in any criminal proceeding, if such person   
had no reasonable cause to believe his conduct was unlawful; provided that, in  
the case of actions brought by or in the right of the corporation, no           
indemnification shall be made with respect to any matter as to which such person
shall have been adjudged to be liable to the corporation unless and only to the 
extent that the adjudicating court determines that such indemnification is      
proper under the circumstances.                                                 

  Messrs. Denning and Ford, the elected representatives of GAP 28, GAP 38,
GAP 47, GAP 48 and GAP Coinvestment to the Board of Directors, are indemnified  
against liability they may incur in their capacity as directors of the Company  
pursuant to the limited partnership agreements of each of GAP 28, GAP 38, GAP 47
and GAP 48.                                                                     

ITEM 21.  EXHIBITS AND FINANCIAL STATEMENT SCHEDULES                            

(a) Exhibits                                                          

                                                                [Download Table]

EXHIBIT                                                                
 NUMBER                            DESCRIPTION                         
-------                            -----------                         
                                                                       
 2.1*      Agreement and Plan of Merger dated as of October 29, 1998 by
           and among the Registrant, Exercise Acquisition Corp. and    
           Transition Systems, Inc.                                    
 2.2**     Agreement of Merger among Alltel Healthcare Information     
           Services, Inc., Alltel Information Services, Inc., Eclipsys 
           Corporation and Eclipsys Solutions Corp. dated as of January
           24, 1997                                                    
 2.3**     Amended and Restated Stock Purchase Agreement among Eclipsys
           Corporation, SDK Medical Computer Services Corporation and  
           the Selling Stockholders listed therein dated June 26, 1997 
 2.4**     Asset Purchase Agreement by and among Motorola, Inc.,       
           Eclipsys Corporation and Emtek Healthcare Corporation dated 
           January 30, 1998                                            
 3.1***    Third Amended and Restated Certificate of Incorporation of  
           the Registrant                                              
 3.2**     Amended and Restated Bylaws of the Registrant               
 4.1**     Specimen certificate for shares of Eclipsys Common Stock    
 5.1       Opinion of Hale and Dorr LLP                                
 8.1       Opinion of Hale and Dorr LLP as to Tax Matters              

II-1

S-4
275th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 275th

                                                                [Download Table]

EXHIBIT                                                                
 NUMBER                            DESCRIPTION                         
-------                            -----------                         
                                                                       
 8.2       Opinion of Foley, Hoag & Eliot LLP as to Tax Matters        
10.1**     Second Amended and Restated Registration Rights Agreement   
10.2**     Second Amended and Restated Stockholders Agreement          
10.3**     Warrant to Purchase Non-Voting Common Stock, dated January  
           24, 1997, granted to First Union Corporation                
10.4**     Warrant to Purchase Non-Voting Common Stock, dated January  
           24, 1997, granted to BT Investment Partners, Inc.           
10.5**+    Information Systems Technology License Agreement, dated as  
           of May 3, 1996, by and among Partners Healthcare System,    
           Inc., Brigham and Women's Hospital, Inc. and Integrated     
           Healthcare Solutions, Inc.                                  
10.6**     Preferred Stock Purchase Agreement by and among Eclipsys    
           Corporation, General Atlantic Partners 47, L.P. and GAP     
           Coinvestment Partners, L.P. dated February 4, 1998          
10.7**     1996 Stock Plan                                             
10.8**     1998 Stock Incentive Plan                                   
10.9***    Amended and Restated 1998 Employee Stock Purchase Plan      
10.10**    Employment Letter, dated as of May 1, 1996, to Harvey J.    
           Wilson from Integrated Healthcare Solutions, Inc.           
10.11**    First Amended and Restated Credit Agreement dated May 29,   
           1998, by and among Eclipsys Corporation, First Union        
           National Bank, f/k/a First Union National Bank of North     
           Carolina as Agent and BankBoston, N.A. as Co-Agent          
10.12***   Letter agreement amending First Amended and Restated Credit 
           Agreement dated May 29, 1998, by and among Eclipsys         
           Corporation, First Union National Bank, f/k/a First Union   
           National Bank of North Carolina as Agent and BankBoston,    
           N.A., as Co-Agent                                           
10.13**    Settlement of Claims Agreement, dated as of March 13, 1998, 
           between ALLTEL Information Services, Inc. and Eclipsys      
           Corporation                                                 
21**       Subsidiaries of the Registrant                              
23.1       Consent of PricewaterhouseCoopers LLP                       
23.2       Consent of PricewaterhouseCoopers LLP                       
23.3       Consent of KPMG Peat Marwick LLP                            
23.4       Consent of PricewaterhouseCoopers LLP                       
23.5       Consent of Ernst & Young LLP                                
23.6       Consent of Hale and Dorr LLP (included in Exhibit 5.1)      
23.7       Consent of Hale and Dorr LLP (included in Exhibit 8.1)      
23.8       Consent of Foley, Hoag & Eliot LLP (included in Exhibit 8.2)
24         Power of Attorney (included on page II-5)                   
99.1*      Opinion of Morgan Stanley & Co. Incorporated                
99.2*      Opinion of BT Alex. Brown Incorporated                      
99.3       Form of Proxy Card of Eclipsys Corporation                  
99.4       Form of Proxy Card of Transition Systems, Inc.              
99.5       Consent of BT Alex. Brown Incorporated                      
99.6       Consent of Morgan Stanley & Co.                             
99.7       Consent of Robert F. Raco                                   
99.8       Consent of Patrick T. Hackett                               

---------------                                                                 
+ Confidential treatment granted on August 6, 1998 in connection with the   
Eclipsys IPO.                                                           
* Included as an annex to the Joint Proxy Statement/Prospectus included     
herein.                                                                 
 ** Incorporated by reference to the Registrant's Registration Statement on Form
S-1, as amended (File No. 333-50781).                                   

II-2

S-4
276th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 276th

*** Incorporated by reference to the Registrant's Quarterly Report on Form 10-Q 
for the quarter ended June 30, 1998 (File No. 000-24539).               

(b) Financial Statement Schedules                                     

None                                                                  

  All schedules have been omitted because they are not required or because
the required information is given in the Registrant's Financial Statements or   
Notes thereto.                                                                  

ITEM 22.  UNDERTAKINGS                                                          

    The undersigned registrant hereby undertakes as follows: that prior to any
public reoffering of the securities registered hereunder through use of a       
prospectus which is a part of this registration statement, by any person or     
party who is deemed to be an underwriter within the meaning of Rule 145(c), the 
issuer undertakes that such reoffering prospectus will contain the information  
called for by the applicable registration form with respect to reofferings by   
persons who may be deemed underwriters, in addition to the information called   
for by the other items of the applicable form.                                  

     The registrant undertakes that every prospectus: (i) that is filed pursuant
to the paragraph immediately preceding, or (ii) that purports to meet the       
requirements of Section 10(a)(3) of the Securities Act and is used in connection
with an offering of securities subject to Rule 415, will be filed as a part of  
an amendment to the registration statement and will not be used until such      
amendment is effective, and that, for purposes of determining any liability     
under the Securities Act, each such post-effective amendment shall be deemed to 
be a new registration statement relating to the securities offered therein, and 
the offering of such securities at that time shall be deemed to be the initial  
bona fide offering thereof.                                                     

     Insofar as indemnification for liabilities arising under the Securities Act
may be permitted to directors, officers and controlling persons of the          
Registrant pursuant to the provisions contained in the Restated Certificate of  
Incorporation of the Registrant and the laws of the State of Delaware, or       
otherwise, the Registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as        
expressed in the Securities Act and is, therefore, unenforceable. In the event  
that a claim for indemnification against such liabilities (other than the       
payment by the Registrant of expenses incurred or paid by a director, officer or
controlling person of the Registrant in the successful defense of any action,   
suit or proceeding) is asserted by such director, officer or controlling person 
in connection with the securities being registered, the Registrant will, unless 
in the opinion of its counsel the matter has been settled by controlling        
precedent, submit to a court of appropriate jurisdiction the question whether   
such indemnification by it is against public policy as expressed in the         
Securities Act and will be governed by the final adjudication of such issue.    

 The undersigned registrant hereby undertakes to respond to requests for
information that is incorporated by reference into the prospectus pursuant to   
Item 4, 10(b), 11 or 13 of this form, within one business day of receipt of such
request, and to send the incorporated documents by first class mail or other    
equally prompt means. This includes information contained in documents filed    
subsequent to the effective date of the registration statement through the date 
of responding to the request.                                                   

The undersigned registrant hereby undertakes to supply by means of a  
post-effective amendment all information concerning a transaction, and the      
company being acquired involved therein, that was not the subject of and        
included in the registration statement when it became effective.                

II-3

S-4
277th Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 277th

SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant
has duly caused this Registration Statement to be signed on its behalf by the   
undersigned, thereunto duly authorized, in Delray Beach, Florida, on this 3rd   
day of December, 1998.                                                          

                        ECLIPSYS CORPORATION

                                By:     /s/ HARVEY J. WILSON
                                            ------------------------------------
                                            Harvey J. Wilson
                                           President and Chief Executive
                                             Officer

II-4

S-4
Last Page of 278
TOC
1st
Previous
Next
↓Bottom
Just 278th

POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Eclipsys Corporation, hereby
severally constitute and appoint Harvey J. Wilson, Robert J. Vanaria, T. Jack   
Risenhoover, II and Brent B. Siler, and each of them singly, our true and lawful
attorneys with full power to them, and each of them singly, to sign for us and  
in our names in the capacities indicated below, the Registration Statement on   
Form S-4 filed herewith and any and all pre-effective and post-effective        
amendments to said Registration Statement, and generally to do all such things  
in our names and on our behalf in our capacities as officers and directors to   
enable Eclipsys Corporation to comply with the provisions of the Securities Act 
of 1933, as amended, and all requirements of the Securities and Exchange        
Commission, hereby ratifying and confirming our signatures as they may be signed
by our said attorneys, or any of them, to said Registration Statement and any   
and all amendments thereto or to any subsequent Registration Statement for the  
same offering.                                                                  

Pursuant to the requirements of the Securities Act of 1933, this      
Registration Statement has been signed by the following persons in the          
capacities and on the dates indicated.                                          

                                                        [Enlarge/Download Table]

                SIGNATURE                                   TITLE                       DATE       
                ---------                                   -----                       ----       
                                                                                                   

           /s/ HARVEY J. WILSON             President and Chief Executive Officer  December 3, 1998
------------------------------------------  (Principal Executive Officer)                          
             Harvey J. Wilson                                                                      

          /s/ ROBERT J. VANARIA             Senior Vice President, Administration  December 3, 1998
------------------------------------------  and Chief Financial Officer                            
            Robert J. Vanaria               (Principal Financial and Accounting                    
                                            Officer)                                               

          /s/ STEVEN A. DENNING             Director                               December 3, 1998
------------------------------------------                                                         
            Steven A. Denning                                                                      

            /s/ G. FRED DIBONA              Director                               December 3, 1998
------------------------------------------                                                         
              G. Fred DiBona                                                                       

             /s/ EUGENE FIFE                Director                               December 3, 1998
------------------------------------------                                                         
               Eugene Fife                                                                         

           /s/ WILLIAM E. FORD              Director                               December 3, 1998
------------------------------------------                                                         
             William E. Ford                                                                       

            /s/ JAY B. PIEPER               Director                               December 3, 1998
------------------------------------------                                                         
              Jay B. Pieper                                                                        

          /s/ RICHARD D. SEVERNS            Director                               December 3, 1998
------------------------------------------                                                         
            Richard D. Severns                                                                     

II-5